"file","id","modified","result","result_description","rob_name","rob_id","rob_description","group_id","group_name"
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-McLaren-1992","2011-02-14 15:12:12 +0000","UNKNOWN","Quote: ""Patients were randomly allocated ......"" - no further information.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-McLaren-1992","2011-02-14 15:12:27 +0000","UNKNOWN","No information.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-McLaren-1992","2011-02-14 15:46:05 +0000","UNKNOWN","Quote: ""Bromperidol decanoate or fluphenazine decanoate in identical ampoules"". Unclear if raters independent and unclear if blinding was successful.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-McLaren-1992","2011-03-23 15:54:42 +0000","UNKNOWN","Unclear if raters were independent and unclear if blinding was successful.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-McLaren-1992","2011-03-23 15:57:36 +0000","UNKNOWN","Insufficient information.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-McLaren-1992","2011-02-14 15:15:46 +0000","YES","Number randomised, and number lost during follow-up reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-McLaren-1992","2011-03-03 11:15:30 +0000","NO","No endpoint scores at Krawiecka-Goldberg scale, NSRS, MARDRS, Simpson & Angus scale, MRSS, AIMS, weight measures and blood samples.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-McLaren-1992","2011-02-14 15:21:38 +0000","NO","Funded by Jannsen Pharmaceuticals - who make bromperidol decanoate.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1990","2011-03-02 11:57:43 +0000","UNKNOWN","Randomised - no further information.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1990","2011-02-14 15:28:31 +0000","UNKNOWN","No information.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1990","2011-02-14 16:06:24 +0000","UNKNOWN","Investigator involved in selection and outcome evaluation, did not access randomisation list and drug administration. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1990","2011-03-23 15:56:06 +0000","UNKNOWN","Unclear if raters were independent and unclear if blinding was successful.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1990","2011-03-23 15:57:29 +0000","UNKNOWN","Insufficient information.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1990","2011-02-14 18:12:56 +0000","UNKNOWN","Rating scale scores reported without denominator.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1990","2011-02-14 16:31:29 +0000","NO","No endpoint scores (CGI, DOTES, TESS Write), scores reported without denominator (CBS, BPRS), vital signs measures - not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1990","2011-02-14 15:34:40 +0000","UNKNOWN","Insufficient information.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1992","2011-06-30 18:07:50 +0100","UNKNOWN","Randomised - no further information.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1992","2011-02-14 15:31:35 +0000","UNKNOWN","No information.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1992","2011-02-15 11:08:08 +0000","UNKNOWN","Quote: ""Drugs were provided in identical packages in order to maintain double-blindness"".","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1992","2011-03-23 15:56:27 +0000","UNKNOWN","Unclear if blinding was successful.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1992","2011-03-23 15:57:14 +0000","UNKNOWN","Insufficient information.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1992","2011-02-14 18:12:49 +0000","NO","Rating scale scores reported without denominator.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1992","2011-02-15 11:17:21 +0000","NO","No endpoint scores (DOTES and TWIS scales), scores without SD (BPRS, HAM-D, SANS, SAPS), no vital signs measures.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1992","2011-02-14 15:34:50 +0000","UNKNOWN","Insufficient information.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Smeraldi-1990","2011-06-30 18:08:54 +0100","UNKNOWN","Randomised (no information about randomisation procedure).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Smeraldi-1990","2011-02-14 13:12:35 +0000","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Smeraldi-1990","2011-02-15 11:07:57 +0000","UNKNOWN","Quote: ""The placebo and bromperidol phials were perfectly identical"". ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Smeraldi-1990","2011-03-23 15:56:49 +0000","UNKNOWN","Unclear if raters were independent and unclear if blinding was successful.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Smeraldi-1990","2011-03-23 15:57:06 +0000","UNKNOWN","Insufficient information.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Smeraldi-1990","2011-02-14 18:12:43 +0000","NO","Rating scale scores reported without denominator.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Smeraldi-1990","2011-02-15 12:25:18 +0000","NO","No endpoint scores (DOTES, SAFTEE-SI), vital signs measures.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Bromperidol decanoate (depot) for schizophrenia [v9.0-For publication].rm5","STD-Smeraldi-1990","2011-02-14 15:34:56 +0000","UNKNOWN","Insufficient information.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Azima-1962","2011-05-18 14:16:46 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Azima-1962","2011-05-18 14:16:46 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Azima-1962","2012-10-02 11:05:10 +0100","YES","“Multi-blind”; “identical placebos”.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Azima-1962","2012-10-02 11:05:12 +0100","UNKNOWN","“Multi-blind”; “evaluation of drug effects is made by different members of the research team and the final conclusion is the result of pooling of the multiple observations”.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Azima-1962","2011-10-13 05:57:06 +0100","YES","No participant left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Azima-1962","2012-04-20 10:11:05 +0100","UNKNOWN","The outcomes that are of interest in the review have been reported in the pre-specific way. The adverse effects were not fully addressed.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Azima-1962","2012-10-02 11:05:19 +0100","NO","Regarding this review the main focus on the anti-anxiety effect of the medication to judge improvement could be a possible risk of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Barbee-1992","2011-05-18 14:17:28 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Barbee-1992","2011-05-18 14:17:28 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Barbee-1992","2011-05-18 14:17:39 +0100","YES","“Double-blind”; “identically appearing placebo tablet”","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Barbee-1992","2011-05-18 14:17:40 +0100","YES","Two investigators administered the scales and were blind to each other’s ratings and the drug assignment.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Barbee-1992","2011-10-13 05:57:10 +0100","YES","No participant left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Barbee-1992","2011-10-08 15:20:42 +0100","NO","The outcomes that are of interest in the review were not fully addressed (Simpson and Angus Scale). The adverse effects were not fully addressed (only the five most frequent).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Barbee-1992","2011-05-18 14:17:51 +0100","YES","The study appears to be free of other sources of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Battaglia-1997","2011-05-18 14:18:20 +0100","YES","Participants were ""sequentially assigned on the basis of a computer-generated table of random numbers.""","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Battaglia-1997","2011-05-18 15:19:09 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Battaglia-1997","2011-05-18 14:18:22 +0100","YES","""Double-blind"". ""The emergency department psychiatrist who treated and rated the patient remained blinded to the identity of the patient’s medication throughout treatment."" The non-blinding of others is unlikely to introduce bias. The ""syringes containing the study drug were prepared by a non-blinded nurse or hospital pharmacist and delivered to the emergency department as needed.""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Battaglia-1997","2011-05-18 14:18:23 +0100","YES","""Double-blind"". ""The emergency department psychiatrist who treated and rated the patient remained blinded to the identity of the patient’s medication throughout treatment."" The non-blinding of others is unlikely to introduce bias.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Battaglia-1997","2011-10-13 05:57:17 +0100","YES","No participant left the trial early. ""Data for two patients were excluded from the efficacy analysis because of receiving antipsychotic medication shortly before entering the study."" Due to the low attrition the risk of bias might be rather low.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Battaglia-1997","2011-05-18 14:18:25 +0100","YES","The outcomes that are of interest in the review have been reported in the pre-specific way.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Battaglia-1997","2011-10-06 15:06:12 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Carpenter-1999","2011-05-18 14:18:45 +0100","UNKNOWN","“A stratified randomization procedure was used to assign drug treatment to balance study groups on gender, prior social function, and past duration of hospital care.” No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Carpenter-1999","2011-05-18 14:18:45 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Carpenter-1999","2011-05-18 14:18:45 +0100","UNKNOWN","“Double-blind”; no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Carpenter-1999","2011-05-18 14:18:45 +0100","UNKNOWN","“Double-blind”; no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Carpenter-1999","2011-10-13 05:57:24 +0100","YES","No participant left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Carpenter-1999","2011-10-08 15:21:04 +0100","NO","The outcomes that are of interest in the review were not fully addressed. The trial authors did not provide raw data of the BPRS total score or the CGI. Reporting on adverse effects was incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Carpenter-1999","2011-05-18 14:18:45 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Cheung-1981","2011-05-18 14:19:06 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Cheung-1981","2011-05-18 14:19:07 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Cheung-1981","2011-05-18 14:19:07 +0100","UNKNOWN","“Double-blind”; no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Cheung-1981","2011-05-18 14:19:07 +0100","UNKNOWN","“Double-blind”; no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Cheung-1981","2012-07-26 16:43:10 +0100","YES","Two participants left the trial early in the benzodiazepine group, the total number of patients leaving the trial early is rather low (6.7%). The analysis was based on completer data, but due to the low attrition the risk of bias might be rather low. Additionally, the trial authors provided a worst-case-scenario analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Cheung-1981","2012-04-20 10:13:05 +0100","UNKNOWN","The outcomes that are of interest in the review have been reported in the pre-specific way. The adverse effects were not fully addressed.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Cheung-1981","2011-10-06 15:06:56 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Chouinard-1993","2011-05-18 14:19:34 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Chouinard-1993","2011-05-18 14:19:34 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Chouinard-1993","2011-10-13 05:24:41 +0100","YES","“Double-blind”. “To ensure double-blind conditions, the clonazepam group received procyclidine placebo with each dose.” The nurse administering the drugs i.m. injections “was not blind to the treatment allocations”, but this was unlikely to introduce bias.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Chouinard-1993","2011-05-18 14:20:04 +0100","YES","“Double-blind”. The evaluating psychiatrist was blind to treatment allocations.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Chouinard-1993","2012-07-26 16:11:28 +0100","YES","One participant left the trial early in the benzodiazepine group; the total number of patients leaving the trial early is rather low (6.25%). The trial authors did not provide any information how they considered with the drop-out in the analysis, but due to the low attrition the risk of bias might be rather low.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Chouinard-1993","2011-10-08 15:21:13 +0100","YES","The outcomes that are of interest in the review have been reported in the pre-specific way with the exception of adverse effects, which were not fully addressed.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Chouinard-1993","2012-04-20 10:13:55 +0100","YES","“Of the 16 patients, 12 (6 in each group) were receiving neuroleptics at study entry.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Dorevitch-1999","2011-05-18 14:20:42 +0100","YES","“Patients were assigned by a table of random numbers.” No further details. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Dorevitch-1999","2011-05-18 14:20:49 +0100","UNKNOWN","No further details. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Dorevitch-1999","2011-05-18 14:20:27 +0100","UNKNOWN","“Double-blind“; no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Dorevitch-1999","2011-05-18 14:20:52 +0100","YES","“Double-blind”; ”All ratings were completed by the same rater, who was blind to the study medications.” Comment: Probably done.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Dorevitch-1999","2011-10-13 05:57:29 +0100","YES","No participant left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Dorevitch-1999","2011-05-18 14:20:56 +0100","NO","The outcomes that are of interest in the review were not fully addressed (e.g. SDs are missing). Adverse effects were not fully addressed.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Dorevitch-1999","2012-04-20 10:15:26 +0100","UNKNOWN","Antipsychotic drug treatment in both study groups additionally to flunitrazepam and haloperidol. Four patients were taking additional medications including mood stabilizers and lorazepam.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Foster-1997","2011-05-18 14:21:14 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Foster-1997","2011-05-18 14:21:14 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Foster-1997","2011-05-18 14:21:14 +0100","UNKNOWN","“Double-blind”; no further details","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Foster-1997","2011-05-18 14:21:19 +0100","YES","“Double-blind”. “All raters were unaware of the specific medication received by the patient.”  Raters were trained by the first author of the trial, and “periodic calibration training sessions were conducted to control for rater drift. Initial training was continued until raters agreed on item scores at least 90% of the time.”","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Foster-1997","2011-10-13 05:57:34 +0100","YES","No participant left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Foster-1997","2011-10-08 15:21:20 +0100","YES","The outcomes that are of interest in the review have been reported in the pre-specific way with the exception of adverse effects, which were not fully addressed.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Foster-1997","2011-10-13 05:26:27 +0100","NO","Baseline-imbalance regarding the diagnosis randomised to the both different treatment groups.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Garza_x002d_Trevino-1989","2011-05-18 14:21:40 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Garza_x002d_Trevino-1989","2011-05-18 14:21:41 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Garza_x002d_Trevino-1989","2012-09-03 15:44:19 +0100","NO","Non-blind.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Garza_x002d_Trevino-1989","2012-09-03 15:44:19 +0100","NO","Non-blind.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Garza_x002d_Trevino-1989","2011-10-13 05:57:40 +0100","YES","No participant left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Garza_x002d_Trevino-1989","2012-04-20 10:17:30 +0100","UNKNOWN","The outcomes that are of interest in the review have been reported in the pre-specific way. No information regarding adverse effects available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Garza_x002d_Trevino-1989","2012-04-20 10:16:41 +0100","UNKNOWN","Baseline-imbalance concerning sex-distribution.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Gundlach-1966","2011-05-18 14:22:07 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Gundlach-1966","2011-05-18 14:22:07 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Gundlach-1966","2012-09-03 15:44:19 +0100","YES","“Double-blind”. “Placebo was matched in appearance.” “The psychiatrists, social workers and other personnel dealing with the patients did not have access the code indicating which patients were treated with diazepam and which with placebo.”","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Gundlach-1966","2011-10-13 05:27:49 +0100","UNKNOWN","“Double-blind”; no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Gundlach-1966","2012-07-26 16:17:06 +0100","NO","The attrition was high (32.7% in the benzodiazepine group and 37.5% in the placebo group).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Gundlach-1966","2011-05-18 14:22:15 +0100","NO","The outcomes that are of interest in the review were not fully addressed.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Gundlach-1966","2011-10-13 05:28:19 +0100","NO","The drop-out rate mentioned in the text differs from the drop-out rate presented in the tables of the publication.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Guz-1972","2011-05-18 14:22:34 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Guz-1972","2011-05-18 14:22:34 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Guz-1972","2011-05-18 14:22:34 +0100","UNKNOWN","“Double-blind”, no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Guz-1972","2011-05-18 14:22:34 +0100","UNKNOWN","“Double-blind”, no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Guz-1972","2011-10-13 05:57:45 +0100","YES","No participant left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Guz-1972","2011-05-18 14:22:40 +0100","NO","The outcomes that are of interest in the review were not fully addressed (e.g. SDs are missing).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Guz-1972","2011-05-18 14:22:34 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hankoff-1962","2011-05-18 14:23:21 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hankoff-1962","2011-05-18 14:23:21 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hankoff-1962","2011-05-18 14:23:23 +0100","YES","“Double-blind”; “All the drugs and their placebos were administered in pink No. 2 capsules.”","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hankoff-1962","2011-05-18 14:23:21 +0100","UNKNOWN","“Double-blind”; no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hankoff-1962","2012-07-26 16:19:37 +0100","UNKNOWN","With 23.2% the attrition was rather high. The authors provided a completer analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hankoff-1962","2011-05-18 14:23:33 +0100","NO","The outcomes that are of interest in the review were not fully addressed.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hankoff-1962","2012-04-20 10:20:24 +0100","UNKNOWN","“Certain variations in the composition of the groups emerged.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hanlon-1969","2011-05-18 14:23:51 +0100","UNKNOWN","Randomly assigned “within sex”; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hanlon-1969","2011-05-18 14:23:51 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hanlon-1969","2011-05-18 14:23:51 +0100","UNKNOWN","“Double-blind”, no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hanlon-1969","2011-05-18 14:23:51 +0100","UNKNOWN","“Double-blind”, no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hanlon-1969","2012-07-26 16:43:42 +0100","UNKNOWN","The attrition was rather low in the thioridazine plus placebo group (4.9%) but moderate in the thioridazine plus chlordiazepoxide group (16.9%), overall 11.1%. The trial authors provided a modified completer-analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hanlon-1969","2011-05-18 14:23:54 +0100","NO","The outcomes that are of interest in the review were not fully addressed (e.g. SDs are missing).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hanlon-1969","2011-05-18 14:23:51 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hanlon-1970","2011-05-18 14:24:13 +0100","UNKNOWN","Randomly assigned “within sex”; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hanlon-1970","2011-05-18 14:24:13 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hanlon-1970","2011-05-18 14:24:13 +0100","UNKNOWN","“Double-blind”, no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hanlon-1970","2011-05-18 14:24:13 +0100","UNKNOWN","“Double-blind”, no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hanlon-1970","2012-07-26 16:24:52 +0100","YES","With 7.1% the overall attrition was rather low (8.5% in the fluphenazine plus chlordiazepoxide group and 5.8% in the fluphenazine plus placebo group). The trial authors provided a modified completer-analysis, but due to the low attrition the risk of bias might be rather low.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hanlon-1970","2011-05-18 14:24:16 +0100","NO","The outcomes that are of interest in the review were not fully addressed (e.g. SDs are missing).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Hanlon-1970","2011-05-18 14:24:13 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Holden-1968","2011-05-18 14:24:33 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Holden-1968","2011-05-18 14:24:33 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Holden-1968","2011-05-18 14:24:37 +0100","YES","“Double-blind”. “The drugs were prepared in identical capsules.” Comment: Probably done.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Holden-1968","2011-05-18 14:24:33 +0100","UNKNOWN","“Double-blind”; no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Holden-1968","2012-07-26 16:25:41 +0100","YES","The attrition was rather low (8.3%). The analysis was based on completer data, but due to the low attrition the risk of bias might be rather low.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Holden-1968","2011-05-18 14:24:41 +0100","NO","The outcomes of interest for this review were not fully addressed (e.g. no raw data regarding the BPRS were provided; SDs were missing).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Holden-1968","2012-04-20 11:01:14 +0100","UNKNOWN","Cross-over study design.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Kurland-1966","2011-05-18 14:24:58 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Kurland-1966","2011-05-18 14:24:59 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Kurland-1966","2011-05-18 14:25:08 +0100","YES","“Double-blind”; “Chlordiazepoxide, imipramine, and placebo were dispensed from the pharmacy in identical opaque white capsules, so that neither patients nor research personnel knew which of theses medications was being administered.” Comment: Probably done.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Kurland-1966","2011-05-18 14:24:59 +0100","UNKNOWN","“Double-blind”, no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Kurland-1966","2012-07-26 16:44:00 +0100","UNKNOWN","The attrition was rather low in the chlordiazepoxide plus chlorpromazine group (6.8%) and moderate in the chlorpromazine plus placebo group (12.5%), overall 9.5%.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Kurland-1966","2011-05-18 14:25:16 +0100","YES","The outcomes that are of interest in the review have been reported in the pre-specific way.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Kurland-1966","2011-05-18 14:24:59 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Kutcher-1989","2011-05-18 14:25:29 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Kutcher-1989","2011-05-18 14:25:29 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Kutcher-1989","2011-05-18 14:25:33 +0100","YES","“Double blind”; tablets were “identical in appearance” Comment: Probably done.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Kutcher-1989","2011-05-18 14:25:34 +0100","YES","“Double-blind”, “Akathisia ratings were repeated blind to the patient’s medication status.” Comment: Probably done.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Kutcher-1989","2012-07-26 16:26:44 +0100","YES","One of 15 participants left the trial early (7.1%). The analysis was based on completer data, but due to the low attrition the risk of bias might be rather low.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Kutcher-1989","2011-05-18 15:29:23 +0100","NO","The outcomes that are of interest in the review were not fully addressed (akathisia scale).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Kutcher-1989","2011-10-06 15:10:15 +0100","NO","“All patients continued on their routine medications (neuroleptics and others) over the duration of the trial.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lerner-1979","2011-05-18 14:25:51 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lerner-1979","2011-05-18 14:25:51 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lerner-1979","2011-05-18 14:25:51 +0100","UNKNOWN","“Double-blind”; no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lerner-1979","2011-05-18 14:25:56 +0100","YES","“Double-blind”; clinical ratings “were performed by consensus of two physicians unaware of the treatment administered.” Comment: Probably done.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lerner-1979","2011-05-18 14:26:00 +0100","NO","The attrition was very high (50%). 4 patients were not rated “because the raters were unavailable.”","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lerner-1979","2011-05-18 14:26:02 +0100","NO","The outcomes that are of interest in the review were not fully addressed (SDs were missing).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lerner-1979","2011-05-18 14:25:51 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lingjaerde-1979","2011-05-18 14:27:35 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lingjaerde-1979","2011-05-18 14:27:35 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lingjaerde-1979","2011-05-18 14:27:39 +0100","YES","“Double-blind”. “Tablets of identical appearance.” Comment: Probably done.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lingjaerde-1979","2011-05-18 14:27:35 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lingjaerde-1979","2011-10-13 08:11:08 +0100","YES","No drop-outs; but the data for one participant regarding the BPRS and for two participants regarding the NOSIE scale were missing. Due to the low attrition the risk of bias might be rather low.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lingjaerde-1979","2011-05-18 14:27:44 +0100","NO","The outcomes that are of interest in the review were not fully addressed (e.g. the SDs were missing).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lingjaerde-1979","2012-09-03 15:44:20 +0100","UNKNOWN","Cross-over study design.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lingjaerde-1982","2011-05-18 14:28:00 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lingjaerde-1982","2011-05-18 14:28:00 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lingjaerde-1982","2011-05-18 14:28:03 +0100","YES","“Double-blind”. “Similar-looking placebo tablets” Comment: Probably done.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lingjaerde-1982","2011-05-18 14:28:00 +0100","UNKNOWN","“Double-blind”; no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lingjaerde-1982","2012-07-26 16:29:02 +0100","UNKNOWN","The attrition was moderate (12.1%). It was not clearly indicated which analysis-method was applied.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lingjaerde-1982","2011-10-13 05:41:42 +0100","NO","The outcomes that are of interest in the review were not fully addressed (incomplete numbers).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Lingjaerde-1982","2012-04-20 11:04:09 +0100","UNKNOWN","Cross-over study design.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Ma-2006","2011-05-18 14:28:33 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Ma-2006","2011-05-18 14:28:33 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Ma-2006","2011-10-07 12:48:08 +0100","UNKNOWN","Single-blind; no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Ma-2006","2011-05-18 14:28:39 +0100","YES","Single-blinded, the raters did not involved in the study. Comment: Probably done.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Ma-2006","2011-10-13 05:57:50 +0100","YES","No participant left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Ma-2006","2011-05-18 14:28:37 +0100","YES","The outcomes that are of interest in the review have been reported in the pre-specific way.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Ma-2006","2011-05-18 14:28:33 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Marneros-1979","2011-10-07 10:39:38 +0100","UNKNOWN","No randomisation mentioned in the publication, but the trial was described as “double-blind.” Thus it was implied that the study was randomised.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Marneros-1979","2011-05-18 14:28:54 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Marneros-1979","2011-05-18 14:28:54 +0100","UNKNOWN","“Double-blind”, no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Marneros-1979","2011-05-18 14:28:54 +0100","UNKNOWN","“Double-blind”, no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Marneros-1979","2011-10-13 05:44:17 +0100","UNKNOWN","Three patients in the camazepame group left the trial early (30%) and no participant in the placebo group; the total number of patients leaving the trial early is moderate (15%). The trial authors provided the individual patient data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Marneros-1979","2011-05-18 14:28:57 +0100","NO","The outcomes that are of interest in the review were not fully addressed. The adverse effects were not fully addressed.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Marneros-1979","2011-05-18 14:28:54 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Merlis-1962","2011-05-18 14:29:49 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Merlis-1962","2011-05-18 14:29:49 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Merlis-1962","2011-05-18 14:29:51 +0100","YES","“Double-blind”. “Capsules of identical appearance, identified on the ward only by code letter.” Comment: Probably done.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Merlis-1962","2011-05-18 14:29:49 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Merlis-1962","2011-10-13 05:58:04 +0100","YES","No participant left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Merlis-1962","2011-10-08 15:22:37 +0100","NO","The outcomes that are of interest in the review were not fully addressed. The trial authors did not provide raw data of the BPRS score or the MMS. Reporting on adverse effects was incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Merlis-1962","2011-10-06 18:16:50 +0100","UNKNOWN","“Neither of the two psychiatrists had had previous experience with the BPRS-Scale.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Minervini-1990","2012-04-20 11:07:29 +0100","YES","Randomly assigned; “Randomisation was balanced for each group of six patients.” No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Minervini-1990","2011-05-18 14:30:33 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Minervini-1990","2012-07-26 16:31:48 +0100","YES","“Alpidem tablets of 50 mg and placebo tablets were identical in size and appearance.” Comment: Probably done.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Minervini-1990","2011-05-18 14:30:33 +0100","UNKNOWN","“Double-blind”; no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Minervini-1990","2011-10-13 05:58:09 +0100","YES","No participant left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Minervini-1990","2011-05-18 14:30:48 +0100","YES","The outcomes have been reported in the pre-specific way.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Minervini-1990","2011-10-13 05:45:10 +0100","NO","The main focus of this investigated trial was on the anti-anxiety effect of the additional benzodiazepine medication. This can be judge as a possible risk of bias. “The patients were all chronic institutionalised schizophrenics whose anxiety was not directly linked to the schizophrenic process.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Morphy-1986","2012-04-20 11:08:41 +0100","YES","Randomly assigned; “randomization was forced so that in each consecutive group of six patients, three patients received alprazolam and three patients received placebo.” No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Morphy-1986","2011-05-18 14:31:38 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Morphy-1986","2011-05-18 14:31:38 +0100","UNKNOWN","“Double-blind”; no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Morphy-1986","2011-05-18 14:31:38 +0100","UNKNOWN","“Double-blind”; no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Morphy-1986","2012-07-26 16:32:41 +0100","YES","One alprazolam-treated patient (6.7%) was dropped from the study early in the protocol and the data were not available for the analyses. Due to the low attrition the risk of bias might be rather low.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Morphy-1986","2011-05-18 14:31:42 +0100","NO","The outcomes of interest for this review were not fully addressed (e.g. no raw data regarding the BPRS were provided). The adverse effects were not fully addressed.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Morphy-1986","2012-04-20 11:09:51 +0100","UNKNOWN","The main focus of this investigated trial was on the anti-anxiety effect of the additional benzodiazepine medication. This can be judged as a possible risk of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Nestoros-1982","2011-05-18 14:32:06 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Nestoros-1982","2011-05-18 14:32:06 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Nestoros-1982","2011-05-18 14:32:09 +0100","YES","“Double-blind”; “matched tablets”. Comment: Probably done.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Nestoros-1982","2011-05-18 14:32:07 +0100","UNKNOWN","“Double-blind”; no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Nestoros-1982","2011-10-13 05:58:13 +0100","YES","No participant left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Nestoros-1982","2011-10-08 15:23:08 +0100","NO","The outcomes that are of interest in the review were not fully addressed. The trial authors did not provide raw data of the BPRS score, the SCL-90, the SARS and the SS-PSE. Reporting on adverse effects was incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Nestoros-1982","2011-10-06 15:10:33 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Nishikawa-1982","2011-05-18 14:32:33 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Nishikawa-1982","2011-05-18 14:32:33 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Nishikawa-1982","2011-10-06 18:17:10 +0100","YES","“Double-blind”. “Drug appearance, with respect to powder colour, taste and volume, was made identical by adding a kind of stomachics.” Comment: Probably done.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Nishikawa-1982","2011-05-18 14:32:33 +0100","UNKNOWN","“Double-blind”; no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Nishikawa-1982","2011-05-18 14:32:40 +0100","YES","Regarding the outcomes of interest for this review in the case of cross-over-studies (only data up to the point of the first cross-over were used), there was no risk of bias due to the attrition: “the treatments with the first allocated drugs were performed in all patients.”","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Nishikawa-1982","2011-10-08 15:23:25 +0100","YES","The outcomes that are of interest in the review have been reported in the pre-specific way with the exception of adverse effects, which were not fully addressed.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Nishikawa-1982","2012-04-20 11:11:18 +0100","UNKNOWN","Cross-over study design.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Pujalte-1994","2011-05-18 14:33:08 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Pujalte-1994","2011-05-18 14:33:09 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Pujalte-1994","2011-05-18 14:33:11 +0100","YES","“Double-blind”; “identical appearance” of the study medication. Comment: Probably done.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Pujalte-1994","2011-05-18 14:33:13 +0100","YES","“Double-blind”. “The patients were all examined by the same independent psychiatrist, who was unaware of the medication dose.” Comment. Probably done.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Pujalte-1994","2011-10-13 05:48:22 +0100","YES","No participant left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Pujalte-1994","2011-10-08 15:23:39 +0100","YES","The outcomes that are of interest in the review have been reported in the pre-specific way. Reporting on adverse effects was incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Pujalte-1994","2011-10-06 15:10:51 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Stevens-1992","2011-05-18 14:58:32 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Stevens-1992","2011-05-18 14:58:32 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Stevens-1992","2011-05-18 14:58:37 +0100","NO","“The study design was open.”","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Stevens-1992","2011-10-13 05:49:17 +0100","YES","The mean outcome (BPRS) was rated “by raters ignorant of the patient’s current medication.” Thus, the study was single-blinded concerning the main-outcome.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Stevens-1992","2012-07-26 16:36:31 +0100","UNKNOWN","The attrition was moderate in the haloperidol plus lorazepam group (18.75%) and in the haloperidol plus placebo group (20.7%), overall 19.7%. The trial authors provided a completer-analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Stevens-1992","2011-10-08 15:23:46 +0100","NO","The outcomes that are of interest in the review were not fully addressed. The trial authors did not provide raw data of the BPRS score (only relative scores). Reporting on adverse effects was incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Stevens-1992","2011-05-18 14:58:33 +0100","UNKNOWN","“to avoid bias introduced by group differences in entry scores that did not reach significance or violated homogeneity of variance, the comparison was based on improvement calculated as the quotient of actual score/initial score.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-TREC_x002d_Rio-2003","2011-05-18 14:59:11 +0100","YES","Randomly assigned; “In Britain one collaborator used Microsoft Excel to generate even random numbers less than 10. These block sizes were than applied to a table of random numbers.” Comment: Probably done.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-TREC_x002d_Rio-2003","2011-05-18 14:58:57 +0100","YES","“To help ensure concealment of allocation, [one collaborator] produced a table of allocation sequence independent of block size. He sent these tables to a Brazilian colleague independent of the TREC team, who ensured that the correct drug was in the consecutively numbered local pack before it was sealed. These packs were constructed of cardboard, were identical, and were sealed firmly with tape, across which the consecutive number was written.” Comment: Probably done.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-TREC_x002d_Rio-2003","2011-05-18 14:59:15 +0100","NO","“Open treatment.”","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-TREC_x002d_Rio-2003","2012-04-21 07:37:27 +0100","YES","The ratings of the primary outcome were performed by raters “blind to the allocated treatment, and unknown to the clinicians looking after the patient.” Comment: Probably done. Thus, concerning the main-outcome (tranquillised or asleep by 20 minutes), the study was single-blinded.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-TREC_x002d_Rio-2003","2012-07-26 16:44:24 +0100","YES","With 2% the overall attrition was rather low (0.7% in the midazolam group and 3.3% in the haloperidol plus promethazine group). Due to the low attrition the risk of bias might be rather low.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-TREC_x002d_Rio-2003","2011-10-08 15:23:58 +0100","YES","The outcomes that are of interest in the review have been reported in the pre-specific way with the exception of adverse effects, which were not fully addressed.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-TREC_x002d_Rio-2003","2011-05-18 14:59:21 +0100","YES","The study appears to be free of other sources of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wang-2000","2011-05-18 14:59:48 +0100","UNKNOWN","randomised according to lottery; allocated by acupuncturist; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wang-2000","2011-05-18 14:59:48 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wang-2000","2011-10-13 05:51:06 +0100","NO","Non-blind.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wang-2000","2011-10-13 05:51:08 +0100","NO","Non-blind.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wang-2000","2011-10-13 05:51:11 +0100","YES","No participant left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wang-2000","2011-10-13 05:51:21 +0100","NO","The outcomes that are of interest in the review were not fully addressed. PANSS total score was assessed but no data were provided in the publication.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wang-2000","2011-05-18 14:59:48 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wang-2003","2011-05-18 15:00:18 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wang-2003","2011-05-18 15:00:18 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wang-2003","2011-05-18 15:00:22 +0100","NO","Not double-blind; no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wang-2003","2011-05-18 15:00:24 +0100","NO","Not double-blind; no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wang-2003","2011-10-13 05:51:33 +0100","YES","No participant left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wang-2003","2011-05-18 15:00:28 +0100","NO","The outcomes that are of interest in the review were not fully addressed (usable data only for 2-week treatment).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wang-2003","2011-05-18 15:00:18 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wyant-1990","2011-05-18 15:01:29 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wyant-1990","2011-05-18 15:01:29 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wyant-1990","2011-05-18 15:01:29 +0100","UNKNOWN","“Single-blind”; no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wyant-1990","2011-05-18 15:01:29 +0100","UNKNOWN","“Single-blind”; no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wyant-1990","2011-10-13 05:51:54 +0100","YES","No participant left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wyant-1990","2011-10-08 15:24:11 +0100","NO","The outcomes that are of interest in the review were not fully addressed (CGI). The adverse effects were not addressed.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Wyant-1990","2011-05-18 15:01:29 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Xuan-2007","2011-05-18 15:01:46 +0100","UNKNOWN","Randomly assigned; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Xuan-2007","2011-05-18 15:01:46 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Xuan-2007","2011-05-18 15:02:05 +0100","NO","Non-blind; no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Xuan-2007","2011-05-18 15:02:08 +0100","NO","Non-blind; no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Xuan-2007","2011-10-13 05:52:13 +0100","YES","No participant left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Xuan-2007","2011-05-18 15:01:56 +0100","NO","The outcomes that are of interest in the review were not fully addressed (TESS score).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for schizophrenia [v5.4-For publication].rm5","STD-Xuan-2007","2011-05-18 15:01:46 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Alprazolam-1992_x002c_-USA","2012-02-23 10:48:35 +0000","UNKNOWN","Randomised - participants were 'randomly allocated', however no further description of randomisation is provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Alprazolam-1992_x002c_-USA","2012-02-17 11:53:18 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Alprazolam-1992_x002c_-USA","2012-03-16 14:09:46 +0000","YES","Double-blind - the investigators who administered the scales were blind to each other's ratings, and DMM was blind to the dose and schedule of treatment. Both investigators were blind to drug assignment.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Alprazolam-1992_x002c_-USA","2012-03-09 09:10:59 +0000","UNKNOWN","Last observation carried forward used for the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Alprazolam-1992_x002c_-USA","2012-03-05 11:47:53 +0000","UNKNOWN","Use of Simpson-Angus Side Effects Profile and 'another side effects rating scale' was mentioned, but no data were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Alprazolam-1992_x002c_-USA","2012-04-27 12:46:18 +0100","NO","Rating scales: trial author JGB administered the BPRS-psychosis subscale, SANS, SAPS and trial author DMM administered the full-scale version of the BPRS - ratings were not a self-report or completed by an independent rater.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-1993_x002c_-CA","2012-02-23 10:49:32 +0000","UNKNOWN","Randomised, however no further description of randomisation is provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-1993_x002c_-CA","2012-02-23 10:50:10 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-1993_x002c_-CA","2012-02-23 10:56:21 +0000","YES","Double blind - the evaluating psychiatrist was blind to treatment allocations and determined the exact dose of medication. The haloperidol group also received procyclidine with each dose - in order to maintain double blind conditions, the clonazepam group received procyclidine placebo with each dose.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-1993_x002c_-CA","2012-12-03 04:41:22 +0000","YES","Follow-up: 88%* - last observation carried forward.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-1993_x002c_-CA","2012-02-27 15:47:49 +0000","UNKNOWN","None detected.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-1993_x002c_-CA","2012-04-27 12:47:44 +0100","NO","Rating scales: completed by a study psychiatrist, not an independent rater.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-1999_x002c_-CHN","2012-03-01 13:14:48 +0000","UNKNOWN","Randomised - no further description.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-1999_x002c_-CHN","2012-03-01 13:15:06 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-1999_x002c_-CHN","2012-03-01 13:15:12 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-1999_x002c_-CHN","2012-03-01 13:10:23 +0000","UNKNOWN","Follow-up: not clear.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-1999_x002c_-CHN","2012-03-01 13:15:29 +0000","UNKNOWN","Unclear. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-1999_x002c_-CHN","2012-04-27 12:53:18 +0100","UNKNOWN","Rating scales: it is unclear who administered the rating scales used.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2003_x002c_-CHN","2012-03-23 11:40:53 +0000","UNKNOWN","Randomised - using random numbers.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2003_x002c_-CHN","2012-03-23 11:40:40 +0000","UNKNOWN","Allocation concealment was not mentioned.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2003_x002c_-CHN","2012-03-23 11:40:46 +0000","UNKNOWN","Blinding was not mentioned.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2003_x002c_-CHN","2012-12-03 04:42:22 +0000","YES","No missing outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2003_x002c_-CHN","2012-03-23 12:15:26 +0000","NO","Although the study protocol is not available, the published report appears to have reported all the pre-specified outcomes.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2003_x002c_-CHN","2012-04-27 12:56:30 +0100","UNKNOWN","Rating scales: it is unclear who administered the rating scales used.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2004_x002c_-CHN","2012-03-08 09:25:16 +0000","YES","Randomised - according to ‘random number and hospital admission order’. No further description on how these numbers were used to ensure randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2004_x002c_-CHN","2012-03-06 15:06:20 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2004_x002c_-CHN","2012-03-06 15:06:32 +0000","NO","Non-blind - open label.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2004_x002c_-CHN","2012-03-09 12:53:25 +0000","NO","Total of 11 participants dropped-out of the study (one from the combination group; one from the clozapine group and nine from the haloperidol group) - reasons not addressed/ reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2004_x002c_-CHN","2012-03-08 09:25:55 +0000","YES","All measured outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2004_x002c_-CHN","2012-04-27 12:56:14 +0100","UNKNOWN","Rating scales: it is unclear who administered the rating scales used.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2005_x002c_-CHN","2012-03-06 09:46:30 +0000","UNKNOWN","Randomised - no further description.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2005_x002c_-CHN","2012-03-06 09:46:45 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2005_x002c_-CHN","2012-03-06 09:47:05 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2005_x002c_-CHN","2012-03-09 12:52:31 +0000","UNKNOWN","Follow-up: not clear.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2005_x002c_-CHN","2012-05-03 15:01:51 +0100","NO","TESS scale was used, but assessment score was not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2005_x002c_-CHN","2012-04-27 12:50:07 +0100","UNKNOWN","Rating scales: not stated who administered rating scales.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2007_x002c_-CHN","2012-03-23 10:58:08 +0000","YES","Randomised - using random numbers.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2007_x002c_-CHN","2012-03-06 12:30:29 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2007_x002c_-CHN","2012-03-06 12:30:33 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2007_x002c_-CHN","2012-03-06 12:31:32 +0000","UNKNOWN","Follow-up: unclear. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2007_x002c_-CHN","2012-03-23 10:59:21 +0000","NO","TESS scale was used, but assessment score was not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Clonazepam-2007_x002c_-CHN","2012-04-27 12:56:39 +0100","UNKNOWN","Rating scales: it is unclear who administered the rating scales used.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Diazepam-1979_x002c_-IL","2012-02-28 16:37:21 +0000","UNKNOWN","Randomised - no further description. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Diazepam-1979_x002c_-IL","2012-02-28 15:39:49 +0000","NO","Alternation between medications (high-dose and moderately high-dose haloperidol).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Diazepam-1979_x002c_-IL","2012-03-16 14:00:47 +0000","UNKNOWN","Observer blind - it is not made clear how trial authors remained blinded to alternation and decrease of haloperidol dosage.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Diazepam-1979_x002c_-IL","2012-12-03 04:42:53 +0000","NO","Follow-up: 50%*.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Diazepam-1979_x002c_-IL","2012-02-28 15:43:55 +0000","UNKNOWN","None detected.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Diazepam-1979_x002c_-IL","2012-04-27 12:51:36 +0100","UNKNOWN","Rating scales: BPRS and CGI were performed by consensus of two physicians (trial authors EL and YL), who were 'unaware of the treatment administered'.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Flunitrazepam-1999_x002c_-IL","2012-02-23 15:38:13 +0000","YES","Randomised - assigned using a table of random numbers.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Flunitrazepam-1999_x002c_-IL","2012-02-23 16:12:25 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Flunitrazepam-1999_x002c_-IL","2012-02-23 16:16:11 +0000","UNKNOWN","All ratings were compiled by author NK, who was blind to the study medications - it is unclear whether dose adjustment was blind.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Flunitrazepam-1999_x002c_-IL","2012-02-27 15:10:52 +0000","YES","Follow-up: 100%.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Flunitrazepam-1999_x002c_-IL","2012-03-16 14:34:28 +0000","UNKNOWN","None detected.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Flunitrazepam-1999_x002c_-IL","2012-04-27 12:48:32 +0100","NO","Rating scales: trial co-author administered rating scales used for the study, not an independent rater.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1989_x002c_-USA","2012-02-27 17:31:17 +0000","UNKNOWN","Randomised, however no further description of randomisation is provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1989_x002c_-USA","2012-02-27 17:34:30 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1989_x002c_-USA","2013-03-18 12:07:13 +0000","NO","Non-blind, the authors state 'we considered that the degree of tranquillisation desired when treating agitated patients is easily ascertained, and thus we did not use control subjects and a blind design'.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1989_x002c_-USA","2012-02-27 17:19:37 +0000","UNKNOWN","Follow-up: not clear.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1989_x002c_-USA","2012-02-27 17:34:43 +0000","UNKNOWN","None detected.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1989_x002c_-USA","2012-04-27 12:49:34 +0100","UNKNOWN","Rating scales: it is unclear who administered the rating scales used to determine baseline agitation ratings.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1991_x002c_-USA","2012-03-01 14:46:35 +0000","UNKNOWN","Randomised - no further description.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1991_x002c_-USA","2012-02-02 15:55:48 +0000","UNKNOWN","Not stated how participants were allocated - 'potential patients for this study were identified when emergency parenteral medication for behavioural control was required'.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1991_x002c_-USA","2012-03-16 13:58:59 +0000","UNKNOWN","Single - parenteral medication was prepared in advance by a member of the research staff who had no direct clinical responsibility for the patient; raters were blind to the treatment condition received by the patient.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1991_x002c_-USA","2012-03-09 12:52:52 +0000","NO","Many participants were unavailable for all ratings - 'the number of patients available for rating after baseline declined in both treatment groups because some were discharged or transferred from the locked intensive care unit'.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1991_x002c_-USA","2012-03-01 16:45:18 +0000","UNKNOWN","Complete data not available - standard deviations not available for most reported outcomes. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1991_x002c_-USA","2012-04-27 12:53:45 +0100","UNKNOWN","Rating scales: OAS ratings were obtained by staff nurses at time of parenteral injection at baseline and then at 2 and 24 hours. BPRS ratings were obtained by 'trained study psychiatrists' at the time of baseline and at 24 and 48 hours. Side effects and sedation were assessed at baseline, 1 hour and 24 hours by clinicians who did not participate in evaluating therapeutic results. It is unclear the extent to which rating scales were administered by an independent rater.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1997_x002c_-USA","2012-03-12 11:29:33 +0000","YES","Randomised - eligible participants were sequentially assigned using a computer-generated table of random numbers to receive one of three therapies.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1997_x002c_-USA","2012-03-12 11:29:43 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1997_x002c_-USA","2012-03-12 11:35:12 +0000","YES","Double-blind - 'the emergency department psychiatrist who treated and rated the patient remained blinded to the identity of the patient's medication throughout treatment.' ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1997_x002c_-USA","2012-03-12 11:40:06 +0000","UNKNOWN","The data from two participants were excluded from the efficacy analysis, as it was later determined that they had both received proscribed antipsychotic medication shortly before entering the study. It is unclear which group(s) these two participants were excluded from.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1997_x002c_-USA","2012-05-17 05:36:57 +0100","UNKNOWN","Sample numbers were not clear as the authors stated that data were only collected if the patient was awake.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1997_x002c_-USA","2012-04-27 12:46:57 +0100","UNKNOWN","Rating scales: administered by the emergency department psychiatrist, who also treated the patient, but 'remained blinded to the identity of the patient's medication throughout'.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1997a_x002c_-USA","2012-02-27 15:06:33 +0000","UNKNOWN","Randomised, however no further description of randomisation is provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1997a_x002c_-USA","2012-02-27 15:06:40 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1997a_x002c_-USA","2012-02-27 15:07:53 +0000","UNKNOWN","Double blind, however no further description of blinding is provided.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1997a_x002c_-USA","2013-03-12 14:33:49 +0000","UNKNOWN","Follow-up: not clear.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1997a_x002c_-USA","2012-02-27 15:50:30 +0000","UNKNOWN","None detected. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1997a_x002c_-USA","2012-04-27 12:48:56 +0100","UNKNOWN","Rating scales: symptom ratings were conducted by one of four raters (psychiatry residents or psychiatric nursing staff). Raters were trained by trial author SF.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1998_x002c_-SA","2012-03-02 09:25:52 +0000","UNKNOWN","Randomised - no further description.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1998_x002c_-SA","2012-03-02 09:25:55 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1998_x002c_-SA","2012-03-02 09:48:54 +0000","UNKNOWN","Double blind - no further description. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1998_x002c_-SA","2012-03-02 16:07:04 +0000","YES","Follow-up: 100%.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1998_x002c_-SA","2012-03-02 09:49:20 +0000","UNKNOWN","None detected. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1998_x002c_-SA","2012-04-27 12:54:02 +0100","UNKNOWN","Rating scales: it is unclear who administered the rating scales used.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1998_x002c_-USA","2012-02-17 15:20:55 +0000","YES","Randomised - 'Participants were assigned to treatment according to computer-generated forced randomisation blocks of four.'","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1998_x002c_-USA","2012-02-17 15:21:03 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1998_x002c_-USA","2012-02-21 09:15:59 +0000","UNKNOWN","Double blind - 'a member of nursing staff, independent of patient assessment or treatment, prepared and coded each injection of equal volume'.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1998_x002c_-USA","2012-02-27 15:11:07 +0000","YES","Follow-up: 100%.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1998_x002c_-USA","2012-04-27 13:44:09 +0100","NO","Authors changed criteria for 'improvement' on the Visual Analogue Scale post-study, after analysis had taken place. Full data not reported (i.e. continuous data for rating scales). Ratings for CGI; VAS and OAS taken at 30, 60, 120 and 180 minutes - but no data were reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-1998_x002c_-USA","2012-04-27 12:47:31 +0100","UNKNOWN","Rating scales: administered by an investigator - it is unclear whether this investigator was an independent rater.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-2001_x002c_-RO-_x0026_-USA","2012-03-01 11:32:37 +0000","UNKNOWN","Randomised - no further description.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-2001_x002c_-RO-_x0026_-USA","2012-03-23 11:35:21 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-2001_x002c_-RO-_x0026_-USA","2012-03-01 11:35:53 +0000","UNKNOWN","Double blind - no further description. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-2001_x002c_-RO-_x0026_-USA","2012-03-01 11:50:39 +0000","YES","ITT analysis used (last observation carried forward).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-2001_x002c_-RO-_x0026_-USA","2012-03-01 11:40:30 +0000","UNKNOWN","The number of participants who reported outcomes from rating scales at baseline and post-baseline differ to total number of participants randomised into each treatment arm. It is stated that not all participants completed both a baseline and post-baseline rating scale.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-2001_x002c_-RO-_x0026_-USA","2013-01-25 05:48:58 +0000","NO","Rating scales: Agitation-Calmness Evaluation Scale (ACES) - single-item 9-point scale, developed by trial sponsors Eli Lilly and Company (results not included). It is unclear who administered the rating scales used.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-2004_x002c_-IN","2012-08-21 10:26:12 +0100","YES","Randomised - 'pragmatic' - computer-generated random numbers list in varying sized blocks of less than 10.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-2004_x002c_-IN","2012-03-08 14:38:25 +0000","YES","A table of allocation sequence independent of block size was produced. Tables were then sent to a colleague independent of the TREC team who ensured that the correct drug was in the consecutively numbered local pack before it was sealed. These packs were constructed of cardboard, were identical, and were sealed firmly with tape, across which the consecutive number was written.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-2004_x002c_-IN","2012-03-30 14:41:17 +0100","NO","Non-blinded - open label: blind until point of treatment assignment, which minimised selection bias.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-2004_x002c_-IN","2012-09-26 10:03:09 +0100","UNKNOWN","Missing data were reported at each level of assessment (total n = 12).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-2004_x002c_-IN","2012-03-08 15:31:25 +0000","YES","All measured outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-2004_x002c_-IN","2012-04-27 12:54:57 +0100","UNKNOWN","Rating scales: study coordinators, who were blind to interventions given, undertook ratings.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-2006_x002c_-USA","2012-03-02 15:10:17 +0000","UNKNOWN","Randomised - no further description.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-2006_x002c_-USA","2012-03-02 15:15:35 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-2006_x002c_-USA","2012-03-02 15:14:03 +0000","UNKNOWN","Double blind - no further description.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-2006_x002c_-USA","2013-03-01 10:41:24 +0000","NO","Follow-up: 94%.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-2006_x002c_-USA","2012-03-02 15:21:59 +0000","UNKNOWN","None detected.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Lorazepam-2006_x002c_-USA","2012-04-27 12:55:16 +0100","UNKNOWN","Rating scales: administered by trained study evaluators, with inter-rater reliability assessed by independent evaluation of a video-taped model.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Midazolam-2003_x002c_-BZ","2012-08-21 10:26:35 +0100","YES","Randomised - 'pragmatic' - Microsoft Excel used to generate even random numbers less than 10 - blocks were then applied to a table of random numbers.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Midazolam-2003_x002c_-BZ","2012-03-08 14:38:16 +0000","YES","A table of allocation sequence independent of block size was produced. Tables were then sent to a colleague independent of the TREC team who ensured that the correct drug was in the consecutively numbered local pack before it was sealed. These packs were constructed of cardboard, were identical, and were sealed firmly with tape, across which the consecutive number was written.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Midazolam-2003_x002c_-BZ","2012-03-30 14:40:59 +0100","NO","Non-blinded - open label: blind until point of treatment assignment, which minimised selection bias.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Midazolam-2003_x002c_-BZ","2012-03-08 12:41:41 +0000","YES","Follow-up: 99% ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Midazolam-2003_x002c_-BZ","2012-03-08 12:41:43 +0000","YES","All measured outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Midazolam-2003_x002c_-BZ","2012-04-27 12:54:36 +0100","YES","Rating scales: raters were nurses/ doctors not involved in the management of the emergency - unknown to treating clinicians.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Midazolam-2006_x002c_-AU","2012-02-28 13:03:15 +0000","YES","Random number tables and serially numbered study packs.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Midazolam-2006_x002c_-AU","2012-02-28 13:04:37 +0000","YES","Codes from study packs remained with the pharmacy until the study was complete.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Midazolam-2006_x002c_-AU","2012-09-26 10:03:09 +0100","NO","Two participants from each treatment group (n = 4) were treated on an 'unblinded' basis - no further details are given.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Midazolam-2006_x002c_-AU","2012-02-28 13:23:50 +0000","NO","The data from 17 study packs were lost, so only data from the remaining 153 participants were used. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Midazolam-2006_x002c_-AU","2012-02-28 13:24:10 +0000","NO","It is not made clear how 17 of the study packs were lost.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Midazolam-2006_x002c_-AU","2012-04-27 12:51:17 +0100","UNKNOWN","The patient's medical records were reviewed to identify adverse effects.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Midazolam-2011_x002c_-BZ","2012-03-07 11:01:08 +0000","YES","Randomised - allocation by 'permuted blocks - each drug regimen was assigned to blocks of five patients and distributed in this order: olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. This assignment was repeated until the total number of subjects (150) was reached.'","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Midazolam-2011_x002c_-BZ","2012-03-07 11:58:17 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Midazolam-2011_x002c_-BZ","2012-03-07 12:03:42 +0000","YES","Double blind - study medications were packaged in identical colour-coded boxes. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Midazolam-2011_x002c_-BZ","2012-03-12 16:12:05 +0000","UNKNOWN","Follow-up: unclear - 'participants were withdrawn from the trial if they requested discontinuation; if the physician suggested withdrawal due to an adverse event; if the treatment showed lack of efficacy; or if the participants were uncooperative.' It is not stated whether this occurred in the study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Midazolam-2011_x002c_-BZ","2012-03-26 12:10:07 +0100","UNKNOWN","Adverse effects/events - unclear whether participants in treatment arms olanzapine and ziprasidone experienced adverse effects/ events. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Benzodiazepines for psychosis-induced aggression or agitation [v8.0-For publication].rm5","STD-Midazolam-2011_x002c_-BZ","2012-03-07 12:16:49 +0000","UNKNOWN","Rating scales were repeatedly administered by two raters - it is unclear whether these were independent raters. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Benzodiazepines for neuroleptic-induced tardive dyskinesia [v10.0-For publication].rm5","STD-Csernansky-1988","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/A-B/Benzodiazepines for neuroleptic-induced tardive dyskinesia [v10.0-For publication].rm5","STD-Weber-1983","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/A-B/Benzodiazepines for neuroleptic-induced tardive dyskinesia [v10.0-For publication].rm5","STD-Xiang-1997","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/A-B/Benperidol for schizophrenia [v7.0-For publication].rm5","STD-Eckmann-1984","2009-05-22 17:37:38 +0100","UNKNOWN","Quote: ""randomisiert zugeteilt"" (English: randomly allocated). No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/A-B/Benperidol for schizophrenia [v7.0-For publication].rm5","STD-Eckmann-1984","2009-05-22 17:37:41 +0100","UNKNOWN","Method not described.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/A-B/Benperidol for schizophrenia [v7.0-For publication].rm5","STD-Eckmann-1984","2009-05-22 17:38:12 +0100","UNKNOWN","Quote: ""double-blind study"". Oral liquid medication. No further details.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Benperidol for schizophrenia [v7.0-For publication].rm5","STD-Eckmann-1984","2009-05-22 17:58:01 +0100","UNKNOWN","The report does not indicate whether participants left the study early. It only says that there were 40 participants. It could be that these were only the study completers.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Benperidol for schizophrenia [v7.0-For publication].rm5","STD-Eckmann-1984","2009-05-22 17:47:13 +0100","NO","The study is only available as an unpublished manuscript. Means and standard deviations of rating scale results were often not indicated.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/A-B/Benperidol for schizophrenia [v7.0-For publication].rm5","STD-Eckmann-1984","2009-05-22 17:47:49 +0100","YES","There was no other clear source of bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle_x002f_Metformin-2008","2013-07-30 17:07:14 +0100","YES","Randomised (computer-generated table in blocks of 8).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle_x002f_Metformin-2008","2013-07-30 17:07:14 +0100","YES","Randomization conduced independently of investigators by a research pharmacist.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle_x002f_Metformin-2008","","UNKNOWN","","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle_x002f_Metformin-2008","","UNKNOWN","","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle_x002f_Metformin-2008","","UNKNOWN","","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle_x002f_Metformin-2008","","UNKNOWN","","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle_x002f_Metformin-2008","","UNKNOWN","","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2003","2013-07-30 17:07:14 +0100","UNKNOWN","Randomised (no further details).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2003","2013-07-30 17:07:14 +0100","UNKNOWN","Randomised (no further details).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2003","","UNKNOWN","","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2003","","UNKNOWN","","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2003","","UNKNOWN","","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2003","","UNKNOWN","","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2003","","UNKNOWN","","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2005a","2013-07-30 17:07:14 +0100","UNKNOWN","Randomised (no further details).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2005a","2013-07-30 17:07:14 +0100","NO","Randomised (no further details).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2005a","","UNKNOWN","","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2005a","","UNKNOWN","","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2005a","","UNKNOWN","","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2005a","","UNKNOWN","","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2005a","","UNKNOWN","","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2005b","2013-07-30 17:07:14 +0100","UNKNOWN","Randomised (no further details).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2005b","2013-07-30 17:07:14 +0100","NO","Randomised (no further details).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2005b","","UNKNOWN","","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2005b","","UNKNOWN","","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2005b","","UNKNOWN","","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2005b","","UNKNOWN","","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2005b","","UNKNOWN","","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006a","2013-07-30 17:07:14 +0100","UNKNOWN","Randomised (no further details).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006a","2013-07-30 17:07:14 +0100","UNKNOWN","Randomised (no further details).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006a","","UNKNOWN","","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006a","","UNKNOWN","","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006a","","UNKNOWN","","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006a","","UNKNOWN","","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006a","","UNKNOWN","","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006b","2013-07-30 17:07:14 +0100","UNKNOWN","Randomised (no further details).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006b","2013-07-30 17:07:14 +0100","UNKNOWN","Randomised (no further details).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006b","","UNKNOWN","","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006b","","UNKNOWN","","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006b","","UNKNOWN","","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006b","","UNKNOWN","","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006b","","UNKNOWN","","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006c","2013-07-30 17:07:14 +0100","YES","Randomised (computer-generated blocks of 4 random numbers).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006c","2013-07-30 17:07:14 +0100","UNKNOWN","Unclear.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006c","","UNKNOWN","","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006c","","UNKNOWN","","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006c","","UNKNOWN","","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006c","","UNKNOWN","","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006c","","UNKNOWN","","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006d","2013-07-30 17:07:14 +0100","UNKNOWN","Randomised (no further details).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006d","2013-07-30 17:07:14 +0100","UNKNOWN","Randomised (no further details).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006d","","UNKNOWN","","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006d","","UNKNOWN","","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006d","","UNKNOWN","","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006d","","UNKNOWN","","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006d","","UNKNOWN","","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006e","2013-07-30 17:07:14 +0100","UNKNOWN","Randomised (no further details).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006e","2013-07-30 17:07:14 +0100","UNKNOWN","Randomised (no further details).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006e","","UNKNOWN","","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006e","","UNKNOWN","","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006e","","UNKNOWN","","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006e","","UNKNOWN","","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2006e","","UNKNOWN","","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007a","2013-07-30 17:07:14 +0100","UNKNOWN","Randomised (no further details).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007a","2013-07-30 17:07:14 +0100","UNKNOWN","Randomised (no further details).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007a","","UNKNOWN","","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007a","","UNKNOWN","","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007a","","UNKNOWN","","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007a","","UNKNOWN","","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007a","","UNKNOWN","","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007b","2013-07-30 17:07:14 +0100","UNKNOWN","Randomised (no further details).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007b","2013-07-30 17:07:14 +0100","UNKNOWN","Randomised (no further details).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007b","","UNKNOWN","","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007b","","UNKNOWN","","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007b","","UNKNOWN","","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007b","","UNKNOWN","","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007b","","UNKNOWN","","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007c","2013-07-30 17:07:14 +0100","UNKNOWN","Randomised (no further details).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007c","2013-07-30 17:07:14 +0100","UNKNOWN","Randomised (no further details).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007c","","UNKNOWN","","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007c","","UNKNOWN","","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007c","","UNKNOWN","","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007c","","UNKNOWN","","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Behavioural interventions for reducing weight gain in schizophrenia [v1.0-For publication].rm5","STD-Lifestyle-2007c","","UNKNOWN","","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Ayurvedic medicine for schizophrenia [v5.0-For publication].rm5","STD-Mahal-1976","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/A-B/Ayurvedic medicine for schizophrenia [v5.0-For publication].rm5","STD-Ramu-1992","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/A-B/Ayurvedic medicine for schizophrenia [v5.0-For publication].rm5","STD-Ramu-1999","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Aranda-2007","2013-10-09 15:28:03 +0100","UNKNOWN","Not described in the report.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Aranda-2007","2013-10-09 15:28:04 +0100","UNKNOWN","Not described in the report.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Aranda-2007","2013-10-09 15:28:04 +0100","NO","This was an open-label study.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Aranda-2007","2013-10-09 15:28:07 +0100","NO","This was an open-label study.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Aranda-2007","2013-10-09 15:28:08 +0100","UNKNOWN","The issue was partially addressed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Aranda-2007","2013-10-09 15:28:09 +0100","UNKNOWN","The study reported multiple outcomes but partially (e.g. no SD for mean end point PANSS score).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Aranda-2007","2013-10-09 15:28:10 +0100","UNKNOWN","This seems to be a well-designed study, but not all results are reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-DelBello-2008","2013-10-09 15:28:47 +0100","UNKNOWN","Details of sequence generation were not mentioned. Because the study population had a narrow age range, the different groups were comparable.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-DelBello-2008","2013-10-09 15:28:48 +0100","UNKNOWN","Not described in the report.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-DelBello-2008","2013-10-09 15:28:49 +0100","NO","This was an open-label trial.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-DelBello-2008","2013-10-09 15:28:53 +0100","NO","This was an open-label trial.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-DelBello-2008","2013-10-09 15:28:58 +0100","YES","Authors reported the number of participants who had to discontinue with the study. The primary aim of the study was to test the tolerability of high- vs low-dose regimens of ziprasidone. Measuring efficacy was not the primary aim of this study. Adverse effects experienced by study participants were reported in sufficient detail.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-DelBello-2008","2013-10-09 15:28:58 +0100","YES","Authors reported many outcome measures, especially adverse effects, in sufficient detail.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-DelBello-2008","2013-10-09 15:29:02 +0100","UNKNOWN","Study participants were selected from 10 centres and met fairly broad inclusion criteria. This could lead to inconclusive evidence of a particular condition. Authors reported findings separately for bipolar disorder and schizophrenia/schizoaffective disorder.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Findling-2008","2013-10-09 15:29:44 +0100","YES","The randomisation was stratified and was done separately across three geographical categories.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Findling-2008","2013-10-09 15:29:45 +0100","UNKNOWN","Not described in the report.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Findling-2008","2013-10-09 15:29:46 +0100","YES","This was a double-blind placebo-controlled trial.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Findling-2008","2013-10-09 15:29:46 +0100","YES","This was a double-blind placebo-controlled trial.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Findling-2008","2013-10-09 15:29:49 +0100","YES","Incomplete outcome data were analysed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Findling-2008","2013-10-09 15:29:50 +0100","YES","Authors reported multiple outcome measures.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Findling-2008","2013-10-09 15:29:50 +0100","YES","This was a well-designed RCT.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Haas-2009","2013-10-09 15:30:34 +0100","YES","Computer-generated schedule.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Haas-2009","2013-10-09 15:30:34 +0100","UNKNOWN","Not described in the report.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Haas-2009","2013-10-09 15:30:35 +0100","YES","This was a double-blind study.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Haas-2009","2013-10-09 15:30:39 +0100","YES","This was a double-blind study.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Haas-2009","2013-10-09 15:30:39 +0100","YES","Incomplete data were accounted for by using intention-to-treat analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Haas-2009","2013-10-09 15:30:40 +0100","YES","Supplementary data in journal website gives details of many of the outcome measures.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Haas-2009","2013-10-09 15:30:41 +0100","YES","This was a well-designed RCT.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Huo-2007","2013-10-09 15:31:14 +0100","UNKNOWN","Not described in the report.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Huo-2007","2013-10-09 15:31:15 +0100","UNKNOWN","Not described in the report.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Huo-2007","2013-10-09 15:31:16 +0100","UNKNOWN","Not described in the report.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Huo-2007","2013-10-09 15:31:17 +0100","UNKNOWN","Not described in the report.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Huo-2007","2013-10-09 15:31:18 +0100","YES","The results accounted for all participants who started the study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Huo-2007","2013-10-09 15:31:18 +0100","YES","The study reported all outcomes it had intended to report at the beginning in the study.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Huo-2007","2013-10-09 15:31:22 +0100","YES","Although the study was in Chinese, we found after translation that reporting was done in a clear and easy to understand way.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Jensen-2008","2013-10-09 15:32:04 +0100","YES","Random sequence was performed using computer-generated randomisation schedule.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Jensen-2008","2013-10-09 15:32:04 +0100","UNKNOWN","Not described in the report.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Jensen-2008","2013-10-09 15:32:05 +0100","NO","This was an open-label study.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Jensen-2008","2013-10-09 15:32:06 +0100","NO","This was an open-label study.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Jensen-2008","2013-10-09 15:32:09 +0100","YES","Intention-to-treat analysis was done using the 'last observation carried forward' method for participants who did not complete the study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Jensen-2008","2013-10-09 15:32:10 +0100","YES","Outcomes were reported in sufficient detail.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Jensen-2008","2013-10-09 15:32:10 +0100","NO","As the study was open label, it was probably subjected to interviewer's bias or researcher's bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kryzhanovskaya-2009","2013-10-09 15:32:53 +0100","UNKNOWN","Not described in the report.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kryzhanovskaya-2009","2013-10-09 15:32:55 +0100","UNKNOWN","Not described in the report.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kryzhanovskaya-2009","2013-10-09 15:32:56 +0100","YES","There was a double-blind phase followed by an open-label phase.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kryzhanovskaya-2009","2013-10-09 15:32:57 +0100","YES","There was a double-blind phase followed by an open-label phase.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kryzhanovskaya-2009","2013-10-09 15:32:59 +0100","YES","Appropriate intention-to-treat analysis was performed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kryzhanovskaya-2009","2013-10-09 15:33:00 +0100","YES","Multiple outcome measures were reported in detail.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kryzhanovskaya-2009","2013-10-09 15:33:01 +0100","YES","This was a well-designed RCT.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kumra-1996","2013-10-09 15:33:39 +0100","YES","Randomisation sequence was done using table of random numbers.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kumra-1996","2013-10-09 15:33:40 +0100","UNKNOWN","Not described in the report.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kumra-1996","2013-10-09 15:33:41 +0100","YES","Raters, treating physicians and nurses were blind to the study status.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kumra-1996","2013-10-09 15:33:42 +0100","YES","Raters were blind to the study status.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kumra-1996","2013-10-09 15:33:45 +0100","YES","Appropriate intention-to-treat analysis was conducted.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kumra-1996","2013-10-09 15:33:46 +0100","NO","Positive findings were highlighted in the 'Results' section. The high incidence of neutropenia in the clozapine group has been reported but not adequately discussed.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kumra-1996","2013-10-09 15:33:48 +0100","NO","This is a well-designed RCT for treatment-resistant schizophrenia in childhood, but the total number of children recruited is small.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kumra-2008","2013-10-09 15:34:37 +0100","YES","Computer-generated randomisation sequence was followed.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kumra-2008","2013-10-09 15:34:38 +0100","YES","Adequate attempts were made to maintain allocation concealment (using numbered containers, centralised telephone, etc).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kumra-2008","2013-10-09 15:34:40 +0100","YES","This was a double-blind RCT, but the details of blinding and how it was maintained had not been described in the report.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kumra-2008","2013-10-09 15:34:41 +0100","YES","This was a double-blind RCT, but the details of blinding and how it was maintained had not been described in the report.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kumra-2008","2013-10-09 15:34:42 +0100","YES","Appropriate intention-to-treat analysis was performed. All participants who had been randomly assigned were included. in the analysis","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kumra-2008","2013-10-09 15:34:46 +0100","YES","Adequate numbers of outcome measures were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Kumra-2008","2013-10-09 15:34:47 +0100","YES","This was a well-designed RCT.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Sikich-2004","2013-10-09 15:35:25 +0100","YES","Computer-generated randomisation schedule, stratified by age.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Sikich-2004","2013-10-09 15:35:29 +0100","UNKNOWN","Not adequately described in the study.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Sikich-2004","2013-10-09 15:35:30 +0100","YES","This was a double-blind study, but the details of how blinding was maintained were not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Sikich-2004","2013-10-09 15:35:31 +0100","UNKNOWN","As the study compares drugs from different classes, the raters could have made a guess about young people being on haloperidol.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Sikich-2004","2013-10-09 15:35:32 +0100","YES","All participants who were randomly assigned were included in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Sikich-2004","2013-10-09 15:35:34 +0100","UNKNOWN","Many different outcome measures were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Sikich-2004","2013-10-09 15:35:35 +0100","NO","The analysis did not use correction techniques to take into account multiple analyses on a small sample. The authors justified this by stating that these analyses were 'exploratory' rather than 'inferential'.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Sikich-2008","2013-10-09 15:36:04 +0100","UNKNOWN","Not adequately described in the study.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Sikich-2008","2013-10-09 15:36:05 +0100","UNKNOWN","Not adequately described in the study.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Sikich-2008","2013-10-09 15:36:06 +0100","YES","This was a double-blind study, and blinding was maintained even after discontinuation of one of the arms (olanzapine group) of the study for ethical reasons.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Sikich-2008","2013-10-09 15:36:07 +0100","YES","Blinding was maintained even after discontinuation of one of the arms of the study.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Sikich-2008","2013-10-09 15:36:07 +0100","YES","All participants who had been randomly assigned were included in the final analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Sikich-2008","2013-10-09 15:36:10 +0100","YES","Multiple outcome measures are described in sufficient detail.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Sikich-2008","2013-10-09 15:36:11 +0100","YES","This is a well-designed RCT.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Swadi-2010","2013-10-09 15:36:43 +0100","YES","Stratified randomisation process, four strata.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Swadi-2010","2013-10-09 15:36:44 +0100","UNKNOWN","Not adequately described in the study.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Swadi-2010","2013-10-09 15:36:46 +0100","NO","Open-label study with blind midpoint and end point assessments.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Swadi-2010","2013-10-09 15:36:47 +0100","NO","Open-label study with blind midpoint and end point assessments.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Swadi-2010","2013-10-09 15:36:48 +0100","YES","Clear flow chart for study patients accounting for all participants.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Swadi-2010","2013-10-09 15:36:51 +0100","YES","No source of selective reporting could be found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Swadi-2010","2013-10-09 15:36:52 +0100","UNKNOWN","Lack of double blindness puts the study under suspicion of further biases.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Xiong-2004","2013-10-09 15:37:12 +0100","UNKNOWN","Not adequately described in the study.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Xiong-2004","2013-10-09 15:37:13 +0100","UNKNOWN","Not adequately described in the study.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Xiong-2004","2013-10-09 15:37:14 +0100","NO","Blinding not clear.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Xiong-2004","2013-10-09 15:37:18 +0100","NO","Blinding not clear.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Xiong-2004","2013-10-09 15:37:19 +0100","YES","Data reported for all participants.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Xiong-2004","2013-10-09 15:37:20 +0100","YES","The study reported all of the outcomes that it had intended to report at the start of study.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for psychosis in adolescents [v2.0-For publication].rm5","STD-Xiong-2004","2013-10-09 15:37:21 +0100","UNKNOWN","Unclear blinding makes this study prone to further biases.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for people with both schizophrenia and depression [v7.0-For publication].rm5","STD-Alfredsson-1984","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for people with both schizophrenia and depression [v7.0-For publication].rm5","STD-Emsley-2003","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/A-B/Atypical antipsychotics for people with both schizophrenia and depression [v7.0-For publication].rm5","STD-Jasovic-1997","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/A-B/Art therapy for schizophrenia or schizophrenia-like illnesses [v5.0-For publication].rm5","STD-Green-1987","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/A-B/Art therapy for schizophrenia or schizophrenia-like illnesses [v5.0-For publication].rm5","STD-Richardson-2002","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/A-B/Aripiprazole versus typical antipsychotic drugs for schizophrenia [v7.0-For publication].rm5","STD-Carson-2000","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus typical antipsychotic drugs for schizophrenia [v7.0-For publication].rm5","STD-Csernansky-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus typical antipsychotic drugs for schizophrenia [v7.0-For publication].rm5","STD-Daniel-2000","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus typical antipsychotic drugs for schizophrenia [v7.0-For publication].rm5","STD-Daniel-2004","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus typical antipsychotic drugs for schizophrenia [v7.0-For publication].rm5","STD-Kane-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus typical antipsychotic drugs for schizophrenia [v7.0-For publication].rm5","STD-Kujawa-2002","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus typical antipsychotic drugs for schizophrenia [v7.0-For publication].rm5","STD-McCue-2006","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus typical antipsychotic drugs for schizophrenia [v7.0-For publication].rm5","STD-Oren-2005","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus typical antipsychotic drugs for schizophrenia [v7.0-For publication].rm5","STD-Wang-2005","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Adson-2003","2009-08-11 10:43:52 +0100","UNKNOWN","Unclear","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Adson-2003","2011-03-23 13:44:52 +0000","NO","Randomised, method not described","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Adson-2003","2011-03-23 13:47:45 +0000","UNKNOWN","Double blind, no further details","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Adson-2003","2011-06-26 23:32:08 +0100","NO","Very high drop-out rate with limited details.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Adson-2003","2010-03-16 10:42:36 +0000","UNKNOWN","Unclear","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Adson-2003","2010-03-16 10:42:39 +0000","UNKNOWN","Unclear","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Carson-2000-a","2009-08-11 10:45:39 +0100","UNKNOWN","Unclear","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Carson-2000-a","2011-03-23 13:48:07 +0000","NO","Randomised, method not described","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Carson-2000-a","2011-03-23 13:48:25 +0000","UNKNOWN","Double blind, method of blinding not described","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Carson-2000-a","2010-02-26 13:36:44 +0000","NO","High attrition rate","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Carson-2000-a","2010-03-16 10:42:43 +0000","UNKNOWN","Unclear","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Carson-2000-a","2010-03-16 10:42:45 +0000","UNKNOWN","Unclear","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Carson-2002-b","2010-03-16 10:30:08 +0000","UNKNOWN","Unclear","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Carson-2002-b","2011-03-23 13:48:58 +0000","NO","Randomised, method not described","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Carson-2002-b","2011-03-23 13:49:07 +0000","UNKNOWN","Double, no further details","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Carson-2002-b","2010-02-26 13:37:08 +0000","NO","High attrition rate, reasons for discontinuation given","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Carson-2002-b","2010-03-16 10:30:21 +0000","UNKNOWN","Unclear ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Carson-2002-b","2010-03-16 10:30:29 +0000","UNKNOWN","Unclear","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Csernansky-2003","2010-03-16 10:30:36 +0000","UNKNOWN","Unclear","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Csernansky-2003","2011-03-23 13:49:21 +0000","NO","Randomised, method not described","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Csernansky-2003","2011-03-23 13:49:30 +0000","UNKNOWN","Double, no further details","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Csernansky-2003","2010-02-26 13:37:15 +0000","NO","High attrition rate","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Csernansky-2003","2010-03-16 10:30:39 +0000","UNKNOWN","Unclear","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Csernansky-2003","2010-03-16 10:30:42 +0000","UNKNOWN","Unclear","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Daniel-2000","2010-03-16 10:30:52 +0000","UNKNOWN","Unclear","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Daniel-2000","2011-06-24 03:15:27 +0100","NO","Randomised, method not described","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Daniel-2000","2010-03-16 10:30:55 +0000","UNKNOWN","Unclear","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Daniel-2000","2010-03-16 10:30:59 +0000","UNKNOWN","Unclear","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Daniel-2000","2010-03-16 10:31:01 +0000","UNKNOWN","Unclear","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Daniel-2000","2010-03-16 10:31:05 +0000","UNKNOWN","Unclear","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Daniel-2004","2010-03-16 10:31:10 +0000","UNKNOWN","Unclear","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Daniel-2004","2011-06-24 03:16:29 +0100","NO","Randomised, method not described","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Daniel-2004","2011-03-23 13:50:01 +0000","UNKNOWN","Double, no further details","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Daniel-2004","2011-06-24 03:16:35 +0100","YES","95% completed study, details of loss of follow-up given","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Daniel-2004","2010-03-16 10:40:39 +0000","YES","appears to be","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Daniel-2004","2010-03-16 10:31:18 +0000","UNKNOWN","Unclear","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Marcus-2005","2010-03-16 10:40:45 +0000","UNKNOWN","Unclear","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Marcus-2005","2011-06-24 03:17:11 +0100","NO","Randomised, method not described","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Marcus-2005","2011-06-24 03:17:16 +0100","UNKNOWN","Double, no further details","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Marcus-2005","2010-02-26 13:37:31 +0000","NO","High attrition rate","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Marcus-2005","2010-03-16 10:40:55 +0000","YES","Appears to be","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Marcus-2005","2010-03-16 10:40:48 +0000","UNKNOWN","Unclear","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Oren-2005","2011-06-24 03:18:24 +0100","YES","Via a central call-in system","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Oren-2005","2011-06-24 03:18:29 +0100","YES","Randomised, permuted block randomisation","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Oren-2005","2011-06-24 03:18:38 +0100","UNKNOWN","Double, no further details","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Oren-2005","2009-08-19 15:55:58 +0100","YES","96.6% competed study","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Oren-2005","2011-06-24 03:18:41 +0100","UNKNOWN","Secondary efficacy measures were not reported in details","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Oren-2005","2010-03-16 10:41:01 +0000","UNKNOWN","Unclear","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2003","2010-03-16 10:41:16 +0000","UNKNOWN","Unclear","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2003","2011-06-24 03:19:48 +0100","NO","Randomised, method not described","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2003","2011-06-24 03:19:51 +0100","UNKNOWN","Double, no further details","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2003","2010-02-26 13:37:40 +0000","NO","High attrition rate","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2003","2010-03-16 10:41:18 +0000","UNKNOWN","Unclear","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus placebo for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2003","2010-03-16 10:41:20 +0000","UNKNOWN","Unclear","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-An-2008","2013-06-25 17:38:21 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-An-2008","2013-06-25 17:38:21 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-An-2008","2013-06-25 17:38:21 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-An-2008","2013-06-25 17:38:21 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-An-2008","2013-09-28 16:17:51 +0100","YES","There was no drop-out.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-An-2008","2013-06-25 17:38:30 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available. Data on use of use of alprazolam, propranolol and anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-An-2008","2013-06-25 17:38:32 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Bai-2007","2013-06-25 17:39:14 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Bai-2007","2013-06-25 17:39:14 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Bai-2007","2013-06-25 17:39:14 +0100","UNKNOWN","Unclear.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Bai-2007","2013-06-25 17:39:14 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Bai-2007","2013-06-25 17:39:17 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Bai-2007","2013-09-28 16:09:31 +0100","NO","The outcome did not include missing data. There were no data on other adverse events. This procedure may have missed important data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Bai-2007","2013-06-25 17:39:21 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Bai-2009","2013-06-25 17:40:19 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Bai-2009","2013-06-25 17:40:19 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Bai-2009","2013-06-25 17:40:19 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Bai-2009","2013-06-25 17:40:19 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Bai-2009","2013-06-25 17:40:22 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Bai-2009","2013-06-25 17:40:24 +0100","NO","Data on liver function, insomnia, somnolence, and sleep disorder were missing or incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Bai-2009","2013-06-25 17:40:26 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ban-2008","2013-06-25 17:41:03 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ban-2008","2013-06-25 17:41:03 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ban-2008","2013-06-25 17:41:03 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ban-2008","2013-06-25 17:41:03 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ban-2008","2013-06-25 17:41:05 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ban-2008","2013-06-25 17:41:07 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available. Data on renal function, EEG, use of benzodiazepines and other medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ban-2008","2013-06-25 17:41:09 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chan-2007","2013-06-25 17:41:58 +0100","YES","Random, permuted block randomisation stratified by centre.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chan-2007","2013-06-25 17:41:31 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chan-2007","2013-06-25 17:42:22 +0100","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in adverse effects. This can be a problem for blinding.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chan-2007","2013-06-25 17:42:24 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chan-2007","2013-09-28 17:18:54 +0100","UNKNOWN","Total number of drop-out = 25%.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chan-2007","2013-06-25 17:42:11 +0100","NO","Only adverse events with an incidence of at least 5% in any treatment group were reported, therefore important side effects may have been missed by this procedure.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chan-2007","2013-06-25 17:42:13 +0100","NO","The study was industry sponsored by the manufacturer of aripiprazole.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chang-2007","2013-06-25 17:42:48 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chang-2007","2013-06-25 17:42:48 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chang-2007","2013-06-25 17:42:48 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chang-2007","2013-06-25 17:42:48 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chang-2007","2013-06-25 17:42:52 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chang-2007","2013-06-25 17:42:55 +0100","NO","Data on TESS total score, blood glucose, liver function, use of benzodiazepines and other medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chang-2007","2013-06-25 17:42:56 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2006","2013-06-25 17:43:21 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2006","2013-06-25 17:43:21 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2006","2013-06-25 17:43:21 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2006","2013-06-25 17:43:21 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2006","2013-06-25 17:43:23 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2006","2013-06-25 17:43:24 +0100","YES","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2006","2013-06-25 17:43:27 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2007a","2013-06-25 17:43:49 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2007a","2013-06-25 17:43:49 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2007a","2013-06-25 17:43:49 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2007a","2013-06-25 17:43:49 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2007a","2013-06-25 17:43:54 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2007a","2013-06-25 17:43:51 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available. Data on blood routine, blood glucose, electrolyte, ECG, liver function were deficient.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2007a","2013-06-25 17:43:53 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2008a","2013-06-25 17:44:30 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2008a","2013-06-25 17:44:30 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2008a","2013-06-25 17:44:30 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2008a","2013-06-25 17:44:30 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2008a","2013-06-25 17:44:33 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2008a","2013-06-25 17:44:35 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available. Data on blood routine, blood glucose, use of propranolol, benzodiazepines and other medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2008a","2013-06-25 17:44:37 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2009","2013-06-25 17:45:04 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2009","2013-06-25 17:45:04 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2009","2013-06-25 17:45:25 +0100","NO","Open label.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2009","2013-06-25 17:45:30 +0100","NO","Open label.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2009","2013-06-25 17:45:10 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2009","2013-06-25 17:45:12 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available. Data on EEG, ECG, urine routine, use of benzhexol, benzodiazepine and propranolol were also missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2009","2013-06-25 17:45:14 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2009a","2013-06-25 23:14:44 +0100","YES","Randomised, random number table.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2009a","2013-06-25 23:14:37 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2009a","2013-06-25 23:14:38 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2009a","2013-06-25 23:14:50 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2009a","2013-06-25 23:15:02 +0100","YES","4% patients were lost to follow up (2/40 vs 1/35), and there were no difference between the two groups.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2009a","2013-06-25 23:15:13 +0100","NO","Data on TESS total score, blood routine, ECG, EEG, use of benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2009a","2013-06-25 23:15:18 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2010","2013-06-25 23:16:46 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2010","2013-09-28 16:36:09 +0100","UNKNOWN","Low riskUnclear riskHigh risk","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2010","2013-06-25 23:16:32 +0100","UNKNOWN","Low riskUnclear riskHigh risk","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2010","2013-06-25 23:16:28 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2010","2013-06-25 23:16:23 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2010","2013-06-25 23:16:19 +0100","NO","Data on TESS total score, nausea/vomiting, dizziness, blurred vision, insomnia, constipation, excitement, use of benzodiazepines and other medicines was missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2010","2013-06-25 23:16:11 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2010a","2013-06-25 17:45:51 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2010a","2013-06-25 17:45:52 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2010a","2013-06-25 17:45:52 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2010a","2013-06-25 17:45:52 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2010a","2013-06-25 17:46:04 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2010a","2013-06-25 17:46:06 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available. Data on use of benzodiazepines and other medicines was missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Chen-2010a","2013-06-25 17:46:08 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Cheng-2009","2013-06-25 17:46:31 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Cheng-2009","2013-06-25 17:46:31 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Cheng-2009","2013-06-25 17:46:31 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Cheng-2009","2013-06-25 17:46:31 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Cheng-2009","2013-06-25 17:46:37 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Cheng-2009","2013-06-25 17:46:35 +0100","NO","Data on CGI-GI score, TESS score, blood routine, urine routine, use of benzodiazepines and anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Cheng-2009","2013-06-25 17:46:33 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-CuiMeng-2008","2013-06-25 17:47:10 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-CuiMeng-2008","2013-06-25 17:47:10 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-CuiMeng-2008","2013-06-25 17:47:10 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-CuiMeng-2008","2013-06-25 17:47:11 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-CuiMeng-2008","2013-06-25 17:47:13 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-CuiMeng-2008","2013-06-25 17:47:15 +0100","NO","Although GQL I - 74 was used to assess Quality of life, no data on score were available. Data on anxiety, somnolence, ECG, use of benzodiazepines and other medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-CuiMeng-2008","2013-06-25 17:47:17 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Dai-2005","2013-06-25 17:47:45 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Dai-2005","2013-06-25 17:47:45 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Dai-2005","2013-06-25 17:47:45 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Dai-2005","2013-06-25 17:47:45 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Dai-2005","2013-06-25 17:47:48 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Dai-2005","2013-06-25 17:48:55 +0100","NO","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Dai-2005","2013-06-25 17:47:51 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Dai-2006","2013-06-25 23:17:52 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Dai-2006","2013-06-25 23:17:56 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Dai-2006","2013-06-25 23:17:56 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Dai-2006","2013-06-25 23:18:04 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Dai-2006","2013-06-25 23:18:28 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Dai-2006","2013-06-25 23:18:25 +0100","YES","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Dai-2006","2013-06-25 23:18:22 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Deng-2008","2013-06-25 17:50:53 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Deng-2008","2013-06-25 17:50:53 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Deng-2008","2013-06-25 17:50:53 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Deng-2008","2013-06-25 17:50:53 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Deng-2008","2013-10-24 15:33:31 +0100","YES","There were no incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Deng-2008","2013-06-25 17:50:57 +0100","NO","Data on TESS total score, ESRS score, blood and urine routines, liver function, use of benzodiazepine and anticholinergic medicine were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Deng-2008","2013-06-25 17:50:55 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Deng-2008a","2013-06-25 17:52:43 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Deng-2008a","2013-06-25 17:52:43 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Deng-2008a","2013-06-25 17:52:43 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Deng-2008a","2013-06-25 17:52:43 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Deng-2008a","2013-10-24 15:33:23 +0100","YES","There were no incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Deng-2008a","2013-06-25 17:52:46 +0100","NO","Data on TESS total score, use of benzhexol, benzodiazepine and propranolol were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Deng-2008a","2013-06-25 17:52:49 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ding-2007","2013-06-25 17:53:16 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ding-2007","2013-06-25 17:53:16 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ding-2007","2013-06-25 17:53:16 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ding-2007","2013-06-25 17:53:16 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ding-2007","2013-06-25 17:53:16 +0100","UNKNOWN","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ding-2007","2013-06-25 17:53:16 +0100","UNKNOWN","Data on BPRS score, TESS score, ECG, EEG were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ding-2007","2013-06-25 17:53:16 +0100","UNKNOWN","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Du-2006","2013-06-25 17:54:29 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Du-2006","2013-06-25 17:54:29 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Du-2006","2013-06-25 17:54:29 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Du-2006","2013-06-25 17:54:29 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Du-2006","2013-10-24 15:34:01 +0100","UNKNOWN","Unclear if there were incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Du-2006","2013-06-25 17:54:32 +0100","YES","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Du-2006","2013-06-25 17:54:33 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fan-2005","2013-06-25 17:55:04 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fan-2005","2013-06-25 17:55:04 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fan-2005","2013-06-25 17:55:04 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fan-2005","2013-06-25 17:55:04 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fan-2005","2013-06-25 17:55:14 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fan-2005","2013-09-28 16:53:45 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available. Data on laboratory tests (urine routine, glucose, liver function) and ECG were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fan-2005","2013-06-25 17:55:18 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fan-2010","2013-06-25 17:55:42 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fan-2010","2013-06-25 17:55:42 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fan-2010","2013-06-25 17:55:42 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fan-2010","2013-06-25 17:55:42 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fan-2010","2013-06-25 17:55:44 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fan-2010","2013-10-24 15:34:24 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available. Data on blood and urine routine, renal function, use of benzodiazepines and other medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fan-2010","2013-06-25 17:55:49 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Feng-2006","2013-06-25 17:56:28 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Feng-2006","2013-06-25 17:56:28 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Feng-2006","2013-06-25 17:56:28 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Feng-2006","2013-06-25 17:56:30 +0100","YES","Blinded evaluation.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Feng-2006","2013-10-24 15:34:45 +0100","YES","The total proportion of loss to follow-up was 13.4% (5/35 vs. 4/34), there no no difference between the two groups.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Feng-2006","2013-06-25 17:56:44 +0100","NO","Data on TESS total score, blood and urine routine, ECG, liver function and other adverse effects were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Feng-2006","2013-06-25 17:56:50 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fleischhacker-2008","2013-06-25 17:57:46 +0100","YES","1:1 randomisation using SARA (System for Automated Randomisation). QTONE an automated touch tone system was used. Statistical blocking factor of four was used and stratified by the study centre.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fleischhacker-2008","2013-06-25 17:57:36 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fleischhacker-2008","2013-06-25 17:57:36 +0100","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in adverse effects. This can be a problem for blinding.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fleischhacker-2008","2013-06-25 17:57:55 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fleischhacker-2008","2013-06-25 17:57:59 +0100","NO","Leaving the study early data within the first six weeks were 25% overall, but data on reason for dropout were not available. The LOCF method was used to account for people leaving the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fleischhacker-2008","2013-06-25 17:58:01 +0100","NO","Data for the predefined primary outcome are available but secondary outcome measures like 30% PANSS total reduction are missing in the six-week interim report. Treatment emergent adverse events are hardly addressed in the interim report.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fleischhacker-2008","2013-09-28 17:04:54 +0100","NO","The study was industry sponsored by the manufacturer of aripiprazole.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fu-2009","2013-06-25 17:59:10 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fu-2009","2013-06-25 17:59:11 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fu-2009","2013-06-25 17:59:11 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fu-2009","2013-06-25 17:59:11 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fu-2009","2013-06-25 17:59:18 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fu-2009","2013-06-25 17:59:20 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available. Data on blood routine, liver function were incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Fu-2009","2013-06-25 17:59:24 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ge-2009","2013-06-25 17:59:47 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ge-2009","2013-06-25 17:59:47 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ge-2009","2013-06-25 17:59:47 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ge-2009","2013-06-25 17:59:47 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ge-2009","2013-06-25 17:59:47 +0100","UNKNOWN","Unclear if there were incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ge-2009","2013-06-25 18:00:00 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ge-2009","2013-06-25 18:00:03 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ge-2010","2013-06-25 18:01:13 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ge-2010","2013-06-25 18:01:13 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ge-2010","2013-06-25 18:01:13 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ge-2010","2013-06-25 18:01:13 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ge-2010","2013-06-25 18:01:16 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ge-2010","2013-06-25 18:01:18 +0100","NO","Data on TESS total score and use of benzodiazepine were missing. Data on weight-average endpoint level were incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ge-2010","2013-06-25 18:01:20 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Guo-2006","2013-06-25 18:01:47 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Guo-2006","2013-06-25 18:01:47 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Guo-2006","2013-06-25 18:01:47 +0100","UNKNOWN","Double.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Guo-2006","2013-06-25 18:01:47 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Guo-2006","2013-06-25 18:01:50 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Guo-2006","2013-06-25 18:01:52 +0100","NO","Data on TESS total score, blood and urine routine, use of benzodiazepines and anticholinergic medicine were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Guo-2006","2013-06-25 18:01:57 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2005","2013-06-25 18:02:23 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2005","2013-06-25 18:02:23 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2005","2013-06-25 18:02:23 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2005","2013-06-25 18:02:23 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2005","2013-06-25 18:02:25 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2005","2013-06-25 18:02:27 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available. Data on laboratory tests (urine routine, hepatorenal function) and EEG were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2005","2013-06-25 18:02:29 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2007","2013-06-25 18:02:48 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2007","2013-06-25 18:02:48 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2007","2013-06-25 18:02:48 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2007","2013-06-25 18:02:49 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2007","2013-09-28 17:12:34 +0100","YES","One patient was lost to follow-up in olanzapine.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2007","2013-06-25 18:02:55 +0100","NO","Data on CGI score, TESS total score, blood and urine routine, use of benzodiazepines anticholinergic medicine were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2007","2013-06-25 18:02:57 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2007a","2013-06-25 18:03:18 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2007a","2013-06-25 18:03:18 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2007a","2013-06-25 18:03:19 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2007a","2013-06-25 18:03:19 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2007a","2013-09-28 17:14:12 +0100","YES","There were no incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2007a","2013-06-25 18:04:40 +0100","NO","Data of TESS total score, blood routine, blood glucose, electrolyte, ECG, liver function was missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Han-2007a","2013-06-25 18:04:43 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Hu-2010","2013-06-25 18:05:27 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Hu-2010","2013-06-25 18:05:27 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Hu-2010","2013-06-25 18:05:27 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Hu-2010","2013-06-25 18:05:27 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Hu-2010","2013-06-25 18:05:29 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Hu-2010","2013-10-24 15:35:44 +0100","NO","Data on TESS total score, blood routine, ECG, liver function, blood glucose, use of benzodiazepines and other medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Hu-2010","2013-06-25 18:05:34 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Huang-2009","2013-06-25 18:05:55 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Huang-2009","2013-06-25 18:05:55 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Huang-2009","2013-06-25 18:05:55 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Huang-2009","2013-06-25 18:05:55 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Huang-2009","2013-06-25 18:05:57 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Huang-2009","2013-06-25 18:05:59 +0100","NO","Although PANSS was used to assess mental state, no end data on score were available. Data on use of benzodiazepines and other medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Huang-2009","2013-06-25 18:06:04 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ji-2007","2013-06-25 18:06:23 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ji-2007","2013-06-25 18:06:23 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ji-2007","2013-06-25 18:06:23 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ji-2007","2013-06-25 18:06:23 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ji-2007","2013-06-25 18:06:28 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ji-2007","2013-06-25 18:06:31 +0100","NO","Data on TESS total score, blood and urine routine, use of benzodiazepines and anticholinergic medicine were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ji-2007","2013-06-25 18:06:34 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Jiang-2009","2013-06-25 18:07:03 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Jiang-2009","2013-06-25 18:07:03 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Jiang-2009","2013-06-25 18:07:03 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Jiang-2009","2013-06-25 18:07:03 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Jiang-2009","2013-06-25 18:07:05 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Jiang-2009","2013-06-25 18:07:07 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available. Data on use of use of alprazolam, propranolol and anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Jiang-2009","2013-06-25 18:07:09 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Jie-2008","2013-09-28 17:22:09 +0100","YES","Randomised, random number table.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Jie-2008","2013-06-25 18:07:37 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Jie-2008","2013-06-25 18:07:37 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Jie-2008","2013-06-25 18:07:40 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Jie-2008","2013-06-25 18:07:46 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Jie-2008","2013-06-25 18:07:51 +0100","NO","Data on somnolence, weight gain, EGG abnormal, salivation, dry mouth, blurred vision (no data) and use of alprazolam, propranolol, anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Jie-2008","2013-06-25 18:08:23 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kane-2009","2013-06-25 18:09:07 +0100","UNKNOWN","No information available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kane-2009","2013-06-25 18:09:08 +0100","UNKNOWN","No further information.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kane-2009","2013-06-25 18:09:10 +0100","UNKNOWN","No details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kane-2009","2013-06-25 18:09:24 +0100","YES","Objective outcomes such as death are unlikely to have been much affected by lack of blinding.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kane-2009","2013-06-25 18:09:26 +0100","YES","LOCF.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kane-2009","2013-06-25 18:09:29 +0100","NO","Only adverse events with an incidence of more than 5% were reported. This procedure may have missed important adverse events.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kane-2009","2013-06-25 18:09:31 +0100","NO","Drug company involvement.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kern-2006","2013-06-25 18:09:54 +0100","UNKNOWN","No information available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kern-2006","2013-06-25 18:10:10 +0100","NO","Open label.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kern-2006","2013-06-25 18:10:12 +0100","NO","Open label.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kern-2006","2013-06-25 18:09:55 +0100","UNKNOWN","No details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kern-2006","2013-06-25 18:09:56 +0100","UNKNOWN","LOCF.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kern-2006","2013-06-25 18:10:22 +0100","NO","Few neuro-cognitive tests were mentioned but usable data was not available from them.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kern-2006","2013-06-25 18:10:23 +0100","NO","Drug company involvement.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kerwin-2007","2013-06-25 18:10:57 +0100","UNKNOWN","No information available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kerwin-2007","2013-06-25 18:11:08 +0100","NO","Open label.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kerwin-2007","2013-06-25 18:11:10 +0100","NO","Open label.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kerwin-2007","2013-06-25 18:11:00 +0100","UNKNOWN","No details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kerwin-2007","2013-06-25 18:11:12 +0100","YES","LOCF.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kerwin-2007","2013-06-25 18:11:37 +0100","NO","Only adverse events with an incidence of more than 5% were reported. This may have missed important adverse events. Some scales used had no reported usable data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kerwin-2007","2013-06-25 18:11:39 +0100","NO","Drug company involvement.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kinon-2004","2013-06-25 18:12:06 +0100","UNKNOWN","Random 1:1, no further details available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kinon-2004","2013-06-25 18:12:06 +0100","UNKNOWN","Not defined.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kinon-2004","2013-06-25 18:12:06 +0100","UNKNOWN","Double. No further details available.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kinon-2004","2013-06-25 18:12:15 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kinon-2004","2013-06-25 18:12:07 +0100","UNKNOWN","The LOCF method was used to account for people leaving the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kinon-2004","2013-06-25 18:12:19 +0100","NO","Adverse effects were reported if ≥ 1% of patients in either treatment group experienced them. Some scales used had no data published.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kinon-2004","2013-06-25 18:12:25 +0100","NO","The study was industry sponsored by the manufacturer of olanzapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kuang-2006","2013-06-25 18:12:47 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kuang-2006","2013-06-25 18:12:47 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kuang-2006","2013-06-25 18:12:47 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kuang-2006","2013-06-25 18:12:48 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kuang-2006","2013-09-28 17:35:20 +0100","YES","The total rate of loss to follow-up was 5% (6/120), and there was no difference between the two group. All 6 participants dropped out because of economic issue.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kuang-2006","2013-09-28 17:35:28 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available. Data on laboratory tests (blood routine, urine routine, glucose, liver function, etc) were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Kuang-2006","2013-06-25 18:12:53 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2006","2013-06-25 18:13:16 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2006","2013-06-25 18:13:16 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2006","2013-06-25 18:13:16 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2006","2013-06-25 18:13:16 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2006","2013-09-29 10:09:40 +0100","YES","The total proportion of loss to follow-up was 4.29% (1/35: 2/35), and there was no difference between the two groups. All because of adverse effects.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2006","2013-06-25 18:13:24 +0100","NO","Data on TESS total score, use of benzodiazepines, benzhexol, and propranolol were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2006","2013-06-25 18:13:25 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2006a","2013-06-25 18:13:47 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2006a","2013-06-25 18:13:47 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2006a","2013-06-25 18:13:47 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2006a","2013-06-25 18:13:47 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2006a","2013-10-24 15:36:47 +0100","YES","The total proportion of loss to follow-up was 2.63% (1/38: 0/38), all because of adverse effects.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2006a","2013-06-25 18:13:52 +0100","NO","Data on TESS total score, blood and urine routine, renal function, use of benzodiazepines and anticholinergic drug were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2006a","2013-06-25 18:13:54 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007","2013-06-25 18:14:21 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007","2013-06-25 18:14:22 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007","2013-06-25 18:14:22 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007","2013-06-25 18:14:22 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007","2013-06-25 18:14:26 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007","2013-06-25 18:14:28 +0100","NO","Although ESRS was used to assess adverse effects, no data on score were available. Data on laboratory tests(blood routine, urine routine, glucose, liver function, etc) and ECG were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007","2013-06-25 18:14:30 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007a","2013-06-25 18:14:54 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007a","2013-06-25 18:14:54 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007a","2013-06-25 18:14:54 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007a","2013-06-25 18:14:54 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007a","2013-06-25 18:14:56 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007a","2013-06-25 18:14:58 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available. Data on use of anti-psychotic drugs and benzhexol were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007a","2013-06-25 18:15:04 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007b","2013-06-25 18:15:26 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007b","2013-06-25 18:15:29 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007b","2013-06-25 18:15:30 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007b","2013-06-25 18:15:30 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007b","2013-06-25 18:15:40 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007b","2013-06-25 18:15:42 +0100","NO","Data onTESS total score, menstrual disorder, lactation, weight gain, EEG, ECG, blood routine, urine routine, hepatorenal function, use of benzhexol, benzodiazepine and propranolol were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007b","2013-06-25 18:15:44 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007c","2013-06-25 18:16:06 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007c","2013-06-25 18:16:09 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007c","2013-06-25 18:16:09 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007c","2013-06-25 18:16:13 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007c","2013-06-25 18:16:14 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007c","2013-06-25 18:16:16 +0100","NO","Data on TESS score, blood routine, EEG, weight, and use of alprazolam, propranolol and anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007c","2013-06-25 18:16:18 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007d","2013-06-25 18:16:47 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007d","2013-06-25 18:16:47 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007d","2013-06-25 18:16:47 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007d","2013-06-25 18:16:47 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007d","2013-06-25 18:16:53 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007d","2013-06-25 18:16:56 +0100","NO","Data on TESS total score, blood routine, renal function, PRL, use of benzodiazepines and anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2007d","2013-06-25 18:16:57 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009","2013-06-25 18:17:30 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009","2013-06-25 18:17:30 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009","2013-06-25 18:17:31 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009","2013-06-25 18:17:33 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009","2013-06-25 18:17:36 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009","2013-06-25 18:17:38 +0100","NO","Data on laboratory tests (urine routine, hepatorenal function), use of alprazolam, propranolol and anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009","2013-06-25 18:17:39 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009a","2013-06-25 18:18:08 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009a","2013-06-25 18:18:08 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009a","2013-06-25 18:18:08 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009a","2013-06-25 18:18:11 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009a","2013-06-25 18:18:14 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009a","2013-06-25 18:18:16 +0100","NO","Data on TESS total score, use of benzodiazepines and other medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009a","2013-06-25 18:18:18 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009b","2013-06-25 18:18:47 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009b","2013-06-25 18:18:47 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009b","2013-06-25 18:18:47 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009b","2013-06-25 18:18:48 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009b","2013-06-25 18:18:52 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009b","2013-06-25 18:18:57 +0100","NO","Data on TESS total score, ECG, EPS, use of benzodiazepines, propranolol, and anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-2009b","2013-06-25 18:18:55 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lian-2008","2013-06-25 18:20:08 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lian-2008","2013-06-25 18:20:08 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lian-2008","2013-06-25 18:20:08 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lian-2008","2013-06-25 18:20:08 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lian-2008","2013-09-29 10:22:51 +0100","YES","There were no incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lian-2008","2013-06-25 18:20:16 +0100","NO","Data of TESS total score, blood and urine routines, liver function, ECG were missing (no data) .","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lian-2008","2013-06-25 18:20:19 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liang-2008","2013-06-25 18:20:52 +0100","UNKNOWN","Randomisation, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liang-2008","2013-06-25 18:20:52 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liang-2008","2013-06-25 18:20:55 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liang-2008","2013-06-25 18:20:56 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liang-2008","2013-09-29 10:24:03 +0100","NO","Six patients were lost to follow-up in risperidone group, four because of adverse effect, two due to progressive disease. No patient was lost to follow-up in aripiprazole group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liang-2008","2013-06-25 18:21:05 +0100","NO","Data on TESS total score, blood routine, use of benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liang-2008","2013-06-25 18:21:07 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2006","2013-06-25 18:21:38 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2006","2013-06-25 18:21:38 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2006","2013-06-25 18:21:38 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2006","2013-06-25 18:21:38 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2006","2013-06-25 18:21:41 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2006","2013-06-25 18:21:43 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available. Data on use of benzodiazepines, benzhexol and propranolol medication were also missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2006","2013-06-25 18:21:45 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2006a","2013-06-25 18:22:34 +0100","UNKNOWN","Randomised, no further details..","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2006a","2013-06-25 18:22:34 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2006a","2013-06-25 18:22:34 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2006a","2013-06-25 18:22:35 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2006a","2013-06-25 18:22:36 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2006a","2013-06-25 18:22:43 +0100","NO","Data on TESS score,blood routine, blood glucose, use of benzodiazepines, benzhexol were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2006a","2013-06-25 18:22:45 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2007","2013-06-25 18:23:10 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2007","2013-06-25 18:23:10 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2007","2013-06-25 18:23:10 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2007","2013-06-25 18:23:10 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2007","2013-06-25 18:23:16 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2007","2013-06-25 18:23:20 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available. Data on use of benzodiazepines, benzhexol and propranolol medication were also missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2007","2013-06-25 18:23:18 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008","2013-06-25 18:23:53 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008","2013-06-25 18:23:53 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008","2013-06-25 18:23:53 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008","2013-06-25 18:23:53 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008","2013-06-25 18:24:02 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008","2013-06-25 18:23:59 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available. Data on use of benzodiazepines, benzhexol and propranolol medication were also missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008","2013-06-25 18:23:57 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008a","2013-06-25 18:24:36 +0100","UNKNOWN","Randomised, no further details..","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008a","2013-06-25 18:24:36 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008a","2013-06-25 18:24:36 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008a","2013-06-25 18:24:37 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008a","2013-06-25 18:24:41 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008a","2013-06-25 18:24:44 +0100","NO","Data on TESS score, blood routine, liver function, use of alprazolam, propranolol and anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008a","2013-06-25 18:24:46 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008b","2013-06-25 18:25:11 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008b","2013-06-25 18:25:11 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008b","2013-06-25 18:25:11 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008b","2013-06-25 18:25:14 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008b","2013-09-29 10:29:49 +0100","UNKNOWN","Unclear if there were incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008b","2013-06-25 18:25:19 +0100","NO","Data on blood and urine routines, ECG, hepatorenal function, use of benzodiazepines and other medicine were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008b","2013-06-25 18:25:17 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008c","2013-06-25 18:25:43 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008c","2013-06-25 18:25:43 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008c","2013-06-25 18:25:43 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008c","2013-06-25 18:25:44 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008c","2013-06-25 18:25:50 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008c","2013-06-25 18:25:52 +0100","NO","Data on TESS total score, hepatorenal function, use of benzodiazepines, propranolol and other medicine were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008c","2013-06-25 18:25:54 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008d","2013-06-25 18:26:35 +0100","YES","Randomised, lottery.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008d","2013-06-25 18:26:30 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008d","2013-06-25 18:26:30 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008d","2013-06-25 18:26:31 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008d","2013-06-25 18:26:37 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008d","2013-06-25 18:26:40 +0100","NO","Data on TESS total score were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2008d","2013-06-25 18:26:42 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009","2013-06-25 18:27:16 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009","2013-06-25 18:27:16 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009","2013-06-25 18:27:16 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009","2013-06-25 18:27:16 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009","2013-09-29 10:35:51 +0100","UNKNOWN","Unclear if there were incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009","2013-06-25 18:27:20 +0100","NO","Data on TESS total score, use of benzodiazepines and benzhexol were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009","2013-06-25 18:27:22 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009a","2013-06-25 18:27:44 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009a","2013-06-25 18:27:44 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009a","2013-06-25 18:27:44 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009a","2013-09-29 10:36:55 +0100","UNKNOWN","Unclear if outcome were assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009a","2013-06-25 18:27:49 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009a","2013-06-25 18:27:52 +0100","NO","Data on TESS total score, use of benzodiazepines and other medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009a","2013-06-25 18:27:54 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009b","2013-06-25 18:28:19 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009b","2013-06-25 18:28:19 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009b","2013-06-25 18:28:19 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009b","2013-06-25 18:28:19 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009b","2013-06-25 18:28:23 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009b","2013-06-25 18:28:28 +0100","NO","The data on TESS total score, headache, insomnia, somnolence, nausea/vomiting, weight gain, extrapyramidal side-effects, blood routine, urine routine, hepatorenal function, use of benzodiazepines and propranolol were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2009b","2013-09-29 10:39:37 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2010","2013-06-25 18:29:02 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2010","2013-06-25 18:29:02 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2010","2013-06-25 18:29:02 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2010","2013-06-25 18:29:03 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2010","2013-06-25 18:29:05 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2010","2013-06-25 18:29:07 +0100","NO","Data on TESS total score, ECG, blood glucose and serum lipids, use of benzodiazepines and other medicine were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Liu-2010","2013-06-25 18:29:09 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-X-2007","2013-06-25 18:19:35 +0100","UNKNOWN","Randomisation, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-X-2007","2013-06-25 18:19:35 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-X-2007","2013-06-25 18:19:35 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-X-2007","2013-06-25 18:19:35 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-X-2007","2013-06-25 18:19:38 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-X-2007","2013-06-25 18:19:40 +0100","NO","Data on TESS total score were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Li-X-2007","2013-06-25 18:19:42 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lou-2007","2013-06-25 18:29:45 +0100","UNKNOWN","Randomised, random number table method.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lou-2007","2013-06-25 18:29:45 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lou-2007","2013-06-25 18:29:45 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lou-2007","2013-06-25 18:29:45 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lou-2007","2013-06-25 18:29:51 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lou-2007","2013-06-25 18:29:53 +0100","NO","Data on TESS total score, ECG, use of benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lou-2007","2013-06-25 18:29:55 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Luo-2008","2013-06-25 18:30:24 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Luo-2008","2013-06-25 18:30:24 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Luo-2008","2013-06-25 18:30:24 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Luo-2008","2013-06-25 18:30:24 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Luo-2008","2013-06-25 18:30:27 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Luo-2008","2013-06-25 18:30:30 +0100","NO","Data on TESS total score were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Luo-2008","2013-06-25 18:30:35 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Luo-2009","2013-06-25 18:31:03 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Luo-2009","2013-06-25 18:31:03 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Luo-2009","2013-06-25 18:31:03 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Luo-2009","2013-06-25 18:31:04 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Luo-2009","2013-06-25 18:31:05 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Luo-2009","2013-06-25 18:31:07 +0100","NO","Data on TESS total score, EPS, tachycardia, menstrual changes, etc. and use of benzhexol, benzodiazepine, propranolol were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Luo-2009","2013-06-25 18:31:13 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lv-2007","2013-06-25 18:31:34 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lv-2007","2013-06-25 18:31:34 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lv-2007","2013-06-25 18:31:34 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lv-2007","2013-06-25 18:31:40 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lv-2007","2013-06-25 18:31:41 +0100","YES","The total proportion of loss to follow-up was 7.5% (1/40: 2/40 ), and there was no difference between the two groups.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lv-2007","2013-06-25 18:31:43 +0100","NO","Data on TESS score, use of benzodiazepines, anticholinergic drug were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Lv-2007","2013-06-25 18:31:49 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ma-2009","2013-06-25 18:32:29 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ma-2009","2013-06-25 18:32:29 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ma-2009","2013-06-25 18:32:29 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ma-2009","2013-06-25 18:32:34 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ma-2009","2013-06-25 18:32:35 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ma-2009","2013-06-25 18:32:41 +0100","NO","Data on TESS total score, blood and urine routine, use of benzodiazepines and anticholinergic medicine were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ma-2009","2013-06-25 18:32:44 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ma-2009a","2013-06-25 18:33:07 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ma-2009a","2013-06-25 18:33:07 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ma-2009a","2013-06-25 18:33:08 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ma-2009a","2013-06-25 18:33:08 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ma-2009a","2013-09-29 10:45:51 +0100","YES","There were no incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ma-2009a","2013-06-25 18:33:20 +0100","NO","Data of TESS total score, tremor, dry mouth, dystonia, use of benzhexol, benzodiazepine and propranolol were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ma-2009a","2013-06-25 18:33:22 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mai-2005","2013-06-25 18:33:46 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mai-2005","2013-06-25 18:33:47 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mai-2005","2013-06-25 18:33:47 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mai-2005","2013-06-25 18:33:47 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mai-2005","2013-06-25 18:33:51 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mai-2005","2013-06-25 18:33:53 +0100","NO","Data on TESS score, use of benzodiazepines, anticholinergic drug were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mai-2005","2013-06-25 18:33:56 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mao-2010","2013-06-25 18:34:27 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mao-2010","2013-06-25 18:34:27 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mao-2010","2013-06-25 18:34:28 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mao-2010","2013-06-25 18:34:28 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mao-2010","2013-06-25 18:34:34 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mao-2010","2013-06-25 18:34:37 +0100","NO","Data on TESS total score, use of benzodiazepines and anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mao-2010","2013-06-25 18:34:38 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-McQuade-2004","2013-06-25 18:35:20 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-McQuade-2004","2013-06-25 18:35:20 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-McQuade-2004","2013-06-25 18:35:20 +0100","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in adverse effects. This can be a problem for blinding.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-McQuade-2004","2013-06-25 18:35:27 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by lack of blinding.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-McQuade-2004","2013-06-25 23:25:51 +0100","NO","Quote:""Because of the high number of participants who discontinued the study (72%) results of analysis by time point are described on the observed case (OC) basis (except for primary outcome), as the last observation-carried-forward analysis would have included a large amount of data carried forward from patients who discontinued the study.""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-McQuade-2004","2013-06-25 23:25:43 +0100","NO","Although inclusion criteria required participants in acute relapse, no data on PANSS positive sub score were available. Data on use of antiparkinson medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-McQuade-2004","2013-06-25 23:25:34 +0100","NO","The study was industry sponsored by the manufacturer of aripiprazole.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mu-2008","2013-06-25 18:36:08 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mu-2008","2013-06-25 18:36:08 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mu-2008","2013-06-25 18:36:08 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mu-2008","2013-06-25 18:36:09 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mu-2008","2013-06-25 18:36:13 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mu-2008","2013-06-25 18:36:15 +0100","NO","Data on TESS total score, use of benzodiazepines and anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mu-2008","2013-06-25 18:36:21 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mu-2010","2013-06-25 18:37:00 +0100","YES","Simple randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mu-2010","2013-06-25 18:36:54 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mu-2010","2013-06-25 18:36:54 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mu-2010","2013-06-25 18:36:54 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mu-2010","2013-06-25 18:37:05 +0100","YES","Two cases lost in risperidone group because of lactation.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mu-2010","2013-09-29 10:51:45 +0100","NO","Data on blood and urine routine, ECG, liver function, use of benzodiazepines and other medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Mu-2010","2013-06-25 18:37:12 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Pan-2007","2013-06-25 18:37:39 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Pan-2007","2013-06-25 18:37:39 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Pan-2007","2013-06-25 18:37:39 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Pan-2007","2013-06-25 18:37:39 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Pan-2007","2013-06-25 18:37:46 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Pan-2007","2013-06-25 18:37:51 +0100","NO","The data on adverse effects were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Pan-2007","2013-06-25 18:37:55 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Peng-2007","2013-06-25 18:38:43 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Peng-2007","2013-06-25 18:38:43 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Peng-2007","2013-06-25 18:38:43 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Peng-2007","2013-06-25 18:38:44 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Peng-2007","2013-09-29 10:54:00 +0100","YES","The total rate of lost to follow-up was 3.5%(3/85), and there was no difference between the two groups (2/44: 1/41).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Peng-2007","2013-06-25 18:39:00 +0100","NO","The data on TESS total score, EEG, liver function, use of benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Peng-2007","2013-06-25 18:39:02 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Peng-2007a","2013-06-25 18:39:53 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Peng-2007a","2013-06-25 18:39:53 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Peng-2007a","2013-06-25 18:39:53 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Peng-2007a","2013-06-25 18:39:57 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Peng-2007a","2013-06-25 18:40:00 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Peng-2007a","2013-06-25 18:40:06 +0100","NO","Data on somnolence, ECG abnormal, mouth dry, constipation blurred vision, use of benzodiazepines were incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Peng-2007a","2013-06-25 18:40:08 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Potkin-2003","2013-06-25 18:42:52 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Potkin-2003","2013-06-25 18:42:52 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Potkin-2003","2013-06-25 18:42:52 +0100","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in adverse effects. This can be a problem for blinding.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Potkin-2003","2013-06-25 18:43:12 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by lack of blinding.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Potkin-2003","2013-09-29 10:57:24 +0100","NO","The overall drop out rate was 36.9 %. The LOCF method was used to account for people leaving the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Potkin-2003","2013-06-25 18:43:19 +0100","NO","For efficacy outcomes there was no standard deviation or standard error indicated which had to be back calculated.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Potkin-2003","2013-06-25 18:43:28 +0100","NO","The study was industry sponsored by the manufacturer of aripiprazole. The study used a fixed dose regimen, where it is difficult to say which comparator doses may be appropriate.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Pu-2007","2013-06-25 18:44:48 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Pu-2007","2013-06-25 18:44:51 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Pu-2007","2013-06-25 18:44:52 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Pu-2007","2013-06-25 18:44:56 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Pu-2007","2013-09-29 10:58:47 +0100","UNKNOWN","Unclear if there were incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Pu-2007","2013-06-25 18:45:02 +0100","YES","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Pu-2007","2013-06-25 18:45:13 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qian-2009","2013-06-25 18:45:47 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qian-2009","2013-06-25 18:45:47 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qian-2009","2013-06-25 18:45:50 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qian-2009","2013-06-25 18:45:51 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qian-2009","2013-09-29 10:59:49 +0100","YES","One patient was lost to follow-up because of economic issues in aripiprazole group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qian-2009","2013-06-25 18:45:58 +0100","NO","Data on TESS total score, blood routine, liver function, blood pressure change, blood glucose change were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qian-2009","2013-06-25 18:46:10 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qin-2008","2013-06-25 18:48:18 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qin-2008","2013-06-25 18:48:18 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qin-2008","2013-06-25 18:48:18 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qin-2008","2013-06-25 18:48:18 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qin-2008","2013-06-25 18:48:30 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qin-2008","2013-06-25 18:48:38 +0100","NO","Data on TESS total score, liver function, blood and urine routines, use of benzodiazepines, propranolol, and anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qin-2008","2013-06-25 18:48:45 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qu-2009","2013-06-25 18:49:42 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qu-2009","2013-06-25 18:49:42 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qu-2009","2013-06-25 18:49:42 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qu-2009","2013-06-25 18:49:42 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qu-2009","2013-06-25 18:49:46 +0100","UNKNOWN","Unclear if there were incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qu-2009","2013-06-25 18:49:55 +0100","NO","Data on GQOLI - 74 score, anxiety, EPS, somnolence, ECG, anxiety, EPS, somnolence, ECG, mouth dry, liver function, use of benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Qu-2009","2013-06-25 18:49:57 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Shan-2008","2013-06-25 18:52:10 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Shan-2008","2013-06-25 18:52:11 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Shan-2008","2013-06-25 18:52:11 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Shan-2008","2013-06-25 18:52:11 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Shan-2008","2013-06-25 18:52:11 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Shan-2008","2013-06-25 18:52:21 +0100","NO","Data on TESS total score, use of benzodiazepines and other medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Shan-2008","2013-06-25 18:52:34 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Shuai-2008","2013-06-25 18:54:07 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Shuai-2008","2013-06-25 18:54:07 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Shuai-2008","2013-06-25 18:54:07 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Shuai-2008","2013-06-25 18:54:07 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Shuai-2008","2013-06-25 18:54:38 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Shuai-2008","2013-06-25 18:54:40 +0100","NO","Data on TESS total score, blood routine, use of benzodiazepines and other medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Shuai-2008","2013-06-25 18:54:49 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2008","2013-06-25 18:55:27 +0100","UNKNOWN","randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2008","2013-06-25 18:55:27 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2008","2013-06-25 18:55:27 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2008","2013-06-25 18:55:30 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2008","2013-06-25 18:55:40 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2008","2013-06-25 18:55:45 +0100","NO","Data on adverse effects were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2008","2013-06-25 18:55:47 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2009","2013-06-25 18:56:33 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2009","2013-06-25 18:56:33 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2009","2013-06-25 18:56:33 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2009","2013-06-25 18:56:33 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2009","2013-06-25 18:56:42 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2009","2013-06-25 18:56:50 +0100","NO","Data on TESS total score and use of benzhexol and benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2009","2013-06-25 18:56:52 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2010","2013-06-25 18:57:29 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2010","2013-06-25 18:57:29 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2010","2013-06-25 18:57:29 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2010","2013-06-25 18:57:29 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2010","2013-06-25 18:57:36 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2010","2013-06-25 18:57:42 +0100","NO","Data on TESS total score, excitement, insomnia, myotonia, akathisia, tremor, use of benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Song-2010","2013-06-25 18:57:49 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Su-2007","2013-06-25 18:58:24 +0100","UNKNOWN","Randomisation, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Su-2007","2013-06-25 18:58:24 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Su-2007","2013-06-25 18:58:24 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Su-2007","2013-06-25 18:58:24 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Su-2007","2013-06-25 18:58:30 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Su-2007","2013-06-25 18:58:37 +0100","NO","Data on TESS total score, use of benzodiazepines and other medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Su-2007","2013-06-25 18:58:43 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Su-2008","2013-06-25 19:01:28 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Su-2008","2013-06-25 19:01:28 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Su-2008","2013-06-25 19:01:28 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Su-2008","2013-06-25 19:01:28 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Su-2008","2013-06-25 19:01:38 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Su-2008","2013-06-25 19:01:45 +0100","NO","Data on TESS total score, lactation, menstrual disorders, excitement, insomnia, myotonia, akathisia, tremor, use of benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Su-2008","2013-06-25 19:01:51 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2006","2013-06-25 23:28:36 +0100","YES","Randomised, stratified randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2006","2013-06-25 19:02:53 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2006","2013-06-25 19:02:53 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2006","2013-06-25 19:02:57 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2006","2013-06-25 19:03:05 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2006","2013-06-25 19:03:11 +0100","YES","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2006","2013-06-25 19:03:17 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2009","2013-06-25 19:04:09 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2009","2013-06-25 19:04:09 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2009","2013-06-25 19:04:09 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2009","2013-06-25 19:04:09 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2009","2013-06-25 19:04:21 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2009","2013-06-25 19:04:27 +0100","NO","Data on TESS total score, use of anticholinergic medicine and benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2009","2013-06-25 19:04:32 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2009a","2013-06-25 19:05:27 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2009a","2013-06-25 19:05:27 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2009a","2013-06-25 19:05:27 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2009a","2013-06-25 19:05:27 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2009a","2013-06-25 19:05:40 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2009a","2013-06-25 19:05:47 +0100","NO","Data on TESS total score, use of benzodiazepine and other medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Sun-2009a","2013-06-25 19:05:54 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tandon-2006","2013-09-29 11:26:58 +0100","YES","4:1 computer-generated randomised schedule using Interactive Voice Response System.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tandon-2006","2013-06-25 19:07:05 +0100","NO","Open label.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tandon-2006","2013-06-25 19:07:11 +0100","NO","Open label.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tandon-2006","2013-06-25 19:07:17 +0100","NO","Open label.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tandon-2006","2013-06-25 19:06:50 +0100","UNKNOWN","LOCF method used to account for people leaving the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tandon-2006","2013-06-25 19:07:34 +0100","NO","Adverse events were reported if they were > 5%. Scales if used were not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tandon-2006","2013-06-25 19:07:41 +0100","NO","Industry sponsored.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2006","2013-06-25 19:08:58 +0100","YES","Simple randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2006","2013-06-25 19:08:45 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2006","2013-06-25 19:08:45 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2006","2013-06-25 19:08:45 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2006","2013-06-25 19:09:04 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2006","2013-06-25 19:09:12 +0100","NO","Data on TESS score, use of benzodiazepines, propranolol and benzhexol were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2006","2013-06-25 19:09:18 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2007","2013-06-25 19:10:29 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2007","2013-06-25 19:10:33 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2007","2013-06-25 19:10:45 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2007","2013-06-25 19:10:45 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2007","2013-06-25 19:11:18 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2007","2013-06-25 19:11:30 +0100","NO","Data on TESS score, EEG, use of benzodiazepines and other medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2007","2013-06-25 19:11:41 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2010","2013-06-25 19:16:57 +0100","YES","Simple randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2010","2013-06-25 19:16:52 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2010","2013-06-25 19:16:52 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2010","2013-06-25 19:16:52 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2010","2013-09-29 11:29:55 +0100","YES","One patient lose to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2010","2013-06-25 19:17:02 +0100","NO","Data on TESS score, use of benzodiazepines and other medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2010","2013-06-25 19:17:04 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2010a","2013-06-25 19:17:29 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2010a","2013-06-25 19:17:29 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2010a","2013-06-25 19:17:29 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2010a","2013-06-25 19:17:29 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2010a","2013-06-25 19:17:31 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2010a","2013-06-25 19:17:35 +0100","NO","Data on TESS total score, insomnia, anxiety, nausea, endocrine, weight gain, headache, dizziness, use of benzodiazepines and other medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tang-2010a","2013-06-25 19:17:36 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tao-2008","2013-06-25 19:18:01 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tao-2008","2013-06-25 19:18:01 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tao-2008","2013-06-25 19:18:01 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tao-2008","2013-06-25 19:18:01 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tao-2008","2013-06-25 19:18:06 +0100","YES","The total rate of loss to follow-up was 4.4%(3/90 vs. 1/90), 1 participant dropped out because of adverse effect, 1 dropped out because of no effect, 2 dropped out because of incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tao-2008","2013-06-25 19:18:07 +0100","YES","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tao-2008","2013-06-25 19:18:09 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tong-2007","2013-06-25 19:19:15 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tong-2007","2013-06-25 19:19:15 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tong-2007","2013-06-25 19:19:15 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tong-2007","2013-06-25 19:19:15 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tong-2007","2013-10-24 15:37:14 +0100","NO","The total rate of lost to follow-up was 26.5% (18/68, 11/36 vs. 7/32). 8 participants dropped out because of progressive disease, 10 dropped out because the trialists could not insist on follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tong-2007","2013-06-25 19:19:33 +0100","NO","Data on TESS total score and use of benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tong-2007","2013-06-25 19:19:35 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tu-2009","2013-06-25 19:19:54 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tu-2009","2013-06-25 19:19:54 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tu-2009","2013-06-25 19:19:54 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tu-2009","2013-06-25 19:19:54 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tu-2009","2013-06-25 19:19:56 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tu-2009","2013-06-25 19:19:58 +0100","NO","Data on adverse effects were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Tu-2009","2013-06-25 19:20:00 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2005","2013-06-25 19:20:21 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2005","2013-06-25 19:20:21 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2005","2013-06-25 19:20:21 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2005","2013-06-25 19:20:22 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2005","2013-10-24 15:37:38 +0100","YES","One patient discontinued therapy due to leucopenia.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2005","2013-09-29 11:37:26 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available. Data on ECG and weight were missing. Data on laboratory tests (hepatorenal function, glucose, electrolytes) were unclear.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2005","2013-06-25 19:20:29 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006","2013-06-25 19:20:57 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006","2013-06-25 19:20:57 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006","2013-06-25 19:20:57 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006","2013-06-25 19:20:57 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006","2013-06-25 19:21:00 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006","2013-06-25 19:21:03 +0100","NO","Data on gastrointestinal (dry mouth, constipation), blurred vision, weight gain and EEG abnormal were unclear. Data on blood and urine routine, blood pressure were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006","2013-06-25 19:21:04 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006a","2013-06-25 19:21:39 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006a","2013-06-25 19:21:39 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006a","2013-06-25 19:21:39 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006a","2013-06-25 19:21:39 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006a","2013-06-25 19:21:41 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006a","2013-06-25 19:21:43 +0100","NO","Although TESS was used to assess adverse effects, no data on score were available. Data on hepatorenal function were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006a","2013-06-25 19:21:45 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006b","2013-06-25 19:23:44 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006b","2013-06-25 19:23:44 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006b","2013-06-25 19:23:44 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006b","2013-06-25 19:23:44 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006b","2013-06-25 19:23:44 +0100","UNKNOWN","Unclear if there was drop-out.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006b","2013-06-25 19:23:46 +0100","NO","Although GQOLI-74 was used to assess quality of life, no data on score were available. Data on EPS, ECG, liver function, and mouth dry were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006b","2013-06-25 19:23:48 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006c","2013-06-25 19:24:14 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006c","2013-06-25 19:24:26 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006c","2013-06-25 19:24:33 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006c","2013-06-25 19:24:36 +0100","UNKNOWN","Not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006c","2013-06-25 19:24:38 +0100","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006c","2013-06-25 19:25:41 +0100","NO","Data on TESS score were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006c","2013-06-25 19:24:45 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006d","2013-06-25 19:26:58 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006d","2013-06-25 19:26:58 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006d","2013-06-25 19:26:58 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006d","2013-06-25 19:26:58 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006d","2013-06-25 19:27:02 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006d","2013-06-25 19:27:06 +0100","NO","Data TESS total score, blood, urine, and stool routine, use of benzodiazepines and anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2006d","2013-06-25 19:27:08 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007","2013-06-25 19:27:55 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007","2013-06-25 19:27:55 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007","2013-06-25 19:27:55 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007","2013-06-25 19:27:55 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007","2013-09-29 11:42:49 +0100","YES","Total proportion of drop-out was 3.15% and the data of the two groups were balanced (2/46: 1/49). Two because of adverse effect, one due to economic issue.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007","2013-06-25 19:28:21 +0100","NO","Data on TESS total score, blood routine, use of benzodiazepines and anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007","2013-06-25 19:28:23 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007a","2013-06-25 19:28:44 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007a","2013-06-25 19:28:44 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007a","2013-06-25 19:28:44 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007a","2013-06-25 19:28:44 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007a","2013-06-25 19:28:46 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007a","2013-06-25 19:28:52 +0100","YES","Data on TESS total score, blood and urine routine, kidney function, electrolyte, use of benzodiazepines and anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007a","2013-06-25 19:28:50 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007d","2013-06-25 19:29:12 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007d","2013-06-25 19:29:12 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007d","2013-06-25 19:29:12 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007d","2013-06-25 19:29:12 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007d","2013-06-25 19:29:14 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007d","2013-06-25 19:29:21 +0100","NO","Data on TESS total score were missing. Data on extrapyramidal symptoms were incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007d","2013-06-25 19:29:23 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007e","2013-06-25 19:29:47 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007e","2013-06-25 19:29:47 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007e","2013-06-25 19:29:47 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007e","2013-06-25 19:29:47 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007e","2013-06-25 19:29:49 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007e","2013-06-25 19:29:51 +0100","NO","Data on TESS total score, ECG, EPS, use of benzodiazepines, propranolol, and anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2007e","2013-06-25 19:29:53 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2008","2013-06-25 19:30:14 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2008","2013-06-25 19:30:14 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2008","2013-06-25 19:30:14 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2008","2013-06-25 19:30:14 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2008","2013-06-25 19:30:18 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2008","2013-06-25 19:30:20 +0100","NO","Although PANSS score decreased rate was used to assess effect, no data were available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2008","2013-06-25 19:30:21 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2008c","2013-06-25 19:30:42 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2008c","2013-06-25 19:30:42 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2008c","2013-06-25 19:30:42 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2008c","2013-06-25 19:30:42 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2008c","2013-06-25 19:30:45 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2008c","2013-06-25 19:30:52 +0100","NO","Data on TESS score, blood and urine routine, ECG. were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2008c","2013-06-25 19:30:54 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2009","2013-06-25 19:31:51 +0100","YES","Stratified random.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2009","2013-06-25 19:31:14 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2009","2013-06-25 19:31:14 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2009","2013-06-25 19:31:15 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2009","2013-09-29 11:48:23 +0100","YES","Total proportion of drop-out was 8.3% and the data of the two groups were balanced.The proportion of missing outcomes was not enough to have a clinically relevant impact on the intervention effect estimate.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2009","2013-06-25 19:32:23 +0100","NO","No data on efficacy were available. Data on other adverse effects were also missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wang-2009","2013-06-25 19:31:16 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2006","2013-06-25 19:35:49 +0100","YES","Random number table.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2006","2013-06-25 19:35:51 +0100","YES","Sealed envelope.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2006","2013-10-24 15:08:17 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2006","2013-06-25 19:36:02 +0100","NO","There was no blinding on outcome assessment.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2006","2013-06-25 19:36:07 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2006","2013-06-25 19:36:21 +0100","NO","Data on TESS total score, blood routine, ECG, liver function, use of benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2006","2013-06-25 19:36:17 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2007","2013-06-25 19:41:10 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2007","2013-06-25 19:41:10 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2007","2013-06-25 19:41:11 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2007","2013-06-25 19:41:11 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2007","2013-09-29 13:34:51 +0100","UNKNOWN","Unclear if there were incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2007","2013-09-29 14:35:59 +0100","NO","Although TESS was used to assess adverse effects, no data on scores were available. Data on urine routine, hepatorenal function and EEG were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2007","2013-06-25 19:42:33 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2009","2013-06-25 23:19:03 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2009","2013-06-25 23:19:07 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2009","2013-06-25 23:19:08 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2009","2013-06-25 23:19:11 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2009","2013-10-24 15:28:32 +0100","UNKNOWN","Unclear if there were incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2009","2013-10-24 15:28:32 +0100","NO","Data on Global state, TESS total score, excitement or agitation insomnia, somnolence, myotonia, akathisia, tremors, use of benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wei-2009","2013-06-25 23:19:22 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wen-2009","2013-06-25 19:45:24 +0100","YES","Random permutation table.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wen-2009","2013-06-25 19:45:07 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wen-2009","2013-06-25 19:45:07 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wen-2009","2013-06-25 19:45:07 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wen-2009","2013-06-25 19:45:29 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wen-2009","2013-06-25 19:45:31 +0100","NO","Data on TESS total score, use of benzodiazepines and other medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wen-2009","2013-06-25 19:45:33 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wen-2009a","2013-06-25 19:46:23 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wen-2009a","2013-06-25 19:46:23 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wen-2009a","2013-06-25 19:46:23 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wen-2009a","2013-06-25 19:46:23 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wen-2009a","2013-06-25 19:46:26 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wen-2009a","2013-06-25 19:46:27 +0100","NO","Data on TESS total score, blood and urine routine, renal unction, use of benzodiazepines and anticholinergic medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wen-2009a","2013-06-25 19:46:28 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wlodzmierz-2006","2013-06-25 19:46:59 +0100","NO","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wlodzmierz-2006","2013-06-25 19:47:01 +0100","NO","Open label.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wlodzmierz-2006","2013-06-25 19:47:04 +0100","NO","Open label.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wlodzmierz-2006","2013-06-25 19:47:06 +0100","NO","Open label.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wlodzmierz-2006","2013-06-25 19:46:58 +0100","UNKNOWN","LOCF method used to account for people leaving the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wlodzmierz-2006","2013-06-25 19:47:09 +0100","NO","Adverse events were reported if they were > 5%. Scales if used were not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wlodzmierz-2006","2013-06-25 19:47:11 +0100","NO","Industry sponsored.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wolf-2007","2013-06-25 19:47:38 +0100","YES","4:1 computer-generated using Interactive Voice Response System.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wolf-2007","2013-06-25 19:47:41 +0100","NO","Open label.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wolf-2007","2013-06-25 19:47:45 +0100","NO","Open label.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wolf-2007","2013-06-25 19:47:47 +0100","NO","Open label.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wolf-2007","2013-06-25 19:47:36 +0100","UNKNOWN","LOCF method used to account for people leaving the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wolf-2007","2013-06-25 19:47:50 +0100","NO","Adverse events were reported if they were > 5%. Scales if used were not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wolf-2007","2013-06-25 19:47:52 +0100","NO","Industry sponsored.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wu-2008","2013-06-25 19:48:19 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wu-2008","2013-06-25 19:48:19 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wu-2008","2013-06-25 19:48:19 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wu-2008","2013-06-25 19:48:19 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wu-2008","2013-06-25 19:48:20 +0100","UNKNOWN","Unclear if there was drop-out.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wu-2008","2013-06-25 19:48:26 +0100","NO","The data on TESS score, blood routine, hepatorenal function, electrolyte were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Wu-2008","2013-06-25 19:48:28 +0100","NO","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xiao-2007","2013-06-25 19:48:51 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xiao-2007","2013-06-25 19:48:51 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xiao-2007","2013-06-25 19:48:51 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xiao-2007","2013-06-25 19:48:51 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xiao-2007","2013-09-29 13:43:25 +0100","UNKNOWN","Unclear if there were incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xiao-2007","2013-06-25 19:48:53 +0100","NO","The data on use of benzhexol, propranolol and benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xiao-2007","2013-06-25 19:48:55 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xie-2008","2013-06-25 19:49:16 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xie-2008","2013-06-25 19:49:16 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xie-2008","2013-06-25 19:49:16 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xie-2008","2013-06-25 19:49:16 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xie-2008","2013-06-25 19:49:21 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xie-2008","2013-06-25 19:49:23 +0100","YES","No imported outcome were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xie-2008","2013-06-25 19:49:27 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xie-2010","2013-06-25 19:49:49 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xie-2010","2013-06-25 19:49:49 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xie-2010","2013-06-25 19:49:49 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xie-2010","2013-06-25 19:49:50 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xie-2010","2013-06-25 19:49:52 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xie-2010","2013-09-29 14:36:06 +0100","NO","Although TESS was used to assess adverse effects, no data on scores were available. Data on blood routine, use of benzodiazepines and other medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xie-2010","2013-06-25 19:49:56 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xu-2007","2013-06-25 19:50:21 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xu-2007","2013-06-25 19:50:21 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xu-2007","2013-06-25 19:50:21 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xu-2007","2013-06-25 19:50:21 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xu-2007","2013-06-25 19:51:07 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xu-2007","2013-09-29 14:36:11 +0100","NO","Although TESS was used to assess adverse effects, no data on scores were available. Data on use of benzhexol and benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xu-2007","2013-06-25 19:51:11 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xu-2010","2013-06-25 19:51:46 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xu-2010","2013-06-25 19:51:46 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xu-2010","2013-06-25 19:51:52 +0100","YES","Double.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xu-2010","2013-06-25 19:51:47 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xu-2010","2013-09-29 13:47:59 +0100","YES","Total proportion of drop-out was 7.7% (2/26 vs. 2/26). Aripiprazole group: 1 because of violation of study scheme, 1 because of bad compliance; risperidone group: 1 because of violation of study scheme, 1 because of drug combination; 1 because of effect.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xu-2010","2013-09-29 13:48:11 +0100","NO","Data on TESS total score, Extrapyramidal reaction scale score, BARS scores were not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Xu-2010","2013-06-25 19:52:02 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2007","2013-06-25 19:52:33 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2007","2013-06-25 19:52:33 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2007","2013-06-25 19:52:33 +0100","UNKNOWN","Double.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2007","2013-06-25 19:52:33 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2007","2013-09-29 13:49:25 +0100","YES","Total proportion of drop-out was 7.7% (2/26 vs. 2/26). Aripiprazole group: 1 because of violation of study scheme, 1 because of bad compliance; risperidone group: 1 because of violation of study scheme, 1 because of drug combination; 1 because of effect.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2007","2013-09-29 13:49:35 +0100","NO","Data on TESS total score, Extrapyramidal reaction scale score, BARS scores were not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2007","2013-06-25 19:52:39 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2008","2013-06-25 19:53:09 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2008","2013-06-25 19:53:09 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2008","2013-06-25 19:53:09 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2008","2013-06-25 19:53:09 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2008","2013-06-25 19:53:11 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2008","2013-09-29 13:50:41 +0100","NO","Although TESS was used to assess adverse effects, no data on scores were available. Data on blood routine, hepatorenal function, EEG, and weight were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2008","2013-06-25 19:53:15 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2008a","2013-06-25 19:53:54 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2008a","2013-06-25 19:53:54 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2008a","2013-06-25 19:53:54 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2008a","2013-06-25 19:53:54 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2008a","2013-06-25 19:53:56 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2008a","2013-09-29 13:51:22 +0100","NO","Although TESS was used to assess adverse effects, no data on scores were available. Data on dizziness, salivate, constipation, weight gain, and renal function were deficient. Data on use of benzodiazepines were also missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2008a","2013-06-25 19:54:06 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2010","2013-06-25 19:54:45 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2010","2013-06-25 19:54:45 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2010","2013-06-25 19:54:45 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2010","2013-06-25 19:54:45 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2010","2013-09-29 13:52:53 +0100","YES","The total proportion of loss to follow up was 6% (4/50 vs. 2/50). Aripiprazole group: 2 cases because of drug combination, 1 case because of adverse effect, 1 case due to family demanded; risperidone group: 2 cases because of drug combination.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2010","2013-06-25 19:54:51 +0100","NO","Data on number of no effect, blood and urine routine, renal function, use of benzodiazepines and other medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yan-2010","2013-06-25 19:54:53 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2006","2013-06-25 19:55:25 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2006","2013-06-25 19:55:26 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2006","2013-06-25 19:55:26 +0100","UNKNOWN","Not stated.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2006","2013-06-25 19:55:26 +0100","UNKNOWN","Not stated.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2006","2013-06-25 19:55:32 +0100","YES","No incomplete outcome.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2006","2013-06-25 19:59:34 +0100","YES","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2006","2013-06-25 19:55:47 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2007","2013-06-25 20:00:29 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2007","2013-06-25 20:00:29 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2007","2013-06-25 20:00:29 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2007","2013-06-25 20:00:29 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2007","2013-06-25 20:00:30 +0100","UNKNOWN","Unclear if there was drop-out.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2007","2013-06-25 20:00:34 +0100","NO","Data on TESS total score and hepatorenal function were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2007","2013-06-25 20:00:34 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008","2013-06-25 20:00:59 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008","2013-06-25 20:00:59 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008","2013-06-25 20:00:59 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008","2013-06-25 20:00:59 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008","2013-09-29 13:55:31 +0100","YES","There were no incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008","2013-06-25 20:01:08 +0100","NO","Data on TESS score, RSESE score, blood and urine routine,hepatorenal function, drugs for adverse events were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008","2013-06-25 20:01:10 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008a","2013-06-25 20:01:40 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008a","2013-06-25 20:01:40 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008a","2013-06-25 20:01:40 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008a","2013-06-25 20:01:40 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008a","2013-09-29 13:57:10 +0100","YES","There were no incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008a","2013-06-25 20:01:48 +0100","NO","Although blood and urine routine, liver function, ECG, weight and other adverse effect, use of benzodiazepines and anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008a","2013-06-25 20:01:50 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008b","2013-06-25 20:02:26 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008b","2013-06-25 20:02:26 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008b","2013-06-25 20:02:26 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008b","2013-06-25 20:02:27 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008b","2013-06-25 20:02:29 +0100","YES","There was no drop-out.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008b","2013-06-25 20:02:39 +0100","NO","Data on TESS total score, blood routine, liver function, blood glucose, weight, use of benzodiazepines and anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2008b","2013-06-25 20:02:45 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2009","2013-06-25 20:03:26 +0100","UNKNOWN","Randomisation, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2009","2013-06-25 20:03:26 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2009","2013-06-25 20:03:26 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2009","2013-06-25 20:03:26 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2009","2013-09-29 13:59:00 +0100","UNKNOWN","Unclear if there were incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2009","2013-06-25 20:03:34 +0100","YES","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yang-2009","2013-06-25 20:03:35 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ye-2005","2013-06-25 20:03:59 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ye-2005","2013-06-25 20:03:59 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ye-2005","2013-06-25 20:03:59 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ye-2005","2013-06-25 20:03:59 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ye-2005","2013-06-25 20:04:06 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ye-2005","2013-06-25 20:04:12 +0100","NO","Data on TESS total score and blood and urine routine, liver function, blood glucose were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ye-2005","2013-06-25 20:04:14 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ye-2005a","2013-06-25 20:04:40 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ye-2005a","2013-06-25 20:04:40 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ye-2005a","2013-06-25 20:04:40 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ye-2005a","2013-06-25 20:04:40 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ye-2005a","2013-09-29 14:00:57 +0100","YES","Two people were lost to follow-up (1/30 VS.1/30) in the two groups, one because of early discharge, one due to refusing further therapy.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ye-2005a","2013-06-25 20:04:54 +0100","NO","Data on TESS total score, blood and urine routine, weight gain, extrapyramidal effects, constipation, somnolence, use of benzodiazepines and other medicine were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Ye-2005a","2013-06-25 20:04:56 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yi-2007","2013-06-25 20:05:29 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yi-2007","2013-06-25 20:05:29 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yi-2007","2013-06-25 20:05:29 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yi-2007","2013-06-25 20:05:29 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yi-2007","2013-09-29 14:02:18 +0100","UNKNOWN","Unclear if there were incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yi-2007","2013-06-25 20:05:32 +0100","YES","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yi-2007","2013-06-25 20:05:35 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2006","2013-06-25 20:06:05 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2006","2013-06-25 20:06:05 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2006","2013-06-25 20:06:05 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2006","2013-06-25 20:06:05 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2006","2013-06-25 20:06:08 +0100","NO","Five people were excluded from analysis due to incomplete outcome data. It is unclear which group these 5 people belonged to.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2006","2013-06-25 20:06:13 +0100","NO","Data on TESS total score and hepatorenal function were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2006","2013-06-25 20:06:18 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2006a","2013-06-25 20:06:51 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2006a","2013-06-25 20:06:51 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2006a","2013-06-25 20:06:51 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2006a","2013-06-25 20:06:51 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2006a","2013-06-25 20:06:55 +0100","UNKNOWN","Unclear if there was incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2006a","2013-06-25 20:06:57 +0100","YES","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2006a","2013-06-25 20:06:59 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2007","2013-06-25 20:07:23 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2007","2013-06-25 20:07:23 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2007","2013-06-25 20:07:23 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2007","2013-06-25 20:07:23 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2007","2013-06-25 20:07:32 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2007","2013-09-29 14:36:17 +0100","NO","Although TESS was used to assess adverse effects, no data on scores were available. Data on liver function and blood glucose were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2007","2013-06-25 20:07:36 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2008","2013-06-25 20:08:08 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2008","2013-06-25 20:08:08 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2008","2013-06-25 20:08:08 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2008","2013-06-25 20:08:08 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2008","2013-06-25 20:08:11 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2008","2013-06-25 20:08:13 +0100","NO","Data on TESS score, blood and urine routine, and renal function were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2008","2013-06-25 20:08:17 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2009","2013-06-25 20:08:47 +0100","YES","Stratified randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2009","2013-06-25 20:08:42 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2009","2013-06-25 20:08:42 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2009","2013-06-25 20:08:42 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2009","2013-06-25 20:08:53 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2009","2013-09-29 14:06:47 +0100","NO","Although TESS was used to assess adverse effects, no data on scores were available. Data on EEG and drugs for adverse events were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-2009","2013-06-25 20:08:57 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-ZG-2007","2013-06-25 20:09:26 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-ZG-2007","2013-06-25 20:09:26 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-ZG-2007","2013-06-25 20:09:26 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-ZG-2007","2013-06-25 20:09:26 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-ZG-2007","2013-06-25 20:09:30 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-ZG-2007","2013-06-25 20:09:36 +0100","NO","Data on blood routine, urine routine, blood glucose,and hepatorenal function were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Yu-ZG-2007","2013-06-25 20:09:38 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2006","2013-06-25 20:10:07 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2006","2013-06-25 20:10:07 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2006","2013-06-25 20:10:07 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2006","2013-06-25 20:10:07 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2006","2013-09-29 14:08:49 +0100","YES","There were no incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2006","2013-09-29 14:36:22 +0100","NO","Although TESS was used to assess adverse effects, no data on scores were available. Data on use of benzhexol and benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2006","2013-06-25 20:10:18 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2006a","2013-06-25 20:10:53 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2006a","2013-06-25 20:10:53 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2006a","2013-06-25 20:10:53 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2006a","2013-06-25 20:10:53 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2006a","2013-06-25 20:10:59 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2006a","2013-06-25 20:11:01 +0100","NO","Data on blood and urine routine, liver function, ECG, use of benzodiazepines and benzhexol were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2006a","2013-06-25 20:11:03 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007","2013-06-25 20:11:32 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007","2013-06-25 20:11:32 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007","2013-06-25 20:11:32 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007","2013-06-25 20:11:32 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007","2013-09-29 14:10:23 +0100","UNKNOWN","Unclear if there were incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007","2013-06-25 20:11:38 +0100","YES","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007","2013-06-25 20:11:53 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007a","2013-06-25 20:12:18 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007a","2013-06-25 20:12:18 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007a","2013-06-25 20:12:18 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007a","2013-06-25 20:12:18 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007a","2013-06-25 20:12:24 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007a","2013-06-25 20:12:30 +0100","NO","Data on blood and urine routines, EEG, use of anticholinergic drug and benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007a","2013-06-25 20:12:32 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007b","2013-06-25 20:13:07 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007b","2013-06-25 20:13:10 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007b","2013-06-25 20:13:10 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007b","2013-06-25 20:13:10 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007b","2013-06-25 20:13:14 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007b","2013-06-25 20:13:20 +0100","NO","Data on various specific adverse effects were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2007b","2013-06-25 20:13:22 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008","2013-06-25 20:14:11 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008","2013-06-25 20:14:12 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008","2013-06-25 20:14:12 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008","2013-06-25 20:14:12 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008","2013-06-25 20:14:14 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008","2013-09-29 14:36:27 +0100","NO","Although ESRS was used to assess adverse effects, no data on scores were available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008","2013-06-25 20:14:32 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008a","2013-06-25 20:15:25 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008a","2013-06-25 20:15:25 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008a","2013-06-25 20:15:25 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008a","2013-06-25 20:15:25 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008a","2013-06-25 20:15:32 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008a","2013-09-29 14:36:35 +0100","NO","Although ESRS was used to assess adverse effects, no data on scores were available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008a","2013-06-25 20:15:37 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008b","2013-06-25 20:16:45 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008b","2013-06-25 20:16:45 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008b","2013-06-25 20:16:46 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008b","2013-06-25 20:16:46 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008b","2013-06-25 20:16:49 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008b","2013-09-29 14:14:37 +0100","NO","Data on TESS score, endocrine change, laboratory tests were missing. No data of Quality of life GQOLI - 74.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2008b","2013-06-25 20:16:58 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009","2013-06-25 20:17:28 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009","2013-06-25 20:17:28 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009","2013-06-25 20:17:28 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009","2013-06-25 20:17:28 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009","2013-06-25 20:17:32 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009","2013-06-25 20:17:35 +0100","NO","Data on TESS, use of benzhexol and benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009","2013-06-25 20:17:40 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009a","2013-06-25 20:18:25 +0100","UNKNOWN","Randomised, random number table.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009a","2013-06-25 20:18:25 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009a","2013-06-25 20:18:25 +0100","UNKNOWN","Single, if the blinding was performed well was unknown.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009a","2013-06-25 20:18:25 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009a","2013-06-25 20:18:28 +0100","UNKNOWN","unclear if there were no incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009a","2013-06-25 20:18:30 +0100","YES","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009a","2013-06-25 20:18:32 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009b","2013-06-25 20:19:04 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009b","2013-06-25 20:19:04 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009b","2013-06-25 20:19:04 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009b","2013-06-25 20:19:04 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009b","2013-06-25 20:19:07 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009b","2013-06-25 20:19:13 +0100","NO","Data on TESS total score, blood and urine routine, blood glucose, use of benzodiazepines and other medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2009b","2013-06-25 20:19:15 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2010","2013-06-25 20:20:37 +0100","YES","Random permutation table.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2010","2013-06-25 20:20:29 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2010","2013-06-25 20:20:30 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2010","2013-06-25 20:20:30 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2010","2013-06-25 20:20:30 +0100","UNKNOWN","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2010","2013-09-29 14:36:43 +0100","NO","Although TESS was used to assess adverse effects, no data on scores were available. Data on use of benzhexol and benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2010","2013-06-25 20:20:43 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2010a","2013-06-25 20:21:28 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2010a","2013-06-25 20:21:28 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2010a","2013-06-25 20:21:28 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2010a","2013-06-25 20:21:28 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2010a","2013-06-25 20:21:28 +0100","UNKNOWN","Unclear if there were incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2010a","2013-06-25 20:21:30 +0100","NO","Data on GQOLI - 74 score, anxiety, EPS, ECG abnormal, mouth dry, liver function, use of benzodiazepines and other medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhang-2010a","2013-06-25 20:21:37 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhao-2006","2013-06-25 20:22:25 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhao-2006","2013-06-25 20:22:25 +0100","UNKNOWN","Not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhao-2006","2013-06-25 20:22:25 +0100","UNKNOWN","Not described.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhao-2006","2013-06-25 20:22:25 +0100","UNKNOWN","Not described.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhao-2006","2013-06-25 20:22:31 +0100","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhao-2006","2013-09-29 14:20:57 +0100","NO","TESS score was measured, but not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhao-2006","2013-06-25 20:22:41 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhao-2007","2013-06-25 20:23:30 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhao-2007","2013-06-25 20:23:30 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhao-2007","2013-06-25 20:23:30 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhao-2007","2013-06-25 20:23:30 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhao-2007","2013-06-25 20:23:36 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhao-2007","2013-06-25 20:23:38 +0100","NO","Data on TESS score, use of benzodiazepines, benzhexol and propranolol were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhao-2007","2013-06-25 20:23:41 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhi-2005","2013-06-25 20:24:13 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhi-2005","2013-06-25 20:24:13 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhi-2005","2013-06-25 20:24:13 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhi-2005","2013-06-25 20:24:13 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhi-2005","2013-06-25 20:24:19 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhi-2005","2013-06-25 20:24:24 +0100","NO","Data on TESS total score, use of benzodiazepines, benzhexol and propranolol were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhi-2005","2013-06-25 20:24:30 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007","2013-06-25 20:25:18 +0100","YES","Random permutation table.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007","2013-06-25 20:25:11 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007","2013-06-25 20:25:11 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007","2013-06-25 20:25:11 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007","2013-06-25 20:25:23 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007","2013-06-25 20:25:25 +0100","NO","Data on TESS score, PANSS negative subscore, cognitive factor, affective symptoms, hepatorenal function, use of benzhexol and benzodiazepines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007","2013-06-25 20:25:27 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007a","2013-06-25 20:26:05 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007a","2013-06-25 20:26:06 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007a","2013-06-25 20:26:06 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007a","2013-06-25 20:26:06 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007a","2013-06-25 20:26:13 +0100","YES","There were no incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007a","2013-06-25 20:26:18 +0100","NO","Data on TESS total score, use of benzodiazepines and anticholinergic medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007a","2013-06-25 20:26:24 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007b","2013-06-25 20:27:12 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007b","2013-06-25 20:27:12 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007b","2013-06-25 20:27:12 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007b","2013-06-25 20:27:17 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007b","2013-06-25 20:27:17 +0100","UNKNOWN","Unclear if there were no incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007b","2013-06-25 20:27:18 +0100","NO","Data on GQOLI - 74 score, use of benzodiazepines and other medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2007b","2013-06-25 20:27:26 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2008","2013-06-25 20:28:05 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2008","2013-06-25 20:28:05 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2008","2013-06-25 20:28:05 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2008","2013-06-25 20:28:05 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2008","2013-06-25 20:28:17 +0100","YES","There were no incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2008","2013-06-25 20:28:27 +0100","NO","Data on TESS total score, EEG, use of benzodiazepines, benzhexol and propranolol were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhou-2008","2013-06-25 20:28:32 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2005","2013-06-25 20:29:35 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2005","2013-06-25 20:29:35 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2005","2013-06-25 20:29:35 +0100","UNKNOWN","Single blind, but whether the blindness was performed well was unclear.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2005","2013-06-25 20:29:35 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2005","2013-06-25 20:29:39 +0100","UNKNOWN","There were drop-outs, but specific digital was not obtained.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2005","2013-06-25 20:30:14 +0100","NO","Data on blood and urine routine, liver function were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2005","2013-06-25 20:30:06 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2008","2013-06-25 20:31:12 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2008","2013-06-25 20:31:12 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2008","2013-06-25 20:31:12 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2008","2013-06-25 20:31:12 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2008","2013-09-29 14:28:03 +0100","YES","Total proportion of drop-out was 3.3% and the data of the two groups were balanced (1/30: 1/30).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2008","2013-06-25 20:31:44 +0100","NO","Data on CGI score, TESS total score, akathisia, tremor, insomnia, constipation, drowsiness sleepiness, weight gain, EEG, blood routine, urine routine, use of benzodiazepine and propranolol were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2008","2013-06-25 20:31:51 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2010","2013-06-25 20:33:06 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2010","2013-06-25 20:33:06 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2010","2013-06-25 20:33:06 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2010","2013-06-25 20:33:06 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2010","2013-09-29 14:29:12 +0100","NO","The total proportion of loss to follow-up was 6.2% (5 people), but it was unclear proportion in every group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2010","2013-06-25 20:33:22 +0100","NO","Data on TESS total score, use of benzodiazepines and other medicines were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zhu-2010","2013-06-25 20:33:31 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zimbroff-2007","2013-06-25 20:36:07 +0100","YES","Random, computer-generated, blocked by centre.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zimbroff-2007","2013-06-25 20:35:51 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zimbroff-2007","2013-06-25 20:36:14 +0100","YES","Double, double dummy administration. Whether blinding was successful has not been examined, but both compounds have similar adverse effects.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zimbroff-2007","2013-06-25 20:37:41 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by lack of blinding.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zimbroff-2007","2013-06-25 20:36:03 +0100","UNKNOWN","LOCF method used to account for people leaving the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zimbroff-2007","2013-06-25 20:36:31 +0100","NO","AIMS, BAS, SAS were portrayed very differently to other scales - allowing computation of data but not giving clear person-based numbers for the ratings.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zimbroff-2007","2013-06-25 20:38:25 +0100","NO","Random sequence generation (selection bias)","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zou-2006","2013-06-25 20:40:41 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zou-2006","2013-06-25 20:40:41 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zou-2006","2013-06-25 20:40:41 +0100","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zou-2006","2013-06-25 20:40:41 +0100","UNKNOWN","Unclear if outcome was assessed blindly.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zou-2006","2013-06-25 20:40:41 +0100","UNKNOWN","Unclear if there was drop-out.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zou-2006","2013-06-25 20:40:43 +0100","YES","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Aripiprazole versus other atypical antipsychotics for schizophrenia [v6.7-For publication].rm5","STD-Zou-2006","2013-06-25 20:40:47 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Aripiprazole for schizophrenia [v10.0-For publication].rm5","STD-Adson-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole for schizophrenia [v10.0-For publication].rm5","STD-Carson-2000-a","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole for schizophrenia [v10.0-For publication].rm5","STD-Carson-2002-b","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole for schizophrenia [v10.0-For publication].rm5","STD-Csernansky-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole for schizophrenia [v10.0-For publication].rm5","STD-Daniel-2000","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole for schizophrenia [v10.0-For publication].rm5","STD-Daniel-2004","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole for schizophrenia [v10.0-For publication].rm5","STD-Kane-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole for schizophrenia [v10.0-For publication].rm5","STD-Kern-2001","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole for schizophrenia [v10.0-For publication].rm5","STD-Kujawa-2002","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole for schizophrenia [v10.0-For publication].rm5","STD-Marcus-2005","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole for schizophrenia [v10.0-For publication].rm5","STD-McQuade-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole for schizophrenia [v10.0-For publication].rm5","STD-Oren-2005","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole for schizophrenia [v10.0-For publication].rm5","STD-Potkin-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole for schizophrenia [v10.0-For publication].rm5","STD-Riera-2004","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Aripiprazole for schizophrenia [v10.0-For publication].rm5","STD-Stock-2005","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Casey-2003","2010-10-29 05:05:09 +0100","YES","Comment: method not stated but authors report this was done via a ""centralised telephone system"". We feel this indicates the likely use of a random sequence generation process.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Casey-2003","2010-10-29 05:05:16 +0100","YES","Comment: this would adequately conceal allocation.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Casey-2003","2010-10-12 04:22:36 +0100","YES","Comment: lack of blinding is less prone to cause bias for outcomes like weight. Lack of blinding may introduce bias for subjective outcomes like adverse events.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Casey-2003","2010-10-29 05:06:08 +0100","UNKNOWN","The total number randomised was 311 but safety data set had 309 people only. Unsure what happened to the rest.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Casey-2003","2010-06-27 11:56:16 +0100","YES","","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Casey-2003","2009-07-03 11:30:51 +0100","NO","Sponsored by interested industry.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Cookson-1986","2010-10-12 04:23:04 +0100","YES","Comment: we feel there is adequate sequence generation","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Cookson-1986","2010-10-12 04:23:18 +0100","UNKNOWN","No mention about concealment of allocation.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Cookson-1986","2010-10-12 04:23:21 +0100","YES","Comment: the methods used if any to ensure participants and trialists were blind to the interventions used are not described. We feel as the primary outcome is objective (weight) inadequate blinding is unlikely to cause bias.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Cookson-1986","2010-10-29 05:08:30 +0100","NO","Scales were used for assessment of mental state and side effects, but no data available from these.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Cookson-1986","2010-06-27 11:59:05 +0100","YES","","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Cookson-1986","2009-07-03 12:19:37 +0100","YES","","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Eli-Lilly-2004","2010-10-29 05:11:28 +0100","UNKNOWN","Comment: as the method is not stated it is not clear whether there was adequate sequence generation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Eli-Lilly-2004","2010-06-27 17:36:39 +0100","UNKNOWN","No data in the report about allocation concealment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Eli-Lilly-2004","2010-10-29 05:11:39 +0100","YES","Comment: the methods used if any to ensure participants and trialists were blind to the interventions used are not reported, but both the intervention medication and the control were in capsule forms. We feel inadequate blinding is not likely to introduce bias for objective outcomes like weight BMI and metabolic syndrome.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Eli-Lilly-2004","2010-10-29 05:13:20 +0100","UNKNOWN","20/68 missing from the control group compared to 37/65 in the intervention group. Reasons for discontinuation differ across both groups particularly in lack of efficacy (3/65 in intervention group and 1/68 in control group), clinical decision/lost to follow-up 3/65 intervention group vs 0/68 in control group and patient decision (3/65 vs 1/68).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Eli-Lilly-2004","2010-10-29 05:13:37 +0100","UNKNOWN","No reports from the various scales mentioned in the methods section. Authors state as the protocol was terminated early ""some planned secondary analysis unfeasible or irrelevant"".","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Eli-Lilly-2004","2009-07-03 12:23:01 +0100","NO","Protocol was terminated early prior to breaking the blind. Sponsored by interested industry.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Newcomer-2008","2010-10-12 04:24:13 +0100","NO","Comment: we do not feel this is an adequate random sequence generation process.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Newcomer-2008","2010-04-20 15:18:28 +0100","UNKNOWN","Not mentioned.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Newcomer-2008","2010-10-29 05:16:33 +0100","YES","Comment: methods taken to ensure blindness not reported. For outcomes like weight, BMI, waist circumference and metabolic syndrome, inadequate blinding is unlikely to cause bias.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Newcomer-2008","2010-10-29 05:16:43 +0100","UNKNOWN","No numerical data on vital signs, ECG and routine laboratory tests.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Newcomer-2008","2010-06-27 12:00:37 +0100","YES","","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems [v4.0-For publication].rm5","STD-Newcomer-2008","2010-10-29 05:16:55 +0100","UNKNOWN","Some authors are employed by an interested drug industry.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Cole-1964","2011-04-04 17:45:31 +0100","YES","Randomised - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Cole-1964","2011-04-04 17:45:33 +0100","YES","Individually numbered containers of medicines.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Cole-1964","2011-04-04 17:45:36 +0100","UNKNOWN","Double blind, untested.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Cole-1964","2011-04-04 17:45:42 +0100","NO","Study attrition reported (not addressed in analysis).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Cole-1964","2011-04-04 17:45:44 +0100","UNKNOWN","No details.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Cole-1964","2011-04-04 17:45:46 +0100","UNKNOWN","No details.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-May-1976","2011-04-04 17:46:33 +0100","YES","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-May-1976","2011-04-04 17:46:39 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-May-1976","2011-04-04 17:46:41 +0100","NO","Open study.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-May-1976","2010-01-07 21:02:06 +0000","UNKNOWN","Study attrition not reported. Successive follow-up studies have diminishing sample size. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-May-1976","2011-04-04 17:46:45 +0100","UNKNOWN","No details.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-May-1976","2010-01-07 21:00:52 +0000","NO","Criteria used to select the ""middle third of prognostic spectrum"" not specified. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Mosher-1995","2011-04-04 17:47:46 +0100","YES","Reported as ""randomly assigned"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Mosher-1995","2010-01-07 21:11:13 +0000","UNKNOWN","No details. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Mosher-1995","2010-01-07 21:04:21 +0000","NO","Treated at different sites.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Mosher-1995","2011-04-04 17:47:49 +0100","UNKNOWN","Data reported for patients receiving minimum duration of treatments (7+ days of hospital treatment or 28+ days of therapeutic milieu).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Mosher-1995","2011-04-04 17:47:51 +0100","UNKNOWN","No details.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Mosher-1995","2011-04-04 17:47:53 +0100","UNKNOWN","No details.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Rappaport-1978","2011-04-04 17:48:44 +0100","YES","Randomly assigned (no further description).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Rappaport-1978","2011-04-04 17:48:45 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Rappaport-1978","2011-04-04 17:48:49 +0100","YES","Reported that ""staff remain blind to whether the patient was receiving medication or placebo"".","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Rappaport-1978","2010-01-07 21:09:17 +0000","UNKNOWN","No details. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Rappaport-1978","2009-10-12 08:53:03 +0100","YES","Differential attrition reported by authors. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Rappaport-1978","2010-01-07 21:11:58 +0000","UNKNOWN","No further details. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Simon-1965","2011-04-04 17:49:28 +0100","YES","Randomised - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Simon-1965","2011-04-04 17:49:30 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Simon-1965","2011-04-04 17:49:32 +0100","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Simon-1965","2011-04-04 17:49:34 +0100","UNKNOWN","No details.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Simon-1965","2011-04-04 17:49:36 +0100","UNKNOWN","No details.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Antipsychotic medication for early episode schizophrenia [v5.0-For publication].rm5","STD-Simon-1965","2011-04-04 17:50:27 +0100","UNKNOWN","No details.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Antipsychotic drug treatment for elderly people with late-onset schizophrenia [v7.0-For publication].rm5","STD-Huang-2007","2011-04-05 12:32:10 +0100","YES","Randomised via random number table. Chumbo Li phoned the author on 26th July, 2010. The author stated that allocation was according to random number table.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Antipsychotic drug treatment for elderly people with late-onset schizophrenia [v7.0-For publication].rm5","STD-Huang-2007","2011-09-28 12:40:50 +0100","UNKNOWN","Allocation concealment not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Antipsychotic drug treatment for elderly people with late-onset schizophrenia [v7.0-For publication].rm5","STD-Huang-2007","2011-09-28 12:40:51 +0100","NO","There was no blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic drug treatment for elderly people with late-onset schizophrenia [v7.0-For publication].rm5","STD-Huang-2007","2011-09-28 12:40:52 +0100","YES","No participants left the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Antipsychotic drug treatment for elderly people with late-onset schizophrenia [v7.0-For publication].rm5","STD-Huang-2007","2011-04-05 12:32:58 +0100","UNKNOWN","The protocol was not located, unsure if selective reporting occurred.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Antipsychotic drug treatment for elderly people with late-onset schizophrenia [v7.0-For publication].rm5","STD-Huang-2007","2011-09-28 12:40:53 +0100","YES","There was no industry funding.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Amphetamines for schizophrenia [v6.0-For publication].rm5","STD-Mathew-1989","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/A-B/Amphetamines for schizophrenia [v6.0-For publication].rm5","STD-Modell-1965","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/A-B/Amphetamines for schizophrenia [v6.0-For publication].rm5","STD-Wolkin-1987","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/A-B/Amphetamines for schizophrenia [v6.0-For publication].rm5","STD-Wolkin-1994","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bai-2005","2008-12-18 10:01:18 +0000","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bai-2005","2008-12-18 10:02:16 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bai-2005","2009-02-05 17:34:28 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Objective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bai-2005","2009-10-28 08:00:11 +0000","UNKNOWN","Single, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bai-2005","2009-07-21 12:12:12 +0100","YES","The rate of leaving the study early was only 5% and data on reasons for leaving early were provided. All data were analysed on an intent to treat basis with the last-observation-carried-forward method. This method is not perfect, but due to the very low attrition the risk of bias was low.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bai-2005","2009-01-21 15:47:21 +0000","NO","The study is only available as an abstract. Data on BPRS and EPS scales were not available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bai-2005","2009-01-22 11:01:20 +0000","UNKNOWN","Insufficient data to judge on baseline imbalance or industry sponsoring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Hwang-2003","2008-12-18 10:02:03 +0000","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Hwang-2003","2008-12-18 10:02:01 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Hwang-2003","2009-02-08 11:19:53 +0000","YES","Double, identical capsules. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Objective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Hwang-2003","2009-10-28 08:01:14 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Hwang-2003","2009-07-21 12:17:49 +0100","YES","The rate of participants leaving the study early was below 10% and data on reasons for leaving early were available. The data were analysed on an intent to treat basis with the last-observation-carried-forward method. This method is not perfect, but due to the very low attrition the risk of bias was low.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Hwang-2003","2009-07-21 12:17:58 +0100","NO","Data on the extrapyramidal symptom scale have not been presented. Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Hwang-2003","2009-02-05 17:06:46 +0000","NO","The study was sponsored by the manufacturer of amisulpride.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lecrubier-2006","2008-12-18 10:02:37 +0000","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lecrubier-2006","2008-12-18 10:03:00 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lecrubier-2006","2009-02-08 11:24:08 +0000","YES","Double, no further details. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Objective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lecrubier-2006","2009-10-28 08:03:18 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lecrubier-2006","2009-07-21 12:47:51 +0100","NO","The rate of leaving the study early was high (57.6%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if they had remained in the study. This assumption can often be wrong and poses a problem given the high attrition.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lecrubier-2006","2009-07-21 12:36:33 +0100","NO","Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lecrubier-2006","2009-02-09 12:40:09 +0000","NO","The study was industry sponsored by the manufacturers of olanzapine and one of the authors is an employee of that company.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-M_x00f6_ller-2005","2008-12-18 10:04:01 +0000","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-M_x00f6_ller-2005","2008-12-18 10:03:59 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-M_x00f6_ller-2005","2009-02-08 11:29:49 +0000","YES","Double, no further details. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Objective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-M_x00f6_ller-2005","2009-10-28 08:04:46 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-M_x00f6_ller-2005","2009-02-08 11:31:49 +0000","NO","Numbers of participants leaving the study early were only reported for the category 'due to adverse effects'. The statistical method used to account for incomplete data was not described.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-M_x00f6_ller-2005","2009-02-08 11:32:28 +0000","NO","The study is only available as an abstract. The data for primary outcomes were either not available or only available in percentage change without a standard deviation.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-M_x00f6_ller-2005","2009-02-08 11:33:04 +0000","NO","The study was sponsored by the manufacturer of amisulpride. Whether there was baseline imbalance could not be judged due to insufficient data.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Mortimer-2004","2008-12-18 10:03:19 +0000","YES","Random, computer-generated randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Mortimer-2004","2009-07-21 12:55:31 +0100","YES","The computer generated randomisation list was prepared and kept outside the study centre. The participant numbers were assigned in strict chronological order in each centre.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Mortimer-2004","2009-02-08 11:27:06 +0000","YES","Double, identical capsules. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Objective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Mortimer-2004","2009-10-28 08:04:15 +0000","UNKNOWN","Double, identical capsules (""to permit dose adjustment whilst maintaining the double-blind, blister packs corresponding to a low and a high dosage were provided""). Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Mortimer-2004","2009-07-21 12:55:59 +0100","UNKNOWN","The rate of leaving the study early was 35.8%. The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can often be wrong. It is unclear whether this led to bias .","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Mortimer-2004","2009-07-21 12:56:05 +0100","NO","Only treatment emergent adverse events occurring in 5% of the participants are presented, therefore important side effects may have been missed by this procedure.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Mortimer-2004","2009-02-05 17:06:11 +0000","NO","The study was sponsored by the manufacturer of amisulpride.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Olie-2006","2009-07-21 13:04:15 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Olie-2006","2009-07-21 13:02:30 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Olie-2006","2009-02-05 17:35:25 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Objective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Olie-2006","2009-10-28 08:05:31 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Olie-2006","2009-02-08 11:36:12 +0000","UNKNOWN","The rate of leaving the study early was about 25%, the analysis was based on the 'least squares mean change' (last-observation-carried-forward). It is unclear whether the degree of attrition and the method used to account for it led to bias. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Olie-2006","2009-07-21 13:03:42 +0100","NO","Predefined laboratory data and data on the Global Assessment of Functioning Scale have not been presented. Treatment emergent adverse events had to occur with an incidence of 5% for reporting, therefore important side effects may have been missed by this procedure.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Olie-2006","2009-07-21 13:03:59 +0100","NO","The study was sponsored by the manufacturers of ziprasidone.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Peuskens-1999","2008-12-18 10:05:13 +0000","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Peuskens-1999","2008-12-18 10:05:11 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Peuskens-1999","2009-02-05 17:35:33 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Objective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Peuskens-1999","2009-10-28 08:06:29 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds in side effects. This may be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Peuskens-1999","2009-07-21 14:17:58 +0100","NO","The rate of leaving the study early was 30.3%. Statistical analysis was based on an intent to treat basis. The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can often be wrong.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Peuskens-1999","2009-07-21 14:18:14 +0100","NO","Data on general functioning (a secondary outcome) were not available. Adverse effects had to occur with an incidence of at least 5% to be reported. Rare but important side effects may have been missed by this procedure.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Peuskens-1999","2009-02-05 17:05:09 +0000","NO","The study was sponsored by the manufacturer of amisulpride.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Sechter-2002","2008-12-18 10:05:44 +0000","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Sechter-2002","2008-12-18 10:05:42 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Sechter-2002","2009-02-08 11:37:52 +0000","YES","Double, no further details. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Objective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Sechter-2002","2009-10-28 08:07:14 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Sechter-2002","2009-07-21 14:24:28 +0100","NO","The rate of participants leaving the study early was considerable (40%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can often be wrong.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Sechter-2002","2009-07-21 14:24:35 +0100","NO","Adverse effects had to occur with an incidence of at least 5% to be reported. Rare but important side effects may have been missed by this procedure.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Sechter-2002","2009-02-05 17:04:57 +0000","NO","The study was sponsored by the manufacturer of amisulpride.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Vanelle-2006","2008-12-18 10:06:14 +0000","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Vanelle-2006","2008-12-18 10:06:13 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Vanelle-2006","2009-02-08 11:40:49 +0000","YES","Double, no further details. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Objective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Vanelle-2006","2009-10-28 08:07:59 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Vanelle-2006","2009-02-11 18:46:14 +0000","YES","The rate of participants leaving the study early was 16.5% and reasons for leaving the study early were provided. The analysis was based on the last-observation carried forward method with two people being excluded due to no exploitable outcome data. In addition there was a per protocol population which excluded subjects with a major protocol deviation. As two different methods with similar results were applied and as the overall attrition was low we do not think that there was a bias.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Vanelle-2006","2009-01-22 09:02:08 +0000","NO","Data on extrapyramidal symptoms were not provided. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Vanelle-2006","2009-07-21 14:36:17 +0100","NO","The study was sponsored by the manufacturers of amisulpride. There was a relatively high number of participants (18) with major protocol deviations.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wagner-2005","2009-02-10 11:54:32 +0000","UNKNOWN","Random, medication containers according to a pseudo-random computer algorithm.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wagner-2005","2008-12-18 10:06:41 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wagner-2005","2009-02-08 11:46:33 +0000","YES","Double, no further details. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Objective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wagner-2005","2009-10-28 08:08:44 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wagner-2005","2009-07-21 14:42:24 +0100","NO","The rate of participants leaving the study early was high (50%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can often be wrong and lead to bias in cases of high attrition.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wagner-2005","2009-02-08 11:47:22 +0000","NO","Additional treatment with biperiden up to 4mg/day was permitted, but data on use of antiparkinson medication was not available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Amisulpride versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wagner-2005","2009-02-05 17:04:36 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-Boyer-1995","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-Carri_x00e8_re-2000","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-Colonna-2000","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-Costa-e-Silva-1989","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-Danion-1999","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-Delcker-1990","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-Klein-1985","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-Loo-1997","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-M_x00f6_ller-1997","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-Paill_x00e8_re_x002d_Martinot-95","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-Peuskens-1999","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-Pichot-1988a","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-Pichot-1988b","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-Puech-1998","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-R_x00fc_ther-1988","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-Saletu-1994","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-Speller-1997","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-Wetzel-1998","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Amisulpride for schizophrenia [v11.3-For publication].rm5","STD-Ziegler-1989","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Advance treatment directives for people with severe mental illness [v8.0-For publication].rm5","STD-Henderson-2004-a","2008-11-05 19:06:59 +0000","YES","Allocation sequence generated using minimization, stratified by team and by severity of patients' condition to ensure even distribution of these features. Predictability of allocation avoided by random reassignment of one patient per batch.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Advance treatment directives for people with severe mental illness [v8.0-For publication].rm5","STD-Henderson-2004-a","2008-11-05 19:07:23 +0000","YES","Allocation not revealed to investigator.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Advance treatment directives for people with severe mental illness [v8.0-For publication].rm5","STD-Henderson-2004-a","2008-11-11 10:48:09 +0000","YES","One investigator collected follow-up data and was blinded to treatment group. Double-blinding not possible due to nature of intervention.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Advance treatment directives for people with severe mental illness [v8.0-For publication].rm5","STD-Henderson-2004-a","2008-11-05 19:24:09 +0000","YES","Intention-to-treat analyses.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Advance treatment directives for people with severe mental illness [v8.0-For publication].rm5","STD-Henderson-2004-a","2008-11-05 19:08:54 +0000","YES","Reported all data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Advance treatment directives for people with severe mental illness [v8.0-For publication].rm5","STD-Henderson-2004-a","2008-11-11 10:48:23 +0000","NO","Rate of hospital admission among control group lower than expected from pilot study. Only 36% of eligible patients agreed to participate. However, had high rate of follow-up for reported outcomes.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Advance treatment directives for people with severe mental illness [v8.0-For publication].rm5","STD-Papageorgiou-2002","2008-11-10 14:28:23 +0000","UNKNOWN","Random allocation using block design in blocks of 12 (6 experimental, 6 control), stratified by first ever or subsequent sectioning. Block randomisation in known block sizes allows for identification of allocation of at least the 12th participant per block if block size is known to investigators.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Advance treatment directives for people with severe mental illness [v8.0-For publication].rm5","STD-Papageorgiou-2002","2008-11-05 19:30:50 +0000","UNKNOWN","Allocation provided in sealed envelopes. Independent colleague selected next envelope. As above, is possible to identify allocation of at least the 12th participant per block. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Advance treatment directives for people with severe mental illness [v8.0-For publication].rm5","STD-Papageorgiou-2002","2008-11-05 19:34:25 +0000","NO","""It was impossible to mask the research assistants to the patients' allocation as they were required to assist patients to make a directive in those allocated to the intervention group. However, systematic bias was unlikely as the primary outcome concerned compulsory hospital admission and was not based on any later assessment by the researcher."" Bias possible for secondary outcome measures.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Advance treatment directives for people with severe mental illness [v8.0-For publication].rm5","STD-Papageorgiou-2002","2008-11-05 19:26:04 +0000","YES","Intention-to-treat analysis, with exception of 5 (1 intervention, 4 control) patients not discharged from hospital.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Advance treatment directives for people with severe mental illness [v8.0-For publication].rm5","STD-Papageorgiou-2002","2008-11-05 19:35:44 +0000","YES","Reported all data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Advance treatment directives for people with severe mental illness [v8.0-For publication].rm5","STD-Papageorgiou-2002","2008-11-11 10:55:02 +0000","NO","In both arms, fewer than expected patients were compulsorily re-admitted, leading to lower statistical power than anticipated. Potential for lack of sustained awareness of directives throughout the 12 months of follow-up. Key workers in one of the two psychiatric services were often not allocated before patients were discharged, potentially reducing the effect of the directives.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Akhondzadeh-2008","2010-01-29 15:14:22 +0000","UNKNOWN","No information available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Akhondzadeh-2008","2010-01-29 15:14:28 +0000","NO","Not done.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Akhondzadeh-2008","2011-11-29 15:42:53 +0000","YES","Both the participants and investigators were blinded to the intervention. Identical appearing tablets were used, effectiveness of this method was not mentioned.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Akhondzadeh-2008","2010-01-29 15:14:51 +0000","YES","No missing outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Akhondzadeh-2008","2010-01-29 15:15:23 +0000","YES","All of the study's pre-specified outcomes are reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Akhondzadeh-2008","2010-01-29 15:15:33 +0000","UNKNOWN","No information available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Buchanan-2008","2010-04-16 16:57:51 +0100","UNKNOWN","No information available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Buchanan-2008","2010-01-29 15:16:57 +0000","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Buchanan-2008","2011-11-29 15:42:53 +0000","YES","Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Buchanan-2008","2010-01-29 15:17:23 +0000","UNKNOWN","No information available.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Buchanan-2008","2010-01-29 15:17:49 +0000","YES","All outcomes measured and reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Buchanan-2008","2010-01-29 15:18:13 +0000","UNKNOWN","Funded by independent bodies, but authors reported affiliation to various drug companies.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Caroff-2007","2010-01-29 15:07:47 +0000","UNKNOWN","No information available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Caroff-2007","2010-01-29 15:19:00 +0000","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Caroff-2007","2010-01-29 15:19:21 +0000","UNKNOWN","No information available.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Caroff-2007","2010-01-29 15:19:38 +0000","UNKNOWN","No information available.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Caroff-2007","2010-01-29 15:19:56 +0000","YES","Not enough information available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Caroff-2007","2010-04-16 16:57:51 +0100","NO","Mention of support from drug company Pfizer.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Chouinard-2007","2010-01-29 15:21:25 +0000","UNKNOWN","No information available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Chouinard-2007","2010-01-29 15:21:39 +0000","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Chouinard-2007","2011-11-29 15:42:53 +0000","YES","Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Chouinard-2007","2010-01-29 15:22:06 +0000","UNKNOWN","No information available.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Chouinard-2007","2010-01-29 15:22:25 +0000","YES","All outcomes measured and reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Chouinard-2007","2011-10-03 17:32:57 +0100","NO","Novartis Canada, a pharmaceutical company name was mentioned in the grant section.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Dyer-2008","2010-01-29 15:25:58 +0000","UNKNOWN","No information available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Dyer-2008","2011-11-29 15:42:54 +0000","UNKNOWN","Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Dyer-2008","2010-01-29 15:26:26 +0000","UNKNOWN","No information available.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Dyer-2008","2010-01-29 15:26:39 +0000","YES","LOCF analysis was performed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Dyer-2008","2010-01-29 15:27:14 +0000","NO","Not all outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Dyer-2008","2010-01-29 15:27:40 +0000","UNKNOWN","There is a mention of drug company affiliation.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Fagerlund-2007","2010-01-29 15:30:18 +0000","NO","No information available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Fagerlund-2007","2010-01-29 15:29:53 +0000","NO","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Fagerlund-2007","2011-11-29 15:42:54 +0000","YES","Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Fagerlund-2007","2010-09-03 13:54:00 +0100","YES","No mention about the data for the patients who left the study early for various reasons.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Fagerlund-2007","2010-01-29 15:29:05 +0000","YES","All outcomes were measured and reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Fagerlund-2007","2010-01-29 15:28:51 +0000","UNKNOWN","Supported by Pfizzer Denmark.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Freudenreich-2005","2010-01-29 15:32:15 +0000","UNKNOWN","No information available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Freudenreich-2005","2010-01-29 15:32:28 +0000","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Freudenreich-2005","2011-11-29 15:42:54 +0000","YES","Both the participants and investigators were blinded to the intervention. Identical appearing tablets were used, effectiveness of this method was not mentioned.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Freudenreich-2005","2010-01-29 15:33:15 +0000","YES","LOCF analysis was performed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Freudenreich-2005","2010-01-29 15:33:33 +0000","NO","Not all the outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Freudenreich-2005","2010-01-29 15:33:45 +0000","NO","Sponsored by Pfizer.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Friedman-2002c","2010-01-29 15:35:17 +0000","UNKNOWN","No information available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Friedman-2002c","2010-01-29 15:35:27 +0000","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Friedman-2002c","2011-11-29 15:42:54 +0000","UNKNOWN","Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Friedman-2002c","2011-11-29 15:42:54 +0000","YES","ITT analysis was performed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Friedman-2002c","2010-01-29 15:36:18 +0000","NO","Not all outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Friedman-2002c","2011-11-29 15:42:54 +0000","NO","Funding was provided by Janssen Research Foundation.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Keefe-2008a","2010-01-29 15:39:13 +0000","YES","Stratified randomisation with 1:1 ratio, computer generated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Keefe-2008a","2010-01-29 15:39:01 +0000","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Keefe-2008a","2011-11-29 15:42:55 +0000","UNKNOWN","Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Keefe-2008a","2010-01-29 15:38:36 +0000","YES","ITT and LOCF data analysis was performed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Keefe-2008a","2010-01-29 15:38:21 +0000","YES","All outcomes measured and reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Keefe-2008a","2011-11-29 15:42:55 +0000","NO","It was supported and funded by Eisai Inc and Pfizer Inc.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Kim-2005b","2010-01-29 15:40:00 +0000","UNKNOWN","Randomised in 1:1 pattern.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Kim-2005b","2010-01-29 15:40:13 +0000","UNKNOWN","Randomised in 1:1 pattern.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Kim-2005b","2011-11-29 15:42:55 +0000","YES","Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Kim-2005b","2010-01-29 15:41:06 +0000","NO","No mention of ITT or LOCF.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Kim-2005b","2010-01-29 15:40:47 +0000","UNKNOWN","Not enough information available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Kim-2005b","2010-01-29 15:41:03 +0000","UNKNOWN","Was funded in part by Inje university, Busan, South Korea.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Kohler-2007","2010-01-29 15:42:08 +0000","UNKNOWN","No information available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Kohler-2007","2010-01-29 15:42:08 +0000","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Kohler-2007","2011-11-29 15:42:55 +0000","YES","Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Kohler-2007","2011-11-29 15:42:55 +0000","NO","No ITT or LOCF analyses were performed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Kohler-2007","2010-01-29 15:42:08 +0000","UNKNOWN","Not enough information available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Kohler-2007","2010-01-29 15:42:08 +0000","UNKNOWN","No information available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Lee-2005","2010-01-29 15:42:59 +0000","UNKNOWN","No information available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Lee-2005","2010-01-29 15:42:59 +0000","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Lee-2005","2011-11-29 15:42:55 +0000","YES","Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Lee-2005","2010-01-29 15:43:04 +0000","YES","LOCF analysis was performed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Lee-2005","2010-01-29 15:42:59 +0000","UNKNOWN","Not enough information available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Lee-2005","2010-01-29 15:42:59 +0000","UNKNOWN","No information available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Nahas-2003","2010-04-16 16:57:55 +0100","UNKNOWN","No information available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Nahas-2003","2010-01-29 15:43:38 +0000","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Nahas-2003","2011-11-29 15:42:55 +0000","YES","Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Nahas-2003","2010-01-29 15:43:46 +0000","YES","All patients completed the study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Nahas-2003","2010-01-29 15:43:38 +0000","UNKNOWN","Not enough information available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Nahas-2003","2010-01-29 15:43:52 +0000","NO","Mention of the name of few pharmaceutical companies.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Schubert-2006","2010-01-29 15:44:21 +0000","UNKNOWN","No information available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Schubert-2006","2010-01-29 15:44:21 +0000","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Schubert-2006","2011-11-29 15:42:56 +0000","YES","Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Schubert-2006","2011-11-29 15:42:56 +0000","YES","LOCF analysis was performed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Schubert-2006","2010-01-29 15:44:28 +0000","YES","All outcomes measured were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Schubert-2006","2010-12-02 12:40:02 +0000","UNKNOWN","No information available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Sharma-2006","2010-01-29 15:44:56 +0000","UNKNOWN","No information available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Sharma-2006","2010-01-29 15:44:57 +0000","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Sharma-2006","2011-11-29 15:42:56 +0000","YES","Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Sharma-2006","2011-11-29 15:42:56 +0000","YES","LOCF analysis was performed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Sharma-2006","2010-01-29 15:44:57 +0000","UNKNOWN","Insufficient information..","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Sharma-2006","2010-01-29 15:44:57 +0000","UNKNOWN","Not much information available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Tugal-2003","2010-01-29 15:45:28 +0000","UNKNOWN","No information available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Tugal-2003","2010-01-29 15:45:28 +0000","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Tugal-2003","2011-11-29 15:42:56 +0000","YES","Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Tugal-2003","2011-11-29 15:42:56 +0000","UNKNOWN","All participants completed the study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Tugal-2003","2010-01-29 15:45:38 +0000","YES","All outcomes were measured and reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Tugal-2003","2011-11-29 15:42:56 +0000","UNKNOWN","Linked with pharmaceutical company-Pfizer.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Tuma-2003","2010-01-29 15:46:17 +0000","NO","No information available.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Tuma-2003","2010-01-29 15:46:21 +0000","NO","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Tuma-2003","2011-11-29 15:42:56 +0000","YES","Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Tuma-2003","2011-11-29 15:42:56 +0000","NO","Drop-outs were not included.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Tuma-2003","2011-11-29 15:42:56 +0000","NO","All outcome measures were not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/A-B/Acetylcholinesterase inhibitors for schizophrenia [v3.0-For publication].rm5","STD-Tuma-2003","2010-01-29 15:46:10 +0000","UNKNOWN","Not much information available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Adamson-1973","2013-11-06 10:20:42 +0000","UNKNOWN","""Divided randomly"", ""matched for sex, mean age, mean weight and mean plasma chlorpromazine concentrations"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Adamson-1973","2013-11-06 10:20:03 +0000","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Adamson-1973","2013-11-06 10:20:07 +0000","UNKNOWN","""Double-blind"", no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Adamson-1973","2013-11-06 10:20:15 +0000","UNKNOWN","""Double-blind"", no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Adamson-1973","2013-11-06 10:20:36 +0000","YES","No losses to follow-up reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Adamson-1973","2013-11-06 10:20:34 +0000","NO","Not all outcomes fully reported, no data reported for BPRS and WWBRS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Adamson-1973","2013-11-06 10:20:31 +0000","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Albert-1980","2013-09-22 06:37:01 +0100","UNKNOWN","""patients were randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Albert-1980","2013-09-22 06:37:19 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Albert-1980","2013-09-22 06:37:43 +0100","YES","""The identity of the medications was masked and the double blind character of the study preserved by inserting an identical placebo injection at two week intervals""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Albert-1980","2013-09-22 06:38:00 +0100","UNKNOWN","""The identity of the medications was masked and the double blind character of the study preserved by inserting an identical placebo injection at two week intervals"". Blinding of outcome assessment not specifically reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Albert-1980","2014-10-08 14:21:46 +0100","UNKNOWN","Number of patients randomised to each group have been reported. However, it is unclear if all participants completed the study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Albert-1980","2013-09-25 14:56:33 +0100","NO","Standard deviations and information on Serious Adverse Events have not been reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Albert-1980","2013-09-22 06:38:45 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Altamura-1985","2013-09-22 06:40:15 +0100","UNKNOWN","""The assignment of order of treatments was randomised"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Altamura-1985","2013-09-22 06:40:28 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Altamura-1985","2013-09-22 06:40:46 +0100","UNKNOWN","An uninvolved person administered the doses and the ampules were not seen by the patients or rater. Other involved personnel might have been unblinded.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Altamura-1985","2013-09-22 06:41:03 +0100","YES","An uninvolved person administered the doses and the ampules were not seen by the rater.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Altamura-1985","2014-10-08 14:22:06 +0100","NO","4/11 participants left early. Reasons are not reported per intervention group. Losses to follow-up/missing data imbalanced in numbers across intervention groups. 2/5 vs 2/6. The study was terminated due to to high incidence of side effects.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Altamura-1985","2014-07-06 09:14:21 +0100","NO","Results for ""unwanted effects"" not reported separately (akinesia, involuntary movement, autonomic disturbances and drowsiness) and only part of the rating scale was used. ""only two scores on the four point rating scale were... used... absent and maximum...no attempt could be made to derive a figure representing a grading of effect"". Although this is mainly a safety study, presence/absence of Serious Adverse Events not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Altamura-1985","2013-09-22 06:43:32 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Asarnow-1988","2013-09-22 06:44:28 +0100","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Asarnow-1988","2013-09-22 06:44:40 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Asarnow-1988","2013-09-22 06:44:51 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Asarnow-1988","2013-09-22 06:44:53 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Asarnow-1988","2013-09-22 06:45:12 +0100","UNKNOWN","Reported data for drop-outs is unclear. ""two patients in the GSLD and PSLD groups and one patient each in the GSSD and PSLD groups dropped out before completion...""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Asarnow-1988","2013-09-25 14:57:42 +0100","NO","Although the results for stated outcomes have been reported, the results are not presented as useful data (i.e. mean, SD). Also, not all expected outcomes were reported (e.g. presence/absence adverse events, serious adverse events)","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Asarnow-1988","2013-09-22 06:45:48 +0100","YES","The study seems to be free of other sources of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Barnes-1983","2013-09-22 06:47:41 +0100","UNKNOWN","""Patients were assigned to two groups by an independent statistician, matched on the basis of age, sex and calculated weekly fluphenazine dose""","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Barnes-1983","2013-09-22 06:47:52 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Barnes-1983","2013-09-22 06:48:03 +0100","UNKNOWN","""double blind...double dummy"" Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Barnes-1983","2013-09-22 06:48:10 +0100","UNKNOWN","Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Barnes-1983","2013-09-22 06:48:39 +0100","YES","In ""the 1-year follow-up results of all patients who had begun the trial, including drop-outs, withdrawals and relapsers, were involved in the analysis...Unfortunately, the  SBAS data were incomplete for one relapsed patient who was abroad from the time of relapse to the end of the trial.""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Barnes-1983","2014-10-08 14:24:14 +0100","NO","Results for SBAS have been reported as percentages, only. Other expected outcomes (e.g. presence/absence of adverse events, serious adverse events have not been reported).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Barnes-1983","2013-09-22 06:49:10 +0100","UNKNOWN","Source of funding has not been reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chien-1973","2013-09-30 07:57:50 +0100","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chien-1973","2013-09-30 07:57:59 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chien-1973","2013-09-30 07:59:56 +0100","UNKNOWN","Blinding of participants and personnel not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chien-1973","2013-09-30 08:00:12 +0100","UNKNOWN","""each patient was rated after 10 days of treatment on a seven-point scale of global improvement by an independent research psychiatrist who had no knowledge of the patient's medication"". Blinding methods of nurses rating NOISE not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chien-1973","2014-07-06 09:19:42 +0100","UNKNOWN","Losses to follow-up not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chien-1973","2013-09-30 08:01:37 +0100","UNKNOWN","Data for NOSIE not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chien-1973","2013-09-30 08:04:20 +0100","YES","""supported in part by Public Health Service research grant MH-16128 from the National Institute of Mental Health.""","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1978","2013-12-04 12:03:12 +0000","UNKNOWN","Random allocation. Methods of randomisation not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1978","2013-09-22 06:53:11 +0100","UNKNOWN","Allocation concealment details not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1978","2013-09-22 06:53:23 +0100","UNKNOWN","""Except for the nurse responsible for giving the injections, the procedure was double blind.""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1978","2013-09-22 06:53:33 +0100","UNKNOWN","Outcome blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1978","2013-09-25 14:59:16 +0100","YES","4 patients did not complete the study. Reasons for dropping out have been described. Number of drop-outs was balanced between the groups. ""Psychiatric evaluations of these four patients were made on the days they left the study and were used ...for the statistical analysis of the rating scale data.""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1978","2013-09-25 15:00:01 +0100","NO","Not all outcomes fully reported. The study reports most but not all expected outcomes (e.g.presence/absence serious adverse events)","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1978","2013-09-22 06:52:47 +0100","UNKNOWN","Source of funding has not been reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1982","2013-09-30 08:05:13 +0100","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1982","2013-09-30 08:08:19 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1982","2013-09-30 08:08:59 +0100","YES"," ""double-blind"". ""Both preparations were administered as identical suspensions in oil"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1982","2013-09-30 08:09:25 +0100","YES","""Assessment of psychiatric symptoms was based on clinical interviews conducted by the psychiatrist...under blind conditions"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1982","2013-09-30 08:10:56 +0100","YES","""Two patients did not complete the 28 week trial...One of these left the country after 12 weeks of treatment with fluphenazine decanoate; the other committed suicide after 22 weeks of treatment with fluphenazine enanthate"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1982","2013-09-30 08:11:21 +0100","NO","Results reported incompletely for BPRS scores. Adverse events,other than EPS and TD not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1982","2013-09-30 08:11:26 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1984","2013-09-22 06:50:42 +0100","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1984","2013-09-22 06:50:56 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1984","2013-09-22 06:51:06 +0100","UNKNOWN","""double -blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1984","2013-09-22 06:51:11 +0100","UNKNOWN","Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1984","2014-07-06 09:27:38 +0100","UNKNOWN","Losses to follow-up have not been reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1984","2014-07-06 09:27:48 +0100","NO","Most of the outcomes have been reported only as P ˂ .05.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Chouinard-1984","2013-09-22 06:51:48 +0100","UNKNOWN","Source of funding has not been reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Cookson-1986","2013-09-22 06:56:26 +0100","UNKNOWN","""...randomly assigned...Separate randomisation sequences were used for male and female patients."" Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Cookson-1986","2013-09-22 06:56:36 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Cookson-1986","2013-09-22 06:56:45 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Cookson-1986","2013-09-22 06:56:53 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Cookson-1986","2014-07-06 09:29:53 +0100","NO","Losses to follow-up are imbalanced. ""Two patients- both on the haloperidol decanoate-dropped out"".  Also, prolactin levels not measured for all subjects i.e.  ""available for six patients on fluphenazine decanoate ...and eight on  haloperidol decanoate.""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Cookson-1986","2013-09-25 15:03:33 +0100","NO","Body weight and prolactin levels have been reported. However, results of clinical assessments not fully reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Cookson-1986","2013-09-22 06:57:43 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Crawford-1974","2013-09-25 15:03:49 +0100","UNKNOWN","""randomly allocated"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Crawford-1974","2013-09-22 06:58:53 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Crawford-1974","2013-09-22 06:59:06 +0100","YES","""double-blind"". ""The preparations employed had identical appearances"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Crawford-1974","2013-09-25 15:04:11 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Crawford-1974","2014-10-08 14:24:27 +0100","NO","2 participants, both from the trifluoperazine hydrochloride group, dropped out ""within four weeks"" of the study and were not included in the analysis. Withdrawal rate was 6/15 in the trifluoperazine hydrochloride group and 2/12 in the fluphenazine group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Crawford-1974","2013-09-25 15:05:07 +0100","NO","Not all outcome data was fully reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Crawford-1974","2013-09-22 06:59:50 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Curry-1972","2013-09-22 07:01:01 +0100","UNKNOWN","""randomised"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Curry-1972","2013-09-22 07:01:13 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Curry-1972","2013-09-22 07:01:23 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Curry-1972","2013-09-22 07:01:25 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Curry-1972","2014-07-06 09:32:06 +0100","UNKNOWN","Losses to follow-up not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Curry-1972","2013-09-25 15:05:27 +0100","NO","Incomplete study results. Results not reported as mean (SD).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Curry-1972","2013-09-22 07:01:55 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Dencker-1973","2013-09-22 07:05:03 +0100","UNKNOWN","Method of sequence generation not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Dencker-1973","2013-09-22 07:05:13 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Dencker-1973","2013-09-25 15:06:23 +0100","UNKNOWN","""double blind"". "" the injections were given by a nurse, who was the only person who knew the code"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Dencker-1973","2013-09-22 07:05:47 +0100","YES","""double blind"". "" the injections were given by a nurse, who was the only person who knew the code."" ""most of rating were made by one psychologist, and the rest by one of the psychiatrists""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Dencker-1973","2013-10-03 12:02:02 +0100","YES","Losses to follow-up balanced in numbers across intervention groups 9% vs 17%.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Dencker-1973","2013-09-25 15:06:48 +0100","NO","Although all outcomes have been reported, data  for most of the outcomes (BPRS, Hamilton depression scale, side effects rating scale, rating scale for extra-pyramidal side effect) cannot be used i.e. only mean reported (SD not reported).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Dencker-1973","2013-09-22 07:08:19 +0100","UNKNOWN","Source of funding not reported","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Donlon-1976","2013-09-30 08:12:54 +0100","UNKNOWN","""assigned...on a random basis"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Donlon-1976","2013-09-30 08:13:02 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Donlon-1976","2013-09-30 08:13:17 +0100","YES","""double blind"", ""FE and FD were supplied in identical bottles"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Donlon-1976","2013-09-30 08:19:53 +0100","UNKNOWN","""double-blind"". Blinding of outcome assessors not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Donlon-1976","2013-09-30 08:19:35 +0100","UNKNOWN","Losses to follow-up not reported. 41 participants randomised, but number in each group not reported. Allocation per group reported for 30 patients: ""Eleven patients either voluntarily dropped out or were lost to follow-up prior to the end of 1 month...3 patients on FE terminated during the second month"", other reasons for leaving early not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Donlon-1976","2014-07-06 09:36:00 +0100","NO","CGI and BPRS results incompletely reported (only P values).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Donlon-1976","2013-09-30 08:20:06 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Dotti-1979","2013-09-30 09:44:40 +0100","UNKNOWN","""Randomised"", no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Dotti-1979","2013-09-30 09:45:10 +0100","UNKNOWN","Medication was prepared in a pharmacy, but no details of allocation concealment reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Dotti-1979","2013-09-30 09:45:28 +0100","UNKNOWN","""Double blind"", no details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Dotti-1979","2013-09-30 09:45:35 +0100","UNKNOWN","""Double blind"", no details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Dotti-1979","2013-09-30 09:51:21 +0100","NO","Four participants left the study early, one from the fluphenazine group and three from the placebo group, reasons not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Dotti-1979","2013-09-30 09:51:45 +0100","YES","All outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Dotti-1979","2013-09-30 09:58:17 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Falloon-1978","2013-09-22 07:09:28 +0100","UNKNOWN","""randomly allocated"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Falloon-1978","2013-09-22 07:09:37 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Falloon-1978","2013-09-25 15:07:26 +0100","UNKNOWN","""double- blind control conditions...active pimozide tablets +inert fluphenazine injections, or...active fluphenazine injections +inert pimozide tablets."" Blinding of personnel unclear.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Falloon-1978","2013-09-22 07:10:02 +0100","UNKNOWN","""double- blind"". Blinding of outcome assessor unclear.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Falloon-1978","2013-09-25 15:07:48 +0100","NO","Three patients (all from one group) were withdrawn, losses to follow-up are unbalanced.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Falloon-1978","2013-09-22 07:10:48 +0100","NO","Incomplete reporting of data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Falloon-1978","2013-09-22 07:10:57 +0100","UNKNOWN","Sources of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Feng-1990","2013-09-22 07:11:50 +0100","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Feng-1990","2013-09-22 07:12:01 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Feng-1990","2013-09-22 07:12:20 +0100","UNKNOWN","""double blind...patients and doctors did not know what kind of medicine to be applied till end of treatment"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Feng-1990","2013-09-22 07:12:30 +0100","UNKNOWN","""double blind...patients and doctors did not know what kind of medicine to be applied till end of treatment"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Feng-1990","2013-09-25 15:14:45 +0100","NO","Losses to follow-up unbalanced between groups: 3 (20%) in the haloperidol group and 1 (7%) in the fluphenazine group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Feng-1990","2013-09-25 15:13:39 +0100","NO","CGI outcome data not reported, no usable data for MIE and SAS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Feng-1990","2013-09-22 07:13:40 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Frangos-1978","2013-10-02 12:12:27 +0100","UNKNOWN","""randomly allocated"", ""according to a randomisation code"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Frangos-1978","2013-09-22 07:14:46 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Frangos-1978","2013-12-04 12:07:38 +0000","UNKNOWN","""all patients were treated with weekly injections; fluspirilene administered every week and fluphenazine decanoate every 2 weeks with placebo...in the between periods"". Blinding details of personnel administering the injections not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Frangos-1978","2013-09-22 07:16:50 +0100","YES","""randomisation code unknown to the investigators involved with the patient evaluation"". ""investigators concerned with drug administration were not involved in the patient evaluations"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Frangos-1978","2014-07-06 09:39:51 +0100","UNKNOWN","No details reported, losses to follow-up not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Frangos-1978","2014-07-06 12:27:45 +0100","NO","Data reported incompletely: only P values for BPRS,  NOISE-30, and extrapyramidal symptoms. Adverse events reported, presence/absence of serious adverse events not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Frangos-1978","2013-09-22 07:17:37 +0100","UNKNOWN","Source of funding has not been reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Goldstein-1978","2013-09-22 07:18:51 +0100","UNKNOWN","""...patient was... assigned by a random method"". Details of method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Goldstein-1978","2013-09-22 07:19:00 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Goldstein-1978","2013-09-25 15:44:22 +0100","UNKNOWN",""" single blind...the patient was blind to the dose level but the treating psychiatrist was not"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Goldstein-1978","2013-09-22 07:19:38 +0100","YES","""...all ratings of clinical behavior were carried out by raters blind to drug and family therapy status.""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Goldstein-1978","2014-07-06 09:41:16 +0100","UNKNOWN","""...eight withdrew after release from the hospital... treatment refusers came from three groups; high dose therapy (two), low dose therapy (three), low dose no therapy (three)."" None of the participants
 from high dose no therapy dropped out.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Goldstein-1978","2013-09-22 07:20:29 +0100","NO","Relapse reported. Data for BPRS not reported as mean SD, data for family therapy not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Goldstein-1978","2013-09-22 07:21:46 +0100","YES","Supported by grants from National Institute for Mental Health","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hirsch-1975","2013-11-06 10:23:25 +0000","UNKNOWN","""Randomly allocated by a research assistant"", no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hirsch-1975","2013-11-06 10:23:31 +0000","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hirsch-1975","2013-11-06 10:23:38 +0000","UNKNOWN","""Double-blind"", ""A number of checks by questionnaires filled out by the doctors, nurses, and the patient's general practitioner confirmed that the double-blind procedure had been successful"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hirsch-1975","2013-11-06 10:23:42 +0000","UNKNOWN","""Double-blind"", details of blinding of outcome assessors not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hirsch-1975","2013-11-06 10:23:49 +0000","YES","""One patient had [drugs from other sources], and he was excluded from the analysis"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hirsch-1975","2013-11-06 10:24:02 +0000","NO","Some outcomes were not fully reported: no data for PSE and SPS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hirsch-1975","2013-11-06 10:23:59 +0000","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hogarty-1979","2013-09-22 07:28:50 +0100","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hogarty-1979","2013-09-22 07:29:01 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hogarty-1979","2013-09-25 15:46:42 +0100","UNKNOWN","""double-blind"". Subjects blinded; ""...providing each patient with an injection and tablets i.e. active injections of fluphenazine decanoate with inactive placebo tablets or placebo injections...with active...tablets. The active and placebo forms of the medication were identical in appearance."" Blinding of details of personnel not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hogarty-1979","2013-09-22 07:30:14 +0100","UNKNOWN","Blinding of details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hogarty-1979","2013-09-25 15:47:30 +0100","UNKNOWN","Insufficient information: number of subjects allocated per group unclear; ""...the analyses included only patients known to be receiving their injection... and who appeared for their prescribed oral medication, independent whether they... took their tablets or not.""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hogarty-1979","2013-09-25 15:47:51 +0100","NO","Outcomes not reported (SSI, HCI, KAS) or incompletely reported (BPRS).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hogarty-1979","2013-09-22 07:31:21 +0100","YES","""...supported by Psychopharmacology Research Branch, National Institute of Mental Health"".","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hogarty-1988","2013-09-22 07:22:46 +0100","UNKNOWN","""random"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hogarty-1988","2013-09-22 07:22:57 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hogarty-1988","2014-07-06 12:15:02 +0100","UNKNOWN","""double-blind"". ""...injections were provided by two non blinded nurses who scrupulously concealed the information on dose assignment from patients and the treating clinical research team. Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hogarty-1988","2014-07-06 12:15:12 +0100","UNKNOWN","""double-blind"". ""...injections were provided by two non blinded nurses who scrupulously concealed the information on dose assignment from patients and the treating clinical research team. Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hogarty-1988","2013-09-25 15:53:42 +0100","YES","Drop-outs have been reported per group of intervention.  Overall losses to follow-up data balanced across intervention groups: 14 (42%) drop-outs at standard dose and 16 (43%) drop-outs at minimal dose, with similar reasons for missing data. Dropouts for clinical reasons (relapse) also balanced.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hogarty-1988","2013-09-25 15:53:47 +0100","NO","Outcome data (BPRS, MRQ, SCL-90, social performance) incompletely reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hogarty-1988","2013-09-22 07:27:35 +0100","YES","Funded by a grant from the Schizophrenia Research Branch, National Institute of Mental Health.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hranov-1998","2013-09-22 07:32:14 +0100","UNKNOWN",""" randomised"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hranov-1998","2013-09-22 07:32:23 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hranov-1998","2013-09-22 07:32:33 +0100","UNKNOWN","Blinding not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hranov-1998","2013-09-22 07:32:35 +0100","UNKNOWN","Blinding not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hranov-1998","2013-09-25 15:58:48 +0100","NO","6 (30%) participants in the fluphenazine group and 4 (19%) in the haloperidol group left the study early. Reasons for leaving early not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hranov-1998","2013-09-25 16:00:00 +0100","NO","Outcome results reported incompletely.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Hranov-1998","2013-09-22 07:33:32 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Jain-1975","2013-09-22 07:34:13 +0100","UNKNOWN","""randomised"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Jain-1975","2013-09-22 07:34:22 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Jain-1975","2013-09-22 07:34:31 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Jain-1975","2013-09-22 07:34:41 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Jain-1975","2013-09-25 16:02:26 +0100","NO","Losses to follow-up unbalanced between groups: 4 (27%) participants left the study early in the pipothiazine group and 1 (5%) in the fluphenazine group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Jain-1975","2013-09-25 16:02:56 +0100","NO","Outcome data incompletely reported for BPRS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Jain-1975","2013-09-22 07:35:26 +0100","YES","Partially supported by Public Health Service Grant from the Department of Health, Education and Welfare, Washington D.C.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Javed-1991","2013-09-22 07:37:43 +0100","UNKNOWN","""randomised"".  Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Javed-1991","2013-09-22 07:37:53 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Javed-1991","2013-09-22 07:38:02 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Javed-1991","2013-09-22 07:38:03 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Javed-1991","2013-09-25 16:03:22 +0100","UNKNOWN","7/45 patients dropped out of the study. 1/7 died and 6/7 ""dropped out for reasons not related to the treatment...did not keep up their appointments."" The number of drop-outs not reported across the intervention group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Javed-1991","2013-09-22 07:38:33 +0100","NO","All outcomes reported as mean scores (without SD): CGI, BPRS, Hamilton, SAS, Side effects checklist (side effects not described). Serious adverse events not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Javed-1991","2013-09-22 07:38:42 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Jolley-1990","2013-09-22 07:39:29 +0100","UNKNOWN","""randomised"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Jolley-1990","2013-10-01 10:40:34 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Jolley-1990","2013-10-01 10:40:34 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Jolley-1990","2013-10-01 10:40:34 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Jolley-1990","2013-10-03 08:45:36 +0100","YES","Losses to follow up balanced across the groups: 5 (19%) in the placebo group and 6 (22%) in the treatment group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Jolley-1990","2013-10-01 10:40:34 +0100","NO","Not all outcomes have been fully reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Jolley-1990","2013-10-01 10:40:34 +0100","YES","Supported by grants from The Department for Health and Social Security, North West Thames Regional Research Fund and the Priory hospital.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Ju-2000","2013-10-02 09:15:49 +0100","UNKNOWN","Randomised, no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Ju-2000","2013-10-02 09:16:00 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Ju-2000","2013-10-01 10:40:48 +0100","UNKNOWN","Not mentioned.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Ju-2000","2013-10-01 10:40:51 +0100","UNKNOWN","Not mentioned.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Ju-2000","2014-07-06 09:52:39 +0100","YES","All the patients complete the 12-week treatment.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Ju-2000","2013-10-01 10:41:04 +0100","YES","All the outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Ju-2000","2013-10-01 10:41:39 +0100","YES","No other sources of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kane-1978","2013-12-04 09:37:16 +0000","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kane-1978","2013-12-04 09:37:16 +0000","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kane-1978","2013-12-04 09:40:23 +0000","UNKNOWN","Blinding details of personnel and patients not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kane-1978","2013-12-04 09:40:26 +0000","YES","""An examination of extrapyramidal side effects was carried out ...by a physician blind to the type of injection received"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kane-1978","2014-07-06 12:16:09 +0100","YES","Losses to follow-up or missing data balanced across intervention groups, with similar reasons for missing data. ""The data was incomplete in 11 patients (22%) due to noncompliance. 10 of these 11 patients missed the 2-week examination. There was no significant difference in compliance between the fluphenazine enanthate and fluphenazine decanoate groups"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kane-1978","2013-12-04 09:41:06 +0000","NO","The study reports only the primary outcome i.e. extrapyramidal symptoms. Other expected outcomes (e.g. relapse, hospital admission, non-EPS adverse events) have not been reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kane-1978","2013-12-04 09:41:23 +0000","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kane-1983","2013-09-22 07:41:10 +0100","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kane-1983","2013-09-22 07:41:21 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kane-1983","2013-09-22 07:41:30 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kane-1983","2013-09-22 07:41:37 +0100","UNKNOWN","Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kane-1983","2013-09-25 16:06:55 +0100","UNKNOWN","Losses to follow-up not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kane-1983","2013-09-25 16:06:26 +0100","NO","Outcome data for BPRS and CGI not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kane-1983","2013-09-22 07:42:11 +0100","YES","""...supported, in part, by grants...from the National Institute of Mental Health"".","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kaneno-1991","2013-09-30 08:26:26 +0100","UNKNOWN","Randomisation details not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kaneno-1991","2013-09-30 08:26:36 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kaneno-1991","2013-09-30 08:26:42 +0100","UNKNOWN","""double blind"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kaneno-1991","2013-09-30 08:26:48 +0100","UNKNOWN","Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kaneno-1991","2014-10-08 15:35:48 +0100","UNKNOWN","All participants (completed and terminated) were entered to the analysis. No missing data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kaneno-1991","2013-09-30 08:42:26 +0100","NO","Data not reported fully for mental state and adverse effects.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kaneno-1991","2013-09-30 08:31:22 +0100","UNKNOWN","The paper is in Japanese.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kelly-1977","2013-09-30 08:31:45 +0100","UNKNOWN","""randomly allocated"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kelly-1977","2013-09-30 08:32:15 +0100","YES","""the key to the allocation [was] known only to the hospital pharmacist and to the nurse administering the injections"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kelly-1977","2013-09-30 08:38:01 +0100","UNKNOWN","Insufficient information: patients may have blinded, nurses were unblinded. ""...the key to the allocation [was] known only to the nurse administering the injections.""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kelly-1977","2013-09-30 08:32:33 +0100","UNKNOWN","Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kelly-1977","2013-09-30 08:38:19 +0100","YES","Number and reasons for missing data balanced. 60 randomised, 53 completed patients. 6 patients relapsed (3 in each group and 1 became pregnant.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kelly-1977","2013-09-30 08:39:43 +0100","NO","No data reported for EPS, data not fully reported for BPRS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kelly-1977","2013-09-30 08:39:53 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Keskiner-1971","2013-09-22 07:43:13 +0100","UNKNOWN","""randomly separated"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Keskiner-1971","2013-09-22 07:43:23 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Keskiner-1971","2013-09-22 07:43:32 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Keskiner-1971","2013-09-22 07:43:34 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Keskiner-1971","2013-09-25 16:07:32 +0100","YES","All participants completed the study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Keskiner-1971","2013-09-25 16:07:51 +0100","NO","Reports reported incompletely. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Keskiner-1971","2013-09-25 16:07:54 +0100","YES","""Supported, in part, by Psychiatric Research Foundation of Missouri and The Squibb Institute for Medical Research, new brunswick, NJ"".","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Khazaie-2005","2013-09-25 11:17:43 +0100","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Khazaie-2005","2013-09-25 11:17:47 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Khazaie-2005","2013-09-25 11:17:50 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Khazaie-2005","2013-09-25 11:17:54 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Khazaie-2005","2014-07-06 09:59:02 +0100","YES","Losses to follow-up balanced in numbers across allocation groups: 7 participants from the 2-week group and 6 from the 6-week group. Reasons for drop-outs not reported per allocation group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Khazaie-2005","2013-09-25 11:18:35 +0100","YES","All outcome results have been reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Khazaie-2005","2013-09-25 11:18:39 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kissling-1985","2013-09-25 16:09:43 +0100","YES","""random allocation (coin throwing)"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kissling-1985","2013-09-22 07:45:13 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kissling-1985","2013-09-22 07:45:22 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kissling-1985","2013-09-22 07:45:24 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kissling-1985","2013-09-25 16:11:37 +0100","NO","Losses to follow-up/missing data imbalanced in numbers or reasons across intervention groups. 10 (30%) of participants in the haloperidol group left the study early and 13 (60%) in the fluphenazine group. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kissling-1985","2013-09-25 16:11:54 +0100","NO","All outcomes have been reported, however data presented is not usable.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kissling-1985","2013-09-25 16:11:56 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kreisman-1988","2013-09-22 07:47:04 +0100","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kreisman-1988","2013-09-22 07:47:15 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kreisman-1988","2013-09-22 07:47:25 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kreisman-1988","2013-09-22 07:47:28 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kreisman-1988","2013-09-25 16:17:06 +0100","NO","132 participants entered the study, the final sample was 51. Reasons for losses to follow-up not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kreisman-1988","2014-07-06 10:04:54 +0100","NO","Outcomes reported as P values.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kreisman-1988","2013-09-22 07:52:43 +0100","UNKNOWN","Source of funding not reported","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kurland-1966","2013-09-22 07:54:01 +0100","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kurland-1966","2013-09-22 07:54:15 +0100","YES","""Medication was administered under a code number known only to the pharmacist.""","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kurland-1966","2013-09-22 07:54:24 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kurland-1966","2013-09-22 07:54:26 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kurland-1966","2013-09-22 07:54:36 +0100","YES","All patients completed the study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kurland-1966","2013-12-04 12:09:31 +0000","YES","All outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Kurland-1966","2013-09-25 16:18:47 +0100","YES","""grant-in aid from the Squibb Institute for Medical Research"".","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Lehmann-1980","2014-02-28 17:25:42 +0000","UNKNOWN","Randomised, details not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Lehmann-1980","2014-02-28 17:25:59 +0000","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Lehmann-1980","2014-02-28 17:26:33 +0000","UNKNOWN","To assure the double-blindness, the patients whose doses were reduced were given placebo injections","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Lehmann-1980","2014-02-28 17:26:46 +0000","UNKNOWN","Double-blind, details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Lehmann-1980","2014-02-28 17:27:06 +0000","YES","Forty patients were randomised and 39 patients were analysed after 24 weeks. There was one drop-out from the high-dosage group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Lehmann-1980","2014-02-28 17:27:26 +0000","UNKNOWN","Unable to use data for EWL-K, other outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Lehmann-1980","2014-02-28 17:27:46 +0000","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Leong-1989","2013-10-02 12:07:21 +0100","NO","""randomised"", ""On admission, the patients were assigned the next available study number in numerical sequence and allocated to receive either pipothiazine palmitate or fluphenazine decanoate"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Leong-1989","2013-09-22 07:56:36 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Leong-1989","2013-09-22 07:56:47 +0100","NO","""The administration of the study medications was open to the person giving the injections...""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Leong-1989","2013-09-22 07:56:59 +0100","YES","""...the patients' symptoms and side effects...were assessed by one of the investigators who had no knowledge of which study medication had been prescribed.""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Leong-1989","2013-09-25 16:22:05 +0100","YES","All participants completed the trial.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Leong-1989","2013-09-25 16:22:12 +0100","YES","All outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Leong-1989","2013-09-22 07:57:24 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Levenson-1976","2013-09-22 07:58:10 +0100","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Levenson-1976","2013-09-22 07:58:21 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Levenson-1976","2013-09-22 07:58:29 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Levenson-1976","2013-09-22 07:58:32 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Levenson-1976","2013-09-25 16:26:49 +0100","YES","""Five patients received an administrative discharge from the study prior ton remission for reasons unrelated to their illness, to the medication they were receiving, or to any other pertinent study variable"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Levenson-1976","2013-09-25 16:26:54 +0100","NO","Clinical outcome (BPRS) reported incompletely.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Levenson-1976","2013-09-22 08:03:02 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Lundin-1990","2013-09-22 08:03:42 +0100","UNKNOWN","""randomly allocated"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Lundin-1990","2013-09-22 08:03:52 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Lundin-1990","2013-09-22 08:04:01 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Lundin-1990","2013-09-22 08:04:03 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Lundin-1990","2013-09-25 16:27:15 +0100","YES","Losses to follow-up / missing data balanced across intervention groups, with similar reasons for missing data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Lundin-1990","2013-09-25 16:27:20 +0100","NO","Results reported incompletely: BPRS, CPRS, CSE, SAS, HRSD, KAS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Lundin-1990","2013-09-25 16:27:19 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-MacCrimmon-1978","2013-09-22 08:06:52 +0100","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-MacCrimmon-1978","2013-09-22 08:07:01 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-MacCrimmon-1978","2013-09-22 08:07:10 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-MacCrimmon-1978","2013-09-22 08:07:12 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-MacCrimmon-1978","2013-09-25 16:29:36 +0100","NO","Losses to follow-up/missing data imbalanced in numbers and reasons across intervention groups. Fluphenazine enanthate 3 (12%) and fluphenazine decaonate 7 (29%).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-MacCrimmon-1978","2013-09-22 08:07:47 +0100","YES","Outcomes have been reported: BPRS, extrapyramidal symptoms, other adverse events and serious adverse events.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-MacCrimmon-1978","2013-09-22 08:07:57 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Magnus-1979","2013-11-10 09:15:07 +0000","UNKNOWN","""Patients were allocated...according to a pre-arranged randomised prescribing list"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Magnus-1979","2013-11-06 11:01:52 +0000","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Magnus-1979","2013-11-06 11:01:59 +0000","NO","Open trial.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Magnus-1979","2013-11-06 11:02:00 +0000","NO","Open trial.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Magnus-1979","2013-11-06 11:02:12 +0000","YES","""All but two (one in each group) completed six months treatment"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Magnus-1979","2013-11-06 11:02:19 +0000","NO","Not all outcomes reported: no SD reported for BPRS and no data for nurse's assessment.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Magnus-1979","2013-11-06 11:02:27 +0000","UNKNOWN","Smith Kline & French Laboratories provided statistical help.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Malm-1974","2013-09-22 08:08:39 +0100","UNKNOWN","""allocated randomly"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Malm-1974","2013-09-22 08:09:00 +0100","UNKNOWN","Details of allocation concealment not reported. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Malm-1974","2013-09-22 08:09:14 +0100","UNKNOWN","""double-blind"". Patients blinded. Nurses administering the injections: not blinded to the study medications.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Malm-1974","2013-09-22 08:09:22 +0100","UNKNOWN","Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Malm-1974","2014-10-08 15:36:14 +0100","UNKNOWN","62 participants were enrolled but number randomised to each group not reported. 5 participants were withdrawn during the first two months, intervention groups not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Malm-1974","2013-09-22 08:09:58 +0100","NO","Outcomes incompletely reported: S-Scale, Side effects, Nurses' ratings (ADL).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Malm-1974","2013-09-22 08:10:23 +0100","YES","""Supported, in part, by a grant from LEO Research Foundation, Helsingborg.""","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Marder-1987","2013-09-22 09:00:47 +0100","UNKNOWN","""randomised"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Marder-1987","2013-09-22 09:01:00 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Marder-1987","2014-07-06 10:17:00 +0100","UNKNOWN","Double-blind. Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Marder-1987","2014-07-06 10:17:04 +0100","UNKNOWN","Double-blind. Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Marder-1987","2013-12-04 12:12:24 +0000","UNKNOWN","2/35 and 6/31 participants left the study early during the first six months"", reasons not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Marder-1987","2014-07-06 10:17:22 +0100","UNKNOWN","Outcomes incompletely reported: SCL-90, SE Scale, IMEPS, Subjective EPS Rating Scale. P values for most outcomes and data at 1 month (SCL-90) and three months (side effects)","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Marder-1987","2013-09-22 09:02:45 +0100","YES","""...supported by Veterans Administration Medical Research and the UCLA Mental Mental Health Clinical Research Center for the Study of schizophrenia; and the national Institute of mental Health grant...E.R. Squibb and Sons...provided the low dose formulation of fluphenazine decanoate.""","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McClelland-1976","2013-11-06 11:16:04 +0000","UNKNOWN","""Random allocation"", no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McClelland-1976","2013-11-06 11:16:10 +0000","YES","""Allocation to the experimental or control group was carried out by the hospital pharmacist"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McClelland-1976","2014-07-06 10:19:02 +0100","YES","""Double-blind design and entailed the 'double-dummy' technique."" ""The manufacturer prepared 10-ml ampules of fluphenazine decanoate, 25mg/ml and inactive preparation containing only sesame oil, as well as 0.5 ml ampules with 25 mg/ml of the drug and a sesame oil placebo"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McClelland-1976","2013-11-06 11:16:29 +0000","UNKNOWN","""Double-blind"", blinding of outcome assessors not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McClelland-1976","2014-10-08 13:57:48 +0100","YES","Two participants in the VHD group left the study early and three in the standard dose group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McClelland-1976","2014-07-06 10:19:26 +0100","NO","No data were reported for the WWBRS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McClelland-1976","2013-11-06 11:16:48 +0000","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McCreadie-1980","2013-09-22 09:09:59 +0100","UNKNOWN","""randomly allocated"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McCreadie-1980","2013-09-22 09:10:10 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McCreadie-1980","2014-10-08 15:36:33 +0100","UNKNOWN","""double-blind"". ""To ensure double-blind conditions patients received active fluphenazine injections and placebo pimozide tablets, or placebo injections and active tablets."" Participants blinded. Blinding details of personnel unclear.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McCreadie-1980","2013-09-25 16:37:05 +0100","UNKNOWN","""double-blind"". Blinding details of outcome assessors unclear.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McCreadie-1980","2014-10-08 15:36:39 +0100","YES","Losses to follow-up and missing data balanced across intervention groups (4/16 vs 3/18), with similar reasons for missing data (relapse: 3/16 vs 3/18; 1 participant dropped out due to non-compliance with medication).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McCreadie-1980","2013-09-22 09:11:15 +0100","NO","Hamiiton-Lorr, Wing and Griffiths scales' results not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McCreadie-1980","2013-09-22 09:11:28 +0100","UNKNOWN","Funding source not reported. Medication supplied by Janssen Pharmaceutical and Squibb.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McCreadie-1982","2013-09-22 09:07:50 +0100","UNKNOWN","""randomly allocated"". Method not reported","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McCreadie-1982","2013-09-22 09:07:59 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McCreadie-1982","2013-09-22 09:08:28 +0100","UNKNOWN","""double-blind"". ""To ensure double blind conditions, patients received either active pimozide tablets and dummy fluphenazine injections or dummy tablets and active injections."" Blinding details of personnel, unclear.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McCreadie-1982","2013-09-22 09:08:30 +0100","UNKNOWN","""double-blind"". Blinding details of outcome assessors,  unclear.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McCreadie-1982","2013-09-25 16:37:42 +0100","YES","Losses to follow-up balanced across intervention groups (38% vs 40%), with similar reasons (exacerbation, adverse events) for missing data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McCreadie-1982","2013-09-22 09:09:03 +0100","NO","Hamilton-Lorr scale, Wing Ward Behaviour Scale results not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McCreadie-1982","2013-09-22 09:09:22 +0100","YES","""...supported by a research grant from Dumfries and Galloway Health Board"". Medication and other materials provided by Janssen Pharmaceutical and Squibb Limited.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McKane-1987","2013-09-22 09:12:13 +0100","UNKNOWN","""randomly allocated"". Method not reported","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McKane-1987","2013-09-22 09:12:23 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McKane-1987","2013-09-22 09:12:31 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McKane-1987","2013-09-22 09:12:33 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McKane-1987","2013-09-25 16:40:29 +0100","NO","Five patients left the study during the run-in period and 17 patients on haloperidol and 16 on fluphenazine entered the study proper. Losses to follow-up/missing data balanced in numbers 6/17 vs 4/16 but imbalanced in reasons (relapse 6/17 vs 1/16; non-compliance: 0/17 vs 2/16; adverse events: 0/17 vs 1/16) across intervention groups.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McKane-1987","2013-09-22 09:13:05 +0100","YES","Outcome results reported: Krawieka, Wing, SAS, AIMS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McKane-1987","2013-09-25 16:40:35 +0100","NO","""Janssen Pharmaceutical...financial and other assistance"".","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McLaren-1992","2013-09-22 09:14:05 +0100","UNKNOWN","""randomly allocated"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McLaren-1992","2013-09-22 09:14:15 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McLaren-1992","2013-10-02 12:24:06 +0100","YES","""double-blind"" ""identical ampoules"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McLaren-1992","2013-09-22 09:14:37 +0100","UNKNOWN","""double-blind"". Blinding details of outcome assessment not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McLaren-1992","2013-09-25 17:08:04 +0100","UNKNOWN","""Two patients, both on fluphenazine decanoate withdrew consent"". ""Five patients, all in the bromperidol decanoate group were withdrawn from the study...following relapse"", ""One other patient, on bromperidol decanoate, was lost to follow-up during the sixth week of the study having deteriorated before contact was lost"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McLaren-1992","2013-09-25 17:08:59 +0100","NO","Data not reported or incomplete for the NSRS, Krawiecka-Goldberg scale, MARDRS, MRSS, SAS, AIMS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-McLaren-1992","2013-09-22 09:15:20 +0100","NO","financial support: Jannsen Pharmaceutical.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Odejide-1982","2013-09-22 09:15:53 +0100","UNKNOWN","""randomised"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Odejide-1982","2013-09-22 09:16:01 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Odejide-1982","2013-09-22 09:16:13 +0100","UNKNOWN","""double-blind"". ""patients were unaware of the contents of their injections"". Blinding details of other personnel (e.g. nurses who administered the injections), not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Odejide-1982","2013-09-22 09:16:26 +0100","YES","""The psychiatrist who evaluated follow-up status, was blind to treatment status...""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Odejide-1982","2014-10-08 14:19:39 +0100","YES","53/70 participants completed the study. Losses to follow-up or missing data balanced across intervention groups.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Odejide-1982","2013-09-25 17:08:46 +0100","NO","Outcomes not reported (PSE) or incompletely reported (BPRS).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Odejide-1982","2013-09-22 09:17:01 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Pinto-1979","2013-09-22 09:17:42 +0100","UNKNOWN","""randomly allocated"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Pinto-1979","2013-09-22 09:17:52 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Pinto-1979","2013-09-22 09:18:10 +0100","UNKNOWN","""double-blind"". Patients blinded, nurses unblinded. ""injections were prepared and administered by nursing staff...neither the clinician nor the patients were aware of the treatment allocation.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Pinto-1979","2013-09-22 09:18:20 +0100","YES","""...rating clinicians in ignorance of the allocation of patients to treatment groups"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Pinto-1979","2013-09-25 17:10:07 +0100","NO","Losses to follow-up/missing data imbalanced in numbers across intervention groups. ""a total of eight patients all in the fluphenazine group, dropped-out of the trial..."".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Pinto-1979","2013-09-25 17:10:10 +0100","NO","Outcome data incompletely reported (BPRS).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Pinto-1979","2013-09-22 09:19:08 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Quitkin-1978","2013-09-22 09:19:53 +0100","UNKNOWN","""random"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Quitkin-1978","2013-09-22 09:20:02 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Quitkin-1978","2013-09-22 09:20:09 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Quitkin-1978","2013-09-22 09:20:12 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Quitkin-1978","2013-09-25 17:16:10 +0100","NO","35/56 participants completed the study; 4 from the penfluridol and 8 from the fluphenazine group left the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Quitkin-1978","2013-09-22 09:24:38 +0100","NO","Outcome data not reported: BPRS, CGI, KASP, KASR.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Quitkin-1978","2013-09-22 09:24:47 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Rifkin-1977","2013-09-22 09:25:25 +0100","UNKNOWN","""random"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Rifkin-1977","2013-09-22 09:25:34 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Rifkin-1977","2013-09-22 09:25:53 +0100","UNKNOWN","""double-blind"". Patients blinded: ""All patients received biweekly injections and daily pills-some being placebo."" Blinding details of personnel not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Rifkin-1977","2013-09-22 09:26:11 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Rifkin-1977","2013-09-22 09:26:54 +0100","UNKNOWN","Number of drop-outs are balanced across the intervention groups but reasons have not been reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Rifkin-1977","2013-09-25 17:16:43 +0100","UNKNOWN","Outcomes not fully reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Rifkin-1977","2013-09-22 09:27:18 +0100","YES","""...supported by national Institute of Mental Health grant...""","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1990","","UNKNOWN","","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1990","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1990","","UNKNOWN","","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1990","","UNKNOWN","","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1990","","UNKNOWN","","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1990","","UNKNOWN","","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Rossi-1990","","UNKNOWN","","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Russell-1982","2013-09-22 09:28:10 +0100","UNKNOWN","""random allocation"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Russell-1982","2013-09-22 09:28:19 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Russell-1982","2013-09-22 09:28:30 +0100","UNKNOWN","""double-blind"". Subjects blinded ""...placebo injections being given...in the intervening weeks..."". Blinding details of personnel not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Russell-1982","2013-09-22 09:28:43 +0100","YES","""double-blind"". ""...a second psychiatrist rated each patient blind...""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Russell-1982","2013-09-25 17:18:30 +0100","UNKNOWN","Two fluspirilene and three fluphenazine patients dropped out after one week"", reasons not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Russell-1982","2014-07-06 12:21:14 +0100","NO","BPRS and CGI incompletely reported (P values). SAS and MACC Behavior Adjustment Scale results not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Russell-1982","2013-09-22 09:29:19 +0100","UNKNOWN","""...supported by McNeil (Canada) laboratories.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schlosberg-1978","2013-09-22 09:29:56 +0100","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schlosberg-1978","2013-09-22 09:30:05 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schlosberg-1978","2013-09-22 09:30:15 +0100","UNKNOWN","""double-blind"". Patients blinded: ""The drugs injected were pipotiazine palmitate, fluphenazine decanoate, and placebo..."". Blinding details of personnel not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schlosberg-1978","2013-09-22 09:30:25 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schlosberg-1978","2013-09-25 17:18:57 +0100","UNKNOWN","Number lost to follow-up not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schlosberg-1978","2013-09-22 09:30:44 +0100","NO","BPSD and NOISE results incompletely reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schlosberg-1978","2013-09-22 09:30:52 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schneider-1981","2013-09-22 09:31:28 +0100","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schneider-1981","2013-09-22 09:31:36 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schneider-1981","2013-09-22 09:31:44 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schneider-1981","2013-09-22 09:31:49 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schneider-1981","2013-09-22 09:32:00 +0100","UNKNOWN","Number of drop-outs not reported per allocation group. 59 patients were randomised, ""a total of 34 patients remained in the study long enough to have at least 10 blood analyses"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schneider-1981","2013-09-25 17:19:54 +0100","NO","Data not reported for CGI.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schneider-1981","2013-09-22 09:32:22 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1976","2013-09-22 09:33:17 +0100","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1976","2013-09-22 09:33:27 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1976","2014-07-06 12:21:39 +0100","UNKNOWN","Patients blinded; blinding details of personnel not reported.""...an injection of depot fluphenazine plus oral placebo or depot placebo plus oral fluphenazine. Both injections and pills...administered under double-blind conditions.""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1976","2013-09-22 09:33:54 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1976","2013-09-22 09:34:03 +0100","UNKNOWN","Insufficient information. Losses to follow-up not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1976","2013-09-22 09:34:16 +0100","NO","Incomplete data. ""Treatment emergent symptoms were evaluated... by both a physician and a nurse...The data in this paper are the nurse's ratings"".","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1976","2013-09-22 09:34:30 +0100","YES","""...supported by the National Institute of Mental Health grants...""","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1979","2013-09-30 08:50:22 +0100","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1979","2013-09-30 08:50:28 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1979","2013-09-30 08:50:32 +0100","UNKNOWN","""double blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1979","2013-09-30 08:50:33 +0100","UNKNOWN","""double blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1979","2013-09-30 08:50:53 +0100","UNKNOWN","Insufficient information. Losses to follow-up not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1979","2013-09-30 08:51:01 +0100","NO","BPRS and SCL-90 results incompletely reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1979","2013-09-30 08:51:00 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1980","2013-09-22 09:35:48 +0100","UNKNOWN","""stratified by sex, randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1980","2013-09-22 09:35:57 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1980","2013-09-22 09:36:09 +0100","UNKNOWN","""double-blind"". ""...either fluphenazine decanoate and oral placebo or fluphenazine hydrochloride and placebo injection."" Patients blinded. Blinding details of personnel not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1980","2013-09-22 09:36:20 +0100","UNKNOWN","""double blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1980","2013-09-29 14:27:28 +0100","YES","""214 (107 from each of the two treatment regimes) entered the one-year ""maintenance phase"" of the study"". ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1980","2013-09-25 17:20:26 +0100","NO","Incomplete report of outcome data (BPRS, Hopkins Symptom Checklist-90, CGI), no data Hamilton Depression Scale. Full BPRS data (mean SD) not reported per allocation group.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1980","2013-09-22 09:37:00 +0100","YES","""...supported by the Nations Institute of Mental Health grants...""","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1997","2013-09-22 09:38:27 +0100","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1997","2013-09-22 09:38:37 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1997","2013-09-22 09:38:45 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1997","2013-09-22 09:38:48 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1997","2013-09-25 17:20:57 +0100","UNKNOWN","Information on losses to follow-up not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1997","2013-09-22 09:39:16 +0100","NO","Outcomes not reported: BPRS, SANS, CGI, Neurological Rating Scale (extrapyramidal symptoms), Early Signs Questionnaire. Family treatment strategies outcomes incompletely reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Schooler-1997","2014-07-06 12:22:51 +0100","UNKNOWN","Source of funding unclear. ""All double-blind medication supplies as well as open label fluphenazine decanoate and fluphenazine hydrochloride were provided courtesy of Bristol-Myers Squibb Company..."". ""multicentre clinical trial...in collaboration with the Division of Treatment and Clinical Research of the national Institute of Mental Health""","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Sharma-1991","2013-09-30 08:54:51 +0100","UNKNOWN","""randomly allocated"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Sharma-1991","2013-09-30 08:52:04 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Sharma-1991","2013-09-30 08:52:08 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Sharma-1991","2013-09-30 08:52:12 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Sharma-1991","2013-09-30 08:54:49 +0100","NO","Losses to follow-up unbalanced in numbers (6/30 fluphenazine vs 10/29 haloperidol) and reasons (treatment failure ""primary reason for withdrawal in one patient on fluphenazine and 5 patients on haloperidol"").","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Sharma-1991","2013-09-30 08:52:53 +0100","NO","CPRS results reported incompletely.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Sharma-1991","2013-09-30 08:52:51 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Shenoy-1981","2013-12-04 08:19:47 +0000","UNKNOWN","""patients were randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Shenoy-1981","2013-12-04 08:19:51 +0000","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Shenoy-1981","2013-12-04 08:19:56 +0000","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Shenoy-1981","2013-12-04 08:20:00 +0000","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Shenoy-1981","2014-10-08 15:38:55 +0100","YES","None of the patients relapsed. 3 participants did not complete the trial: 2 in the active and 1 in the placebo group. All drop-out were due to ""failure to meet appointments"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Shenoy-1981","2013-12-04 08:20:19 +0000","YES","All outcomes have been reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Shenoy-1981","2013-12-04 08:20:24 +0000","UNKNOWN","Source of funding has not been reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Shu-1983","2013-09-22 09:44:29 +0100","UNKNOWN","""randomised"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Shu-1983","2013-09-22 09:44:41 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Shu-1983","2013-09-22 09:44:54 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Shu-1983","2013-09-22 09:44:56 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Shu-1983","2014-07-06 12:23:54 +0100","YES","Losses to follow-up balanced across intervention groups: 3 (18%) lost in the fluphenazine group and 2 (11%) in the penflurdidol group, with similar reasons for missing data (exacerbation).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Shu-1983","2014-07-06 10:41:47 +0100","YES","Outcome data have been reported: CGI, A standardized psychiatric Assessment Scale for Chronic psychiatric Patients, rating Scale for Extramidal Side Effects (Simpson G M)","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Shu-1983","2013-09-22 09:45:39 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Simon-1978","2013-09-22 09:46:13 +0100","UNKNOWN","""balanced randomization"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Simon-1978","2013-09-22 09:46:25 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Simon-1978","2013-09-22 09:46:38 +0100","NO","""open study""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Simon-1978","2013-09-25 17:21:44 +0100","NO","""open study""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Simon-1978","2013-09-26 07:35:35 +0100","NO","39 participants left the study early, 14 in the fluphenazine group, 15 in the pipothiazine group and 10 in the standard neuroleptics group. Reasons were similar across groups. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Simon-1978","2013-09-25 17:22:43 +0100","YES","All outcome data has been reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Simon-1978","2013-09-22 09:50:42 +0100","UNKNOWN","""...supported by a grant from the Fondation de L'Industrie pharmaceutique pour la recherche...""","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Singh-1979","2013-09-22 09:51:08 +0100","UNKNOWN","""randomly assigned"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Singh-1979","2013-09-22 09:51:27 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Singh-1979","2013-09-22 09:51:41 +0100","UNKNOWN","""double blind"". Patients blinded; "" ...test medications were administered blind...on alternate two weeks, patients in the pipotiazine group received an injection of sesame oil..."". Blinding details of personnel not reported","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Singh-1979","2013-09-22 09:51:50 +0100","UNKNOWN","""double blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Singh-1979","2013-09-22 09:51:59 +0100","YES","All patients completed the study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Singh-1979","2013-09-25 17:22:55 +0100","YES","Outcome data reported for BPRS and side effects.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Singh-1979","2013-09-22 09:52:20 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Song-1993","2013-09-22 09:53:10 +0100","UNKNOWN","""randomised"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Song-1993","2013-09-22 09:53:25 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Song-1993","2013-09-22 09:53:40 +0100","UNKNOWN","""double blindness in pipotiazine palmitate group and Fluphenazine Decanoate group, and one non-blindness pipotiazine palmitate group"". Details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Song-1993","2013-09-22 09:53:48 +0100","UNKNOWN","""double blindness in pipotiazine palmitate group and Fluphenazine Decanoate group, and one non-blindness pipotiazine palmitate group"". Details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Song-1993","2014-07-06 10:43:37 +0100","UNKNOWN","Losses to follow-up not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Song-1993","2013-09-26 07:36:00 +0100","NO","Outcome data for TESS not reported fully.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Song-1993","2013-09-22 09:54:23 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Van-Praag-1970","2013-09-22 09:55:13 +0100","UNKNOWN","""divided at random"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Van-Praag-1970","2013-09-22 09:55:22 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Van-Praag-1970","2013-09-22 09:56:00 +0100","YES","""One category received active fluphenazine orally and placebo injections; the other received oral placebos and injections of fluphenazine enanthate...The test drug and placebo were contained in identical capsules...Active fluid and placebo fluid were indistinguishable...Strict double-blind conditions prevailed throughout the experiment.""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Van-Praag-1970","2013-09-25 17:23:45 +0100","YES","""Strict double-blind conditions prevailed throughout the experiment.""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Van-Praag-1970","2013-09-26 07:39:59 +0100","NO","Missing data imbalanced across intervention groups 8% (oral group) versus 25% (depot group): 2 participants in the depo category left the study early due to deterioration of symptoms, a further patient in the depot category left due to encephalitis. 1 participant in the oral category due to severe oligophrenia.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Van-Praag-1970","2013-09-25 17:24:19 +0100","NO","Outcome data not fully reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Van-Praag-1970","2013-09-22 09:56:54 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Van-Praag-1973","2013-09-22 09:57:17 +0100","UNKNOWN","""randomly divided"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Van-Praag-1973","2013-09-22 09:57:28 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Van-Praag-1973","2013-09-22 09:57:39 +0100","UNKNOWN","""The conditions of a double-blind test were ensured"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Van-Praag-1973","2013-09-22 09:57:50 +0100","YES","""The evaluators- physicians and nurses- were blind to the distribution of enanthate and decanoate...""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Van-Praag-1973","2013-09-26 07:43:10 +0100","YES","Missing data balanced across intervention groups: 2 (14%) participants from the enanthate group and 1 (6%) from the decanoate group, with similar reasons for missing data. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Van-Praag-1973","2013-09-22 09:58:27 +0100","NO","Outcome data not reported (Wing Scale A and Scale B)","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Van-Praag-1973","2013-09-22 09:58:30 +0100","UNKNOWN","Source of funding not reported","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Walker-1983","2013-09-22 09:59:14 +0100","UNKNOWN","""randomly allocated"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Walker-1983","2013-09-22 09:59:28 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Walker-1983","2013-09-22 09:59:38 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Walker-1983","2013-09-22 09:59:40 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Walker-1983","2013-09-22 09:59:54 +0100","UNKNOWN","Missed data per allocation group unclear. ""Forty five patients entered the trial. Six patients failed to return following the first interview and so were discounted. One patient returned to her home country, and so failed to attend for the final assessment"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Walker-1983","2013-09-25 17:25:46 +0100","NO","Outcome data incompletely reported (SD not reported): CGI, BPRS, Krawiecka, Goldberg & Vaughan Rating Scale.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Walker-1983","2013-09-22 10:00:15 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Wistedt-1983","2013-09-22 10:03:16 +0100","UNKNOWN","""allocated randomly"". Method not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Wistedt-1983","2013-09-22 10:03:29 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Wistedt-1983","2013-09-22 10:03:40 +0100","UNKNOWN","""double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Wistedt-1983","2013-09-22 10:04:03 +0100","YES","""The injections were given by a nurse who did not participate in the assessment.""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Wistedt-1983","2014-07-06 12:13:37 +0100","UNKNOWN","Missing data balanced across intervention groups (27% fluphenazine group vs 40% flupenthixol group). Reasons for losses to follow-up not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Wistedt-1983","2013-09-25 17:26:20 +0100","NO","Incomplete outcome data: CGI, CPRS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Wistedt-1983","2013-09-22 10:04:38 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Wistedt-1984","2013-09-22 10:01:24 +0100","UNKNOWN","""allocated to the two groups according to a randomisation list...Patients were balanced in groups of six"" Details not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Wistedt-1984","2013-09-22 10:01:34 +0100","UNKNOWN","Details of allocation concealment not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Wistedt-1984","2013-09-22 10:01:50 +0100","UNKNOWN","""Injections were give double-blind"". Blinding details not reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Wistedt-1984","2013-09-22 10:02:18 +0100","UNKNOWN","Blinding details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Wistedt-1984","2013-09-22 10:02:33 +0100","YES","Missing data balanced across intervention groups (15% fluphenazine vs 15% haloperidol), with similar reasons for missing data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Wistedt-1984","2013-09-25 17:27:12 +0100","YES","All primary outcomes reported: CPRS, CGI, EPS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Wistedt-1984","2013-09-22 10:02:52 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Woggon-1977","2014-02-28 17:10:01 +0000","UNKNOWN","""Randomised"", no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Woggon-1977","2014-02-28 17:10:11 +0000","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Woggon-1977","2014-02-28 17:21:45 +0000","UNKNOWN","The tests were performed double-blind. The dosage of both drugs and the additional medications were prescribed by an investigator who himself did not take part in the ratings.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Woggon-1977","2014-02-28 17:21:59 +0000","UNKNOWN","Double-blind, details not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Woggon-1977","2014-02-28 17:22:19 +0000","YES","No losses to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Woggon-1977","2014-02-28 17:24:34 +0000","UNKNOWN","Data for side effects not usable, other outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Fluphenazine decanoate (depot) and enanthate for schizophrenia [v9.0-For publication].rm5","STD-Woggon-1977","2014-02-28 17:25:03 +0000","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Flupenthixol versus placebo for schizophrenia [v2.0-For publication].rm5","STD-Johnstone-1978","2012-03-12 14:02:06 +0000","YES","Reports state - ""randomly allocated"" to one of three groups. Author replied that randomisation undertaken by a randomised number code.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Flupenthixol versus placebo for schizophrenia [v2.0-For publication].rm5","STD-Johnstone-1978","2012-03-12 14:02:37 +0000","YES","Author informed us that number code was controlled by hospital pharmacy.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Flupenthixol versus placebo for schizophrenia [v2.0-For publication].rm5","STD-Johnstone-1978","2012-03-12 14:05:12 +0000","YES","Reports state - ""double blind"". All given orphenadrine to minimise parkinsonian adverse-effects. Author assured us that ward staff and patients were blind to drug allocation.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol versus placebo for schizophrenia [v2.0-For publication].rm5","STD-Johnstone-1978","2012-03-12 14:06:20 +0000","YES","Author undertook assessments blind to the drug allocation.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol versus placebo for schizophrenia [v2.0-For publication].rm5","STD-Johnstone-1978","2012-03-05 13:33:58 +0000","YES","All participants completed the study and were included in the final analysis.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","At the end of the study - 4 weeks"
"../ALL-2015-06/C-F/Flupenthixol versus placebo for schizophrenia [v2.0-For publication].rm5","STD-Johnstone-1978","2012-08-10 21:26:24 +0100","NO","Two additional people who scored 4 on social functioning assessment had been readmitted with recurrence of psychosis at least once since discharge from hospital - author omitted them from calculation of results: unclear original group of allocation.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.02","At follow-up - 12 months"
"../ALL-2015-06/C-F/Flupenthixol versus placebo for schizophrenia [v2.0-For publication].rm5","STD-Johnstone-1978","2012-03-16 09:48:02 +0000","UNKNOWN","No protocol is available. We could not compare outcomes in protocol and final reports.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Flupenthixol versus placebo for schizophrenia [v2.0-For publication].rm5","STD-Johnstone-1978","2012-03-12 14:08:54 +0000","UNKNOWN","Author thanked Lundbeck for making preparations of flupenthixol isomers and for their interest and encouragement.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication] (1).rm5","STD-Liu-2000","2013-11-21 15:21:40 +0000","UNKNOWN","First matched for gender, age, then randomised. No details as to how the randomisation sequence was generated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication] (1).rm5","STD-Liu-2000","2012-05-14 15:49:06 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication] (1).rm5","STD-Liu-2000","2013-11-19 18:14:36 +0000","NO","Procedure not described, assumed to be open.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication] (1).rm5","STD-Liu-2000","2013-11-19 18:14:38 +0000","NO","Procedure not described, assumed to be open.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication] (1).rm5","STD-Liu-2000","2013-11-21 15:22:41 +0000","NO","The publication did not describe whether there were participants who discontinued the trial prematurely and how this was addressed in the statistical analysis. We therefore rated it as unclear in this regard.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication] (1).rm5","STD-Liu-2000","2013-11-20 20:52:06 +0000","YES","No obvious selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication] (1).rm5","STD-Liu-2000","2013-11-20 20:52:12 +0000","YES","No clear evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Cookson-1983","2010-04-13 17:55:47 +0100","UNKNOWN","Mentions that patients were randomly allocated to either of the treatment groups. No information about process of sequence generation given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Cookson-1983","2010-04-13 17:56:24 +0100","UNKNOWN","Method of allocation concealment not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Cookson-1983","2010-05-16 14:32:19 +0100","YES","Double blinding was possible as depot was available in 2% and 10% solutions. No information on test of blinding though.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Cookson-1983","2010-05-16 17:32:56 +0100","NO","Attrition was 20%. Attrition was explained but was unequal in intervention groups.There is no information how this was dealt with in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Cookson-1983","2010-04-13 18:00:49 +0100","NO","Some outcomes of interest in the review were reported incompletely so cannot be entered in meta-analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Cookson-1983","2010-05-16 19:09:57 +0100","YES","No other bias noted.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Cookson-1987","2010-04-13 18:03:00 +0100","UNKNOWN","Mentions that patients were randomly allocated to either of the treatment groups. No information about process of sequence generation given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Cookson-1987","2010-04-13 18:03:49 +0100","UNKNOWN","Method of concealment not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Cookson-1987","2010-04-13 18:04:41 +0100","UNKNOWN","Mentions that the study was double blind. No other information given.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Cookson-1987","2010-05-16 15:02:48 +0100","YES","All participants completed the study but some declined to give blood samples after 24 weeks. Data for mental state and attrition includes all participants.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Cookson-1987","2010-04-13 19:28:13 +0100","NO","Some outcomes of interest (some side effects and plasma levels of drugs) in the review were reported incompletely so cannot be entered in meta-analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Cookson-1987","2010-05-16 19:16:23 +0100","NO","Authors thank Lundbeck 'for their financial assistance'. Supplementary neuroleptics allowed during the trial might have affected outcomes.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Eberhard-1986","2010-04-13 18:15:10 +0100","UNKNOWN","Mentions that patients were randomised to either of the treatment groups. No information about process of sequence generation given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Eberhard-1986","2010-04-13 18:40:14 +0100","UNKNOWN","Method of allocation concealment not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Eberhard-1986","2010-05-16 14:30:27 +0100","UNKNOWN","States it is double blind study. No other information given.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Eberhard-1986","2010-05-16 15:34:39 +0100","YES","All patients completed the first period (24 weeks) taken into account for analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Eberhard-1986","2010-04-13 19:29:56 +0100","NO","Outcome of interest regarding Mental State were reported incompletely so cannot be entered in meta-analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Eberhard-1986","2010-05-16 19:22:39 +0100","NO","Authors thank Janssen Pharmaceutica, Belgium and Janssen-Pharma, Sweden for 'active collaboration' in the study. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Eufe-1979","2013-04-11 14:54:22 +0100","UNKNOWN","'Allocated according to chance'. No other information.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Eufe-1979","2010-04-13 18:39:54 +0100","UNKNOWN","Method of allocation concealment not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Eufe-1979","2010-05-16 17:00:37 +0100","UNKNOWN","Says it is double blind. 'Same injection interval and dose kept constant', no other information.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Eufe-1979","2013-02-21 12:00:24 +0000","YES","Intention-to-treat analyses done, LOCF, only 3 patients dropped out.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Eufe-1979","2014-04-29 16:57:04 +0100","UNKNOWN","Some outcomes of interest regarding Mental State, side effects and nurses assessments were reported incompletely so cannot be entered in meta-analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Eufe-1979","2013-02-21 12:00:36 +0000","YES","No obvious other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Gerlach-1975","2010-04-13 18:17:26 +0100","UNKNOWN","Mentions that patients were randomly divided into groups. No information about process of sequence generation given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Gerlach-1975","2010-04-13 18:39:37 +0100","UNKNOWN","Method of allocation concealment not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Gerlach-1975","2010-05-16 16:59:22 +0100","UNKNOWN","Says it is double blind study. Blinding of participants explained but not for personnel and outcome assessors.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Gerlach-1975","2010-05-16 16:33:51 +0100","NO","Attrition was 6.66%. There is no information how this was dealt with in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Gerlach-1975","2010-04-13 19:33:06 +0100","NO","Some outcomes of interest regarding Global Impression, Mental State and side effects were reported incompletely so cannot be entered in meta-analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Gerlach-1975","2010-05-16 16:42:56 +0100","NO","Authors thank Janssenpharma and H.Lundbeck & Co for 'drugs used and statistical analyses'.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Javed-1991","2010-04-13 18:18:48 +0100","UNKNOWN","Mentions that patients received either of the drugs according to randomisation. No information about process of sequence generation given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Javed-1991","2010-04-13 18:39:16 +0100","UNKNOWN","Method of allocation concealment not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Javed-1991","2014-05-06 12:42:35 +0100","UNKNOWN","States it is a double-blind comparative trial. No other information given.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Javed-1991","2010-05-16 16:36:49 +0100","NO","Attrition was 15.55% out of reasons not related to the treatment. Number of participants dropping out of each arm of the study not clarified. There is no information how this was dealt with in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Javed-1991","2010-05-11 18:21:38 +0100","NO","Some outcomes of interest regarding Mental State and Global Impression were reported incompletely so cannot be entered in meta-analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Javed-1991","2010-05-16 14:29:09 +0100","NO","Authors thank Lundbeck & Co. for unclear reasons.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Johnson-1987","2010-04-13 18:21:37 +0100","YES","Patients were allocated to groups on basis of sealed computer randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Johnson-1987","2010-04-13 18:38:55 +0100","UNKNOWN","Method of allocation concealment not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Johnson-1987","2010-05-16 16:58:08 +0100","UNKNOWN","Mentions it is 'double blind'. Assessors were blind to evaluations of other assessors and all previous assessments of their own and also to depot dosages. No information on blinding for personnel or participants or test for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Johnson-1987","2010-04-13 18:56:01 +0100","YES","Data was lost for 1 out of 60 participants in the study and analysis was based on all remaining participants.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Johnson-1987","2010-04-13 19:35:38 +0100","NO","Some outcomes of interest regarding Global Impression, Social Function, Mental State and side effects were reported incompletely so cannot be entered in meta-analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Johnson-1987","2010-05-16 14:29:00 +0100","NO","Authors thank Lundbeck Limited for 'a generous grant and statistical analyses of results'.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Kelly-1977","2010-04-13 18:22:36 +0100","UNKNOWN","Mentions that patients were randomly allocated to treatment groups. No information about process of sequence generation given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Kelly-1977","2010-04-13 18:37:52 +0100","UNKNOWN","Method of allocation concealment not described but says that the key to the concealment was known only to the hospital pharmacist and the nurse administering the injections implying that the raters were kept unaware of this.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Kelly-1977","2010-04-13 18:57:46 +0100","UNKNOWN","No specific information given.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Kelly-1977","2010-05-16 17:38:58 +0100","NO","Attrition was 11.66%. There is no information how this was dealt with in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Kelly-1977","2010-04-13 19:36:23 +0100","NO","Some outcomes of interest regarding Mental State and side effects were reported incompletely so cannot be entered in meta-analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Kelly-1977","2010-04-13 19:36:37 +0100","YES","No other bias evident.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Lundin-1990","2010-04-13 18:23:17 +0100","UNKNOWN","Mentions that patients were randomly allocated to either of the drugs. No information about process of sequence generation given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Lundin-1990","2010-04-13 18:34:05 +0100","UNKNOWN","Method of allocation concealment not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Lundin-1990","2010-05-16 14:28:05 +0100","UNKNOWN","States design was double blind. No other information given. No test for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Lundin-1990","2010-05-16 16:36:19 +0100","NO","Reasons for attrition (34.48%) explained but there is imbalance in numbers and reasons for attrition across intervention groups. There is no information how this was dealt with in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Lundin-1990","2010-04-13 19:37:46 +0100","NO","Some outcomes of interest regarding Global Impression, Social Function, Mental State and side effects were reported incompletely so cannot be entered in meta-analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Lundin-1990","2010-04-13 19:38:01 +0100","YES","No other bias evident.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Martyns-1993","2010-04-13 18:24:03 +0100","UNKNOWN","Mentions that patients were randomly allocated to two treatment groups. No information about process of sequence generation given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Martyns-1993","2010-04-13 18:33:44 +0100","UNKNOWN","Method of allocation concealment not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Martyns-1993","2010-05-16 16:55:07 +0100","UNKNOWN","Mentions it is 'double blind'. Nurse administering the depot was blind to assessments and the assessment team was blind to the drug administered. No explanation of blinding regarding participants. No information on test for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Martyns-1993","2010-04-13 19:07:14 +0100","YES","All participants completed the study and were included in analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Martyns-1993","2010-04-13 19:38:56 +0100","NO","Some outcomes of interest regarding Global Impression and Mental State were reported incompletely so cannot be entered in meta-analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Martyns-1993","2010-05-16 19:38:27 +0100","YES","No other bias evident.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-McCreadie-1979","2010-04-13 18:24:28 +0100","UNKNOWN","Mentions that patients were randomly allocated to either of the treatment groups. No information about process of sequence generation given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-McCreadie-1979","2010-04-13 18:33:32 +0100","YES","Codes were used for allocation concealment","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-McCreadie-1979","2010-05-16 16:54:03 +0100","UNKNOWN","Mentions it is 'double blind' but does not explain about blinding regarding participants. Both the nurses and assessing psychiatrists were blind to the dosages of depots given to patients. This 'Blindness' was also tested.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-McCreadie-1979","2014-05-06 12:42:35 +0100","YES","All participants completed the study. One participant refused to give blood samples. Data from this outcome are not usable.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-McCreadie-1979","2010-04-13 19:40:27 +0100","NO","Some outcomes of interest regarding Mental State, side effects and ward behaviour were reported incompletely so cannot be entered in meta-analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-McCreadie-1979","2014-05-06 12:42:35 +0100","NO","Authors have thanked personnel of Lundbeck Ltd. for unclear reasons. Short wash-out period of 2 weeks only.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Pinto-1979","2010-04-13 18:25:38 +0100","UNKNOWN","Mentions that patients were randomly allocated for treatment to either of the groups. No information about process of sequence generation given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Pinto-1979","2010-05-16 14:20:36 +0100","UNKNOWN","Method of allocation concealment not described but states rating clinicians were ignorant of allocation of patients.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Pinto-1979","2010-05-16 16:53:25 +0100","YES","Mentions it is 'double blind'. Rating clinicians and patients were kept ignorant of treatment allocation. No information for test of blinding though.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Pinto-1979","2010-05-16 16:36:03 +0100","NO","Attrition was 12.5%, all from the fluphenazine arm of the trial. Though reasons for attrition were explained, there is no information how this was dealt with in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Pinto-1979","2010-04-13 19:41:36 +0100","NO","Some outcomes of interest regarding Mental State were reported incompletely so cannot be entered in meta-analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Pinto-1979","2010-05-16 19:42:40 +0100","NO","For 3 patients pre-study treatment not specified.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Steinert-1986","2010-04-13 18:26:33 +0100","UNKNOWN","Mentions that patients were randomly assigned to either of the treatments. No information about process of sequence generation given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Steinert-1986","2010-04-13 18:32:09 +0100","UNKNOWN","Method of allocation concealment not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Steinert-1986","2010-05-16 16:51:55 +0100","YES","Trial was blind to patient, nurse and doctor. No information on test of blinding though.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Steinert-1986","2010-05-16 16:35:54 +0100","NO","Attrition was 41.02%. In 9 cases reasons for dropping out was unrelated to any of the outcomes. There is no information how this was dealt with in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Steinert-1986","2010-04-13 19:42:10 +0100","NO","Some outcomes of interest regarding Mental State and side effects were reported incompletely so cannot be entered in meta-analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Steinert-1986","2014-05-06 12:42:35 +0100","NO","No mention of wash-out period.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Wistedt-1982","2010-04-13 18:29:22 +0100","UNKNOWN","Mentions that patients were randomised into either of the groups. No information about process of sequence generation given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Wistedt-1982","2010-05-16 14:16:25 +0100","UNKNOWN","Method of allocation concealment not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Wistedt-1982","2010-05-16 16:52:13 +0100","UNKNOWN","Says trial is double blind. No other information given.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Wistedt-1982","2010-05-16 14:12:24 +0100","YES","All participants completed the trial and were included in analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Wistedt-1982","2010-04-13 19:24:50 +0100","NO","Some outcomes of interest regarding mental state, side effects and non-clinical outcomes not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Wistedt-1982","2014-05-06 12:39:49 +0100","NO","Ampoules of flupenthixol supplied by Lundbeck.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Wistedt-1983","2010-04-13 18:30:34 +0100","UNKNOWN","Mentions that patients were allocated randomly to either of the treatment groups. No information about process of sequence generation given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Wistedt-1983","2010-05-16 14:16:34 +0100","UNKNOWN","Method of allocation concealment not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Wistedt-1983","2010-05-16 14:10:23 +0100","UNKNOWN","Says it is double blind. Injections were given by a nurse who did not participate in assessments. Blinding of participants not explained. No information on test of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Wistedt-1983","2010-05-16 21:52:10 +0100","NO","Attrition was 43.75% in 2 years but reasons not discussed. There is no information how this was dealt with in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Wistedt-1983","2010-04-13 19:26:50 +0100","NO","Some outcomes of assessments regarding Global Impression and Mental State not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders [v4.0-For publication].rm5","STD-Wistedt-1983","2010-05-11 18:45:26 +0100","YES","No other bias evident.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Barrowclough-2001","2009-07-17 10:20:22 +0100","YES","Randomised, computer generated","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Barrowclough-2001","2009-07-17 10:20:32 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Barrowclough-2001","2009-07-17 10:20:50 +0100","NO","Single, untested","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Barrowclough-2001","2009-07-17 10:30:05 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Barrowclough-2001","2009-07-17 10:30:13 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Barrowclough-2001","2010-01-15 11:09:26 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Bloch-1995","2009-07-17 10:30:47 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Bloch-1995","2009-07-17 10:30:53 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Bloch-1995","2009-07-17 10:31:14 +0100","NO","Not blinded","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Bloch-1995","2009-07-17 10:31:26 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Bloch-1995","2009-07-17 10:31:32 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Bloch-1995","2010-01-15 11:35:13 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Bradley-2006","2009-03-30 17:01:54 +0100","UNKNOWN","Randomised - no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Bradley-2006","2009-03-30 17:01:34 +0100","UNKNOWN","Randomised by a staff member who drew names from a canister and, without looking at the names","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Bradley-2006","2009-03-30 17:01:32 +0100","UNKNOWN","Single blind, independent researchers who were blind to study condition, untested","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Bradley-2006","2009-03-30 17:01:31 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Bradley-2006","2009-03-30 17:00:39 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Bradley-2006","2010-01-15 11:36:09 +0000","YES","Principally funded by grant 1997-0219 from the Victorian Health Promotion Foundation","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Buchkremer-1995","2009-07-17 10:34:08 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Buchkremer-1995","2009-07-17 10:33:25 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Buchkremer-1995","2009-07-17 10:33:19 +0100","NO","Not blinded","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Buchkremer-1995","2009-07-17 10:35:00 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Buchkremer-1995","2009-07-17 10:34:53 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Buchkremer-1995","2010-01-15 11:37:43 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Carra-2007","2009-04-01 11:19:19 +0100","YES","Randomised using random numbers table","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Carra-2007","2009-04-01 12:34:28 +0100","YES","'Allocation concealment was ensured by the external involvement of a statistician (C.M.), who was not involved in enrolling participants, and was responsible for the method of sequence generation'","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Carra-2007","2010-09-22 13:39:36 +0100","UNKNOWN","Follow-up assessments were carried out by research assistants blind about the treatment assigned, untested.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Carra-2007","2009-04-01 12:43:41 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Carra-2007","2009-04-01 12:43:30 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Carra-2007","2009-04-01 12:43:51 +0100","YES","Grant ","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Chen-2005","2010-01-15 11:39:23 +0000","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Chen-2005","2010-01-15 11:40:06 +0000","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Chen-2005","2010-01-15 11:40:17 +0000","UNKNOWN","No details","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Chen-2005","2010-01-15 11:39:07 +0000","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Chen-2005","2010-01-15 11:38:52 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Chen-2005","2010-01-15 11:38:50 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Chien-2004","2009-07-17 10:40:09 +0100","YES","Randomsied, by computer generation","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Chien-2004","2009-07-17 10:40:18 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Chien-2004","2009-07-17 10:40:41 +0100","UNKNOWN","No reported","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Chien-2004","2009-07-17 10:40:50 +0100","UNKNOWN","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Chien-2004","2009-07-17 10:40:54 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Chien-2004","2010-01-15 11:40:25 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Dai-2007","2009-11-18 10:47:02 +0000","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Dai-2007","2009-11-18 10:47:07 +0000","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Dai-2007","2009-11-18 10:47:15 +0000","UNKNOWN","No details","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Dai-2007","2009-11-18 10:47:29 +0000","UNKNOWN","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Dai-2007","2009-11-18 10:47:34 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Dai-2007","2009-11-18 10:47:41 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-De-Giacomo-1997","2009-07-17 10:41:05 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-De-Giacomo-1997","2009-07-17 10:41:11 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-De-Giacomo-1997","2009-07-17 10:41:24 +0100","NO","Not blind","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-De-Giacomo-1997","2009-07-17 10:41:32 +0100","UNKNOWN","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-De-Giacomo-1997","2009-07-17 10:41:45 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-De-Giacomo-1997","2010-01-15 11:40:38 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Du-2005","2009-11-18 10:53:13 +0000","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Du-2005","2009-11-18 10:53:20 +0000","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Du-2005","2009-11-18 10:53:24 +0000","UNKNOWN","No details","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Du-2005","2010-01-15 11:40:50 +0000","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Du-2005","2009-11-18 10:53:39 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Du-2005","2009-11-18 10:53:47 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Dyck-2002","2009-03-31 10:53:51 +0100","NO","Randomised by pulling papers out of a hat labelled with study group","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Dyck-2002","2009-03-31 10:54:08 +0100","NO","No","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Dyck-2002","2009-03-31 10:47:42 +0100","NO","Open study","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Dyck-2002","2009-03-31 10:51:41 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Dyck-2002","2009-03-31 10:50:52 +0100","NO","Not all outcome data reported","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Dyck-2002","2009-03-31 10:50:57 +0100","YES","Grant from the National Institute of Mental Health","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Falloon-1981","2009-07-17 11:35:31 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Falloon-1981","2009-07-17 11:35:38 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Falloon-1981","2009-07-17 11:35:50 +0100","NO","Not blind","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Falloon-1981","2009-07-17 11:37:32 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Falloon-1981","2010-01-15 11:42:02 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Falloon-1981","2010-01-15 11:42:04 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Fernandez-1998","2009-07-17 11:36:14 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Fernandez-1998","2009-07-17 11:36:19 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Fernandez-1998","2009-07-17 11:36:26 +0100","NO","Not blind","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Fernandez-1998","2009-07-17 11:37:28 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Fernandez-1998","2009-07-17 11:36:38 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Fernandez-1998","2010-01-15 11:42:08 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Glynn-1992","2009-07-17 11:36:51 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Glynn-1992","2009-07-17 11:36:56 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Glynn-1992","2009-07-17 11:37:04 +0100","NO","Not blind","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Glynn-1992","2009-07-17 11:37:24 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Glynn-1992","2009-07-17 11:37:44 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Glynn-1992","2010-01-15 11:42:19 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Goldstein-1978","2009-07-17 11:37:58 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Goldstein-1978","2009-07-17 11:38:03 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Goldstein-1978","2009-07-17 11:38:16 +0100","UNKNOWN","Single blind, untested","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Goldstein-1978","2009-07-17 11:39:55 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Goldstein-1978","2009-07-17 11:38:41 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Goldstein-1978","2010-01-15 11:42:36 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Gong-2007","2010-09-22 13:39:39 +0100","NO","Quasi-randomised","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Gong-2007","2010-09-22 13:39:39 +0100","NO","According to admission sequence","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Gong-2007","2009-12-15 14:51:55 +0000","NO","Open","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Gong-2007","2010-01-15 11:43:02 +0000","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Gong-2007","2009-12-15 14:52:14 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Gong-2007","2009-12-15 14:52:19 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Guo-2007","2009-12-14 11:50:10 +0000","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Guo-2007","2009-12-14 11:50:13 +0000","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Guo-2007","2009-12-14 11:54:50 +0000","NO","Open study","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Guo-2007","2009-12-14 12:24:56 +0000","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Guo-2007","2009-12-14 11:52:51 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Guo-2007","2009-12-14 11:52:54 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Herz-2000","2009-07-17 11:39:18 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Herz-2000","2009-07-17 11:39:31 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Herz-2000","2009-07-17 11:39:39 +0100","NO","Not blind","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Herz-2000","2009-07-17 11:39:52 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Herz-2000","2009-07-17 11:40:03 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Herz-2000","2010-01-15 11:44:03 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1986","2009-07-17 11:40:35 +0100","NO","Quasi-randomised","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1986","2009-07-17 11:40:49 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1986","2009-07-17 11:40:54 +0100","NO","Not blind","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1986","2010-01-15 11:44:17 +0000","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1986","2009-07-17 11:41:14 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1986","2010-01-15 11:44:21 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1997","2009-07-17 11:41:27 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1997","2009-07-17 11:41:33 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1997","2009-07-17 11:41:41 +0100","NO","No blind","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1997","2009-07-17 11:41:55 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1997","2009-07-17 11:42:03 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1997","2010-01-15 11:44:26 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leavey-2004","2009-07-17 11:42:24 +0100","UNKNOWN","Randomised by block, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leavey-2004","2009-07-17 11:42:30 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leavey-2004","2009-07-17 11:42:44 +0100","UNKNOWN","Single blind, untested","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leavey-2004","2009-07-17 11:42:57 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leavey-2004","2009-07-17 11:43:01 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leavey-2004","2010-01-15 11:44:31 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leff-1982","2010-09-22 13:39:41 +0100","YES","Randomised, by random numbers table","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leff-1982","2009-07-17 11:45:43 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leff-1982","2009-07-17 11:46:05 +0100","NO","Not blind","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leff-1982","2009-07-17 11:53:46 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leff-1982","2009-07-17 11:46:25 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leff-1982","2010-01-15 11:52:24 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leff-1989","2009-07-17 11:55:15 +0100","YES","Randomised, by random numbers table","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leff-1989","2009-07-17 11:54:51 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leff-1989","2009-07-17 11:54:44 +0100","UNKNOWN","Single, untested","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leff-1989","2009-07-17 12:01:05 +0100","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leff-1989","2009-07-17 11:57:01 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leff-1989","2010-01-15 11:52:37 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leff-2001","2009-07-17 12:01:41 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leff-2001","2009-07-17 12:01:37 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leff-2001","2009-07-17 12:01:30 +0100","UNKNOWN","Single blind, untested","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leff-2001","2009-07-17 12:01:56 +0100","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leff-2001","2009-07-17 12:02:10 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Leff-2001","2010-01-15 11:53:08 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Li-2004","2010-01-08 15:04:56 +0000","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Li-2004","2010-01-08 15:05:00 +0000","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Li-2004","2010-01-08 15:05:09 +0000","UNKNOWN","No details","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Li-2004","2010-01-08 15:05:31 +0000","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Li-2004","2010-01-08 15:05:16 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Li-2004","2010-01-08 15:05:19 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Li-2005a","2009-12-15 16:05:48 +0000","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Li-2005a","2009-12-15 16:05:52 +0000","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Li-2005a","2009-12-15 16:06:31 +0000","NO","Open study","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Li-2005a","2010-09-22 13:39:42 +0100","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Li-2005a","2009-12-15 16:06:23 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Li-2005a","2009-12-15 16:06:26 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Linszen-1996","2009-07-17 12:14:53 +0100","YES","Randomised, by random numbers table","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Linszen-1996","2009-07-17 12:13:59 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Linszen-1996","2009-07-17 12:14:08 +0100","UNKNOWN","Single, untested","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Linszen-1996","2009-07-17 12:14:45 +0100","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Linszen-1996","2009-07-17 12:14:39 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Linszen-1996","2010-01-15 11:53:19 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Liu-2003","2009-12-14 16:30:29 +0000","NO","Randomised, according to hospital admission","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Liu-2003","2009-12-14 16:30:04 +0000","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Liu-2003","2009-12-14 16:30:36 +0000","UNKNOWN","No details","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Liu-2003","2010-01-15 11:53:55 +0000","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Liu-2003","2009-12-14 16:30:41 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Liu-2003","2009-12-14 16:30:43 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Liu-2007","2009-12-14 14:23:53 +0000","UNKNOWN","Randomised, no details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Liu-2007","2009-12-14 14:24:07 +0000","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Liu-2007","2009-12-14 14:24:22 +0000","NO","Open study","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Liu-2007","2010-09-22 13:39:43 +0100","UNKNOWN","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Liu-2007","2009-12-14 14:24:30 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Liu-2007","2009-12-14 14:24:33 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Luping-2007","2009-12-10 13:34:31 +0000","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Luping-2007","2009-12-10 13:34:36 +0000","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Luping-2007","2009-12-10 13:35:16 +0000","UNKNOWN","No details","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Luping-2007","2009-12-10 13:35:51 +0000","UNKNOWN","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Luping-2007","2009-12-10 13:35:58 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Luping-2007","2009-12-10 13:36:00 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Lv-2003","2009-11-16 11:11:06 +0000","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Lv-2003","2009-11-16 11:11:11 +0000","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Lv-2003","2009-11-16 11:11:16 +0000","UNKNOWN","No details","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Lv-2003","2009-11-16 11:11:40 +0000","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Lv-2003","2009-11-16 11:11:30 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Lv-2003","2009-11-16 11:11:33 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Magliano-2006","2009-03-31 14:56:51 +0100","YES","Computer randomisation","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Magliano-2006","2009-07-17 12:15:19 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Magliano-2006","2009-03-31 14:56:25 +0100","NO","Open study","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Magliano-2006","2010-01-15 11:54:26 +0000","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Magliano-2006","2009-03-31 14:56:04 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Magliano-2006","2010-01-15 11:55:31 +0000","UNKNOWN","Grants from the M. Lugli Foundation and from Italy’s National Institute","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Mak-1997","2009-07-17 12:33:36 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Mak-1997","2009-07-17 12:33:45 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Mak-1997","2009-07-17 12:33:56 +0100","NO","Not blind","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Mak-1997","2010-01-15 11:55:53 +0000","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Mak-1997","2009-07-17 12:34:19 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Mak-1997","2010-01-15 11:55:46 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-McFarlane-1995","2009-07-17 12:34:25 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-McFarlane-1995","2009-07-17 12:34:35 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-McFarlane-1995","2009-07-17 12:34:59 +0100","UNKNOWN","Partial blinding, untested","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-McFarlane-1995","2009-07-17 12:35:11 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-McFarlane-1995","2009-07-17 12:35:16 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-McFarlane-1995","2010-01-15 11:56:11 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Merinder-1999","2009-07-17 12:35:35 +0100","UNKNOWN","Randomised by block, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Merinder-1999","2009-07-17 12:35:42 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Merinder-1999","2009-07-17 12:36:08 +0100","UNKNOWN","Single, untested","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Merinder-1999","2010-01-15 11:56:17 +0000","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Merinder-1999","2009-07-17 12:36:30 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Merinder-1999","2010-01-15 11:56:22 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Posner-1992","2009-07-17 12:40:21 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Posner-1992","2009-07-17 12:40:25 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Posner-1992","2009-07-17 12:40:29 +0100","UNKNOWN","Not stated","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Posner-1992","2010-01-15 11:59:37 +0000","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Posner-1992","2009-07-17 12:40:45 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Posner-1992","2010-01-15 11:59:31 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Qiu-2002","2009-12-21 10:28:48 +0000","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Qiu-2002","2009-11-16 10:48:30 +0000","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Qiu-2002","2009-11-16 10:48:39 +0000","UNKNOWN","Not reported","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Qiu-2002","2009-11-16 10:48:57 +0000","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Qiu-2002","2009-11-16 10:49:07 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Qiu-2002","2009-11-16 10:49:17 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Ran-2003","2009-07-17 12:41:59 +0100","YES","Randomised, computer generated","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Ran-2003","2009-07-17 12:41:22 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Ran-2003","2009-07-17 12:41:55 +0100","UNKNOWN","Assessors blind, no further details","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Ran-2003","2010-01-15 11:59:58 +0000","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Ran-2003","2009-07-17 12:42:14 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Ran-2003","2010-01-15 11:59:53 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Randolph-1994","2009-07-17 12:42:27 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Randolph-1994","2009-07-17 12:42:33 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Randolph-1994","2009-07-17 12:42:36 +0100","UNKNOWN","Not stated","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Randolph-1994","2009-07-17 12:42:53 +0100","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Randolph-1994","2009-07-17 12:42:49 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Randolph-1994","2010-01-15 12:00:06 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Schooler-1997","2009-07-17 12:43:05 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Schooler-1997","2009-07-17 12:43:09 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Schooler-1997","2009-07-17 12:43:12 +0100","UNKNOWN","Not stated","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Schooler-1997","2009-07-17 12:44:53 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Schooler-1997","2009-07-17 12:43:25 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Schooler-1997","2009-04-01 16:23:48 +0100","YES","Grant from NIMH","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Shi-2000","2009-07-17 12:44:49 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Shi-2000","2009-07-17 12:44:59 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Shi-2000","2009-07-17 12:45:03 +0100","UNKNOWN","Not stated","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Shi-2000","2009-07-17 12:45:14 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Shi-2000","2009-07-17 12:45:18 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Shi-2000","2010-01-15 12:00:23 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Szmukler-2003","2009-07-17 12:45:31 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Szmukler-2003","2009-07-17 12:45:35 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Szmukler-2003","2009-07-17 12:45:47 +0100","NO","Not blinded","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Szmukler-2003","2009-07-17 12:48:04 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Szmukler-2003","2009-07-17 12:46:02 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Szmukler-2003","2010-01-15 12:00:26 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Tan-2007","2009-12-10 16:38:31 +0000","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Tan-2007","2009-12-10 16:38:35 +0000","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Tan-2007","2009-12-10 16:38:48 +0000","NO","Open study","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Tan-2007","2010-01-13 14:39:54 +0000","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Tan-2007","2010-01-13 14:39:30 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Tan-2007","2010-01-13 14:39:34 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Tarrier-1988","2009-07-17 12:46:18 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Tarrier-1988","2009-07-17 12:46:25 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Tarrier-1988","2009-07-17 12:46:30 +0100","UNKNOWN","Single, untested","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Tarrier-1988","2009-07-17 12:47:58 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Tarrier-1988","2009-07-17 12:46:40 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Tarrier-1988","2010-01-15 12:01:21 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Vaughan-1992","2009-07-17 12:47:53 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Vaughan-1992","2009-07-17 12:48:22 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Vaughan-1992","2009-07-17 12:48:59 +0100","UNKNOWN","Single blind","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Vaughan-1992","2009-07-17 12:49:08 +0100","YES","Study attrition reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Vaughan-1992","2009-07-17 12:48:55 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Vaughan-1992","2010-01-15 12:01:28 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Wang-2006","2009-12-17 13:12:52 +0000","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Wang-2006","2009-12-17 13:12:38 +0000","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Wang-2006","2009-12-17 13:13:01 +0000","NO","None","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Wang-2006","2009-12-21 11:04:30 +0000","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Wang-2006","2009-12-17 13:13:06 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Wang-2006","2009-12-17 13:13:09 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Xiang-1994","2009-07-17 12:50:02 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Xiang-1994","2009-07-17 12:50:09 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Xiang-1994","2009-07-17 12:50:13 +0100","UNKNOWN","Double blind, untested","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Xiang-1994","2009-07-17 12:52:01 +0100","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Xiang-1994","2009-07-17 12:50:32 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Xiang-1994","2010-01-15 12:01:45 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Xiang-2005","2010-01-15 12:02:00 +0000","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Xiang-2005","2010-01-15 12:02:00 +0000","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Xiang-2005","2010-01-15 12:02:26 +0000","NO","Open study","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Xiang-2005","2010-01-15 12:02:00 +0000","UNKNOWN","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Xiang-2005","2010-01-15 12:02:00 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Xiang-2005","2010-01-15 12:02:00 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Xiong-1994","2009-07-17 12:51:22 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Xiong-1994","2009-07-17 12:51:27 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Xiong-1994","2010-01-15 12:03:17 +0000","UNKNOWN","Single blind, untested","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Xiong-1994","2009-07-17 12:51:57 +0100","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Xiong-1994","2009-07-17 12:52:16 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Xiong-1994","2010-01-15 12:03:08 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhang-1994","2009-07-17 12:54:56 +0100","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhang-1994","2009-07-17 12:55:04 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhang-1994","2010-01-15 12:03:31 +0000","UNKNOWN","Single, untested","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhang-1994","2009-07-17 12:55:28 +0100","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhang-1994","2009-07-17 12:55:46 +0100","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhang-1994","2010-01-15 12:03:33 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhang-2006a","2009-12-21 16:02:46 +0000","UNKNOWN","Randomised, no details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhang-2006a","2009-12-21 16:02:54 +0000","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhang-2006a","2010-01-15 12:04:03 +0000","NO","Open study","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhang-2006a","2010-01-15 12:03:47 +0000","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhang-2006a","2009-12-21 16:03:04 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhang-2006a","2009-12-21 16:03:08 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhang-2006b","2009-12-21 12:30:43 +0000","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhang-2006b","2009-12-21 12:30:46 +0000","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhang-2006b","2009-12-21 12:30:53 +0000","UNKNOWN","No details","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhang-2006b","2009-12-21 12:31:15 +0000","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhang-2006b","2009-12-21 12:31:09 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhang-2006b","2009-12-21 12:31:12 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhou-2007","2009-12-21 16:42:31 +0000","UNKNOWN","Randomised, no further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhou-2007","2009-12-21 16:42:34 +0000","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhou-2007","2009-12-21 16:43:05 +0000","NO","Open study","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhou-2007","2009-12-21 16:43:23 +0000","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhou-2007","2009-12-21 16:43:29 +0000","UNKNOWN","No details","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Family intervention for schizophrenia [v14.0-For publication].rm5","STD-Zhou-2007","2009-12-21 16:43:31 +0000","UNKNOWN","No details","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Barber-1988_x002a_","2012-11-08 03:21:32 +0000","YES","Simple random sampling - ""using a table of random numbers, 200 patient code numbers were randomly selected and divided into 2 groups of 100 each, random assignment of subjects to control and experimental group was determined by a flip of a coin such that 'heads' represented the control group and 'tails' represented the experimental group. The subjects were subsequently alternately assigned to the groups after the initial toss of coin so that the groups were equal"" (p66).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Barber-1988_x002a_","2012-09-13 13:49:35 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Barber-1988_x002a_","2012-09-19 15:03:11 +0100","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Barber-1988_x002a_","2012-09-19 15:00:47 +0100","NO","Attrition: 65% - 200 participants were originally randomised - 100 each to receive either the family workshop or routine clinical information. Out of n = 100 assigned to workshop, n = 44 participants agreed to participate, however only n = 39 attended, and only n = 36 returned both pre-tests and post-tests and were included in the analysis. Out of n = 100 assigned to routine clinical information, only n = 38 agreed to participate in the study, and only n = 34 completed the study and were included in data and analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Barber-1988_x002a_","2012-09-19 14:27:13 +0100","YES","All specified outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Barber-1988_x002a_","2012-10-16 14:38:42 +0100","NO","Rating scales: not clear whether raters were independent of treatment. SFCS developed by trial investigator.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Shinde-2005","2014-03-03 11:11:50 +0000","UNKNOWN","Randomised – ""random number table was used to assort 20 patients and their caregivers"" – no further information.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Shinde-2005","2014-03-03 11:11:50 +0000","NO","Non-blinded.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Shinde-2005","2014-03-03 11:11:50 +0000","NO","Non-blinded.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Shinde-2005","2014-03-03 11:11:50 +0000","UNKNOWN","Control group - n = 17 people with schizophrenia and their caregivers completed the 3-month follow-up assessment.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Shinde-2005","2012-09-27 12:34:44 +0100","YES","None detected.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Shinde-2005","2012-09-27 12:34:40 +0100","UNKNOWN","Rating scales: FEICS described as a self-report scale - unclear whether raters of remaining scales were independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Smith-1987","2012-09-20 15:34:20 +0100","UNKNOWN","Randomised - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Smith-1987","2012-09-20 15:12:04 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Smith-1987","2013-08-22 16:44:57 +0100","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Smith-1987","2012-09-20 15:29:03 +0100","YES","Quote, ""there were no drop-outs during the intervention period"" (p646).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Smith-1987","2012-11-08 06:31:33 +0000","UNKNOWN","All data were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Smith-1987","2012-09-25 11:52:32 +0100","UNKNOWN","Rating scales: not clear whether raters were independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Youssef-1987","2012-09-25 15:45:53 +0100","UNKNOWN","Randomised - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Youssef-1987","2012-09-20 15:12:36 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Youssef-1987","2012-09-25 15:54:44 +0100","NO","Quote: ""subjects were approached by the investigator and informed verbally of the purpose of the study"" (p613).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Youssef-1987","2012-09-25 16:28:30 +0100","NO","It is stated that, quote, ""initially a total of 42 patients with affective disorders were approached for possible inclusion in this investigation. Of this number, 12 patients were excluded from the initial sample for the following reasons: families' refusal to participate in this study, reluctance to join all three education sessions, and/or difficulties in tracing some patients and their families during the follow-up period"" (p613). It is unclear whether these participants had been randomised into either the intervention or control group, or whether data were collected for these participants. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Youssef-1987","2012-09-25 16:25:16 +0100","NO","Statistical data for the GAS were not reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Family intervention (brief) for schizophrenia [v2.0-For publication].rm5","STD-Youssef-1987","2012-09-25 15:43:05 +0100","YES","Rating scales: not clear whether raters were independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Exercise therapy for schizophrenia [v6.0-For publication].rm5","STD-Beebe-2005","2009-07-06 18:53:30 +0100","YES","Allocation schedule designed by statistician.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Exercise therapy for schizophrenia [v6.0-For publication].rm5","STD-Beebe-2005","2009-09-03 23:59:27 +0100","UNKNOWN","No details given.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Exercise therapy for schizophrenia [v6.0-For publication].rm5","STD-Beebe-2005","2010-02-16 16:38:31 +0000","YES","Single, researcher blinded to group status, untested.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Exercise therapy for schizophrenia [v6.0-For publication].rm5","STD-Beebe-2005","2009-09-30 19:42:30 +0100","NO","83.3% of participants in the analysis (10/12). Two participants in the exercise arm did not attend first session. These participants were excluded from the results. ","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Exercise therapy for schizophrenia [v6.0-For publication].rm5","STD-Beebe-2005","2009-09-15 13:23:11 +0100","NO","Several SDs were not reported for PANSS, BMI, and Percentage Body Fat.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Exercise therapy for schizophrenia [v6.0-For publication].rm5","STD-Beebe-2005","2009-07-06 18:55:25 +0100","NO","Small sample size.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Exercise therapy for schizophrenia [v6.0-For publication].rm5","STD-Duraiswamy-2007","2009-07-06 18:57:41 +0100","YES","Computer generated.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Exercise therapy for schizophrenia [v6.0-For publication].rm5","STD-Duraiswamy-2007","2009-09-03 23:59:45 +0100","UNKNOWN","No details given.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Exercise therapy for schizophrenia [v6.0-For publication].rm5","STD-Duraiswamy-2007","2010-02-16 16:38:35 +0000","YES","Single, researcher blinded to group status, untested.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Exercise therapy for schizophrenia [v6.0-For publication].rm5","STD-Duraiswamy-2007","2009-09-30 19:43:18 +0100","NO","67.2% of participants in the analysis (41/61). Then participants in each study arm left early because of disinterest and long distance from hospital. These participants were excluded from the results.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Exercise therapy for schizophrenia [v6.0-For publication].rm5","STD-Duraiswamy-2007","2009-09-04 00:15:30 +0100","NO","Quality of life total data not reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Exercise therapy for schizophrenia [v6.0-For publication].rm5","STD-Duraiswamy-2007","2009-07-06 19:23:51 +0100","NO","No true control group used. Exercise compared with yoga. Same therapist delivered both conditions.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Exercise therapy for schizophrenia [v6.0-For publication].rm5","STD-Marzaloni-2008","2009-07-06 19:33:07 +0100","YES","Two options for group assignments were identified on","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Exercise therapy for schizophrenia [v6.0-For publication].rm5","STD-Marzaloni-2008","2009-07-06 19:32:31 +0100","YES","Random draw by an independent observer uninvolved","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Exercise therapy for schizophrenia [v6.0-For publication].rm5","STD-Marzaloni-2008","2010-02-16 16:38:04 +0000","UNKNOWN","Single, researcher blinded to group status, untested.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Exercise therapy for schizophrenia [v6.0-For publication].rm5","STD-Marzaloni-2008","2009-04-29 19:32:20 +0100","YES","100% of participants in the analysis (13/13).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Exercise therapy for schizophrenia [v6.0-For publication].rm5","STD-Marzaloni-2008","2009-09-04 00:18:55 +0100","NO","Not all anthropometric measurements were reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Exercise therapy for schizophrenia [v6.0-For publication].rm5","STD-Marzaloni-2008","2009-07-06 19:27:54 +0100","NO","Small sample size.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Alvarez_x002d_Spain","2010-06-02 13:43:25 +0100","YES","Randomised using computer generated random numbers","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Alvarez_x002d_Spain","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Alvarez_x002d_Spain","2010-06-02 13:43:38 +0100","NO","Single","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Alvarez_x002d_Spain","2010-06-02 13:44:17 +0100","NO","Study attrition not reported","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Alvarez_x002d_Spain","2010-06-02 13:43:57 +0100","NO","SAPS data not reported","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Alvarez_x002d_Spain","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Amminger_x002d_Austria","2011-03-03 15:52:34 +0000","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Amminger_x002d_Austria","2011-03-03 15:52:37 +0000","UNKNOWN","No described.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Amminger_x002d_Austria","2011-03-03 15:52:42 +0000","UNKNOWN","Double blind, untested.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Amminger_x002d_Austria","2011-03-03 15:52:44 +0000","NO","Study attrition not described.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Amminger_x002d_Austria","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Amminger_x002d_Austria","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Berger_x002d_Australia","2011-03-03 15:53:59 +0000","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Berger_x002d_Australia","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Berger_x002d_Australia","2011-03-03 15:54:01 +0000","UNKNOWN","Double blind, untested.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Berger_x002d_Australia","2011-03-03 15:54:03 +0000","YES","Study attrition reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Berger_x002d_Australia","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Berger_x002d_Australia","2009-06-29 12:16:07 +0100","YES","Funded by Swiss National Science Foundation; Margaret and Walter Lichtenstein Foundation, National Health and Medical Research Council of Australia' the Colonial Foundation of Australia, and a National Alliance for Reasearch on Schizophrenia and Depression.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-EDIE_x002d_UK","2011-03-03 15:54:46 +0000","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-EDIE_x002d_UK","2011-03-03 15:54:49 +0000","YES","By independent clerical worker, using sealed envelopes.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-EDIE_x002d_UK","2011-03-03 15:54:51 +0000","NO","Single blind.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-EDIE_x002d_UK","2011-03-03 15:54:57 +0000","YES","Study attrition reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-EDIE_x002d_UK","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-EDIE_x002d_UK","2011-03-03 15:55:04 +0000","YES","Funded by North-West NHS Executive.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Edwards_x002d_Australia","2011-03-03 15:56:33 +0000","YES","Computer generated randomisation.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Edwards_x002d_Australia","2011-03-03 15:56:38 +0000","UNKNOWN","Insufficient details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Edwards_x002d_Australia","2011-03-03 15:56:40 +0000","NO","Single blind.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Edwards_x002d_Australia","2011-03-03 15:56:42 +0000","NO","Study attrition not reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Edwards_x002d_Australia","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Edwards_x002d_Australia","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-EIPS_x002d_Germany","2011-03-03 15:57:19 +0000","YES","Randomised by computer generated numbers.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-EIPS_x002d_Germany","2011-03-03 15:57:21 +0000","UNKNOWN","Using sealed envelopes.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-EIPS_x002d_Germany","2011-03-03 15:57:23 +0000","NO","Not stated.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-EIPS_x002d_Germany","2011-03-03 15:57:27 +0000","NO","Study attrition only part reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-EIPS_x002d_Germany","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-EIPS_x002d_Germany","2011-03-03 15:57:33 +0000","YES","Funded by the German Federal Ministry of Education and Research.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Jackson_x002d_Australia","2011-03-03 15:58:26 +0000","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Jackson_x002d_Australia","2011-03-03 15:58:28 +0000","YES","Randomised by independent statistician.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Jackson_x002d_Australia","2011-03-03 15:58:34 +0000","NO","Single, untested.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Jackson_x002d_Australia","2011-03-03 15:58:37 +0000","YES","Study attrition reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Jackson_x002d_Australia","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Jackson_x002d_Australia","2011-03-03 15:58:44 +0000","YES","Funded by NH&MRC grant.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Killackey_x002d_Australia","2011-03-03 15:59:42 +0000","YES","Randomised, computer generated.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Killackey_x002d_Australia","2011-03-03 15:59:48 +0000","UNKNOWN","Not reported.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Killackey_x002d_Australia","2011-03-03 15:59:49 +0000","UNKNOWN","Not reported.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Killackey_x002d_Australia","2011-03-03 15:59:53 +0000","YES","Study attrition reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Killackey_x002d_Australia","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Killackey_x002d_Australia","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Leavey_x002d_UK","2011-03-03 16:00:35 +0000","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Leavey_x002d_UK","2011-03-03 16:00:38 +0000","YES","Using sealed envelopes, drawn by individuals with no connection to the study.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Leavey_x002d_UK","2011-03-03 16:00:39 +0000","YES","Single, untested.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Leavey_x002d_UK","2011-03-03 16:00:42 +0000","YES","Study attrition reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Leavey_x002d_UK","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Leavey_x002d_UK","2011-03-03 16:00:45 +0000","YES","Funded by NHS Executive, London Research and Development Programme.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-LEO_x002d_CAT_x002d_UK","2011-03-03 16:21:53 +0000","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-LEO_x002d_CAT_x002d_UK","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-LEO_x002d_CAT_x002d_UK","2011-03-03 16:21:58 +0000","NO","Open study.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-LEO_x002d_CAT_x002d_UK","2011-03-03 16:22:00 +0000","NO","Study attrition not reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-LEO_x002d_CAT_x002d_UK","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-LEO_x002d_CAT_x002d_UK","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-LifeSPAN_x002d_Australia","2011-03-03 16:22:48 +0000","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-LifeSPAN_x002d_Australia","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-LifeSPAN_x002d_Australia","2011-03-03 16:22:50 +0000","NO","Single blind.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-LifeSPAN_x002d_Australia","2011-03-03 16:22:52 +0000","YES","Study attrition reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-LifeSPAN_x002d_Australia","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-LifeSPAN_x002d_Australia","2011-03-03 16:22:55 +0000","YES","Funded by the Government of Australia.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Linszen_x002d_Amsterdam","2011-03-03 16:23:31 +0000","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Linszen_x002d_Amsterdam","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Linszen_x002d_Amsterdam","2010-11-16 13:26:29 +0000","NO","No details.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Linszen_x002d_Amsterdam","2011-03-03 16:23:37 +0000","NO","Study attrition not reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Linszen_x002d_Amsterdam","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Linszen_x002d_Amsterdam","2011-03-03 16:23:42 +0000","UNKNOWN","Part funded by 'Praeventiefonds'.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-LIPS_x002d_Germany","2011-03-03 16:24:51 +0000","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-LIPS_x002d_Germany","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-LIPS_x002d_Germany","2011-03-03 16:24:54 +0000","NO","Open label.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-LIPS_x002d_Germany","2011-03-03 16:24:57 +0000","YES","Study attrition reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-LIPS_x002d_Germany","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-LIPS_x002d_Germany","2011-03-03 16:25:00 +0000","NO","Funded by German Federal Ministry for Educaton and research BMBF grant and Sanofi Synthelabo, Germany.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-OPUS_x002d_Scandinavia","2011-03-03 16:26:56 +0000","YES","Randomised, computer generated.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-OPUS_x002d_Scandinavia","2011-03-03 16:26:58 +0000","YES","Secretary drew lots, which the investigators had no knowledge.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-OPUS_x002d_Scandinavia","2011-03-03 16:27:07 +0000","YES","Independent assessors aware of treatment allocation; 5-year follow-up assessors unaware of treatment allocation.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-OPUS_x002d_Scandinavia","2011-03-03 16:27:09 +0000","YES","Study attrition reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-OPUS_x002d_Scandinavia","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-OPUS_x002d_Scandinavia","2011-03-03 16:27:25 +0000","YES","Grants from the Danish Ministry of Health, Danish Ministry of Social Affairs, University of Copenhagen, Copenhagen Hospital Cooperation, Danish Medical Research Council, Wørners Foundation, and the Stanley Wada Research Foundation.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-PACE_x002d_Australia","2011-03-03 16:30:07 +0000","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-PACE_x002d_Australia","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-PACE_x002d_Australia","2011-03-03 16:30:10 +0000","NO","Not blinded.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-PACE_x002d_Australia","2011-03-03 16:30:11 +0000","NO","Study attrition not reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-PACE_x002d_Australia","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-PACE_x002d_Australia","2011-03-03 16:30:15 +0000","UNKNOWN","Funding by the Commonwealth Government of Australia Research and Development Grants Advisory Committee, and Janssen-Cilag Pharmaceuticals; Australian Rotary Health Research Fund grant.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-PRIME_x002d_USA","2011-03-03 16:37:24 +0000","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-PRIME_x002d_USA","2011-03-03 16:37:26 +0000","YES","Pills dispensed in prepackaged packs, prelabelled by site number and sequential subject number within site.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-PRIME_x002d_USA","2011-03-03 16:37:29 +0000","UNKNOWN","Double blind, untested.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-PRIME_x002d_USA","2011-03-03 16:37:34 +0000","YES","Study attrition reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-PRIME_x002d_USA","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-PRIME_x002d_USA","2011-03-03 16:37:36 +0000","NO","Funding Eli Lilly and Company.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Uzenoff_x002d_USA","2011-03-03 16:38:56 +0000","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Uzenoff_x002d_USA","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Uzenoff_x002d_USA","2011-03-03 16:39:03 +0000","NO","Not blinded.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Uzenoff_x002d_USA","2011-03-03 16:39:06 +0000","YES","Study attrition reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Uzenoff_x002d_USA","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Uzenoff_x002d_USA","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Zhang_x002d_China","2011-03-03 16:39:50 +0000","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Zhang_x002d_China","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Zhang_x002d_China","2011-03-03 16:39:53 +0000","NO","Not reported.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Zhang_x002d_China","2011-03-03 16:39:55 +0000","YES","Study attrition reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Zhang_x002d_China","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Early intervention for psychosis [v7.0-For publication].rm5","STD-Zhang_x002d_China","2010-11-16 13:26:29 +0000","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Drama therapy for schizophrenia or schizophrenia-like illnesses [v3.0-For publication].rm5","STD-Gutride-1973","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Drama therapy for schizophrenia or schizophrenia-like illnesses [v3.0-For publication].rm5","STD-Nitsun-1974","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Drama therapy for schizophrenia or schizophrenia-like illnesses [v3.0-For publication].rm5","STD-Qu-2000","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Drama therapy for schizophrenia or schizophrenia-like illnesses [v3.0-For publication].rm5","STD-Whetstone-1986","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Drama therapy for schizophrenia or schizophrenia-like illnesses [v3.0-For publication].rm5","STD-Zhou-2002","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Distraction techniques for schizophrenia [v4.0-For publication].rm5","STD-Buccheri-1996","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Distraction techniques for schizophrenia [v4.0-For publication].rm5","STD-Cole-1997","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Distraction techniques for schizophrenia [v4.0-For publication].rm5","STD-Lamontagne-1983","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Distraction techniques for schizophrenia [v4.0-For publication].rm5","STD-Medalia-2000","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Distraction techniques for schizophrenia [v4.0-For publication].rm5","STD-Tarrier-1993","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot pipotiazine palmitate and undecylenate for schizophrenia [v7.0-For publication].rm5","STD-Albert-1980","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot pipotiazine palmitate and undecylenate for schizophrenia [v7.0-For publication].rm5","STD-Bechelli-1985","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot pipotiazine palmitate and undecylenate for schizophrenia [v7.0-For publication].rm5","STD-Bechelli-1986","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot pipotiazine palmitate and undecylenate for schizophrenia [v7.0-For publication].rm5","STD-Chai-1998","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot pipotiazine palmitate and undecylenate for schizophrenia [v7.0-For publication].rm5","STD-Chouinard-1978","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot pipotiazine palmitate and undecylenate for schizophrenia [v7.0-For publication].rm5","STD-Dencker-1973","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot pipotiazine palmitate and undecylenate for schizophrenia [v7.0-For publication].rm5","STD-Dencker-1978","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot pipotiazine palmitate and undecylenate for schizophrenia [v7.0-For publication].rm5","STD-Jain-1975","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot pipotiazine palmitate and undecylenate for schizophrenia [v7.0-For publication].rm5","STD-Leong-1989","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot pipotiazine palmitate and undecylenate for schizophrenia [v7.0-For publication].rm5","STD-Robak-1973","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot pipotiazine palmitate and undecylenate for schizophrenia [v7.0-For publication].rm5","STD-Schlosberg-1978","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot pipotiazine palmitate and undecylenate for schizophrenia [v7.0-For publication].rm5","STD-Schneider-1981","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot pipotiazine palmitate and undecylenate for schizophrenia [v7.0-For publication].rm5","STD-Simon-1978","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot pipotiazine palmitate and undecylenate for schizophrenia [v7.0-For publication].rm5","STD-Singh-1979","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot pipotiazine palmitate and undecylenate for schizophrenia [v7.0-For publication].rm5","STD-Steinert-1986","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot pipotiazine palmitate and undecylenate for schizophrenia [v7.0-For publication].rm5","STD-Vereecken-1972","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot pipotiazine palmitate and undecylenate for schizophrenia [v7.0-For publication].rm5","STD-Woggon-1977","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot pipotiazine palmitate and undecylenate for schizophrenia [v7.0-For publication].rm5","STD-Yan_x002d_hua-1993","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot haloperidol decanoate for schizophrenia [v4.0-For publication].rm5","STD-Bechelli-1985","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot haloperidol decanoate for schizophrenia [v4.0-For publication].rm5","STD-Chouinard-1984","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot haloperidol decanoate for schizophrenia [v4.0-For publication].rm5","STD-Cookson-1986","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot haloperidol decanoate for schizophrenia [v4.0-For publication].rm5","STD-Eberhard-1986","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot haloperidol decanoate for schizophrenia [v4.0-For publication].rm5","STD-Eklund-1991","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot haloperidol decanoate for schizophrenia [v4.0-For publication].rm5","STD-Kissling-1985","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot haloperidol decanoate for schizophrenia [v4.0-For publication].rm5","STD-McKane-1987","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot haloperidol decanoate for schizophrenia [v4.0-For publication].rm5","STD-Wistedt-1984","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot haloperidol decanoate for schizophrenia [v4.0-For publication].rm5","STD-Wistedt-1991","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot haloperidol decanoate for schizophrenia [v4.0-For publication].rm5","STD-Zissis-1982","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Depot haloperidol decanoate for schizophrenia [v4.0-For publication].rm5","STD-Zuardi-1983","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Glick-1986","2009-08-12 15:37:01 +0100","UNKNOWN","""randomly assigned"" - subcategorised by diagnosis, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Glick-1986","2009-06-02 18:06:13 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Glick-1986","2009-06-02 18:06:55 +0100","NO","Not blinded by design.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Glick-1986","2009-06-02 18:21:49 +0100","UNKNOWN","The reasons for leaving the study are not mentioned. ","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Glick-1986","2009-07-07 04:28:01 +0100","UNKNOWN","Methods described consistent with outcomes reported, no protocol available.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Glick-1986","2009-07-07 04:29:32 +0100","UNKNOWN","Authors did not declare sources of support and the interests in study.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Linn-1979","2009-08-06 17:03:11 +0100","UNKNOWN","Randomised - no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Linn-1979","2009-06-11 16:26:29 +0100","YES","By means of sealed envelope corresponding to patient's number.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Linn-1979","2009-07-07 04:32:01 +0100","YES","Independent raters, authors affirm that outcome data blinded.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Linn-1979","2009-06-11 16:33:08 +0100","UNKNOWN","Major reason for leaving the study was moving from area but not reported by group of allocation.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Linn-1979","2009-07-07 04:30:36 +0100","UNKNOWN","Methods described consistent with outcomes reported, no protocol available.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Linn-1979","2009-07-07 04:30:48 +0100","UNKNOWN","It was not reported whether blinding was successful. Authors did not declare sources of support and interests in the study.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Meltzoff-1966","2009-08-06 17:05:00 +0100","YES","Randomised - 80 cards shuffled by use of table of random numbers.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Meltzoff-1966","2009-08-12 13:48:17 +0100","UNKNOWN","Deck of cards kept in custody of research personnel, top card drown only when name of patient brought in. Researchers noted 42% married (outpatient) versus 27% married (day treatment) - but no information on how many variables they compared.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Meltzoff-1966","2009-07-07 04:34:57 +0100","UNKNOWN","Research personnel had no dealing with patients, but patients were questioned about their day by their assessor.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Meltzoff-1966","2009-06-11 16:02:45 +0100","UNKNOWN","Missing data on 29 interviews reported but not explained.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Meltzoff-1966","2009-07-07 04:34:08 +0100","UNKNOWN","Methods described consistent with outcomes reported, no protocol available.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Meltzoff-1966","2009-08-12 15:43:44 +0100","UNKNOWN","It was not reported whether blinding was successful. Authors did not declare sources of support and interests in the study. 11 subjects were removed from the study after randomisation - the reasons stated as poor attendance or failure to attend.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Weldon-1979","2009-08-12 15:43:58 +0100","UNKNOWN","""Randomly assigned"" (no details).","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Weldon-1979","2009-07-07 04:37:17 +0100","UNKNOWN","No details on concealment.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Weldon-1979","2009-06-02 18:51:09 +0100","NO","Not blinded by design.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Weldon-1979","2009-06-11 16:01:50 +0100","YES","No loss to follow up. ","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Weldon-1979","2009-07-07 04:38:15 +0100","UNKNOWN","Methods described consistent with outcomes reported, no protocol available.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Day hospital versus outpatient care for people with schizophrenia [v7.0-For publication].rm5","STD-Weldon-1979","2009-07-07 04:38:48 +0100","UNKNOWN","Due to small sample size and short duration of the study. ","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Creed_x002d_UK_x002d_1990","2010-09-20 09:52:10 +0100","YES","Randomly assorted cards in sealed envelopes in blocks of six.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Creed_x002d_UK_x002d_1990","2010-09-20 09:52:11 +0100","YES","Sealed envelopes.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Creed_x002d_UK_x002d_1990","2010-09-20 09:52:11 +0100","NO","Not blind.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Creed_x002d_UK_x002d_1990","2010-09-13 08:44:12 +0100","NO","Further analyses considered only those patients who were fully assessed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Creed_x002d_UK_x002d_1990","2011-01-16 10:04:38 +0000","YES","Expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Creed_x002d_UK_x002d_1990","2010-09-22 13:49:21 +0100","UNKNOWN","No sample size calculation. Protocol not available. Study was performed with grants from the National Unit for Psychiatric Research and Development and the Department of Health and Social Security.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Creed_x002d_UK_x002d_1996","2010-09-20 09:52:27 +0100","YES","Randomly assorted cards in sealed envelopes in blocks of six.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Creed_x002d_UK_x002d_1996","2010-09-20 09:52:27 +0100","YES","Sealed envelopes opened by an independent administrator.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Creed_x002d_UK_x002d_1996","2010-09-20 09:52:29 +0100","NO","Not blind.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Creed_x002d_UK_x002d_1996","2010-09-13 08:45:44 +0100","NO","4 inpatient and 4 day patients were excluded due to diagnosis or early discharge. Five inpatients were transferred to the day hospital because of lack of beds, and 11 day patients were transferred to the inpatient unit because they were too ill for the day hospital.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Creed_x002d_UK_x002d_1996","2011-01-16 10:05:00 +0000","YES","Expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Creed_x002d_UK_x002d_1996","2010-09-22 13:49:45 +0100","UNKNOWN","No sample size calculation. Protocol not available. Study funded by the Department of Health, the North Western Regional Health Authority, and the Mental Health Foundation.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Dick_x002d_UK_x002d_1985","2010-09-20 14:52:06 +0100","UNKNOWN","Randomised. No further details given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Dick_x002d_UK_x002d_1985","2010-09-20 14:52:06 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Dick_x002d_UK_x002d_1985","2010-09-20 14:52:11 +0100","NO","Not blind.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Dick_x002d_UK_x002d_1985","2010-09-20 14:53:20 +0100","UNKNOWN","91 patients were enrolled in the study, 64 patients were followed up to one year. Reasons for default were split about equally between the patient having moved to an unknown address, and the patient refusing further co-operation. No further details given.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Dick_x002d_UK_x002d_1985","2011-01-16 10:07:16 +0000","YES","Expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Dick_x002d_UK_x002d_1985","2010-09-22 13:50:08 +0100","UNKNOWN","No sample size calculation. Protocol not available. Study supported by a grant from the Health Services Research Committee of the Chief Scientist, Scottish Home and Health Department.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Herz_x002d_US_x002d_1971","2010-09-20 09:57:12 +0100","YES","Table of random numbers.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Herz_x002d_US_x002d_1971","2010-09-20 09:57:12 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Herz_x002d_US_x002d_1971","2010-09-20 09:57:13 +0100","NO","Not blind.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Herz_x002d_US_x002d_1971","2011-03-26 16:21:48 +0000","NO","At each follow-up period, the number of patients actually evaluated was fewer than the 45 who were in each group (""The two- and four-week cross-section evaluations were not done on the first 13 patients""; some could not be interviewed: ""out of town""; ""could not be located""; ""refused to be interviewed""; ""patient no longer in therapy with [the resident]""). No further details given.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Herz_x002d_US_x002d_1971","2011-07-14 00:37:00 +0100","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Herz_x002d_US_x002d_1971","2010-09-22 13:50:25 +0100","UNKNOWN","No sample size calculation. Protocol not available. Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Kallert_x002d_EU_x002d_2007","2010-09-21 08:42:22 +0100","YES","“A computerized random-number generator created an allocation sequence”.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Kallert_x002d_EU_x002d_2007","2010-09-21 08:42:22 +0100","YES","“Opaque, sealed envelopes”.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Kallert_x002d_EU_x002d_2007","2011-07-14 00:38:44 +0100","NO","Not blinded.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Kallert_x002d_EU_x002d_2007","2011-03-13 17:09:50 +0000","YES","“The initial attrition rates from randomization to admission varied significantly among settings and centres, with rates for the total sample of 7.9% for those allocated to day hospitals and 1.5% for those allocated to day hospitals”; “follow-up rates for the total sample assessed at admission were 87.0% at discharge, 76.5% 3 months after discharge, and 68.1% 12 months after discharge”. Missing values were imputed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Kallert_x002d_EU_x002d_2007","2011-01-16 10:07:34 +0000","YES","Expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Kallert_x002d_EU_x002d_2007","2011-07-14 00:38:55 +0100","YES","Study supported by the European Commision (Quality of life and Management of Living Resources Programme: QLG4-CT-2000-01700). Support for travel and accommodation for EDEN project meetings provided by Pfizer Pharmaceutical Co.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Kris_x002d_US_x002d_1965","2010-09-20 14:53:50 +0100","UNKNOWN","Randomly selected, no further details given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Kris_x002d_US_x002d_1965","2010-09-20 14:53:50 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Kris_x002d_US_x002d_1965","2010-09-20 14:53:56 +0100","NO","Not blind.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Kris_x002d_US_x002d_1965","2010-09-20 14:53:50 +0100","UNKNOWN","No information provided.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Kris_x002d_US_x002d_1965","2010-09-20 14:53:58 +0100","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Kris_x002d_US_x002d_1965","2010-09-22 13:51:11 +0100","UNKNOWN","No sample size calculation. Protocol not available. Source of support not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Schene_x002d_NL_x002d_1993","2011-03-26 16:21:48 +0000","UNKNOWN","""Randomised"". No further details given but 14 later withdrawn because of ""incorrect randomisation procedure"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Schene_x002d_NL_x002d_1993","2010-09-20 09:59:10 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Schene_x002d_NL_x002d_1993","2010-09-20 09:59:11 +0100","NO","Not blind.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Schene_x002d_NL_x002d_1993","2011-04-05 09:00:32 +0100","NO","On admission: ""21 (9%) of all randomized patients had to be transferred to a closed ward""; ""10 (5%) patients did not accept the result of the randomization"" ""28 (13%) patients decided [...] against admission"" ""4 patients (2%) refused to participate in the study"" ""9 (4%) were excluded for other reasons"". 31 (21%) patients had dropped out by discharge, 12 (8%) patients dropped out at 6 month follow up (""admission less than 28 days""; ""transfer to a closed ward for more than 28 days""; ""patients’ refusal to participate"").","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Schene_x002d_NL_x002d_1993","2010-09-20 09:59:31 +0100","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Schene_x002d_NL_x002d_1993","2010-09-22 13:51:28 +0100","UNKNOWN","No sample size calculation. Protocol not available. Supported by grants from the Prevention Fund and National Fund for Mental Health (Netherlands).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Sledge_x002d_US_x002d_1996","2011-03-26 16:21:48 +0000","NO","""Random assignment""; ""if a consenting patient was randomly assigned to a treatment setting that was full [...] the patient was assigned (i.e. “rolled over” or switched) to the other condition.""","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Sledge_x002d_US_x002d_1996","2010-09-20 10:00:28 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Sledge_x002d_US_x002d_1996","2010-09-20 10:00:29 +0100","NO","Not blind.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Sledge_x002d_US_x002d_1996","2011-07-14 13:53:22 +0100","UNKNOWN","""Attrition from the panel of 197 patients who completed the initial interview was 7% (N = 14) at the discharge interview, 25% (N = 49) at the 2-month follow-up, 25% (N = 49) at the 5-month follow-up, and 28% (N = 55) at the 10-month follow-up"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Sledge_x002d_US_x002d_1996","2011-01-16 10:08:06 +0000","YES","Expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Sledge_x002d_US_x002d_1996","2010-09-22 13:52:31 +0100","UNKNOWN","No sample size calculation. Protocol not available. Supported by grant SMH-47638 from the Substance Abuse and Mental Health Source Administration (USA).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Wiersma_x002d_NL_x002d_1989","2011-03-26 16:21:48 +0000","UNKNOWN","""Randomised in blocks"". No further details given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Wiersma_x002d_NL_x002d_1989","2010-09-20 10:01:35 +0100","UNKNOWN","No information provided. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Wiersma_x002d_NL_x002d_1989","2010-09-20 10:01:40 +0100","NO","Not blind.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Wiersma_x002d_NL_x002d_1989","2011-04-05 09:33:33 +0100","UNKNOWN","Only 34 of the 54 schizophrenic patients (68%) participated in the 2 year interviews, 24 (71%) of 34 experimental and 10 (63%) of 16 controls. No further details given.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Wiersma_x002d_NL_x002d_1989","2010-09-20 10:01:46 +0100","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Wiersma_x002d_NL_x002d_1989","2010-09-22 13:52:44 +0100","UNKNOWN","No sample size calculation. Protocol not available. Source of support not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Zwerling_x002d_US_x002d_1964","2011-03-26 16:21:48 +0000","YES","Random list of ""D"" (day hospital) and ""I"" (inpatient) prepared and numbered sequentially. Day hospital project book contained the number sequence. Each patient entered into the book in sequence.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Zwerling_x002d_US_x002d_1964","2011-03-26 16:21:48 +0000","YES","Telephone answering service revealed name and number of patient, and then the random designation of ""D"" or ""I"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Zwerling_x002d_US_x002d_1964","2010-09-20 10:05:27 +0100","NO","Not blind.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Zwerling_x002d_US_x002d_1964","2011-07-14 13:56:34 +0100","NO","Reasons for rejection of patients designated to day hospitalisation: 22 (34%) had medical or surgical problems, 2 patients did not have family to provide medical care at home, 9 (14%) had travel complications, 20 (31%) patients behaviour required 24-hour hospitalisation. In 8 cases, patients remained in inpatient care after being admitted during the night or weekend.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Zwerling_x002d_US_x002d_1964","2010-09-20 10:05:51 +0100","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Day hospital versus admission for acute psychiatric disorders [v6.0-For publication].rm5","STD-Zwerling_x002d_US_x002d_1964","2010-09-22 13:52:59 +0100","UNKNOWN","No sample size calculation. Protocol not available. Supported by a grant from the National Institute of Mental Health (MH-01132).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Dance therapy for schizophrenia [v10.0-For publication].rm5","STD-Rohricht-2006","2013-03-25 10:47:03 +0000","UNKNOWN","Randomised in blocks, no details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Dance therapy for schizophrenia [v10.0-For publication].rm5","STD-Rohricht-2006","2008-09-22 14:53:32 +0100","YES","Sealed envelope.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Dance therapy for schizophrenia [v10.0-For publication].rm5","STD-Rohricht-2006","2008-11-11 13:53:44 +0000","UNKNOWN","Single, but not tested.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Dance therapy for schizophrenia [v10.0-For publication].rm5","STD-Rohricht-2006","2008-11-12 14:03:19 +0000","NO","40% participants lost at follow-up, not addressed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Dance therapy for schizophrenia [v10.0-For publication].rm5","STD-Rohricht-2006","2008-09-22 14:53:39 +0100","YES","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Dance therapy for schizophrenia [v10.0-For publication].rm5","STD-Rohricht-2006","2013-03-25 10:47:13 +0000","YES","Study supported by East London & The City Mental Health Trust and an unconditional grant by Pfizer and Wyeth.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Compulsory community and involuntary outpatient treatment for people with severe mental disorders [v10.0-For publication].rm5","STD-Burns-2013","2014-10-14 12:51:03 +0100","YES","Consenting participants were randomly assigned (ratio 1:1) by an independent statistician to be discharged from hospital either on CTO or Section 17 leave. Randomisation used random permuted blocks with lengths of two, four, and six, and stratified for sex (male or female), schizophrenic diagnosis (yes or no) and duration of illness (<2 years or ≥2 years). Assignments were enclosed in sequentially numbered, opaque, sealed envelopes and stored by a researcher independent to the trial team. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Compulsory community and involuntary outpatient treatment for people with severe mental disorders [v10.0-For publication].rm5","STD-Burns-2013","2014-10-14 12:51:06 +0100","UNKNOWN","The details of the sequence remained unknown to all members of the trial team until recruitment, data collection, and analyses were completed. Randomisation took place after consent was obtained and the baseline interview was done. The envelope was opened on the day of the interview by the independent researcher after recording the participant’s trial identification number on the envelope. She then communicated the randomised allocation to the recruiting researcher by telephone.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Compulsory community and involuntary outpatient treatment for people with severe mental disorders [v10.0-For publication].rm5","STD-Burns-2013","2014-11-24 13:56:03 +0000","NO","See above - randomisation involved allocation to two different types of legal status. It was therefore both impossible and unlawful to mask research assistants, treating clinicians or patients.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Compulsory community and involuntary outpatient treatment for people with severe mental disorders [v10.0-For publication].rm5","STD-Burns-2013","2014-05-12 14:52:45 +0100","YES","There was no attrition for the primary outcome measure, or health service use; outcome data on psychiatric symptoms and the GAF were only available on 70% of the sample.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Compulsory community and involuntary outpatient treatment for people with severe mental disorders [v10.0-For publication].rm5","STD-Burns-2013","2014-10-14 13:14:26 +0100","YES","","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Compulsory community and involuntary outpatient treatment for people with severe mental disorders [v10.0-For publication].rm5","STD-Burns-2013","2014-11-24 13:56:17 +0000","NO","Section 17 patients swapped to a CTO might have been more severely ill than those remaining on Section 17 as per the protocol. There is uncertainty concerning the control condition. Although the length of ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Compulsory community and involuntary outpatient treatment for people with severe mental disorders [v10.0-For publication].rm5","STD-Steadman-2001","2012-12-18 12:14:53 +0000","YES","The study used a random number list to identify assignment to either the intervention or control group. In this study, a random number list was generated by computer, which then split 200 numbers between one group and the other. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Compulsory community and involuntary outpatient treatment for people with severe mental disorders [v10.0-For publication].rm5","STD-Steadman-2001","2012-12-18 12:15:09 +0000","UNKNOWN","Unclear. The printed list was maintained in the research team's office in a locked file. When the treatment team had completed their treatment plan, they called the research team who checked the computer list to see whether the client was to be assigned to the experimental or comparison group.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Compulsory community and involuntary outpatient treatment for people with severe mental disorders [v10.0-For publication].rm5","STD-Steadman-2001","2014-10-14 12:48:11 +0100","UNKNOWN","No specific mention in the study but did use self-report measures for at least some of the outcomes, which are effectively self-blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Compulsory community and involuntary outpatient treatment for people with severe mental disorders [v10.0-For publication].rm5","STD-Steadman-2001","2014-11-24 12:58:17 +0000","NO","Only between 57 and 68 per cent of the participants completed interviews at one, five, and 11 months after hospital discharge. Only some outcomes were assessed by ITT analysis","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Compulsory community and involuntary outpatient treatment for people with severe mental disorders [v10.0-For publication].rm5","STD-Steadman-2001","2014-10-14 13:09:23 +0100","UNKNOWN","Unclear from paper","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Compulsory community and involuntary outpatient treatment for people with severe mental disorders [v10.0-For publication].rm5","STD-Steadman-2001","2014-10-14 13:09:27 +0100","UNKNOWN","Unclear, no conflict of interests reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Compulsory community and involuntary outpatient treatment for people with severe mental disorders [v10.0-For publication].rm5","STD-Swartz-1999","2014-10-14 12:49:23 +0100","UNKNOWN","Stated to be randomised but did not describe process.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Compulsory community and involuntary outpatient treatment for people with severe mental disorders [v10.0-For publication].rm5","STD-Swartz-1999","2014-10-14 12:49:36 +0100","UNKNOWN","Stated to be randomised but did not describe process.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Compulsory community and involuntary outpatient treatment for people with severe mental disorders [v10.0-For publication].rm5","STD-Swartz-1999","2014-10-14 12:48:58 +0100","UNKNOWN","No specific mention in the study but used self-report measures for at least some of the outcomes, which are effectively self-blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Compulsory community and involuntary outpatient treatment for people with severe mental disorders [v10.0-For publication].rm5","STD-Swartz-1999","2014-11-24 12:58:17 +0000","YES","Of the identified eligible patients, about 12% refused to participate. Subsequent attrition from the study was 18.2% (N = 48) but bias was minimised by ITT analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Compulsory community and involuntary outpatient treatment for people with severe mental disorders [v10.0-For publication].rm5","STD-Swartz-1999","2014-10-14 13:08:50 +0100","UNKNOWN","Unclear from paper.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Compulsory community and involuntary outpatient treatment for people with severe mental disorders [v10.0-For publication].rm5","STD-Swartz-1999","2014-10-14 13:08:02 +0100","UNKNOWN","Unclear, no conflicts of interest reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Compliance therapy for schizophrenia [v4.0-For publication].rm5","STD-O_x0027_Donnell-2003","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Community mental health teams (CMHTs) for people with severe mental illnesses and disordered personality [v9.0-For publication].rm5","STD-Burns-1993","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Community mental health teams (CMHTs) for people with severe mental illnesses and disordered personality [v9.0-For publication].rm5","STD-Merson-1992","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Community mental health teams (CMHTs) for people with severe mental illnesses and disordered personality [v9.0-For publication].rm5","STD-Tyrer-1998","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Collaborative care approaches for people with severe mental illness [v2.0-For publication].rm5","STD-Bauer-2006","2012-05-18 10:24:42 +0100","YES","
","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Collaborative care approaches for people with severe mental illness [v2.0-For publication].rm5","STD-Bauer-2006","2012-02-08 12:48:05 +0000","UNKNOWN","
","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Collaborative care approaches for people with severe mental illness [v2.0-For publication].rm5","STD-Bauer-2006","2013-10-02 14:32:47 +0100","NO","Data on the completeness of outcome data for each main outcome is not reported. Discrepencies exist between figures reported in the text (amended figures were provided by study authors when emailed) and the CONSORT flowchart (","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Collaborative care approaches for people with severe mental illness [v2.0-For publication].rm5","STD-Bauer-2006","2013-07-29 13:54:55 +0100","UNKNOWN","
","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Collaborative care approaches for people with severe mental illness [v2.0-For publication].rm5","STD-Bauer-2006","2013-10-02 14:32:47 +0100","UNKNOWN","Participants in the intervention group were older (48.10 ± 4 compared with 44.6 ± 9.4); more likely to have had a prior suicide attempt (76% compared with 56%); and more likely to have had a substance use disorder diagnosis (79% compared with 65%). Review authors agree that the risk of other bias is unclear.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Collaborative care approaches for people with severe mental illness [v2.0-For publication].rm5","STD-Bauer-2006","2012-02-08 12:47:51 +0000","NO","
","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Collaborative care approaches for people with severe mental illness [v2.0-For publication].rm5","STD-Bauer-2006","2012-09-23 20:38:36 +0100","NO","
","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive rehabilitation for people with schizophrenia and related conditions [v4.0-For publication].rm5","STD-Medalia-1998","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive rehabilitation for people with schizophrenia and related conditions [v4.0-For publication].rm5","STD-Tompkins-1995","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive rehabilitation for people with schizophrenia and related conditions [v4.0-For publication].rm5","STD-Wykes-1999","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Bechdolf-2004","2011-03-08 11:25:59 +0000","YES","Computer-generated random numbers, blocks of 8.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Bechdolf-2004","2011-03-08 11:38:34 +0000","YES","Allocation in sealed envelopes and opened at time of treatment allocation.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Bechdolf-2004","2011-03-08 11:38:42 +0000","YES","Single - most assessments by independent raters not involved in treatment.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Bechdolf-2004","2011-03-08 11:38:51 +0000","YES","Investigated by comparing sociodemographic data, psychopathology and compliance ratings at pretreatment stage for group whose ratings were missing at post-treatment or follow-up with the remaining participants for whom scores existed. Intention to treat analysis undertaken.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Bechdolf-2004","2011-03-08 11:39:07 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Bechdolf-2004","2011-03-08 11:39:15 +0000","YES","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Buchkremer-1997","2011-03-08 11:40:52 +0000","YES","Randomisation carried out by an independent institution.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Buchkremer-1997","2011-09-01 16:34:07 +0100","YES","Randomisation carried out by an independent institution.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Buchkremer-1997","2011-03-08 11:40:58 +0000","NO","Data recorded by trained project staff who were not blind with respect to the group of allocation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Buchkremer-1997","2012-01-27 20:32:21 +0000","YES","Modified intention-to-treat approach all who attended > 1 group session included in main analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Buchkremer-1997","2012-02-07 15:12:52 +0000","NO","Data for BPRS, SANS, GAS and others were reported by individual groups only.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Buchkremer-1997","2012-01-27 20:32:44 +0000","UNKNOWN","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Cather-2005","2012-01-27 20:34:36 +0000","YES","Randomised - stratified by severity of symptoms (PANNS < 63) and gender - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Cather-2005","2011-09-01 15:52:58 +0100","NO","Allocation carried out by an ""independent rater"" (not blinded).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Cather-2005","2011-03-08 11:42:41 +0000","YES","Rater blind to allocation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Cather-2005","2011-03-08 11:42:50 +0000","NO","No intention-to-treat analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Cather-2005","2011-03-08 11:42:58 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Cather-2005","2011-03-08 11:43:47 +0000","YES","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Drury-2000","2011-03-08 11:44:38 +0000","UNKNOWN","Random allocation, using stratified sampling technique.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Drury-2000","2011-03-08 11:44:46 +0000","UNKNOWN","Insufficient information.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Drury-2000","2011-03-08 11:44:53 +0000","NO","All participants were rated by first author with a subset rated blindly by two other authors.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Drury-2000","2011-03-08 11:45:01 +0000","YES","Completer analysis of outcomes. No intention to treat analysis of people who left early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Drury-2000","2011-03-08 11:45:09 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Drury-2000","2011-03-08 11:45:16 +0000","YES","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Durham-2003","2011-03-08 11:46:42 +0000","YES","Randomisation procedure (sealed envelope technique) devised by the project statistician, carried out separately within each treatment centre using randomised permuted blocking.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Durham-2003","2011-03-08 11:46:55 +0000","YES","Administered centrally by the non-clinical project coordinator.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Durham-2003","2011-03-08 11:47:02 +0000","YES","Independent raters.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Durham-2003","2011-03-08 11:47:09 +0000","YES","Analyses repeated with missing values replaced either with previous values carried forward or with group means, and the same pattern of significance was found.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Durham-2003","2011-03-08 11:47:20 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Durham-2003","2011-03-08 11:47:30 +0000","YES","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Garety-2008-a","2011-03-10 11:25:38 +0000","YES","Randomisation - stratified within each of five participating centres and within in-patient or out-patient status at the time of relapse.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Garety-2008-a","2011-03-10 11:25:42 +0000","YES","Randomisation schedules independently generated by a trial randomisation service in a separate location from all trial centres (accessed by telephone).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Garety-2008-a","2011-03-10 11:25:45 +0000","YES","Primary outcome (relapse) was masked. 88% of secondary outcomes were completed masked (i.e. the allocation of the patient had not been revealed to the assessor).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Garety-2008-a","2011-03-10 11:25:48 +0000","YES","Intention-to-treat analysis was undertaken.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Garety-2008-a","2011-03-10 11:25:51 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Garety-2008-a","2011-03-10 11:25:54 +0000","YES","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Haddock-1999","2011-03-10 11:23:39 +0000","UNKNOWN","Randomised - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Haddock-1999","2011-03-10 11:23:39 +0000","UNKNOWN","Insufficient information.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Haddock-1999","2011-03-10 11:26:06 +0000","YES","At outcome - no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Haddock-1999","2011-03-10 11:26:17 +0000","NO","Completer data (less than 5% drop out).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Haddock-1999","2011-03-10 11:26:24 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Haddock-1999","2011-03-10 11:27:11 +0000","YES","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Haddock-2009","2011-03-10 11:27:37 +0000","YES","Randomised with computer-generated sequences.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Haddock-2009","2011-09-01 15:52:57 +0100","YES","""Independent allocation"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Haddock-2009","2011-03-10 11:28:00 +0000","YES","Masking maintained by ensuring therapists and assessors were housed in separate accommodation, therapy files were kept separately from data and clinical staff was repeatedly instructed not to disclose any knowledge of therapy group to assessors.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Haddock-2009","2011-03-10 11:28:09 +0000","YES","Intention-to-treat analysis undertaken.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Haddock-2009","2011-03-10 11:28:19 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Haddock-2009","2011-03-10 11:28:28 +0000","NO","Different samples (i.e. inpatient and outpatient) and therefore opportunities to observe base rates of violent behaviour will vary as a function of sample.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Jackson-2008","2011-03-10 11:25:21 +0000","YES","Randomised - stratified according to affective and non-affective psychotic diagnosis.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Jackson-2008","2011-03-10 11:24:56 +0000","YES","Allocation was conducted by independent statistician.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Jackson-2008","2011-03-10 11:25:00 +0000","YES","Single - raters blind to allocated treatment.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Jackson-2008","2012-02-24 11:47:01 +0000","YES","Missing values in each of the outcome measures for any individual at time points subsequent to baseline were assumed to have occurred at random, given observed pretreatment scores. Multiple Imputation was used to compensate for missing data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Jackson-2008","2011-03-10 11:25:06 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Jackson-2008","2012-01-27 19:54:52 +0000","NO","The participant group contained fewer patients with schizophreniform disorder (40.3%) than expected by chance (refusers = 62.7%). There were also significantly more patients with schizoaffective disorder in the participant group (11.3%) than in the refuser group (1.6%).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Kemp-1998","2011-03-10 11:29:09 +0000","UNKNOWN","Reports random allocation - no detail provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Kemp-1998","2011-03-10 11:29:09 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Kemp-1998","2011-03-10 11:29:19 +0000","NO","Blinding not reported.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Kemp-1998","2011-03-10 11:29:22 +0000","NO","Completer data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Kemp-1998","2011-03-10 11:29:28 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Kemp-1998","2011-03-10 11:29:30 +0000","YES","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Klingberg-2009","2011-03-10 11:30:19 +0000","UNKNOWN","Insufficient detail.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Klingberg-2009","2011-03-10 11:30:19 +0000","UNKNOWN","Insufficient detail.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Klingberg-2009","2011-03-10 11:30:24 +0000","YES","Raters blind to allocation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Klingberg-2009","2011-03-10 11:30:27 +0000","NO","Completer data reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Klingberg-2009","2011-03-10 11:30:30 +0000","NO","Trial is ongoing and outcome with regard to negative symptoms has yet to be reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Klingberg-2009","2011-03-10 11:30:33 +0000","YES","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Levine-1998","2011-03-10 11:31:09 +0000","UNKNOWN","Reports random allocation - no detail provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Levine-1998","2011-03-10 11:31:09 +0000","UNKNOWN","Insufficient details provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Levine-1998","2011-03-10 11:31:13 +0000","YES","Raters unaware of allocation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Levine-1998","2011-03-10 11:31:17 +0000","NO","Completer analysis only.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Levine-1998","2011-03-10 11:31:21 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Levine-1998","2011-03-10 11:31:26 +0000","NO","Sample size of only 6 participants per group.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002","2011-09-01 15:52:57 +0100","YES","""Independent, concealed randomisation"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002","2011-09-01 15:52:57 +0100","YES","Described as ""concealed"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002","2011-03-10 11:32:10 +0000","YES","Raters blind to treatment allocation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002","2011-03-10 11:32:12 +0000","YES","Intention-to-treat regressional analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002","2011-03-10 11:32:15 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002","2011-03-10 11:32:20 +0000","YES","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002-_x002d_-Liverpool","2011-09-01 15:52:57 +0100","YES","""Independent, concealed randomisation"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002-_x002d_-Liverpool","2011-09-01 15:52:57 +0100","YES","Described as ""concealed"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002-_x002d_-Liverpool","2011-03-10 11:32:57 +0000","YES","Raters blind to treatment allocation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002-_x002d_-Liverpool","2011-03-10 11:32:59 +0000","YES","Intention-to-treat regressional analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002-_x002d_-Liverpool","2011-03-10 11:33:01 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002-_x002d_-Liverpool","2011-03-10 11:33:04 +0000","YES","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002-_x002d_-Manchester","2011-09-01 15:52:57 +0100","YES","""Independent, concealed randomisation"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002-_x002d_-Manchester","2011-09-01 15:52:57 +0100","YES","Described as ""concealed"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002-_x002d_-Manchester","2011-03-10 11:33:43 +0000","YES","Raters blind to treatment allocation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002-_x002d_-Manchester","2011-03-10 11:33:46 +0000","YES","Intention-to-treat regressional analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002-_x002d_-Manchester","2011-03-10 11:33:48 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002-_x002d_-Manchester","2011-03-10 11:33:50 +0000","YES","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002-_x002d_-Nottingham","2011-09-01 15:52:57 +0100","YES","""Independent, concealed randomisation"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002-_x002d_-Nottingham","2011-09-01 15:52:57 +0100","YES","Described as ""concealed"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002-_x002d_-Nottingham","2011-03-10 11:34:23 +0000","YES","Raters blind to treatment allocation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002-_x002d_-Nottingham","2011-03-10 11:34:25 +0000","YES","Intention-to-treat regressional analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002-_x002d_-Nottingham","2011-03-10 11:34:27 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Lewis-2002-_x002d_-Nottingham","2011-03-10 11:34:32 +0000","YES","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-O_x0027_Donnell-2003","2011-03-10 11:35:21 +0000","UNKNOWN","Reports random allocation - no detail provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-O_x0027_Donnell-2003","2011-03-10 11:35:24 +0000","YES","Insufficient details provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-O_x0027_Donnell-2003","2011-03-10 11:35:28 +0000","NO","Raters blind to allocation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-O_x0027_Donnell-2003","2011-03-10 11:35:31 +0000","YES","Completer data reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-O_x0027_Donnell-2003","2011-03-10 11:35:34 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-O_x0027_Donnell-2003","2011-03-10 11:35:21 +0000","UNKNOWN","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Penn-2009","2011-03-10 11:36:29 +0000","UNKNOWN","Randomised - computer generated - stratified by sex.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Penn-2009","2011-03-10 11:36:29 +0000","UNKNOWN","Randomisation conducted by Research Assistant blind to correspondence between random number and treatment group.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Penn-2009","2011-03-10 11:36:33 +0000","YES","Raters blind to allocation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Penn-2009","2011-03-10 11:36:35 +0000","YES","Intention-to-treat analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Penn-2009","2011-03-10 11:36:37 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Penn-2009","2011-03-10 11:36:39 +0000","YES","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Pinto-1999","2011-03-10 11:37:08 +0000","UNKNOWN","Reports random allocation - no detail provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Pinto-1999","2011-03-10 11:37:08 +0000","UNKNOWN","Insufficient details provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Pinto-1999","2011-03-10 11:37:16 +0000","NO","No report of blinding raters to allocation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Pinto-1999","2011-09-01 16:35:13 +0100","UNKNOWN","Insufficient details provided.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Pinto-1999","2011-03-10 11:37:19 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Pinto-1999","2011-03-10 11:37:24 +0000","YES","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Sensky-2000","2011-03-10 11:38:23 +0000","UNKNOWN","Reports random allocation - no detail provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Sensky-2000","2011-03-10 11:38:23 +0000","UNKNOWN","No detail provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Sensky-2000","2011-03-10 11:38:29 +0000","YES","Raters blind to treatment condition.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Sensky-2000","2011-03-10 11:38:31 +0000","YES","Intention-to-treat analysis undertaken.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Sensky-2000","2011-03-10 11:38:33 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Sensky-2000","2011-03-10 11:38:36 +0000","YES","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Tarrier-1999-a","2011-03-10 11:39:28 +0000","YES","Stratified block randomisation procedure.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Tarrier-1999-a","2011-03-10 11:39:30 +0000","YES","Allocation contained in sealed envelopes - undertaken by independent third party.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Tarrier-1999-a","2011-03-10 11:39:33 +0000","YES","Raters blind to treatment condition.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Tarrier-1999-a","2011-03-10 11:39:35 +0000","NO","Completer data reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Tarrier-1999-a","2011-03-10 11:39:38 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Tarrier-1999-a","2011-03-10 11:39:43 +0000","YES","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Turkington-2000","2011-03-10 11:40:38 +0000","YES","Reports random allocation - no detail provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Turkington-2000","2011-03-10 11:40:40 +0000","YES","Reports allocation concealment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Turkington-2000","2011-03-10 11:40:43 +0000","YES","Raters blind to treatment condition.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Turkington-2000","2011-03-10 11:40:20 +0000","UNKNOWN","No detail provided.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Turkington-2000","2011-03-10 11:40:46 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Turkington-2000","2011-03-10 11:40:51 +0000","YES","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Valmaggia-2005","2011-03-10 11:41:25 +0000","UNKNOWN","Randomisation not described.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Valmaggia-2005","2011-03-10 11:41:31 +0000","YES","To ensure the anonymity of participants, each individual was given a code, and coordinator used form to communicate results of random assignment to local therapist.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Valmaggia-2005","2011-03-10 11:41:35 +0000","YES","Raters blind to allocation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Valmaggia-2005","2011-03-10 11:41:38 +0000","YES","Intention-to-treat analysis undertaken.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Valmaggia-2005","2011-03-10 11:41:40 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia [v5.0-For publication] (1).rm5","STD-Valmaggia-2005","2011-03-10 11:41:43 +0000","YES","No clear indication of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Bechdolf-2004","2010-11-09 09:56:51 +0000","YES","Computer-generated random numbers, blocks of 8.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Bechdolf-2004","2010-11-09 09:57:05 +0000","YES","Allocation in sealed envelopes and opened at time of treatment allocation.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Bechdolf-2004","2010-11-09 09:57:45 +0000","YES","Single - most assessments by independent raters not involved in treatment.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Bechdolf-2004","2010-11-09 09:58:14 +0000","YES","Investigated by comparing sociodemographic data, psychopathology and compliance ratings at pretreatment stage for group whose ratings were missing at post-treatment or follow-up with the remaining participants for whom scores existed. Intention to treat analysis undertaken.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Bechdolf-2004","2010-11-08 18:22:53 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Bechdolf-2004","2010-09-09 11:12:41 +0100","YES","No clear indication of other bias. ","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Buchkremer-1997","2010-11-09 10:09:29 +0000","YES","Randomisation carried out by an independent institution.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Buchkremer-1997","2011-02-01 15:48:44 +0000","YES"," ","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Buchkremer-1997","2010-11-09 10:10:00 +0000","NO","Data recorded by trained project staff who were not blind with respect to the group of allocation.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Buchkremer-1997","2010-11-09 10:10:30 +0000","YES","Modified intention-to-treat approach all who attended >1 group session included in main analysis.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Buchkremer-1997","2010-11-09 10:10:43 +0000","NO","Data for BPRS, SANS, GAS and others was reported by individual groups only.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Buchkremer-1997","2010-09-15 12:19:13 +0100","UNKNOWN","No clear indication of other bias","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Cather-2005","2010-11-09 15:27:41 +0000","YES","Randomised - stratified by severity of symptoms (PANNS <63) and gender - no further details. ","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Cather-2005","2010-11-09 15:27:21 +0000","NO","Allocation carried out by an ""independent rater"" (not blinded).","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Cather-2005","2010-11-09 15:27:47 +0000","YES","Rater blind to allocation.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Cather-2005","2010-11-09 15:27:59 +0000","NO","No intention-to-treat analysis.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Cather-2005","2010-11-08 18:25:18 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Cather-2005","2010-11-09 15:28:03 +0000","YES","No clear indication of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Drury-2000","2010-09-09 11:22:26 +0100","UNKNOWN","Random allocation, using stratified sampling technique.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Drury-2000","2010-11-09 15:08:10 +0000","UNKNOWN","Insufficient information.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Drury-2000","2010-03-21 18:12:02 +0000","NO","All participants were rated by first author with a subset rated blindly by two other authors. ","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Drury-2000","2010-11-09 15:08:27 +0000","YES","Completer analysis of outcomes. No intention to treat analysis of people who left early.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Drury-2000","2010-11-08 18:25:22 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Drury-2000","2010-11-08 18:23:11 +0000","YES","No clear indication of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Durham-2003","2010-11-08 18:11:54 +0000","YES","Randomisation procedure (sealed envelope technique) devised by the project statistician, carried out separately within each treatment centre using randomised permuted blocking.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Durham-2003","2010-11-08 18:12:03 +0000","YES","Administered centrally by the non-clinical project coordinator.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Durham-2003","2010-11-08 18:12:08 +0000","YES","Independent raters.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Durham-2003","2010-11-08 18:12:18 +0000","YES","Analyses repeated with missing values replaced either with previous values carried forward or with group means, and the same pattern of significance was found.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Durham-2003","2010-11-08 18:21:14 +0000","YES","We did not have the study protocol but see no indication of selective reporting. ","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Durham-2003","2010-11-08 18:23:18 +0000","YES","No clear indication of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Garety-2008","2010-11-09 17:26:28 +0000","YES","Randomisation - stratified within each of five participating centres and within in-patient or out-patient status at the time of relapse.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Garety-2008","2010-11-09 17:26:50 +0000","YES","Randomisation schedules independently generated by a trial randomisation service in a separate location from all trial centres (accessed by telephone).","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Garety-2008","2010-11-09 17:27:04 +0000","YES","Primary outcome (relapse) was masked. 88% of secondary outcomes were completed masked (i.e. the allocation of the patient had not been revealed to the assessor).","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Garety-2008","2010-11-09 17:27:24 +0000","YES","Intention-to-treat analysis was undertaken.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Garety-2008","2010-11-08 18:21:24 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Garety-2008","2010-11-08 18:23:24 +0000","YES","No clear indication of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Haddock-1999","2010-11-09 10:12:00 +0000","UNKNOWN","Randomised - no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Haddock-1999","2010-11-09 10:12:09 +0000","UNKNOWN","Insufficient information.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Haddock-1999","2010-11-09 17:20:30 +0000","YES","At outcome - no further details. ","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Haddock-1999","2010-11-09 10:12:14 +0000","NO","Completer data (less than 5% drop out).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Haddock-1999","2010-11-08 18:21:28 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Haddock-1999","2010-11-08 18:23:28 +0000","YES","No clear indication of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Haddock-2009","2010-11-09 15:10:54 +0000","YES","Randomised with computer-generated sequences.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Haddock-2009","2010-11-09 15:11:01 +0000","YES","""Independent allocation"".","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Haddock-2009","2010-11-09 15:11:23 +0000","YES","Masking maintained by ensuring therapists and assessors were housed in separate accommodation, therapy files were kept separately from data and clinical staff was repeatedly instructed not to disclose any knowledge of therapy group to assessors.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Haddock-2009","2010-11-09 15:11:30 +0000","YES","Intention-to-treat analysis undertaken.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Haddock-2009","2010-11-08 18:21:33 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Haddock-2009","2010-03-21 14:24:10 +0000","NO","Different samples (i.e. inpatient and outpatient) and therefore opportunities to observe base rates of violent behaviour will vary as a function of sample.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Jackson-2008","2010-11-09 14:50:35 +0000","YES","Radnomised - stratified according to affective and non-affective psychotic diagnosis.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Jackson-2008","2010-11-09 14:50:47 +0000","YES","Allocation was conducted by independent statistician.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Jackson-2008","2010-11-09 14:51:37 +0000","YES","Single - raters blind to allocated treatment. ","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Jackson-2008","2011-02-01 15:49:16 +0000","YES","Missing values in each of the outcome measures for any individual at time points subsequent to baseline were assumed to have occurred at random, given observed pretreatment scores. Ten multiply imputed (MI) datasets were generated using the PAN package (","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Jackson-2008","2010-11-08 18:21:37 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Jackson-2008","2010-11-08 14:44:37 +0000","NO","The participant group contained fewer patients with schizophreniform disorder (40.3%) than expected by chance (refusers=62.7%). There were also significantly more patients with schizoaffective disorder in the participant group (11.3%) than in the refuser group (1.6%).","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Kemp-1998","2010-11-09 09:12:19 +0000","UNKNOWN","Reports random allocation - no detail provided. ","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Kemp-1998","2010-11-09 09:44:05 +0000","UNKNOWN","No information reported. ","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Kemp-1998","2010-11-09 09:44:08 +0000","NO","Blinding not reported.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Kemp-1998","2010-11-09 09:44:12 +0000","NO","Completer data.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Kemp-1998","2010-11-08 18:21:41 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Kemp-1998","2010-11-08 18:23:43 +0000","YES","No clear indication of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Klingberg-2009","2010-11-09 09:38:22 +0000","UNKNOWN","Insufficient detail.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Klingberg-2009","2010-11-09 09:38:31 +0000","UNKNOWN","Insufficient detail.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Klingberg-2009","2010-11-09 09:38:34 +0000","YES","Raters blind to allocation.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Klingberg-2009","2010-11-09 09:38:35 +0000","NO","Completer data reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Klingberg-2009","2010-11-09 09:38:39 +0000","NO","Trial is ongoing and outcome with regard to negative symptoms has yet to be reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Klingberg-2009","2010-11-08 18:23:48 +0000","YES","No clear indication of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Levine-1998","2010-11-09 09:12:19 +0000","UNKNOWN","Reports random allocation - no detail provided.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Levine-1998","2010-11-09 09:38:00 +0000","UNKNOWN","Insufficient details provided.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Levine-1998","2010-11-09 09:38:03 +0000","YES","Raters unaware of allocation.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Levine-1998","2010-11-09 09:38:04 +0000","NO","Completer analysis only.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Levine-1998","2010-11-08 18:21:53 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Levine-1998","2010-03-21 19:21:01 +0000","NO","Sample size of only 6 participants per group. ","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002","2010-11-09 09:32:00 +0000","YES","""Independent, concealed randomisation"".","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002","2010-11-09 09:32:00 +0000","YES","Described as ""concealed"".","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002","2010-11-09 09:32:00 +0000","YES","Raters blind to treatment allocation.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002","2010-11-09 09:32:00 +0000","YES","Intention-to-treat regressional analysis.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002","2010-11-08 18:21:57 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002","2010-11-08 18:23:58 +0000","YES","No clear indication of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002-_x002d_-Liverpool","2010-11-09 09:31:54 +0000","YES","""Independent, concealed randomisation"".","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002-_x002d_-Liverpool","2010-11-09 09:31:54 +0000","YES","Described as ""concealed"".","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002-_x002d_-Liverpool","2010-11-09 09:31:54 +0000","YES","Raters blind to treatment allocation.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002-_x002d_-Liverpool","2010-11-09 09:31:54 +0000","YES","Intention-to-treat regressional analysis.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002-_x002d_-Liverpool","2010-11-08 18:22:01 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002-_x002d_-Liverpool","2010-11-08 18:24:04 +0000","YES","No clear indication of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002-_x002d_-Manchester","2010-11-09 09:31:46 +0000","YES","""Independent, concealed randomisation"".","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002-_x002d_-Manchester","2010-11-09 09:31:46 +0000","YES","Described as ""concealed"".","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002-_x002d_-Manchester","2010-11-09 09:31:46 +0000","YES","Raters blind to treatment allocation.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002-_x002d_-Manchester","2010-11-09 09:31:46 +0000","YES","Intention-to-treat regressional analysis.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002-_x002d_-Manchester","2010-11-08 18:22:04 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002-_x002d_-Manchester","2010-11-08 18:24:08 +0000","YES","No clear indication of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002-_x002d_-Nottingham","2010-11-09 09:22:16 +0000","YES","""Independent, concealed randomisation"".","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002-_x002d_-Nottingham","2010-11-09 09:21:47 +0000","YES","Described as ""concealed"".","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002-_x002d_-Nottingham","2010-11-09 09:21:51 +0000","YES","Raters blind to treatment allocation.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002-_x002d_-Nottingham","2010-11-09 09:22:06 +0000","YES","Intention-to-treat regressional analysis.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002-_x002d_-Nottingham","2010-11-08 18:22:07 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Lewis-2002-_x002d_-Nottingham","2010-11-08 18:24:18 +0000","YES","No clear indication of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-O_x0027_Donnell-2003","2010-11-09 09:12:19 +0000","UNKNOWN","Reports random allocation - no detail provided.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-O_x0027_Donnell-2003","2011-03-10 11:34:51 +0000","UNKNOWN","Insufficient details provided.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-O_x0027_Donnell-2003","2010-11-09 09:12:28 +0000","YES","Raters blind to allocation.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-O_x0027_Donnell-2003","2010-11-09 09:12:36 +0000","NO","Completer data reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-O_x0027_Donnell-2003","2010-11-08 18:22:11 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-O_x0027_Donnell-2003","2010-11-08 18:24:22 +0000","YES","No clear indication of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Penn-2009","2010-11-09 09:02:59 +0000","UNKNOWN","Randomised - computer generated - stratified by sex.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Penn-2009","2010-11-09 09:03:12 +0000","UNKNOWN","Randomisation conducted by Research Assistant blind to correspondence between random number and treatment group.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Penn-2009","2010-11-09 09:03:27 +0000","YES","Raters blind to allocation.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Penn-2009","2010-11-09 09:03:33 +0000","YES","Intention-to-treat analysis.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Penn-2009","2010-11-08 18:22:16 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Penn-2009","2010-11-08 18:24:26 +0000","YES","No clear indication of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Pinto-1999","2010-11-09 09:00:18 +0000","UNKNOWN","Reports random allocation - no detail provided.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Pinto-1999","2010-11-09 09:00:25 +0000","UNKNOWN","Insufficient details provided.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Pinto-1999","2010-11-09 09:00:30 +0000","NO","No report of blinding raters to allocation.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Pinto-1999","2011-02-01 15:59:50 +0000","UNKNOWN"," ","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Pinto-1999","2010-11-08 18:22:20 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Pinto-1999","2010-11-08 18:24:30 +0000","YES","No clear indication of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Sensky-2000","2010-11-09 08:58:12 +0000","UNKNOWN","Reports random allocation - no detail provided.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Sensky-2000","2010-11-09 08:58:18 +0000","UNKNOWN","No detail provided.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Sensky-2000","2010-11-09 08:58:23 +0000","YES","Raters blind to treatment condition.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Sensky-2000","2010-11-09 08:58:32 +0000","YES","Intention-to-treat analysis undertaken.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Sensky-2000","2010-11-08 18:22:24 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Sensky-2000","2010-11-08 18:24:34 +0000","YES","No clear indication of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Tarrier-1999","2011-03-10 11:38:47 +0000","YES","Reports random allocation - no detail provided.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Tarrier-1999","2011-03-10 11:38:47 +0000","YES","No detail provided.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Tarrier-1999","2010-11-09 08:57:28 +0000","YES","Raters blind to treatment condition.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Tarrier-1999","2011-03-10 11:38:47 +0000","NO","Intention-to-treat analysis undertaken.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Tarrier-1999","2010-11-08 18:22:27 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Tarrier-1999","2010-11-08 18:24:38 +0000","YES","No clear indication of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Turkington-2000","2010-11-09 08:56:40 +0000","YES","Reports random allocation - no detail provided.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Turkington-2000","2010-11-09 08:56:32 +0000","YES","Reports allocation concealment.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Turkington-2000","2010-11-09 08:56:25 +0000","YES","Raters blind to treatment condition.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Turkington-2000","2010-11-09 08:56:18 +0000","UNKNOWN","No detail provided.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Turkington-2000","2010-11-08 18:22:31 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Turkington-2000","2010-11-08 18:24:42 +0000","YES","No clear indication of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Valmaggia-2005","2010-11-08 18:36:28 +0000","UNKNOWN","Randomisation not described. ","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Valmaggia-2005","2010-11-08 18:36:42 +0000","YES","To ensure the anonymity of participants, each individual was given a code, and coordinator used form to communicate results of random assignment to local therapist.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Valmaggia-2005","2010-11-08 18:36:48 +0000","YES","Raters blind to allocation.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Valmaggia-2005","2010-11-08 18:36:58 +0000","YES","Intention-to-treat analysis undertaken.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Valmaggia-2005","2010-11-08 18:22:35 +0000","YES","We did not have the study protocol but see no indication of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [v11.0-For publication].rm5","STD-Valmaggia-2005","2010-11-08 18:24:49 +0000","YES","No clear indication of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Atmaca-2003","2009-08-14 14:50:03 +0100","UNKNOWN","Quote: ""The patients were randomly divided into 4 treatment group..""","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Atmaca-2003","2009-01-15 15:13:41 +0000","NO","No information. Probably not done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Atmaca-2003","2009-08-14 14:50:08 +0100","YES","Quote: ""raters were blind to drug assignment."" ""The prescribing physician was not blind to assignment""","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Atmaca-2003","2009-08-14 14:50:29 +0100","UNKNOWN","Intention-to-treat analysis was not undertaken.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Atmaca-2003","2009-01-15 15:14:25 +0000","YES","Review authors do not believe this will introduce bias.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Atmaca-2003","2009-01-15 15:14:31 +0000","YES","Review authors have not found other sources of bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Azorin-2001","2009-01-15 15:30:55 +0000","UNKNOWN","Comment: Incomplete information.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Azorin-2001","2009-01-15 15:31:13 +0000","NO","No information. Probably not done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Azorin-2001","2009-01-15 15:31:34 +0000","YES","Comment: Probably done. The success of blinding was not evaluated.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Azorin-2001","2009-01-15 15:31:57 +0000","UNKNOWN","Comment: ITT “considered patients randomly assigned with at least one post-dose BPRS evaluation”.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Azorin-2001","2009-01-15 15:32:31 +0000","YES","Review authors do not believe this will introduce bias.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Azorin-2001","2009-01-15 15:32:54 +0000","UNKNOWN","Study supported by a grant from Novartis Pharma S.A.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bitter-2004","2009-02-02 00:35:05 +0000","UNKNOWN","Comment: Incomplete information.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bitter-2004","2009-01-15 15:33:59 +0000","NO","Probably not done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bitter-2004","2009-02-02 00:35:06 +0000","YES","Comment: The success of blinding was not evaluated.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bitter-2004","2009-04-30 12:58:42 +0100","NO","Comment: patients analysed were all those had at least one post-baseline measurement.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bitter-2004","2009-01-20 18:55:19 +0000","NO","Quote: “Spontaneously reported adverse events with an incidence of 5% in either treatment group or with a statistically significant difference ( P < .05) between groups”.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bitter-2004","2009-01-15 15:36:09 +0000","UNKNOWN","The study was sponsored by Eli Lilly and company.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bondolfi-1998","2009-01-15 15:36:48 +0000","UNKNOWN","Comment: Incomplete information.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bondolfi-1998","2009-01-15 15:37:03 +0000","NO","No information. Probably not done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bondolfi-1998","2009-01-15 15:37:25 +0000","YES","Comment: Probably done. The success of blinding was not evaluated.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bondolfi-1998","2009-01-15 15:37:46 +0000","YES","Analysis by intention to treat and LOCF.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bondolfi-1998","2009-01-15 15:38:03 +0000","NO","Quote: “Adverse events reported by 5% or more of either treatment group during the trial”.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Bondolfi-1998","2010-10-05 11:48:06 +0100","YES","Study supported by a grant from industry of both study drugs. The study used low clozapine doses.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Breier-1999","2009-01-15 15:38:56 +0000","UNKNOWN","Comment: Incomplete information.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Breier-1999","2009-01-15 15:39:14 +0000","NO","No information. Probably not done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Breier-1999","2009-04-30 13:00:50 +0100","YES","Comment: Probably done. The success of blinding was not evaluated.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Breier-1999","2009-02-02 00:35:37 +0000","NO","Exclusion of 5 patients after randomisation who were not considered in the total sample. Incomplete information. ITT was not performed.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Breier-1999","2009-01-15 15:40:06 +0000","YES","Review authors do not believe this will introduce bias.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Breier-1999","2009-01-15 15:40:30 +0000","NO","Quote: “Nineteen of the 29 patients underwent a drug-free period before random assignment”. Comment: Probably performance bias. Author from Industry.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Conley-2003","2009-02-02 00:36:22 +0000","UNKNOWN","Comment: Probably not done.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Conley-2003","2009-01-15 15:41:18 +0000","NO","No information. Probably not done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Conley-2003","2009-04-30 13:02:14 +0100","YES","Comment: Probably done. The success of blinding was not evaluated.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Conley-2003","2009-04-30 13:02:27 +0100","NO","0/5 missing from clozapine and 3/8 missing from olanzapine. LOCF for patients completing at least two weeks. ITT was not performed.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Conley-2003","2009-01-15 15:42:57 +0000","NO","Adverse events that occurred only in one person were not reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Conley-2003","2009-01-15 15:43:13 +0000","YES","Review authors have not found other sources of bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Heinrich-1994","2009-02-02 00:36:59 +0000","UNKNOWN","Comment: Incomplete information.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Heinrich-1994","2009-01-15 15:44:06 +0000","NO","No information. Probably not done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Heinrich-1994","2009-02-02 00:37:01 +0000","YES","Comment: Probably done. The success of blinding was not evaluated.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Heinrich-1994","2009-04-30 13:15:34 +0100","YES","6/20 missing from clozapine, 13/19 from risperidone 8 mg and 9/20 from risperidone 4 mg. Intention to treat analyses and LOCF.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Heinrich-1994","2009-10-06 00:24:14 +0100","NO","Adverse events considered only the most frequent spontaneously reported adverse experience.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Heinrich-1994","2009-01-15 15:46:00 +0000","YES","Review authors have not found other sources of bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Krakowski-2006","2009-02-02 00:37:27 +0000","UNKNOWN","Comment: Incomplete information.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Krakowski-2006","2009-01-15 15:47:19 +0000","NO","Probably not done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Krakowski-2006","2009-01-15 15:47:49 +0000","YES","Comment: Probably done.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Krakowski-2006","2009-04-30 15:42:45 +0100","YES","13/37 missing from clozapine and 11/37 missing from olanzapine. Analysis by intention-to-treat was used.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Krakowski-2006","2009-01-15 15:48:24 +0000","NO","Adverse events assessed but it was not reported in the article.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Krakowski-2006","2009-02-02 00:37:30 +0000","NO","Quote: “The setting limits the generalisability of the findings”.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Kumra-2008","2009-04-30 15:44:55 +0100","YES","Quote: “...medication were assigned to their groups by research pharmacist with a computer-generated randomisation schedule.”","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Kumra-2008","2009-01-15 15:49:43 +0000","NO","Probably not done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Kumra-2008","2009-01-15 15:50:02 +0000","YES","Quote: “medication was administered under double-blind condition”. The success of blinding was not evaluated.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Kumra-2008","2009-04-30 15:45:26 +0100","NO","Comment: ITT considered all patients who received at least one dose of study medication.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Kumra-2008","2009-04-30 15:45:31 +0100","NO","Side-effects: Study reported only the participants who gained >7% of their baseline body weight.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Kumra-2008","2009-01-15 15:51:15 +0000","YES","Review authors have not found other sources of bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Li--2002","2009-02-18 20:05:48 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Li--2002","2009-02-18 20:08:38 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Li--2002","2010-10-05 14:46:46 +0100","UNKNOWN","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter, probably leads a low risk of bias.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Li--2002","2009-02-18 20:07:32 +0000","UNKNOWN","The authors only mention two participants leaving the study early due to adverse events in the clozapine group. There is some doubt whether all data on leaving the study early have been presented.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Li--2002","2009-02-18 20:08:19 +0000","YES","We did not find evidence for selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Li--2002","2009-02-18 20:07:53 +0000","UNKNOWN","There were no data on pre study medication, therefore baseline imbalance can not be excluded.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Li--2003","2009-02-18 20:09:22 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Li--2003","2009-02-18 20:09:25 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Li--2003","2009-04-30 15:49:24 +0100","UNKNOWN","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter, probably leads a low risk of bias.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Li--2003","2009-02-18 20:10:18 +0000","UNKNOWN","The authors describe only one participant in the quetiapine group who left the","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Li--2003","2009-02-18 20:10:34 +0000","NO","The study duration was eight weeks, but outcomes only at four weeks were available.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Li--2003","2009-02-18 20:10:24 +0000","UNKNOWN","The allowed dose range was not indicated.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Li--2005","2009-02-18 19:57:22 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Li--2005","2009-02-18 19:57:51 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Li--2005","2010-10-05 12:05:11 +0100","UNKNOWN","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter, probably leads a low risk of bias.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Li--2005","2010-10-05 12:09:12 +0100","NO","The overall attrition was 9.1%. Those leaving early were only reported due to any reason. Only completer data were assessed.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Li--2005","2009-02-18 20:00:42 +0000","NO","There was no reporting on adverse effects","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Li--2005","2009-02-18 20:01:11 +0000","UNKNOWN","Baseline characteristics have not been presented for both groups separately. Therefore, baseline imbalance can not be excluded. Furthermore, there was no wash-out period.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lin-2003","2009-01-15 18:52:24 +0000","UNKNOWN","Comment: Incomplete information.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lin-2003","2009-01-15 18:52:26 +0000","NO","No information. Probably not done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lin-2003","2009-01-15 18:52:54 +0000","YES","Probably done. The success of blinding was not evaluated.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lin-2003","2009-01-15 18:53:08 +0000","UNKNOWN","No information on abstract.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lin-2003","2009-01-15 18:53:14 +0000","UNKNOWN","No information on abstract.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lin-2003","2009-01-15 18:53:29 +0000","NO","Quote: “Patients taking clozapine for more 5 month were allocated on a random to two groups: one maintained on clozapine and another switched to zotepine”","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lindenberg-1997","2009-01-15 18:55:19 +0000","UNKNOWN","Comment: Incomplete information.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lindenberg-1997","2009-01-15 18:55:31 +0000","NO","Probably not done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lindenberg-1997","2009-01-15 18:55:47 +0000","YES","Comment: Probably done. The success of blinding was not evaluated.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lindenberg-1997","2009-04-30 16:15:24 +0100","NO","7/25 missing from clozapine and 10/25 missing from zotepine. ITT was not performed.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lindenberg-1997","2009-01-15 18:56:23 +0000","NO","Comment: Data from sub sample was not used in our review.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Lindenberg-1997","2009-04-30 16:15:34 +0100","UNKNOWN","Quote: “This study was sponsored and monitored by Klinge Pharma (manufacturer of zotepine)”.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Liu--2004","2009-02-18 20:11:26 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Liu--2004","2009-02-18 20:11:30 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Liu--2004","2009-04-30 16:14:20 +0100","UNKNOWN","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter, probably leads a low risk of bias.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Liu--2004","2009-02-18 20:12:29 +0000","UNKNOWN","The authors mention five participants leaving the study early, three due to adverse events in the clozapine group and two due to unclear reasons in the quetiapine group. These five subjects were not included in the analysis. There is some doubt whether all data on leaving the study early have been presented.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Liu--2004","2009-02-18 20:12:31 +0000","NO","The mean doses of the medications used were not indicated.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Liu--2004","2009-04-30 16:14:34 +0100","NO","Clozapine was titrated to 400 mg/day within 10 days. Such a fast dose increase can be accompanied by a higher rate of adverse effects.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-McGurk-2005","2009-01-15 18:57:10 +0000","UNKNOWN","Comment: Incomplete information.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-McGurk-2005","2009-01-15 18:57:31 +0000","NO","Probably not done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-McGurk-2005","2009-04-30 16:16:54 +0100","YES","Comment: Probably done.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-McGurk-2005","2009-01-15 18:58:02 +0000","YES","30/47 missing from clozapine and 32/50 risperidone. ITT was not performed.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-McGurk-2005","2009-01-15 18:58:18 +0000","YES","Review authors do not believe this will introduce bias.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-McGurk-2005","2009-01-15 18:58:32 +0000","YES","Review authors have not found other sources of bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Meltzer-2003","2009-02-02 00:39:30 +0000","UNKNOWN","Comment: Probably not done.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Meltzer-2003","2009-01-15 18:59:15 +0000","NO","No Information. Probably not done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Meltzer-2003","2009-04-30 16:18:28 +0100","YES","Comment: Probably done. The rater’s masking was monitored by external service.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Meltzer-2003","2009-01-15 18:59:53 +0000","YES","Quote: “All data obtained was used in intent-to-treat analysis”","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Meltzer-2003","2009-01-15 19:00:09 +0000","YES","Review authors do not believe this will introduce bias.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Meltzer-2003","2009-01-15 19:00:24 +0000","YES","The study sponsor was Novartis Pharmaceuticals Corp.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Moresco-2004","2009-02-02 00:39:57 +0000","UNKNOWN","Comment: Information incomplete.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Moresco-2004","2009-01-15 19:01:12 +0000","NO","Probably not done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Moresco-2004","2009-01-15 19:01:28 +0000","YES","Comment: Probably done. The success of blinding was not evaluated.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Moresco-2004","2009-01-20 19:04:38 +0000","NO","ITT not performed.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Moresco-2004","2009-01-15 19:02:02 +0000","UNKNOWN","No information about form to assess the adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Moresco-2004","2009-01-15 19:02:24 +0000","UNKNOWN","Quote: “Study was partially supported by Eli-Lilly”","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Naber-2005","2009-02-02 00:40:19 +0000","UNKNOWN","Comment: Incomplete information.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Naber-2005","2009-01-15 19:03:13 +0000","NO","No information. Probably not done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Naber-2005","2009-02-02 00:40:20 +0000","YES","Comment: Probably done. Identical capsules were used.The success of blinding was not evaluated.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Naber-2005","2009-01-15 19:03:50 +0000","NO","Comment: ITT considered the patients with at least one post-baseline value.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Naber-2005","2009-01-15 19:04:13 +0000","NO","Adverse event were recorded from spontaneously report. Probably reporting bias.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Naber-2005","2009-01-15 19:04:46 +0000","UNKNOWN","Study funded by Lilly Deutschland GmbH.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Ren-2002","2009-04-30 16:22:28 +0100","YES","Allocation: random, ball drawing out of a covered box. Probably yes.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Ren-2002","2009-02-18 20:16:28 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Ren-2002","2010-10-05 14:26:07 +0100","UNKNOWN","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter, probably leads a low risk of bias.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Ren-2002","2009-02-18 20:17:11 +0000","NO","Data on leaving the study early were not provided.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Ren-2002","2009-02-18 20:17:13 +0000","NO","Secondary outcomes were poorly reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Ren-2002","2009-02-18 20:17:15 +0000","UNKNOWN","The allowed dose ranges were not indicated.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Sacchetti-2006","2009-04-12 21:44:48 +0100","UNKNOWN","Comment: Incomplete information.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Sacchetti-2006","2009-01-15 19:06:02 +0000","NO","No information. Probably not done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Sacchetti-2006","2010-10-05 14:27:06 +0100","YES","Comment: Probably done. The success of blinding was not evaluated.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Sacchetti-2006","2009-01-15 19:06:34 +0000","YES","Analysis by intention to treat and LOCF.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Sacchetti-2006","2009-01-15 19:06:58 +0000","UNKNOWN","No information on abstract.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Sacchetti-2006","2009-01-15 19:06:54 +0000","UNKNOWN","No information on abstract.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Shaw-2006","2009-01-15 19:07:36 +0000","YES","Quote: ""Random allocation used a random-numbers chart and was conducted  in blocks of 4"".","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Shaw-2006","2009-01-15 19:07:52 +0000","YES","Quote: “Numbered containers were used to implement the random allocation sequence..”","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Shaw-2006","2009-01-16 12:06:49 +0000","YES","Quote: “Participants and those administering and assessing the intervention and assessing outcomes were blind..” “The success of the blinding was not formally assessed”. ","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Shaw-2006","2009-01-20 19:06:31 +0000","YES","No participant was loss during trial on clozapine group. 1/13 was missing from olanzapine group. Analysis by intention to treat and LOCF","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Shaw-2006","2009-01-15 19:08:36 +0000","YES","Review authors do not believe this will introduce bias.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Shaw-2006","2009-01-15 19:08:53 +0000","YES","Review authors have not found other sources of bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Tollefson-2001","2009-01-29 14:52:23 +0000","UNKNOWN","Comment: Incomplete information.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Tollefson-2001","2009-01-15 19:09:40 +0000","NO","No information. Probably not done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Tollefson-2001","2010-10-05 14:35:05 +0100","YES","Comment: Probably done. The success of blinding was not evaluated.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Tollefson-2001","2009-01-15 19:10:38 +0000","NO","Quote: “All end point analyses used a last observation carried forward (LOCF) algorithm” Comment: OC technique for weekly measures of patients with at least  one post-baseline measurement. ITT analysis was not performed.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Tollefson-2001","2009-02-02 00:41:21 +0000","NO","Spontaneously Reported Treatment-Emergent Adverse Events with an Incidence of ≥5% in either Treatment Group, or with a statistically significant difference (P","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Tollefson-2001","2009-01-15 19:12:25 +0000","YES","Review authors have not found other sources of bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Volavka-2002","2009-01-15 19:12:53 +0000","UNKNOWN","Comment: Incomplete information.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Volavka-2002","2009-01-15 19:13:09 +0000","NO","No information. Probably not done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Volavka-2002","2009-01-15 19:13:24 +0000","YES","Comment: Probably done.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Volavka-2002","2009-01-15 19:13:43 +0000","NO","18/40 missing from clozapine, 13/39 from olanzapine and 19/41 from risperidone. ITT was not performed.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Volavka-2002","2010-10-05 14:40:17 +0100","NO","Some outcomes were reported on subgroup from the entire sample (Czobor 2002, Volavka 2004, Bilder 2001, Lindenmayer 2003).The author reported the use of the Quality of Life Scale, but the results are not on article, (Bilder 2001).","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Volavka-2002","2009-02-02 00:41:47 +0000","NO","“The olanzapine arm was added in November 1997 and required a modified randomisation procedure”..."" it entails the potential for a bias that could be manifested as a cohort effect.”","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wahlbeck-2000","2009-02-02 00:42:02 +0000","YES","Quote: “Patients were individually assigned to open label treatment by computer-generated randomisation”.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wahlbeck-2000","2009-01-15 19:15:50 +0000","YES","Comment: Probably done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wahlbeck-2000","2009-01-15 19:16:05 +0000","YES","Comment: probably done. The success of blinding was not evaluated.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wahlbeck-2000","2009-01-15 19:16:25 +0000","YES","6/11 missing from clozapine and 1/9 missing from risperidone. Analysis by intention to treat and LOCF.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wahlbeck-2000","2009-01-15 19:16:38 +0000","YES","Review authors do not believe this will introduce bias.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wahlbeck-2000","2009-01-15 19:17:03 +0000","NO","Quote: ""Readers have to bear in mind that the low statistical power of this study may hides some clinically relevant differences in drug efficacy"".","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wang-2002","2009-02-18 20:13:33 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wang-2002","2009-02-18 20:13:35 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wang-2002","2010-10-05 14:45:12 +0100","UNKNOWN","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter, probably leads a low risk of bias.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wang-2002","2009-02-18 20:14:43 +0000","NO","Data on leaving the study early were not provided.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wang-2002","2009-02-18 20:14:44 +0000","NO","Data were not available for all of the predefined adverse effect outcomes.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Wang-2002","2009-04-30 16:36:47 +0100","NO","The sponsor was unclear. The upper dose range limit of clozapine was 400 mg/day which was reached rather quickly (10 days), which could mean a disadvantage for clozapine in terms of side-effects.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Zhou-2000","2009-02-18 20:19:33 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Zhou-2000","2009-02-18 20:19:35 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Zhou-2000","2010-10-05 14:45:43 +0100","UNKNOWN","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter, probably leads a low risk of bias.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Zhou-2000","2009-02-18 20:20:21 +0000","YES","No participant left the study early.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Zhou-2000","2009-02-18 20:20:23 +0000","YES","No clear evidence for selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Clozapine versus other atypical antipsychotics for schizophrenia [v5.0-For publication].rm5","STD-Zhou-2000","2009-02-18 20:20:25 +0000","UNKNOWN","The description of blinding differed between the abstract (double-blind) and the method section (single-blind).","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Clotiapine for acute psychotic illnesses [v10.0-Unmarked for publication 8 Oct 2012].rm5","STD-Itoh-1969","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Clotiapine for acute psychotic illnesses [v10.0-Unmarked for publication 8 Oct 2012].rm5","STD-Jacobsson-1974","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Clotiapine for acute psychotic illnesses [v10.0-Unmarked for publication 8 Oct 2012].rm5","STD-Perales-1974","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Clotiapine for acute psychotic illnesses [v10.0-Unmarked for publication 8 Oct 2012].rm5","STD-Subramaney-1998","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Clotiapine for acute psychotic illnesses [v10.0-Unmarked for publication 8 Oct 2012].rm5","STD-Uys-1996","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cholinergic medication for neuroleptic-induced tardive dyskinesia [v9.0-For publication].rm5","STD-Beckham-1981","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cholinergic medication for neuroleptic-induced tardive dyskinesia [v9.0-For publication].rm5","STD-de-Montigny-1979","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cholinergic medication for neuroleptic-induced tardive dyskinesia [v9.0-For publication].rm5","STD-Gelenberg-1990","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cholinergic medication for neuroleptic-induced tardive dyskinesia [v9.0-For publication].rm5","STD-George-1981","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cholinergic medication for neuroleptic-induced tardive dyskinesia [v9.0-For publication].rm5","STD-Jackson-1978","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cholinergic medication for neuroleptic-induced tardive dyskinesia [v9.0-For publication].rm5","STD-Jackson-1979","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cholinergic medication for neuroleptic-induced tardive dyskinesia [v9.0-For publication].rm5","STD-Kocher-1980","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cholinergic medication for neuroleptic-induced tardive dyskinesia [v9.0-For publication].rm5","STD-Lucius-1976","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cholinergic medication for neuroleptic-induced tardive dyskinesia [v9.0-For publication].rm5","STD-Price-1982","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cholinergic medication for neuroleptic-induced tardive dyskinesia [v9.0-For publication].rm5","STD-Tarsy-1977","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Cholinergic medication for neuroleptic-induced tardive dyskinesia [v9.0-For publication].rm5","STD-Yagi-1990","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Abrams-1958","2012-10-23 13:38:03 +0100","UNKNOWN","""Divided, at random, into two groups"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Abrams-1958","2012-10-23 13:37:48 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Abrams-1958","2012-10-23 13:37:48 +0100","UNKNOWN","""The experimental group received chlorpromazine under the name of ""Thoraxine A"", ""The control group, received a placebo, the same size, shape and colour as the chlorpromazine. As a differentiation from the chlorpromazine, the placebo was known as ""Thorazine B"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Abrams-1958","2012-10-23 13:37:48 +0100","UNKNOWN"," No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Abrams-1958","2012-10-23 13:37:48 +0100","UNKNOWN","""During the course of the experiment several patients had to be eliminated from both groups for various reasons so that the final chlorpromazine group consisted of 18 patients while the final placebo group consisted of 16 patients"". Reasons for leaving the study early not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Abrams-1958","2012-10-23 13:37:53 +0100","NO","No SDs reported for MSRPP, Weschler Bellvue Intelligence Scale or Rorschach tests. No useable data for adverse effects.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Abrams-1958","2012-10-23 13:37:48 +0100","UNKNOWN"," Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Baker-1959","2012-10-23 13:38:48 +0100","UNKNOWN","""Order determined by random selection"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Baker-1959","2012-10-23 13:38:48 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Baker-1959","2012-10-23 13:39:39 +0100","YES","""Matching tablets"" were used.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Baker-1959","2012-10-23 13:39:41 +0100","YES","""The total number of tablets for each five-week period (378) were put in a separate envelope, labelled ""A"", ""B"", or ""C"" and a code was kept showing which tablets any patient was taking during any given period [...] It was thus possible to keep the handling and the knowledge of the identity of the tablets under the control of a person other than the psychiatric assessor of results until the trial was completed.""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Baker-1959","2012-10-23 13:39:54 +0100","NO","""There were no deaths in this group, but one patient (Case 120) was so uncooperative in taking tablets that it was decided to abandon the attempt, in her case"". Three participants are not accounted for in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Baker-1959","2012-10-23 13:39:29 +0100","UNKNOWN","Unable to use BPRS data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Baker-1959","2013-06-19 08:31:44 +0100","UNKNOWN","""These three substances were supplied in matching tablets by Messrs. Smith & Nephew, the sponsors of the new drug"".","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ban-1975","2012-10-23 13:40:24 +0100","UNKNOWN","""Randomised"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ban-1975","2012-10-23 13:40:24 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ban-1975","2012-10-23 13:40:46 +0100","YES","""All medication was supplied in capsules identical in appearance, taste and smell""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ban-1975","2012-10-23 13:40:24 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ban-1975","2012-10-23 13:40:50 +0100","YES"," There were no losses to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ban-1975","2012-10-23 13:40:52 +0100","NO","No means and SDs reported for BPRS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ban-1975","2013-06-19 08:32:01 +0100","UNKNOWN","Drugs supplied by Pfizer (Canada) Inc, Montreal, Canada.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Bishop-1963","2012-10-23 13:52:06 +0100","UNKNOWN","""Divided at random"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Bishop-1963","2012-10-23 13:41:52 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Bishop-1963","2012-10-23 13:41:52 +0100","UNKNOWN","""Double blind"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Bishop-1963","2012-10-23 13:41:52 +0100","UNKNOWN","""Double blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Bishop-1963","2012-10-23 13:41:52 +0100","UNKNOWN"," No losses to follow-up in the chlorpromazine or placebo groups.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Bishop-1963","2012-10-23 13:41:53 +0100","UNKNOWN","No data reported for the BPRS, Lorr scale or Tulane Research Battery.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Bishop-1963","2012-10-30 13:58:35 +0000","UNKNOWN"," Study supported by PHS Grant MY-3701 (Psychopharmacology Service Centre - NIMII). Benzquinamide supplied by Charles Pfizer and Company, Inc, New York","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Borison-1991","2012-10-23 14:39:19 +0100","UNKNOWN","""Subjects were assigned on a double-blind, random basis"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Borison-1991","2012-10-23 14:39:19 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Borison-1991","2012-10-23 14:39:19 +0100","UNKNOWN","""Double blind"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Borison-1991","2012-10-23 14:39:19 +0100","UNKNOWN","""Double blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Borison-1991","2012-10-23 14:39:19 +0100","UNKNOWN","""Early terminators from treatment were analysed using last observation carried forward"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Borison-1991","2012-10-23 14:39:37 +0100","NO","Use of SAS not pre-specified in methods. No data reported for adverse effects.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Borison-1991","2012-11-01 08:37:41 +0000","NO"," Borison and Diamond in prison for research fraud. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Chouinard-1990","2012-10-23 14:40:03 +0100","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Chouinard-1990","2012-10-23 14:40:12 +0100","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Chouinard-1990","2012-10-24 08:12:18 +0100","YES","""Double blind"", ""The trial drugs were provided in the form of identical white opaque gelatin capsules"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Chouinard-1990","2012-10-23 14:40:03 +0100","UNKNOWN","""Double blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Chouinard-1990","2012-10-23 14:40:03 +0100","UNKNOWN","""Four  chlorpromazine-treated patients  failed to complete the trial: 3 on account of side effects (1 case of leucopenia and 2 of  hypotension) and 1 on account of  inefficacy. Seven placebo-treated patients did not complete the clinical trial (1 case of  abnormal liver  function, 5 of inefficacy, and 1 patient for administrative reasons)."" Last observation carried forward method used.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Chouinard-1990","2012-10-24 08:12:26 +0100","NO","No SDs reported for BPRS and CGI. No useable data reported for adverse effects.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Chouinard-1990","2012-10-23 14:40:04 +0100","UNKNOWN"," Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1961","2012-10-24 08:14:53 +0100","YES","Participants ""individually matched into triplets. Random assignment of triplet members to treatment groups"", ""drawn by a table of random numbers""","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1961","2012-10-24 08:13:30 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1961","2013-11-25 17:28:05 +0000","YES","""Double-blind"", ""neither the patients nor the personnel involved in the care or evaluation of the subjects were informed of any individual's medication until the end of the study. Medications were dispensed in individually labeled bottles so that identification by code was not possible"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1961","2012-10-24 08:14:59 +0100","YES","""Double-blind"", """"neither the patients nor the personnel involved in the care or evaluation of the subjects were informed of any individual's medication until the end of the study"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1961","2012-10-24 08:15:06 +0100","YES"," One participant in the chlorpromazine group was withdrawn due to agranulocytosis, along with the other two participants in her ""triplet"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1961","2012-10-24 08:15:09 +0100","NO","No data reported for OBRS, and no useable data reported for psychological tests.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1961","2013-06-19 08:32:31 +0100","UNKNOWN","Medications supplied by Dr Fred Alexander of Smith, Kline, and French Laboratories.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1967","2012-10-24 08:16:15 +0100","UNKNOWN","""Assigned at random"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1967","2012-10-24 08:16:15 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1967","2012-10-24 08:16:24 +0100","YES","""Double-blind procedure in which neither the investigators nor the subjects knew who was receiving chlorpromazine. Medications were dispensed in identical-appearing capsules from individual stock bottle labeled only with the patient's name.""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1967","2012-10-24 08:16:25 +0100","YES","""Double-blind procedure in which neither the investigators nor the subjects knew who was receiving chlorpromazine"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1967","2013-11-25 17:53:34 +0000","UNKNOWN","""11 subjects taking chlorpromazine were unable to tolerate the full 800 mg over the 10-week trial""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1967","2012-10-24 08:16:34 +0100","NO","No data reported for BPRS, PRS, OBRS, Perdue Pegboard test, Digit Symbol Test and physiological measures.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1967","2013-06-19 08:32:42 +0100","UNKNOWN","Supported by Grant MH-04260 from the US Public Health Service.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1968a","2012-10-24 08:17:23 +0100","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1968a","2012-10-24 08:17:23 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1968a","2012-10-24 08:17:46 +0100","YES","""Identically appearing capsules from each subject's individually labelled stock bottle to meet the double-blind requirements of the study""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1968a","2012-10-24 08:17:23 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1968a","2012-10-24 08:17:50 +0100","YES","""Sixty six patients completed the study. Two patients were dropped from the CPZ group because of skin rashes and a third because of a severe behavioural reaction"", ""Three were dropped form the no drug group [...] one patient in TRP group completed only 13 weeks before undergoing surgery"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1968a","2012-10-24 08:17:51 +0100","NO","No SDs reported for Oklahoma Rating Scale and psychological tests. No data reported for physiological tests.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1968a","2013-06-19 08:56:25 +0100","NO"," Supported by grants from the National Institute of Mental Health, US Public Health Service and McNeil Laboratories Inc, Fort Washington, Pennsylvania.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1968b","2012-10-24 08:18:10 +0100","UNKNOWN","""Randomly assigned"" no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1968b","2012-10-24 08:18:10 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1968b","2012-10-24 08:18:48 +0100","YES","Double-blind"", ""All medications were identical in appearance"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1968b","2012-10-24 08:18:10 +0100","UNKNOWN","Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1968b","2012-10-24 08:18:53 +0100","YES","""Sixty seven patients completed the study. One patient was dropped from the CPZ group because of agranulocytosis; one was lost form the BPZ group when she eloped.""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1968b","2012-10-24 08:18:54 +0100","NO","No useable data was reported for global improvement, OBRS, IMPS, Perdue Pegboard, Digit Symbol test and physiological tests.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1968b","2013-06-19 08:56:32 +0100","NO"," Supported by grants from US Public Heath Service and AH Robins Company.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1970a","2012-10-24 08:19:22 +0100","UNKNOWN","""Randomly assigned by sex"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1970a","2012-10-24 08:19:22 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1970a","2012-10-24 08:19:29 +0100","YES","""Identically appearing capsules"", ""double-blind, with medications dispensed from individual stock bottles labelled only with the patient's name""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1970a","2012-10-24 08:19:22 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1970a","2012-10-24 08:19:33 +0100","YES","""One subject was dropped form the CPZ group because of abnormal liver function tests; another subject on CPZ was terminated 2 weeks early because of surgery"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1970a","2012-10-24 08:19:35 +0100","NO","No SDs reported for BPRS, NOSIE and the various psychological tests.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1970a","2013-06-19 08:56:41 +0100","NO"," Supported in part by US Public Health Service Grant, Research Scientist Development Award from National Institute of Mental Health. Endo Laboratories provided the medication and partial support.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1970b","2012-10-24 08:19:49 +0100","UNKNOWN","""Subjects were assigned by block randomisation"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1970b","2012-10-24 08:19:49 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1970b","2012-10-24 08:19:49 +0100","UNKNOWN"," No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1970b","2012-10-24 08:19:49 +0100","UNKNOWN"," No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1970b","2012-10-24 08:20:03 +0100","NO","""During the course of the study one subject was dropped because of rash and anaemia, one because of agranulocytosis, two because of elopement from the hospital, and two because of requisite surgery"". Study does not report which from groups the losses to follow-ups occurred.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1970b","2012-10-24 08:20:07 +0100","NO","No SDs reported for CGI, BPRS, IMPS, and OBRS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1970b","2012-10-24 08:20:08 +0100","YES"," Supported by USPHS grant and Research Scientist Development Award.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1971","2012-10-24 08:20:24 +0100","UNKNOWN","""Patients were assigned to treatment randomly in blocks of four"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1971","2012-10-24 08:20:24 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1971","2012-10-24 08:20:38 +0100","YES","""Double-blind"", ""identical appearing medication was administered from a bottle labelled only with the patient's name"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1971","2012-10-24 08:20:24 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1971","2012-10-24 08:20:49 +0100","YES","""Of the 75 subjects completing the study, one placebo subject was terminated because of behavioural deterioration after only three weeks observation and one subject taking fluphenazine was discharged from the hospital as markedly improved after only two weeks observation. In both instances, final measures were obtained and their data were retained for the final analysis. Eleven additional subjects were started in the study but were dropped without obtaining final measures for a variety of reasons: in the placebo group there was one subject absent without permission (AWOL), one on convalescent leave, and one subject transferred to another hospital; in the thioridazine group there were two AWOL subjects and one with medication intolerance; in the chlorpromazine group there was one AWOL and two subjects who refused oral medication; in the fluphenazine group there was one administrative transfer and one AWOL.""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1971","2012-10-24 08:20:58 +0100","NO","No SDs reported for BPRS, NOSIE and the psychological tests.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1971","2013-06-19 08:34:24 +0100","UNKNOWN","Supported by Public Health Service grant and Research Scientist Award. Medication provided by Smith Kline & French Laboratories, Sandoz Inc and ER SQuibb & Sons.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1972","2012-10-24 08:21:55 +0100","UNKNOWN","""Allocation to treatment was random, but provided for balancing of groups by sex and age"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1972","2012-10-24 08:21:55 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1972","2012-10-24 08:21:59 +0100","YES","""Double-blind"", identical appearing medication in capsule form was administered orally to each subject rom his individual stock bottle labelled only with his name"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1972","2012-10-24 08:21:55 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1972","2013-11-25 17:34:37 +0000","YES","""Five patients were lost from the study: 2 from the PL group because of a grand mal seizure in one, and a cardiac arrhythmia in the second; 2 from the CPZ group because of abnormal liver function in one and a severe allergic reaction dermatitis with photo-sensitivity on the other; 1 from the LOX group because of a hip fracture"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1972","2012-10-24 08:22:06 +0100","NO","No SDs reported for BPRS, NOSIE and weight gain. No data reported for physical tests.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1972","2013-06-19 08:56:54 +0100","NO"," Supported by a grant from USPHS and a grant-in-aid from Lederle Laboratories.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1977","2012-10-24 08:22:21 +0100","UNKNOWN","""Allocation to treatment by sex was random"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1977","2012-10-24 08:22:21 +0100","UNKNOWN"," No information reported","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1977","2012-10-24 08:22:32 +0100","YES","""Double-blind"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1977","2012-10-24 08:22:21 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1977","2012-10-24 08:22:21 +0100","UNKNOWN","""Of the 27 subjects who started, three failed to complete the full 12 weeks of study: one female subject in the butaclamol group became excited and agitated during the 4th week of treatment, exacerbated a labile hypertension, and was dropped at the end of the 4th week as treatment failure. Two male subjects in the placebo group also manifested clinical deterioration, one at the 8th week and one at the 11th week of treatment, and were terminated as treatment failures. In each instance, final rating were obtained and their data were retained in the analysis"". Last observation carried forward method used.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1977","2012-10-24 08:22:40 +0100","NO","No SDs reported for BPRS, CGI and NOSIE, and no data reported for physical tests.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Clark-1977","2013-06-19 08:57:01 +0100","NO","Supported in part by a USPHS grant and a grant-in-aid from Ayerst Laboratories, NY.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cohen-1968","2012-10-24 08:22:54 +0100","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cohen-1968","2012-10-24 08:22:54 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cohen-1968","2012-10-24 08:22:54 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cohen-1968","2012-10-24 08:22:54 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cohen-1968","2012-10-24 08:22:59 +0100","YES"," No losses to follow-up reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cohen-1968","2012-10-24 08:23:02 +0100","NO","No SDs reported for social aggression and manifest anxiety state.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cohen-1968","2012-10-24 08:23:04 +0100","YES"," Supported by grants from the National Institute of Mental Health, Public Health Service.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cole-1964","2012-10-24 08:31:18 +0100","UNKNOWN","""Stratified by sex with randomised assignment to drug treatment within each sex group"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cole-1964","2012-10-24 08:31:18 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cole-1964","2012-10-24 10:14:37 +0100","YES","""Double-blind"" oral medication ""prepared as standard No. 2 pink capsules"", IM from ""1 cc glass ampules"" with sterile saline for placebo.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cole-1964","2012-10-24 08:31:18 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cole-1964","2012-10-24 08:31:55 +0100","UNKNOWN"," 119 out of 463 participants were lost to follow-up. Reasons for loss to follow-up were balanced across groups, apart from treatment failure where ""the majority of patients who were dropped because of treatment failure were on placebo"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cole-1964","2012-10-24 08:31:58 +0100","NO","Data was not reported by group for Global Rating of Severity of Mental Illness & Global Rating of Improvements, IMPS and Burdock Ward Behaviour Rating Scale.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cole-1964","2012-10-24 08:32:02 +0100","YES"," Supported by NIMH grants.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cooper-2000","2012-10-24 08:32:18 +0100","UNKNOWN","""All eligible patients were allocated a study number and randomly assigned in blocks of six"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cooper-2000","2012-10-24 08:32:14 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cooper-2000","2012-10-24 08:32:41 +0100","YES","""A double-dummy technique was used to maintain blinding because of differences in capsule and tablet appearances, i.e. patients received active zotepine plus placebo chlorpromazine or placebo zotepine plus active chlorpromazine or double placebo."" ","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cooper-2000","2012-10-24 08:32:14 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cooper-2000","2012-10-24 08:33:02 +0100","UNKNOWN","""A total of 89 patients completed the full 8-week study."" ""Sixty-nine patients withdrew from the study"" Reasons for leaving the study not fully described.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cooper-2000","2012-10-24 08:33:05 +0100","NO","For adverse effects it is unclear if data includes withdrawals. We are unsure of the data reported for BPRS, SANS, CGI, AIMS, COSTART and EPMS. No means and SDs were reported for Simpson and Angus.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Cooper-2000","2012-10-24 08:33:06 +0100","NO"," Funded by Knoll Pharmaceuticals. Data analysis was by Knoll in conjunction with Dr Cooper.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Dean-1958","2012-10-24 08:33:21 +0100","UNKNOWN"," No information reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Dean-1958","2012-10-24 08:33:21 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Dean-1958","2013-11-25 17:54:12 +0000","UNKNOWN","""Until the patients were receiving 1000 mg of chlorpromazine a day, the hospital pharmacist was was the only person who knew which patients were receiving placebos. At the 1000 mg level the ward physician checked the master list to determine who was on the placebos"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Dean-1958","2012-10-24 08:33:21 +0100","UNKNOWN"," No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Dean-1958","2012-10-24 08:33:24 +0100","YES"," There were no losses to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Dean-1958","2012-10-24 08:33:25 +0100","YES","All expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Dean-1958","2013-06-19 08:36:26 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Engelhardt-1960","2012-10-24 08:33:41 +0100","UNKNOWN","""Drug assignment was random"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Engelhardt-1960","2012-10-24 08:33:41 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Engelhardt-1960","2012-10-24 08:33:44 +0100","YES","""The treating psychiatrist did not know which agent the patient received"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Engelhardt-1960","2012-10-29 09:34:03 +0000","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Engelhardt-1960","2012-10-24 08:33:41 +0100","UNKNOWN","""The overall drop-out rate was 36.4% (63 out of 173 patients), while for individual agents the rates were as follows: placebo, 33.9%; and chlorpromazine, 40.3%"". Reasons for loss to follow-up not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Engelhardt-1960","2012-10-24 08:33:41 +0100","UNKNOWN","Other reports have greater 'N' (of which the 173 above are assumed to be an unbiased sub-sample) but no data is usable from these papers.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Engelhardt-1960","2012-10-24 08:33:48 +0100","YES"," Study supported in part by a grant from National Institute of Mental Health, US Public Health Service.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Fink-1963","2012-10-24 08:34:00 +0100","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Fink-1963","2012-10-24 08:34:00 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Fink-1963","2012-10-24 08:34:03 +0100","YES","""Each medication was dissolved in a highly flavoured liquid vehicle and each patient received 40ml per day from individually labelled bottles"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Fink-1963","2012-10-24 08:34:00 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Fink-1963","2012-10-24 08:34:00 +0100","UNKNOWN","""Of the 173 patients starting medication, 19 did not complete the study because of psychiatric reasons [...] 5 for medical complications [...] 5 patients received an active placebo in a methodological substudy and are not included in this analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Fink-1963","2012-10-24 08:34:08 +0100","NO","No useable data reported for the MSRPP and no SDs reported for Rorschach tests.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Fink-1963","2012-10-24 08:34:09 +0100","YES"," Partly funded by National Institute of Mental Health, USPHS.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Fleming-1959","2012-10-24 08:34:20 +0100","UNKNOWN","""Patients were sub-divided, upon a random basis, into 3 equal groups"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Fleming-1959","2012-10-24 08:34:20 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Fleming-1959","2012-10-24 08:34:24 +0100","YES","""the tablets of the 3 treatments were identical in appearance, the hospital dispenser alone knowing to which treatment any particular patient had been assigned at the outset"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Fleming-1959","2012-10-24 08:34:20 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Fleming-1959","2012-10-24 08:34:29 +0100","YES","""The loss of patients was equally distributed""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Fleming-1959","2012-10-24 08:34:33 +0100","NO","No SD reported for Powick Psychiatric Rating Scale.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Fleming-1959","2013-06-19 08:36:46 +0100","UNKNOWN"," John Wyeth & Bro. supplied the promazine, Messrs, May & Baker Ltd supplied chlorpromazine and placebo tablets.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Grygier-1958","2012-10-24 08:35:23 +0100","UNKNOWN","""selected two groups, matching them as closely as possible"", ""pharmacist decided at random"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Grygier-1958","2012-10-24 08:35:32 +0100","YES","""The pharmacist decided at random which group would receive chlorpromazine and which inert tablets, and only she had this information at any time"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Grygier-1958","2012-10-24 08:34:46 +0100","UNKNOWN"," No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Grygier-1958","2012-10-24 08:34:46 +0100","UNKNOWN","""At the end of the experiment both raters were asked to ""guess"" the composition of the chlorpromazine group"" no further details reported, implies assessors were blind for treatment allocation.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Grygier-1958","2012-10-24 08:35:37 +0100","NO","""Three pairs were lost: one due to death from unassociated causes; two due to major side-effects"". Both members of a pair removed from analysis when one left.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Grygier-1958","2012-10-24 08:35:40 +0100","NO","No SDs reported for Albany Behavioral Rating Scale.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Grygier-1958","2012-10-24 08:34:47 +0100","UNKNOWN"," Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Gwynne-1962","2012-10-24 10:36:59 +0100","UNKNOWN","""Three groups of 26 patients each (13 males and 13 females) were formed by random selection from the basic group"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Gwynne-1962","2012-10-24 10:36:59 +0100","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Gwynne-1962","2012-10-24 10:36:59 +0100","UNKNOWN","""All drugs and placebo were identical in appearance and taste."" No further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Gwynne-1962","2012-10-24 10:36:59 +0100","UNKNOWN"," No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Gwynne-1962","2012-10-24 10:37:07 +0100","YES"," In the placebo group, one participant left the study early due to adverse effects and two due to unmanageability. There were no losses to follow-up in the chlorpromazine group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Gwynne-1962","2012-10-24 10:37:08 +0100","NO","No means and SDs reported for MSRPP.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Gwynne-1962","2013-06-19 08:37:06 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hall-1955","2012-10-24 08:35:52 +0100","UNKNOWN","""Randomised selection"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hall-1955","2012-10-24 08:35:57 +0100","YES","""The drug manufacturer supplied the material in 10 coded batches. Half of the batches contained drug, and half placebo (terra alba), and code letters were assigned at random to these batches. In turn, these codes letters were assigned in serial fashion to","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hall-1955","2012-10-24 08:35:59 +0100","YES","""identical-appearing placebo""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hall-1955","2012-10-24 08:36:26 +0100","UNKNOWN","""Double-blind"", ""the participating technicians, psychiatrists and psychologist recorded their judgments as the whether the patient received drug or placebo"", ""the psychiatrists and psychologist were neither completely ""blind"" nor completely ""unblind"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hall-1955","2012-10-24 08:36:02 +0100","YES","""The three patients who developed jaundice were eliminated from the project"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hall-1955","2013-11-25 17:48:52 +0000","NO","There were no useable data for specific symptoms and liver biopsy data was only reported for a non-random subset of participants.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hall-1955","2012-10-24 08:36:11 +0100","NO"," Smith, Kline & French Laboratories provided chlorpromazine, partly supported the study with a grant for statistical analysis and provided other assistance.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hamill-1975","2012-10-24 08:36:46 +0100","YES","""Assignment of patients to the chlorpromazine or the placebo group was determined using a table of random numbers"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hamill-1975","2012-10-24 08:36:45 +0100","UNKNOWN","""Patients were given a number from 1 to 44 according to the randomisation and without the participation of the research psychiatrist"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hamill-1975","2012-10-24 08:36:45 +0100","UNKNOWN"," No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hamill-1975","2012-10-24 08:36:45 +0100","UNKNOWN"," No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hamill-1975","2012-10-24 08:36:50 +0100","YES","""Of the 44 patients evaluated, 11 were dropped from the study during the 5 day period. OF the 111 dropped patients, 6 were in the drug group and 5 in the placebo group."" Reasons for leaving the study early balanced across groups.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hamill-1975","2012-10-24 08:36:55 +0100","NO","No useable data reported for the BPRS and NOSIE and no SDs reported for CGI.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hamill-1975","2012-10-24 08:36:45 +0100","UNKNOWN"," Source of funding not reported. Placebo provided by Smith Kline & French Laboratories, Philadelphia, Pa.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hamilton-1960","2012-10-24 08:37:05 +0100","UNKNOWN","""Each of these 3 groups was randomly coupled with another group, and the names of the patients in the 3 pairs of groups given to the hospital pharmacist. He randomly selected one pair of no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hamilton-1960","2012-10-24 08:37:05 +0100","UNKNOWN","""Pharmacist [...] randomly selected"" groups, no further details reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hamilton-1960","2012-10-24 08:37:15 +0100","YES","""Form the point of view of the patients, nurses and physicians, there were 27 patients receiving one kind of tablet and 27 patients receiving the other kind, but only the pharmacist knew which of the patients were receiving active and which inert tablets. All the tablets were sugar-coated nad the placebo tablets were indistinguishable from the active drugs. ""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hamilton-1960","2012-10-24 08:37:17 +0100","YES","""The patients were assessed on Behaviour in the ward by the charge nurses and on Symtoms by the physician""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hamilton-1960","2012-10-24 08:37:20 +0100","YES"," There were no losses to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hamilton-1960","2012-10-24 08:37:44 +0100","NO","No means and SDs reported for mental state and a nurse-rated behaviour scale.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hamilton-1960","2012-10-24 08:37:06 +0100","UNKNOWN"," Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hankoff-1962","2012-10-24 10:39:06 +0100","UNKNOWN","""Patients were randomly assigned to treatment groups"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hankoff-1962","2012-10-24 10:39:06 +0100","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hankoff-1962","2012-10-24 10:40:36 +0100","YES","""All the drugs and their placebos were administered in pink No.2 capsules""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hankoff-1962","2012-10-24 10:39:06 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hankoff-1962","2012-10-24 10:40:38 +0100","YES","""Of 174 patients starting in the project, 134 completed the two-week drug trial. The 40 patients who failed to complete the study usually did not return for appointments. An occasional patient in this total of 40 was dropped for reasons of protocol violation"" .","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hankoff-1962","2012-10-24 10:40:41 +0100","NO","No SDs reported for Manifest Anxiety and Affect Adjective Checklist.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hankoff-1962","2012-10-24 10:40:42 +0100","YES","Supported by a grant from the US Public Health Service.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hine-1958","2012-10-24 08:38:07 +0100","YES","""Matched pairs"" based on withdrawal symptoms ""and one member of this pair was assigned to the treatment group by the toss of a coin","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hine-1958","2012-10-24 08:38:01 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hine-1958","2012-10-24 08:38:02 +0100","UNKNOWN","""corresponding placebo tablets or solution"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hine-1958","2012-10-24 08:38:10 +0100","YES","""The results of this assignment were not known to the judges, raters or other ward personnel"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hine-1958","2013-11-25 17:51:51 +0000","YES","""It was necessary to discontinue medication during the third week on one patient in the treatment group because of the development of severe angioneurotic edema. This patient was eliminated from the project"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hine-1958","2012-10-24 08:38:14 +0100","NO","No data reported for the Southeast Louisiana Hospital Behavior Rating Scale.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hine-1958","2013-06-19 08:37:39 +0100","UNKNOWN"," Drugs provided by Smith Kline & French Laboratories","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1973","2012-10-24 08:38:27 +0100","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1973","2012-10-24 08:38:27 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1973","2013-11-25 17:52:36 +0000","YES","""Assigned on a double-blind basis to identical looking 100 mg or 50 mg tablets of chlorpromazine or placebo"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1973","2012-10-24 08:38:27 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1973","2012-10-24 08:38:27 +0100","UNKNOWN"," Losses to follow-up not clearly reported. Reasons for leaving the study early reported, but not according to group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1973","2012-10-24 08:38:36 +0100","NO","No SDs reported for BPRS, Symptom Checklist, IMPS, Springfield Symptom Inventory, Major Role Adjustment Inventory, Katz Adjustment Scale, Casework Evaluation Schedu","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Hogarty-1973","2013-06-19 08:38:22 +0100","UNKNOWN","Chlorpromazine  was supplied by Smith Kline & French Laboratories, Philadelphia.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Klein-1973","2012-10-24 08:38:53 +0100","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Klein-1973","2012-10-24 08:38:53 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Klein-1973","2013-11-25 17:56:12 +0000","YES","""Medication was administered in a highly flavoured liquid placebo, and each patient received a constant 40 ml/day from individually labelled bottles"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Klein-1973","2012-10-24 08:38:53 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Klein-1973","2012-10-24 08:38:59 +0100","YES"," There were no losses to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Klein-1973","2013-11-25 17:56:29 +0000","NO","No SDs reported for MSRPP.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Klein-1973","2013-06-19 08:38:30 +0100","UNKNOWN","Smith Kline & French Laboratories and Wellcome and Co supplied the drugs.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Kurland-1961","2012-10-24 08:39:14 +0100","UNKNOWN","""The choice of the particular drug to be used in any case was based on a predetermined random selection"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Kurland-1961","2012-10-24 08:39:14 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Kurland-1961","2012-10-24 08:39:17 +0100","YES","""The drugs were dispensed in standard unmarked capsules [...] coloured pink to mask all identifying consistencies and colours of the drugs"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Kurland-1961","2012-10-24 08:39:21 +0100","YES","""Ratings were blind, in that raters did not know which drug the patients was receiving"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Kurland-1961","2012-10-24 08:39:23 +0100","NO","""Of the 238 patients who met all population restrictions, 187 remained  in the project at least 10 days [...] Fifty-nine patients completed the prescribed six-week treatment course.""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Kurland-1961","2012-10-24 08:39:26 +0100","NO","No SDs reported for the MSRPP, Psychotic Reaction Profile and Psychiatric Scale of Target Symptoms.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Kurland-1961","2013-06-19 08:38:59 +0100","UNKNOWN","Drugs provided by Smith Kline & French Laboratories, Squibb Laboratories, Shering Corporation and Warner-Chilcott Laboratories.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Letemendia-1967","2012-10-24 08:39:40 +0100","YES","Groups matched according to age, length of hospital stay and severity, ""The designation of the two groups was determined by tossing a coin"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Letemendia-1967","2012-10-24 08:39:38 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Letemendia-1967","2012-10-24 08:39:43 +0100","YES","""Neither patients, doctors, nor nurses knew which patients were being given chlorpromazine and which placebo. All medication was dispensed in uniform amber-coloured capsules. Each patient was supplied from a separated bottle, replenished weekly according to the design by an independent party"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Letemendia-1967","2012-10-24 08:39:38 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Letemendia-1967","2012-10-24 08:39:38 +0100","UNKNOWN","""Of the 30 patients who initially fulfilled out conditions, one died from a cerebrovascular accident during the period of preliminary observations, and a second was eliminated because of slow phasic changes in mental state"". Two losses to follow-up, but unclear is before or after randomisation.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Letemendia-1967","2012-10-24 08:39:47 +0100","NO","No SDs reported for mental state and behaviour scale","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Letemendia-1967","2012-10-24 08:39:48 +0100","YES"," Supported by a grant from the Rockefeller foundation.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Nishikawa-1982","2012-10-24 08:40:07 +0100","UNKNOWN","""Randomly assigned"" no further information reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Nishikawa-1982","2012-10-24 08:40:07 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Nishikawa-1982","2012-10-24 08:42:20 +0100","YES","""Drug appearance, with respect to powder colour, taste and volume, was  made identical by adding a kind of stomachics.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Nishikawa-1982","2012-10-24 08:40:07 +0100","UNKNOWN","""Double-bind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Nishikawa-1982","2013-11-25 17:59:40 +0000","UNKNOWN","""Then nine patients were dropped from the study for various reasons. These reasons included: failure to report to the hospital for scheduled appointments (N = 3); admissions to other hospitals (N = 2); strong requests from the patient not to change the previous drugs (N = 3); and a suicide after admission to the hospital (N = 1)"". Number of participants and reasons for leaving the study early not reported by groups.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Nishikawa-1982","2012-10-24 08:40:13 +0100","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Nishikawa-1982","2013-06-19 08:39:35 +0100","UNKNOWN"," Drugs provided by SMP (Sankyo, Japan).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Payne-1960","2012-10-24 08:42:39 +0100","UNKNOWN","""The patients were divided into three groups of seven persons"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Payne-1960","2012-10-24 08:42:39 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Payne-1960","2012-10-24 08:42:41 +0100","YES","""All three types of tablet were exactly the same colour, size and shape. Each patient's medication was supplied to the wards in identical containers bearing the patient's name only. The physician and ward personnel were unaware of which patient was receiving which tablet; the latter being known only to the pharmacist and not divulged until the completion of the investigation"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Payne-1960","2012-10-24 08:42:39 +0100","UNKNOWN","""Double-blind"" no further information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Payne-1960","2012-10-24 08:42:49 +0100","UNKNOWN"," Did not report any losses to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Payne-1960","2012-10-24 08:42:44 +0100","NO","Results for categories of 'improved', 'much improved' and 'unimproved' not fully reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Payne-1960","2013-06-19 08:39:57 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Peet-1981","2012-10-24 08:43:01 +0100","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Peet-1981","2012-10-24 08:43:01 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Peet-1981","2012-10-24 08:43:05 +0100","YES","""Capsules of identical appearance""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Peet-1981","2012-10-24 08:43:01 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Peet-1981","2012-11-05 07:43:15 +0000","YES"," 6 patients left the study early from the propanolol and chlorpromazine groups, and 9 from the placebo group. Reasons for loss evenly distributes across groups.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Peet-1981","2012-10-24 08:43:12 +0100","NO","No means or SDs reported for IMPS, NOSIE and Discharge Readiness Inventory.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Peet-1981","2012-10-24 08:43:01 +0100","UNKNOWN"," Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Prien-1968","2012-10-24 08:43:29 +0100","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Prien-1968","2012-10-24 08:43:29 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Prien-1968","2012-10-24 08:43:29 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Prien-1968","2012-10-24 08:43:29 +0100","UNKNOWN"," No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Prien-1968","2012-11-05 07:43:49 +0000","YES","""The placebo group had the highest percentage of dropout (38%), followed by the high dose group (25%), and the low dose group (15%). Terminations due to side effects were most frequent in the high dose group, while the placebo group had the highest incidence of dropouts due to deteriorated behavior."" Losses to follow-up balanced across intervention groups, with similar reasons for missing data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Prien-1968","2012-10-24 08:43:37 +0100","NO","No SD for IMPS, NOSIE, Discharge Readiness Inventory.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Prien-1968","2012-10-24 08:43:39 +0100","YES"," The study appears to be free of other sources of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ramu-1999","2012-10-24 10:42:27 +0100","UNKNOWN","""Randomly allocated"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ramu-1999","2012-10-24 10:42:27 +0100","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ramu-1999","2012-10-24 10:42:34 +0100","YES","""The medicines and placebo were administered in the form of identical tablets"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ramu-1999","2012-10-24 10:42:27 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ramu-1999","2012-10-24 10:42:27 +0100","UNKNOWN","""Out of 136 patients 108 who have completed the treatment for a period of 2 months were taken for final assessment. The remaining 28 were dropouts for reasons of escape and leaving without medical advice"". Number randomised to each group not reported. Number lost from each group not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ramu-1999","2012-10-24 10:42:41 +0100","NO","Unclear which rating scales are reported in the results tables.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ramu-1999","2012-10-24 10:42:27 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ramu-1999a","2012-10-24 10:43:05 +0100","NO"," No information reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ramu-1999a","2012-10-24 10:43:01 +0100","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ramu-1999a","2012-10-24 10:43:01 +0100","UNKNOWN","""Sugar coated uniform tablets of the trial drugs"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ramu-1999a","2012-10-24 10:43:01 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ramu-1999a","2012-10-28 10:04:39 +0000","NO","""78 cases were taken for the study. Of them, 13 cases were dropped out for various reasons"" N randomised to each group not reported. Reasons for losses and number of losses to follow-up per group not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ramu-1999a","2012-10-24 10:43:15 +0100","NO","N reported for global improvement differs from N reported in each group.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Ramu-1999a","2013-06-19 08:40:17 +0100","UNKNOWN","Drugs supplied by M/s Eros Pharma, Bangalore.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Rappaport-1978","2012-10-24 08:43:50 +0100","UNKNOWN","""Assigned randomly"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Rappaport-1978","2012-10-24 08:43:50 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Rappaport-1978","2012-10-24 08:44:11 +0100","UNKNOWN","""physician [...] and the nursing staff remained blind as to whether the patient was receiving medication or placebos"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Rappaport-1978","2012-10-24 08:44:19 +0100","YES","""Ratings were made by a trained research assistant who was unaware as  to what the patient's medication condition was while he was hospitalised"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Rappaport-1978","2012-10-24 08:44:22 +0100","NO","""The 80 patients in this study represented 63% of the total sample (127) studied while in the hospital. It was noted that during the follow-up period, there was a significantly larger attrition of subjects from the  group assigned to placebo while in the hospital than the group assigned to chlorpromazine (45% vs 26%).""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Rappaport-1978","2012-10-24 08:44:25 +0100","NO","Unclear when outcomes recorded. Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Rappaport-1978","2012-10-24 08:44:27 +0100","YES"," Supported California Department of Mental Hygiene and the National  Institute of Mental Health and from the Wickes Foundation and Esalen Institute.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Reardon-1966","2012-10-24 08:44:41 +0100","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Reardon-1966","2012-10-24 08:44:41 +0100","UNKNOWN","""Randomly assigned trifluoroperazine, chlorpromazine or placebo by the pharmacy"" no further details reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Reardon-1966","2012-10-24 08:44:41 +0100","UNKNOWN","""Neither the ward personnel nor the investigator knew which drug the patient received"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Reardon-1966","2012-10-24 08:44:41 +0100","UNKNOWN","""Neither the ward personnel nor the investigator knew which drug the patient received"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Reardon-1966","2012-10-24 09:33:22 +0100","YES","""An additional three subjects, one from each group, had to be removed from the study because of transfer or home leave"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Reardon-1966","2012-10-24 09:33:25 +0100","NO","No means or SDs reported for the MMPI. Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Reardon-1966","2013-06-19 08:40:34 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Reschke-1974","2012-10-24 09:33:37 +0100","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Reschke-1974","2012-10-24 09:33:37 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Reschke-1974","2012-10-24 09:33:37 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Reschke-1974","2012-10-24 09:33:37 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Reschke-1974","2012-10-24 09:33:41 +0100","YES"," There were no losses to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Reschke-1974","2012-10-24 09:33:44 +0100","NO","No means and SDs reported for BPRS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Reschke-1974","2012-10-24 09:33:37 +0100","UNKNOWN"," Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Saretsky-1966","2012-10-24 09:33:59 +0100","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Saretsky-1966","2012-10-24 09:33:59 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Saretsky-1966","2012-10-24 09:34:02 +0100","YES","""The two kinds of pills were identical in size, shape, colour, and taste.""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Saretsky-1966","2012-10-24 09:34:04 +0100","YES","""Throughout the experiment, whether the patient received the drug or a placebo was not known to anyone connected with the experiment.""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Saretsky-1966","2012-10-24 09:34:06 +0100","YES"," There were no losses to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Saretsky-1966","2012-10-24 09:34:08 +0100","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Saretsky-1966","2012-10-24 09:33:59 +0100","UNKNOWN"," Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Schiele-1961","2012-10-24 09:34:19 +0100","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Schiele-1961","2012-10-24 09:34:19 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Schiele-1961","2012-10-24 09:34:21 +0100","YES","""During the first 16 weeks, the study was carried out under strict double-blind conditions. Each patient had his individual bottle of medication; the capsules were identical in appearance, and only the hospital pharmacist had the code for determining which patient was receiving each kind of medication"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Schiele-1961","2012-10-24 09:34:19 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Schiele-1961","2012-10-24 09:34:19 +0100","UNKNOWN","""During the thirteenth week. a third patient who was in the trifluoperazine group eloped from the hospital."" Only 43 participants took the MMPI three times.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Schiele-1961","2012-10-24 09:34:24 +0100","NO","No SD reported for the MBS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Schiele-1961","2012-10-24 09:34:19 +0100","UNKNOWN"," Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Serafetinides-1972","2012-10-24 09:34:45 +0100","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Serafetinides-1972","2012-10-24 09:34:46 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Serafetinides-1972","2012-10-24 09:34:46 +0100","UNKNOWN","""All medications were prepared in identically appearing capsules"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Serafetinides-1972","2012-10-24 09:34:46 +0100","UNKNOWN"," No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Serafetinides-1972","2012-10-24 09:34:48 +0100","YES","""Four of the 57 subjects, three on CPZ, and one on PL,failed  to complete the 12 weeks of study. The PL subject and one CPZ  subject were terminated because of behavioural deterioration after 4 and 8 weeks respectively. The other two CPZ subjects developed intestinal obstruction secondary to massive fecal  impactions and were terminated in the 7th week of study.""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Serafetinides-1972","2013-11-25 18:11:31 +0000","NO","No data was reported for the psychological function tests.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Serafetinides-1972","2012-10-24 09:34:53 +0100","YES"," Supported in part by a US Public Health Service Grant.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Shepherd-1956","2012-10-24 09:35:10 +0100","UNKNOWN","The 24 patients were divided into three groups of eight (A,B, and C) by random selection"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Shepherd-1956","2012-10-24 09:35:10 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Shepherd-1956","2012-10-24 09:35:19 +0100","YES","Two kinds of inert substances were employed, one indistinguishable from reserpine, the other from chlorpromazine. Nobody but the ward doctor allocating the drugs and the dispenser knew which patients were receiving drugs and which patients were on placebo"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Shepherd-1956","2012-10-24 09:35:22 +0100","YES","""Weekly clinical assessments were carried out by one of us (DCW) who was unaware of the nature of individual prescriptions"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Shepherd-1956","2012-10-24 09:35:25 +0100","YES"," There were no losses to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Shepherd-1956","2012-10-24 09:35:28 +0100","NO","Adverse effects were not reported for each individual arm.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Shepherd-1956","2013-06-19 08:40:58 +0100","UNKNOWN"," Messrs Ciba supplied serpasil and dummy tablets, Messrs May and Baker supplied dummy tablets.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Simon-1958","2012-10-24 09:35:49 +0100","YES","""Assigned to one of 4 treatment groups on a random basis [...] the staff was kept ignorant of the order within the random list"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Simon-1958","2012-10-24 09:35:47 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Simon-1958","2012-10-24 09:35:47 +0100","UNKNOWN"," No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Simon-1958","2012-10-24 09:35:47 +0100","UNKNOWN"," No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Simon-1958","2012-10-24 09:35:54 +0100","YES"," There were no losses to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Simon-1958","2012-10-24 09:35:57 +0100","NO","No data was reported for the Scale of Occupational Adjustment.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Simon-1958","2012-10-24 09:35:48 +0100","UNKNOWN"," Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Smith-1961","2012-10-24 09:36:06 +0100","UNKNOWN","The 45 patients were divided into three matched groups on the basis of age, illness duration and predominant symptomatology"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Smith-1961","2012-10-24 09:36:06 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Smith-1961","2012-10-24 09:36:11 +0100","YES","""Neither the patients nor the attending physicians knew what medication was being given. An identifying code was available but not broken until the end of the study.""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Smith-1961","2012-10-24 09:36:06 +0100","UNKNOWN","""Neither the patients nor the attending physicians knew what medication was being given."" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Smith-1961","2012-10-24 09:36:07 +0100","UNKNOWN"," Two participants lost to follow-up in the chlorpromazine group and two in the clordiazepoxide group, reasons for leaving the study early not reported. Unclear whether there were any losses in the placebo group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Smith-1961","2012-10-24 09:36:15 +0100","YES","All expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Smith-1961","2012-10-24 09:36:07 +0100","UNKNOWN"," Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Somerville-1960","2012-10-24 09:36:29 +0100","UNKNOWN","""Random choice"" matched on symptoms, age, and duration of illness, no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Somerville-1960","2012-10-24 09:36:29 +0100","UNKNOWN","""A doctor who had no duties connected with the ward concerned allotted each of the groups to a particular therapy"" no further details reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Somerville-1960","2012-10-24 09:36:33 +0100","YES","""The two placebos were identical in appearance with the respective active tablets.""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Somerville-1960","2012-10-24 09:36:29 +0100","UNKNOWN"," No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Somerville-1960","2012-10-24 09:36:37 +0100","YES"," There were no losses to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Somerville-1960","2012-10-24 09:36:40 +0100","YES","All expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Somerville-1960","2013-06-19 08:41:18 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Spohn-1977","2012-10-24 09:36:58 +0100","UNKNOWN","""Random assignment"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Spohn-1977","2012-10-24 09:36:58 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Spohn-1977","2012-10-24 09:36:58 +0100","UNKNOWN","""During the drug treatment period, patients, project personnel, and hospital personnel were ""blind"" to the patients' drug status"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Spohn-1977","2012-10-24 09:36:58 +0100","UNKNOWN","""During the drug treatment period, patients, project personnel, and hospital personnel were ""blind"" to the patients' drug status"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Spohn-1977","2012-10-24 09:36:58 +0100","UNKNOWN"," Losses to follow-up not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Spohn-1977","2012-10-24 09:37:05 +0100","NO","Means and SDs were not reported for the Global Severity Scale, Global improvement Scale and the Ward Behaviour Rating Scale.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Spohn-1977","2013-06-19 08:41:32 +0100","UNKNOWN","Chlorpromazine supplied by Smith Kline and French Laboratories.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Tetreault-1969","2012-10-24 09:37:21 +0100","YES","""Patients received one of the tested drugs according to a random number table"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Tetreault-1969","2012-10-24 09:37:20 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Tetreault-1969","2012-10-24 09:37:23 +0100","YES","""TPS-23 (50mg, chlorpromazine (100 mg) and placebo presented in identical white capsules; they were distributed on the ward in containers on which only the patient's name appeared. The double-blind technique was followed throughout the experiment"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Tetreault-1969","2012-10-24 09:37:20 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Tetreault-1969","2012-10-24 09:37:26 +0100","YES"," There were no losses to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Tetreault-1969","2012-10-24 09:37:28 +0100","YES","All expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Tetreault-1969","2012-10-24 09:37:30 +0100","NO"," Partly supported by a grant-in-aid from Sandoz (Canada) Ltd.  who supplied the drugs.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Vaughan-1955","2012-10-24 09:37:48 +0100","UNKNOWN","""By random selection"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Vaughan-1955","2012-10-24 09:37:48 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Vaughan-1955","2012-10-24 09:37:48 +0100","UNKNOWN","""The hospital pharmacist alone knowing which patients were receiving chlorpromazine and which the placebo"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Vaughan-1955","2012-10-24 09:37:48 +0100","UNKNOWN","""The hospital pharmacist alone knowing which patients were receiving chlorpromazine and which the placebo"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Vaughan-1955","2012-10-24 09:37:48 +0100","UNKNOWN"," Losses to follow-up not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Vaughan-1955","2012-10-24 09:37:53 +0100","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Vaughan-1955","2012-10-24 09:37:48 +0100","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Walsh-1959","2012-10-24 09:38:09 +0100","UNKNOWN","""Allocation of a preparation to a group was purely arbitrary"", participants matched on age, hospitalisation, adjustment, psychotic behaviour, and activity/withdrawal. No further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Walsh-1959","2012-10-24 09:38:09 +0100","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Walsh-1959","2012-10-24 09:38:16 +0100","YES","As this involved periodic changes in the number and/or size  of the tablets, the number and/or size of the tablets given to the placebo group was altered simultaneously. Neither the doctor nor the ward staff were aware of the nature of the preparation being given to a particular patient. A separate bottle was assigned to each patient and in this supplies of the specific preparation were issued at weekly intervals"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Walsh-1959","2012-10-24 09:38:09 +0100","UNKNOWN","""Neither the doctor nor the ward staff were aware of the nature of the preparation being given to a particular patient"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Walsh-1959","2012-10-24 09:38:18 +0100","YES"," There were no losses to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Walsh-1959","2012-10-24 09:38:21 +0100","NO","No SDs were reported for Rowell 'Psychoticism' Rating Scale and the Venables Activity-Withdrawal Rating Scale.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Walsh-1959","2013-11-25 18:18:30 +0000","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Weckowicz-1960","2012-10-24 10:44:43 +0100","NO","""On the basis of rating they were divided into three matched groups"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Weckowicz-1960","2012-10-24 10:44:39 +0100","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Weckowicz-1960","2012-10-24 10:44:45 +0100","YES","""The patients in the three groups received respectively from bottles marked ""A"", ""B"" and ""C"" 50mg tablets which looked exactly the same"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Weckowicz-1960","2012-10-24 10:44:39 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Weckowicz-1960","2012-10-24 10:44:51 +0100","YES","For the outcome global impression ""the number [of participants] is less than 16 in the groups, because some patients refused to take their medication"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Weckowicz-1960","2012-10-24 10:44:55 +0100","NO","N and SD not reported for the Weyburn assessment scale.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Weckowicz-1960","2012-10-24 10:44:58 +0100","YES","Funded by the Rockefeller Foundation and the Federal Fund.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Xiong-1994","2012-10-24 10:23:17 +0100","UNKNOWN","Randomly divided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Xiong-1994","2012-10-24 09:40:42 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Xiong-1994","2012-10-24 09:40:42 +0100","UNKNOWN","Double blind.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Xiong-1994","2012-10-24 09:43:50 +0100","UNKNOWN","Double blind.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Xiong-1994","2012-10-24 09:43:45 +0100","NO","Drop outs are unaccounted for in the final analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Xiong-1994","2012-10-24 10:23:24 +0100","YES","All measured outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Chlorpromazine versus placebo for schizophrenia [v14.0-For publication].rm5","STD-Xiong-1994","2012-10-24 09:43:40 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Chouinard-1976","2009-01-15 16:07:20 +0000","UNKNOWN","Block randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Chouinard-1976","2009-01-15 16:25:11 +0000","UNKNOWN","Not mentioned.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Chouinard-1976","2009-01-23 16:02:31 +0000","YES","Double, tablets of identical appearance, same amount of tablets and treatment scheme to all patients.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Chouinard-1976","2009-02-12 14:47:55 +0000","YES","1 person lost to follow-up, data at the time of loss (5th wk) reported as end data.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Chouinard-1976","2009-02-09 14:08:26 +0000","YES","All outcomes reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Chouinard-1976","2009-01-15 16:07:31 +0000","YES","Supported in part by the Medical Research Council of Canada and by an FCAC grant (Financial Consumer Agency of Canada, Quebec).","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Clark-1972","2009-01-23 16:03:45 +0000","UNKNOWN","Block randomisation, no details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Clark-1972","2009-01-15 16:24:51 +0000","UNKNOWN","Not mentioned.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Clark-1972","2009-01-23 16:03:46 +0000","YES","Double, same volume of medication.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Clark-1972","2009-02-09 14:12:55 +0000","NO","6 lost: 2 from CPZ 300mg/day group included, other 4 assumed divided equally in our groups (numbers not included here).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Clark-1972","2009-02-09 14:13:10 +0000","NO","No SD for continuous data.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Clark-1972","2009-02-09 14:13:21 +0000","UNKNOWN","Medication supplied by Smith, Kline and French Laboratories.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Prien-1968","2009-01-12 15:16:01 +0000","UNKNOWN","No details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Prien-1968","2009-01-15 16:25:57 +0000","UNKNOWN","Not mentioned.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Prien-1968","2009-01-15 16:24:05 +0000","YES","Double, identical liquid administration.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Prien-1968","2009-02-09 14:21:05 +0000","YES","Lost to follow up: 51 of high dose group (41 disabling adverse effects, 10 other), 31 of low dose group (4 disabling adverse effects, 27 other).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Prien-1968","2009-02-09 14:24:09 +0000","NO","No SD for several outcomes, several outcomes not reported (see above). ","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Prien-1968","2009-01-23 16:05:08 +0000","YES","Supported by Public Health Service grants from the National Institute of Mental Health and by Public Health Service.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Wode_x002d_Helgodt-1978","2009-02-10 17:13:55 +0000","UNKNOWN","
","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Wode_x002d_Helgodt-1978","2009-01-15 16:26:04 +0000","UNKNOWN","Not mentioned.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Wode_x002d_Helgodt-1978","2009-01-15 17:29:02 +0000","YES","Double dummy, same tablet numbers and shape.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Wode_x002d_Helgodt-1978","2009-02-09 14:35:56 +0000","YES","Loss to follow-up: 4 patients dropped out by 2 weeks due to dose-adjustments for ethical reasons (2 x extreme somnolence, 2 x insufficient effect on severe psychosis) and 6 patients dropped out during the last 2 weeks (2 x insufficient antipsychotic effect, 1 x improvement but severe elevation of transaminase levels, 2 x improved but insisted to be discharged, 1 x refused further medication) in the text described from which group.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Wode_x002d_Helgodt-1978","2009-02-09 14:36:11 +0000","NO","For some scales only graphs without numeric data.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/C-F/Chlorpromazine dose for people with schizophrenia [v3.0-For publication].rm5","STD-Wode_x002d_Helgodt-1978","2009-01-23 16:07:07 +0000","YES","Supported by grants from the Swedish Medical Research Council, National Institutes of Health (Bethesda, Maryland, USA), F.Hoffmann-La Roche (Basle, Switzerland), 'F""ornade Liv' Mutual Group Life Insurance Company (Stockholm, Sweden), Svenska L""akares""allskapet: Anton och Dorothea Bexelius Minnesfond, Bror Gadelius Minnesfond, Karolina Institutets Fonder, AB Leo (Sweden) and Magnus Bergvalls Stiftelse.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/C-F/Chinese herbal medicine for schizophrenia [v9.0-For publication].rm5","STD-Chen-1997","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chinese herbal medicine for schizophrenia [v9.0-For publication].rm5","STD-Luo-1997-a","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chinese herbal medicine for schizophrenia [v9.0-For publication].rm5","STD-Meng-1996","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chinese herbal medicine for schizophrenia [v9.0-For publication].rm5","STD-Zhang-1987","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chinese herbal medicine for schizophrenia [v9.0-For publication].rm5","STD-Zhang-1997","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chinese herbal medicine for schizophrenia [v9.0-For publication].rm5","STD-Zhang-2001","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Chinese herbal medicine for schizophrenia [v9.0-For publication].rm5","STD-Zhu-1996","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cessation of medication for people with schizophrenia already stable on chlorpromazine [v5.0-For publication].rm5","STD-Andrews-1976","2008-04-25 12:51:35 +0100","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cessation of medication for people with schizophrenia already stable on chlorpromazine [v5.0-For publication].rm5","STD-Caffey-1964","2008-04-25 12:51:35 +0100","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cessation of medication for people with schizophrenia already stable on chlorpromazine [v5.0-For publication].rm5","STD-Freeman-1962","2008-04-25 12:51:35 +0100","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cessation of medication for people with schizophrenia already stable on chlorpromazine [v5.0-For publication].rm5","STD-Greenberg-1966","2008-04-25 12:51:35 +0100","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cessation of medication for people with schizophrenia already stable on chlorpromazine [v5.0-For publication].rm5","STD-Hogarty-1973-a","2008-04-25 12:51:35 +0100","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cessation of medication for people with schizophrenia already stable on chlorpromazine [v5.0-For publication].rm5","STD-Mathur-1981","2008-04-25 12:51:35 +0100","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cessation of medication for people with schizophrenia already stable on chlorpromazine [v5.0-For publication].rm5","STD-Morton-1968","2008-04-25 12:51:35 +0100","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cessation of medication for people with schizophrenia already stable on chlorpromazine [v5.0-For publication].rm5","STD-Pigache-1973","2008-04-25 12:51:35 +0100","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cessation of medication for people with schizophrenia already stable on chlorpromazine [v5.0-For publication].rm5","STD-Shawver-1959","2008-04-25 12:51:35 +0100","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cessation of medication for people with schizophrenia already stable on chlorpromazine [v5.0-For publication].rm5","STD-Zeller-1956","2008-04-25 12:51:35 +0100","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Carpenter-1991","2013-05-23 17:10:27 +0100","UNKNOWN","""Patients were randomly assigned, within prognostic strata"", no further details (p.69).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Carpenter-1991","2013-05-23 17:13:24 +0100","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Carpenter-1991","2013-05-23 17:14:01 +0100","YES","""Double-blind"", ""identical placebo tablets"" (p.69), ""number of carbamazepine tablets was adjusted by a nonblind psychiatrist"" (p.70).","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Carpenter-1991","2013-05-23 17:14:03 +0100","UNKNOWN","""Double-blind"", ""identical placebo tablets"" (p.69), ""number of carbamazepine tablets was adjusted by a nonblind psychiatrist"" (p.70).","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Carpenter-1991","2013-05-23 17:14:05 +0100","YES","""Double-blind"", ""identical placebo tablets"" (p.69).","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Carpenter-1991","2013-05-23 17:14:08 +0100","YES","""Blind rater"" (p.69).","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Carpenter-1991","2013-05-23 17:14:10 +0100","YES","Same dropout rate in each group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Carpenter-1991","2013-05-23 17:14:13 +0100","YES","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Carpenter-1991","2013-05-23 17:14:15 +0100","YES","No other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Dose-1987","2013-05-23 17:14:27 +0100","UNKNOWN","""Randomized"", ""randomly assigned"" (p.304) - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Dose-1987","2013-05-23 17:11:12 +0100","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Dose-1987","2013-05-23 17:14:47 +0100","YES","""Double-blind"" - no further details (p.304).","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Dose-1987","2013-05-23 17:14:49 +0100","UNKNOWN","""Double-blind"" - no further details (p.304).","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Dose-1987","2013-05-23 17:14:50 +0100","YES","""Double-blind"" - no further details (p.304).","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Dose-1987","2013-05-23 17:14:50 +0100","UNKNOWN","""Double-blind"" - no further details (p.304).","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Dose-1987","2013-05-23 17:14:59 +0100","YES","""No patients dropped out because of side effects or adverse reactions"" (p.306).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Dose-1987","2013-05-23 17:15:06 +0100","NO","CGI results not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Dose-1987","2013-05-23 17:15:07 +0100","UNKNOWN","""Dosages of haloperidol, chlorprothixene and biperiden, as well as the occurrence of side effects, differed significantly (...) between the carbamazepine and placebo group"" (p.307-8).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-He_x00df_linger-1998","2013-05-23 17:15:24 +0100","UNKNOWN","""Randomly assigned"" (p.311).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-He_x00df_linger-1998","2013-05-23 17:15:26 +0100","YES","""Sealed envelopes"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-He_x00df_linger-1998","2013-05-23 17:15:30 +0100","YES","""Psychiatrist (...) was blind to medication and drug levels. However, he had access to the nursing charts"" (p.311). Patients were not aware of the treatment (information received by letter).","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-He_x00df_linger-1998","2013-05-23 17:15:34 +0100","UNKNOWN","""Psychiatrist (...) was blind to medication and drug levels. However, he had access to the nursing charts"" (p.311) Patients were not aware of the treatment (information received by letter).","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-He_x00df_linger-1998","2013-05-23 17:15:37 +0100","YES","""Psychiatrist (...) was blind to medication and drug levels. However, he had access to the nursing charts"" (p.311). Patients were not aware of the treatment (information received by letter).","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-He_x00df_linger-1998","2013-05-23 17:15:41 +0100","UNKNOWN","""Psychiatrist (...) was blind to medication and drug levels. However, he had access to the nursing charts"" (p.311). Patients were not aware of the treatment (information received by letter).","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-He_x00df_linger-1998","2013-05-23 17:15:51 +0100","YES","""25 out of 27 patients completed the study protocol"", 2 CBZ dropouts, ITT analysis (p.311).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-He_x00df_linger-1998","2013-05-23 17:15:49 +0100","YES","No selective outcome reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-He_x00df_linger-1998","2013-05-23 17:15:57 +0100","YES","No other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Llorca-1993","2013-05-23 17:16:17 +0100","YES","""Randomized succession using a latin square procedure"" (p.565).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Llorca-1993","2013-05-23 17:11:13 +0100","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Llorca-1993","2013-05-23 17:16:25 +0100","YES","""Tout au long de l'étude, les patients sont à l'insu du traitement recu. Durant les 4 phase de l'expérimentation, patients et investigateurs sont à l'insu de la médication adjuvante recue"". ""Afin de maintenir les conditions de double aveugle, les résultats des dosages pratiqués sont collectés au fur et à mesure de l'étude par un médecin différent du cotateur (M.A.W.)"". ""capsules identiques"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Llorca-1993","2013-05-23 17:16:29 +0100","YES","""Tout au long de l'étude, les patients sont à l'insu du traitement recu. Durant les 4 phase de l'expérimentation, patients et investigateurs sont à l'insu de la médication adjuvante recue"". ""Afin de maintenir les conditions de double aveugle, les résultats des dosages pratiqués sont collectés au fur et à mesure de l'étude par un médecin différent du cotateur (M.A.W.)"" ""capsules identiques"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Llorca-1993","2013-05-23 17:16:32 +0100","YES","""Tout au long de l'étude, les patients sont à l'insu du traitement recu. Durant les 4 phase de l'expérimentation, patients et investigateurs sont à l'insu de la médication adjuvante recue"". ""Afin de maintenir les conditions de double aveugle, les résultats des dosages pratiqués sont collectés au fur et à mesure de l'étude par un médecin différent du cotateur (M.A.W.)"". ""capsules identiques"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Llorca-1993","2013-05-23 17:16:35 +0100","YES","""Tout au long de l'étude, les patients sont à l'insu du traitement recu. Durant les 4 phase de l'expérimentation, patients et investigateurs sont à l'insu de la médication adjuvante recue"". ""Afin de maintenir les conditions de double aveugle, les résultats des dosages pratiqués sont collectés au fur et à mesure de l'étude par un médecin différent du cotateur (M.A.W.)"". ""capsules identiques"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Llorca-1993","2013-05-23 17:16:38 +0100","YES","No participant left the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Llorca-1993","2013-05-23 17:16:41 +0100","NO","No SDs reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Llorca-1993","2013-05-23 17:16:43 +0100","YES","No clear evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Mair-1990","2013-05-23 17:16:50 +0100","YES","""random number list"" (p.79).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Mair-1990","2013-05-23 17:11:13 +0100","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Mair-1990","2013-05-23 17:16:59 +0100","YES","Blinding not described (an open study) (p.79).","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Mair-1990","2013-05-23 17:17:05 +0100","UNKNOWN","Blinding not described (an open study) (p.79).","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Mair-1990","2013-05-23 17:17:09 +0100","YES","Blinding not described (an open study) (p.79).","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Mair-1990","2013-05-23 17:17:11 +0100","UNKNOWN","Blinding not described (an open study) (p.79).","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Mair-1990","2013-05-23 17:17:15 +0100","UNKNOWN","It was not mentioned whether there were dropouts or not.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Mair-1990","2013-05-23 17:17:17 +0100","NO","No SDs reported for CGI and BPRS, no data reported for FSUCL and Webster Scale.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Mair-1990","2013-05-23 17:17:20 +0100","YES","No other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Martin_x002d_Munoz-1989","2013-05-23 17:17:32 +0100","YES","""Allocated (...) randomly using a coin toss method"" (letter).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Martin_x002d_Munoz-1989","2013-05-23 17:12:06 +0100","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Martin_x002d_Munoz-1989","2013-05-23 17:17:43 +0100","YES","""Doble ciego"", no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Martin_x002d_Munoz-1989","2013-05-23 17:17:47 +0100","UNKNOWN","""Doble ciego"", no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Martin_x002d_Munoz-1989","2013-05-23 17:17:50 +0100","YES","""Doble ciego"", no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Martin_x002d_Munoz-1989","2013-05-23 17:17:53 +0100","UNKNOWN","""Doble ciego"", no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Martin_x002d_Munoz-1989","2013-05-23 17:17:56 +0100","YES","No dropouts (according to the letter).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Martin_x002d_Munoz-1989","2013-05-23 17:17:59 +0100","NO","No SD's in BPRS, UKU-scale results not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Martin_x002d_Munoz-1989","2013-05-23 17:18:02 +0100","YES","No clear evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Nachshoni-1994","2013-05-23 17:18:27 +0100","UNKNOWN","""Random allocation list"" (p.24).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Nachshoni-1994","2013-05-23 17:18:17 +0100","YES","""Dr. Joseph Levin was the control psychiatrist who knew what the patients were receiving, according to a random allocation list"" (letter from the authors). It appears that other members of the team were blind to allocation.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Nachshoni-1994","2013-05-23 17:18:32 +0100","YES","""Double-blind design"" (p.24), patients and personal were blind, tablets were identical (letter).","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Nachshoni-1994","2013-05-23 17:18:39 +0100","YES","""Double-blind design"" (p.24), patients and personal were blind, tablets were identical (letter).","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Nachshoni-1994","2013-05-23 17:18:42 +0100","YES","""Double-blind design"" (p.24), patients and personal were blind, tablets were identical (letter).","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Nachshoni-1994","2013-05-23 17:18:20 +0100","YES","""Ratings were done by psychiatrist, who was blind to whether the patients were receiving placebo or carbamazepine"" (p.23).","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Nachshoni-1994","2013-05-23 17:18:46 +0100","YES","""Two patients were withdrawn, one from each group"" (p.24).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Nachshoni-1994","2013-05-23 17:18:49 +0100","YES","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Nachshoni-1994","2013-05-23 17:18:52 +0100","YES","No other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Neppe-1983","2013-05-23 17:19:10 +0100","YES","""Randomized"" (p.326), ""random number list"" (letter).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Neppe-1983","2013-05-23 17:12:07 +0100","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Neppe-1983","2013-05-23 17:19:14 +0100","YES","""Double blind"" (p.326).","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Neppe-1983","2013-05-23 17:19:19 +0100","UNKNOWN","""Double blind"" (p.326).","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Neppe-1983","2013-05-23 17:19:21 +0100","YES","""Double blind"" (p.326).","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Neppe-1983","2013-05-23 17:19:24 +0100","UNKNOWN","""Double blind"" (p.326).","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Neppe-1983","2013-05-23 17:19:05 +0100","UNKNOWN","""Two out of six patients in the control group compared to zero out of three in the intervention group dropped out [out of 13]"" (p.327).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Neppe-1983","2013-05-23 17:19:30 +0100","NO","No SDs for BPRS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Neppe-1983","2013-05-23 17:19:33 +0100","YES","No other bias (""one [subject had] a history of contaminating cannabis use"", p.327).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Simhandl-1996","2013-05-23 18:16:56 +0100","UNKNOWN","""Random"", no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Simhandl-1996","2013-05-23 17:19:41 +0100","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Simhandl-1996","2013-05-23 17:19:52 +0100","YES","""Double-blind"", no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Simhandl-1996","2013-05-23 17:19:56 +0100","UNKNOWN","""Double-blind"", no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Simhandl-1996","2013-05-23 17:19:59 +0100","YES","""Double-blind"", no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Simhandl-1996","2013-05-23 17:20:02 +0100","UNKNOWN","""Double-blind"", no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Simhandl-1996","2013-05-23 17:19:45 +0100","YES","Two patients in each group dropped out, both because of non-compliance.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Simhandl-1996","2013-05-23 17:20:05 +0100","UNKNOWN","The study is only available as an abstract.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Simhandl-1996","2013-05-23 17:20:08 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Svestka-1989","2013-05-23 18:16:49 +0100","UNKNOWN","""Randomised"" - no further details (""intraindividual comparison"", p.276).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Svestka-1989","2013-05-23 17:12:26 +0100","UNKNOWN","No information available.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Svestka-1989","2013-05-23 17:12:27 +0100","UNKNOWN","No information available.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Svestka-1989","2013-05-23 17:12:28 +0100","UNKNOWN","No information available.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Svestka-1989","2013-05-23 17:12:28 +0100","UNKNOWN","No information available.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","Objective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Svestka-1989","2013-05-23 17:12:29 +0100","UNKNOWN","No information available.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.02","Subjective outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Svestka-1989","2013-05-23 17:20:24 +0100","YES","Two out of 20 participants in the intervention group dropped out compared to zero out of 18 in the control group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Svestka-1989","2013-05-23 17:20:27 +0100","NO","No SDs and global scores reported for BPRS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Carbamazepine for schizophrenia [v10.0-For publication].rm5","STD-Svestka-1989","2013-05-23 17:20:29 +0100","YES","No other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Akerele-2007","2014-07-29 18:19:10 +0100","YES","""Not stratified, 50:50 uniform distribution of groups of 4"" - unclear exactly how randomised.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Akerele-2007","2012-01-19 15:35:16 +0000","UNKNOWN","Not mentioned.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Akerele-2007","2012-01-19 15:36:49 +0000","UNKNOWN","Risperidone and olanzapine in gelatin capsules containing riboflavin - unclear if successful - not tested.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Akerele-2007","2012-01-19 15:36:58 +0000","UNKNOWN","Unclear if successful - not tested.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Akerele-2007","2012-01-19 15:37:03 +0000","UNKNOWN","Unclear if successful - not tested.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Akerele-2007","2014-10-01 10:25:38 +0100","UNKNOWN","No indication in report how managed losses to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Akerele-2007","2012-01-19 15:53:39 +0000","NO","Some outcomes reported by group, others not. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Akerele-2007","2012-01-19 15:54:27 +0000","UNKNOWN","Funded by company with pecuniary interest in result (Eli Lilly - producers of olanzapine).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Bonsack-2011","2014-10-01 10:25:38 +0100","YES","Computer-generated allocation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Bonsack-2011","2014-07-29 18:24:59 +0100","YES","Closed envelopes, kept by member of administrative staff.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Bonsack-2011","2014-07-29 18:25:00 +0100","YES","Assessments by independent parties, participants blind.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Bonsack-2011","2014-07-29 18:25:01 +0100","YES","Assessments by independent parties, participants blind.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Bonsack-2011","2014-07-29 18:25:02 +0100","YES","Assessments by independent parties, participants blind.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Bonsack-2011","2014-07-29 18:25:04 +0100","YES","Missing data were handled using last observation carried forward.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Bonsack-2011","2014-07-29 18:25:04 +0100","UNKNOWN","Not specified.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Bonsack-2011","2014-07-29 18:25:05 +0100","UNKNOWN","Not specified.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Brunette-2011","2014-07-29 18:25:37 +0100","UNKNOWN","Block randomisation by site, yet method unclear.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Brunette-2011","2014-07-29 18:25:38 +0100","UNKNOWN","Not specified.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Brunette-2011","2014-10-01 10:25:39 +0100","NO","Clinicians and participants not blinded.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Brunette-2011","2014-10-01 10:25:39 +0100","NO","Clinicians and participants not blinded.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Brunette-2011","2014-07-29 18:25:41 +0100","YES","Raters making assessments were blinded.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Brunette-2011","2014-07-29 18:25:41 +0100","UNKNOWN","Not specified.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Brunette-2011","2014-07-29 18:25:42 +0100","UNKNOWN","Not specified.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Brunette-2011","2014-07-29 18:25:43 +0100","YES","None of the authors report any financial relationships with commercial interest with regard to the present study.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Edwards-2006","2014-09-23 16:41:11 +0100","YES","Quote: 'Randomization codes were computer generated and placed in sealed envelopes, managed by a nonclinical","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Edwards-2006","2014-07-29 18:26:54 +0100","YES","Quote: 'Attempts to maintain rater blindness included use of separate rooms and administrative procedures for project staff, limiting information recorded in clinical notes, and requesting participants and clinicians not to disclose treatment conditions to raters.'","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Edwards-2006","2014-07-29 18:26:55 +0100","YES","Quote: 'A single-blind randomised controlled trial.'","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Edwards-2006","2014-07-29 18:26:58 +0100","YES","Quote: 'A single-blind randomised controlled trial.'","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Edwards-2006","2014-07-29 18:27:01 +0100","YES","Quote: 'Two-way random effects intra-class correlation coefficients (ICC) with absolute agreement' were derived at levels 'suggesting excellent reliability.'","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Edwards-2006","2014-07-29 18:27:03 +0100","YES","Quote: 'Follow-up rates were similar across intervention conditions.'","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Edwards-2006","2014-07-29 18:27:05 +0100","UNKNOWN","Not specified.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Edwards-2006","2014-07-29 18:27:05 +0100","UNKNOWN","Not specified.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Hjorthoj-2013","2014-07-29 18:28:15 +0100","YES","Computerised central randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Hjorthoj-2013","2014-07-29 18:30:07 +0100","YES","Outcome assessor was kept blind to allocation.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Hjorthoj-2013","2014-10-01 10:25:39 +0100","NO","Fourteen patients or managers accidentally broke the blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Hjorthoj-2013","2014-07-29 18:30:11 +0100","UNKNOWN","Not specified.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Hjorthoj-2013","2014-07-29 18:30:12 +0100","UNKNOWN","Not specified.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Hjorthoj-2013","2014-07-29 18:30:13 +0100","UNKNOWN","Not specified.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Hjorthoj-2013","2014-07-29 18:30:14 +0100","UNKNOWN","Not specified.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Hjorthoj-2013","2014-07-29 18:30:15 +0100","UNKNOWN","Not specified.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Leweke-2012","2014-07-29 18:35:20 +0100","YES","Prepared by person uninvolved in study.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Leweke-2012","2014-07-29 18:35:22 +0100","YES","Prepared by person uninvolved in study.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Leweke-2012","2014-07-29 18:35:23 +0100","YES","Prepared by person uninvolved in study.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Leweke-2012","2014-07-29 18:35:24 +0100","YES","Prepared by person uninvolved in study.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Leweke-2012","2014-07-29 18:35:24 +0100","YES","Prepared by person uninvolved in study.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Leweke-2012","2014-07-29 18:35:26 +0100","YES","Last observation carried forward.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Leweke-2012","2014-07-29 18:35:27 +0100","UNKNOWN","Not specified.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Leweke-2012","2014-07-29 18:35:27 +0100","UNKNOWN","Not specified.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Madigan-2012","2014-10-01 10:25:39 +0100","YES","ComputeriSed randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Madigan-2012","2014-07-29 18:36:26 +0100","YES","Single blind (uninvolved researcher responsible for randomisation).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Madigan-2012","2014-07-29 18:36:27 +0100","YES","Single blind (uninvolved researcher responsible for randomisation).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Madigan-2012","2014-07-29 18:36:28 +0100","YES","Single blind (uninvolved researcher responsible for randomisation); rater remained blind until final assessment.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Madigan-2012","2014-07-29 18:36:29 +0100","YES","Single blind (uninvolved researcher responsible for randomisation); rater remained blind until final assessment.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Madigan-2012","2014-10-01 10:25:39 +0100","UNKNOWN","Data were analysed on an intention-to-treat basis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Madigan-2012","2014-07-29 18:36:31 +0100","UNKNOWN","No indication.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-Madigan-2012","2014-07-29 18:36:31 +0100","UNKNOWN","No indication.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-van-Nimwegen-2008","2014-07-08 07:57:16 +0100","UNKNOWN","Not specified.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-van-Nimwegen-2008","2014-07-08 07:57:22 +0100","YES","Double blind.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-van-Nimwegen-2008","2014-07-08 07:57:26 +0100","YES","Double blind.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-van-Nimwegen-2008","2014-07-08 07:57:29 +0100","YES","Double blind.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-van-Nimwegen-2008","2014-07-08 07:57:32 +0100","UNKNOWN","Not specified.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-van-Nimwegen-2008","2014-07-08 07:57:34 +0100","UNKNOWN","Not specified.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-van-Nimwegen-2008","2014-07-08 07:57:37 +0100","UNKNOWN","Not specified.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/C-F/Cannabis and schizophrenia [v5.0-For publication].rm5","STD-van-Nimwegen-2008","2013-08-13 11:46:23 +0100","YES","Eli-Lilly funded the trial, yet were not involved in the design of the study, analyses, or interpretation of results.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Ananth-1987","2010-11-25 10:25:17 +0000","UNKNOWN","""Pre coded"" randomisation, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Ananth-1987","2010-08-06 09:48:17 +0100","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Ananth-1987","2010-11-25 10:20:58 +0000","UNKNOWN","""Double"" - no further details.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Ananth-1987","2010-08-06 09:48:17 +0100","UNKNOWN","No information about compliance.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Ananth-1987","2010-08-06 16:30:10 +0100","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Ananth-1987","2010-08-06 19:32:55 +0100","UNKNOWN","Very small sample size; crossover design.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Burner-1989","2010-11-25 10:22:03 +0000","UNKNOWN","""Random allocation"", allocated in a placebo 3: progabide 10 ratio.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Burner-1989","2010-08-06 09:48:45 +0100","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Burner-1989","2010-11-25 10:20:58 +0000","UNKNOWN","""Double"" - no further details.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Burner-1989","2010-11-25 10:24:36 +0000","UNKNOWN","One person left progabide group early (day 19) - confusional state & depressive symptoms. No details were provided about this patient. Person with manic-depressive illness (1) not possible to separate from final analysis.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Burner-1989","2010-08-06 16:30:15 +0100","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Burner-1989","2010-08-06 19:32:16 +0100","UNKNOWN","Very small sample size.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Fisk-1987","2010-11-25 10:23:28 +0000","YES","Randomised, stratified by age, sex, hospital, inpatient or community-based status, and high or low pretrial TD, using computer program (different weights).","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Fisk-1987","2010-11-25 10:23:34 +0000","YES","Co-ordinated by hospital pharmacists.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Fisk-1987","2010-11-25 10:20:58 +0000","UNKNOWN","""Double"" - no further details.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Fisk-1987","2011-03-01 12:19:35 +0000","UNKNOWN","Not possible to separate people with manic-depressive psychosis or recurrent depression from the analysis. 15 people left early (11 on sodium valproate group and 4 on placebo); reasons - protocol violation, poor compliance, ill-health, pneumonia, unstable medication. No details were provided about these patients.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Fisk-1987","2010-08-06 16:30:20 +0100","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Fisk-1987","2010-08-06 16:40:08 +0100","UNKNOWN","Small sample size.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Gerlach-1978","2010-11-25 10:22:03 +0000","UNKNOWN","""Random allocation"", no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Gerlach-1978","2010-08-06 09:49:49 +0100","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Gerlach-1978","2010-11-25 10:20:58 +0000","UNKNOWN","""Double"" - no further details.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Gerlach-1978","2010-11-25 10:23:07 +0000","UNKNOWN","Two people left study early (refusal to continue medication); unclear about the treatment status of these people.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Gerlach-1978","2010-08-06 16:30:25 +0100","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Gerlach-1978","2010-08-06 19:32:22 +0100","UNKNOWN","Very small sample size; crossover design.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Linnoila-1976","2010-11-25 10:22:36 +0000","UNKNOWN","""Random allocation"", using 2 X 2 Latin square.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Linnoila-1976","2010-08-06 09:50:07 +0100","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Linnoila-1976","2010-11-25 10:20:58 +0000","UNKNOWN","""Double"" - no further details.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Linnoila-1976","2010-11-25 10:22:44 +0000","UNKNOWN","One person left early (valproate).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Linnoila-1976","2010-08-06 16:30:29 +0100","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Linnoila-1976","2010-08-06 19:32:28 +0100","UNKNOWN","Small sample size; crossover design.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Nair-1978","2010-11-25 10:22:03 +0000","UNKNOWN","""Random allocation"", no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Nair-1978","2010-08-06 09:50:20 +0100","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Nair-1978","2010-11-25 10:20:58 +0000","UNKNOWN","""Double"" - no further details.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Nair-1978","2010-08-06 09:50:20 +0100","UNKNOWN","Data about improvement and compliance not possible to extract.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Nair-1978","2010-08-06 16:30:34 +0100","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Nair-1978","2010-08-06 19:32:34 +0100","UNKNOWN","Very small sample size; crossover design.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Stewart-1982","2010-11-25 10:21:18 +0000","UNKNOWN","""Random allocation"", sequential assignment determined by prepackaged medication bottles.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Stewart-1982","2010-08-06 09:50:58 +0100","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Stewart-1982","2010-11-25 10:20:58 +0000","UNKNOWN","""Double"" - no further details.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Stewart-1982","2010-08-06 09:50:58 +0100","UNKNOWN","3 (1 baclofen) people left study early due to poor compliance, protocol violation, adverse reactions. No further details were given about these patients.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Stewart-1982","2010-08-06 16:30:40 +0100","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Stewart-1982","2010-08-06 16:41:03 +0100","UNKNOWN","Small sample size.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Thaker-1987","2010-11-25 10:20:05 +0000","UNKNOWN","""Random allocation"", no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Thaker-1987","2010-08-06 09:51:25 +0100","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Thaker-1987","2010-11-25 10:20:17 +0000","UNKNOWN","""Double"" - no further details.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Thaker-1987","2010-08-06 09:51:32 +0100","YES","No person left study early.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Thaker-1987","2010-08-06 16:30:46 +0100","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia [v13.0-For publication].rm5","STD-Thaker-1987","2010-08-06 19:32:41 +0100","UNKNOWN","Very small sample size; crossover design.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Lerner-2001","2015-02-20 12:05:44 +0000","UNKNOWN","Randomised, no further details were provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Lerner-2001","2013-04-20 06:04:53 +0100","UNKNOWN","Not described by authors.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Lerner-2001","2013-12-26 22:08:55 +0000","UNKNOWN","""The study design was double blind, with crossover and placebo control."" No further details were provided.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Lerner-2001","2013-12-26 22:08:43 +0000","UNKNOWN","""The raters were kept blind to the results"". The specific method by which blinding was achieved was not described.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Lerner-2001","2015-03-18 14:43:59 +0000","YES","No attrition among participants was reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Lerner-2001","2013-12-27 00:37:06 +0000","NO","Not all outcomes were accounted for e.g. the specific number of participants who showed none, minimal, moderate or marked improvement in their tardive dyskinesia symptoms from both arms of the study were not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Lerner-2001","2013-12-26 22:23:48 +0000","UNKNOWN","The authors did not give details as to what extent raters in the study were independent. It was not mentioned if any funding was received for the study. The specific diagnostic criteria used for inclusion of participants in the study was not mentioned.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Lerner-2007","2015-02-20 12:05:31 +0000","UNKNOWN","Randomised, no further descriptions.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Lerner-2007","2013-04-20 05:52:54 +0100","UNKNOWN","Specific method of allocation concealment not described. "" After breaking the code following database lock......""","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Lerner-2007","2013-12-26 22:15:01 +0000","UNKNOWN","Double blind, no further details was provided.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Lerner-2007","2013-12-27 00:55:35 +0000","UNKNOWN","""The plasma levels of Vitamin B6 were not reported to the raters, in order to keep them 'blind' to the patients' drug assignment."" The specific method by which blinding was achieved was not described. The extent to which the raters were independent was not mentioned by the authors.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Lerner-2007","2015-02-20 12:06:02 +0000","YES","All participants randomised at the beginning of the study were accounted for.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Lerner-2007","2013-12-26 22:34:55 +0000","YES","There is no evidence of selective reporting in the study.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Lerner-2007","2013-12-26 22:15:42 +0000","YES","Funded by Stanley Medical Research Institute.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Miodownik-2003","2014-01-28 09:39:15 +0000","UNKNOWN","Randomised, no further description.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Miodownik-2003","2014-01-28 09:39:53 +0000","UNKNOWN","No specific method of allocation was described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Miodownik-2003","2014-01-28 09:41:33 +0000","UNKNOWN","Double blind, no further details were provided.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Miodownik-2003","2014-01-28 09:44:18 +0000","UNKNOWN","""patients and investigators were blinded to the results of pyridoxal phosphate assessment"". The specific method by which this was achieved was not stated. The level to which raters were independent is unknown.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Miodownik-2003","2015-02-20 12:06:06 +0000","YES","All randomised participants were accounted for at the end of the trial.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Miodownik-2003","2014-01-28 09:45:39 +0000","YES","No evidence of selective reporting was found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia [v2.0-For publication].rm5","STD-Miodownik-2003","2014-01-28 09:47:52 +0000","UNKNOWN","The authors did not state if there was any source of funding. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Baker-2002","2013-09-25 12:32:15 +0100","UNKNOWN","Randomised. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Baker-2002","2013-08-22 14:27:37 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Baker-2002","2013-05-01 02:23:49 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Baker-2002","2013-06-07 04:00:16 +0100","YES","Authors state: Interviewers formally blind to patient group allocation.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Baker-2002","2013-06-05 07:44:35 +0100","NO","Full ITT analysis with imputed data for all missing values not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Baker-2002","2013-05-30 04:45:12 +0100","UNKNOWN","All outcomes of interest fully reported for each intervention. No protocol available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Baker-2002","2013-09-25 12:32:15 +0100","YES","No details. No evidence of other bias are occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Baker-2006","2013-06-04 04:05:23 +0100","UNKNOWN","Participants drew a card from an envelope but no details provided regarding the generation of the random sequence or whether cards were shuffled beforehand.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Baker-2006","2013-05-10 05:54:12 +0100","UNKNOWN","Patients drew a card from an envelope. No further details provided so it is unclear if envelope was opaque and sealed. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Baker-2006","2013-05-01 02:24:10 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Baker-2006","2013-05-31 02:19:15 +0100","YES","Raters blind so detection bias rated as low.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Baker-2006","2013-09-25 12:32:15 +0100","UNKNOWN","Number and reason for missing data clearly reported in flow sheet. Missing outcome data balanced across groups. Full ITT analysis with imputed data for all missing values not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Baker-2006","2013-05-30 04:47:35 +0100","UNKNOWN","In the report, the results are fully reported. There is no protocol.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Baker-2006","2013-04-02 04:10:45 +0100","YES","Funded by public institution. No evidence other biases are occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Barrowclough-2001","2013-05-10 05:35:04 +0100","YES","Computer-generated list stratified for sex and three types of substance use.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Barrowclough-2001","2013-04-02 04:14:35 +0100","YES","Allocated by third party.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Barrowclough-2001","2013-09-25 12:32:16 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Barrowclough-2001","2013-05-31 02:18:55 +0100","YES","Raters independent and blind so detection bias rated as low.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Barrowclough-2001","2013-05-24 04:30:56 +0100","UNKNOWN","Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Barrowclough-2001","2013-05-13 05:32:45 +0100","YES","No selective reporting evident between study protocol (N0244032344) and published article.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Barrowclough-2001","2013-09-25 12:32:16 +0100","YES","Funded by public institution (local health authorities). No evidence other bias occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Barrowclough-2010","2013-09-25 12:32:16 +0100","YES","Computer-generated, algorithm taking into account substance type (alcohol alone, drugs alone, or alcohol and drugs) and NHS trust.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Barrowclough-2010","2013-04-04 02:34:30 +0100","YES","Researcher not involved in the study generated sequence. Remote independent service. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Barrowclough-2010","2013-05-30 13:02:28 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. ","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Barrowclough-2010","2013-05-30 13:05:04 +0100","YES","For the primary outcome of hospital admission data were obtained from participant psychiatric case notes and is unlikely to be affected by blinding. For other outcomes involving self-report, precautions were taken to maintain the blindness. Throughout the trial, 135 breaks in the blindness of an assessor were reported in total. However, only one assessment was completed unblinded; in all other cases a new “blind” assessor was allocated.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Barrowclough-2010","2013-05-24 04:29:30 +0100","UNKNOWN","Flow sheet provided describing reasons for incomplete data and deaths. Evenly balanced between treatment groups. No missing values for primary outcome measure (re-hospitalisation/or death).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Barrowclough-2010","2013-05-24 03:34:56 +0100","YES","All outcomes of interest fully reported and these match the trial protocol.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Barrowclough-2010","2013-04-02 04:02:55 +0100","YES","Authors independent of funding, No input from funding sources on protocol.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bechdolf-2011","2013-04-02 04:40:59 +0100","UNKNOWN","Stratified for gender and SUD, single and multiple. Sequence generation not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bechdolf-2011","2013-04-05 02:36:09 +0100","UNKNOWN","Researcher not involved in the study generated sequence. Insufficient information to permit judgement.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bechdolf-2011","2013-09-25 12:32:18 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bechdolf-2011","2013-05-31 02:18:44 +0100","YES","Raters blinded so detection bias was rated as low.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bechdolf-2011","2013-05-24 04:30:12 +0100","UNKNOWN","Missing data have been imputed using appropriate methods (LOCF).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bechdolf-2011","2013-05-30 04:49:08 +0100","UNKNOWN","Rating of mental state not fully reported (numerical data not provided for PANSS, GAF) both secondary outcomes reported as not significantly different between groups over time.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bechdolf-2011","2013-05-22 05:02:29 +0100","YES","None according to authors.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bellack-2006","2013-05-31 09:39:28 +0100","YES","Randomised using an adaptive urn procedure adjusted for sex, psychiatric diagnosis, drug of choice and number of substance use disorders. Separate randomisation was conducted for participants from community clinics and VA centre. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bellack-2006","2013-04-03 02:45:52 +0100","UNKNOWN","No details provided","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bellack-2006","2013-09-25 12:32:18 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bellack-2006","2013-05-31 02:18:32 +0100","YES","Primary outcome was urinalysis results so the review authors judge that this outcome is not likely to be influenced by a lack of blinding. Moreover, raters were blind to treatment assignment.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bellack-2006","2013-05-29 04:47:07 +0100","NO","46 patients failed to initiate treatment and 19 failed to become engaged (analysis was based on subset of 110 patients who were engaged in treatment) so ITT analysis was not completed. Missing data were not balanced across interventions. Missing outcomes are enough to induce clinically relevant bias in observed effect size.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bellack-2006","2013-05-31 06:28:35 +0100","UNKNOWN","No protocol was available. Author states there was conflicting data on substance use between self-report, drug screens and clinical ratings (SCID) of dependence.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bellack-2006","2013-05-22 05:07:27 +0100","YES","Supported by NIDA grant. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bond-1991a","2013-09-25 12:32:19 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bond-1991a","2013-09-25 12:32:19 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bond-1991a","2013-09-25 12:32:19 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bond-1991a","2013-05-31 02:17:48 +0100","UNKNOWN","Unclear if raters were blind.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bond-1991a","2013-05-24 03:13:22 +0100","NO","Lost to follow-up: 57% (24/42 18 months and 50% (21/42) did not receive treatment as planned and no reasons given for missing or lost to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bond-1991a","2013-09-25 12:32:19 +0100","UNKNOWN","No protocol to compare outcomes reported. In the published auricles, means and SD were not reported, but were kindly provided by the author.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bond-1991a","2013-05-14 09:50:24 +0100","YES","No evidence other biases are occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bond-1991b","2013-09-25 12:32:19 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bond-1991b","2013-09-25 12:32:20 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bond-1991b","2013-09-25 12:32:21 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bond-1991b","2013-05-31 02:17:38 +0100","UNKNOWN","Not stated if raters were blind.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bond-1991b","2013-05-22 05:15:57 +0100","UNKNOWN","Lost to follow-up: 33% (14/42) 18 months. No ITT analysis and no reasons given for missing or lost to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bond-1991b","2013-09-25 12:32:22 +0100","UNKNOWN","No protocol to compare outcomes reported. In the published auricles, means and SD were not reported, but were kindly provided by the author.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bond-1991b","2013-09-25 12:32:22 +0100","UNKNOWN","No evidence other biases are occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bonsack-2011","2013-09-25 12:32:22 +0100","YES","Computer-generated, blocks of 8.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bonsack-2011","2013-05-10 05:55:39 +0100","UNKNOWN","Numbered sealed envelopes held by administration staff not involved with the research. Remains unclear whether envelopes were sequentially numbered, opaque and sealed.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bonsack-2011","2013-09-25 12:32:22 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bonsack-2011","2013-05-31 02:17:23 +0100","YES","Raters were blinded so detection risk rated as low.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bonsack-2011","2013-05-24 04:32:16 +0100","UNKNOWN","Lost to follow-up: 13% (8/62) 1 year. Used ITT and replaced missing values with LOCF. Missing values balanced across treatments.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bonsack-2011","2013-05-30 04:53:48 +0100","UNKNOWN","Reports fully all outcomes of interest (means, SD and n) mentioned in the Methods. No protocol.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Bonsack-2011","2013-09-25 12:32:22 +0100","YES","No evidence of other bias occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Burnam-1995","2013-04-03 03:02:46 +0100","UNKNOWN","Randomised, no further description. Assignment to non-residential group was set at twice that of the other groups requiring a larger sample size.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Burnam-1995","2013-09-25 12:32:24 +0100","UNKNOWN","Unclear, no details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Burnam-1995","2013-09-25 12:32:24 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Burnam-1995","2013-05-31 02:17:09 +0100","UNKNOWN","Unclear if raters were independent or blind.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Burnam-1995","2013-09-25 12:32:24 +0100","UNKNOWN","No reasons given for dropouts.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Burnam-1995","2013-09-25 12:32:24 +0100","UNKNOWN","No protocol to compare outcomes reported. In the published articles, means and SD were not reported, but were kindly provided by the author.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Burnam-1995","2013-09-25 12:32:24 +0100","YES","No evidence other biases are occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Chandler-2006","2013-09-25 12:32:24 +0100","YES","Randomised, computer-generated in blocks of two, then blocks of three.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Chandler-2006","2013-09-25 12:32:24 +0100","YES","Randomisation used an algorithm [template] supplied by the evaluator. A research assistant maintained the data which documented eligibility and randomisation, and it was reviewed weekly by the evaluator (Personal communication).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Chandler-2006","2013-05-01 02:25:55 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Chandler-2006","2013-05-31 06:29:20 +0100","UNKNOWN","Primary outcomes: clinician/participant mediated - rating - Unclear. Secondary outcomes: some clinician/participant mediated -rating - Unclear. Some outcomes were administrative which would have a low risk of bias.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Chandler-2006","2013-05-24 03:15:23 +0100","NO","Did not employ direct evaluation of substance use to assess the impact of the intervention. Unknown attrition rate among controls no interview was conducted leading to high risk of bias.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Chandler-2006","2013-04-03 03:08:36 +0100","UNKNOWN","Relied on administrative data to analyse results not taking into consideration moving out of area, recovered or death. Controls had less follow-up time post-release due to randomisation procedure.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Chandler-2006","2013-05-22 05:21:33 +0100","UNKNOWN","Study was funded by a State grant to evaluate service in Alameda county.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Drake-1998a","2013-09-25 12:32:26 +0100","UNKNOWN","Randomised. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Drake-1998a","2013-09-25 12:32:26 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Drake-1998a","2013-09-25 12:32:26 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Drake-1998a","2013-09-25 12:32:26 +0100","YES","Primary outcome: clinician/participant mediated rating - unclear. Secondary outcomes: some are clinician/participant mediated – rating – unclear. Interviewer blind so detection bias was rated as low.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Drake-1998a","2013-09-25 12:32:26 +0100","UNKNOWN","Number of lost to follow-up is reported, but reason for missing data are not reported for each group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Drake-1998a","2013-09-25 12:32:27 +0100","UNKNOWN","Pre-specified outcomes of interest are reported. No protocol to compare results.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Drake-1998a","2013-09-25 12:32:27 +0100","YES","No evidence other biases are occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Edwards-2006","2013-04-03 03:15:18 +0100","YES","Randomised codes were computer generated and placed in sealed envelopes.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Edwards-2006","2013-04-03 03:13:45 +0100","YES","Randomisation codes were managed by a non-clinical member of the research team.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Edwards-2006","2013-09-25 12:32:27 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Edwards-2006","2013-05-31 02:15:50 +0100","YES","Raters independent and blind to treatment condition.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Edwards-2006","2013-09-25 12:32:27 +0100","UNKNOWN","Missing data were handled using LOCF and analyses of cases with complete data were also undertaken. Due to positive skewness some variables were transformed (untransformed scores are displayed).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Edwards-2006","2013-09-25 12:32:27 +0100","UNKNOWN","Pre-specified outcomes of interest are reported. No protocol to make judgement on selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Edwards-2006","2013-09-25 12:32:27 +0100","YES","Funded by the Victorian Government Dept of Human Services. No information available. No evidence of other bias occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Essock-2006","2013-05-24 05:13:03 +0100","YES","Randomised using separate computer-generated randomisation stream for each site.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Essock-2006","2013-09-25 12:32:29 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Essock-2006","2013-09-25 12:32:29 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Essock-2006","2013-05-31 02:15:35 +0100","YES","Raters were blind to allocation.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Essock-2006","2013-05-22 05:25:29 +0100","UNKNOWN","Insufficient reporting of missing data (number and reason for missing data are reported for the total sample, not for each intervention group). Seven randomised subjects were lost for administrative reason, but their intervention allocation was not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Essock-2006","2013-05-30 04:56:20 +0100","UNKNOWN","Listed outcomes of interest are fully reported for each site, one site had better outcomes than the other. Author provided further data of combined sites for each treatment.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Essock-2006","2013-09-25 12:32:29 +0100","YES","Public funded. No further details. No evidence other biases are occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Godley-1994","2013-09-25 12:32:29 +0100","UNKNOWN","No description of the process.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Godley-1994","2013-09-25 12:32:29 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Godley-1994","2013-09-25 12:32:29 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Godley-1994","2013-05-31 02:15:17 +0100","UNKNOWN","Not stated if raters were blinded.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Godley-1994","2013-09-25 12:32:29 +0100","NO","Insufficient reporting of missing data (number and reason for missing data are reported not for each intervention group).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Godley-1994","2013-04-03 03:27:28 +0100","NO","Results are presented for each site, not combined for each treatment. Combined data from randomised and non-randomised sites. Unusable.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Godley-1994","2013-04-03 03:27:09 +0100","YES","No details.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Graeber-2003","2013-09-25 12:32:29 +0100","UNKNOWN","Randomised in a yoked fashion, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Graeber-2003","2013-09-25 12:32:30 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Graeber-2003","2013-09-25 12:32:30 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Graeber-2003","2013-05-31 02:08:49 +0100","NO","Raters not blind.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Graeber-2003","2013-05-24 04:37:02 +0100","YES","Lost to follow-up: 7% (2/30) 6 months. No missing data for primary outcome.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Graeber-2003","2013-09-25 12:32:31 +0100","UNKNOWN","Pilot study, no protocol to make judgement on selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Graeber-2003","2013-05-13 04:53:07 +0100","YES","No evidence other bias are occurring. With only two therapists, each nested within a single treatment does not allow treatment effects to be independent of therapists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hellerstein-1995","2013-09-25 12:32:32 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hellerstein-1995","2013-04-03 03:46:10 +0100","UNKNOWN","No details provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hellerstein-1995","2013-09-25 12:32:32 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hellerstein-1995","2013-05-31 02:22:49 +0100","UNKNOWN","Not stated if raters were blind to allocation.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hellerstein-1995","2013-09-25 12:32:32 +0100","NO","Reasons for dropping out of study or not starting (non-starters, n=18) not given.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hellerstein-1995","2013-09-25 12:32:32 +0100","UNKNOWN","Raw means were not reported for primary outcome, only change from baseline scores.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hellerstein-1995","2013-09-25 12:32:32 +0100","YES","No evidence other bias occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hickman-1997","2013-09-25 12:32:32 +0100","UNKNOWN","No details. Randomised from the group of people attending relevant treatment programs at the time the experiment was conducted.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hickman-1997","2013-05-14 09:48:38 +0100","NO","No details provided. ""Procedure selection was modified to allow for participant refusal and to minimise disruption to an existing treatment program.""","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hickman-1997","2013-09-25 12:32:33 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hickman-1997","2013-05-31 02:15:03 +0100","UNKNOWN","Not stated if raters were blind to allocation.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hickman-1997","2013-05-24 04:35:43 +0100","YES","Lost to follow-up: 0% (0/30) 3 months. No missing outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hickman-1997","2013-09-25 12:32:33 +0100","UNKNOWN","Phd thesis, study did not undergo peer review via publication. No protocol to make judgement on selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hickman-1997","2013-09-25 12:32:33 +0100","YES","No evidence other bias occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hjorthoj-2013","2013-09-25 12:32:33 +0100","YES","computer generated random sequence stratified by cannabis use per day and type of TAU (some had case management or ACT depending on referral source), block size varied between 6, 8 and 10.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hjorthoj-2013","2013-04-04 05:31:12 +0100","YES","Researcher not involved in the study generated the sequence, was known only to the Copenhagen Trial unit. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hjorthoj-2013","2013-05-01 02:29:39 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hjorthoj-2013","2013-05-31 02:14:49 +0100","YES","Raters blind to treatment assignment.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hjorthoj-2013","2013-05-24 04:13:56 +0100","YES","Lost to follow-up: 34% (35/103) 10 months. Detailed flow chart provided, reasons for missing values are provided for each group. Full ITT analysis provided with missing values handled by multiple imputations.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hjorthoj-2013","2013-04-04 05:32:22 +0100","YES","Outcomes fully reported and were not different to trial protocol.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Hjorthoj-2013","2013-09-25 12:32:36 +0100","YES","No evidence other bias occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Jerrell-1995a","2013-05-10 05:37:47 +0100","YES","Randomised (using the urn method) balanced for age, ethnicity, diagnosis, substance use severity and level of psychiatric functioning. Non-randomised sample was excluded from this analysis (data provided by author).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Jerrell-1995a","2013-09-25 12:49:18 +0100","UNKNOWN","Unclear.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Jerrell-1995a","2013-09-25 12:32:36 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Jerrell-1995a","2013-05-31 02:14:28 +0100","UNKNOWN","Unclear if raters were blind to allocation.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Jerrell-1995a","2013-06-06 02:10:01 +0100","NO","Lost to follow-up: 47% (22/47) 18 months. No ITT analysis with missing values imputed. No reasons given for lost to evaluation.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Jerrell-1995a","2013-05-24 04:39:58 +0100","UNKNOWN","Insufficient information to permit judgement of 'yes' or 'no' as no protocol was available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Jerrell-1995a","2013-09-25 12:32:36 +0100","YES","No evidence other bias occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Jerrell-1995b","2013-05-10 05:37:53 +0100","YES","Randomised (using the urn method) balanced for age, ethnicity, diagnosis, substance use severity and level of psychiatric functioning. Non-randomised sample was excluded from this analysis (data provided by author).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Jerrell-1995b","2013-09-25 12:32:37 +0100","UNKNOWN","Unclear.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Jerrell-1995b","2013-09-25 12:32:37 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Jerrell-1995b","2013-05-31 02:14:17 +0100","UNKNOWN","Unclear if raters were blind to allocation.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Jerrell-1995b","2013-06-06 02:10:25 +0100","NO","No ITT analysis with missing values imputed. No reasons given for lost to evaluation.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Jerrell-1995b","2013-05-24 04:39:41 +0100","UNKNOWN","Insufficient information to permit judgement of 'yes' or 'no' as no protocol was available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Jerrell-1995b","2013-09-25 12:32:37 +0100","YES","No evidence other bias occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Kavanagh-2004","2013-04-04 03:12:31 +0100","YES","Permutations table for each site.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Kavanagh-2004","2013-04-04 03:15:41 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Kavanagh-2004","2013-09-25 12:32:37 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Kavanagh-2004","2013-05-31 02:14:02 +0100","YES","Raters blinded.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Kavanagh-2004","2013-05-30 05:35:32 +0100","UNKNOWN","One SC subject had baseline data carried forward as missing data at 3, 6, and 12 month follow-ups.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Kavanagh-2004","2013-05-30 05:37:34 +0100","UNKNOWN","Pilot study, no protocol. Five SOS participants did not proceed beyond initial rapport building stage so two analyses were done; one with all SOS subjects (n=13) and another one including SOS treated (n=8)","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Kavanagh-2004","2013-09-25 12:32:37 +0100","YES","No evidence other bias occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Kemp-2007","2013-05-01 02:32:59 +0100","YES","Randomised, cards were shuffled, numbered and placed in sealed envelopes. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Kemp-2007","2013-05-10 05:56:44 +0100","UNKNOWN","Numbered sealed envelopes with the allocation placed into a box by a third person. Envelopes were then drawn in order from the box each time a patient was randomised. Unclear whether envelopes were opaque.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Kemp-2007","2013-05-31 02:10:38 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Kemp-2007","2013-09-25 12:32:38 +0100","NO","Measures that were clinician-rated were all performed by the clinician providing the treatment and were therefore not blind.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Kemp-2007","2013-05-24 04:40:27 +0100","UNKNOWN","Lost to follow-up: 16% (3/19) 6 months. Three patients dropped out of the TAU group, no explanation was given. No ITT analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Kemp-2007","2013-05-22 06:24:53 +0100","UNKNOWN","Insufficient information to permit judgement of 'yes' or 'no' as no protocol was available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Kemp-2007","2013-04-05 03:33:02 +0100","NO","Had extreme baseline imbalance in substance use (AUDIT), DASS and self-efficacy score. This could be due to low subject numbers recruited for study.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Lehman-1993","2013-06-07 04:02:28 +0100","YES","Randomised using the urn method. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Lehman-1993","2013-09-25 12:32:38 +0100","UNKNOWN","Unclear, no details provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Lehman-1993","2013-09-25 12:32:38 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Lehman-1993","2013-05-31 02:24:14 +0100","UNKNOWN","Blindness not stated.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Lehman-1993","2013-06-07 04:02:51 +0100","YES","Lost to follow-up: 0% (0/29) 1 year. No missing outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Lehman-1993","2013-05-24 04:38:53 +0100","UNKNOWN","Insufficient information to permit judgement of 'yes' or 'no' as no protocol was available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Lehman-1993","2013-09-25 12:32:39 +0100","YES","No evidence other bias occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Madigan-2013","2013-04-19 03:23:28 +0100","YES","Computer generated, block randomised, 2:1 (CBT/MI:TAU) ratio.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Madigan-2013","2013-04-19 03:24:11 +0100","UNKNOWN","Randomisation was conducted by a researcher uninvolved in the provision or assessment of interventions. Concealment not described in sufficient detail to allow a definite judgement.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Madigan-2013","2013-09-25 12:32:39 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Madigan-2013","2013-05-31 02:11:16 +0100","YES","Raters of clinical outcomes blind to treatment allocation.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Madigan-2013","2013-05-24 03:19:29 +0100","UNKNOWN","Similar reasons for missing data across groups. Missing values were not imputed for ITT analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Madigan-2013","2013-05-24 04:39:07 +0100","UNKNOWN","Insufficient information to permit judgement of 'yes' or 'no' as no protocol was available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Madigan-2013","2013-09-25 12:32:39 +0100","YES","No evidence other bias occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Maloney-2006","2013-09-25 12:32:39 +0100","UNKNOWN","Randomised, computer-generated procedure with no matching procedures. Participants were randomly assigned to one of four groups. Group sizes were not equivalent due to early jail releases, which necessitated the discontinuation of new participants being randomly assigned to the treatment groups after May 2003.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Maloney-2006","2013-09-25 12:32:39 +0100","NO","Randomisation and participants’ assignment to treatment groups were implemented by the treatment team’s researchers.  ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Maloney-2006","2013-09-25 12:32:39 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Maloney-2006","2013-05-31 02:24:50 +0100","NO","Raters were not blind so detection risk of bias was considered high for these outcomes.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Maloney-2006","2013-06-09 14:56:15 +0100","NO","Lost to follow-up: 14% (19/135) 30 months. No ITT analysis. Due to early jail releases there was unequal discontinuation of new participants randomly assigned to the treatment groups after May 2003. These participants were not included in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Maloney-2006","2013-05-28 06:50:09 +0100","NO","No usable data, many of the outcomes reported for site, not by treatment arm.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Maloney-2006","2013-09-25 12:32:39 +0100","YES","No evidence other bias occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-McDonell-2013","2013-06-03 07:23:00 +0100","YES","Randomised using an urn randomised procedure balancing groups on gender, substance use severity, mood vs psychotic disorder and psychiatric hospitalisation in the past year. Further correspondence verified a computer programme was used for randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-McDonell-2013","2013-04-05 05:09:19 +0100","UNKNOWN","Researcher not involved in the study generated the sequence. No further details on concealment prior to allocation.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-McDonell-2013","2013-09-25 12:32:40 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-McDonell-2013","2013-05-31 02:11:52 +0100","YES","Primary outcome was urinalysis results so the review authors judge that this outcome is not likely to be influenced by blinding. Raters were blind to treatment allocation.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-McDonell-2013","2013-05-24 04:22:37 +0100","UNKNOWN","Only 42% (n=38) completed 12 weeks of CM and 65% (n=55) completed TAU. Imputed values were used for missing data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-McDonell-2013","2013-04-19 03:27:43 +0100","YES","The study protocol (NCT00809770) is available and all of the study's specified (primary and secondary) outcomes that are of interest in the review have been reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-McDonell-2013","2013-04-05 05:20:21 +0100","UNKNOWN","Five patients were forced into CM and two were administratively removed with unknown consequences. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Morse-2006","2013-09-25 12:32:41 +0100","UNKNOWN","Randomised (no further description).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Morse-2006","2013-04-04 03:36:24 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Morse-2006","2013-09-25 12:32:41 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Morse-2006","2013-05-31 02:12:06 +0100","UNKNOWN","Not clear if raters were independent or blind.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Morse-2006","2013-05-24 03:24:04 +0100","UNKNOWN","Lost to follow-up: 24% (47/196) 2 years. Full ITT analysis not reported. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Morse-2006","2013-05-31 06:30:08 +0100","NO","Lost to treatment and evaluation not reported by group. No usable data, only skewed data are reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Morse-2006","2013-09-25 12:32:41 +0100","YES","No evidence other bias occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Naeem-2005","2013-09-25 12:32:41 +0100","YES","Randomised; random numbers computer-generated/sealed envelopes stratified by site. Ratio of 2:1 for CBT:TAU.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Naeem-2005","2013-05-10 05:57:27 +0100","UNKNOWN","Sealed envelopes opened at the time of treatment allocation. Unclear if envelopes were sequentially numbered and opaque.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Naeem-2005","2013-09-25 12:32:41 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Naeem-2005","2013-05-31 02:12:22 +0100","YES","Raters blind to treatment allocation.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Naeem-2005","2013-09-25 12:32:42 +0100","UNKNOWN","No reasons are given for withdrawals; 10 subjects dropped out of treatment versus 5 patients from TAU. Missing values were imputed for full ITT analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Naeem-2005","2013-05-24 04:47:29 +0100","UNKNOWN","Insufficient information to permit judgement of 'yes' or 'no' as no protocol was available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Naeem-2005","2013-09-25 12:32:42 +0100","YES","No evidence other bias occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Nagel-2009","2013-05-10 05:40:32 +0100","YES","Block randomisation, random number sequence. No further details provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Nagel-2009","2013-04-05 05:46:19 +0100","UNKNOWN","No details provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Nagel-2009","2013-09-25 12:32:42 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Nagel-2009","2013-05-31 02:12:40 +0100","NO","Raters were not blind to treatment allocation.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Nagel-2009","2013-05-24 04:45:39 +0100","UNKNOWN","Lost to follow-up: 29% (14/49) 18 months. Full ITT was conducted.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Nagel-2009","2013-05-15 05:18:11 +0100","UNKNOWN","The original protocol (NCR00192582) could not be accessed as only the final article was listed. Selective reporting was unclear.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Nagel-2009","2013-05-14 09:46:41 +0100","UNKNOWN","Follow-up data at 12 and 18 months confounded, as both groups received treatment. Only T1 data is informative regarding group differences.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Swanson-1999","2013-09-25 12:32:43 +0100","YES","Randomised (using random number table).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Swanson-1999","2013-05-13 05:09:20 +0100","NO","Therapist consulted a random number table to determine group assignment. May have influenced section bias.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Swanson-1999","2013-09-25 12:32:43 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Swanson-1999","2013-05-31 02:13:08 +0100","UNKNOWN","Not clear if raters independent or blind to allocation. Primary outcome measure was time to next appointment.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Swanson-1999","2013-06-06 02:05:48 +0100","YES","Lost to follow-up: 0%, (0/93) 3 months.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Swanson-1999","2013-05-24 04:46:26 +0100","UNKNOWN","Insufficient information to permit judgement of 'yes' or 'no' as no protocol was available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Swanson-1999","2013-09-25 12:32:44 +0100","YES","No evidence other bias occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Tracy-2007","2013-05-10 05:41:53 +0100","YES","Randomised using a table. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Tracy-2007","2013-04-08 05:11:45 +0100","UNKNOWN","No details provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Tracy-2007","2013-09-25 12:32:44 +0100","UNKNOWN","Clinician/participant mediated and participants and personnel not blinded. Unclear risk.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Tracy-2007","2013-05-31 02:13:25 +0100","UNKNOWN","Not stated if raters were blind to allocation.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Tracy-2007","2013-05-30 05:51:08 +0100","UNKNOWN","Four patients in the TAU (assessment only) group did not complete the study, no further details are provided. Analyses adjusted for greater cocaine use using covariate.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Tracy-2007","2013-05-30 07:23:36 +0100","NO","Gender, specific diagnoses and age not reported for participants. Mean and SDs not provided for alcohol and substance use; percentages (and chi-square statistics) are provided for some outcomes but not subject number (N) for each group.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychosocial interventions for people with both severe mental illness and substance misuse [v10.2-For publication].rm5","STD-Tracy-2007","2013-09-25 12:32:44 +0100","YES","No evidence other biases are occurring.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for siblings of people with severe mental illness [v2.0-For publication].rm5","STD-Chien-2007","2013-11-04 15:42:13 +0000","UNKNOWN","Randomisation method not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for siblings of people with severe mental illness [v2.0-For publication].rm5","STD-Chien-2007","2013-11-04 15:42:14 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for siblings of people with severe mental illness [v2.0-For publication].rm5","STD-Chien-2007","2015-02-10 14:05:47 +0000","UNKNOWN","The therapist could not be blinded in order to facilitate the group. Participants were not blinded.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for siblings of people with severe mental illness [v2.0-For publication].rm5","STD-Chien-2007","2013-11-04 15:42:16 +0000","YES","Single blind - One researcher who administered the pre and post-tests assessments was blinded to the allocation.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for siblings of people with severe mental illness [v2.0-For publication].rm5","STD-Chien-2007","2013-11-04 15:42:17 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for siblings of people with severe mental illness [v2.0-For publication].rm5","STD-Chien-2007","2013-11-04 15:42:17 +0000","YES","All measured outcomes were reported.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for siblings of people with severe mental illness [v2.0-For publication].rm5","STD-Chien-2007","2013-11-04 15:42:18 +0000","YES","None obvious.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Both-2004","2010-01-25 15:30:58 +0000","UNKNOWN","Randomised, but no detail described.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Both-2004","2010-01-25 15:30:48 +0000","UNKNOWN","Not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Both-2004","2008-12-09 10:19:24 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Both-2004","2008-12-09 10:21:09 +0000","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Both-2004","2008-12-09 10:21:27 +0000","YES","All measured outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Both-2004","2010-01-25 15:32:09 +0000","UNKNOWN","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Both-2004a","2008-12-09 13:17:23 +0000","UNKNOWN","Randomised, no further description.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Both-2004a","2010-02-18 14:25:45 +0000","UNKNOWN","Not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Both-2004a","2008-12-09 13:17:32 +0000","UNKNOWN","Not stated. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Both-2004a","2008-12-09 13:19:02 +0000","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Both-2004a","2008-12-09 13:19:38 +0000","YES","All measured outcomes were reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Both-2004a","2010-02-18 14:25:53 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-1995","2010-01-25 15:32:57 +0000","YES","Randomised by independent third party.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-1995","2010-06-22 14:29:53 +0100","UNKNOWN","Unclear.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-1995","2011-03-16 16:08:57 +0000","NO","Blind rating for readmission (independent criterion as researchers had no influence on this). Relapse data, compliance data and other outcomes where not blindly rated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-1995","2010-07-25 19:22:48 +0100","NO","44 patients dropped out before start of intervention and were not included in analysis but compared on socio-demographic and other characteristics to trial group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-1995","2010-06-22 14:30:49 +0100","YES","All measured outcomes reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-1995","2010-06-22 14:30:35 +0100","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-1995a","2010-02-18 14:53:40 +0000","UNKNOWN","Randomisation method not stated. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-1995a","2010-02-18 14:53:32 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-1995a","2010-02-18 14:53:23 +0000","NO","Not stated. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-1995a","2011-03-16 16:09:39 +0000","UNKNOWN","Not stated concerning total dropout and ITT (intention to treat criteria fulfilled).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-1995a","2011-03-16 16:09:44 +0000","YES","Only compliance and readmission measured and reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-1995a","2011-03-16 16:09:48 +0000","NO","Control patients were not given as much therapist time.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-1999","2011-03-19 02:27:46 +0000","YES","Randomisation carried out by an independent institution.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-1999","2011-03-19 02:28:00 +0000","YES","Patients included before randomisation, given participant numbers, separated from patient identification data. Allocation of  patent-numbers to intervention/control  done subsequently.  ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-1999","2010-02-18 14:56:48 +0000","YES","Single blind (assessor blind). ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-1999","2010-06-22 14:33:59 +0100","YES","ITT(Intention treat principle) used.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-1999","2010-06-22 14:34:09 +0100","YES","ITT(Intention treat principle) used.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-1999","2010-06-22 14:34:15 +0100","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2003","2008-12-09 09:51:01 +0000","UNKNOWN","Randomised, but no randomisation detail described.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2003","2011-03-19 02:28:18 +0000","UNKNOWN","Not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2003","2011-03-19 02:28:19 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2003","2011-03-19 02:28:22 +0000","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2003","2011-03-19 02:28:24 +0000","YES","All measured outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2003","2010-02-18 14:57:27 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2006","2010-02-11 14:24:28 +0000","UNKNOWN","Randomisation method not stated. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2006","2010-02-11 14:24:32 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2006","2010-02-11 14:24:35 +0000","UNKNOWN","Not stated. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2006","2010-02-11 14:25:07 +0000","YES","No incomplete outcome data. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2006","2010-02-11 14:25:06 +0000","YES","All measured outcomes reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2006","2010-02-11 14:25:04 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2007","2010-02-10 10:01:57 +0000","UNKNOWN","Randomisation method not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2007","2010-02-10 10:02:01 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2007","2010-02-10 10:02:07 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2007","2010-02-10 10:02:15 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2007","2010-02-10 10:02:29 +0000","YES","All measured outcomes reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2007","2010-02-10 10:02:28 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2007a","2010-02-08 15:17:56 +0000","YES","Randomised by tossing a coin.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2007a","2010-02-08 15:18:00 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2007a","2010-02-08 15:18:04 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2007a","2010-02-08 15:18:36 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2007a","2010-02-08 15:18:32 +0000","YES","All measured outcomes reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2007a","2010-07-25 20:17:45 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2007b","2010-02-11 14:34:48 +0000","UNKNOWN","Randomisation method not stated. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2007b","2010-02-11 14:34:51 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2007b","2010-02-11 14:34:55 +0000","UNKNOWN","Not stated. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2007b","2010-02-11 14:35:27 +0000","YES","No incomplete outcome data. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2007b","2010-02-11 14:35:28 +0000","NO","PANSS, ITAQ scores measured, but not reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2007b","2010-02-11 14:35:30 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2009","2010-02-08 16:50:29 +0000","UNKNOWN","Randomisation method not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2009","2010-02-08 16:50:35 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2009","2010-02-08 16:50:38 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2009","2010-02-08 16:50:51 +0000","YES","No incomplete data. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2009","2010-02-08 16:51:32 +0000","NO","Some scale data (SSQ-6, SES) were not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Group-2009","2010-02-08 16:51:40 +0000","YES"," None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Individual-1996","2010-02-18 15:06:15 +0000","YES","Using a random numbers table","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Individual-1996","2010-02-18 15:06:20 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Individual-1996","2010-07-25 20:16:35 +0100","NO","Open label.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Individual-1996","2010-02-18 15:06:27 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Individual-1996","2010-06-22 14:35:37 +0100","YES","All measured outcomes reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Individual-1996","2010-06-22 14:34:57 +0100","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Unclear-2005","2010-02-06 16:08:12 +0000","UNKNOWN","Randomisation method not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Unclear-2005","2010-02-06 16:09:16 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Unclear-2005","2010-02-06 16:09:13 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Unclear-2005","2010-02-06 16:10:48 +0000","NO","Drop out was excluded in the analysis. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Unclear-2005","2010-02-06 16:09:30 +0000","YES","All measured outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Brief-_x002d_-Unclear-2005","2010-02-06 16:09:37 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-1996","2010-02-18 15:11:47 +0000","YES","Using computer generated random number card.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-1996","2010-02-18 15:11:50 +0000","YES","Sealed envelopes.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-1996","2010-02-18 15:11:53 +0000","YES","Single blind.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-1996","2010-06-22 14:36:31 +0100","YES","No incomplete outcome data. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-1996","2010-06-22 14:36:23 +0100","YES","All measured outcomes reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-1996","2010-06-22 14:36:12 +0100","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2004","2008-12-09 09:55:39 +0000","UNKNOWN","Randomised, but further detail provided on randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2004","2010-02-18 15:14:00 +0000","UNKNOWN","Not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2004","2008-12-09 09:56:31 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2004","2011-03-19 02:33:08 +0000","NO","Drop-out was excluded from final analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2004","2008-12-09 10:00:51 +0000","YES","All measured outcomes were reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2004","2010-02-18 15:14:08 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2006","2010-02-11 15:42:14 +0000","UNKNOWN","Randomisation method not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2006","2011-03-19 02:33:35 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2006","2010-02-11 15:42:24 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2006","2010-02-11 15:42:56 +0000","YES","No incomplete outcome data. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2006","2010-02-11 15:42:55 +0000","YES","All measured outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2006","2010-02-11 15:42:54 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2008","2010-02-11 13:52:32 +0000","UNKNOWN","Randomisation method not stated. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2008","2010-02-11 13:52:36 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2008","2010-02-11 13:52:40 +0000","UNKNOWN","Not stated. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2008","2010-02-11 13:53:12 +0000","YES","ITT was used. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2008","2010-02-11 13:53:11 +0000","YES","All measured outcomes reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2008","2010-02-11 13:53:10 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2008a","2010-02-18 13:36:51 +0000","UNKNOWN","Randomisation method not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2008a","2010-02-18 13:36:55 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2008a","2010-02-18 13:37:00 +0000","UNKNOWN","Not described.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2008a","2010-02-18 13:37:28 +0000","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2008a","2010-02-18 13:37:26 +0000","YES","All measured outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2008a","2010-02-18 13:37:25 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2008b","2010-02-12 11:19:19 +0000","YES","Randomised with random number table. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2008b","2010-02-12 11:19:22 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2008b","2010-02-12 11:19:25 +0000","UNKNOWN","Not stated. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2008b","2011-03-19 02:34:42 +0000","NO","ITT was not used, drop-outs were excluded from analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2008b","2010-02-12 11:20:00 +0000","YES","All measured outcomes reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Both-2008b","2010-02-12 11:19:59 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-1988","2010-06-22 14:36:51 +0100","UNKNOWN","Randomization stated as stratified but no further information concerning method","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-1988","2010-02-18 15:18:14 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-1988","2010-02-18 15:18:19 +0000","YES","Some outcomes (relapse, EE, PSE ratings) are assessed single blind.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-1988","2010-06-22 14:37:18 +0100","YES","All treatment or assessment dropouts were included in analyses","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-1988","2010-06-22 14:37:21 +0100","YES","None obvious. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-1988","2010-06-22 14:37:25 +0100","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2004","2008-12-08 15:07:36 +0000","UNKNOWN","Patients were randomly divided into two groups, no further detail on randomisation method. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2004","2010-02-18 15:19:01 +0000","UNKNOWN","Not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2004","2008-12-08 15:33:02 +0000","UNKNOWN","Not stated. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2004","2008-12-08 15:33:00 +0000","YES","No incomplete outcome data. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2004","2008-12-08 15:32:45 +0000","YES","All measured outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2004","2010-02-18 15:19:09 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2005","2010-07-25 17:32:25 +0100","YES","Randomised - each participating Centre received a list with randomisation order (from a central study site) ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2005","2008-12-18 15:38:33 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2005","2010-06-22 14:40:30 +0100","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2005","2010-02-18 15:21:45 +0000","UNKNOWN","No incomplete outcome. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2005","2010-06-22 14:39:40 +0100","YES","None obvious. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2005","2011-03-19 02:36:42 +0000","UNKNOWN","Control group contained many protocol deviating patients.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2006","2008-12-17 15:21:28 +0000","YES","Randomised with random number table. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2006","2008-12-17 15:21:43 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2006","2008-12-17 15:23:44 +0000","YES","Single blind - assessor blind.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2006","2011-03-19 02:38:21 +0000","NO","Drop-outs were excluded from final analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2006","2008-12-17 15:24:43 +0000","YES","All measured outcomes were reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2006","2010-02-18 15:20:38 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2007","2010-02-10 13:11:32 +0000","UNKNOWN","Randomisation method not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2007","2010-02-10 13:11:37 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2007","2010-02-10 13:12:06 +0000","YES","Single blind.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2007","2010-02-10 13:11:52 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2007","2010-02-10 13:11:59 +0000","YES","All outcome reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2007","2010-02-10 13:12:04 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2008","2010-02-08 15:05:08 +0000","UNKNOWN","Randomisation method not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2008","2010-02-08 15:05:05 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2008","2010-02-08 15:05:12 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2008","2010-02-08 15:05:27 +0000","YES","No incomplete outcome data. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2008","2010-02-08 15:05:42 +0000","YES","All measured outcomes reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Group-2008","2010-02-08 15:05:48 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-03a","2008-12-08 14:54:03 +0000","UNKNOWN","Patients randomly divided into two group, no further detail on randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-03a","2010-02-18 15:24:56 +0000","UNKNOWN","Not described. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-03a","2008-12-08 14:54:20 +0000","UNKNOWN","Blinding is not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-03a","2008-12-08 14:55:19 +0000","YES","No incomplete outcome data","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-03a","2008-12-08 14:55:52 +0000","YES","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-03a","2010-02-18 15:27:05 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-03b","2008-12-09 12:29:27 +0000","YES","Randomised by draw lots.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-03b","2010-02-18 15:29:21 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-03b","2008-12-09 12:38:07 +0000","UNKNOWN","Not stated. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-03b","2011-03-21 16:06:38 +0000","NO","Incomplete outcome data at follow-up was excluded from analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-03b","2008-12-09 12:45:22 +0000","YES","All measured outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-03b","2010-02-18 15:29:27 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-03c","2008-12-09 14:12:09 +0000","YES","Randomised with random number table. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-03c","2010-02-18 15:33:02 +0000","UNKNOWN","Not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-03c","2008-12-09 14:13:47 +0000","YES","Double blind. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-03c","2009-12-15 13:55:11 +0000","NO","Addressed in some outcomes, but not others. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-03c","2008-12-09 14:25:50 +0000","YES","All measured outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-03c","2010-02-18 15:35:45 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-93","2011-03-21 16:08:14 +0000","YES","Randomisation method used: dice.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-93","2010-02-18 15:37:04 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-93","2010-02-18 15:37:07 +0000","YES","Some outcomes are assessed single blind.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-93","2011-03-21 16:08:16 +0000","UNKNOWN","Not stated, but only one subject retired from the study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-93","2010-06-22 14:41:48 +0100","YES","None obvious. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Individual-93","2010-06-22 14:41:52 +0100","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-1988","2010-02-18 15:38:28 +0000","UNKNOWN","Method not described. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-1988","2010-02-18 15:38:36 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-1988","2010-02-18 15:38:42 +0000","UNKNOWN","Not stated. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-1988","2010-02-18 15:39:02 +0000","YES","No incomplete outcome data. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-1988","2010-02-18 15:39:22 +0000","NO","Some scale scores were measured, but no mean or SD reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-1988","2010-02-18 15:39:31 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-1996","2011-03-21 16:10:33 +0000","YES","Block randomisation using computer.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-1996","2010-02-18 15:39:56 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-1996","2011-03-21 16:10:35 +0000","YES","Single blind.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-1996","2011-03-21 16:10:52 +0000","YES","ITT-analysis and completer analysis performed and drop-out reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-1996","2010-06-22 14:42:42 +0100","YES","None obvious. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-1996","2010-06-22 14:42:45 +0100","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2005","2010-02-18 13:45:08 +0000","UNKNOWN","Randomisaiton method not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2005","2010-02-18 13:45:12 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2005","2010-02-18 13:45:15 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2005","2010-02-18 13:45:24 +0000","UNKNOWN","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2005","2010-02-18 13:45:35 +0000","UNKNOWN","All measured outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2005","2010-02-18 13:45:39 +0000","UNKNOWN","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2005a","2010-02-15 10:33:31 +0000","UNKNOWN","Randomisation method not described.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2005a","2010-02-15 10:33:34 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2005a","2010-02-15 10:33:38 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2005a","2010-02-15 10:34:24 +0000","YES","No incomplete outcome data. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2005a","2010-02-15 10:34:23 +0000","NO","BPRS and SOSS score measured but not reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2005a","2010-02-15 10:34:21 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2006","2010-02-11 11:43:11 +0000","UNKNOWN","Randomisation method not stated. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2006","2010-02-11 11:43:17 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2006","2010-02-11 11:43:23 +0000","UNKNOWN","Not stated. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2006","2010-02-11 11:44:22 +0000","YES","No incomplete data. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2006","2010-02-11 11:44:17 +0000","YES","All measured outcomes reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2006","2010-02-11 11:44:23 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2007","2010-02-11 14:13:00 +0000","UNKNOWN","Randomisation method not stated. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2007","2010-02-11 14:13:07 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2007","2010-02-11 14:13:10 +0000","UNKNOWN","Not stated. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2007","2010-02-11 14:13:34 +0000","YES","No incomplete outcome data. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2007","2010-02-11 14:13:35 +0000","YES","All measured outcomes reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Standard-_x002d_-Unclear-2007","2010-02-11 14:13:38 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2001","2008-12-08 14:58:21 +0000","UNKNOWN","Patients randomly divided into two groups, no further detail on randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2001","2010-02-18 15:40:26 +0000","UNKNOWN","Not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2001","2010-02-18 15:40:29 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2001","2011-03-22 15:23:25 +0000","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2001","2008-12-08 14:59:51 +0000","YES","All measured outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2001","2010-02-18 15:40:35 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2005","2008-12-09 10:37:40 +0000","UNKNOWN","Randomised, without further description.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2005","2010-02-18 15:41:57 +0000","UNKNOWN","Not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2005","2008-12-09 10:37:51 +0000","UNKNOWN","Not stated. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2005","2008-12-09 10:42:20 +0000","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2005","2008-12-09 10:42:34 +0000","YES","All measured outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2005","2010-02-18 15:42:04 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2007","2010-02-11 13:21:57 +0000","YES","Randomised with random number table. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2007","2010-02-11 13:21:02 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2007","2010-02-11 13:21:06 +0000","UNKNOWN","Not stated. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2007","2011-03-22 15:24:33 +0000","NO","Drop-outs were excluded from analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2007","2010-02-11 13:21:48 +0000","NO","MRSS was measured but not reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2007","2010-02-11 13:21:44 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2007a","2010-02-11 13:04:48 +0000","UNKNOWN","Randomisation method not stated. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2007a","2010-02-11 13:04:52 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2007a","2010-02-11 13:04:57 +0000","UNKNOWN","Not stated. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2007a","2010-02-11 13:05:31 +0000","YES","No incomplete data. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2007a","2010-02-11 13:05:29 +0000","YES","All measured outcomes reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2007a","2010-02-11 13:05:28 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2008","2010-02-12 13:27:47 +0000","UNKNOWN","Randomisation method not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2008","2010-02-12 13:27:51 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2008","2010-02-12 13:27:54 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2008","2010-02-12 13:28:19 +0000","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2008","2010-02-12 13:28:18 +0000","YES","All measured outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Both-2008","2010-02-12 13:28:16 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Group-1996","2010-02-18 15:42:24 +0000","UNKNOWN","No description.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Group-1996","2010-02-18 15:42:31 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Group-1996","2010-02-18 15:42:33 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Group-1996","2010-02-18 15:42:38 +0000","YES","No incomplete outcome.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Group-1996","2010-02-18 15:42:41 +0000","YES","Everything measured are reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Group-1996","2010-02-18 15:42:45 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Group-2008","2010-02-08 11:30:46 +0000","UNKNOWN","Randomisation method not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Group-2008","2010-02-08 11:30:53 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Group-2008","2010-02-08 11:30:57 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Group-2008","2010-02-08 11:31:21 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Group-2008","2010-02-08 11:31:20 +0000","YES","All measured outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Group-2008","2011-03-22 15:26:36 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Individual-2008","2010-02-08 14:26:48 +0000","UNKNOWN","Randomisation method not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Individual-2008","2010-02-08 14:26:51 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Individual-2008","2010-02-08 14:26:55 +0000","UNKNOWN","Not stated. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Individual-2008","2010-02-08 14:38:53 +0000","NO","Drop outs were excluded from analysis. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Individual-2008","2010-02-08 14:34:43 +0000","YES","All measured outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Individual-2008","2010-02-08 14:34:49 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Unclear-2008","2010-02-11 14:58:18 +0000","UNKNOWN","Randomisation method not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Unclear-2008","2010-02-11 14:58:21 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Unclear-2008","2010-02-11 14:58:23 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Unclear-2008","2010-02-11 14:59:00 +0000","YES","No incomplete data. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Unclear-2008","2010-02-11 14:58:58 +0000","YES","All measured outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation for schizophrenia [v9.0-For publication].rm5","STD-Unclear-_x002d_-Unclear-2008","2010-02-11 14:58:57 +0000","YES","None obvious. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Liu-2004","2013-11-24 20:11:55 +0000","UNKNOWN","Randomised, but no detail described.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Liu-2004","2013-11-24 20:11:55 +0000","UNKNOWN","Not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Liu-2004","2013-11-24 20:22:10 +0000","UNKNOWN","Not stated.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Liu-2004","2013-11-24 20:23:54 +0000","UNKNOWN","Not stated.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Liu-2004","2013-11-24 20:23:50 +0000","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Liu-2004","2013-11-24 20:23:44 +0000","YES","All measured outcomes were reported.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Liu-2004","2013-11-24 20:11:55 +0000","UNKNOWN","None obvious.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Tom-1989","2013-11-29 13:41:03 +0000","YES","Randomised: the first name drawn and assigned to either Interveniton group or control group.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Tom-1989","2013-11-29 13:41:02 +0000","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Tom-1989","2013-11-29 13:41:01 +0000","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Tom-1989","2013-11-29 13:41:01 +0000","UNKNOWN","Not reported.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Tom-1989","2015-02-09 13:50:22 +0000","NO","Leaving the study early: Intervention group: n =- 3 excluded as did not attend the sufficient sessions; Control group: n = 3 for failure to attend or complete the program. No ITT analysis.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Tom-1989","2013-11-29 15:40:27 +0000","NO","No means or SDs reported for all outcomes scales - only data for attrition were usable in data and analysis.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Tom-1989","2013-11-17 03:31:13 +0000","UNKNOWN","No further info.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Zhang-2004","2013-11-24 20:13:13 +0000","UNKNOWN","Randomised, no further description.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Zhang-2004","2013-11-24 20:13:13 +0000","UNKNOWN","Not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Zhang-2004","2013-11-24 20:22:36 +0000","UNKNOWN","Not stated.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Zhang-2004","2013-11-24 20:23:35 +0000","UNKNOWN","Not stated.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Zhang-2004","2013-11-24 20:23:26 +0000","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Zhang-2004","2013-11-24 20:23:06 +0000","YES","All measured outcomes were reported","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Both-_x002d_-Zhang-2004","2013-11-24 20:22:36 +0000","YES","None obvious.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Aguglia-2007","2013-11-28 22:15:27 +0000","UNKNOWN","No description of random allocation provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Aguglia-2007","2013-11-28 22:15:34 +0000","UNKNOWN","No information provided on allocation concealment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Aguglia-2007","2015-03-05 14:30:23 +0000","NO","Study participants were blind to randomisation. Quote: “The patients were blindly randomised by the experimenter into two groups”. The authors have recommended a double-blind study. Quote: “Though the staff carrying out psychoeducation and standard psychosocial intervention and the staff administering the scales were different, the open label design of the study could bring some biases. A double blind study should be recommended”.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Aguglia-2007","2015-03-05 14:30:23 +0000","UNKNOWN","Although the study is an open-label design, the staff carrying out psychoeducation intervention and the staff administering the scales were different.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Aguglia-2007","2015-03-05 14:30:23 +0000","NO","No specific reasons given for dropouts (n = 15). Quote: “135 patients finished the study; 15 dropped out for different reasons unrelated to the study”. No mention of how attrition was addressed in the analysis. Quote: “The percentage of the participants hospitalised between 1 and 3 times during the 12 months resulted to be 13% after 6 months, and 3,3% after a year with a difference of 9.7% for the study group; while for the control group the variation went from 17.7% at 6 months to 10.5% after 1 year with an improvement of 7,2%”.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Aguglia-2007","2013-12-01 16:02:56 +0000","UNKNOWN","Most outcomes are reported but no clarity on number of participants used in the analysis.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Aguglia-2007","2013-11-28 22:16:57 +0000","UNKNOWN","Funding: not stated.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Bauml-2007","2013-11-27 21:44:07 +0000","YES","Group randomisation was done centrally; the groups were formed independently in each study centre.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Bauml-2007","2015-03-05 14:30:23 +0000","YES","Randomisation was done centrally.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Bauml-2007","2013-11-27 21:44:11 +0000","UNKNOWN","Not reported.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Bauml-2007","2015-03-05 14:30:23 +0000","NO","Therapist not blinded.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Bauml-2007","2015-03-05 14:30:23 +0000","NO","Dropout: 19 patients excluded for formal reasons or due to premature discontinuation of the intervention, no ITT analysis.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Bauml-2007","2013-11-27 21:44:36 +0000","YES","All the outcome measures were reported.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Bauml-2007","2014-06-12 14:30:13 +0100","UNKNOWN","Funding: German Ministry of Research and Technology (0701854 = 819754-3). The first 2 years of the Psychosis Information (PIP) Study were supported by a grant from the German Ministry of Science and Research (BMFT). The long-term follow-up of the sub-sample from the TechnicalUniversity of Munich was supported by a grant from the DORIST-Fondin Kreuzlingen, Switzerland.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Bechdolf-2004","2013-11-26 21:26:46 +0000","YES","Random: quote ""...by computer-generated random numbers for blocks of eight participants, the results were placed in sealed envelopes and only opened at the time of treatment"" (p22). Blind assessments by carrying out most of the assessments by independent raters.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Bechdolf-2004","2013-11-17 02:53:25 +0000","YES","Placed in sealed envelopes and only opened at the time of treatment allocation","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Bechdolf-2004","2013-11-27 20:36:09 +0000","UNKNOWN","Quote, ""with regard to psychopathology and compliance measures, we made attempts to blind assessments by carrying out most of the assessments by independent raters who were not involved in the treatment"" (p22). ","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Bechdolf-2004","2013-11-27 20:38:57 +0000","YES","Blind assessments by carrying out most of the assessments by independent raters.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Bechdolf-2004","2015-03-05 14:30:24 +0000","NO","n = 17 participants lost to follow-up.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Bechdolf-2004","2015-03-05 14:30:24 +0000","NO","MSQoL not reported, will be reported elsewhere. Continuous scores for PANSS and compliance differ between published reports at 6 months and 24 months. Results from the 24-month report show significant difference in results - data from the first published report were used for short-term and medium-term outcomes.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Bechdolf-2004","2013-11-26 21:22:22 +0000","YES","This work was supported by grant from the Koln For-tune Program (191/1998) Faculty of Medicine, University of Cologne, Germany.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Chan-2007","2013-11-24 20:13:13 +0000","UNKNOWN","Randomisation method not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Chan-2007","2013-11-24 20:13:13 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Chan-2007","2013-11-24 20:28:08 +0000","UNKNOWN","Not stated.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Chan-2007","2013-11-24 20:28:09 +0000","UNKNOWN","Not stated.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Chan-2007","2013-12-02 11:53:35 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Chan-2007","2013-11-24 20:13:13 +0000","YES","All measured outcomes reported. ","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Chan-2007","2013-11-24 20:13:13 +0000","YES","None obvious. ","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Chan-2009","2015-03-05 14:30:24 +0000","YES","Random assignment generated by drawing lots. Quote: ""After their written consent was obtained, the participants were randomly assigned to experimental and control groups by drawing lots"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Chan-2009","2013-11-24 20:29:37 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Chan-2009","2015-03-05 14:30:24 +0000","UNKNOWN","No clear description of blinding of participants or raters. Quote: ""All the pre- and post-tests were conducted by an assigned mental health nurse who was not involved in the intervention to avoid bias"". Not clear from this quote whether the mental health nurse was blind to intervention.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Chan-2009","2013-11-24 20:29:40 +0000","UNKNOWN","Not stated.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Chan-2009","2015-02-09 14:11:34 +0000","YES","No dropouts and no cases excluded.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Chan-2009","2013-11-24 20:29:52 +0000","NO","Some scale data (SSQ-6, SES) were not reported.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Chan-2009","2013-11-24 20:29:53 +0000","YES","None obvious.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Coyle-1988","2015-03-05 14:30:24 +0000","YES","Stratified random assignment: stratified according to age, sex, race. Then a stratified random assignment was performed ensuring there were equal numbers of participants in sub categories.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Coyle-1988","2013-11-29 13:33:18 +0000","UNKNOWN","No allocation concealment from those delivering the intervention as all 3 workers delivering the intervention delivered all 3 interventions. No other allocation concealments mentioned.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Coyle-1988","2013-11-29 13:33:16 +0000","UNKNOWN","None reported.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Coyle-1988","2013-11-17 02:57:02 +0000","UNKNOWN","Not reported","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Coyle-1988","2015-02-09 13:52:12 +0000","UNKNOWN","Dropouts accounted for: In the individual therapy group: n = 1 died of medical causes,n = 1 hospitalised, n = 1 did not complete the data. In the medication use group: n = 1 dropped out, n = 1 hospitalised, n = 1 did not complete the data; In the social skills training group: n = 3 dropped out, n = 1 hospitalised; In the psychoeducational group: n = 4 dropped out, n = 2 hospitalised. ITT analysis was not applied.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Coyle-1988","2015-03-05 14:30:24 +0000","UNKNOWN","Only means reported with no SDs.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Coyle-1988","2013-11-29 13:34:59 +0000","UNKNOWN","Interested participants self-selected themselves to be part of the study.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Dai-2007","2013-11-24 20:13:13 +0000","UNKNOWN","Randomisation method not stated. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Dai-2007","2013-11-24 20:13:13 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Dai-2007","2013-11-24 20:29:02 +0000","UNKNOWN","Not stated.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Dai-2007","2013-11-24 20:29:03 +0000","UNKNOWN","Not stated.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Dai-2007","2013-11-24 20:29:10 +0000","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Dai-2007","2013-11-24 20:13:13 +0000","NO","PANSS, ITAQ scores measured, but not reported. ","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Dai-2007","2013-11-24 20:13:13 +0000","YES","None obvious. ","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Hornung-1995","2013-12-01 21:57:43 +0000","YES","Randomised by independent third party, in which age, sex, prognosis and medication compliance were balanced by preliminary matching. Randomisation by an independent institution, ZMBT.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Hornung-1995","2013-11-24 20:24:36 +0000","UNKNOWN","Unclear.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Hornung-1995","2013-11-24 20:24:43 +0000","NO","Blind rating for readmission (independent criterion as researchers had no influence on this). Relapse data, compliance data and other outcomes where not blindly rated.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Hornung-1995","2013-11-24 20:25:13 +0000","NO","Blind rating for readmission (independent criterion as researchers had no influence on this). Relapse data, compliance data and other outcomes where not blindly rated.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Hornung-1995","2015-02-09 13:52:41 +0000","NO","n = 44 patients dropped out before start of intervention and were not included in analysis but compared on socio-demographic and other characteristics to trial group.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Hornung-1995","2013-11-24 20:25:18 +0000","YES","All measured outcomes reported.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Hornung-1995","2013-11-24 20:25:19 +0000","YES","None obvious.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Li-2003","2013-11-24 20:13:13 +0000","UNKNOWN","Randomised, but no randomisation detail described.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Li-2003","2013-11-24 20:13:13 +0000","UNKNOWN","Not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Li-2003","2013-11-24 20:27:07 +0000","UNKNOWN","Not stated.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Li-2003","2013-11-24 20:27:08 +0000","UNKNOWN","Not stated.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Li-2003","2015-03-05 14:12:20 +0000","NO","Those leaving early were excluded from the analysis","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Li-2003","2013-11-24 20:13:13 +0000","YES","All measured outcomes were reported.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Li-2003","2013-11-24 20:13:13 +0000","YES","None obvious. ","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Lv-2007","2013-11-24 20:13:13 +0000","YES","Randomised by tossing a coin.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Lv-2007","2013-11-24 20:13:13 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Lv-2007","2013-11-24 20:28:34 +0000","UNKNOWN","Not stated.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Lv-2007","2013-11-24 20:28:37 +0000","UNKNOWN","Not stated.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Lv-2007","2013-11-24 20:28:45 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Lv-2007","2013-11-24 20:13:13 +0000","YES","All measured outcomes reported. ","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Lv-2007","2013-11-24 20:13:13 +0000","YES","None obvious.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Merinder-1999","2013-11-24 20:26:36 +0000","YES","Randomisation carried out by an independent institution.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Merinder-1999","2013-12-01 16:04:50 +0000","YES","Patients included before randomisation, given participant numbers, separated from patient identification data. Allocation of patent-numbers to intervention/control done subsequently. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Merinder-1999","2013-11-24 20:26:36 +0000","YES","Single blind (assessor blind).","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Merinder-1999","2013-11-24 20:26:41 +0000","YES","Single blind (assessor blind).","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Merinder-1999","2015-03-05 14:30:25 +0000","YES","ITT used.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Merinder-1999","2015-03-05 14:30:25 +0000","YES","ITT used.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Merinder-1999","2013-11-24 20:26:48 +0000","UNKNOWN","None obvious.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Razali-1995","2013-11-24 20:13:13 +0000","UNKNOWN","Randomisation method not stated. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Razali-1995","2013-11-24 20:13:13 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Razali-1995","2013-11-24 20:25:34 +0000","UNKNOWN","Not stated.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Razali-1995","2013-11-24 20:25:36 +0000","UNKNOWN","Not stated.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Razali-1995","2015-03-05 14:30:25 +0000","UNKNOWN","Not stated concerning total dropout and ITT (intention-to treat-criteria fulfilled).","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Razali-1995","2013-11-24 20:13:13 +0000","YES","Only compliance and readmission measured and reported.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Razali-1995","2013-11-24 20:13:13 +0000","NO","Control patients were not given as much therapist time.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Zhang-2006","2013-11-24 20:13:13 +0000","UNKNOWN","Randomisation method not stated. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Zhang-2006","2013-11-24 20:13:13 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Zhang-2006","2013-11-24 20:27:44 +0000","UNKNOWN","Not stated.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Zhang-2006","2013-11-24 20:27:44 +0000","UNKNOWN","Not stated.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Zhang-2006","2013-11-24 20:27:49 +0000","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Zhang-2006","2013-11-24 20:13:13 +0000","YES","All measured outcomes reported. ","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Group-_x002d_-Zhang-2006","2013-11-24 20:13:13 +0000","YES","None obvious. ","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Cunningham-2001","2015-03-05 14:30:25 +0000","YES","Following initial assessment, participants were allocated by means of random numbers in sealed envelopes to either intervention or control group.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Cunningham-2001","2015-03-05 14:30:25 +0000","YES","Randomszation was conducted at the trial centre and was remote from the assessors.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Cunningham-2001","2015-03-05 14:30:25 +0000","UNKNOWN","Patients were followed up by a research psychiatrist who was not blind to group status.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Cunningham-2001","2013-11-17 03:01:10 +0000","UNKNOWN","No reported","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Cunningham-2001","2013-11-29 11:16:13 +0000","UNKNOWN","No information given on why participants dropped out. Quote:” Nine patients in the intervention group (14.8%) and nine in the control group (17.0%) dropped out prematurely”. High number of relapse rate in the study. Quote “Over the 12 months of follow-up, 22 (36.1%) of the intervention group and 22 (41.5%) of the control group relapsed”. Exclusions not clearly reported for some outcome data. Quote: “Such data were only available on the 46 subjects who had neither relapsed nor dropped-out”.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Cunningham-2001","2015-02-09 14:11:56 +0000","UNKNOWN","All outcome data are reported but lack of clarity on some main outcomes, such as PANSS no means or SD reported. Lack of clarity on dropouts and relapse rates at every follow-up stage.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Cunningham-2001","2013-11-29 11:16:39 +0000","YES","Funding: funded by the Medical Research Council of Great Britain","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Macpherson-1996","2013-11-24 20:13:13 +0000","YES","Using a random numbers table","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Macpherson-1996","2013-11-24 20:13:13 +0000","UNKNOWN","Not stated. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Macpherson-1996","2013-11-24 20:30:33 +0000","NO","Open label","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Macpherson-1996","2013-11-24 20:30:35 +0000","NO","Open label","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Macpherson-1996","2013-11-24 20:30:28 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Macpherson-1996","2013-11-24 20:13:13 +0000","YES","All measured outcomes reported. ","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Macpherson-1996","2013-11-24 20:13:13 +0000","YES","None obvious. ","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Nasr-2009","2013-11-29 10:21:58 +0000","YES","Random allocation done independently. Quote: “Patients with schizophrenia were randomly allocated to one of two groups, a psychoeducation group or a non-psychoeducation group” (p5). ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Nasr-2009","2015-03-05 14:30:25 +0000","YES","An independent controlled randomly allocated the individuals to either the psychoeducation or control group. Quote: ""The researcher was not involved in the randomisation of the patients and families, which was performed at the institution.""","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Nasr-2009","2013-11-29 10:20:59 +0000","UNKNOWN","No blinding information given on patients and families, the researcher was not involved in randomisation but no clear information whether they were blinded.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Nasr-2009","2013-11-29 10:20:54 +0000","UNKNOWN","As above.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Nasr-2009","2015-02-09 13:53:55 +0000","NO","n = 8 individuals were lost at follow-up. Only addressed: one died (psycho-education group). No mention of the n = 7 that were dropped/lost at the follow-up stage and from which group. No mention of whether they were excluded from the analysis.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Nasr-2009","2015-03-05 14:30:25 +0000","UNKNOWN","Number of relapses was collected but not reported in the paper. Quote: ""The questionnaire was designed to collect information about age, sex, educational level, birth order, number of siblings, marital status, number of children, occupation and work status, and to gather details about the illness (age at onset, number of admissions in hospital, number of relapses, family history of mental illness and so on). Information on age, sex, educational level, number of siblings, marital status, number of children, occupation and work status is reported.""","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Individual-_x002d_-Nasr-2009","2013-11-29 10:21:15 +0000","UNKNOWN","Funding not stated.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Unclear-_x002d_-Li-2005","2013-11-24 20:13:13 +0000","UNKNOWN","Randomisation method not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Unclear-_x002d_-Li-2005","2013-11-24 20:13:13 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Unclear-_x002d_-Li-2005","2013-11-24 20:31:28 +0000","UNKNOWN","Not stated.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Unclear-_x002d_-Li-2005","2013-11-24 20:31:29 +0000","UNKNOWN","Not stated.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Unclear-_x002d_-Li-2005","2014-10-21 14:45:11 +0100","NO","Those leaving early were excluded from the analysis.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Unclear-_x002d_-Li-2005","2013-11-24 20:13:13 +0000","YES","All measured outcomes reported.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Psychoeducation (brief) for people with serious mental illness [v2.2-For publication].rm5","STD-Unclear-_x002d_-Li-2005","2013-11-24 20:13:13 +0000","YES","None obvious.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Burgoyne-1983","2009-09-29 14:31:57 +0100","YES","Using a book of random numbers.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Burgoyne-1983","2009-11-24 16:09:20 +0000","NO","Allocation not concealed from research assistant who allocated to groups and made the prompt telephone calls.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Burgoyne-1983","2009-09-29 14:33:30 +0100","UNKNOWN","Not discussed.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Burgoyne-1983","2009-09-29 14:33:55 +0100","YES","All participants included in analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Burgoyne-1983","2009-09-29 14:34:23 +0100","YES","All outcomes reported for each group.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Burgoyne-1983","2009-09-29 14:36:08 +0100","NO","Data likely skewed to show smaller effect of telephone prompts due to low prevalence of telephone ownership in this study population.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Kitcheman-2008","2009-09-29 12:42:39 +0100","YES","Using an on-line computer program.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Kitcheman-2008","2009-09-29 13:01:34 +0100","YES","Allocation concealed to all researchers but trial co-ordinator.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Kitcheman-2008","2010-01-18 17:12:06 +0000","UNKNOWN","Blinding to patients and clinic staff and those collecting data.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Kitcheman-2008","2010-01-18 17:12:19 +0000","YES","Quote: ""We were able to acquire all but one record for the primary outcome"". It is not clear which subgroup this record belonged to. Unlikely to have a significant effect on results.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Kitcheman-2008","2010-03-11 13:42:09 +0000","YES","Clearly reported all outcomes.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Kitcheman-2008","2010-01-18 17:12:35 +0000","YES","No indication of other biases. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Kluger-1983","2009-09-29 14:37:45 +0100","UNKNOWN","Quote: 'Subjects were randomly assigned'. Consecutive attenders at the clinic were assigned to a 'random list' of interventions. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Kluger-1983","2010-03-11 13:41:48 +0000","NO","Quote: 'A health paraprofessional' allocated the participants to each intervention when they at the clinic using a random list of interventions.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Kluger-1983","2009-09-29 14:39:56 +0100","UNKNOWN","Not discussed.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Kluger-1983","2009-09-29 14:42:54 +0100","YES","All participants included in analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Kluger-1983","2009-09-29 14:42:52 +0100","YES","All groups reported on.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Kluger-1983","2009-09-29 14:42:47 +0100","NO","The separate analysis of those participants who were allocated to telephone prompts but could not be contacted by 'phone may have led to a greater effect size in the telephone prompt groups.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Swenson-1988","2009-09-29 14:43:28 +0100","UNKNOWN","Quote: 'Block randomisation' Not discussed further.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Swenson-1988","2009-09-29 14:43:41 +0100","UNKNOWN","Not discussed.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Swenson-1988","2009-09-29 14:43:48 +0100","UNKNOWN","Not discussed.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Swenson-1988","2009-09-29 14:44:14 +0100","YES","All participants accounted for and included in analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Swenson-1988","2009-09-29 14:44:55 +0100","YES","All intended outcomes reported for each group.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Prompts to encourage appointment attendance for people with serious mental illness [v7.0-For publication].rm5","STD-Swenson-1988","2009-09-29 14:51:04 +0100","NO","The participants were clients who phoned themselves to make an appointment which may lead to an artificially high attendance rate. The average waiting time was only eight days so increasing the chances of attending the appointment. The study included children referred to the service so the findings may not be applicable to the general adult population. Appointments on a Monday were excluded which will have an unknown effect on the results.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Problem solving skills for schizophrenia [v10.0-For publication].rm5","STD-Bradshaw-1993","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Problem solving skills for schizophrenia [v10.0-For publication].rm5","STD-Mayang-1990","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Problem solving skills for schizophrenia [v10.0-For publication].rm5","STD-Tarrier-1993","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Berger-2007","2009-02-25 12:03:36 +0000","YES","Randomised code list.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Berger-2007","2009-02-25 12:03:37 +0000","YES","Sealed envelopes.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Berger-2007","2009-02-25 12:03:39 +0000","YES","Key to allocation code kept from participants and researchers until end of data entry.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Berger-2007","2009-01-27 12:51:59 +0000","YES","Missing data from those who left early dealt with by multiple imputation.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Berger-2007","2009-02-25 12:03:55 +0000","NO","Several outcomes not reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Berger-2007","2009-02-25 12:03:58 +0000","NO","Main author consultant for several major antipsychotic drug companies.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Emsley-2002","2009-02-02 13:14:18 +0000","UNKNOWN","No description given.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Emsley-2002","2009-02-02 13:14:17 +0000","UNKNOWN","No description given.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Emsley-2002","2009-02-02 13:14:14 +0000","UNKNOWN","No description given.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Emsley-2002","2009-02-06 10:35:46 +0000","YES","LOCF, ITT.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Emsley-2002","2009-02-25 12:12:26 +0000","YES","All outcomes reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Emsley-2002","2009-02-25 12:49:33 +0000","UNKNOWN","Grant sponsored, medication supplied by Laxdale Ltd.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Emsley-2006","2009-02-25 12:18:04 +0000","UNKNOWN","Assignment of numbers by independent clinical trials company but not described how achieved.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Emsley-2006","2009-02-25 12:18:09 +0000","YES","Identical sealed packs.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Emsley-2006","2009-02-25 12:18:17 +0000","YES","Identical sealed packs, identical capsules, code not broken until after trial.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Emsley-2006","2009-02-06 10:42:05 +0000","YES","LOCF, ITT.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Emsley-2006","2009-02-25 12:18:21 +0000","YES","All outcomes reported but most data presentation unusable.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Emsley-2006","2009-02-25 12:18:39 +0000","UNKNOWN","Supported by grant from Stanley Medical/Alliance Research Institute, medication supplied by Amarin Neuroscience Ltd.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Fenton-2001","2009-02-25 12:19:35 +0000","UNKNOWN","No description given.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Fenton-2001","2009-02-25 12:19:38 +0000","UNKNOWN","No description given.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Fenton-2001","2009-02-25 12:19:46 +0000","YES","Identical capsules used, raters blind to treatment.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Fenton-2001","2009-02-25 12:19:48 +0000","YES","LOCF, ITT.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Fenton-2001","2009-02-25 12:19:53 +0000","YES","All outcomes reported and presented with means and SD.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Fenton-2001","2009-02-25 12:19:59 +0000","UNKNOWN","Supported by grant from Stanley Medical/Alliance Research Institute.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Peet-2001a","2009-02-25 12:21:16 +0000","YES","Unique randomisation number generated by a company independent to the trial.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Peet-2001a","2009-02-25 12:21:20 +0000","YES","Pre-coded packages, code kept from researchers.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Peet-2001a","2009-02-25 12:21:24 +0000","YES","Identical capsules in appearance and taste, raters blind to allocation.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Peet-2001a","2009-02-25 12:21:28 +0000","UNKNOWN","Loss to follow up described but how this data was dealt with not described.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Peet-2001a","2009-02-25 12:21:33 +0000","YES","All outcomes reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Peet-2001a","2009-02-10 11:58:00 +0000","NO","Laxdale Ltd supplied trial medication and some financial support.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Peet-2001b","2009-02-25 12:22:31 +0000","YES","Unique randomisation number generated by a company independent to the trial.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Peet-2001b","2009-02-25 12:22:35 +0000","YES","Pre-coded packages, code kept from researchers.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Peet-2001b","2009-02-25 12:22:39 +0000","YES","Identical capsules in appearance and taste, raters blind to allocation.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Peet-2001b","2009-02-25 12:22:43 +0000","UNKNOWN","Loss to follow up described but how this data was dealt with not described.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Peet-2001b","2009-02-25 12:22:47 +0000","YES","All outcomes reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Peet-2001b","2009-02-10 11:58:35 +0000","NO","Laxdale Ltd supplied trial medication and some financial support.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Peet-2002","2009-02-25 12:24:16 +0000","YES","Unique randomisation number generated by a company independent to the trial.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Peet-2002","2009-02-25 12:24:22 +0000","YES","Pre-coded packages, code kept from researchers.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Peet-2002","2009-02-25 12:24:26 +0000","YES","Identical capsules in appearance and taste, raters blind to allocation.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Peet-2002","2009-02-25 12:24:33 +0000","UNKNOWN","Loss to follow up described but how this data was dealt with not described.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Peet-2002","2009-02-25 12:24:37 +0000","NO","Some outcomes had no data presentation in results.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Peet-2002","2009-02-25 12:29:51 +0000","NO","Main author Dr. Malcolm Peet received research funding from Laxdale, Prof. Horrobin was an employee of Laxdale at the time and other members of the E-E Multicentre Study Group received remuneration from Laxdale for the time spent on the study. Laxdale supplied medication for trial.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Wolkin-1986","2009-02-25 12:50:34 +0000","UNKNOWN","No description given.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Wolkin-1986","2009-02-25 12:50:37 +0000","UNKNOWN","No description given.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Wolkin-1986","2009-02-25 12:50:41 +0000","UNKNOWN","No description given.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Wolkin-1986","2009-02-25 12:50:46 +0000","NO","Significant loss occurred but not addressed in text.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Wolkin-1986","2009-02-25 12:50:50 +0000","YES","All outcomes reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Polyunsaturated fatty acid supplementation for schizophrenia [v11.0-For publication].rm5","STD-Wolkin-1986","2009-02-25 12:50:55 +0000","UNKNOWN","Supported in part by Efamol ltd.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Abuzzahab-1980_x002a_","2013-09-11 14:39:37 +0100","NO","Double blind: no description of randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Abuzzahab-1980_x002a_","2012-06-21 14:05:01 +0100","UNKNOWN","No description of allocation concealment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Abuzzahab-1980_x002a_","2013-09-11 14:39:41 +0100","UNKNOWN","Double blind: no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Abuzzahab-1980_x002a_","2013-09-12 09:59:06 +0100","NO","Follow-up: 24%, quote: 'fifteen patients continued treatment for the full three years. During the first year of treatment, 22 patients left and 29 left during the third year of treatment. Six patients terminated during the second year' (p548). Ultimate numbers of people leaving the study early and reasons are not explained.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Abuzzahab-1980_x002a_","2013-09-11 14:25:27 +0100","NO","No data reported for CGI; Katz Adjustment Scale. Overall reporting was poor, with no SD provided for continuous-scale data and use of unclear denominators.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Abuzzahab-1980_x002a_","2013-09-12 09:59:52 +0100","UNKNOWN","Rating scales: raters were not stated to be independent of treatment, quote: ‘…the same psychiatrist evaluated patients in pretreatment, weekly during the first month, monthly during the first year, and at 3-month intervals during the second and third years’ (p72).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Amin-1977","2013-09-12 11:58:35 +0100","UNKNOWN","Randomised: no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Amin-1977","2013-09-12 11:58:40 +0100","UNKNOWN","Randomly assigned: no further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Amin-1977","2013-09-12 11:57:32 +0100","UNKNOWN","Double blind: no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Amin-1977","2013-09-12 10:01:44 +0100","UNKNOWN","Follow-up: 100% (LOCF), 75% completed the study, pimozide: n = 2 did not complete the trial. Quote: 'one was discontinued after 28 days due to severe amenorrhoea, insomnia and tremor, and the second participant was discontinued after 56 days for administrative reasons'; trifluoperazine: n = 3 did not complete the trial: quote: 'one patient was discontinued after 28 days because of clinical deterioration, and the other two participants were discontinued after 84 days for administrative reasons' (p16). It is not clear whether these were included in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Amin-1977","2012-06-25 12:27:59 +0100","UNKNOWN","No continuous data provided for the BPRS. Quote: 'one patient was not rated on the CGI', no further description (p16).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Amin-1977","2013-09-12 10:01:54 +0100","UNKNOWN","Rating scales: raters were not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Andersen-1972","2012-06-20 16:06:39 +0100","NO","No description of randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Andersen-1972","2012-06-21 14:04:55 +0100","UNKNOWN","No description of allocation concealment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Andersen-1972","2013-09-12 11:57:34 +0100","UNKNOWN","Double blind: trifluoperazine was administered twice a day and pimozide was administered once a day; therefore dummy tablets were used to preserve double-blind conditions.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Andersen-1972","2013-09-11 14:40:59 +0100","YES","Follow-up: 90%, n = 2 (one from each group) withdrew from the study after 3 weeks because of 'deterioration with psychomotor excitation' (p3). They were excluded from final results, which present data for n = 38 (n = 19 in each treatment group).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Andersen-1972","2013-02-06 12:01:50 +0000","NO","No standard deviations reported with continuous data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Andersen-1972","2013-09-12 10:21:11 +0100","UNKNOWN","Rating scales: raters were independent of treatment: quote: They 'were not members of the hospital staff and had no contact with patients except in connection with the ratings [and were] unaware which drug the patient was receiving and knew nothing about the patients' behaviour in the wards' (p3).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Anumonye-1976","2013-09-12 11:56:20 +0100","UNKNOWN","Randomised: participants were 'matched for age and duration of illness' and were randomly assigned (p19), no further details provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Anumonye-1976","2012-06-21 14:04:52 +0100","UNKNOWN","No description of allocation concealment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Anumonye-1976","2013-09-12 11:59:22 +0100","UNKNOWN","Single blind: participants were blinded to the intervention. Quote: 'the attending physician knew only that the patient was given either chlorpromazine or pimozide, which had been pre-packaged for each patient', and 'drugs were administered separately by a single-blind procedure' (p19). Whether blinding has been successful has not been tested.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Anumonye-1976","2013-09-12 11:59:28 +0100","UNKNOWN","Follow-up: (after the 4-week comparison of chlorpromazine vs placebo), all 24 participants completed the initial 4-week course on admission. On discharge, 4 participants on pimozide and 2 on chlorpromazine did not return to the clinic. Details of attrition are not clear. However it is clear that none of the participants discontinued the trial because of adverse effects. Late clinical global assessment and side effects (at 6 and 12 months) are reported for only 8 participants on pimozide who continued with follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Anumonye-1976","2013-09-11 14:25:34 +0100","NO","Statistical reporting was incomplete. No adverse effects were presented for participants taking chlorpromazine.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Anumonye-1976","2013-09-12 11:59:43 +0100","UNKNOWN","Rating scales: completed by an independent psychologist.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Barnes-1983","2013-09-12 11:56:24 +0100","YES","Randomised: participants were matched on the basis of age, sex and weekly fluphenazine dose; assigned by independent statistician.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Barnes-1983","2013-09-11 14:42:02 +0100","YES","Allocation by an independent statistician. (unpublished data) **contact with trial author stated that an independent statistician randomly allocated participants using a series of selected envelopes, when all participants gave their consent for inclusion in the study, the envelopes were opened and participants were randomly allocated accordingly.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Barnes-1983","2013-09-12 11:57:36 +0100","UNKNOWN","Double blind: double dummy design, assessor blind (unpublished data). Those allocated to the fluphenazine group continued to receive their dose unchanged but were given additional placebo tablets, and those who were allocated pimozide received additional placebo injections (p194).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Barnes-1983","2013-09-12 10:35:15 +0100","YES","Follow-up: 100% (LOCF), data on number of people leaving the trial early have been indicated and accounted for. SBAS assessments were completed for all participants except one at the endpoint assessment, as the participant was abroad from the time of relapse until the end of the trial. 1-Year follow-up of all participants who had begun the trial, including all withdrawals, early leavers and relapsed participants who were involved in the analysis (p195).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Barnes-1983","2012-06-21 16:52:25 +0100","UNKNOWN","None detected.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Barnes-1983","2013-09-12 12:00:12 +0100","UNKNOWN","Rating scales: raters were not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Chouinard-1970","2013-09-12 11:56:25 +0100","UNKNOWN","Randomised: no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Chouinard-1970","2013-09-11 14:42:30 +0100","UNKNOWN","'Randomly assigned' (p599): no further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Chouinard-1970","2013-09-12 12:00:37 +0100","UNKNOWN","Double blind: Quote, 'drugs were supplied in identical capsules' (p599). Not clear as to who was blinded. Not tested if blinding was successful.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Chouinard-1970","2013-09-12 12:00:53 +0100","YES","Follow-up: 100% (LOCF). Quote: 'one male patient treated with pimozide was discontinued the study after 54 days of drug treatment due to severely disorganised psychotic behaviour which could not be controlled by intramuscular chlorpromazine administration' (p600).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Chouinard-1970","2013-09-11 14:25:39 +0100","UNKNOWN","Nurses Observation Scale for Inpatient Evaluation (NOSIE) stated as used, but no data were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Chouinard-1970","2013-09-12 12:01:17 +0100","NO","Rating scales: raters not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Chouinard-1982","2013-09-12 11:56:26 +0100","UNKNOWN","Randomised: no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Chouinard-1982","2013-09-12 10:39:38 +0100","UNKNOWN","'Randomly assigned' (p13), no further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Chouinard-1982","2013-09-12 11:57:39 +0100","UNKNOWN","Double blind: pimozide and chlorpromazine were administered in 'identical capsules under double-blind conditions' (p14). Pimozide was given once in the morning, and chlorpromazine was administered on an equally divided regimen to aid blinding, participants receiving pimozide were given a placebo tablet at night. Participants who required additional medication received doses under double-blind conditions. No further details related to success of blinding methods.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Chouinard-1982","2013-09-12 10:39:57 +0100","YES","Follow-up, 100%. All participants completed the 4-week trial.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Chouinard-1982","2013-09-11 14:25:41 +0100","NO","Statistical reporting was incomplete (no SDs). Treatment Emergent Symptom Form and Extrapyramidal Symptom Rating Scale stated as used, but no data were reported; results from laboratory tests not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Chouinard-1982","2013-09-12 12:02:13 +0100","UNKNOWN","Rating scales: raters not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Claghorn-1974","2013-09-12 11:56:26 +0100","UNKNOWN","Randomised: no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Claghorn-1974","2013-09-12 10:41:10 +0100","UNKNOWN","'Random assignment' (p1006), no further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Claghorn-1974","2013-09-12 11:57:40 +0100","UNKNOWN","Double blind: Medication was supplied in identical appearing capsules (p1006): no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Claghorn-1974","2013-09-12 10:41:16 +0100","UNKNOWN","Follow-up, unclear: no details provided.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Claghorn-1974","2012-06-25 14:16:11 +0100","NO","Statistical reporting was incomplete for all scale data (no SDs).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Claghorn-1974","2013-09-12 12:02:05 +0100","UNKNOWN","Rating scales: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Clark-1975_x002a_","2013-09-12 12:03:22 +0100","YES","Randomised: Quote, 'patients were allocated to treatment in random fashion in blocks of 8 with 3 allocated to pimozide, 3 to thioridazine and 2 to placebo' (p137).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Clark-1975_x002a_","2013-09-12 12:03:16 +0100","YES","Randomly allocated: Quote, 'patients were allocated to treatment in random fashion in blocks of 8' (p137).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Clark-1975_x002a_","2013-09-12 11:57:41 +0100","YES","Double blind: Quote: 'each patient received medication from her own individual stock bottle labelled with her name only, and the double blind technique was followed throughout. All medication was prepared in identically-appearing capsules' (p137).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Clark-1975_x002a_","2013-09-12 12:04:35 +0100","UNKNOWN","Follow-up: 60%. All participants terminating before two weeks were dropped from the study, 3 participants in pimozide group and 1 each in thioridazine and placebo groups left the study in less than 2 weeks. Of the remaining 35 participants, only 24 completed the full 24 weeks. Of the 11 who completed more than 2 weeks but less than 24 weeks of the study, n = 2 each in pimozide and thioridazine group and n = 5 in placebo group were withdrawn as treatment failures; n = 1 in placebo was found to have glaucoma; n = 1 in thioridazine developed an intercurrent medical complication not related to drug therapy.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Clark-1975_x002a_","2012-06-25 14:16:24 +0100","NO","Statistical reporting was incomplete for all scale data (no SDs).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Clark-1975_x002a_","2013-09-12 12:01:21 +0100","NO","Rating scales: research nurse and project psychiatrist not stated to be independent to the study.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Denijs-1973","2013-09-12 11:56:29 +0100","UNKNOWN","Randomised: participants were, Quote: 'randomly divided between two groups' (p50).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Denijs-1973","2013-09-12 11:46:11 +0100","UNKNOWN","'Randomly divided' (p50), no further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Denijs-1973","2013-09-12 11:57:42 +0100","UNKNOWN","Double blind: phase 3 was conducted under 'strict double-blind conditions' (p50). Pimozide and placebo tablets were identical in appearance; were packed in quantities sufficient for at least six months. Quote: 'for the double blind phase","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Denijs-1973","2013-09-12 12:04:07 +0100","YES","Follow-up: 100% (LOCF). 38 of 40 participants completed the six-month double-blind trial. Two participants withdrawn from the study, who had completed four months of the trial before dropping, were accounted for and included in the final evaluation of results. One participant receiving pimozide was withdrawn because of illness and died a few days later, toxic-infectious shock was determined as the cause of death: quote 'no phenomena suggestive of drug-related death were found' (p55). The other participant, receiving placebo, experienced a considerable increase in psychotic symptoms, refused to take medication and had to be withdrawn from the study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Denijs-1973","2012-06-26 12:31:35 +0100","NO","Statistical reporting was incomplete for all scale data (no SDs).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Denijs-1973","2013-09-12 12:02:07 +0100","UNKNOWN","Rating scales: raters not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-De-Ronchi-1996","2013-09-12 11:56:28 +0100","UNKNOWN","Randomised: no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-De-Ronchi-1996","2012-08-15 10:46:33 +0100","UNKNOWN","Not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-De-Ronchi-1996","2013-02-06 12:01:53 +0000","NO","Single blind (participant).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-De-Ronchi-1996","2013-09-12 12:05:26 +0100","YES","Follow-up: 100% (LOCF). n = 1 participant treated with 300 mg/d levosulpiride alone dropped out after 15 days because of menstrual delay, mammary tension, galactorrhoea, tachycardia and tremors.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-De-Ronchi-1996","2012-08-15 11:13:42 +0100","UNKNOWN","None detected.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-De-Ronchi-1996","2013-09-12 12:02:06 +0100","UNKNOWN","Rating scales: raters not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Donlon-1977","2013-09-12 11:56:30 +0100","UNKNOWN","Randomised: no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Donlon-1977","2013-09-12 11:47:13 +0100","UNKNOWN","Participants were, Quote: 'assigned randomly... by a disinterested third party' (p120). No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Donlon-1977","2013-09-12 11:57:43 +0100","UNKNOWN","Double blind: no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Donlon-1977","2013-09-12 12:05:45 +0100","UNKNOWN","Follow-up: 67% with pimozide. n = 3 were uncooperative, n = 2 experienced limiting side effects, n = 2 thought the drug was ineffective and n = 2 were withdrawn for 'personal reasons'; in fluphenazine: n = 1 were uncooperative, n = 1 failed to return, n = 2 experienced limiting side effects, n = 1 thought the drug was ineffective, n = 1 withdrew because they thought that the drug was ineffective, and n = 1 were withdrawn and required amitriptyline.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Donlon-1977","2012-07-18 15:01:07 +0100","NO","Statistical reporting was incomplete for all scale data (no SDs).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Donlon-1977","2013-09-12 11:58:06 +0100","UNKNOWN","Rating scales: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Falloon-1978","2013-09-11 14:47:26 +0100","UNKNOWN","Randomised: 'randomly allocated' (p61) no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Falloon-1978","2013-09-11 14:47:31 +0100","UNKNOWN","'Randomly allocated': no further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Falloon-1978","2013-09-12 12:06:12 +0100","UNKNOWN","Double blind: double dummy; Quote, 'in order to preserve double blind conditions, patients were required to take both an injection and a tablet' (p60).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Falloon-1978","2013-09-11 14:47:39 +0100","UNKNOWN","Follow-up: 86%; for the 12-month trial period, only data for n = 38 participants for adverse effects. From n = 53 people who consented to enter the trial, quote: 'a few patients were withdrawn at a later stage of the trial because of an unsatisfactory response to treatment... a further group of patients (7%) commenced the trial regime in hospital, but did not continue the medication after the first monthly follow-up; small number refused to continue treatment or relapsed soon after discharge' (p62). Unclear reporting, exact numbers are not made clear.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Falloon-1978","2012-06-28 14:38:15 +0100","NO","Statistical reporting was incomplete for all scale data (no SDs).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Falloon-1978","2013-09-11 14:25:53 +0100","UNKNOWN","Rating scales: Clinical and social assessments were made independently by the research clinician and a social worker employing a standardised interview (p61).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Friedman-2011","2013-09-11 14:47:45 +0100","UNKNOWN","Randomised: in a 1:1 fashion (p1290).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Friedman-2011","2012-07-16 15:11:39 +0100","UNKNOWN","Not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Friedman-2011","2013-09-11 14:47:53 +0100","UNKNOWN","Double blind: physician blinded (p1290) not tested whether successful.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Friedman-2011","2013-09-12 12:06:31 +0100","UNKNOWN","Follow-up: 100% (LOCF). 85% of participants completed the study, n = 1 randomly assigned to pimozide withdrew early because of severe EPS, and n = 2 withdrew because of severe adverse events deemed unrelated to the study medication. In total n = 5 randomly assigned to placebo withdrew early (n = 2 because of intensified positive symptoms; n = 1 because of an episode of bigeminy; n = 1 because of hypotension, and n = 1 after withdrawal of consent).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Friedman-2011","2013-09-11 14:25:55 +0100","UNKNOWN","Mention of specific adverse effects was made (hypersalivation), and it was stated that other side effects showed no significant difference; however, none were reported (p1292).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Friedman-2011","2013-09-11 14:25:55 +0100","NO","Rating scales: ESRS ratings were carried out by different personnel from those performing the PANSS and functional competence ratings.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Gowardman-1973","2013-09-11 14:48:18 +0100","UNKNOWN","Randomised: 'randomly allotted by the hospital pharmacist' (p487); no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Gowardman-1973","2013-09-11 14:48:23 +0100","YES","'Randomly allotted': allocation by the hospital pharmacist, suggesting adequate separation of allocation and treatment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Gowardman-1973","2013-09-12 11:50:21 +0100","YES","Double blind: Quote, 'investigators did not know who was receiving which drug. The drugs were supplied in identical capsules' (p487). To ensure participant blinding, those receiving pimozide were given the active medication in the morning and a matched placebo in the evening, and participants receiving haloperidol were given the active medication in both the morning and the evening, the capsules were indistinguishable in outward appearance (p488).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Gowardman-1973","2013-09-11 14:48:43 +0100","YES","Follow-up: 100%, 'all patients completed the trial period of three months' (p488).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Gowardman-1973","2013-09-11 14:25:57 +0100","NO","Adverse effects were mentioned (including dystonic reactions and Parkinsonism); however, neither specific side effects nor group numbers were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Gowardman-1973","2012-06-28 16:10:02 +0100","UNKNOWN","Rating scales: not stated.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Gross-1974_x002a_","2013-09-11 14:49:05 +0100","UNKNOWN","Randomised: 'randomly assigned' (p698). No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Gross-1974_x002a_","2013-09-11 14:49:10 +0100","UNKNOWN","'Randomly assigned': no further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Gross-1974_x002a_","2013-09-11 14:49:18 +0100","UNKNOWN","Double blind: 'identical appearing capsules' provided (p698): no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Gross-1974_x002a_","2013-09-11 14:25:59 +0100","NO","Follow-up: 59%24% of pimozide-treated participants, 45% of trifluoperazine-treated participants and 55% of placebo-treated participants failed to complete the study for various reasons.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Gross-1974_x002a_","2012-07-09 16:33:49 +0100","NO","Statistical reporting was incomplete for all scale data (no SDs).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Gross-1974_x002a_","2013-09-11 14:25:59 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Gunduz_x002d_Bruce-2013","2013-09-11 14:49:27 +0100","UNKNOWN","Randomised: participants were 'randomized to identical-looking pimozide or placebo capsules by the research pharmacist who was not involved with the subjects' (p345). No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Gunduz_x002d_Bruce-2013","2013-09-11 14:49:30 +0100","UNKNOWN","No details: participants were 'stratified as to whether they were receiving psychoactive medications such as mood stabilizers' to ensure that equal numbers were randomly assigned to either group based on treatment profile (p345).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Gunduz_x002d_Bruce-2013","2013-09-11 14:49:37 +0100","UNKNOWN","Double blind: 'identical-looking pimozide or placebo capsules' provided (p345) no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Gunduz_x002d_Bruce-2013","2013-09-11 14:49:42 +0100","UNKNOWN","Follow-up: 88%. Four participants left the study early before medication was given; 'twenty-eight subjects completed most of the study procedures' (p345). Of the 28 participants remaining in the study, two participants from the pimozide augmentation group left early, n = 1 because of early termination caused by QTc prolongation, and n = 1 as the result of withdrawn consent (LOCF).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Gunduz_x002d_Bruce-2013","2013-09-11 14:26:01 +0100","NO","Protocol to the study stated that socioeconomic status; weight; Strauss Carpenter level of function; Schedule for the Deficit Syndrome; neurocognitive battery; AIMS; and EPS using the Simpson-Angus Scale would each be assessed; however, no data were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Gunduz_x002d_Bruce-2013","2013-02-07 11:22:32 +0000","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Haas-1982","2013-09-11 14:49:46 +0100","NO","Double blind: randomisation not described.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Haas-1982","2012-07-10 16:35:57 +0100","NO","No description of allocation concealment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Haas-1982","2013-09-11 14:49:50 +0100","UNKNOWN","Double-blind: 'presentation of the drugs was identical in liquid form' (p71). No further details. Not tested if blinding was successful.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Haas-1982","2013-09-11 14:49:59 +0100","NO","Follow-up: 93%. 28 participants completed the trial. One expressed the wish to quit at the end of day 10, and another developed severe side effects.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Haas-1982","2013-01-23 06:48:32 +0000","NO","Statistical reporting was incomplete for all scale data (no SDs).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Haas-1982","2013-09-11 14:26:03 +0100","UNKNOWN","Rating scales: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Huber-1971","2013-09-11 14:50:03 +0100","UNKNOWN","Randomised: 'randomly assigned' (p304). No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Huber-1971","2012-07-10 16:36:11 +0100","UNKNOWN","No description of allocation concealment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Huber-1971","2013-09-11 17:01:53 +0100","UNKNOWN","Double blind: 'Double blind procedure was followed throughout'. No further details. Not tested if blinding was successful.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Huber-1971","2013-09-12 12:07:47 +0100","NO","Follow-up: 95%. 19 participants completed the trial. One participant dropped out before beginning the medication phase after developing severe hyperpyrexia. Analysis was completed on 19 participants.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Huber-1971","2012-07-20 12:30:36 +0100","NO","Statistical reporting was incomplete for all scale data (no SDs).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Huber-1971","2013-09-11 14:26:03 +0100","UNKNOWN","Rating scales: BPRS was completed at beginning and end of study by the psychiatrist; NOISE was completed at four-week intervals throughout the study; CGI was obtained from both the psychiatrist and nursing services.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Kline-1977","2013-09-11 14:50:24 +0100","NO","Double blind: no description of randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Kline-1977","2012-07-10 16:43:42 +0100","NO","No description of allocation concealment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Kline-1977","2013-09-11 14:50:29 +0100","UNKNOWN","Double blind: no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Kline-1977","2013-09-12 12:08:06 +0100","NO","Follow-up: unclear, data reported for all participants by 16 weeks for global state using the CGI, but data incomplete for mental state using the BPRS, with around 52% of participants lost in the total. LOCF for global state data. Numbers of participants leaving the study are inconsistently reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Kline-1977","2013-09-11 14:50:37 +0100","NO","Statistical data incomplete: only 'final' CGI data provided for all participants in results as LOCF, but data for BPRS were presented for each time of rating. Complete numbers of participants lost to follow-up are unclear.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Kline-1977","2013-09-11 14:26:06 +0100","UNKNOWN","Rating scales: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Kolivakis-1974","2013-09-11 14:50:40 +0100","UNKNOWN","Randomised: 'randomly assigned' (p999). No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Kolivakis-1974","2013-09-11 14:50:44 +0100","UNKNOWN","'Randomly assigned': no further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Kolivakis-1974","2013-09-11 14:50:50 +0100","UNKNOWN","Double blind: 'identical appearing capsules' (p999). No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Kolivakis-1974","2013-09-11 14:51:05 +0100","NO","Follow-up: 67%: attrition included; n = 4 participants in both groups with 'intensified symptoms'; n = 3 receiving pimozide and n = 4 receiving chlorpromazine refused or forgot to take the medication; and n = 1 suicide was reported in the chlorpromazine group (this participant was receiving 75 mg chlorpromazine daily upon admission to the study; two weeks into the study, a 'fit of rage' resulted in a fracture to his arm and loss of his job). Chlorpromazine was increased to 225 mg daily. Six days later, while taking the same dosage, he committed suicide (p1002). Only data for the remaining n = 35 are presented in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Kolivakis-1974","2012-07-12 09:38:43 +0100","NO","For mental state outcomes using the BPRS, quote, 'under the protocol, only patients whose symptoms had been brought under control with other neuroleptics were evaluated. Since a large number of the symptoms at the start of the study were rated 2 (","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Kolivakis-1974","2013-09-11 14:26:08 +0100","UNKNOWN","Rating scales: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Kudo-1972","2013-09-11 14:51:43 +0100","UNKNOWN","Randomised: the order in which participants received pimozide was randomly assigned. Participants were matched in pairs for sex, clinical picture and age, the exact method was not described (p686).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Kudo-1972","2012-07-12 11:36:18 +0100","UNKNOWN","No description of allocation concealment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Kudo-1972","2013-09-11 14:52:22 +0100","UNKNOWN","Double blind: tablets were identical in appearance (p686). No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Kudo-1972","2013-09-12 12:08:49 +0100","NO","Follow-up: 92%. One participant from each group left early before completion. No further details provided.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Kudo-1972","2012-07-12 11:42:34 +0100","UNKNOWN","None obvious. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Kudo-1972","2012-07-12 11:42:38 +0100","UNKNOWN","Rating scales: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McCreadie-1980","2013-09-11 14:52:48 +0100","UNKNOWN","Randomised: no further description.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McCreadie-1980","2013-09-11 14:53:06 +0100","UNKNOWN","'Blindly allocated': no further description.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McCreadie-1980","2013-09-11 14:53:30 +0100","YES","Double blind: 'to ensure double-blind conditions, participants received active fluphenazine injections and placebo pimozide tablets, or placebo fluphenazine injections and active pimozide tablets'.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McCreadie-1980","2013-09-12 12:09:16 +0100","UNKNOWN","Follow-up: 97%. One participant receiving pimozide refused all medication from the sixth month and therefore was withdrawn from the trial; 'he was counted neither as a relapse nor as a non-relapse' (p512).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McCreadie-1980","2012-05-03 11:22:27 +0100","NO","Not all data reported for listed outcomes.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McCreadie-1980","2013-09-12 12:09:26 +0100","UNKNOWN","Rating scales: participants' mental state was assessed independently by two psychiatrists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McCreadie-1982_x002a_","2013-09-11 14:54:15 +0100","UNKNOWN","Randomised: no further description.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McCreadie-1982_x002a_","2013-09-11 14:54:52 +0100","UNKNOWN","'Blindly allocated': no further description.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McCreadie-1982_x002a_","2013-09-11 14:55:01 +0100","YES","Double blind: 'to ensure double-blind conditions, participants received active fluphenazine injections and placebo pimozide tablets, or placebo fluphenazine injections and active pimozide tablets'.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McCreadie-1982_x002a_","2013-09-12 12:09:43 +0100","NO","Follow-up: 58%. n = 5/13 taking pimozide and n = 6/15 taking fluphenazine were withdrawn (reasons included exacerbation of positive symptoms; depression; suicidal ideas and attempts; family request to withdraw; tardive dyskinesia and complaints of tiredness).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McCreadie-1982_x002a_","2012-05-03 15:04:10 +0100","NO","Not all data reported for listed outcomes.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McCreadie-1982_x002a_","2013-09-12 12:09:50 +0100","UNKNOWN","Rating scales: participants' mental state was assessed independently by two psychiatrists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McCreadie-1987","2013-09-11 14:56:26 +0100","UNKNOWN","Randomised: participants were randomly allocated to receive either medication.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McCreadie-1987","2012-07-17 09:40:46 +0100","UNKNOWN","No description of allocation concealment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McCreadie-1987","2013-09-11 14:56:33 +0100","UNKNOWN","Double blind: 'double dummy design', no further description.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McCreadie-1987","2013-09-12 12:10:07 +0100","NO","Follow-up: 91%. n = 15/23 receiving pimozide completed the five weeks of treatment (n = 3 refused to continue; n = 1 discharged himself against medical advice; n = 1 developed skin rash), and a further n = 3 switched to maintenance therapy; n = 17/23 receiving flupenthixol completed the five weeks (n = 1 was discharged with no significant elevation in plasma prolactin levels; n = 1 was discharged and left Scotland; n = 1 discharged himself against medical advice, and a further n = 3 switched to maintenance therapy).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McCreadie-1987","2012-07-17 09:08:22 +0100","UNKNOWN","Numbers of participants differ between the original reports and the follow-up reports.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McCreadie-1987","2012-08-17 12:27:06 +0100","NO","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McInnes-1978","2013-09-12 12:10:22 +0100","YES","Randomised: participants were 'randomly assigned' by 'flicking a coin', using a 'double blind code' (p171).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McInnes-1978","2012-07-17 09:40:51 +0100","UNKNOWN","No description of allocation concealment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McInnes-1978","2013-09-11 14:58:07 +0100","UNKNOWN","Double blind: no further description.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McInnes-1978","2012-07-17 09:43:07 +0100","UNKNOWN","Follow-up: unclear. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McInnes-1978","2012-07-17 09:44:01 +0100","UNKNOWN","None detected. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-McInnes-1978","2012-07-17 09:46:01 +0100","UNKNOWN","Rating scales: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Nishikawa-1985","2013-09-11 14:59:02 +0100","UNKNOWN","Randomised: no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Nishikawa-1985","2013-09-11 14:59:06 +0100","UNKNOWN","Participants were 'randomly assigned' (p1162): no further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Nishikawa-1985","2013-09-11 14:59:11 +0100","YES","Double blind: drug appearance, taste, volume made identical 'by adding a common gastric acid' (p1162).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Nishikawa-1985","2013-09-12 12:10:46 +0100","NO","Follow-up: Of n = 106, six participants left early because they took drugs irregularly and therefore were excluded from the final data and analysis. A further number of n = 76 discontinued designated use of assigned drugs through overdosage (n = 21) or relapse (n = 55). It is not clear whether the additional n = 76 remained in the analysis for mental state (these data were subsequently considered unusable).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Nishikawa-1985","2012-07-18 17:37:08 +0100","NO","Some data are not reported for each participant group. Scale data are presented without standard deviations. Data from a previous trial were 'utilised for retrospective placebo control' (p1162). ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Nishikawa-1985","2012-07-18 17:00:11 +0100","UNKNOWN","Rating scales: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Pecknold-1980","2013-09-11 14:59:44 +0100","UNKNOWN","Randomised: no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Pecknold-1980","2013-09-11 14:59:58 +0100","UNKNOWN","'Randomly assigned' (p209): no further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Pecknold-1980","2013-09-11 15:00:04 +0100","UNKNOWN","Double blind: no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Pecknold-1980","2013-11-05 12:05:59 +0000","NO","Follow-up: 80% completed the study, two participants left early from each treatment group: with pimozide, both participants discontinued treatment because of rapid deterioration without control of psychotic symptoms and the presence of limiting side effects. With chlorpromazine, one participant left early owing to lack of symptom control and one owing to limiting side effects. Results were missing from two participants in the chlorpromazine group for improvement using the BPRS. Data for these participants were not included in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Pecknold-1980","2012-07-24 17:03:10 +0100","NO","No statistical data reported for the CGI (Item II). ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Pecknold-1980","2013-09-11 15:00:54 +0100","UNKNOWN","Rating scales: treating psychiatrist, not independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Pinard-1972","2013-09-11 15:01:47 +0100","YES","Randomised: number table, blocks of 5, matched for treatment, symptom severity (BPRS), sex, ward, evaluator (p22).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Pinard-1972","2012-07-20 12:22:29 +0100","UNKNOWN","No description of allocation concealment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Pinard-1972","2013-09-11 15:01:55 +0100","UNKNOWN","Double blind: no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Pinard-1972","2013-09-12 12:11:28 +0100","NO","Follow-up: n = 6 participants left during the study. 'Of these, n = 3 were on trifluoperazine and n = 2 on placebo. They had suffered psychotic setbacks and two had suicidal thoughts. The sixth was on pimozide and had to undergo surgery for an acute cholecystitis' (p23). A further n = 6 were not accounted for.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Pinard-1972","2012-07-20 12:31:17 +0100","NO","Statistical reporting was incomplete for all scale data (no SDs).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Pinard-1972","2012-07-20 12:17:01 +0100","UNKNOWN","Rating scales: independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Silverstone-1984","2013-09-11 15:02:13 +0100","UNKNOWN","Randomised: no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Silverstone-1984","2012-07-20 12:49:49 +0100","UNKNOWN","No description of allocation concealment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Silverstone-1984","2013-09-11 15:02:28 +0100","UNKNOWN","Double blind: matching capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Silverstone-1984","2013-09-12 12:11:45 +0100","NO","Follow-up: 82%. n = 18 completed the 28 days of treatment; n = 3 were withdrawn from the haloperidol group, of these, two were unwilling to continue after developing EPS and left the hospital against advice. n = 1 participant taking pimozide was withdrawn because of intercurrent illness. It is unclear whether these participants were included in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Silverstone-1984","2012-07-20 15:16:58 +0100","UNKNOWN","None detected. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Silverstone-1984","2013-09-11 15:02:55 +0100","NO","Rating scales: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Vergara-1977","2013-09-11 15:04:10 +0100","UNKNOWN","Randomised: participants were 'randomly assigned', no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Vergara-1977","2012-07-20 16:27:26 +0100","UNKNOWN","No description of allocation concealment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Vergara-1977","2013-09-11 15:04:15 +0100","UNKNOWN","Double blind: no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Vergara-1977","2013-09-11 15:04:49 +0100","UNKNOWN","Follow-up: unclear, 80% completed the study: In the pimozide group, n = 8/10 completed the study (n = 1 was withdrawn because of clinical deterioration; n = 1 was withdrawn because of drowsiness and dizziness), and in the trifluoperazine group, n = 8/10 completed the study (n = 1 was withdrawn because of clinical deterioration; n = 1 was withdrawn because of tremor and rigidity). All participants are accounted for under CGI results. It is unclear how many were included in the overall analysis (for BPRS and adverse effects).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Vergara-1977","2013-09-11 15:04:55 +0100","NO","Statistical reporting was incomplete for all scale data (no SDs). No data were reported using TESS; individual adverse effects were not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Vergara-1977","2012-07-20 16:26:52 +0100","UNKNOWN","Rating scales: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Wilson-1982_x002a_","2013-09-11 15:05:20 +0100","UNKNOWN","Randomised: 'randomly assigned', no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Wilson-1982_x002a_","2012-07-23 10:01:18 +0100","UNKNOWN","No description of allocation concealment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Wilson-1982_x002a_","2013-09-11 15:05:43 +0100","UNKNOWN","Double blind: 'double blind fashion', both single daily doses, identical capsules (p62).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Wilson-1982_x002a_","2013-09-12 12:12:18 +0100","NO","Follow-up: 55%. n = 19 failed to complete the study after being enrolled for at least one week. For pimozide, reasons included uncooperativeness (n = 3), limiting of adverse reaction (n = 1), drug ineffectiveness (n = 2) and other reasons (n = 2); for chlorpromazine, reasons included uncooperativeness (n = 2), failure to return (n = 1), limiting adverse reaction (n = 4), drug ineffectiveness (n = 2) and other reasons (n = 2) (p64).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Wilson-1982_x002a_","2013-08-06 19:05:29 +0100","NO","Statistical reporting was incomplete for all scale data (no SDs). Data not reported for 'adverse drug experiences'.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pimozide for schizophrenia or related psychoses [v10.0-For publication].rm5","STD-Wilson-1982_x002a_","2013-09-11 15:06:17 +0100","UNKNOWN","Rating scales: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pharmacological treatments for psychosis-related polydipsia [v6.0-For publication].rm5","STD-Alexander-1991","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pharmacological treatments for psychosis-related polydipsia [v6.0-For publication].rm5","STD-Nishikawa-1996","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pharmacological interventions for clozapine-induced hypersalivation [v6.0-For publication].rm5","STD-Fan-1996","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Pharmacological interventions for clozapine-induced hypersalivation [v6.0-For publication].rm5","STD-Gong-1998","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Pharmacological interventions for clozapine-induced hypersalivation [v6.0-For publication].rm5","STD-Kang-1993","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Pharmacological interventions for clozapine-induced hypersalivation [v6.0-For publication].rm5","STD-Kreinin-2005","","NO","C - Inadequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Pharmacological interventions for clozapine-induced hypersalivation [v6.0-For publication].rm5","STD-Li-1993","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Pharmacological interventions for clozapine-induced hypersalivation [v6.0-For publication].rm5","STD-Li-2004","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Pharmacological interventions for clozapine-induced hypersalivation [v6.0-For publication].rm5","STD-Lin-1999","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Pharmacological interventions for clozapine-induced hypersalivation [v6.0-For publication].rm5","STD-Lu-1998","","UNKNOWN","D - Not used","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Pharmacological interventions for clozapine-induced hypersalivation [v6.0-For publication].rm5","STD-Qian-1996","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Pharmacological interventions for clozapine-induced hypersalivation [v6.0-For publication].rm5","STD-Ren-2001","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Pharmacological interventions for clozapine-induced hypersalivation [v6.0-For publication].rm5","STD-Wang-1998","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Pharmacological interventions for clozapine-induced hypersalivation [v6.0-For publication].rm5","STD-Yang-1997","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Pharmacological interventions for clozapine-induced hypersalivation [v6.0-For publication].rm5","STD-Yao-1994","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Pharmacological interventions for clozapine-induced hypersalivation [v6.0-For publication].rm5","STD-Yuan-2000","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Pharmacological interventions for clozapine-induced hypersalivation [v6.0-For publication].rm5","STD-Zhou-1996","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Adelson-1962","2011-09-25 20:15:07 +0100","UNKNOWN","Randomly assigned to different treatments.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Adelson-1962","2011-09-25 20:15:07 +0100","UNKNOWN","Random assignment carried out by person having no other contact with the study and the entire study staff had no knowledge of the assignments made.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Adelson-1962","2011-09-25 20:16:29 +0100","YES","Double - all drugs supplied in two capsule sizes using Parke-Davis standard pink capsules to appear identical. The manufactory laboratory of the school of pharmacy packaged the drugs in bottles which were labelled with only the patients´ name, cohort number, capsule size. None of the direct treating staff were aware of the design of the study, the drugs used, how many agents there were and whether or not there were any patients on placebo.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Adelson-1962","2013-11-17 19:26:27 +0000","YES","Double - all drugs supplied in two capsule sizes using Parke-Davis standard pink capsules to appear identical. The manufactory laboratory of the school of pharmacy packaged the drugs in bottles which were labelled with only the patients´ name, cohort number, capsule size. None of the direct treating staff were aware of the design of the study, the drugs used, how many agents there were and whether or not there were any patients on placebo.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Adelson-1962","2011-09-25 20:16:46 +0100","UNKNOWN","2 chlorpromazine participants died and were replaced in order to maintain the analysis of variance design. 1 out of 48 perphenazine and 10 out of 144 participants from the low-potency drug group left the study early, which is an acceptable rate.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Adelson-1962","2011-09-25 20:15:07 +0100","NO","MSRPP no SD, MMPI no data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Adelson-1962","2011-09-25 20:15:07 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hanlon-1965","2011-09-25 20:15:07 +0100","UNKNOWN","Randomly assigned, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hanlon-1965","2011-09-25 20:15:07 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hanlon-1965","2013-11-17 19:27:34 +0000","YES","Double - drugs dispensed in standard unmarked pink capsules no. 1 & 0 size, the treating ward physicians were only aware of the various drugs and dosages involved in the study.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hanlon-1965","2013-11-17 19:27:46 +0000","YES","Double - drugs dispensed in standard unmarked pink capsules no. 1 & 0 size, the treating ward physicians were only aware of the various drugs and dosages involved in the study.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hanlon-1965","2011-09-25 20:18:40 +0100","NO","8 out of 53 (15%) participants from the perphenazine group and 46 out of 210 from the low-potency group left the study early and not included in the final analysis (completers only).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hanlon-1965","2013-11-17 20:38:23 +0000","NO","MSRPP, MMPI, MACC (all no usable data, no means, no SDs).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hanlon-1965","2014-01-07 16:36:05 +0000","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Kurland-1961","2011-09-25 20:15:07 +0100","UNKNOWN","Random selection, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Kurland-1961","2011-09-25 20:15:07 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Kurland-1961","2014-01-07 16:35:39 +0000","YES","Double. Dispensed in unmarked capsules of #0 and #1 size coloured pink to mask all identifying consistencies and colours of the drugs.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Kurland-1961","2014-01-07 16:35:48 +0000","YES","Double. Dispensed in unmarked capsules of #0 and #1 size coloured pink to mask all identifying consistencies and colours of the drugs.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Kurland-1961","2011-10-10 14:10:39 +0100","NO","32 out of 36 from the perphenazine group left the study early (89%) of which 22% dropped out due to EPS. 26 out of 33 from the low-potency group left early (79%). LOCF was applied.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Kurland-1961","2013-11-17 20:40:56 +0000","NO","MSRPP (no SD), PRP and PSTS (no usable data).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Kurland-1961","2014-01-07 16:35:57 +0000","UNKNOWN","On the first two days of the study, participants received intramuscular medication, after that they were given oral mediations.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Shalev-1993","2011-09-25 20:15:07 +0100","UNKNOWN","Randomly assigned, no further details.        ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Shalev-1993","2013-11-17 13:55:07 +0000","YES","""Treating psychiatrists were blind to the sequence in which the drugs were to be given to the patient.""","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Shalev-1993","2013-11-17 19:28:23 +0000","NO","Not described, probably open.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Shalev-1993","2013-11-17 19:28:28 +0000","NO","Not described, probably open.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Shalev-1993","2011-09-25 20:20:01 +0100","NO","15 participants left the study early but it is not mentioned how many from which drug group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Shalev-1993","2011-10-10 14:11:21 +0100","YES","No evidence for selective outcome reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Shalev-1993","2013-05-31 13:02:59 +0100","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Amakusa-1973","2013-06-19 16:27:12 +0100","YES","Randomised – matched-pair design. Quote: “two patients of the same sex, an age difference of less than 10 years and with similar symptoms were classified as a pair then randomly allocated to either intervention or control (p3). ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Amakusa-1973","2014-05-12 09:18:14 +0100","YES","An independent controller randomly allocated the matched pairs to either Sulpiride or perphenazine.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Amakusa-1973","2014-05-12 09:18:14 +0100","YES","Double blind – quote: “test and control tablets had similar external appearance… [the tablets] were placed in bags which were packed into cans of identical design and appearance” (p3-4). An independent controller randomly allocated the matched pairs to either Sulpiride or perphenazine.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Amakusa-1973","2015-01-13 13:41:56 +0000","UNKNOWN","14% (n = 9) excluded from analysis: n = 5 receiving sulpiride (n = 3 refused drugs; n = 1 given electro-shock therapy; n = 1 given other drugs for marked excitation) and n = 4 receiving perphenazine (n = 1 discarding drugs; n = 1 refusing drugs; n = 1 due to acute colitis; and n = 1 given other drugs) (ITT used).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Amakusa-1973","2013-06-19 16:28:13 +0100","UNKNOWN","None detected.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Amakusa-1973","2013-09-19 11:34:58 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Bennett-1961","2013-06-26 14:05:46 +0100","UNKNOWN","Randomised - no further details. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Bennett-1961","2013-06-26 14:06:03 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Bennett-1961","2015-01-26 14:50:32 +0000","NO","Single-blind (implied) - all participants were given identical-looking placebo 14 days prior to treatment; there is no mention of blinding at treatment commencing.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Bennett-1961","2015-01-12 14:47:29 +0000","NO","Follow-up 90% - n = 2 people left early (n = 1 from the chlorpromazine group; n = 1 from the prochlorperazine), no explanation provided; not clear which numbers are completed in full analysis and by which group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Bennett-1961","2015-01-26 14:50:32 +0000","NO","Non-reported data by group include: improvement; behaviour (MSRPP); mental state (CEPS); side effects; laboratory testing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Bennett-1961","2013-09-19 11:34:54 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-CATIE-2005","2014-05-12 09:18:14 +0100","YES","Randomised: no further details – emailed authors 18/11/13 – Jeffrey Lieberman (","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-CATIE-2005","2013-12-11 14:26:30 +0000","UNKNOWN","As above.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-CATIE-2005","2014-05-12 09:18:14 +0100","YES","Quote, “[b]ecause of product labelling, quetiapine and ziprasidone are given twice daily and olanzapine, perphenazine, and Risperidone once daily. To protect blinding, half the patients randomly assigned to perphenazine, olanzapine and Risperidone were assigned to twice-daily dosing and half to once-daily dosing” (p1211).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-CATIE-2005","2015-01-26 14:42:12 +0000","YES","Quote, “all data from one site (33 patients) were excluded before analysis, owing to concern about the integrity of data from that site before the end of the study and before unblinding” (p1212).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-CATIE-2005","2013-12-11 14:33:41 +0000","YES","None detected.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-CATIE-2005","2015-01-13 13:49:07 +0000","UNKNOWN","Other: quote, “Two-hundred thirty-one patients with tardive dyskinesia were excluded from random assignment to perphenazine. ziprasidone was added to the trial after approximately 40% of the patients had been enrolled. Consequently, comparisons involving the perphenazine group were limited to patients without tardive dyskinesia, and comparisons involving the ziprasidone group were limited to the cohort of patients who underwent randomisation after ziprasidone was added” (p1211).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Chouinard-1975","2013-06-27 12:19:42 +0100","UNKNOWN","Randomised - quote, ""within [groups of] 12 patients, individuals were randomly assigned to one of the four treatment drugs"" (p1296). ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Chouinard-1975","2013-06-27 14:57:45 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Chouinard-1975","2013-06-27 15:13:28 +0100","UNKNOWN","Double blind - identical-appearing tablets used. Each participant received one tablet three times per day and two at bedtime. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Chouinard-1975","2015-01-12 14:48:39 +0000","YES","Of N = 96 entering the study, n = 16 did not complete the full 12-week course because of, quote, ""poor response to treatment...but all completed at least four weeks"" (p1299), i.e. those that relapsed. For participants leaving the study early, they were rated before being excluded from the study, and these evaluations were used in the final analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Chouinard-1975","2013-06-27 15:11:10 +0100","NO","No (useable) data reported for CGI, BPRS, IMPS or laboratory tests (only P values, or df reported).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Chouinard-1975","2013-09-19 11:34:51 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Chouinard-1977","2013-07-11 13:46:56 +0100","UNKNOWN","Random - no further details. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Chouinard-1977","2013-07-11 13:47:00 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Chouinard-1977","2013-07-11 13:47:21 +0100","YES","Double: ECG readings (primary outcome) taken by cardiologist unaware “as to factors under study” (p.952). Drugs were administered in identically-appearing tablets.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Chouinard-1977","2015-01-12 14:49:12 +0000","NO","N = 1 perphenazine and n = 2 perphenazine-amitriptyline participants were hospitalised and excluded from study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Chouinard-1977","2013-07-11 13:47:50 +0100","YES","None detected.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Chouinard-1977","2013-09-19 11:34:37 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Collins-1967","2013-07-11 16:29:31 +0100","UNKNOWN","Random – “allotted to treatment groups at random”.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Collins-1967","2013-07-11 16:29:35 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Collins-1967","2013-07-11 16:29:42 +0100","YES","Double – quote, “neither nursing staff nor doctors concerned knew which tablets were which” (p1428).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Collins-1967","2015-01-12 14:49:26 +0000","YES","No losses - N = 29 participants in each treatment group completed the trial.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Collins-1967","2013-07-11 16:29:59 +0100","YES","Not all adverse effects reported in full; not all means and SD reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Collins-1967","2013-09-19 11:34:31 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Dehnel-1968","2013-12-16 16:50:12 +0000","UNKNOWN","Quote, “Randomly divided into two groups” (p170) – no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Dehnel-1968","2013-12-16 16:50:12 +0000","UNKNOWN","Quote, “the investigator who cared for the patient and the other raters did not know which of the two agents any patient was receiving” (p170).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Dehnel-1968","2013-12-16 16:50:40 +0000","YES","Double: all medications, quote, “as well as the placebo were dispensed in tablets identical in appearance. Medications for each patient during the active drug period were supplied by the pharmacy in an individual bottle with only the patient’s name and study number appearing on the bottle label” (p170). Strict double blind conditions adhered to until the end of study.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Dehnel-1968","2015-01-12 14:49:47 +0000","UNKNOWN","Four participants left the study early (n = 2 from each treatment group); clopenthixol: n = 1 discontinued after 6 weeks due to side effects (severe hand and arm tremor), n = 1 discontinued due to worsening of psychiatric condition after 4 weeks. Perphenazine: n = 1 lost from the study when released from hospital against medical advice after first week; n = 1 discontinued due to worsening of psychiatric condition after 4 weeks.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Dehnel-1968","2013-12-16 16:50:12 +0000","UNKNOWN","No means or standard deviation reported for scale data (BPRS or PIP).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Dehnel-1968","2013-12-16 16:50:12 +0000","UNKNOWN","Raters: All outcome measures taken by study investigator or nurse. Unclear whether they were independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Eckmann-1984","2013-07-16 13:46:05 +0100","UNKNOWN","Randomised - quote: ""randomisiert zugeteilt"" (English: randomly allocated). No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Eckmann-1984","2013-07-16 13:46:15 +0100","UNKNOWN","Not described. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Eckmann-1984","2013-07-16 13:46:43 +0100","UNKNOWN","Double-blind: Oral liquid medication. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Eckmann-1984","2013-07-16 13:47:11 +0100","UNKNOWN","No details of people leaving early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Eckmann-1984","2013-07-16 13:47:48 +0100","NO","No means or standard deviations reported in results section. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Eckmann-1984","2013-09-19 11:34:21 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Fruensgaard-1978","2013-07-18 15:08:59 +0100","UNKNOWN","“Randomly assigned” – no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Fruensgaard-1978","2013-07-18 15:17:45 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Fruensgaard-1978","2013-07-18 15:17:56 +0100","UNKNOWN","Double-blind stated – no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Fruensgaard-1978","2015-01-12 14:50:41 +0000","UNKNOWN","21% (n = 10) dropped-out of the study and excluded from analysis – n = 5 from perphenazine group and n = 5 for loxapine group (reasons only provided for n = 2 ‘inadequate therapeutic response, and n = 2 aversion to continued treatment). Not fully addressed (ITT used).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Fruensgaard-1978","2015-01-26 14:43:28 +0000","NO","Not all adverse event data reported; no means or SDs reported for BPRS, CGI, NOSIE.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Fruensgaard-1978","2013-09-19 11:34:13 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Hanlon-1964","2013-07-18 16:41:24 +0100","UNKNOWN","Randomised – no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Hanlon-1964","2013-07-18 16:41:36 +0100","UNKNOWN","Not stated. Quote: “ultimate medical responsibility for the patients remained in the hands of the ward physicians, who were aware of the design and study-drugs” (p53).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Hanlon-1964","2013-07-18 16:41:42 +0100","UNKNOWN","Stated double blind; quote, “medication, administered in a double blind fashion, was dispensed to the wards from the pharmacy in containers identified only by the patient name and number” (p53). However, see above (allocation concealment).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Hanlon-1964","2015-01-12 14:51:08 +0000","UNKNOWN","11% (n = 13) dropped-out of the study. Quote, ""n = 5 placebo patients were discontinued and transferred to the infirmary for medical reasons unrelated to treatment; the remaining three patients were described as either overactive, restless or agitated. One perphenazine patient was dropped because of hypotension and elevated temperature, and another because of nausea and weakness"" (p55). Another n = 5 participants were lost in the two other treatment arms.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Hanlon-1964","2015-01-26 14:43:49 +0000","NO","No SD or P values reported for scale data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Hanlon-1964","2013-07-18 16:46:18 +0100","NO","Raters: not independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Hanlon-1965","2013-09-16 16:27:24 +0100","UNKNOWN","Randomised: no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Hanlon-1965","2013-09-19 14:19:32 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Hanlon-1965","2013-09-16 16:57:18 +0100","UNKNOWN","Double-blind: identical pink unmarked capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Hanlon-1965","2015-01-12 14:52:02 +0000","NO","Follow-up: 76% in first evaluation at five days; of the n = 421 randomised, n = 322 remained on the project for at least five days. The n = 99 were not included in any of the post-treatment analyses; the majority of these participants were considered ‘unacceptable on the basis of selection criteria’; n = 5 early side-effect cases; others refused oral medication or were dropped for administrative treatment ‘unrelated to drug treatment’. Remaining post-treatment evaluations: 68% in second evaluation at 15","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Hanlon-1965","2015-01-26 14:44:11 +0000","UNKNOWN","No SD or P values reported for scale data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Hanlon-1965","2013-09-17 17:07:36 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Hoyberg-1993","2013-09-19 14:19:00 +0100","UNKNOWN","Randomised: no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Hoyberg-1993","2013-09-19 14:19:38 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Hoyberg-1993","2013-09-19 14:34:55 +0100","UNKNOWN","Double-blind: identical tablets.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Hoyberg-1993","2015-01-26 14:44:40 +0000","UNKNOWN","Seventy-eight participants (73%) completed the full 8-week trial period; n = 29 withdrew prematurely, of these n = 8 receiving risperidone and n = 6 receiving perphenazine were withdrawn due to adverse effects; n = 2 receiving risperidone and n = 3 receiving perphenazine were withdrawn due to lack of therapeutic effect; n = 4 receiving risperidone and n = 6 receiving perphenazine were withdrawn because they stopped attending the control visits. All participants that had attended at least one clinical assessment were included in the ITT analysis or endpoint analysis (N = 101; n = 50 receiving risperidone and n = 51 receiving perphenazine). All prematurely withdrawn participants were included in side effects analysis, whereas other therapeutic measures were analysed ITT.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Hoyberg-1993","2013-09-19 14:34:28 +0100","NO","CGI scale reported as an outcome measure, however no data are reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Hoyberg-1993","2013-09-19 14:34:42 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Imai-1980","2013-09-26 09:22:33 +0100","UNKNOWN","Randomised: no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Imai-1980","2013-09-26 09:24:45 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Imai-1980","2013-09-26 09:22:58 +0100","UNKNOWN","Double-blind: no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Imai-1980","2013-09-26 09:33:15 +0100","UNKNOWN","No details.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Imai-1980","2013-09-26 09:33:22 +0100","UNKNOWN","No details.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Imai-1980","2013-09-26 09:34:20 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1969","2013-09-26 10:55:32 +0100","YES","Randomised: randomisation by numbers, quote: ""patients with the same type of disorder, clinical features and sex and with differences in ages of less than ten years were paired among those examined by the same physicians at each institution, and the data obtained were analysed by the sequential trial technique of Armitage upon conclusion of the study period. After the code had been broken, the pairs were untied and the data evaluated for testing for the therapeutic efficacy of the two drugs"" (p7). Random number table used (p8).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1969","2013-09-26 11:12:51 +0100","YES","Quote, ""bottles were coded so that neither the investigators nor the patients knew whether clothiapine or placebo was being administered at any given time, [and] every investigator was instructed to retain an allocation schedule in a sealed envelope for each matched pair assigned to him in case of medical emergency of a patient under study"" (p8) - no such emergency happened and all envelopes were returned unopened to the central statistical unit upon completion of the study. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1969","2013-09-26 10:57:43 +0100","YES","Double-blind: identical shape and colour of tablets. Quote, ""medication and analysis of data obtained were performed by the controlled double-blind method"" (p8). ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1969","2013-09-26 11:40:47 +0100","UNKNOWN","No details. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1969","2013-09-26 11:37:11 +0100","UNKNOWN","None detected.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1969","2013-09-26 11:39:48 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1969-II","2013-09-26 14:15:11 +0100","YES","Randomised - randomisation by numbers.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1969-II","2013-09-26 14:15:18 +0100","UNKNOWN","Not clear.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1969-II","2013-09-26 14:13:26 +0100","UNKNOWN","Double-blind: no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1969-II","2013-09-26 14:15:21 +0100","UNKNOWN","Not clear.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1969-II","2013-09-26 14:15:24 +0100","UNKNOWN","Not clear.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1969-II","2013-09-26 15:20:57 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1969-III","2013-09-26 14:47:28 +0100","YES","Randomised: randomisation by numbers.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1969-III","2013-09-26 15:20:43 +0100","UNKNOWN","Not clear.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1969-III","2013-09-26 14:47:44 +0100","UNKNOWN","Double-blind: identical shape and colour of tablets.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1969-III","2013-09-26 15:20:44 +0100","UNKNOWN","Not clear.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1969-III","2013-09-26 15:20:46 +0100","UNKNOWN","Not clear.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1969-III","2013-09-26 15:20:54 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1976","2013-09-26 15:52:00 +0100","UNKNOWN","Randomised: no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1976","2013-09-26 16:09:06 +0100","UNKNOWN","Not clear.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1976","2013-09-26 16:08:59 +0100","UNKNOWN","Double-blind: no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1976","2013-09-26 16:09:06 +0100","UNKNOWN","Not clear.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1976","2013-09-26 16:09:08 +0100","UNKNOWN","Not clear.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Itoh-1976","2013-09-26 16:09:12 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Kane-2003","2013-12-17 15:01:45 +0000","UNKNOWN","Randomised – no further details; emailed authors 15/11/13.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Kane-2003","2013-12-17 15:01:00 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Kane-2003","2015-01-26 14:45:52 +0000","YES","Double-blind treatment phase: treatment-resistant participants, as previously diagnosed, entered a 6-week, open-label treatment phase (olanzapine vs risperidone) to confirm treatment-resistance. If completed, entered 2- to 10-day single-blind placebo wash-out phase; afterwards randomised to double-blind treatment with perphenazine vs aripiprazole.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Kane-2003","2015-01-13 15:47:14 +0000","YES","N = 512 screened; n = 416 entered open-label treatment phase with olanzapine and Risperidone to confirm treatment resistant; n = 334 completed; of these, n = 34 discontinued due to reasons including adverse events, withdrawal of consent, lost to follow-up; lack of efficacy, patient unreliability, and other causes. N = 300 entered double-blind randomised study phase; of these, n = 225 (75%) completed the full 6-week study (n = 110 receiving aripiprazole; n = 115 receiving perphenazine); of the n = 75 who discontinued, n = 33 was due to adverse events; n = 18 was due to lack of efficacy; n = 11 was due to consent withdrawal; n = 13 unknown cause.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Kane-2003","2013-12-17 15:02:03 +0000","YES","None detected from cross-checking published protocol and review.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Kane-2003","2013-12-17 15:02:07 +0000","NO","Rating scales: raters not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Kurihara-1983","2013-09-26 16:48:18 +0100","UNKNOWN","Randomised: no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Kurihara-1983","2013-09-26 16:48:25 +0100","UNKNOWN","Not clear.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Kurihara-1983","2013-09-26 16:48:49 +0100","UNKNOWN","Double-blind: identical appearance of capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Kurihara-1983","2013-09-26 16:48:26 +0100","UNKNOWN","Not clear.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Kurihara-1983","2013-09-26 16:48:26 +0100","UNKNOWN","Not clear.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Kurihara-1983","2013-09-26 16:48:30 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Kurland-1961","2013-10-01 16:00:01 +0100","UNKNOWN","Randomised: quote, ""the choice of the particular drug to be used in any case was based on a predetermined random selection of the compounds"" (p4).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Kurland-1961","2013-10-01 09:47:52 +0100","UNKNOWN","Quote, ""the physician knew a patient had six chances in eight of being given a phenothiazine compound, but did not know which drug was being given, or whether the patient was receiving one of the placebos"" (p4).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Kurland-1961","2013-10-01 16:10:45 +0100","UNKNOWN","Double-blind: identical capsules; quote, ""drugs were dispensed in standard unmarked capsules... coloured pink to mask all identifying consistencies and colours of the drugs"" (p4). Treatment information was “secured from the pharmacist and recorded in the patient’s chart by a member of the nursing staff” (p5). Quote, ""all clinical and research personnel working with patients were bound to the double-blind stipulation imposed by the research plan"" (p6).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Kurland-1961","2015-01-12 14:58:39 +0000","NO","Quote, ""those patients on whom data were incomplete, together with those not receiving medication for at least then days, were excluded from the study"" (p6). Unclear which participants dropped-out of which treatment arm. One publication makes reference to N = 277 included in the study and presents data for those. Whereas the subsequently-published paper refers to N = 238 included after screening people eligible for study. ITT used.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Kurland-1961","2015-01-26 14:46:29 +0000","UNKNOWN","No SD or P values reported for scale data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Kurland-1961","2015-01-26 14:46:29 +0000","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Lepola-1989","2013-10-04 11:46:47 +0100","UNKNOWN","Randomised: no further details. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Lepola-1989","2013-10-04 11:47:22 +0100","UNKNOWN","Not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Lepola-1989","2013-10-04 11:50:16 +0100","UNKNOWN","Double-blind: identical tablets - no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Lepola-1989","2013-10-04 11:50:02 +0100","UNKNOWN","None detected.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Lepola-1989","2013-10-04 11:50:07 +0100","UNKNOWN","None detected.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Lepola-1989","2013-10-04 11:52:14 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Naukkarinen-2000","2013-12-17 16:53:45 +0000","YES","Randomised: quote, “performed on the basis of clusters, or blocks, for each investigator, such that patients within a block for a given investigator were randomised in a 1:1 ratio” (p7).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Naukkarinen-2000","2014-05-12 09:18:14 +0100","YES","Randomisation schedule was, quote, “generated on block size, number of treatments, and number of investigative sites included in the study. The study drugs were assigned to medication kits by a computer-generated random sequence in such a way that there was a 1:1 ratio of olanzapine to perphenazine- treated patients” (p7). Participants were assigned on their first visit and those who met inclusion criteria were randomly allocated to double-blind at the second visit by assignment of a unique kit number.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Naukkarinen-2000","2013-12-17 16:53:49 +0000","YES","Medication kit contained double-blind study medication for each participant; blinding of study was preserved by allowing a “minimum number of Lilly personnel” to see the randomisation table and codes before completion of the study (p7).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Naukkarinen-2000","2015-01-12 14:59:24 +0000","NO","High attrition, with 38% completing the study. Four separate reports provide different numbers of participants included. N = 60 originally randomised, however only n = 46 made reference to follow-up reports. Of the n = 46, only n = 23 (n = 12 in olanzapine and n = 11 in perphenazine) completed the study. N = 53 included in the safety analysis, and n = 46 included in efficacy analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Naukkarinen-2000","2015-01-26 14:50:32 +0000","NO","Data not provided for CGI, PGI, UKU-ConSat, UKU side effects – authors contact 13/11/13 for request of full-published version, no response.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Naukkarinen-2000","2013-12-17 16:53:55 +0000","NO","Rating scales: raters not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Remvig-1987","2013-10-04 14:52:57 +0100","UNKNOWN","Randomised: no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Remvig-1987","2013-10-07 14:25:27 +0100","UNKNOWN","Not described. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Remvig-1987","2013-10-07 09:50:47 +0100","UNKNOWN","Double-blind: quote, ""double-blind, double-dummy"" (p147). ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Remvig-1987","2015-01-12 14:59:40 +0000","NO","Quote, ""all patients treated for 3 weeks (21 days) or more were included in the statistical processing of data"" (p148). Fourteen participants (n = 5 on zuclopenthixol; n = 9 on perphenazine) had not been treated for the 3-week minimum, and were excluded - reasons including insufficient effect, undesired effect, or discharge from hospital. Binary data analysed with 74% (ITT); continuous data using CGI scale presented data for n = 25 (46%), no LOCF used.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Remvig-1987","2013-10-07 15:08:23 +0100","NO","Quote: ""because of the great variation in total scores among the patients, they were stratified ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Remvig-1987","2013-10-07 15:25:42 +0100","NO","Quote: ""no additional neuroleptic treatment was allowed"" (p148), however, it is later stated that ""most patients received benzodiazepines... and 12 patients received an additional neuroleptic in the form of methotrimeprazine"" (p149). ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Sun-2000","2014-01-07 10:42:10 +0000","UNKNOWN","Randomised – no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Sun-2000","2014-01-07 10:42:08 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Sun-2000","2014-01-07 10:42:07 +0000","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Sun-2000","2014-01-07 10:42:07 +0000","UNKNOWN","No details.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Sun-2000","2014-01-07 10:42:05 +0000","UNKNOWN","No details.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Sun-2000","2014-01-07 10:41:58 +0000","UNKNOWN","No details as to blinding; two raters involved in administering BPRS and TESS.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Takahashi-1982","2013-10-08 11:11:57 +0100","YES","Randomised: quote, ""participants were assigned randomly"" (p258). 'Randomised code' referred to, which was broken only at the end of treatment period.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Takahashi-1982","2013-10-08 10:58:24 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Takahashi-1982","2015-01-26 14:47:53 +0000","YES","Double-blind: implied - decoding of drugs at the end of week 12. Code broken at the end of treatment period. Double-dummy design.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Takahashi-1982","2015-01-12 15:00:38 +0000","NO","Of N = 205 randomised, n = 7 were excluded, either because they had been given other neuroleptics or they revealed physical disease during the trial prior to breaking the randomisation code. A total of n = 198 were included in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Takahashi-1982","2015-01-26 14:48:12 +0000","UNKNOWN","No means, SD or P values reported for scale data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Takahashi-1982","2013-10-08 11:24:03 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Van-Praag-1976","2013-10-08 14:39:50 +0100","UNKNOWN","Randomised: no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Van-Praag-1976","2013-10-08 15:52:52 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Van-Praag-1976","2013-10-08 16:11:10 +0100","YES","Double-blind: implied - identical capsules. Quote, ""raters and patients were unaware of the type of medication or its dosage; nor were they informed of the biochemical results"" (p549).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Van-Praag-1976","2015-01-12 15:00:58 +0000","YES","Four participants (n = 3 receiving perphenazine; n = 1 receiving clozapine) failed to complete the study. All cases were due to presence of severe motor unrest, anxiety or aggression non-responsive to permitted medication. ITT used.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Van-Praag-1976","2013-10-08 15:53:04 +0100","UNKNOWN","No means or SD reported for scale data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Van-Praag-1976","2013-10-08 15:53:09 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Wang-2008a","2015-01-27 10:27:36 +0000","UNKNOWN","‘Randomised’ – no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Wang-2008a","2015-01-27 10:27:39 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Wang-2008a","2015-01-27 10:27:40 +0000","UNKNOWN","No description.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Wang-2008a","2015-01-27 10:27:41 +0000","NO","Not all outcome measures reported; adverse events not reported fully by group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Wang-2008a","2015-01-27 10:27:43 +0000","UNKNOWN","As above.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Wang-2008a","2015-01-27 10:27:44 +0000","UNKNOWN","No details of funding/ who administered rating scales.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Wang-2008b","2015-01-27 10:28:23 +0000","UNKNOWN","Randomised – no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Wang-2008b","2015-01-27 10:28:28 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Wang-2008b","2015-01-27 10:28:33 +0000","UNKNOWN","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Wang-2008b","2015-01-27 10:28:42 +0000","UNKNOWN","No description.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Wang-2008b","2015-01-27 10:28:44 +0000","YES","None detected.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Wang-2008b","2015-01-27 10:28:55 +0000","UNKNOWN","Rating scales: raters not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Wang-2008c","2014-01-13 14:33:44 +0000","UNKNOWN","Randomised – no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Wang-2008c","2014-01-13 14:33:50 +0000","UNKNOWN","Not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Wang-2008c","2014-01-13 14:33:45 +0000","UNKNOWN","Not described.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Wang-2008c","2015-01-12 15:02:30 +0000","UNKNOWN","In the quetiapine group, n = 1 left the study due to drowsiness. In the perphenazine group n = 3 left due to EPS. Missing data from participants leaving the study early were not included in analyses.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Wang-2008c","2014-01-13 14:33:49 +0000","UNKNOWN","None detected.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Wang-2008c","2014-01-13 14:33:43 +0000","UNKNOWN","Rating scales: raters not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Woggon-1978","2013-10-09 11:48:02 +0100","UNKNOWN","Randomised: no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Woggon-1978","2013-10-09 11:48:10 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Woggon-1978","2013-10-09 11:48:22 +0100","UNKNOWN","Double-blind: no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Woggon-1978","2013-10-09 12:07:23 +0100","YES","None detected.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Woggon-1978","2013-10-09 11:53:50 +0100","NO","No means or SDs reported for continuous outcomes and scale data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Woggon-1978","2013-10-09 11:52:15 +0100","UNKNOWN","Raters: not stated to be independent of treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Zhang-2010","2014-01-13 10:55:33 +0000","UNKNOWN","Randomised – no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Zhang-2010","2014-01-13 10:55:34 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Zhang-2010","2014-01-13 10:55:34 +0000","UNKNOWN","No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Zhang-2010","2014-01-13 10:58:27 +0000","NO","One participant not included in results nor accounted for.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Zhang-2010","2014-01-13 10:56:12 +0000","NO","Not all adverse events reported by group – unable to include some missing group data. No data reported using BPRS or TESS scales.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perphenazine for schizophrenia [v6.2-For publication].rm5","STD-Zhang-2010","2014-01-13 10:56:18 +0000","UNKNOWN","No details as to funding or who administered rating scales.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Ananth-1977","2014-03-17 15:38:09 +0000","UNKNOWN","Randomised but no further description.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Ananth-1977","2013-05-10 12:40:43 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Ananth-1977","2013-05-10 12:40:46 +0100","YES","Reported as double blind.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Ananth-1977","2013-06-08 18:17:50 +0100","UNKNOWN","Not reported. ","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Ananth-1977","2013-06-07 17:10:26 +0100","UNKNOWN","14/15 (93%) analysed in Propericiazine group, 10/15 (67%) analysed in Chlorpromazine group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Ananth-1977","2013-06-20 20:19:59 +0100","NO","Data on BPRS, TESS and CGI were not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Ananth-1977","2013-06-08 18:06:48 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Grant-1965","2014-03-17 15:38:09 +0000","UNKNOWN","Randomised but no further description.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Grant-1965","2013-06-08 18:08:41 +0100","UNKNOWN","Not reported. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Grant-1965","2013-06-08 11:30:37 +0100","YES","Matched appearance tablets/syrup. Quote '","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Grant-1965","2013-06-08 18:07:42 +0100","UNKNOWN","Not reported. ","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Grant-1965","2013-06-08 11:31:55 +0100","UNKNOWN","One patient who received pericyazine was excluded from the final analysis due to experiencing facial pallor to an extent that the drug was stopped. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Grant-1965","2013-06-08 18:09:50 +0100","YES","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Grant-1965","2013-06-08 18:08:51 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Iwanaga-1980","2014-01-29 21:51:46 +0000","UNKNOWN","Randomised but no further description.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Iwanaga-1980","2013-05-10 12:53:40 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Iwanaga-1980","2013-05-10 12:53:41 +0100","YES","Reported as double blind.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Iwanaga-1980","2013-06-08 18:10:15 +0100","UNKNOWN","Not reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Iwanaga-1980","2013-06-08 18:28:22 +0100","YES","Last Observation Carried Forward (LOCF) was used for the three participants who left the typical antipsychotic group early. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Iwanaga-1980","2013-06-08 16:45:31 +0100","YES","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Iwanaga-1980","2013-06-08 16:45:34 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Leitch-1965","2013-05-11 23:19:06 +0100","YES","'...when a patient started on the trial the hospital pharmacist allocated him or her to one or other drug according to a randomized list'","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Leitch-1965","2013-05-10 12:55:50 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Leitch-1965","2013-05-10 12:55:52 +0100","NO","Identical tablets of the two drugs were not obtained.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Leitch-1965","2013-06-08 18:10:59 +0100","NO","Single blind so unlikely.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Leitch-1965","2013-06-08 18:11:06 +0100","NO","Seven people left the study early however it was not reported which intervention they had received and no ITT analysis was attempted. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Leitch-1965","2013-06-08 16:45:44 +0100","YES","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Leitch-1965","2013-06-08 15:40:02 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Rasch-1966","2013-06-08 16:39:10 +0100","UNKNOWN","""The sequence was determined by random selection""","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Rasch-1966","2013-06-08 18:11:25 +0100","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Rasch-1966","2013-05-10 12:58:53 +0100","YES","Identical tablets used, blinded study.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Rasch-1966","2013-06-08 18:19:03 +0100","UNKNOWN","Reported to be a blind study with identical tables but no there was no mention of the blinding of outcome assessors. ","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Rasch-1966","2014-03-17 15:29:52 +0000","NO","From the 52 patients selected, 1 died, 2 were excluded due to physical diseases, 1 cheated with tablets, 6 were excluded because their condition appeared to be too unstable at a closer evaluation and 1 patient was excluded at a later stage of the trial due to developing a severe liver disease. It was unclear which intervention those who left the study early received","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Rasch-1966","2013-06-08 16:46:45 +0100","YES","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Pericyazine for schizophrenia [v7.0-For publication].rm5","STD-Rasch-1966","2013-06-08 16:47:52 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Bender-1997","2012-09-01 11:26:28 +0100","YES","""randomized"" (p.61); ""A randomization schedule was produced by a validated computer program"" (p.63)","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Bender-1997","2013-06-03 15:22:32 +0100","UNKNOWN","Not indicated","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Bender-1997","2012-09-01 11:33:29 +0100","YES","""double-blind"" (p.61); ""Study medication was administered in capsules indistinguishable in colour, size, form, smell and consistency"" (p.63)","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","Objective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Bender-1997","2012-09-01 11:33:50 +0100","YES","""double-blind"" (p.61); ""Study medication was administered in capsules indistinguishable in colour, size, form, smell and consistency"" (p.63)","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.02","Subjective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Bender-1997","2013-12-11 09:37:49 +0000","YES","""double-blind"" (p.61)","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","Objective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Bender-1997","2013-12-11 09:37:49 +0000","UNKNOWN","""double-blind"" (p.61)","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.02","Subjective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Bender-1997","2012-09-01 11:35:11 +0100","NO","37% dropout rate, not evenly distributed between groups (13/50 and 19/45)","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Bender-1997","2013-06-03 15:22:37 +0100","YES","No selective reporting","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Bender-1997","2013-06-03 15:22:39 +0100","YES","No other bias","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Dieterle-1991","2012-09-01 11:42:04 +0100","UNKNOWN","""randomised"" (p18)","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Dieterle-1991","2013-06-03 15:22:20 +0100","UNKNOWN","Not indicated","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Dieterle-1991","2012-09-01 11:44:42 +0100","YES","""double blind""; ""identical capsules"" (p.18)","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","Objective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Dieterle-1991","2012-09-01 11:45:09 +0100","YES","""double blind""; ""identical capsules"" (p.18)","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.02","Subjective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Dieterle-1991","2012-09-01 11:45:34 +0100","YES","""double blind"" (p.18)","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","Objective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Dieterle-1991","2012-09-01 11:45:32 +0100","UNKNOWN","""double blind"" (p.18)","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.02","Subjective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Dieterle-1991","2012-09-01 11:46:47 +0100","UNKNOWN","50% dropout rate, not evenly distributed (12/20 and 8/20)","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Dieterle-1991","2013-06-03 15:22:13 +0100","NO","No SDs for CGI, SANS","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Dieterle-1991","2013-06-03 15:22:15 +0100","YES","No other bias","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Klimke-1993","2012-09-01 11:55:18 +0100","UNKNOWN","""randomly assigned"" (p.25)","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Klimke-1993","2013-06-03 15:22:00 +0100","UNKNOWN","Not indicated","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Klimke-1993","2012-09-01 11:57:41 +0100","YES","""double blind"" (p.25); ""Patients and treating psychiatrists were blind to the treatment conditions"" (p.26)","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","Objective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Klimke-1993","2012-09-01 11:59:27 +0100","UNKNOWN","""double blind"" (p.25); ""Patients and treating psychiatrists were blind to the treatment conditions"" (p.26)","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.02","Subjective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Klimke-1993","2012-09-01 11:59:29 +0100","YES","""double blind"" (p.25)","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","Objective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Klimke-1993","2012-09-01 11:59:23 +0100","UNKNOWN","""double blind"" (p.25)","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.02","Subjective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Klimke-1993","2012-09-01 12:00:17 +0100","NO","40% dropout rate, not evenly distributed (7/25 and 13/25)","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Klimke-1993","2013-06-03 15:21:23 +0100","YES","No selective reporting","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Klimke-1993","2013-06-03 15:21:30 +0100","YES","No other bias","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-R_x00fc_ther-1988","2013-06-03 15:21:37 +0100","UNKNOWN","""zufällige Zuteilung"" (p.65)","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-R_x00fc_ther-1988","2013-06-03 15:20:52 +0100","UNKNOWN","Not indicated","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-R_x00fc_ther-1988","2013-06-03 15:21:39 +0100","YES","""doppelblind"" (p.70)","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","Objective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-R_x00fc_ther-1988","2013-06-03 15:21:41 +0100","UNKNOWN","""doppelblind"" (p.70)","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.02","Subjective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-R_x00fc_ther-1988","2013-06-03 15:21:48 +0100","YES","""doppelblind"" (p.70)","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","Objective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-R_x00fc_ther-1988","2013-06-03 15:21:49 +0100","UNKNOWN","""doppelblind"" (p.70)","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.02","Subjective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-R_x00fc_ther-1988","2013-06-03 15:21:06 +0100","YES","Low dropout rate, evenly distributed between groups (2/15 and 3/15)","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-R_x00fc_ther-1988","2013-06-03 15:21:07 +0100","NO","Not all SDs provided","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-R_x00fc_ther-1988","2013-06-03 15:21:09 +0100","YES","No other bias","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Schmidt-1982","2013-06-03 15:20:23 +0100","UNKNOWN","""Randomisiert"" (p.531)","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Schmidt-1982","2013-06-03 15:20:25 +0100","UNKNOWN","Not indicated","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Schmidt-1982","2012-10-17 12:24:22 +0100","YES","""Doppel-Blind"" (p.530)","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","Objective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Schmidt-1982","2012-10-17 12:23:59 +0100","UNKNOWN","""Doppel-Blind"" (p.530)","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.02","Subjective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Schmidt-1982","2012-10-17 12:24:24 +0100","YES","""Doppel-Blind"" (p.530)","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","Objective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Schmidt-1982","2012-10-17 12:24:17 +0100","UNKNOWN","""Doppel-Blind"" (p.530)","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.02","Subjective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Schmidt-1982","2013-06-03 15:20:32 +0100","YES","Low dropout rate, evenly distributed (2/17 and 2/15)","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Schmidt-1982","2013-06-03 15:20:34 +0100","NO","Not all SDs provided","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Schmidt-1982","2013-06-03 15:20:36 +0100","YES","No other bias","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Tybura-2012","2013-11-15 17:27:41 +0000","YES","Personal communication from Jerzy Samochowiec: ""Both recruiting centers had a simple program generating random allocations. The program was writen by our statistician (P.M.) and allowed random allocation of each patient meeting the study criteria. The program was a simple randomization tool, i.e. it allowed random (with a probability of 33,3%) allocation of each qualified patient to one of three treatment groups.""","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Tybura-2012","2013-02-17 10:41:46 +0000","YES","Personal communication from Jerzy Samochowiec: ""The processes of initial qualification and randomization were separated. Senior researchers in each center were asked for a random allocation by physicians willing to qualify a patient to the study. The patient was registered in the study database and allocation to one of the study groups was performed as described above. Database records and randomization was a duty of a senior researcher. Hence, the physician deciding to qualify a patient to the study could not predict to which group the patient will be allocated. The allocation was done by another person and was final. The whole system worked like with two 'randomization centers'.""","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Tybura-2012","2013-02-17 10:43:54 +0000","YES","""Open study"". Lack of blinding would not be so important for objective outcomes.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","Objective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Tybura-2012","2013-02-17 10:42:43 +0000","NO","""Open study"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.02","Subjective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Tybura-2012","2013-02-17 10:43:40 +0000","YES","""Open study"". Lack of blinding would not be so important for objective outcomes.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","Objective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Tybura-2012","2013-02-17 10:44:12 +0000","NO","""Open study"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.02","Subjective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Tybura-2012","2013-12-11 09:37:49 +0000","NO","Dropout rate 24%-32%. Reasons for dropout not indicated. LOCF analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Tybura-2012","2013-02-17 11:14:19 +0000","YES","No indication of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Tybura-2012","2013-02-17 11:14:35 +0000","YES","No obvious other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Wetzel-1991","2012-09-01 12:13:37 +0100","UNKNOWN","randomized (""Zufallsprinzip"") (p.24)","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Wetzel-1991","2013-06-03 15:19:39 +0100","UNKNOWN","Not indicated","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Wetzel-1991","2013-06-03 15:19:42 +0100","YES","""Double blind"" (p.23)","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","Objective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Wetzel-1991","2013-06-03 15:19:52 +0100","UNKNOWN","""Double blind"" (p.23)","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.02","Subjective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Wetzel-1991","2013-06-03 15:19:54 +0100","YES","""Double blind"" (p.23)","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","Objective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Wetzel-1991","2013-06-03 15:19:56 +0100","UNKNOWN","""Double blind"" (p.23)","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.02","Subjective outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Wetzel-1991","2012-09-01 14:44:33 +0100","UNKNOWN","20% dropout rate, not evenly distributed (3/21 and 5/20)","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Wetzel-1991","2013-06-03 15:20:09 +0100","NO","No SDs or mean values provided","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Perazine for schizophrenia [v9.0-For publication].rm5","STD-Wetzel-1991","2013-06-03 15:20:11 +0100","YES","No other bias","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Canuso-2009","2009-03-16 18:39:36 +0000","YES","Stratified by site in blocks of five by an interactive voice response system.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Canuso-2009","2008-11-26 20:32:56 +0000","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Canuso-2009","2009-05-13 16:06:13 +0100","YES","Double.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Canuso-2009","2009-05-13 15:57:46 +0100","YES","All participants reported in outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Canuso-2009","2009-06-08 10:20:28 +0100","NO","399 participants were randomised, but only 394 were included in analysis. Reported adverse events only when they occurred in at least five per cent of the study population.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Canuso-2009","2009-03-16 18:42:44 +0000","NO","Funded by Ortho-McNeil Janssen Scientific Affairs.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Cleton-2007","2009-03-16 18:44:19 +0000","UNKNOWN","Randomised - undescribed.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Cleton-2007","2009-03-16 18:45:34 +0000","UNKNOWN","Undescribed.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Cleton-2007","2009-03-16 18:44:35 +0000","UNKNOWN","Double - undescribed.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Cleton-2007","2009-03-16 18:52:35 +0000","NO","Preliminary data only.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Cleton-2007","2009-03-16 18:46:20 +0000","UNKNOWN","Preliminary data only.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Cleton-2007","2009-08-06 09:07:38 +0100","NO","Funding from Johnson & Johnson Pharmaceutical Services, LLC and Johnson & Johnson Pharmaceutical Research & Development.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Davidson-2007","2009-03-16 18:48:28 +0000","YES","Computer-generated, stratified by site.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Davidson-2007","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Davidson-2007","2009-03-16 18:47:56 +0000","UNKNOWN","Double - not described.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Davidson-2007","2009-03-16 18:48:27 +0000","YES","All participants reported in outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Davidson-2007","2009-06-08 10:26:10 +0100","NO","618 participants were randomised, but only 605 were included in analysis. Reported adverse events only when they occurred in at least five per cent of the study population.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Davidson-2007","2009-06-08 10:26:15 +0100","NO","Sponsored by Johnson & Johnson Pharmaceutical Services, LLC., and Johnson & Johnson Pharmaceutical Research and Development (J & J PRD).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Kane-2007","2009-03-16 18:53:45 +0000","YES","Randomised - computer-generated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Kane-2007","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Kane-2007","2009-03-16 18:53:40 +0000","UNKNOWN","Double - not described.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Kane-2007","2009-03-16 19:00:01 +0000","YES","All participants are reported in outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Kane-2007","2009-06-08 10:33:16 +0100","NO","Reported adverse events only when they occurred in at least five per cent of the study population.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Kane-2007","2009-07-19 21:57:35 +0100","NO","Sponsored by Johnson & Johnson Pharmaceutical Research and Development.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Kramer-2007","2009-08-06 09:26:16 +0100","YES","Computer-generated, voice-response system.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Kramer-2007","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Kramer-2007","2009-03-16 19:51:41 +0000","UNKNOWN","Double - not described.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Kramer-2007","2009-08-06 09:26:24 +0100","YES","207 patients were randomised but only 205 patients were included in the intention-to-treat analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Kramer-2007","2009-06-08 10:36:59 +0100","NO","Reported adverse events only when they occurred in at least five per cent of the study population.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Kramer-2007","2009-08-06 09:26:40 +0100","NO","Study was funded by Johnson & Johnson Pharmaceutical Research and Development.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Luthringer-2007","2009-06-08 10:38:23 +0100","YES","Computer-generated, permuted blocks, stratified by sex, assigned by call centre.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Luthringer-2007","2008-11-25 18:04:57 +0000","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Luthringer-2007","2009-03-16 19:54:23 +0000","UNKNOWN","Double - not described.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Luthringer-2007","2009-03-16 19:59:38 +0000","NO","","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Luthringer-2007","2009-08-06 09:31:28 +0100","NO","Reported demographics for patients completing the study, but adverse events were reported for safety analysis set. Did not report change in CGI-S score, change in PANSS score and various mean change in serum levels.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Luthringer-2007","2009-08-06 09:31:37 +0100","NO","Study supported by Johnson & Johnson Pharmaceutical Research and Development.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Marder-2007","2009-06-08 10:39:11 +0100","YES","Computer-generated, stratified by site, assigned by voice-response system.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Marder-2007","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Marder-2007","2009-03-16 20:00:27 +0000","UNKNOWN","Double - not described.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Marder-2007","2009-08-06 09:34:26 +0100","YES","444 participants were randomised but only 432 were included in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Marder-2007","2009-08-06 09:34:30 +0100","NO","Reported adverse events only when they occurred in at least five per cent of the study population.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Marder-2007","2009-08-06 09:34:39 +0100","NO","Study sponsored by Johnson & Johnson Pharmaceutical Research and Development.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Tzimos-2008","2009-03-16 20:02:23 +0000","YES","Permuted blocks of treatment stratified by study site.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Tzimos-2008","2008-05-09 15:14:07 +0100","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Tzimos-2008","2009-03-16 20:02:31 +0000","UNKNOWN","Double - not described.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Tzimos-2008","2009-03-16 20:04:53 +0000","YES","All participants reported in outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Tzimos-2008","2009-07-03 14:06:41 +0100","NO","Reported adverse events only when they occurred in at least five per cent of the study population.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Oral paliperidone for schizophrenia [v8.0-For publication].rm5","STD-Tzimos-2008","2009-08-06 09:40:22 +0100","NO","Study supported by Johnson & Johnson Pharmaceutical Research & Development, LLC.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Atmaca-2003","2009-02-06 15:00:36 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Atmaca-2003","2009-02-06 15:00:36 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Atmaca-2003","2009-02-12 16:05:34 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Atmaca-2003","2009-02-15 16:00:04 +0000","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Atmaca-2003","2009-02-10 13:37:22 +0000","YES","Three subjects in the control groups left the study early (5.4%). Reason for drop-out were not assessed, only completer data were presented. But due to the very low rate we do not think that there was a risk of bias.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Atmaca-2003","2009-02-12 12:17:46 +0000","YES","Probably free of bias. The study focused on serum leptin and triglyceride levels which were adequately described.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Atmaca-2003","2010-02-15 06:27:31 +0000","UNKNOWN","Data on the allowed dose range have not been presented. Furthermore, the pre-study treatment was quite heterogeneous as 19 participants had never taken any psychotropic drugs while most other participants had a long history of previous treatment. Sponsorship was neutral.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Bai-2005","2009-02-06 15:02:53 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Bai-2005","2009-02-06 15:02:53 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Bai-2005","2009-02-12 16:05:49 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Bai-2005","2009-02-15 16:00:04 +0000","UNKNOWN","Single, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Bai-2005","2010-02-17 12:52:28 +0000","YES","The rate of leaving the study early was low (5%), data on reasons for drop-out were provided. All data were analysed on an intent to treat basis with the last-observation- carried forward-method. This method is not perfect, but due to the very low attrition, the risk of bias was low.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Bai-2005","2009-02-06 15:02:54 +0000","NO","The study is only available as an abstract. Data on BPRS and EPS scales were not available.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Bai-2005","2009-02-06 15:02:54 +0000","UNKNOWN","Insufficient data to judge on baseline imbalance or industry sponsoring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Bitter-2004","2008-12-17 22:33:17 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Bitter-2004","2008-12-17 22:33:20 +0000","UNKNOWN","No further details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Bitter-2004","2009-07-28 12:56:06 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Bitter-2004","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Bitter-2004","2009-02-16 12:38:48 +0000","NO","The attrition was high (42.1%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption might be wrong, especially in case of high attrition.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Bitter-2004","2009-02-16 12:39:01 +0000","NO","Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Bitter-2004","2009-02-10 10:41:46 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Breier-2005","2009-01-29 20:32:39 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Breier-2005","2009-01-29 20:32:45 +0000","UNKNOWN","No further details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Breier-2005","2009-02-12 16:04:13 +0000","YES","Double, no further details. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Breier-2005","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Breier-2005","2009-02-16 12:39:32 +0000","NO","The attrition was high (48.9%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. Additionally mixed models analysis was performed but it is unclear whether any statistical method can account for such high numbers of leaving the study early.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Breier-2005","2009-02-16 12:39:47 +0000","NO","Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Breier-2005","2009-02-10 10:42:05 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Canive-2000","2008-12-17 22:33:31 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Canive-2000","2010-02-17 12:57:08 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Canive-2000","2009-07-28 13:08:24 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Canive-2000","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Canive-2000","2009-02-10 11:00:31 +0000","NO","Data on leaving the study early were not available.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Canive-2000","2009-01-29 21:19:03 +0000","NO","Data were only presented as a poster, data on primary outcomes were missing.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Canive-2000","2009-01-29 21:20:53 +0000","NO","The study was sponsored by the manufacturers of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-CN138003","2009-01-29 20:32:26 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-CN138003","2009-01-29 20:32:28 +0000","UNKNOWN","No further details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-CN138003","2009-07-28 12:58:21 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-CN138003","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-CN138003","2009-02-08 17:51:50 +0000","NO","The attrition rate within the first six weeks was 25% overall, but data on reason for leaving the study early were not available. The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-CN138003","2009-02-15 16:11:01 +0000","NO","Data for the predefined primary outcome are available but secondary outcome measures like 30% PANSS total reduction are missing in the six weeks interim report. Treatment emergent adverse events were hardly addressed in the interim report.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-CN138003","2009-02-12 14:13:03 +0000","NO","The study was sponsored by the manufacturer of aripiprazole.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Conley-2001","2009-02-06 15:18:56 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Conley-2001","2009-02-06 15:18:57 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Conley-2001","2009-07-28 13:08:11 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Conley-2001","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Conley-2001","2009-02-15 16:14:33 +0000","UNKNOWN","The attrition rate was possibly acceptable (25.5%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. It is unclear whether this led to bias.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Conley-2001","2010-02-15 06:26:11 +0000","NO","Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Conley-2001","2009-02-15 16:14:44 +0000","NO","The study was sponsored by the manufacturer of risperidone. Total number of participants was very low (n=13), which may limit the validity of results.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Conley-2003","2008-12-17 22:34:43 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Conley-2003","2008-12-17 22:34:46 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Conley-2003","2009-07-28 13:12:52 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Conley-2003","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Conley-2003","2009-02-15 16:19:24 +0000","UNKNOWN","The attrition rate was possibly acceptable (23%).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Conley-2003","2009-02-16 12:45:34 +0000","NO","Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Conley-2003","2010-02-14 17:54:50 +0000","NO","The fixed dose of olanzapine was rather high (50mg/day), and the total number of participants were rather low (N=13). The study had a neutral sponsor. ","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Dollfus-2005","2009-02-06 15:21:03 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Dollfus-2005","2009-02-06 15:21:03 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Dollfus-2005","2009-07-28 13:17:52 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Dollfus-2005","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Dollfus-2005","2009-02-15 16:16:34 +0000","NO","Data on leaving the study early were not published separately for each group, the overall attrition was possibly acceptable (25%). (Data on both treatment attrition rates were provided from contact of the author).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Dollfus-2005","2009-02-06 15:23:09 +0000","NO","Data on efficacy outcomes were incompletely reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Dollfus-2005","2009-02-06 15:23:09 +0000","NO","The study was sponsored by the manufacturers of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Dolnak-2001","2008-12-17 22:35:15 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Dolnak-2001","2008-12-17 22:35:18 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Dolnak-2001","2009-07-28 13:19:46 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Dolnak-2001","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Dolnak-2001","2009-01-29 21:51:25 +0000","NO","No data on leaving the study early available.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Dolnak-2001","2009-01-29 21:51:47 +0000","UNKNOWN","Insufficient data.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Dolnak-2001","2010-02-14 19:55:08 +0000","UNKNOWN","Insufficient data. Sponsorship unclear.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Gureje-2003","2009-02-06 15:24:19 +0000","YES","Random, computer-generated randomisation.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Gureje-2003","2009-02-06 15:24:19 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Gureje-2003","2009-07-28 13:24:51 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Gureje-2003","2009-02-15 16:00:04 +0000","UNKNOWN","Double, double-dummy design. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Gureje-2003","2009-02-15 16:17:09 +0000","NO","The overall attrition was high (55.4%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Gureje-2003","2009-02-16 12:46:14 +0000","NO","Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Gureje-2003","2009-02-10 10:43:06 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Jeste-2003","2009-02-06 15:25:27 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Jeste-2003","2009-02-06 15:25:27 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Jeste-2003","2009-07-28 13:29:31 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Jeste-2003","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Jeste-2003","2009-02-15 16:18:31 +0000","UNKNOWN","Number of participants leaving the study early was possibly acceptable (23.9%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. It is unclear whether this led to bias.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Jeste-2003","2009-02-16 12:47:41 +0000","NO","Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Jeste-2003","2009-02-11 10:35:47 +0000","NO","The study was sponsored by the manufacturer of risperidone. The mean age of included subjects was about 71 years. Probably due to this reason the upper dose range limit of risperidone was rather low (3mg/day) compared with olanzapine (20mg/day).","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Keefe-2006","2009-02-06 15:26:31 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Keefe-2006","2009-02-06 15:26:31 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Keefe-2006","2009-07-28 13:33:57 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Keefe-2006","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Keefe-2006","2009-02-16 12:48:05 +0000","NO","The attrition rate was high (62.8%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Keefe-2006","2009-02-16 12:47:59 +0000","NO","Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Keefe-2006","2009-02-06 15:26:31 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006a","2008-12-17 22:38:26 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006a","2008-12-17 22:38:29 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006a","2009-07-28 13:34:49 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006a","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006a","2009-02-16 12:48:16 +0000","NO","The attrition rate was high (62.7%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006a","2009-01-29 22:38:55 +0000","NO","Secondary outcomes were not fully reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006a","2009-02-10 10:43:34 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006b","2009-02-06 15:27:46 +0000","YES","Random, computer-generated randomisation.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006b","2009-02-06 15:27:46 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006b","2009-07-28 13:36:30 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006b","2009-02-15 16:00:04 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006b","2009-02-12 15:17:46 +0000","NO","The drop-out rate was high (54.9%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong, especially in case of high attrition.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006b","2009-02-12 12:22:25 +0000","NO","Numbers of participants with antiparkinson medication or leukopenia were not indicated.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006b","2009-02-06 15:27:47 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Krakowski-2006","2008-12-17 22:38:59 +0000","UNKNOWN","Random, block randomisation (block size of 3).","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Krakowski-2006","2008-12-17 22:39:03 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Krakowski-2006","2009-07-28 13:39:35 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Krakowski-2006","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding. ","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Krakowski-2006","2009-02-15 16:21:34 +0000","NO","Number of participants leaving the study early was considerable (33.3%).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Krakowski-2006","2009-02-07 12:33:50 +0000","NO","Data on adverse effects or use of antiparkinson medication were not presented. ","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Krakowski-2006","2010-02-17 13:16:00 +0000","NO","There was no wash-out period, pre study antipsychotic medication was gradually discontinued during the first six weeks leading to an overlap of medications. Sponsorship was neutral.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kumra-2007","2008-12-17 22:39:23 +0000","YES","Random, computer-generated randomisation.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kumra-2007","2008-12-17 22:39:26 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kumra-2007","2009-07-28 13:45:01 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kumra-2007","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kumra-2007","2009-02-16 12:48:53 +0000","UNKNOWN","Number of participants leaving the study early were moderate (28.2%). The statistical analysis was based on mixed effects model. It is unclear whether this led to bias.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kumra-2007","2009-02-15 16:22:21 +0000","NO","Data on adverse effects were incompletely reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kumra-2007","2010-02-14 19:52:04 +0000","UNKNOWN","The age range of participants included was 10 to 18 years. Sponsorship was neutral.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lecrubier-2006","2009-02-06 15:29:45 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lecrubier-2006","2009-02-06 15:29:45 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lecrubier-2006","2009-07-28 13:46:52 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lecrubier-2006","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lecrubier-2006","2009-02-16 12:54:20 +0000","NO","The rate of leaving the study early was high (57.6%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong and poses problem given the high attrition.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lecrubier-2006","2009-02-15 16:22:42 +0000","NO","Only those adverse events were reported that occurred with an incidence of at least 10%, therefore rare but important side effects may have been missed by this procedure.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lecrubier-2006","2009-02-12 14:19:06 +0000","NO","The study was industry sponsored by the manufacturer of olanzapine and one of the authors is employee of that company. A fixed dose regimen was used where it might be difficult to decide which comparator doses are appropriate.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lieberman-2005","2009-02-06 15:31:22 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lieberman-2005","2009-02-06 15:31:22 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lieberman-2005","2009-07-28 13:47:47 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lieberman-2005","2009-02-15 16:00:04 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lieberman-2005","2009-02-12 15:19:34 +0000","NO","The attrition rate was high (75%), and it is unclear whether any statistical method can account for such a high drop-out rate. Efficacy outcomes were evaluated based on mixed effects model analysis.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lieberman-2005","2009-02-12 12:25:23 +0000","YES","There was no evidence of selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lieberman-2005","2010-02-17 13:23:12 +0000","UNKNOWN","Dose ranges were quite different, the upper dose range of olanzapine was 30 mg whereas risperidone could only be titrated up to ","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McEvoy-2006","2009-02-06 15:33:04 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McEvoy-2006","2009-02-06 15:33:04 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McEvoy-2006","2009-07-28 13:48:54 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McEvoy-2006","2009-02-15 16:00:04 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McEvoy-2006","2009-02-15 16:23:36 +0000","NO","The overall attrition rate was high (74%). It is doubtful that the validity of the results was unaffected.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McEvoy-2006","2009-02-12 12:27:10 +0000","NO","Due to small numbers and the very high attrition only data on 26 weeks treatment (rather than 52 weeks) were presented.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McEvoy-2006","2010-02-14 19:49:22 +0000","UNKNOWN","Dose ranges were quite different, the upper dose range of olanzapine was 30 mg whereas risperidone could only be titrated up to 6mg /day. Patients had a history of former inefficacy to one of the medications. It was excluded that the same medication could be given again but still this might implicate a risk of bias due to baseline imbalance in terms of former treatment. There was no wash out period. Sponsorship was neutral.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McEvoy-2007","2009-02-06 15:34:08 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McEvoy-2007","2009-02-06 15:34:08 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McEvoy-2007","2009-07-28 13:49:55 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McEvoy-2007","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McEvoy-2007","2010-02-17 13:25:43 +0000","NO","The attrition rate was high (70.3.%). Analysis was based on mixed effects model and secondary on last-observation-carried forward and observed cases. It is unclear whether any statistical method can account for such a high drop-out rate.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McEvoy-2007","2009-02-10 12:07:49 +0000","NO","Adverse events were presented only in case of moderate or worse severity.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McEvoy-2007","2009-02-10 10:45:51 +0000","NO","The study was sponsored by the manufacturer of quetiapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McQuade-2004","2009-02-06 15:35:23 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McQuade-2004","2009-02-06 15:35:23 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McQuade-2004","2009-07-28 13:52:10 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by lack of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McQuade-2004","2009-07-28 13:52:14 +0100","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McQuade-2004","2009-02-12 14:20:42 +0000","NO","Quote: "" Because of the high number of participants who discontinued the study","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McQuade-2004","2009-02-15 16:24:16 +0000","NO","Although inclusion criteria required participants in acute relapse, no data on the PANSS positive subscore were available. Data on use of antiparkinson medication were missing.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-McQuade-2004","2009-02-06 15:35:23 +0000","NO","The study was industry sponsored by the manufacturer of aripiprazole.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Meltzer-2003","2008-12-17 22:41:43 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Meltzer-2003","2008-12-17 22:41:45 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Meltzer-2003","2009-02-12 16:10:11 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Meltzer-2003","2009-02-15 16:00:04 +0000","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Meltzer-2003","2009-02-15 16:24:43 +0000","UNKNOWN","The number of participants leaving the study early was high (38.7%). It is unclear whether any statistical method can account for such a high attrition rate.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Meltzer-2003","2009-02-12 12:39:01 +0000","NO","Data on ESRS scales were not available.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Meltzer-2003","2010-02-14 19:47:51 +0000","NO","The study was sponsored by the manufacturer of clozapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Moresco-2004","2009-07-28 10:01:59 +0100","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Moresco-2004","2008-12-17 22:42:05 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Moresco-2004","2009-07-28 14:00:09 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Moresco-2004","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Moresco-2004","2009-02-16 12:58:15 +0000","NO","Numbers of leaving the study early were high (34.8%). The statistical analysis was based on completer data.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Moresco-2004","2009-01-29 23:23:34 +0000","NO","Data on EPS scales were incompletely reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Moresco-2004","2009-02-10 10:46:33 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Mori-2004","2009-02-06 15:36:49 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Mori-2004","2009-02-06 15:36:49 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Mori-2004","2009-07-28 14:01:40 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Mori-2004","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Mori-2004","2009-02-12 15:20:30 +0000","NO","There were no data on attrition available.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Mori-2004","2009-02-12 13:26:42 +0000","NO","Adverse events were not reported. Numbers on use of antiparkinson medication have not been presented.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Mori-2004","2010-02-14 19:46:01 +0000","NO","There was no wash-out period. The previous antipsychotic treatment was gradually tapered over four weeks. Thus, during a period of 4 weeks the participants were on two drugs.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Mortimer-2004","2009-02-06 15:37:59 +0000","YES","Random, computer-generated randomisation.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Mortimer-2004","2009-02-09 12:47:21 +0000","YES","Computer generated randomisation list was prepared and kept outside the study centre. Quote: Patient numbers were assigned in strict chronological order in each centre.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Mortimer-2004","2009-07-28 14:02:52 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Mortimer-2004","2009-02-15 16:00:04 +0000","UNKNOWN","Double, identical capsules. Quote: ""to permit dose adjustment whilst maintaining the double-blind, blister packs corresponding to a low and a high dosage were provided"".","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Mortimer-2004","2009-02-16 12:58:49 +0000","NO","The rate of leaving the study early was high (35.8%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. It is unclear whether this led to bias.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Mortimer-2004","2009-02-16 12:59:03 +0000","NO","Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Mortimer-2004","2009-02-09 12:48:05 +0000","NO","The study was sponsored by the manufacturer of amisulpride.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Naber-2005","2009-02-06 16:16:21 +0000","YES","Random, computer-generated randomisation.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Naber-2005","2009-02-06 16:16:25 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Naber-2005","2009-07-28 14:11:56 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Naber-2005","2009-02-15 16:00:04 +0000","YES","Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Naber-2005","2009-02-16 12:59:16 +0000","NO","The attrition rate was high (62.3%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong, given the high number of attrition. Completer data were also available.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Naber-2005","2010-02-17 13:33:47 +0000","NO","Adverse effects data were not fully addressed (data on non fastening blood glucose level were not presented).","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Naber-2005","2009-02-10 10:46:57 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Ozguven-2004","2009-02-06 15:38:51 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Ozguven-2004","2009-02-06 15:38:51 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Ozguven-2004","2009-02-12 16:11:00 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Ozguven-2004","2009-02-15 16:00:04 +0000","UNKNOWN","Single, rater blind. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Ozguven-2004","2009-02-16 13:00:19 +0000","YES","The attrition rate was rather low (13%), there was no further explanation on the statistical method that was used, but due to the low attrition the risk of bias is rather low.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Ozguven-2004","2009-02-06 15:38:51 +0000","NO","The data were only published as an abstract. Data was only available in percent change.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Ozguven-2004","2010-02-14 19:42:40 +0000","UNKNOWN","Unclear due to insufficient information.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Purdon-2000","2009-02-06 15:39:46 +0000","YES","Random, computer-generated randomisation.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Purdon-2000","2009-02-06 15:39:46 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Purdon-2000","2009-07-28 14:15:16 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Purdon-2000","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Purdon-2000","2009-02-16 13:00:32 +0000","NO","The attrition rate was high (54.8%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Purdon-2000","2009-02-15 16:27:54 +0000","YES","The study focused on neuropsychological changes, data for efficacy and EPS scales were also presented, probably ok.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Purdon-2000","2009-02-10 10:47:22 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Riedel-2007","2009-02-06 15:40:51 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Riedel-2007","2009-02-06 15:40:51 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Riedel-2007","2009-08-03 07:51:05 +0100","YES","Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Riedel-2007","2009-02-12 16:04:13 +0000","UNKNOWN","Double, no further details. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Riedel-2007","2010-02-17 13:37:50 +0000","NO","The attrition rate was high (61.5%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong, given the high number of attrition.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Riedel-2007","2009-02-12 12:48:20 +0000","NO","Data on global state have not been presented.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Riedel-2007","2009-02-06 15:40:52 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Robinson-2006","2009-02-06 15:42:08 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Robinson-2006","2009-02-06 15:42:08 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Robinson-2006","2009-02-12 16:11:17 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Robinson-2006","2009-02-15 16:00:04 +0000","UNKNOWN","Single-blind, rater-blinded. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Robinson-2006","2009-02-16 13:01:19 +0000","UNKNOWN","Data on leaving the study early is incomplete. The overall attrition is moderate (28%). Eight patients were excluded from the analysis for various reasons. Analysis was based on mixed effects model.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Robinson-2006","2009-02-06 15:42:08 +0000","NO","The study included first episode schizophrenic patients but data on PANSS change were not presented.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Robinson-2006","2010-02-14 19:41:30 +0000","UNKNOWN","Quote:"" .. the study was designed to detect differences in our primary analysis at alpha= 0.05 with 80% power based upon 130 subjects, the stability analysis included only 47 subjects and therefore might lack adequate power"".","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sacchetti-2004","2009-02-06 15:43:25 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sacchetti-2004","2009-02-06 15:43:25 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sacchetti-2004","2009-02-12 16:11:41 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sacchetti-2004","2009-02-15 16:00:04 +0000","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sacchetti-2004","2009-02-16 13:01:55 +0000","UNKNOWN","The attrition rate was moderate (18.6%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. It is unclear whether this led to bias.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sacchetti-2004","2009-02-12 12:50:47 +0000","NO","Efficacy data (PANSS) were only presented as per cent change, without indications of standard deviations, standard errors, p-values or ranges. Only interim data after half the patients had been recruited have been presented.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sacchetti-2004","2009-02-06 15:43:26 +0000","NO","The study was sponsored by the manufacturer of quetiapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Shaw-2006","2008-12-17 22:44:57 +0000","YES","Random, random-numbers chart, blocks of 4.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Shaw-2006","2009-01-30 09:24:20 +0000","YES","Quote: Numbered containers were used to implement the random allocation sequence.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Shaw-2006","2009-07-28 14:18:49 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Shaw-2006","2009-02-15 16:00:04 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Shaw-2006","2009-02-09 13:21:02 +0000","YES","Only one subject left the study early (4%). The attrition rate was very low, therefore a risk of bias is rather not expected.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Shaw-2006","2009-01-30 09:33:31 +0000","YES","Review authors do not believe this will introduce bias.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Shaw-2006","2010-02-14 19:39:27 +0000","UNKNOWN","Upper dose limit of clozapine was 500mg/day. The low age of included participants and the small number of included subjects also has to be taken into account. Sponsorship was neutral.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sikich-2004","2009-02-06 15:46:06 +0000","YES","Random, computer-generated randomisation.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sikich-2004","2009-02-06 15:46:06 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sikich-2004","2009-07-28 14:19:29 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sikich-2004","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sikich-2004","2009-02-16 13:03:10 +0000","NO","The attrition rate was rather high (33.3%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. It is unclear whether this led to bias.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sikich-2004","2009-02-15 16:29:48 +0000","YES","No evidence for selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sikich-2004","2010-02-17 14:20:23 +0000","NO","Quote: ""....this ..study has a number of limitations including limited sample size, differences in the diagnosis of participants, use of co-comitant medication, variations in age and perpetual status"".","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Simpson-2004","2008-12-17 22:45:24 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Simpson-2004","2008-12-17 22:45:25 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Simpson-2004","2009-07-28 14:20:07 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Simpson-2004","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Simpson-2004","2009-02-16 13:03:45 +0000","NO","The overall attrition rate was high (42.8%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Simpson-2004","2009-02-15 16:30:43 +0000","NO","The study focused on acutely ill schizophrenic or schizoaffective patients but data on positive symptoms were not provided.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Simpson-2004","2009-02-15 16:30:50 +0000","NO","The study was sponsored by the manufacturer of ziprasidone. Upper dose limit of olanzapine was 15 mg/day, which is below the maximum dose for this medication.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sirota-2006","2009-02-06 15:48:00 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sirota-2006","2009-02-06 15:48:00 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sirota-2006","2009-02-12 16:12:40 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sirota-2006","2009-02-15 16:00:04 +0000","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sirota-2006","2009-02-15 16:31:19 +0000","YES","The attrition rate was quite low (12%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. For the reason of low attrition the risk of bias can be considered as low.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sirota-2006","2009-02-15 16:31:29 +0000","NO","Efficacy data (PANSS, SANS) were only presented as median change. There were no data on EPS and cardiac effects.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sirota-2006","2009-02-12 12:51:41 +0000","NO","The study was sponsored by the manufacturer of quetiapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Stroup-2006","2009-02-15 16:32:19 +0000","UNKNOWN","Random, 2 steps of randomisation before and after the availability of ziprasidone, subjects were re-randomised to other medication than in phase 1.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Stroup-2006","2009-02-06 15:49:40 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Stroup-2006","2009-07-28 14:21:48 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Stroup-2006","2009-02-15 16:00:04 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Stroup-2006","2010-02-17 13:46:53 +0000","NO","The attrition rate was high (72.5%). Efficacy data analysis was based on mixed effect models. It is unclear whether any statistical method can account for such high rates of leaving the study early.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Stroup-2006","2009-02-06 15:49:41 +0000","NO","Use of antiparkinson medication was permitted but data on this was not available.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Stroup-2006","2009-02-06 15:49:41 +0000","UNKNOWN","Patients had a history of former intolerance to atypical antipsychotic treatment but baseline data on this was not provided.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2003a","2009-02-06 15:50:51 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2003a","2009-02-06 15:50:51 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2003a","2009-07-28 14:22:23 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2003a","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2003a","2009-02-06 15:50:52 +0000","NO","Data on subjects leaving the study early were not available.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2003a","2009-02-11 11:16:02 +0000","NO","Allowed study medication dose ranges were not indicated. A publication was not available.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2003a","2010-02-14 19:37:35 +0000","UNKNOWN","Insufficient information. Sponsorship was neutral.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2003b","2009-02-06 15:52:04 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2003b","2009-02-06 15:52:04 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2003b","2009-07-28 14:22:48 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2003b","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2003b","2009-02-06 15:52:04 +0000","NO","Data on the overall attrition rate were not available.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2003b","2009-02-06 15:52:04 +0000","NO","For some metabolic parameters there were no data available.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2003b","2010-02-14 19:37:23 +0000","UNKNOWN","There was a certain baseline imbalance in terms of mean age, which was not statistically significant. Sponsorship was neutral.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2005","2008-12-17 22:48:07 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2005","2008-12-17 22:48:11 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2005","2009-07-28 14:23:56 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2005","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2005","2009-01-30 10:14:47 +0000","NO","Data on subjects leaving the study early were not available.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2005","2009-02-11 11:16:13 +0000","NO","Allowed study medication dose ranges were not indicated. A publication was not available.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2005","2010-02-14 19:36:27 +0000","UNKNOWN","Insufficient information. Sponsorship was neutral.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Tollefson-2001","2008-12-17 22:48:30 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Tollefson-2001","2008-12-17 22:48:32 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Tollefson-2001","2009-07-28 14:24:55 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Tollefson-2001","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Tollefson-2001","2010-02-17 13:50:04 +0000","NO","The attrition rate was high (40.1%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong, given the rather high number of attrition.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Tollefson-2001","2009-02-16 13:10:33 +0000","NO","Adverse events had to occur with an incidence of more than 5% or with a statistically significant difference of p<0.05 for being reported. Important side effects may have been missed by this procedure.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Tollefson-2001","2009-02-10 10:49:18 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Tran-1997","2009-02-06 15:53:25 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Tran-1997","2009-02-06 15:53:25 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Tran-1997","2009-07-28 14:25:11 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Tran-1997","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Tran-1997","2010-02-17 13:50:42 +0000","NO","The attrition rate was high (47.5 %). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong, given the rather high number of attrition.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Tran-1997","2010-02-17 13:50:45 +0000","NO","Adverse effects were only reported in the case of a significant difference between groups, therefore important side effects may have been missed by this procedure.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Tran-1997","2009-02-10 10:49:26 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Van-Nimwegen-2006","2009-02-06 15:54:36 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Van-Nimwegen-2006","2009-02-06 15:54:37 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Van-Nimwegen-2006","2009-07-28 14:25:34 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Van-Nimwegen-2006","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Van-Nimwegen-2006","2009-02-06 15:54:37 +0000","NO","Data on leaving the study early were not provided.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Van-Nimwegen-2006","2009-02-06 15:54:37 +0000","NO","Outcome reporting was incomplete, standard deviation values were not published.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Van-Nimwegen-2006","2009-02-16 13:12:02 +0000","UNKNOWN","Additional usage of cannabis. ","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Vanelle-2006","2009-02-06 15:56:03 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Vanelle-2006","2009-02-06 15:56:03 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Vanelle-2006","2009-07-28 14:25:58 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Vanelle-2006","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Vanelle-2006","2009-02-12 14:31:11 +0000","YES","The rate of participants leaving the study early was 16.5% and reasons for leaving the study early were provided. The analysis was based on the last-observation carried forward method with two people being excluded due to no exploitable outcome data. In addition there was a per protocol population which excluded subjects with a major protocol deviation. As two different methods with similar results were applied and as the overall attrition was low we do not think that there was a bias.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Vanelle-2006","2009-02-06 15:56:04 +0000","NO","Data on extrapyramidal symptoms were not provided.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Vanelle-2006","2009-02-12 14:31:34 +0000","NO","The study was sponsored by the manufacturer of amisulpride.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Volavka-2002","2009-02-06 15:57:41 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Volavka-2002","2009-02-06 15:57:42 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Volavka-2002","2009-07-28 14:26:46 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Volavka-2002","2009-02-15 16:00:04 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Volavka-2002","2009-02-15 16:37:21 +0000","NO","The attrition rate was high (41.7%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong, given the rather high number of attrition.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Volavka-2002","2009-02-06 15:57:42 +0000","NO","Some outcomes were reported on subgroup from the entire sample. Quality of life scale data is not provided.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Volavka-2002","2010-02-17 13:53:54 +0000","NO","Quote: ""The olanzapine arm was added in November 1997 and required a modified randomisation procedure""... It entails the potential for a bias that could be manifested as a cohort effect.""","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Voruganti-2007","2009-02-06 15:59:04 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Voruganti-2007","2009-02-06 15:59:04 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Voruganti-2007","2009-02-12 16:14:15 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Voruganti-2007","2009-02-15 16:00:04 +0000","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Voruganti-2007","2009-02-15 16:37:55 +0000","NO","There is a discrepancy between the abstract in the text. While according to the abstract there were fewer participants leaving the study early in the olanzapine group, this finding was no longer mentioned in the text according to which the overall attrition was only 1.2%.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Voruganti-2007","2009-02-15 16:37:42 +0000","NO","Use of antiparkinson medication was permitted but data were not presented.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Voruganti-2007","2009-02-06 15:59:05 +0000","NO","The study was sponsored by the manufacturer of quetiapine. There was no wash-out period.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wagner-2005","2009-02-09 13:12:53 +0000","UNKNOWN","Random, medication containers according to a pseudo-random computer algorithm.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wagner-2005","2009-02-06 16:00:29 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wagner-2005","2009-07-28 14:27:56 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wagner-2005","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wagner-2005","2009-02-12 14:33:57 +0000","NO","The rate of participants leaving the study early was high (50%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong and lead to bias in cases of high attrition.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wagner-2005","2009-02-15 16:38:14 +0000","NO","Additional treatment with biperiden up to 4mg/day was permitted, but data on use of antiparkinson medication was not available.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wagner-2005","2009-02-06 16:00:30 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wang-2002","2008-12-17 22:51:49 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wang-2002","2008-12-17 22:51:26 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wang-2002","2009-07-28 14:29:09 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wang-2002","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wang-2002","2009-01-30 10:47:06 +0000","NO","Data on leaving the study early were not provided.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wang-2002","2009-02-15 16:38:24 +0000","NO","Data were not available for all of the predefined adverse effect outcomes.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wang-2002","2009-02-15 16:39:23 +0000","NO","The sponsor was unclear. The upper dose range limit of clozapine was 400mg/day which was reached rather quickly (10 days), which could mean a disadvantage for clozapine in terms of side effects.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wang-2006","2009-02-06 16:01:16 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wang-2006","2009-02-06 16:01:16 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wang-2006","2009-07-28 14:30:29 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wang-2006","2009-02-15 16:00:04 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wang-2006","2009-02-06 16:01:17 +0000","NO","Data on leaving the study early were not available.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wang-2006","2009-02-15 16:40:25 +0000","NO","Standard deviations for the primary outcome were not available.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wang-2006","2009-02-10 10:50:53 +0000","NO","Dose ranges were not indicated. The study was sponsored by the manufacturer of risperidone.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wynn-2007","2009-02-06 16:02:22 +0000","UNKNOWN","Random, 33 participants were assigned to a three-arm randomisation (1:1:1, blocks of 15) and 18 participants with a history of adverse experiences with haloperidol were assigned to a two-arm randomisation (1:1) for risperidone and olanzapine only.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wynn-2007","2009-02-06 16:02:22 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wynn-2007","2009-07-28 14:30:55 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Objective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wynn-2007","2009-02-15 16:00:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Subjective outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wynn-2007","2009-02-06 16:02:23 +0000","NO","Data on leaving the study early were not available.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wynn-2007","2010-02-17 13:59:21 +0000","NO","Efficacy outcomes as change of PANSS score were not reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Olanzapine versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Wynn-2007","2009-02-10 10:51:05 +0000","NO","The study was sponsored by the manufacturer of risperidone.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Altamura-1999-_x0028_HGBQ_x0029_","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Avasthi-2001","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Barak-2002","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Beasley-1996a-_x0028_HGAD_x0029_","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Beasley-1996b-_x0028_HGAP_x0029_","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Beasley-1997-_x0028_E003_x0029_","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Bernardo-2001-_x0028_HGDD_x0029_","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Beuzen-1998-_x0028_HGCF_x0029_","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Bitter-2004-_x0028_HGCK_x0029_","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Casey-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Chan-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Chang-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Chaudhry-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Chen-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Conley-1998","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Conley-2001","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Corrigan-2004","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-de-Haan-2002","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-de-Hann-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Esel-2001","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-He-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-HGBJ-_x0028_Finland_x0029_","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-HGBL-1997","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-HGCJ-_x0028_Hong-Kong_x0029_","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-HGCQ-_x0028_Turkey_x0029_-2000","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-HGCU-_x0028_Taiwan_x0029_-1998","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-HGDV-_x0028_Morocco_x0029_-1999","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-HGFH-_x0028_Korea_x0029_-1998","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Ishigooka-2001","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Jakovljevic1999-HGCH","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Jeste-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Jones-1998-_x0028_P022_x0029_","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Kelly-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Kern-2001","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Lecrubier-1999","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Lieberman-2003-_x0028_HGDH","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Lima-2003-_x0028_HGHS_x0029_","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Littrell-1999","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Loza-1999-_x0028_HGDT_x0029_","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Malyarov-1999","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Martin-2002","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-McQuade-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Meltzer-_x0028_InterSept_x0029_","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Naber-2001-_x0028_HGBF_x0029_","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Namjoshi-2002","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Ritchie-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Rosenheck-2003_x0028_HGFI_x0029_","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Simpson-2004","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Svestka-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Thomas-1998-_x0028_HGBU_x0029_","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Tollefson-1997_x0028_HGAJ_x0029_","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Tollefson-1997-Conti","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Tollefson-1999_x0028_HGDY_x0029_","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Tran-1997-_x0028_HGBG_x0029_","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Wang-2002","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Olanzapine for schizophrenia [v12.0-For publication].rm5","STD-Wang-2003","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia [v12.0-For publication].rm5","STD-Buruma-1982","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia [v12.0-For publication].rm5","STD-Hebenstreit-1986","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Nidotherapy for people with schizophrenia [v3.0-For publication].rm5","STD-Ranger-2009","2012-11-30 05:35:18 +0000","YES","Randomised - ""randomly allocated by an independent statistician using a random numbers design with no stratification of groups, to either nidotherapy or control groups"" (p129).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Nidotherapy for people with schizophrenia [v3.0-For publication].rm5","STD-Ranger-2009","2012-11-30 05:35:45 +0000","YES","""Patients were assessed [...] by [researchers] MR and KI who remained blind of trial allocation"" (p129).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Nidotherapy for people with schizophrenia [v3.0-For publication].rm5","STD-Ranger-2009","2012-12-30 05:09:11 +0000","UNKNOWN","Single blind. Rater MR was external to the trial team, and was not made aware of the form of management each participant received.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Nidotherapy for people with schizophrenia [v3.0-For publication].rm5","STD-Ranger-2009","2012-12-30 05:09:02 +0000","YES","""The main nidotherapists also had roles as support workers in the team, thus knowledge of their involvement did not disclose the nature of their intervention"" (p129). Participants and other staff were instructed in advance not to disclose any information to study assessors.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Nidotherapy for people with schizophrenia [v3.0-For publication].rm5","STD-Ranger-2009","2013-02-07 11:16:15 +0000","NO","Loss to follow-up uncertain: numbers reported in trial inconsistent.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Nidotherapy for people with schizophrenia [v3.0-For publication].rm5","STD-Ranger-2009","2012-07-25 12:04:21 +0100","NO","SFQ patient version results mentioned but not reported.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Nidotherapy for people with schizophrenia [v3.0-For publication].rm5","STD-Ranger-2009","2012-07-25 12:04:12 +0100","UNKNOWN","Co-author of study developed the HEAS (Homeless Acceptance and Assessment Scale) from which the EAS (Engagement and Acceptance Scale) is derived.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Newer atypical antipsychotic medication versus clozapine for schizophrenia [v9.0-For publication].rm5","STD-Olanzapine-1998","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Newer atypical antipsychotic medication versus clozapine for schizophrenia [v9.0-For publication].rm5","STD-Olanzapine-2000","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Newer atypical antipsychotic medication versus clozapine for schizophrenia [v9.0-For publication].rm5","STD-Remox_x002f_Risp_x002f_Zote-1996","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Newer atypical antipsychotic medication versus clozapine for schizophrenia [v9.0-For publication].rm5","STD-Remoxipride-1994","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Newer atypical antipsychotic medication versus clozapine for schizophrenia [v9.0-For publication].rm5","STD-Risperidone-1998a","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Newer atypical antipsychotic medication versus clozapine for schizophrenia [v9.0-For publication].rm5","STD-Risperidone-1998b","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Newer atypical antipsychotic medication versus clozapine for schizophrenia [v9.0-For publication].rm5","STD-Risperidone-1999","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Newer atypical antipsychotic medication versus clozapine for schizophrenia [v9.0-For publication].rm5","STD-Risperidone-2000","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Ceccato-2009","2011-02-24 13:36:16 +0000","YES","Randomised - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Ceccato-2009","2011-02-24 13:36:18 +0000","UNKNOWN","No details given.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Ceccato-2009","2011-07-17 11:34:09 +0100","YES","Assessors were masked to treatment.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Ceccato-2009","2011-02-09 15:21:57 +0000","YES","No drop outs. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Ceccato-2009","2011-02-09 15:21:45 +0000","UNKNOWN","All outcomes were considered in the analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Ceccato-2009","2011-02-22 10:01:32 +0000","UNKNOWN","Adequate music therapy method: unclear (highly structured approach, relational aspects unclear).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-He-2005","2010-12-01 16:50:07 +0000","UNKNOWN","No details given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-He-2005","2010-12-01 16:50:10 +0000","UNKNOWN","No details given.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-He-2005","2010-12-01 16:50:13 +0000","UNKNOWN","No details given.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-He-2005","2011-02-24 13:33:40 +0000","UNKNOWN","No information about how many participants have completed the study can be found in the results or discussion part of the article. According to the study design (only inpatients) and Chinese reporting standards (drop outs are usually reported if there are any) we assume that all participants have completed the study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-He-2005","2011-02-02 07:46:44 +0000","YES","All outcome measures were considered in the analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-He-2005","2011-02-24 09:33:48 +0000","NO","Adequate music therapy method: yes.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Li-2007","2010-12-01 16:50:26 +0000","UNKNOWN","No details given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Li-2007","2010-12-01 16:50:23 +0000","UNKNOWN","No details given.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Li-2007","2010-12-08 13:41:07 +0000","UNKNOWN","No details given.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Li-2007","2011-02-24 09:20:17 +0000","YES","All 60 participants completed the trial. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Li-2007","2011-02-02 07:51:07 +0000","YES","All outcome measures were considered in the analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Li-2007","2011-02-24 09:33:28 +0000","UNKNOWN","Adequate music therapy method: yes.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Talwar-2006","2010-11-30 09:17:17 +0000","YES","Computer-generated list of random numbers.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Talwar-2006","2011-02-02 07:52:00 +0000","YES","Randomisation was conducted by a person independent of the researcher, and extensive steps were taken to mask the researcher to the participants' allocation status.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Talwar-2006","2011-10-11 10:08:02 +0100","YES","Interviews were conducted by a researcher masked to treatment condition; a test of the success of masking was provided: Interviewer attempted to guess the allocation status of each of the participants after three month follow-up data had been collected (kappa = .31, P <. 01).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Talwar-2006","2011-10-05 15:55:15 +0100","YES","In this review, only the actually observed data were used, not the imputed data. Multiple imputation is not recommended when only dependent variables are missing (","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Talwar-2006","2011-02-02 08:08:50 +0000","YES","All outcome measures were considered in the analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Talwar-2006","2011-02-22 10:00:51 +0000","YES","Adequate music therapy method: yes.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Tang-1994","2011-02-02 08:10:48 +0000","UNKNOWN","No details given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Tang-1994","2010-12-01 16:54:28 +0000","UNKNOWN","No details given.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Tang-1994","2011-02-02 08:13:10 +0000","YES","Nurses who did the SANS and DAS assessment for participants were blind to treatment status.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Tang-1994","2010-12-01 16:55:04 +0000","YES","All 76 participants completed the trial.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Tang-1994","2011-02-02 08:14:37 +0000","YES","All outcome measures were considered in the analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Tang-1994","2011-02-24 09:33:14 +0000","UNKNOWN","Adequate music therapy method: yes.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Ulrich-2007","2010-12-01 16:56:00 +0000","YES","A die was thrown.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Ulrich-2007","2010-12-01 16:56:08 +0000","UNKNOWN","No details given. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Ulrich-2007","2011-02-09 15:07:26 +0000","YES","Researchers and patients were blinded to the fact that research of music therapy was the study aim.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Ulrich-2007","2011-10-11 10:08:03 +0100","YES","Drop outs were reported. Intention-to-treat analysis was used: Participants whose diagnosis was changed after inclusion in the study were not excluded.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Ulrich-2007","2011-02-02 08:16:23 +0000","YES","All outcome measures were considered in the analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Ulrich-2007","2011-02-24 09:33:06 +0000","YES","Adequate music therapy method: yes.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Wen-2005","2010-12-02 10:48:08 +0000","UNKNOWN","No details given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Wen-2005","2010-12-02 10:48:16 +0000","UNKNOWN","No details given.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Wen-2005","2010-12-08 13:39:44 +0000","UNKNOWN","No details given. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Wen-2005","2011-02-24 12:50:23 +0000","YES","All participants completed the trial. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Wen-2005","2011-02-02 11:52:15 +0000","YES","All outcome measures were considered in the analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Wen-2005","2011-02-24 12:56:18 +0000","UNKNOWN","Adequate music therapy method: yes.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Yang-1998","2010-12-02 10:55:02 +0000","UNKNOWN","No details given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Yang-1998","2010-12-02 10:55:08 +0000","UNKNOWN","No details given.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Yang-1998","2010-12-02 10:55:14 +0000","UNKNOWN","No details given.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Yang-1998","2011-02-02 11:56:05 +0000","UNKNOWN","Two drop outs were reported and the reported data are based on a total number excluding the drop outs. No participants with complete data were excluded.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Yang-1998","2011-02-02 11:56:12 +0000","YES","All outcome measures were considered in the analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Music therapy for people with schizophrenia and schizophrenia-like disorders [v7.0-For publication].rm5","STD-Yang-1998","2011-02-22 09:24:35 +0000","YES","Adequate music therapy method: yes.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Cao-2003","2008-07-16 17:30:24 +0100","UNKNOWN","""Randomised"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Cao-2003","2008-07-15 17:02:23 +0100","UNKNOWN","No description.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Cao-2003","2008-09-17 18:48:31 +0100","UNKNOWN","Raters did not treat participants - no other description.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Cao-2003","2008-07-16 17:31:42 +0100","YES","No direct description, judgement from tables in 'Results'.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Cao-2003","2008-07-16 17:30:47 +0100","YES","Reported all data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Chen-1999","2008-07-16 17:32:11 +0100","NO","By registration number - odd or even","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Chen-1999","2008-07-16 12:00:03 +0100","UNKNOWN","No description.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Chen-1999","2008-07-16 17:32:51 +0100","NO","Therapist provided evaluation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Chen-1999","2008-07-16 17:33:07 +0100","YES","No direct description, judgement from tables in 'Results'.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Chen-1999","2008-07-16 17:33:17 +0100","YES","Reported all data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Lu-1999","2008-07-16 17:34:04 +0100","UNKNOWN","Matched by age, gender, course and educational level - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Lu-1999","2008-07-16 12:22:32 +0100","UNKNOWN","No description.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Lu-1999","2008-07-16 17:34:17 +0100","YES","Single blinding, two raters did not conduct treatment.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Lu-1999","2008-07-16 12:44:51 +0100","YES","Three patients could not comply morita therapy, another two were lost because of the family relatives did not collaborate after they were discharged.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Lu-1999","2008-07-16 17:34:42 +0100","YES","Reported all data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Lv-2002","2008-07-16 17:36:35 +0100","UNKNOWN","""Randomised"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Lv-2002","2008-07-16 12:43:21 +0100","UNKNOWN","No description.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Lv-2002","2008-07-16 17:36:44 +0100","YES","Single blinding, two raters did not conduct treatment.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Lv-2002","2008-07-16 17:36:58 +0100","YES","No direct description, judgement from tables in 'Results'.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Lv-2002","2008-07-16 17:37:07 +0100","YES","Reported all data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Sheng-2006","2008-07-17 13:12:22 +0100","NO","By registration number - odd or even.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Sheng-2006","2008-07-17 12:57:42 +0100","UNKNOWN","No description.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Sheng-2006","2008-07-17 12:58:14 +0100","YES","Two raters did not conduct treatment.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Sheng-2006","2008-09-17 18:49:53 +0100","YES","Two patients leaving study early: one lost due to discharging from hospital (modified Morita therapy group), one discontinued because of relapse (standard care group).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Sheng-2006","2008-07-19 13:47:49 +0100","NO","Only completed outcome data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Tang-2002","2008-07-17 08:13:22 +0100","YES","Randomised method was draw lots. Numbers of two groups were same.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Tang-2002","2008-07-16 12:56:59 +0100","UNKNOWN","No description.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Tang-2002","2008-07-17 08:12:42 +0100","YES","Nurses provided evaluation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Tang-2002","2008-07-17 07:57:26 +0100","YES","No direct description, judgement from tables in 'Results'.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Tang-2002","2008-07-17 07:56:56 +0100","YES","Reported all data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wang-1994","2008-07-17 08:15:22 +0100","UNKNOWN","""Randomised"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wang-1994","2008-07-16 13:05:51 +0100","UNKNOWN","No description.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wang-1994","2008-07-17 08:15:03 +0100","YES","Single blinding, four raters did not conduct treatment.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wang-1994","2008-07-17 08:14:05 +0100","UNKNOWN","No direct description, judgement from tables in 'Results'.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wang-1994","2008-07-17 08:13:45 +0100","UNKNOWN","Reported all data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wang-2000","2008-07-17 08:15:33 +0100","UNKNOWN","""Randomised"" - no further details..","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wang-2000","2008-07-16 13:12:21 +0100","UNKNOWN","No description.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wang-2000","2008-07-17 08:16:36 +0100","UNKNOWN","Three doctors provided evaluation through using BPRS and SANS. Two nurses provided assessment through using NOSIE.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wang-2000","2008-07-17 08:16:18 +0100","YES","No direct description, judgement from tables in 'Results'.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wang-2000","2008-07-17 08:15:51 +0100","YES","Reported all data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wang-2002","2008-07-17 08:18:29 +0100","UNKNOWN","""Randomised"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wang-2002","2008-07-16 13:39:59 +0100","UNKNOWN","No description.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wang-2002","2008-07-16 13:40:13 +0100","UNKNOWN","No description.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wang-2002","2008-07-17 08:18:06 +0100","UNKNOWN","No direct description, judgement from tables in 'Results'.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wang-2002","2008-07-17 08:18:13 +0100","UNKNOWN","Reported all data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wei-2005","2008-07-16 13:49:52 +0100","YES","The randomised method was draw lots. The numbers of two groups were same.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wei-2005","2008-07-16 13:52:24 +0100","UNKNOWN","No description.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wei-2005","2008-07-16 13:57:25 +0100","NO","The designer of the trial provided evaluation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wei-2005","2008-09-17 18:51:03 +0100","YES","No direct description, judgement from tables in 'Results'.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wei-2005","2008-07-16 13:59:49 +0100","UNKNOWN","They reported all the data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wu-1999","2008-07-16 17:26:37 +0100","UNKNOWN","Randomly selected - no further description.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wu-1999","2008-07-16 14:01:42 +0100","UNKNOWN","No description.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wu-1999","2008-07-16 14:01:45 +0100","UNKNOWN","No description.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wu-1999","2008-07-16 14:04:20 +0100","UNKNOWN","No description.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Wu-1999","2008-07-16 17:26:52 +0100","YES","Reported all data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Zhu-2002","2008-07-16 17:27:45 +0100","UNKNOWN","Randomly drawn from 5 wards - no further detail.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Zhu-2002","2008-07-16 14:12:32 +0100","UNKNOWN","No description.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Zhu-2002","2008-07-16 14:13:11 +0100","NO","No description.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Zhu-2002","2008-07-16 14:15:34 +0100","UNKNOWN","No description.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Morita therapy for schizophrenia [v6.0-For publication].rm5","STD-Zhu-2002","2008-07-16 14:15:39 +0100","UNKNOWN","No description.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Bersudsky-2005a","2011-01-12 10:29:17 +0000","YES","Patients received valnoctamide or identical capsules of placebo as assigned by the control psychiatrist according to random order.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Bersudsky-2005a","2011-01-12 10:33:31 +0000","UNKNOWN","No details given","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Bersudsky-2005a","2011-01-12 10:33:11 +0000","YES","We performed a double-blind controlled trial of valnoctamide in mania","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Bersudsky-2005a","2011-01-12 10:33:56 +0000","UNKNOWN","Forty-one patients were randomised over three years.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Bersudsky-2005a","2011-01-12 10:34:44 +0000","YES","Final analysis of all efficacy variables was performed using last observation carried forward (LOCF) data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Bersudsky-2005a","2011-01-12 10:34:59 +0000","YES","Conflict of interest: None of the authors has any interest, direct or indirect, in the current patent for valnoctamide synthesis.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Biederman-1979","2011-01-12 10:36:45 +0000","UNKNOWN","""Randomised"" - ""prearranged random sequence"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Biederman-1979","2011-01-12 10:36:30 +0000","YES","Coded container prepared before admission to study.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Biederman-1979","2011-01-12 10:36:59 +0000","YES","Double: both patients and raters were blind to the treatment/control status - capsules identical - adverse effects not described.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Biederman-1979","2011-01-12 10:37:10 +0000","YES","7 dropped out before week 4, reasons given and data included in analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Biederman-1979","2011-01-12 10:52:51 +0000","NO","3 in lithium group dropped out before week 3, data excluded from analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Biederman-1979","2011-01-12 10:53:18 +0000","UNKNOWN","No conflict of interest reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Brockington-1978","2011-01-12 10:54:21 +0000","UNKNOWN","No description given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Brockington-1978","2011-01-12 10:54:35 +0000","UNKNOWN","No description given.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Brockington-1978","2011-01-12 10:54:48 +0000","YES","""Capsules were given on a double blind basis""","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Brockington-1978","2011-01-12 10:55:09 +0000","YES","Most of the numbers add up and reasons given for people dropping out.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Brockington-1978","2011-01-12 10:55:35 +0000","NO","Weelky BPRS were administered but there is no data reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Brockington-1978","2011-01-12 10:55:59 +0000","YES","No obvious conflict of interest.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Chengappa-2007","2011-01-12 10:56:32 +0000","YES","Patients were randomly assigned to one of the groups.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Chengappa-2007","2011-01-12 10:56:41 +0000","UNKNOWN","No details given.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Chengappa-2007","2011-01-12 10:57:01 +0000","UNKNOWN","Treatment was administered in a double-blind model.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Chengappa-2007","2011-01-12 10:57:37 +0000","YES","All patients entering the study were accounted for and all predefined outcome data reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Chengappa-2007","2011-01-12 10:58:08 +0000","UNKNOWN","Patients who had achieved a ‡20% decrease from baseline in their Positive and 5 Negative Syndrome Scale (PANSS) total scores were given the opportunity to continue for an additional 8 weeks of double-blind treatment.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Chengappa-2007","2011-01-12 10:58:23 +0000","YES","No conflict of interest reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Greil-1997","2011-01-12 10:58:51 +0000","YES","""Randomisation lists were produced for each centre in advance"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Greil-1997","2011-01-12 11:00:16 +0000","YES","""The lists were kept at the coordinating study centre in Munich. and psychiatrist in charge od a study patient was informed about the treatment group by phone"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Greil-1997","2011-01-12 11:00:25 +0000","UNKNOWN","No details given.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Greil-1997","2011-01-12 11:00:43 +0000","YES","Intention to treat analysis and sub-analysis done for study completers.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Greil-1997","2011-01-12 11:01:03 +0000","YES","Various strategies were used by specialised members of the coordination centre in Munich to control the validity and internal consistency of data e.g. comparison of medical reports, observer ratings and self ratings.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Greil-1997","2011-01-12 11:01:13 +0000","UNKNOWN","No conflict of interest mentioned.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Johnson-1970","2011-01-12 11:01:44 +0000","YES","Used ""table with random numbers"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Johnson-1970","2011-01-12 11:01:54 +0000","UNKNOWN","No details given","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Johnson-1970","2011-01-12 11:02:08 +0000","UNKNOWN","Participant and rater blind, not the treating psychiatrist.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Johnson-1970","2011-01-12 11:02:21 +0000","UNKNOWN","""One schizoaffective refused medication"" but no details given.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Johnson-1970","2011-01-12 11:02:35 +0000","UNKNOWN","""Statistical comparisons were limited to those patients who completed the study protocol and for whom complete data were available"".","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Johnson-1970","2011-01-12 11:02:57 +0000","UNKNOWN","This work was supported by USPHS grant MH 17436 and MH 04669.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Mattes-1984","2011-01-12 11:03:30 +0000","UNKNOWN","""at time of study initiation, one of the two medications, lithium or fluphenazine, was changed to placebo, double-b","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Mattes-1984","2011-01-12 11:03:40 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Mattes-1984","2011-01-12 11:03:50 +0000","YES","Attempts to maintain at least single blindness described ""Lithium blood levels were thereafter monitored monthly by a non treating psychiatrist, who ordered the dose of a patient on active lithium (keeping the treating doctors blind).""","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Mattes-1984","2011-01-12 11:04:05 +0000","UNKNOWN","Loss to follow up quantified, reasons for losses not clear.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Mattes-1984","2011-01-12 11:04:16 +0000","UNKNOWN","Mentioned mental state at relapse but reported no quantitative data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Mattes-1984","2011-01-12 11:04:31 +0000","YES","No clear conflicts of interest.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Mishory-2000","2011-01-12 11:04:54 +0000","YES","the bipolar manic and schizoaffective manic patients were randomised separately.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Mishory-2000","2011-01-12 11:05:06 +0000","YES","The patients received phenytoin or identical capsules of placebo as assigned by the control psychiatrist according to random order.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Mishory-2000","2011-01-12 11:05:24 +0000","YES","Patients received identical capsules of phenytoin or placebo to ensure blinding and weekly ratings were conducted by a psychiatrist blind to the study drug.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Mishory-2000","2011-01-12 11:05:48 +0000","NO","9 patients who left the study within 3 weeks, their data was excluded.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Mishory-2000","2011-01-12 11:05:59 +0000","YES","All predefined outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Mishory-2000","2011-01-12 11:06:07 +0000","UNKNOWN","No conflict of interest reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Prien-1972","2011-01-12 11:07:03 +0000","YES","Patients were randomly assigned to lithium carbonate or chlorpromazine.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Prien-1972","2011-01-12 11:07:11 +0000","UNKNOWN","Only the treatment physician knew the identity of the patient's study medication.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Prien-1972","2011-01-12 11:07:20 +0000","YES","Other treatment personnel and the clinical raters operated under double blind conditions.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Prien-1972","2011-01-12 11:08:07 +0000","YES","21 patients left the study early for various reasons. Each early terminator was evaluated at the time of he was dropped from the study and this score was used as his variate in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Prien-1972","2011-01-12 11:08:16 +0000","UNKNOWN","Results were described for all predefined outcome but data was not given in a format, which could be quantitatively analysed.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Mood stabilisers for schizoaffective disorder [v1.0-For publication].rm5","STD-Prien-1972","2011-01-12 11:08:25 +0000","UNKNOWN","Recieved USPHS grants.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Monetary incentives for schizophrenia [v3.0-For publication].rm5","STD-Thorpe-1962","2009-08-04 22:29:55 +0100","UNKNOWN","No description: ""the twenty-five patients were split into five groups of five by a random-selection technique"".","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Monetary incentives for schizophrenia [v3.0-For publication].rm5","STD-Thorpe-1962","2009-08-04 22:30:05 +0100","UNKNOWN","No description: ""these groups were numbered one to five and patients within each group worked together in a small circle"".","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Monetary incentives for schizophrenia [v3.0-For publication].rm5","STD-Thorpe-1962","2009-08-10 16:38:44 +0100","YES","Not practical to blind participants to treatment, unclear if raters blind to allocation: ""patients in groups 1 and 4 were informed that they would be working for money and paid according to how many dolls they were able to assemble as a group. Patients in groups 1,2, and 5 were informed that they would be assembling dolls but would not receive any payment"".","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Monetary incentives for schizophrenia [v3.0-For publication].rm5","STD-Thorpe-1962","2009-07-22 15:03:56 +0100","UNKNOWN","No description.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Monetary incentives for schizophrenia [v3.0-For publication].rm5","STD-Thorpe-1962","2009-08-04 22:34:47 +0100","YES","All outcomes reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Monetary incentives for schizophrenia [v3.0-For publication].rm5","STD-Thorpe-1962","2009-08-04 22:35:08 +0100","YES","No description of author affiliations given, but thought other biases unlikely.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Molindone for schizophrenia and severe mental illness [v4.0-For publication].rm5","STD-Binder-1981","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Molindone for schizophrenia and severe mental illness [v4.0-For publication].rm5","STD-Brauzer-1971","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Molindone for schizophrenia and severe mental illness [v4.0-For publication].rm5","STD-Clark-1970","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Molindone for schizophrenia and severe mental illness [v4.0-For publication].rm5","STD-Dufresne-1993","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Molindone for schizophrenia and severe mental illness [v4.0-For publication].rm5","STD-Escobar-1985","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Molindone for schizophrenia and severe mental illness [v4.0-For publication].rm5","STD-Freeman-1969","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Molindone for schizophrenia and severe mental illness [v4.0-For publication].rm5","STD-Gallant-1968","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Molindone for schizophrenia and severe mental illness [v4.0-For publication].rm5","STD-Glazer-1990","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Molindone for schizophrenia and severe mental illness [v4.0-For publication].rm5","STD-Heikkinen-1993","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Molindone for schizophrenia and severe mental illness [v4.0-For publication].rm5","STD-Itil-1972","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Molindone for schizophrenia and severe mental illness [v4.0-For publication].rm5","STD-Mielke-1977","","UNKNOWN","D - Not used","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Molindone for schizophrenia and severe mental illness [v4.0-For publication].rm5","STD-Ramsay-1970","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Molindone for schizophrenia and severe mental illness [v4.0-For publication].rm5","STD-Simpson-1971","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Molindone for schizophrenia and severe mental illness [v4.0-For publication].rm5","STD-Smythies-1982","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Emsley-2006","2010-05-12 14:25:17 +0100","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Emsley-2006","2010-05-12 14:25:18 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Emsley-2006","2010-05-12 14:25:19 +0100","YES","Double, untested.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Emsley-2006","2010-05-12 14:25:19 +0100","YES","Study attrition reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Emsley-2006","2010-05-12 14:25:20 +0100","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Emsley-2006","2010-05-12 14:25:21 +0100","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Glazer-1985","2010-05-12 14:25:25 +0100","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Glazer-1985","2010-05-12 14:25:26 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Glazer-1985","2010-05-12 14:25:27 +0100","UNKNOWN","Double, untested.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Glazer-1985","2010-05-12 14:25:27 +0100","YES","Study attrition reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Glazer-1985","2010-05-12 14:25:28 +0100","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Glazer-1985","2010-05-12 14:25:29 +0100","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Kojima-1992","2010-05-12 14:25:33 +0100","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Kojima-1992","2010-05-12 14:25:34 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Kojima-1992","2010-05-12 14:25:35 +0100","UNKNOWN","Double, untested.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Kojima-1992","2010-05-12 14:25:35 +0100","YES","Study attrition reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Kojima-1992","2010-05-12 10:50:42 +0100","UNKNOWN","No details. Data presented for only 33 matched pairs out of 42.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Kojima-1992","2010-05-12 14:25:37 +0100","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Libov-2007","2010-05-12 14:25:42 +0100","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Libov-2007","2010-05-12 14:25:44 +0100","UNKNOWN","No described.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Libov-2007","2010-05-12 14:25:44 +0100","UNKNOWN","Double, untested.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Libov-2007","2010-05-12 14:25:45 +0100","YES","Study attrition reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Libov-2007","2010-05-12 14:25:45 +0100","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Libov-2007","2010-05-12 14:25:46 +0100","YES","Research grant.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Mackay-1980","2010-05-12 14:26:01 +0100","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Mackay-1980","2010-05-12 14:26:02 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Mackay-1980","2010-05-12 14:26:02 +0100","UNKNOWN","Double, untested.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Mackay-1980","2010-05-12 14:26:03 +0100","YES","Study attrition reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Mackay-1980","2010-05-12 14:26:03 +0100","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Mackay-1980","2010-05-12 14:26:04 +0100","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Matsunaga-1988","2010-05-12 14:26:07 +0100","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Matsunaga-1988","2010-05-12 14:26:08 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Matsunaga-1988","2010-05-12 14:26:08 +0100","UNKNOWN","Double, untested.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Matsunaga-1988","2010-05-12 14:26:09 +0100","YES","Study attrition reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Matsunaga-1988","2010-05-12 14:26:10 +0100","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Matsunaga-1988","2010-05-12 14:26:11 +0100","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Mosnik-1997","2010-05-12 14:26:15 +0100","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Mosnik-1997","2010-05-12 14:26:16 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Mosnik-1997","2010-05-12 14:26:16 +0100","UNKNOWN","Double, untested.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Mosnik-1997","2010-05-12 14:26:17 +0100","YES","Study attrition reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Mosnik-1997","2010-05-12 14:26:18 +0100","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Mosnik-1997","2010-05-12 14:26:18 +0100","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Mouret-1991","2010-05-12 14:26:24 +0100","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Mouret-1991","2010-05-12 14:26:24 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Mouret-1991","2010-05-12 14:26:25 +0100","UNKNOWN","Double, untested.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Mouret-1991","2010-05-12 14:26:26 +0100","UNKNOWN","Study attrition unclear.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Mouret-1991","2010-05-12 14:26:27 +0100","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Mouret-1991","2010-05-12 14:26:28 +0100","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Wolkin-1986","2010-05-12 14:26:32 +0100","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Wolkin-1986","2010-05-12 14:26:32 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Wolkin-1986","2010-05-12 14:26:33 +0100","UNKNOWN","Double, untested.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Wolkin-1986","2010-05-12 14:26:33 +0100","UNKNOWN","Study attrition unclear.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Wolkin-1986","2010-05-12 14:26:34 +0100","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Miscellaneous treatments for neuroleptic-induced tardive dyskinesia [v11.0-For publication].rm5","STD-Wolkin-1986","2010-05-12 14:26:35 +0100","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Andrews-1976","2012-04-14 18:14:49 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Andrews-1976","2012-04-14 18:14:49 +0100","YES","Pharmacists held the key.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Andrews-1976","2012-04-14 18:14:49 +0100","UNKNOWN","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Andrews-1976","2012-04-14 18:14:49 +0100","YES","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Andrews-1976","2012-04-14 18:14:49 +0100","YES","All participants completed the trial.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Andrews-1976","2012-04-14 18:14:49 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Andrews-1976","2012-04-14 18:14:49 +0100","YES","No obvious other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Arato-2002","2012-04-14 18:27:15 +0100","YES","Randomised, computer-generated randomised code.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Arato-2002","2012-04-14 18:27:15 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Arato-2002","2012-04-14 18:27:15 +0100","UNKNOWN","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Arato-2002","2012-04-14 18:27:15 +0100","YES","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Arato-2002","2012-04-14 18:27:15 +0100","NO","64% of the participants left the study early, most due to relapse. The rate was higher in the placebo group (86%) than in the medication group (~57%). This was probably not a problem for the primary outcome relapse, but for secondary outcomes for which the last-observation-carried-forward method was used. Appropriate survival curve analysis was used for the primary outcome relapse.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Arato-2002","2012-04-14 18:27:15 +0100","YES","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Arato-2002","2012-04-14 18:27:15 +0100","YES","No obvious other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Baro-1970","2012-04-14 18:27:15 +0100","UNKNOWN","Matched pairs were formed and then randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Baro-1970","2012-04-14 18:27:15 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Baro-1970","2012-04-14 18:27:16 +0100","UNKNOWN","Double, indistinguishable placebo.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Baro-1970","2012-04-14 18:27:16 +0100","YES","Double, indistinguishable placebo.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Baro-1970","2012-04-14 18:27:16 +0100","YES","Apart from those participants who relapsed no participant left the study early and relapse was the only outcome.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Baro-1970","2012-04-14 18:27:16 +0100","NO","Adverse events were not reported for the double-blind phase.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Baro-1970","2012-04-14 18:27:16 +0100","YES","No obvious other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Beasley-2003","2012-04-14 18:27:16 +0100","YES","Randomised, 2:1 ratio, by an interactive voice response system.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Beasley-2003","2012-04-14 18:27:16 +0100","YES","Interactive voice response system.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Beasley-2003","2012-04-14 18:27:16 +0100","UNKNOWN","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Beasley-2003","2012-04-14 18:27:16 +0100","YES","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Beasley-2003","2012-04-14 18:27:16 +0100","NO","The overall attrition of 26% was acceptable, but many more participants in the placebo group than in the olanzapine group left the study early. Kaplan-Meier survival analysis was used for the analysis of relapse, ANOVA based on last-observation-carried-forward was used for continuous outcomes.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Beasley-2003","2012-04-14 18:27:17 +0100","NO","Only those adverse events with a frequency of at least 10% were reported. Use of antiparkinson medication has not been reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Beasley-2003","2012-04-14 18:27:17 +0100","NO","The study was terminated early when there was a sufficient difference, but this was preplanned.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Blackburn-1981","2012-04-14 18:27:17 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Blackburn-1981","2012-04-14 18:27:17 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Blackburn-1981","2012-04-14 18:27:18 +0100","NO","Double, thiamine chloride used as placebo, participants and nurses were told that a new medication was given, but nurses soon new that this was a placebo.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Blackburn-1981","2012-04-14 18:27:18 +0100","YES","Double, thiamine chloride used as placebo, participants and nurses were told that a new medication was given, but nurses soon new that this was a placebo.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Blackburn-1981","2012-04-14 18:27:18 +0100","YES","Only completers were included in the statistical analysis, but because the drop-out rate was only 13% we did not consider this a source of bias.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Blackburn-1981","2012-04-14 18:27:18 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Blackburn-1981","2012-04-14 18:27:18 +0100","YES","No clear other risk of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Boonstra-2011","2012-04-14 18:27:18 +0100","YES","An independent rater created randomisation lists stratified for gender with randomly permuted blocks of 4 allocation groups.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Boonstra-2011","2012-04-14 18:27:18 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Boonstra-2011","2012-04-14 18:27:19 +0100","NO","Open study.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Boonstra-2011","2012-04-14 18:27:19 +0100","YES","Open study.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Boonstra-2011","2012-04-14 18:27:19 +0100","YES","5 out of 20 participants left the study early (25%). Probably an acceptable rate, there was no big difference between drug and placebo group. Kaplan-Meier survival curves were used for the primary outcome relapse.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Boonstra-2011","2012-04-14 18:27:19 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Boonstra-2011","2012-04-14 18:27:19 +0100","NO","Premature termination after interim analysis.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Caffey-1964","2012-04-14 18:27:20 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Caffey-1964","2012-04-14 18:27:20 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Caffey-1964","2012-04-14 18:27:20 +0100","NO","Double, identical tablets. However, placebo dose reduction group received medication only every other day. Therefore, blinding was not fully maintained.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Caffey-1964","2012-04-14 18:27:20 +0100","YES","Double, identical tablets. However, placebo dose reduction group received medication only every other day. Therefore, blinding was not fully maintained.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Caffey-1964","2012-04-14 18:27:20 +0100","UNKNOWN","It is unclear whether there were dropouts or whether the authors analysed only study completers.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Caffey-1964","2012-04-14 18:27:20 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Caffey-1964","2012-04-14 18:27:20 +0100","UNKNOWN","22 participants who had relapsed in the first 8 weeks were entered in the study again. As the number is small, it is unclear whether they affected the results.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Channabasavanna-1987","2012-04-14 18:27:21 +0100","UNKNOWN","N.i., but double-blind study.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Channabasavanna-1987","2012-04-14 18:27:21 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Channabasavanna-1987","2012-04-14 18:27:21 +0100","UNKNOWN","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Channabasavanna-1987","2012-04-14 18:27:21 +0100","YES","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Channabasavanna-1987","2012-04-14 18:27:21 +0100","YES","Only study completers were used in the final analysis, but as there were only two dropouts (one in each group) this was not necessarily a problem.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Channabasavanna-1987","2012-04-14 18:27:21 +0100","YES","Rating scale results were not reported, but these were not of interest for the review.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Channabasavanna-1987","2012-04-14 18:27:21 +0100","YES","No clear evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Chen-2010","2012-04-14 18:27:22 +0100","YES","Sequence by computer, fixed block size of four without stratification.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Chen-2010","2012-04-14 18:27:22 +0100","YES","AstraZeneca prepared individually numbered sets of study drugs, packed them according to the randomisation sequence and then shipped them to the study team in numbered but apparently identical capsules.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Chen-2010","2012-04-14 18:27:22 +0100","UNKNOWN","Identical capsules, ""investigators, patients and all research staff were blind to the study drugs and the block size"".","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Chen-2010","2012-04-14 18:27:22 +0100","YES","Identical capsules, ""investigators, patients and all research staff were blind to the study drugs and the block size"".","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Chen-2010","2012-04-14 18:27:22 +0100","NO","72% of the participants left the study early. As most participants dropped out after relapse this outcome was not affected, but it is a source of bias for other outcomes. Survival analysis for the primary outcome relapse.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Chen-2010","2012-04-14 18:27:22 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Chen-2010","2012-04-14 18:27:22 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Cheung-1981","2012-04-14 18:27:23 +0100","UNKNOWN","Randomly in group of 15 each, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Cheung-1981","2012-04-14 18:27:23 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Cheung-1981","2012-04-14 18:27:23 +0100","UNKNOWN","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Cheung-1981","2012-04-14 18:27:23 +0100","YES","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Cheung-1981","2012-04-14 18:27:23 +0100","NO","12 participants left the study early (40%), among those 10 from the placebo group and 8 for relapse. Outcomes other than relapse and leaving early are clearly prone to bias due to this difference in leaving the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Cheung-1981","2012-04-14 18:27:23 +0100","YES","Use of benzodiazepines was not indicated, but this was not an outcome of interest in our review.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Cheung-1981","2012-04-14 18:27:23 +0100","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Clark-1975","2012-04-14 18:27:24 +0100","YES","Random, in blocks of eight, stratified for age, duration ill and time since last admission.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Clark-1975","2012-04-14 18:27:24 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Clark-1975","2012-04-14 18:27:24 +0100","UNKNOWN","Double, identical capsules, each participant had an individual stock bottle.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Clark-1975","2012-04-14 18:27:24 +0100","YES","Double, identical capsules, each participant had an individual stock bottle.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Clark-1975","2012-04-14 18:27:24 +0100","NO","Overall 36% left the study early. The specific reasons why the participants dropped out were not indicated by group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Clark-1975","2012-04-14 18:27:24 +0100","YES","No clear source for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Clark-1975","2012-04-14 18:27:24 +0100","YES","No clear other sources of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Cooper-2000","2012-04-14 18:27:25 +0100","YES","Computer-generated randomisation list.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Cooper-2000","2012-04-14 18:27:25 +0100","YES","Allocation to treatment was on a double-blind basis, codes were not broken until the time of analysis.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Cooper-2000","2012-04-14 18:27:25 +0100","UNKNOWN","Double-blind, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Cooper-2000","2012-04-14 18:27:25 +0100","YES","Double-blind, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Cooper-2000","2012-04-14 18:27:25 +0100","NO","The overall rate of participants leaving the study early was very high (76%) and many more participants in the placebo group than in the drug group dropped out due to relapse. Kaplan-Meier survival analysis was used for primary outcome relapse. No full ITT analysis, only those participants with at least one post-baseline assessment were included, but only two participants were excluded on this basis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Cooper-2000","2012-04-14 18:27:26 +0100","NO","Only those adverse events that were reported on at least four occasions and serious adverse events were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Cooper-2000","2012-04-14 18:27:26 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Crow-1986","2012-04-14 18:27:26 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Crow-1986","2012-04-14 18:27:26 +0100","UNKNOWN","Allocation lists prepared by pharmacy for five antipsychotic drugs mentioned below, concealment is unclear.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Crow-1986","2012-04-14 18:27:26 +0100","UNKNOWN","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Crow-1986","2012-04-14 18:27:26 +0100","YES","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Crow-1986","2012-04-14 18:27:26 +0100","YES","No clear bias. overall rate of leaving early of 11% is acceptable. Survival curve analysis was used for the primary outcome relapse.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Crow-1986","2012-04-14 18:27:26 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Crow-1986","2012-04-14 18:27:27 +0100","NO","Blind was broken when a participant relapsed.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Denijs-1973","2012-04-14 18:27:27 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Denijs-1973","2012-04-14 18:27:27 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Denijs-1973","2012-04-14 18:27:27 +0100","UNKNOWN","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Denijs-1973","2012-04-14 18:27:27 +0100","YES","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Denijs-1973","2012-04-14 18:27:27 +0100","YES","2 (5%) of the participants left the study early which is an acceptable rate. Both participants were included in the endpoint analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Denijs-1973","2012-04-14 18:27:27 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Denijs-1973","2012-04-14 18:27:27 +0100","YES","No clear evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Doddi-1979","2012-04-14 18:27:28 +0100","UNKNOWN","No details (just reported as a ""randomised study”).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Doddi-1979","2012-04-14 18:27:28 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Doddi-1979","2012-04-14 18:27:28 +0100","UNKNOWN","Double-blind (""patients and authors were not aware of the allocated treatment”).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Doddi-1979","2012-04-14 18:27:28 +0100","YES","Double-blind (""patients and authors were not aware of the allocated treatment”).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Doddi-1979","2012-04-14 18:27:28 +0100","UNKNOWN","25% of the participants dropped out, all due to relapse. This may still be acceptable.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Doddi-1979","2012-03-31 15:06:11 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Doddi-1979","2012-03-31 15:05:27 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Eklund-1991","2012-04-14 18:27:29 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Eklund-1991","2012-04-14 18:27:29 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Eklund-1991","2012-04-14 18:27:29 +0100","UNKNOWN","Double, placebo injections, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Eklund-1991","2012-04-14 18:27:29 +0100","YES","Double, placebo injections, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Eklund-1991","2012-04-14 18:27:29 +0100","NO","A considerable number of participants (42%) left the study early. The number was clearly higher in the placebo group and the reasons differed. Data were analysed on an intent-to-treat basis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Eklund-1991","2012-04-14 18:27:29 +0100","YES","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Eklund-1991","2012-04-14 18:27:29 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Elie-1975","2012-04-14 18:27:30 +0100","YES","Random number table.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Elie-1975","2012-04-14 18:27:30 +0100","YES","All personnel except for the treating psychiatrist remained unaware of the code until the end of the study.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Elie-1975","2012-04-14 18:27:30 +0100","UNKNOWN","Double (patients, scientists, nurses, only the treating psychiatrist knew the treatment).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Elie-1975","2012-04-14 18:27:30 +0100","YES","Double (patients, scientists, nurses, only the treating psychiatrist knew the treatment).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Elie-1975","2012-04-14 18:27:30 +0100","YES","One participant in the placebo group left the study prematurely which is an acceptable rate.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Elie-1975","2012-04-14 18:27:30 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Elie-1975","2012-04-14 18:27:30 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Freeman-1962","2012-04-14 18:27:30 +0100","UNKNOWN","Participants were ranked for morbidity, then matched, then randomised.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Freeman-1962","2012-04-14 18:27:30 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Freeman-1962","2012-04-14 18:27:30 +0100","YES","Double, identical capsules, each participant was provided medication in individual container. Staff guessed on which medication the participants were but could not guess adequately.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Freeman-1962","2012-04-14 18:27:30 +0100","YES","Double, identical capsules, each participant was provided medication in individual container. Staff guessed on which medication the participants were but could not guess adequately.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Freeman-1962","2012-04-14 18:27:31 +0100","UNKNOWN","It can be that there were participants leaving the study early but this was not clearly reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Freeman-1962","2012-04-14 18:27:31 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Freeman-1962","2012-04-14 18:27:31 +0100","NO","Blind was broken once a participant relapsed.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gallant-1974","2012-04-14 18:27:31 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gallant-1974","2012-04-14 18:27:31 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gallant-1974","2012-04-14 18:27:31 +0100","UNKNOWN","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gallant-1974","2012-04-14 18:27:31 +0100","YES","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gallant-1974","2012-04-14 18:27:32 +0100","NO","It is not entirely clear, whether there were dropouts in addition to 18 participants (7 drug, 11 placebo, 36%) who left the study early due to relapse. However, the 36% drop out rate can be a problem for other outcomes.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gallant-1974","2012-04-14 18:27:32 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gallant-1974","2012-04-14 18:27:32 +0100","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gardos-1984","2012-04-14 18:27:32 +0100","UNKNOWN","Randomised, 3:1 ratio (information obtained from author).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gardos-1984","2012-04-14 18:27:32 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gardos-1984","2012-04-14 18:27:32 +0100","UNKNOWN","Double, ‘matching placebos’ and sesame oil for fluphenazine decanoate treated participants.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gardos-1984","2012-04-14 18:27:32 +0100","YES","Double, ‘matching placebos’ and sesame oil for fluphenazine decanoate treated participants.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gardos-1984","2012-04-14 18:27:32 +0100","YES","The differential dropout rate (placebo group 8/27, 0/9 maintenance group, all due to relapse) can have biased other outcomes than relapse and leaving the study early. But data on such other outcomes were not available anyways.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gardos-1984","2012-04-14 18:27:33 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gardos-1984","2012-04-14 18:27:33 +0100","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Garfield-1966","2012-04-14 18:27:34 +0100","YES","Matched in three groups according to age and hospitalisation, then randomised using a table of random numbers.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Garfield-1966","2012-04-14 18:27:34 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Garfield-1966","2012-04-14 18:27:34 +0100","UNKNOWN","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Garfield-1966","2012-04-14 18:27:34 +0100","YES","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Garfield-1966","2012-04-14 18:27:34 +0100","NO","There was a considerable number of participants leaving the study early (28%). The approach how missing data were handled is not specified.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Garfield-1966","2012-04-14 18:27:34 +0100","YES","Only two factors of the IMPS were presented, but this was no outcome of interest.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Garfield-1966","2012-04-14 18:27:34 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gitlin-1988","2012-04-14 18:27:34 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gitlin-1988","2012-04-14 18:27:34 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gitlin-1988","2012-04-14 18:27:34 +0100","UNKNOWN","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gitlin-1988","2012-04-14 18:27:35 +0100","YES","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gitlin-1988","2012-04-14 18:27:35 +0100","UNKNOWN","Unclear, because not indicated.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gitlin-1988","2012-04-14 18:27:35 +0100","NO","Data not presented for both groups separately.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gitlin-1988","2012-04-14 18:27:35 +0100","UNKNOWN","Unclear - baseline imbalance can not be addressed.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Goldberg-1981","2012-04-14 18:27:36 +0100","UNKNOWN","Random, no further deatils.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Goldberg-1981","2012-04-14 18:27:36 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Goldberg-1981","2012-04-14 18:27:36 +0100","UNKNOWN","Double, placebo injection.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Goldberg-1981","2012-04-14 18:27:36 +0100","YES","Double, placebo injection.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Goldberg-1981","2012-04-14 18:27:36 +0100","YES","3 out of 30 participants (10%) left the study early which is an acceptable rate, irrespective of the statistical analysis (completer analysis).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Goldberg-1981","2012-04-14 18:27:36 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Goldberg-1981","2012-04-14 18:27:36 +0100","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gross-1960","2012-04-14 18:27:37 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gross-1960","2012-04-14 18:27:37 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gross-1960","2012-04-14 18:27:37 +0100","UNKNOWN","Double, unidentifiable capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gross-1960","2012-04-14 18:27:37 +0100","YES","Double, unidentifiable capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gross-1960","2012-04-14 18:27:37 +0100","UNKNOWN","Whether participants left the study early is unclear.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gross-1960","2012-04-14 18:27:37 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gross-1960","2012-04-14 18:27:37 +0100","NO","In case of relapse the blind was broken.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gross-1974","2012-04-14 18:27:38 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gross-1974","2012-04-14 18:27:38 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gross-1974","2012-04-14 18:27:38 +0100","UNKNOWN","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gross-1974","2012-04-14 18:27:38 +0100","YES","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gross-1974","2012-04-14 18:27:38 +0100","NO","The overall number of participants leaving the study early (41%) was considerable, with a higher drop-out rate in the placebo group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gross-1974","2012-04-14 18:27:38 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Gross-1974","2012-04-14 18:27:38 +0100","YES","No clear evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hershon-1972","2012-04-14 18:27:39 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hershon-1972","2012-04-14 18:27:39 +0100","YES","Capsules dispensed by the hospital pharmacist who was the only person who knew what the capsules were and to whom they were given.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hershon-1972","2012-04-14 18:27:39 +0100","UNKNOWN","Double, placebo capsules, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hershon-1972","2012-04-14 18:27:39 +0100","YES","Double, placebo capsules, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hershon-1972","2012-04-14 18:27:39 +0100","YES","16% left the study early, all but one due to relapse. This appears acceptable. relapse and death were the only outcomes.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hershon-1972","2012-04-14 18:27:39 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hershon-1972","2012-04-14 18:27:39 +0100","NO","Participants with a relapse were probably removed from the study and the blind broken. Study was probably terminated early.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hirsch-1973","2012-04-14 18:27:40 +0100","UNKNOWN","Randomly allocated by research assistant.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hirsch-1973","2012-04-14 18:27:40 +0100","YES","Apart from the research assistant no one knew who was on drug or placebo until the data were analysed.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hirsch-1973","2012-04-14 18:27:40 +0100","YES","Double, sesame oil injections, unmarked ampoules. Blinding was tested at the end of the trial and it worked.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hirsch-1973","2012-04-14 18:27:40 +0100","YES","Double, sesame oil injections, unmarked ampoules. Blinding was tested at the end of the trial and it worked.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hirsch-1973","2012-04-14 18:27:40 +0100","UNKNOWN","Overall, 43% of the participants left the study early (no complete ITT for some outcomes).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hirsch-1973","2012-04-14 18:27:40 +0100","YES","No evidence for selected reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hirsch-1973","2010-08-10 09:16:17 +0100","YES","No evidence of other bias","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hirsch-1996","2012-04-14 18:27:41 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hirsch-1996","2012-04-14 18:27:41 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hirsch-1996","2012-04-14 18:27:41 +0100","UNKNOWN","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hirsch-1996","2012-04-14 18:27:41 +0100","YES","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hirsch-1996","2012-04-14 18:27:41 +0100","UNKNOWN","Uncear, whether there were any drop-outs.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hirsch-1996","2012-04-14 18:27:41 +0100","NO","No useable data because data of the randomised subsample have not been presented.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hirsch-1996","2012-04-14 18:27:41 +0100","YES","No clear evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hogarty-1973","2012-04-14 18:27:42 +0100","UNKNOWN","Randomly assigned, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hogarty-1973","2012-04-14 18:27:42 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hogarty-1973","2012-04-14 18:27:42 +0100","UNKNOWN","Double, identical capsules, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hogarty-1973","2012-04-14 18:27:42 +0100","YES","Double, identical capsules, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hogarty-1973","2012-04-14 18:27:42 +0100","YES","Relatively few participants left the study early due to reasons other than relapse which was the only outcome (n=31). Although it is unclear in which group they occurred the small percentage does not represent an important risk of bias.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hogarty-1973","2012-04-14 18:27:42 +0100","YES","No clear evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hogarty-1973","2012-04-14 18:27:42 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hough-2010","2012-04-14 18:27:43 +0100","YES","Patients were randomised in a 1 to 1 ratio (via a sponsor prepared, computer generated randomisation scheme, assigned by an interactive voice system).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hough-2010","2012-04-14 18:27:43 +0100","YES","Interactive voice system.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hough-2010","2012-04-14 18:27:43 +0100","UNKNOWN","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hough-2010","2012-04-14 18:27:43 +0100","YES","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hough-2010","2012-04-14 18:27:43 +0100","NO","Overall high drop-out rate (45%). Clearly more participants in the placebo group (95) than in the drug group (31) left the study early due to relapse. This imbalance may have biased the results of other outcomes such as adverse events. Kaplan-Meier survival curve analysis was used for the primary outcome relapse.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hough-2010","2012-04-14 18:27:43 +0100","YES","Those adverse events that occurred in at least 2% of the participants and severe adverse events were presented. We feel that's acceptable.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Hough-2010","2012-04-14 18:27:43 +0100","NO","Study was stopped early after an interim analysis.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kane-1979","2012-04-14 18:27:44 +0100","UNKNOWN","Matched, then each pair randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kane-1979","2012-04-14 18:27:44 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kane-1979","2012-04-14 18:27:44 +0100","UNKNOWN","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kane-1979","2012-04-14 18:27:44 +0100","YES","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kane-1979","2012-04-14 18:27:44 +0100","YES","Two participant in the drug group (1 relapse, 1 unclear) left the study early, and 7/8 participants in the placebo group dropped out due to relapse. As relapse and dropout were the only outcomes, this did not lead to bias.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kane-1979","2012-04-14 18:27:44 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kane-1979","2012-04-14 18:27:44 +0100","YES","No clear evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kane-1982","2012-04-14 18:27:45 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kane-1982","2012-04-14 18:27:45 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kane-1982","2012-04-14 18:27:45 +0100","UNKNOWN","Double, all participants received both pills and injections (active or placebo) to maintain double-blind conditions.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kane-1982","2012-04-14 18:27:45 +0100","YES","Double, all participants received both pills and injections (active or placebo) to maintain double-blind conditions.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kane-1982","2012-04-14 18:27:45 +0100","NO","20 out of 28 participants  left the study early, 10 for other reasons than relapse, which was the only outcome apart from leaving the study early. This may present a bias.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kane-1982","2012-04-14 18:27:45 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kane-1982","2012-04-14 18:27:45 +0100","UNKNOWN","The design was changed during the study in that only non-compliant patients were randomised to depot fluphenazine or depot placebo, and the randomisation was changed to 2-1-1 (placebo, oral fluphenazine, depot fluphenazine). It is unclear whether this biased the results.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Keskiner-1968","2012-04-14 18:27:45 +0100","UNKNOWN","Randomly assigned, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Keskiner-1968","2012-04-14 18:27:46 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Keskiner-1968","2012-04-14 18:27:46 +0100","UNKNOWN","Double, placebo treated participants received injections of sesame oil in a similar amount.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Keskiner-1968","2012-04-14 18:27:46 +0100","YES","Double, placebo treated participants received injections of sesame oil in a similar amount.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Keskiner-1968","2012-04-14 18:27:46 +0100","YES","No participant left the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Keskiner-1968","2012-04-14 18:27:46 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Keskiner-1968","2012-04-14 18:27:46 +0100","NO","In case of deterioration the participants received additional antipsychotic drugs. This is a problem for the analysis of side-effects.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kramer-2007","2012-04-14 18:27:47 +0100","YES","Randomised, computerized randomisation and stratification scheme.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kramer-2007","2012-04-14 18:27:47 +0100","YES","Interactive voice-response system.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kramer-2007","2012-04-14 18:27:47 +0100","UNKNOWN","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kramer-2007","2012-04-14 18:27:47 +0100","YES","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kramer-2007","2012-04-14 18:27:47 +0100","NO","Only 28 out of 207 participants left the study prematurely for another reason than relapse. Therefore, missing outcomes may not pose a problem for the primary outcome which was assessed with the Kaplan-Meier method. Nevertheless, high discontinuations due to relapse (75/207) which were much more frequent in the placebo group than in the drug group pose a major problem for secondary outcomes. No full ITT (participants had to receive at least one dose post-baseline) but only two participants were excluded on this basis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kramer-2007","2012-04-14 18:27:47 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kramer-2007","2012-04-14 18:27:47 +0100","NO","Study was terminated after an interim analysis showed a clear advantage of paliperidone.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kurland-1975","2012-04-14 18:27:48 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kurland-1975","2012-04-14 18:27:48 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kurland-1975","2012-04-14 18:27:48 +0100","UNKNOWN","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kurland-1975","2012-04-14 18:27:48 +0100","YES","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kurland-1975","2012-04-14 18:27:48 +0100","NO","12 of 35 participants left the study early (34%), 11 of them were in the placebo group. As all participants in the placebo group discontinued due to relapse, the primary outcome is not affected. But the results of all other outcomes are biased by this effect.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kurland-1975","2012-04-14 18:27:48 +0100","YES","Results on rating scales have not been reported, but these were not outcomes of interest in our review.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Kurland-1975","2010-08-10 10:07:01 +0100","YES","No clear other bias","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Leff-1971","2012-04-14 18:27:48 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Leff-1971","2012-04-14 18:27:49 +0100","YES","Trial medication was held by the unit secretary and dispensed to Julian Leff who gave it to the treating consultant. Only the unit secretary knew which pills were active drug and which were placebo.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Leff-1971","2012-04-14 18:27:49 +0100","YES","Double, no further details. But side-effects were not troublesome in any patient and therefore doctors concerned probably received no clues about whether a patient was on active drug or not.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Leff-1971","2012-04-14 18:27:49 +0100","YES","Double, no further details. But side-effects were not troublesome in any patient and therefore doctors concerned probably received no clues about whether a patient was on active drug or not.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Leff-1971","2012-04-14 18:27:49 +0100","NO","Overall drop-out rate was 60%, almost all due to relapse which occured much more frequently in the placebo group. This poses a problem for other outcomes than relapse.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Leff-1971","2012-04-14 18:27:49 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Leff-1971","2012-04-14 18:27:49 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Levine-1980","2012-04-14 18:27:49 +0100","UNKNOWN","Random 2:1, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Levine-1980","2012-04-14 18:27:50 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Levine-1980","2012-04-14 18:27:50 +0100","UNKNOWN","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Levine-1980","2012-04-14 18:27:50 +0100","YES","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Levine-1980","2012-04-14 18:27:50 +0100","UNKNOWN","It is unclear whether there were participants who left the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Levine-1980","2012-04-14 18:27:50 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Levine-1980","2012-04-14 18:27:50 +0100","YES","No clear evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Marjerrison-1964","2012-04-14 18:27:51 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Marjerrison-1964","2012-04-14 18:27:51 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Marjerrison-1964","2012-04-14 18:27:51 +0100","UNKNOWN","Double, different colours.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Marjerrison-1964","2012-04-14 18:27:51 +0100","YES","Double, different colours.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Marjerrison-1964","2012-04-14 18:27:51 +0100","YES","Drop-outs 10 out of 88 is acceptable (11%), although only completers were analysed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Marjerrison-1964","2012-04-14 18:27:51 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Marjerrison-1964","2012-04-14 18:27:51 +0100","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-McCreadie-1989","2012-04-14 18:27:51 +0100","UNKNOWN","Randomisation assumed.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-McCreadie-1989","2012-04-14 18:27:51 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-McCreadie-1989","2012-04-14 18:27:52 +0100","UNKNOWN","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-McCreadie-1989","2012-04-14 18:27:52 +0100","YES","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-McCreadie-1989","2012-04-14 18:27:52 +0100","UNKNOWN","It is unclear whether there were missing data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-McCreadie-1989","2012-04-14 18:27:52 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-McCreadie-1989","2012-04-14 18:27:52 +0100","UNKNOWN","Not entirely clear.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Melnyk-1966","2012-04-14 18:27:52 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Melnyk-1966","2012-04-14 18:27:52 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Melnyk-1966","2012-04-14 18:27:53 +0100","UNKNOWN","Double, ""the staff, patients and investigators were not aware of which patients were to receive placebo instead of their medication”.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Melnyk-1966","2012-04-14 18:27:53 +0100","YES","Double, ""the staff, patients and investigators were not aware of which patients were to receive placebo instead of their medication”.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Melnyk-1966","2012-04-14 18:27:53 +0100","UNKNOWN","It was not reported whether participants left the study early, but it is well possible that there weren’t any, because it was a relatively short inpatient study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Melnyk-1966","2012-04-14 18:27:53 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Melnyk-1966","2012-04-14 18:27:53 +0100","YES","No clear evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Morton-1968","2012-04-14 18:27:53 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Morton-1968","2012-04-14 18:27:53 +0100","YES","The hospital pharmacist was responsible for supplying placebo and active drugs to the ward, no one concerned with the care of patients knew which patients were started on placebo.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Morton-1968","2012-04-14 18:27:53 +0100","NO","Double, identical tablets, but in most cases nurses made correct forecasts on who was on drug and who was on placebo.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Morton-1968","2012-04-14 18:27:54 +0100","YES","Double, identical tablets, but in most cases nurses made correct forecasts on who was on drug and who was on placebo.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Morton-1968","2012-04-14 18:27:54 +0100","UNKNOWN","It is unclear whether there were dropouts.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Morton-1968","2012-04-14 18:27:54 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Morton-1968","2012-04-14 18:27:54 +0100","NO","Blind was broken when a participant relapsed.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Nishikawa-1982","2012-04-14 18:27:54 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Nishikawa-1982","2012-04-14 18:27:54 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Nishikawa-1982","2012-04-14 18:27:55 +0100","UNKNOWN","Double, drug appearance was made identical with respect to taste, colour and volume by adding a kind of ""stomatics”.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Nishikawa-1982","2012-04-14 18:27:55 +0100","YES","Double, drug appearance was made identical with respect to taste, colour and volume by adding a kind of ""stomatics”.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Nishikawa-1982","2012-04-14 18:27:55 +0100","YES","No participant left the study early due to other reasons than relapse in the first phase of the study, the only outcome apart from leaving the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Nishikawa-1982","2012-04-14 18:27:55 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Nishikawa-1982","2012-04-14 18:27:55 +0100","NO","The doses used were very low for Western standards. The study was initially planned as a cross-over trial, but due to high dropout rates after the first phase only the first treatment phase was analysed. Nevertheless, this did not interfere with the aims of our review.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Nishikawa-1984","2012-04-14 18:27:55 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Nishikawa-1984","2012-04-14 18:27:55 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Nishikawa-1984","2012-04-14 18:27:55 +0100","UNKNOWN","Double, drug appearance was made identical with respect to powder, color, tast and volume by adding a gastric acid.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Nishikawa-1984","2012-04-14 18:27:56 +0100","YES","Double, drug appearance was made identical with respect to powder, color, tast and volume by adding a gastric acid.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Nishikawa-1984","2012-04-14 18:27:56 +0100","UNKNOWN","While in the placebo group and in the haloperidol group the rates of participants leaving early due to other reasons were low, 9 out of 12 participants in the propericiazine group discontinued due to overdose. It is questionable whether relapse rates could be accurately measured, because most participants did not reach the endpoint.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Nishikawa-1984","2012-04-14 18:27:56 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Nishikawa-1984","2012-04-14 18:27:56 +0100","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Odejide-1982","2012-04-14 18:27:57 +0100","YES","Participants were matched for age, sex, duration of illness, and severity of symptoms in the preceding episode and then assigned based on a randomised schedule.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Odejide-1982","2012-04-14 18:27:57 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Odejide-1982","2012-04-14 18:27:57 +0100","UNKNOWN","Double, evaluating psychiatrist and participants were unaware of the contents of their injections. It seems that treating psychiatrist was aware of the treatment.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Odejide-1982","2012-04-14 18:27:57 +0100","YES","Double, evaluating psychiatrist and participants were unaware of the contents of their injections. It seems that treating psychiatrist was aware of the treatment.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Odejide-1982","2012-04-14 18:27:57 +0100","NO","Overall drop-out rate drug 40%, placebo 66%, most due to relapse. This poses a risk for bias for other outcomes. Completer analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Odejide-1982","2012-04-14 18:27:57 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Odejide-1982","2012-04-14 18:27:57 +0100","YES","No clear evidence for other sources of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Olson-1962","2012-04-14 18:27:58 +0100","UNKNOWN","Randomly selected and then assigned.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Olson-1962","2012-04-14 18:27:58 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Olson-1962","2012-04-14 18:27:58 +0100","UNKNOWN","Identical pink capsules. Nurses, raters and patients were blind to the procedure. Treating physician was led to believe that half of the patients were on placebo, the other half on drug.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Olson-1962","2012-04-14 18:27:58 +0100","YES","Identical pink capsules. Nurses, raters and patients were blind to the procedure. Treating physician was led to believe that half of the patients were on placebo, the other half on drug.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Olson-1962","2012-04-14 18:27:58 +0100","UNKNOWN","It is unclear how many participants left the study during the first month.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Olson-1962","2012-04-14 18:27:58 +0100","NO","Data on behaviour scales were not reported, including aggressive behaviour which was an outcome in our review.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Olson-1962","2012-04-14 18:27:58 +0100","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Ota-1973","2012-04-14 18:27:58 +0100","UNKNOWN","Unclear, randomisation assumed due to double-blinding.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Ota-1973","2012-04-14 18:27:58 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Ota-1973","2012-04-14 18:27:59 +0100","UNKNOWN","Double, all participants received both (placebo) tablets and (placebo) liquid, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Ota-1973","2012-04-14 18:27:59 +0100","YES","Double, all participants received both (placebo) tablets and (placebo) liquid, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Ota-1973","2012-04-14 18:27:59 +0100","YES","Acceptable dropout rate (10%), which should not affect other outcomes (completer analysis).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Ota-1973","2012-04-14 18:27:59 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Ota-1973","2012-04-14 18:27:59 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Peuskens-2007","2012-04-14 18:28:00 +0100","YES","Correct randomisation assumed, because recent study from industry.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Peuskens-2007","2012-04-14 18:28:00 +0100","YES","Correct allocation concealment assumed, because recent study from industry.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Peuskens-2007","2012-04-14 18:28:00 +0100","UNKNOWN","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Peuskens-2007","2012-04-14 18:28:00 +0100","YES","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Peuskens-2007","2012-04-14 18:28:00 +0100","NO","Overall drop-out rate was 41%, most of them due to relapse (76%), which occured much more frequently in the placebo group. This difference in attrition may have biased the results of other outcomes than relapse. Kaplan-Meier survival curve analysis was used for the primary outcome relapse.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Peuskens-2007","2012-04-14 18:28:00 +0100","NO","Only adverse events with a frequency of at least 5% were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Peuskens-2007","2012-04-14 18:28:00 +0100","NO","The study was terminated early after an interim analysis showed a clear superiority of quetiapine; there were certain baseline discrepancies in terms of mean age, duration ill and number of previous episodes.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pfizer-2000","2012-04-14 18:28:01 +0100","YES","Computer-generated randomised code.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pfizer-2000","2012-04-14 18:28:01 +0100","YES","Treatment cards numbered for each subject entering double-blind phase, investigator and pharmacist was to allocate numbers to subjects in strict sequence of entry to study.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pfizer-2000","2012-04-14 18:28:01 +0100","UNKNOWN","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pfizer-2000","2012-04-14 18:28:01 +0100","YES","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pfizer-2000","2012-04-14 18:28:01 +0100","NO","68% overall dropout, most due to relapse, which occured much more frequently in the placebo group, thus not a problem for this outcome and for drop-out but for other outcomes.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pfizer-2000","2012-04-14 18:28:01 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pfizer-2000","2012-04-14 18:28:01 +0100","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pietzcker-1993","2012-04-14 18:28:02 +0100","YES","Centrally randomised by a specialised unit using an ""adaptive randomisation method”.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pietzcker-1993","2012-04-14 18:28:02 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pietzcker-1993","2012-04-14 18:28:02 +0100","UNKNOWN","Open, only key rating scales were additionally rated by a second blind assessor.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pietzcker-1993","2012-04-14 18:28:02 +0100","YES","Open, only key rating scales were additionally rated by a second blind assessor.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pietzcker-1993","2012-04-14 18:28:02 +0100","NO","High two year discontinuation rate of 43.7%. Analysis was intention-to-treat based on Kaplan-Meier survival curve analysis, completer analyses were presented in addition if different. A risk of bias can not be excluded given the high discontinuation rate.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pietzcker-1993","2012-04-14 18:28:02 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pietzcker-1993","2012-04-14 18:28:02 +0100","YES","No clear evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pigott-2003","2012-04-14 18:28:03 +0100","YES","Correct randomisation assumed, because recent study from industry..","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pigott-2003","2012-04-14 18:28:03 +0100","YES","Correct allocation concealment assumed, because recent study from industry.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pigott-2003","2012-04-14 18:28:03 +0100","UNKNOWN","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pigott-2003","2012-04-14 18:28:03 +0100","YES","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pigott-2003","2012-04-14 18:28:03 +0100","NO","A high number of participants (62.2%) left the study early, mostly because of relapse (61%), which was more frequent in the placebo group. For other outcomes this could be a problem. For the primary outcome survival analysis was used which was not a full ITT (one post-baseline/dose) but only few participants were excluded.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pigott-2003","2012-04-14 18:28:03 +0100","NO","Only those adverse events that occurred in at least 5% of the participants in either group were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Pigott-2003","2012-04-14 18:28:03 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Prien-1968","2012-04-14 18:28:04 +0100","UNKNOWN","Randomly assigned, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Prien-1968","2012-04-14 18:28:04 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Prien-1968","2012-04-14 18:28:04 +0100","UNKNOWN","Double, liquid formulation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Prien-1968","2012-04-14 18:28:04 +0100","YES","Double, liquid formulation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Prien-1968","2012-04-14 18:28:04 +0100","NO","Overall 26% dropped out (of which 87% due to relapse). 15% of the participants in the drug group compared to 38% of the participants in the placebo group left the study early. This difference in attrition is a problem for the analysis of other outcomes than relapse.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Prien-1968","2012-04-14 18:28:04 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Prien-1968","2012-04-14 18:28:04 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Prien-1969","2012-04-14 18:28:04 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Prien-1969","2012-04-14 18:28:04 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Prien-1969","2012-04-14 18:28:05 +0100","UNKNOWN","Double, identical capsules. Whether blinding was successful was not assessed, although in one group high doses associated with a lot of side-effects were administered.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Prien-1969","2012-04-14 18:28:05 +0100","YES","Double, identical capsules. Whether blinding was successful was not assessed, although in one group high doses associated with a lot of side-effects were administered.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Prien-1969","2012-04-14 18:28:05 +0100","NO","The overall attrition was considerable (33%) and clearly more participants discontinued the study early in the placebo group (53%) than in the two drug groups (23%), mainly due to inefficacy, which can be a problem for other outcomes than relapse. Not all participants were included in the final analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Prien-1969","2012-04-14 18:28:05 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Prien-1969","2012-04-14 18:28:05 +0100","NO","The high-dose group used too high doses (80mg/day) for current standards, even the low-dose would nowadays be considered to be quite high /15mg/day).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Rifkin-1979","2012-04-14 18:28:06 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Rifkin-1979","2012-04-14 18:28:06 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Rifkin-1979","2012-04-14 18:28:06 +0100","YES","Double-dummy technique, procyclidine was added to fluphenazine to avoid unmasking by extrapyramidal side-effects.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Rifkin-1979","2012-04-14 18:28:06 +0100","YES","Double-dummy technique, procyclidine was added to fluphenazine to avoid unmasking by extrapyramidal side-effects.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Rifkin-1979","2012-04-14 18:28:06 +0100","NO","67% of the participants discontinued the study due to relapse (41%) or other reasons. More participants in the drug group discontinued due to adverse events, while more participants in the placebo group discontinued due to relapse. This differential attrition can cause bias.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Rifkin-1979","2012-04-14 18:28:06 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Rifkin-1979","2012-04-14 18:28:06 +0100","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Roelofs-1974","2012-04-14 18:28:07 +0100","UNKNOWN","Divided into two comparable groups by an unbiased statistician.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Roelofs-1974","2012-04-14 18:28:07 +0100","UNKNOWN","Procedure not explained.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Roelofs-1974","2012-04-14 18:28:07 +0100","UNKNOWN","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Roelofs-1974","2012-04-14 18:28:07 +0100","YES","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Roelofs-1974","2012-04-14 18:28:07 +0100","YES","No participant left the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Roelofs-1974","2012-04-14 18:28:07 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Roelofs-1974","2012-04-14 18:28:07 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Ruskin-1991","2012-04-14 18:28:08 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Ruskin-1991","2012-04-14 18:28:08 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Ruskin-1991","2012-04-14 18:28:08 +0100","UNKNOWN","Double, ""participants and investigators were blind to treatment”, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Ruskin-1991","2012-04-14 18:28:08 +0100","YES","Double, ""participants and investigators were blind to treatment”, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Ruskin-1991","2012-04-14 18:28:08 +0100","UNKNOWN","47% of the participants left the study early, most of them due to a relapse (55%). This attrition can be a source of bias for other outcomes than relapse.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Ruskin-1991","2012-04-14 18:28:08 +0100","NO","Data on quality of life were not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Ruskin-1991","2012-04-14 18:28:08 +0100","YES","No clear evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Sampath-1992","2012-04-14 18:28:09 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Sampath-1992","2012-04-14 18:28:09 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Sampath-1992","2012-04-14 18:28:09 +0100","UNKNOWN","Double, placebo was sesame oil of identical volume and identical in physical appearance.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Sampath-1992","2012-04-14 18:28:09 +0100","YES","Double, placebo was sesame oil of identical volume and identical in physical appearance.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Sampath-1992","2012-04-14 18:28:09 +0100","UNKNOWN","There is no statement on participants leaving the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Sampath-1992","2012-04-14 18:28:09 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Sampath-1992","2012-04-14 18:28:09 +0100","NO","There was a baseline imbalance in terms of gender and in terms of baseline fluphenazine dose.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Schering-Plough-2010","2012-04-14 18:28:10 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Schering-Plough-2010","2012-04-14 18:28:10 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Schering-Plough-2010","2012-04-14 18:28:10 +0100","UNKNOWN","Double, identical capsules in taste.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Schering-Plough-2010","2012-04-14 18:28:10 +0100","YES","Double, identical capsules in taste.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Schering-Plough-2010","2012-04-14 18:28:10 +0100","NO","High dropout rate, but exact number of drop-outs could not be calculated. Drop-outs were not clearly enough reported. Survival curve analysis was used for the primary outcome relapse.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Schering-Plough-2010","2012-04-14 18:28:10 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Schering-Plough-2010","2012-04-14 18:28:10 +0100","YES","No evidence for selective reporting.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Schiele-1961","2012-04-05 10:44:15 +0100","UNKNOWN","Random, no further details","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Schiele-1961","2012-04-14 18:28:10 +0100","YES","Only the hospital pharmacist had the code on what medication the patient was on","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Schiele-1961","2012-04-14 18:28:11 +0100","UNKNOWN","Double, identical capsules, each participant had his own container.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Schiele-1961","2012-04-14 18:28:11 +0100","YES","Double, identical capsules, each participant had his own container.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Schiele-1961","2012-04-14 18:28:11 +0100","YES","Only 3 out of 80 participants left the study early and the reasons were well described.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Schiele-1961","2012-04-14 18:28:11 +0100","YES","No selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Schiele-1961","2012-04-14 18:28:11 +0100","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Shawver-1959","2012-04-14 18:28:11 +0100","UNKNOWN","Matched and then randomised by a research assistant.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Shawver-1959","2012-04-14 18:28:11 +0100","YES","By a research assistant who carefully guarded the identity of patients and the assigned treatment regimen. Furthermore, medication was assigned by the director of professional services who kept the names for use in case a patient had to be withdrawn from the study.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Shawver-1959","2012-04-14 18:28:11 +0100","UNKNOWN","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Shawver-1959","2012-04-14 18:28:12 +0100","YES","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Shawver-1959","2012-04-14 18:28:12 +0100","YES","Overall 11% dropped out, most of them due to relapse (88%) in the placebo group. As relapse, drop-out and suicide were the only outcomes, this did not produce a risk of bias.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Shawver-1959","2012-04-14 18:28:12 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Shawver-1959","2012-04-14 18:28:12 +0100","YES","No clear evidence of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Spohn-1986","2012-04-14 18:28:12 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Spohn-1986","2012-04-14 18:28:12 +0100","UNKNOWN","Procedure not explained.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Spohn-1986","2012-04-14 18:28:12 +0100","UNKNOWN","Double, placebo matching in kind and dose the previous medication.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Spohn-1986","2012-04-14 18:28:12 +0100","YES","Double, placebo matching in kind and dose the previous medication.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Spohn-1986","2012-04-14 18:28:12 +0100","UNKNOWN","Unclear, because these have not been indicated.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Spohn-1986","2012-04-14 18:28:13 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Spohn-1986","2012-04-14 18:28:13 +0100","UNKNOWN","Unclear, baseline data have not been presented for both groups separately.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Troshinsky-1962","2012-04-14 18:28:13 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Troshinsky-1962","2012-04-14 18:28:13 +0100","YES","Psychiatrist without contact to the participants held the key and filled the medication containers.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Troshinsky-1962","2012-04-14 18:28:13 +0100","UNKNOWN","Double, exact placebo replicas.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Troshinsky-1962","2012-04-14 18:28:13 +0100","YES","Double, exact placebo replicas.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Troshinsky-1962","2012-04-14 18:28:13 +0100","UNKNOWN","Unclear - whether participants discontinued the study prematurely was not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Troshinsky-1962","2012-04-14 18:28:14 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Troshinsky-1962","2012-04-14 18:28:14 +0100","NO","Some placebo participants continued to take medication, study terminated early.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Vandecasteele-1974","2012-04-14 18:28:14 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Vandecasteele-1974","2012-04-14 18:28:14 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Vandecasteele-1974","2012-04-14 18:28:14 +0100","UNKNOWN","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Vandecasteele-1974","2012-04-14 18:28:14 +0100","YES","Double, identical capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Vandecasteele-1974","2012-04-14 18:28:14 +0100","YES","No participant left the study prematurely.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Vandecasteele-1974","2012-04-14 18:28:15 +0100","NO","Data on side-effects and the mental state were not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Vandecasteele-1974","2012-04-14 18:28:15 +0100","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Whittaker-1963","2012-04-14 18:24:07 +0100","UNKNOWN","Arbitrarily allocated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Whittaker-1963","2012-04-14 18:23:51 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Whittaker-1963","2012-04-14 18:24:07 +0100","YES","Double - only the pharmacist knew which bottles were active. Participants were asked whether they were aware of the medication, but only one realised a change in taste. Nurses were also asked, but did not guess the correct medication better than by chance alone.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Whittaker-1963","2012-04-14 18:24:07 +0100","YES","Double - only the pharmacist knew which bottles were active. Participants were asked whether they were aware of the medication, but only one realised a change in taste. Nurses were also asked, but did not guess the correct medication better than by chance alone.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Whittaker-1963","2012-04-14 18:24:08 +0100","UNKNOWN","Dropouts were not reported. It is not clear, whether there really no dropouts.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Whittaker-1963","2012-04-14 18:24:08 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Whittaker-1963","2012-04-14 18:24:08 +0100","YES","No clear evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Wistedt-1981","2012-04-14 18:22:11 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Wistedt-1981","2012-04-14 18:22:11 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Wistedt-1981","2012-04-14 18:22:11 +0100","UNKNOWN","Double, placebo sesame oil.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Wistedt-1981","2012-04-14 18:22:11 +0100","YES","Double, placebo sesame oil.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Wistedt-1981","2012-04-14 18:22:11 +0100","YES","Overall 3 (7%) out of 41 participants left the study early. Although only completers were analysed, due to the low rate this is not a problem.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Wistedt-1981","2012-04-14 18:22:11 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Wistedt-1981","2012-04-14 18:22:07 +0100","YES","No obvious risk for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Zissis-1982","2012-04-14 18:20:56 +0100","YES","Randomly assigned according to pre-established randomisation code.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Zissis-1982","2012-04-14 18:20:56 +0100","YES","Randomisation code was unknown to the evaluating investigators.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Zissis-1982","2012-04-14 18:20:56 +0100","UNKNOWN","Double, administered by a particular nurse.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Zissis-1982","2012-04-14 18:20:55 +0100","YES","Double, administered by a particular nurse.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Zissis-1982","2012-04-14 18:20:56 +0100","YES","12 out of 16 participants in the placebo group compared to 0 out of 16 in the haloperidol group were withdrawn from the trial due to inefficacy of treatment. As the only outcomes were relapse, number of participants improved and leaving the study early this should not have been a problem.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Zissis-1982","2012-04-14 18:20:56 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Maintenance treatment with antipsychotic drugs for schizophrenia [v3.2-For publication].rm5","STD-Zissis-1982","2012-04-14 18:20:56 +0100","YES","No other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Bagadia-1980","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Bishop-1970","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Charalampous-1974","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Clark-1972","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Clark-1975","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Clark-1977","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Du-2003","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Dube-1976","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Dubin-1996","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Fruensgaard-1977","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Fruensgaard-1978","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Gallant-1971","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Huang-1997","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Kiloh-1976","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Kramer-1978","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Li-2004","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Li-2005a","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Li-2005b","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Liu-2005","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Lu-2003","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Malik-1980","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Moore-1975","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Moyano-1975","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Pool-1976","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Rifkin-1984","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Schiele-1975","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Selman-1976","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Seth-1979","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Shopsin-1972","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Simpson-1976","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Steinbook-1973","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Tu-2004","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Tuason-1984","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Tuason-1986","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Van-Der-Velde-1975","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Vyas-1980","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Wang-1996","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Wang-2005a","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Wang-2005b","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Xue-2004","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Loxapine for schizophrenia [v10.0-For publication].rm5","STD-Zhang-2005","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Brown-1983","2010-12-08 11:57:40 +0000","UNKNOWN","""randomly assigned"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Brown-1983","2010-12-19 11:33:31 +0000","UNKNOWN","No details provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Brown-1983","2010-12-08 10:39:18 +0000","NO","Not blinded.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Brown-1983","2010-12-08 10:52:44 +0000","NO","""Two patients dropped out of the life skills training and one patients dropped out of the control condition."" No further informations given.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Brown-1983","2010-12-08 10:53:31 +0000","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Brown-1983","2010-12-08 12:15:08 +0000","UNKNOWN","Small sample size. Protocol not available. Source of support not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Campbell-1983","2010-12-08 11:57:57 +0000","UNKNOWN","""randomly assigned"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Campbell-1983","2010-12-19 11:33:26 +0000","UNKNOWN","No details provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Campbell-1983","2010-12-08 12:14:28 +0000","NO","Not blinded.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Campbell-1983","2010-12-08 12:14:30 +0000","YES","All included patients completed the trial.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Campbell-1983","2011-01-25 12:39:19 +0000","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Campbell-1983","2010-12-08 12:15:21 +0000","UNKNOWN","Very small sample size. Protocol not available. Source of support not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Chen-2009","2011-01-25 10:19:29 +0000","UNKNOWN","""randomised"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Chen-2009","2011-01-25 10:19:08 +0000","UNKNOWN","No details provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Chen-2009","2011-01-25 10:19:47 +0000","NO","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Chen-2009","2011-01-25 10:19:49 +0000","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Chen-2009","2011-01-25 10:20:00 +0000","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Chen-2009","2011-01-25 10:19:09 +0000","UNKNOWN","No sample size calculation. Protocol not available. Source of support not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Patterson-2003","2010-12-08 13:11:06 +0000","UNKNOWN","""randomly assigned"" - four out of eight facilities were randomly chosen into study. Ten patients were recruited from each site and two facilities were randomly assigned to either experimental or control group - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Patterson-2003","2010-12-19 11:33:22 +0000","UNKNOWN","No details provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Patterson-2003","2011-10-26 13:56:12 +0100","YES","Assessors were blinded to participants' treatment condition.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Patterson-2003","2010-12-08 13:16:05 +0000","NO","""Eight of the 40 participants dropped out after the baseline assessment and were excluded from further analysis"". No further information given.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Patterson-2003","2011-05-12 14:51:49 +0100","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Patterson-2003","2010-12-08 13:17:30 +0000","UNKNOWN","Small sample size. Protocol not available. Support for this work was provided, in part, by the National Institute of Mental Health (NIMH) grants, and, in part, by the VISN-22 Mental Illness Research Education and Clinical Center (MIRECC) of the U.S. Department of Veterans Affairs.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Patterson-2006","2010-12-08 13:23:14 +0000","UNKNOWN","""randomised"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Patterson-2006","2010-12-19 11:33:13 +0000","UNKNOWN","No details provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Patterson-2006","2011-10-26 13:56:12 +0100","YES","Assessors were blinded to participants' treatment condition.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Patterson-2006","2010-12-08 13:30:43 +0000","YES","Intention-to-treat consisted of participants who attended at least one session of their assigned intervention and completed both a baseline and follow-up assessment. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Patterson-2006","2010-12-08 13:31:03 +0000","NO","Not all expected outcomes reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Patterson-2006","2010-12-08 13:28:58 +0000","UNKNOWN","No sample size calculation. Protocol not available. Source of support not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Zhao-2007","2010-12-08 13:42:08 +0000","YES","Randomisation was done with random number tables.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Zhao-2007","2010-12-19 11:32:57 +0000","UNKNOWN","No details provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Zhao-2007","2011-01-20 10:00:37 +0000","NO","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Zhao-2007","2010-12-08 13:43:00 +0000","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Zhao-2007","2010-12-19 11:32:30 +0000","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Zhao-2007","2010-12-19 11:32:11 +0000","UNKNOWN","No sample size calculation. Protocol not available. Source of support not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Zheng-2006","2011-01-20 11:40:26 +0000","YES","Randomisation was done with random number tables.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Zheng-2006","2010-12-19 11:33:07 +0000","UNKNOWN","No details provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Zheng-2006","2011-01-20 10:00:16 +0000","NO","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Zheng-2006","2010-12-08 13:47:07 +0000","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Zheng-2006","2010-12-19 11:32:39 +0000","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Life skills programmes for chronic mental illnesses [v10.0-For publication].rm5","STD-Zheng-2006","2010-12-19 11:32:15 +0000","UNKNOWN","No sample size calculation. Protocol not available. Source of support not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Burhan-1969","2013-04-05 14:53:16 +0100","UNKNOWN","Quote: ""...100 were randomly assigned by the admissions office to the study cohort""- no further details provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Burhan-1969","2013-04-05 12:24:43 +0100","NO","Quote: ""The patients in the cohort were assigned to me as the investigator, and I became their therapist"". Comment: probably not done. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Burhan-1969","2014-01-14 13:48:02 +0000","NO","Quote: ""I interviewed each patient in the study cohort as soon as possible after he was admitted. I told him and his family that he would leave hospital in two or three weeks, sooner if possible.."" Comment: probably not done. All patients and investigators had the knowledge to which group the patients were assigned.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Burhan-1969","2013-04-05 09:55:49 +0100","UNKNOWN","No details.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Burhan-1969","2013-04-05 09:56:19 +0100","UNKNOWN","No details.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Burhan-1969","2013-04-05 09:56:21 +0100","UNKNOWN","None detected.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Glick-1975","2013-01-02 18:13:19 +0000","YES","'Patients remained in the long or short term group regardless of final diagnosis, to avoid any incentive to bias diagnostic judgments...' 'Envelopes with the assignment to short - or long - term treatment enclosed, were prepared by the research staff and opened by the ward clerk one at a time after each patient was admitted...","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Glick-1975","2013-01-02 17:58:32 +0000","YES"," 'Envelopes with the assignment to short - or long - term treatment enclosed, were prepared by the research staff and opened by the ward clerk one at a time after each patient was admitted... All patients were told their treatment assignment within an hour or so of their admission.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Glick-1975","2014-01-14 13:48:02 +0000","NO","Both patients and investigators had knowledge of the group to which they were assigned. Patients in treatment group were informed of the duration of their stay and investigators were not blinded either.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Glick-1975","2014-01-14 13:48:02 +0000","UNKNOWN","Of the 255 patients admitted during the 26-month intake period of the study, 20 were excluded. The 235 patients left, remained in the study until completion. Of these, 141 were diagnosed as having schizophrenia and 74 as 'non-schizophrenics' with diagnoses of affective disorders, neuroses and severe personality disorders.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Glick-1975","2013-04-05 09:56:28 +0100","UNKNOWN","No details.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Glick-1975","2013-04-05 09:56:30 +0100","UNKNOWN","None detected.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Glick-1976","2013-01-02 18:14:57 +0000","YES","'Patients remained in the long or short term group regardless of final diagnosis, to avoid any incentive to bias diagnostic judgments...' 'Envelopes with the assignment to short - or long - term treatment enclosed, were prepared by the research staff and opened by the ward clerk one at a time after each patient was admitted...","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Glick-1976","2013-01-02 18:15:34 +0000","YES","'Envelopes with the assignment to short - or long - term treatment enclosed, were prepared by the research staff and opened by the ward clerk one at a time after each patient was admitted... All patients were told their treatment assignment within an hour or so of their admission...'","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Glick-1976","2013-01-06 13:46:17 +0000","NO","'...none of the ward staff knew which treatment assignment the next patient would receive but they were also told of the assignment when the envelope was opened ...'","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Glick-1976","2014-01-14 13:48:02 +0000","UNKNOWN","Of the 255 patients admitted during the 26-month intake period of the study, 20 were excluded. The 235 patients left, remained in the study until completion. Of these, 141 were diagnosed as having schizophrenia and 74 as 'non-schizophrenics' with diagnoses of affective disorders, neuroses and severe personality disorders.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Glick-1976","2013-04-05 09:59:48 +0100","UNKNOWN","No details.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Glick-1976","2013-04-05 09:59:50 +0100","UNKNOWN","None detected.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Herz-1975","2013-01-02 18:26:36 +0000","NO","The study randomly assigned 175 newly admitted inpatients to 3 treatment groups. It gave no details as to how this was done, particularly whether there was any process of random sequence generation. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Herz-1975","2014-01-14 13:48:02 +0000","NO","Other than broadly stating (as above) that the participants were randomised to the study groups, the paper made no reference to allocation concealment during the process of randomisation.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Herz-1975","2014-01-14 13:48:02 +0000","NO","The methodology makes no reference to either single or double blinding. The therapeutic teams as well as participants were apparently aware of what treatment group had been assigned.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Herz-1975","2014-01-14 13:48:02 +0000","YES","The study made no reference to attrition or drop outs. All 175 participants apparently completed the study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Herz-1975","2013-04-05 10:00:31 +0100","UNKNOWN","No details.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Herz-1975","2013-04-05 10:00:33 +0100","UNKNOWN","None detected.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Hirsch-1979_x002a_","2013-04-05 14:56:58 +0100","NO","Quote: ""immediately on admission, patients were allocated at random... allocation was done the moment the patients were admitted to avoid any possibility of bias..."". These were the only references to randomisation in the methodology. There is no reference to any process of random sequence generation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Hirsch-1979_x002a_","2013-01-02 18:55:13 +0000","NO","There was no process of allocation concealment described in the methodology. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Hirsch-1979_x002a_","2013-01-02 18:57:20 +0000","NO","The study did not utilise single or double blinding during allocation or treatment. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Hirsch-1979_x002a_","2014-01-14 13:48:02 +0000","NO","15% of eligible participants were missed or excluded because of failure to obtain or complete an interview. 20% of eligible participants assigned to one or the other group were excluded because they left hospital in less than four days.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Hirsch-1979_x002a_","2013-04-05 10:00:39 +0100","UNKNOWN","No details.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Hirsch-1979_x002a_","2013-04-05 10:00:40 +0100","UNKNOWN","None detected.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Kennedy-1980","2013-04-25 09:28:08 +0100","UNKNOWN","Quote 2: ""Once a patient had been allotted, any readmissions were to the same ward. Patients could be excluded from randomisation in the interests of continuity of care, and about 1 in 4 were so managed"" (page 205-206). Comment: probably done; however randomisation process was not explicitly defined. Allocation was randomised at the start however this was then breached for 25% of readmitted patients to ensure the continuity of care.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Kennedy-1980","2014-01-14 13:48:02 +0000","NO","Comment: Both clinicians and patiens had knowledge of the allocation and patients allocated to the short-stay group were informed of the discharge plan at the time of assignment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Kennedy-1980","2013-04-05 14:24:46 +0100","NO","Probably not done. Comment: No mention of blinding of observers. The authors and clinical team had knowledge of allocated intervention after assignment.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Kennedy-1980","2013-04-05 10:01:02 +0100","UNKNOWN","No information provided on incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Kennedy-1980","2013-04-05 10:01:09 +0100","UNKNOWN","It is not clear whether the outcome of previously determined three measures (PSS, FEF, GP form) were reported for both experimental and control groups. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Length of hospitalisation for people with severe mental illness [v8.2-For publication].rm5","STD-Kennedy-1980","2013-04-05 10:01:17 +0100","UNKNOWN","None detected.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Lamotrigine for schizophrenia [v3.0-For publication].rm5","STD-Akhondzadeh-2005","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Lamotrigine for schizophrenia [v3.0-For publication].rm5","STD-Goff-2006a","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Lamotrigine for schizophrenia [v3.0-For publication].rm5","STD-Goff-2006b","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Lamotrigine for schizophrenia [v3.0-For publication].rm5","STD-Kremer-2004","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Lamotrigine for schizophrenia [v3.0-For publication].rm5","STD-Tiihonen-2003","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Amantadine-2005","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Amantadine-2005b","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Cog_x002f_Behav-2003","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Cog_x002f_Behav-2005a","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Cog_x002f_Behav-2005b","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Cog_x002f_Behav-2006a","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Cog_x002f_Behav-2006b","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-D_x002d_Fenfluramine-1988","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Dextroamphetam-1965","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Famotidine-2004","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Fluoxetine-2002","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Fluoxetine-2003","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Fluvoxamine-2004","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Metformin-2006","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Nizatidine-2003a","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Nizatidine-2003b","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Nizatidine-2004","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Phenylpropanol-2002","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Reboxetine-2003","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Sibutramine-2005a","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Sibutramine-2005b","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Topiramate-2005","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Interventions to reduce weight gain in schizophrenia [v4.0-For publication].rm5","STD-Topirimate-2006","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Aviles-2001","2008-12-08 14:25:03 +0000","YES","Computer generated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Aviles-2001","2008-12-09 17:26:27 +0000","YES","Telephone system, fully concealed.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Aviles-2001","2008-12-08 14:33:36 +0000","YES","Participants, care-givers and interviewers blind to group of allocation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Aviles-2001","2008-12-09 17:28:45 +0000","UNKNOWN","Routine data - fully ascertained.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Aviles-2001","2008-12-09 17:28:58 +0000","UNKNOWN","Quality of life data not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Aviles-2001","2009-02-11 11:40:04 +0000","UNKNOWN","Researchers' prior beliefs not clear.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Benson-2006","2008-12-08 14:26:48 +0000","UNKNOWN","Randomised - no further details. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Benson-2006","2008-12-16 09:52:22 +0000","YES","Opaque envelopes.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Benson-2006","2008-12-08 14:35:35 +0000","YES","Carers and researchers unaware of group of allocation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Benson-2006","2008-12-16 10:30:30 +0000","YES","Clearly described.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Benson-2006","2008-12-16 10:31:07 +0000","YES","Reporting rather un-selective, too many outcomes reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Benson-2006","2008-12-16 10:33:42 +0000","NO","Several authors worked in institutions likely to be sympathetic to positive outcome of prayer.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Byrd-1988","2008-12-08 14:23:28 +0000","YES","Computer generated list.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Byrd-1988","2008-11-03 16:22:16 +0000","UNKNOWN","Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Byrd-1988","2008-12-08 14:30:37 +0000","YES","Those rating outcomes not aware group of allocation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Byrd-1988","2008-12-09 17:44:21 +0000","UNKNOWN","Full reporting. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Byrd-1988","2009-02-11 11:42:34 +0000","UNKNOWN","Primary outcomes clearly reported, but many secondary outcomes also emphasised in the trial's report.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Byrd-1988","2008-12-09 17:42:04 +0000","NO","Clear expression of prior belief in the positive effects of prayer.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Collipp-1969","2008-12-08 14:23:37 +0000","YES","Randomly selecting names.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Collipp-1969","2008-12-08 14:23:50 +0000","UNKNOWN","Unclear.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Collipp-1969","2009-02-11 11:43:53 +0000","YES","Children with leukaemia and their parents did not know they were in a trial, all physicians blinded, those praying unaware of participation in study.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Collipp-1969","2009-02-16 13:37:11 +0000","YES","For usable outcomes all data reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Collipp-1969","2009-02-16 13:36:46 +0000","NO","Clinical state and quality of life data poorly reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Collipp-1969","2009-02-16 14:41:29 +0000","NO","Concluded article with statement ""every physician has prescribed this remedy [prayer] and nearly every physician has seen it succeed"" - bias likely.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Harris-1999","2008-12-08 14:24:30 +0000","UNKNOWN","Assigned on basis of record number. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Harris-1999","2008-12-08 14:24:35 +0000","YES","Adequate.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Harris-1999","2008-12-08 14:32:55 +0000","YES","Participants blind, CCU staff, data collectors and statisticians blind to group of allocation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Harris-1999","2009-02-02 16:08:11 +0000","YES","Full follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Harris-1999","2008-12-16 10:39:21 +0000","UNKNOWN","Over-reporting of outcomes that were not primary. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Harris-1999","2009-02-11 11:45:20 +0000","UNKNOWN","No clear indication that researchers had strong prior beliefs.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Joyce-1964","2008-12-08 14:22:39 +0000","YES","Spin of a coin.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Joyce-1964","2009-02-16 13:35:53 +0000","UNKNOWN","Unclear.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Joyce-1964","2008-12-08 14:29:32 +0000","YES","Participants not aware of participation in trial, rater unaware of group of allocation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Joyce-1964","2009-02-16 13:35:15 +0000","UNKNOWN","Clearly reported clinical state. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Joyce-1964","2009-02-16 13:34:31 +0000","NO","Did not clearly report loss to follow up. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Joyce-1964","2009-02-16 14:40:15 +0000","YES","Undertaken by two researchers, one of whom started with the belief that prayer 'worked' and the other that it did not - no clear other biases.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Krucoff--2001","2008-12-08 14:27:08 +0000","UNKNOWN","Randomised - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Krucoff--2001","2008-12-17 10:16:04 +0000","YES","Opaque envelopes.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Krucoff--2001","2008-12-09 17:50:48 +0000","YES","Patients, family, staff.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Krucoff--2001","2008-12-09 17:55:04 +0000","YES","Clear ascertainment of outcome data. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Krucoff--2001","2008-12-09 17:54:57 +0000","YES","No indication of selective reporting. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Krucoff--2001","2009-02-11 11:48:29 +0000","UNKNOWN","Researchers' prior beliefs unclear.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Leibovici-2001","2008-12-09 19:50:27 +0000","YES","Toss of coin.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Leibovici-2001","2008-12-08 14:27:32 +0000","UNKNOWN","Unclear.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Leibovici-2001","2008-12-08 14:34:08 +0000","YES","Did not obtain consent from participants to maintain blindness.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Leibovici-2001","2009-02-02 16:09:35 +0000","YES","No loss to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Leibovici-2001","2008-12-09 19:50:34 +0000","YES","Full record ascertainment.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Leibovici-2001","2009-02-11 11:49:44 +0000","UNKNOWN","Researchers' prior belief is unclear.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Walker-1997","2008-12-08 14:25:39 +0000","YES","Computer generated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Walker-1997","2008-12-08 14:25:44 +0000","UNKNOWN","Unclear.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Walker-1997","2009-02-16 13:31:42 +0000","UNKNOWN","Double, untested.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Walker-1997","2009-02-16 13:33:47 +0000","YES","Good reporting of loss to follow up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Walker-1997","2009-02-16 13:32:22 +0000","UNKNOWN","Unclear, poor reporting of continuous data.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Intercessory prayer for the alleviation of ill health [v13.0-For publication].rm5","STD-Walker-1997","2009-02-16 13:33:07 +0000","YES","No clear other bias. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Aberg_x002d_Wistedt_x002d_Sweden","2009-05-28 14:38:23 +0100","UNKNOWN","Randomised. No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Aberg_x002d_Wistedt_x002d_Sweden","2009-05-28 14:38:23 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Aberg_x002d_Wistedt_x002d_Sweden","2009-06-15 20:14:17 +0100","UNKNOWN","Primary outcome: not available.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Aberg_x002d_Wistedt_x002d_Sweden","2009-05-28 15:18:01 +0100","UNKNOWN","The study did not address this outcome.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Aberg_x002d_Wistedt_x002d_Sweden","2009-05-28 15:20:12 +0100","NO","More outcomes of interest are reported incompletely.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Aberg_x002d_Wistedt_x002d_Sweden","2009-05-30 19:50:25 +0100","YES","No details. No evident other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Audini_x002d_UK","2009-05-28 16:14:13 +0100","UNKNOWN","Randomised. No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Audini_x002d_UK","2009-05-28 16:14:13 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Audini_x002d_UK","2009-06-05 12:24:52 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Audini_x002d_UK","2009-05-28 16:17:32 +0100","YES","Number and reason for attrition reported. Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Audini_x002d_UK","2009-05-28 16:27:29 +0100","YES","All listed outcomes are reported completely.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Audini_x002d_UK","2010-09-06 20:41:20 +0100","YES","No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bjorkman_x002d_Sweden","2010-09-06 20:43:48 +0100","YES","Randomised: used a computer random number generator.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bjorkman_x002d_Sweden","2009-05-28 16:40:04 +0100","UNKNOWN","Random selection performed by one of the trialist. No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bjorkman_x002d_Sweden","2010-09-06 20:44:06 +0100","UNKNOWN","Primary outcomes: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bjorkman_x002d_Sweden","2009-05-28 17:51:17 +0100","UNKNOWN","Analysis performed on an ITT basis, but ""clients who were not available for or refused contact at follow-up were excluded from the respective analysis on an individual basis"".","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bjorkman_x002d_Sweden","2009-05-28 16:40:57 +0100","YES","All listed outcomes of interest reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bjorkman_x002d_Sweden","2010-09-06 20:44:24 +0100","YES","No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Chicago1","2009-05-28 17:55:32 +0100","UNKNOWN","Randomised. No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Chicago1","2010-09-08 20:18:40 +0100","UNKNOWN","Random assignment achieved by individual sealed envelops (not specified if opaque), the assignment is carried out by a person unconnected to research programme.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Chicago1","2009-06-15 20:16:39 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Chicago1","2009-06-21 14:08:24 +0100","NO","Missing outcome data not balanced in numbers across intervention groups, but similar reasons for missing data across groups.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Chicago1","2009-05-28 18:47:25 +0100","NO","Some outcomes of interest are reported incompletely and are not usable (due to missing SD or sample size providing data).","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Chicago1","2010-09-06 20:49:02 +0100","YES","Public funded (by the State Department of Mental Health). No further details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1","2009-05-28 19:03:07 +0100","UNKNOWN","Randomised for single centre. No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1","2009-05-28 18:48:58 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1","2009-06-15 20:17:16 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1","2009-05-28 19:56:44 +0100","UNKNOWN","Number of lost to follow up reported, but no reasons for missing data provided.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1","2009-05-28 19:57:30 +0100","NO","Pre-specified outcomes not reported (medication compliance) or reported incompletely (days in hospital: SD missing).","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1","2010-09-06 20:55:06 +0100","YES","No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1-_x0028_A_x0029_","2009-06-15 20:17:34 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1-_x0028_A_x0029_","2009-06-12 10:52:25 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1-_x0028_A_x0029_","2009-06-12 10:52:25 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1-_x0028_A_x0029_","2009-06-12 10:52:25 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1-_x0028_A_x0029_","2009-06-12 10:52:25 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1-_x0028_A_x0029_","2009-06-12 10:52:25 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1-_x0028_B_x0029_","2009-06-12 11:03:14 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1-_x0028_B_x0029_","2009-06-12 11:03:14 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1-_x0028_B_x0029_","2009-06-12 11:03:14 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1-_x0028_B_x0029_","2009-06-12 11:03:14 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1-_x0028_B_x0029_","2009-06-12 11:03:15 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1-_x0028_B_x0029_","2009-06-12 11:03:15 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1-_x0028_C_x0029_","2009-06-12 11:03:37 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1-_x0028_C_x0029_","2009-06-12 11:03:37 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1-_x0028_C_x0029_","2009-06-12 11:03:37 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1-_x0028_C_x0029_","2009-06-12 11:03:37 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1-_x0028_C_x0029_","2009-06-12 11:03:37 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bond_x002d_Indiana1-_x0028_C_x0029_","2009-06-12 11:03:47 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bush_x002d_Georgia","2009-06-12 10:56:48 +0100","UNKNOWN","Randomised. No further details. ","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bush_x002d_Georgia","2009-06-12 10:56:54 +0100","UNKNOWN","No details. ","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bush_x002d_Georgia","2009-06-15 20:18:22 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bush_x002d_Georgia","2009-06-18 17:09:21 +0100","YES","No missing outcome data.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bush_x002d_Georgia","2010-06-24 12:14:04 +0100","NO","Outcomes not pre-stated. Most of the reported outcomes are reported incompletely (not usable data).","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Bush_x002d_Georgia","2010-09-06 20:58:47 +0100","YES","No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Chandler_x002d_California1","2009-05-28 20:22:20 +0100","UNKNOWN","Randomised for single centre. No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Chandler_x002d_California1","2009-05-28 20:03:55 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Chandler_x002d_California1","2009-06-15 20:18:53 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Chandler_x002d_California1","2009-05-28 21:43:16 +0100","UNKNOWN","Number of lost to follow up reported, but no reasons for missing data provided. LOCF for continuous data.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Chandler_x002d_California1","2009-06-12 19:40:54 +0100","NO","Listed outcomes of interest not reported (continuous data from scales not reported; days in hospital reported only for site A, no SD).","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Chandler_x002d_California1","2010-09-06 21:04:06 +0100","YES","Public funded (California Department of Mental Health, MIMH). No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Chandler_x002d_California1-_x0028_A_x0029_","2009-06-15 20:18:59 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Chandler_x002d_California1-_x0028_A_x0029_","2009-06-12 11:03:22 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Chandler_x002d_California1-_x0028_A_x0029_","2009-06-12 11:03:22 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Chandler_x002d_California1-_x0028_A_x0029_","2009-06-12 11:03:22 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Chandler_x002d_California1-_x0028_A_x0029_","2009-06-12 11:03:22 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Chandler_x002d_California1-_x0028_A_x0029_","2009-06-12 11:03:22 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Chandler_x002d_California1-_x0028_B_x0029_","2009-06-12 11:08:54 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Chandler_x002d_California1-_x0028_B_x0029_","2009-06-12 11:03:29 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Chandler_x002d_California1-_x0028_B_x0029_","2009-06-12 11:03:29 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Chandler_x002d_California1-_x0028_B_x0029_","2009-06-12 11:03:29 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Chandler_x002d_California1-_x0028_B_x0029_","2009-06-12 11:03:30 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Chandler_x002d_California1-_x0028_B_x0029_","2009-06-12 11:03:57 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Curtis_x002d_New-York","2010-03-08 19:08:56 +0000","UNKNOWN","Randomised. No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Curtis_x002d_New-York","2010-03-08 19:08:56 +0000","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Curtis_x002d_New-York","2010-03-08 19:30:09 +0000","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Curtis_x002d_New-York","2010-03-08 19:08:56 +0000","UNKNOWN","Missing data are not addressed.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Curtis_x002d_New-York","2010-03-08 19:09:12 +0000","YES","Listed outcomes are reported completely.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Curtis_x002d_New-York","2010-09-06 21:11:13 +0100","YES","Funded by public institution ('New York City Health and Hospitals Corporation' and foundations). No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp","2009-05-29 11:52:55 +0100","UNKNOWN","Randomised. No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp","2009-05-29 11:52:55 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp","2010-09-06 21:14:59 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp","2009-05-29 12:01:18 +0100","UNKNOWN","Number of lost to follow up is reported, but reason for missing data is not reported for each randomised group of treatment (it is reported overall, information not usable).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp","2009-05-29 12:01:38 +0100","YES","Pre-specified outcomes of interest are reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp","2010-09-06 21:15:10 +0100","YES","No information available. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_A_x0029_","2009-06-15 20:20:00 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_A_x0029_","2009-06-12 11:04:13 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_A_x0029_","2009-06-12 11:04:13 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_A_x0029_","2009-06-12 11:04:13 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_A_x0029_","2009-06-12 11:04:13 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_A_x0029_","2009-06-12 11:04:13 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_B_x0029_","2009-06-12 11:04:19 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_B_x0029_","2009-06-12 11:04:19 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_B_x0029_","2009-06-12 11:04:19 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_B_x0029_","2009-06-12 11:04:19 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_B_x0029_","2009-06-12 11:04:19 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_B_x0029_","2009-06-12 11:04:19 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_C_x0029_","2009-06-12 11:04:25 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_C_x0029_","2009-06-12 11:04:26 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_C_x0029_","2009-06-12 11:04:26 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_C_x0029_","2009-06-12 11:04:26 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_C_x0029_","2009-06-12 11:04:26 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_C_x0029_","2009-06-12 11:04:26 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_D_x0029_","2009-06-12 11:04:33 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_D_x0029_","2009-06-12 11:04:33 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_D_x0029_","2009-06-12 11:04:33 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_D_x0029_","2009-06-12 11:04:33 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_D_x0029_","2009-06-12 11:04:34 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_D_x0029_","2009-06-12 11:04:34 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_E_x0029_","2009-06-12 11:04:38 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_E_x0029_","2009-06-12 11:04:38 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_E_x0029_","2009-06-12 11:04:39 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_E_x0029_","2009-06-12 11:04:39 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_E_x0029_","2009-06-12 11:04:39 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_E_x0029_","2009-06-12 11:04:39 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_F_x0029_","2009-06-12 11:04:44 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_F_x0029_","2009-06-12 11:04:44 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_F_x0029_","2009-06-12 11:04:44 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_F_x0029_","2009-06-12 11:04:44 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_F_x0029_","2009-06-12 11:04:44 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_F_x0029_","2009-06-12 11:04:44 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_G_x0029_","2009-06-12 11:04:48 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_G_x0029_","2009-06-12 11:04:48 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_G_x0029_","2009-06-12 11:04:48 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_G_x0029_","2009-06-12 11:04:48 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_G_x0029_","2009-06-12 11:04:48 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Drake_x002d_NHamp-_x0028_G_x0029_","2009-06-12 11:04:48 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Essock_x002d_Connecticut1","2009-06-26 18:58:43 +0100","UNKNOWN","Randomised. Randomisation counterbalanced ""so that within each site clients had 50% likelihood of being assigned to either ICM or non-ICM and counterbalanced so that clients hospitalised at the time of assignment had 50% likelihood of being assigned to either ICM or non-ICM.""","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Essock_x002d_Connecticut1","2009-05-29 13:18:44 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Essock_x002d_Connecticut1","2009-06-15 20:20:52 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Essock_x002d_Connecticut1","2009-05-29 14:57:52 +0100","YES","Number and reason for missing data clearly reported. Missing outcome data balanced across intervention group. ","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Essock_x002d_Connecticut1","2009-05-29 13:18:56 +0100","NO","Listed outcome of interest are not reported or are reported incompletely.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Essock_x002d_Connecticut1","2010-09-06 21:23:58 +0100","YES","Funded by public health institutes and private foundation. No other details provided. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Essock_x002d_Connecticut2","2009-05-29 15:00:03 +0100","YES","Randomised using separate computer-generated randomisation stream for each site.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Essock_x002d_Connecticut2","2009-05-29 14:59:56 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Essock_x002d_Connecticut2","2009-05-29 14:59:56 +0100","UNKNOWN","No details.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Essock_x002d_Connecticut2","2009-06-18 17:00:51 +0100","UNKNOWN","Insufficient reporting of missing data (number and reason for missing data are reported for the total sample, not for each intervention group). Seven randomised subjects were lost for administrative reason, but their intervention allocation was not reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Essock_x002d_Connecticut2","2009-06-17 10:35:49 +0100","NO","Listed outcomes of interest are fully reported for each site, but authors do not provide sample size data are referred to.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Essock_x002d_Connecticut2","2010-09-06 21:28:06 +0100","YES","Public funded. No further details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Ford_x002d_UK","2010-09-08 20:14:39 +0100","YES","Randomised. Sequence of random number generated by computer programme.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Ford_x002d_UK","2009-05-29 15:44:48 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Ford_x002d_UK","2009-06-15 20:22:00 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Ford_x002d_UK","2010-06-24 12:17:21 +0100","NO","Number and reason for missing dichotomous outcome data reported; imbalance in number and reason for missing data across intervention group. For continuous outcome data, this issue is not addressed.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Ford_x002d_UK","2009-05-29 15:44:58 +0100","YES","Listed outcome of interest reported and if not reported, reason is provided (i.e. social support data are not reported due to high level of missing data).","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Ford_x002d_UK","2010-09-06 21:30:04 +0100","YES","No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Hampton_x002d_Illinois","2010-09-07 09:40:50 +0100","UNKNOWN","Randomised. No further details. Although not explicit, authors of review assumed an independent randomisation for each centre. Authors reported: ""Project staff recruited clients on varying days to reduce bias"" - authors of this review interpreted this as meaning that different days were used for recruitment to the whole study and not that group of allocation was determined by day.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Hampton_x002d_Illinois","2009-05-29 17:39:49 +0100","UNKNOWN","Described as ""blinded randomisation"". No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Hampton_x002d_Illinois","2010-09-07 09:41:18 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Hampton_x002d_Illinois","2009-06-01 17:24:06 +0100","UNKNOWN","Insufficient reporting of attrition/exclusions to permit judgement.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Hampton_x002d_Illinois","2009-06-29 12:01:43 +0100","NO","In both centres, ","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Hampton_x002d_Illinois","2010-09-07 09:42:36 +0100","UNKNOWN","Public funded (National Institute of Mental Health and Developmental Disabilities). In ","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Hampton_x002d_Illinois-_x0028_A_x0029_","2009-06-15 20:22:23 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Hampton_x002d_Illinois-_x0028_A_x0029_","2009-06-12 11:05:14 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Hampton_x002d_Illinois-_x0028_A_x0029_","2009-06-12 11:05:14 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Hampton_x002d_Illinois-_x0028_A_x0029_","2009-06-12 11:05:14 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Hampton_x002d_Illinois-_x0028_A_x0029_","2009-06-12 11:05:14 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Hampton_x002d_Illinois-_x0028_A_x0029_","2009-06-12 11:05:15 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Hampton_x002d_Illinois-_x0028_B_x0029_","2009-06-12 11:05:20 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Hampton_x002d_Illinois-_x0028_B_x0029_","2009-06-12 11:05:20 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Hampton_x002d_Illinois-_x0028_B_x0029_","2009-06-12 11:05:21 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Hampton_x002d_Illinois-_x0028_B_x0029_","2009-06-12 11:05:21 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Hampton_x002d_Illinois-_x0028_B_x0029_","2009-06-12 11:05:21 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Hampton_x002d_Illinois-_x0028_B_x0029_","2009-06-12 11:05:21 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Harrison_x002d_Read_x002d_UK","2010-09-08 20:18:40 +0100","YES","Random sequence generated by computer programme.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Harrison_x002d_Read_x002d_UK","2009-05-30 10:49:33 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Harrison_x002d_Read_x002d_UK","2009-06-05 12:49:39 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Harrison_x002d_Read_x002d_UK","2009-05-30 10:51:30 +0100","UNKNOWN","Number of lost to follow up reported, but reason for attrition is not reported. Number of lost to follow up balanced between two group. Some participants are excluded after randomisation, but reason for exclusion is not stated.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Harrison_x002d_Read_x002d_UK","2009-05-30 10:50:15 +0100","YES","Listed outcomes of interest are fully reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Harrison_x002d_Read_x002d_UK","2010-09-07 10:21:09 +0100","YES","Public funded (Nation Health Service). No further details. No evidence of other bias.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Herinckx_x002d_Oregon","2009-05-29 21:32:27 +0100","UNKNOWN","Randomised. Ratio randomisation between interventions: ICM:SC = 2:1. No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Herinckx_x002d_Oregon","2009-05-29 21:03:57 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Herinckx_x002d_Oregon","2009-06-05 12:50:44 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Herinckx_x002d_Oregon","2009-05-29 21:31:09 +0100","UNKNOWN","Missing data are not addressed.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Herinckx_x002d_Oregon","2009-05-29 21:30:50 +0100","NO","Not all listed outcomes of interest are reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Herinckx_x002d_Oregon","2010-09-07 10:26:17 +0100","YES","No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Holloway_x002d_UK","2009-05-29 21:33:31 +0100","UNKNOWN","Randomised. No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Holloway_x002d_UK","2009-05-29 21:33:49 +0100","UNKNOWN","Randomisation by sealed envelops (not stated if opaque).","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Holloway_x002d_UK","2009-06-15 20:29:44 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Holloway_x002d_UK","2009-06-12 19:40:51 +0100","YES","NO - Secondary outcomes: imbalance in numbers for missing data across intervention groups.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Holloway_x002d_UK","2009-05-29 21:34:34 +0100","YES","All listed outcomes of interest are fully reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Holloway_x002d_UK","2010-09-07 10:30:35 +0100","YES","No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Jerrell_x002d_SCarolina1","2009-05-29 22:17:49 +0100","UNKNOWN","Randomised. No further details","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Jerrell_x002d_SCarolina1","2009-05-29 22:23:55 +0100","UNKNOWN","No informations.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Jerrell_x002d_SCarolina1","2009-06-05 12:53:51 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Jerrell_x002d_SCarolina1","2009-06-17 11:02:55 +0100","UNKNOWN","Number of randomised participants is not stated, as it is reported only number of randomised participants completing the study period.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Jerrell_x002d_SCarolina1","2009-05-29 22:24:16 +0100","NO","Listed outcome of interest not reported or reported incompletely (i.e. service use: no SD)","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Jerrell_x002d_SCarolina1","2010-09-07 10:34:32 +0100","YES","Public funded (National Institute of Mental Health). No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Johnston_x002d_Australia","2009-05-29 22:26:06 +0100","UNKNOWN","Randomised. No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Johnston_x002d_Australia","2009-05-29 22:26:06 +0100","UNKNOWN","No details","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Johnston_x002d_Australia","2009-06-15 20:30:50 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Johnston_x002d_Australia","2010-09-07 10:38:25 +0100","YES","NO - Secondary outcomes: imbalance in numbers for missing data across intervention groups.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Johnston_x002d_Australia","2009-05-29 22:26:17 +0100","YES","All listed outcome of interest are fully reported","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Johnston_x002d_Australia","2010-09-07 10:38:34 +0100","YES","No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Lehman_x002d_Maryland1","2009-05-30 12:56:24 +0100","UNKNOWN","Randomised (stratified random assignment). No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Lehman_x002d_Maryland1","2009-05-30 12:56:24 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Lehman_x002d_Maryland1","2009-06-15 20:31:14 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Lehman_x002d_Maryland1","2009-05-30 14:37:21 +0100","UNKNOWN","Insufficient reporting of attrition/exclusion (no reasons for missing data provided).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Lehman_x002d_Maryland1","2009-05-30 12:56:28 +0100","NO","Not all listed outcomes of interest are reported completely.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Lehman_x002d_Maryland1","2010-09-07 10:43:19 +0100","YES","Public funded (Centre for Mental Health Services, Maryland). No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Macias_x002d_Utah","2009-05-30 14:41:51 +0100","UNKNOWN","Randomised. No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Macias_x002d_Utah","2009-05-30 14:41:51 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Macias_x002d_Utah","2009-06-05 12:56:59 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Macias_x002d_Utah","2009-05-30 14:42:37 +0100","UNKNOWN","Insufficient reporting of attrition/exclusion (no reasons for missing data provided).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Macias_x002d_Utah","2009-05-30 20:17:48 +0100","UNKNOWN","One listed outcome of interest is not reported completely (Utah Case Management Consumer Assessment Record: no summary report, no SD)","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Macias_x002d_Utah","2010-09-07 10:45:06 +0100","YES","Funded by public institution (NIMH). No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Marshall_x002d_UK","2009-05-30 14:48:11 +0100","YES","Randomisation by permuted block. No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Marshall_x002d_UK","2009-05-30 14:48:07 +0100","UNKNOWN","Randomisation by sealed envelopes (not stated if opaque)","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Marshall_x002d_UK","2009-06-15 20:31:43 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Marshall_x002d_UK","2010-09-07 10:47:37 +0100","UNKNOWN","Insufficient reporting of attrition/exclusion (no reasons for missing data provided). Lost to follow up reported on 7 months, not on 14 months. Reason for attrition reported only for the experimental sample.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Marshall_x002d_UK","2009-05-30 14:48:22 +0100","YES","Listed outcomes reported completely.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Marshall_x002d_UK","2010-09-07 10:47:50 +0100","YES","No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-McDonel_x002d_Indiana","2009-05-30 15:44:36 +0100","UNKNOWN","Randomised. No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-McDonel_x002d_Indiana","2009-05-30 15:44:36 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-McDonel_x002d_Indiana","2010-09-07 10:52:19 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear. ","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-McDonel_x002d_Indiana","2009-05-30 20:18:00 +0100","UNKNOWN","Insufficient reporting of attrition/exclusion (number of missing data is reported, but no reasons is provided). Not clearly reported number of randomised to each group (some participants refused to participate and their number was not clearly accounted in each group).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-McDonel_x002d_Indiana","2009-06-05 12:58:55 +0100","NO","Some listed outcomes of interest are reported incompletely (sample size not reported for social functioning and admission).","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-McDonel_x002d_Indiana","2010-09-07 10:52:37 +0100","YES","Public funded (NIMH grant). No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-McDonel_x002d_Indiana-_x0028_A_x0029_","2009-06-15 20:32:09 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-McDonel_x002d_Indiana-_x0028_A_x0029_","2009-06-12 11:05:30 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-McDonel_x002d_Indiana-_x0028_A_x0029_","2009-06-12 11:05:30 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-McDonel_x002d_Indiana-_x0028_A_x0029_","2009-06-12 11:05:30 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-McDonel_x002d_Indiana-_x0028_A_x0029_","2009-06-12 11:05:30 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-McDonel_x002d_Indiana-_x0028_A_x0029_","2009-06-12 11:05:30 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-McDonel_x002d_Indiana-_x0028_B_x0029_","2009-06-12 11:05:36 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-McDonel_x002d_Indiana-_x0028_B_x0029_","2009-06-12 11:05:36 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-McDonel_x002d_Indiana-_x0028_B_x0029_","2009-06-12 11:05:36 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-McDonel_x002d_Indiana-_x0028_B_x0029_","2009-06-12 11:05:36 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-McDonel_x002d_Indiana-_x0028_B_x0029_","2009-06-12 11:05:36 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-McDonel_x002d_Indiana-_x0028_B_x0029_","2009-06-12 11:05:36 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Morse_x002d_Missouri1","2010-09-07 10:59:09 +0100","UNKNOWN","Randomised. No further details. Participants lost to follow-up within first month were replaced, replacement was performed through random allocation.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Morse_x002d_Missouri1","2009-06-12 11:45:05 +0100","UNKNOWN","Not described.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Morse_x002d_Missouri1","2009-06-15 20:33:20 +0100","UNKNOWN","Primary outcome: not available.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Morse_x002d_Missouri1","2009-06-17 17:18:13 +0100","UNKNOWN","Number and reasons for lost to follow up incompletely reported. ","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Morse_x002d_Missouri1","2009-06-12 11:47:31 +0100","NO","All data presented but not usable due to N for treatment groups missing.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Morse_x002d_Missouri1","2010-09-07 10:59:30 +0100","YES","Public funded (grants from National Institute of Mental Health). No further details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Morse_x002d_Missouri3","2009-06-15 20:33:50 +0100","UNKNOWN","Randomised, but no description given.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Morse_x002d_Missouri3","2009-06-11 15:09:20 +0100","UNKNOWN","Not described.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Morse_x002d_Missouri3","2009-06-12 11:43:57 +0100","UNKNOWN","Primary outcome: not available.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Morse_x002d_Missouri3","2009-06-11 18:41:55 +0100","UNKNOWN","Attrition described for the total sample and analysed for effect on outcome. Number and reason for loss to follow up not reported for single arm.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Morse_x002d_Missouri3","2009-06-11 15:10:02 +0100","YES","All outcomes reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Morse_x002d_Missouri3","2010-09-07 11:03:03 +0100","YES","No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Muijen_x002d_UK2","2009-05-30 18:06:09 +0100","UNKNOWN","Randomised. No details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Muijen_x002d_UK2","2009-05-30 18:06:09 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Muijen_x002d_UK2","2010-09-07 11:15:18 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear. ","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Muijen_x002d_UK2","2009-05-30 20:18:09 +0100","UNKNOWN","Number of lost to follow up is stated, but reason for attrition is reported generically, referred to the entire sample size and not the single intervention sample.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Muijen_x002d_UK2","2009-05-30 18:06:24 +0100","NO","All listed outcomes of interests are fully reported (but some economic outcomes missing any variance measurement).","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Muijen_x002d_UK2","2010-09-07 11:15:33 +0100","YES","No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Muller_x002d_Clemm_x002d_Canada","2009-06-18 16:44:11 +0100","UNKNOWN","Randomised. No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Muller_x002d_Clemm_x002d_Canada","2009-05-30 18:58:32 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Muller_x002d_Clemm_x002d_Canada","2010-09-07 11:17:36 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear. ","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Muller_x002d_Clemm_x002d_Canada","2009-05-30 19:44:43 +0100","UNKNOWN","Number randomised not clearly reported, as authors declared that ""Clients who withdrew from the study within the first 6 months were replaced by other clients"".","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Muller_x002d_Clemm_x002d_Canada","2009-05-30 20:18:14 +0100","NO","Outcome length of hospitalisation reported incompletely (no SD).","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Muller_x002d_Clemm_x002d_Canada","2010-09-07 11:17:46 +0100","YES","No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Okpaku_x002d_Tennessee","2009-05-20 15:07:49 +0100","UNKNOWN","Randomised. No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Okpaku_x002d_Tennessee","2009-05-20 15:07:53 +0100","UNKNOWN","No details. ","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Okpaku_x002d_Tennessee","2010-09-07 11:46:12 +0100","UNKNOWN","Primary outcome: not available. ","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Okpaku_x002d_Tennessee","2009-06-26 19:44:32 +0100","UNKNOWN","Insufficient reporting of attrition/exclusion to permit judgement (number for missing to follow up is reported, but reason is not reported).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Okpaku_x002d_Tennessee","2009-06-17 11:21:40 +0100","NO","More listed outcomes of interest are reported incompletely.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Okpaku_x002d_Tennessee","2010-09-07 11:46:24 +0100","YES","Public funded (grant from the Social Security Administration). No further details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-OPUS_x002d_Denmark","2010-09-07 11:52:17 +0100","YES","Randomised. In Copenhagen, allocation sequence was computer generated. In Aahrus a secretary drew a lot among five red and five white lots from a black box. Central randomisation. Randomisation was 1:1, in block of 6, stratified for each of the 5 centres.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-OPUS_x002d_Denmark","2010-09-07 11:52:38 +0100","YES","In Copenhagen, randomisation was carried out through centralised telephone allocation.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-OPUS_x002d_Denmark","2010-09-07 11:52:46 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear. ","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-OPUS_x002d_Denmark","2009-05-30 20:24:10 +0100","YES","Number and reason for missing data are clearly reported. Analysis were conducted on an ITT basis.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-OPUS_x002d_Denmark","2009-05-19 18:31:39 +0100","NO","Authors reported the change of primary outcome stated in the protocol (from ""relapse and positive symptoms"" to ""psychotic and negative symptoms"") as high attrition occurred in the former outcome measurements. Some listed outcome of interest are not reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-OPUS_x002d_Denmark","2010-09-07 11:53:14 +0100","YES","Public funded. None declaration of interest. no further details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Pique_x002d_California","2010-09-07 11:55:18 +0100","YES","Randomised. Stratified by sex, ethnicity, recruitment centre, assignment to intervention 2:1. Randomisation sequence constructed by independent investigator using a table of random permutation.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Pique_x002d_California","2010-09-07 11:55:30 +0100","UNKNOWN","Randomisation sequence sealed in opaque envelopes, unused assignment envelopes kept in a locked container (available to the recruiter psychiatrists).","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Pique_x002d_California","2010-09-07 11:55:37 +0100","UNKNOWN","Primary outcome: not available. ","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Pique_x002d_California","2009-06-17 11:22:01 +0100","UNKNOWN","Author did not address this outcome. Reason for missing outcome data is not reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Pique_x002d_California","2009-06-05 18:45:46 +0100","NO","Listed outcome of interest reported incompletely (costs: no mean, no SD).","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Pique_x002d_California","2010-09-07 11:55:48 +0100","YES","No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Quinlivan_x002d_California","2009-05-30 20:51:13 +0100","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Quinlivan_x002d_California","2010-09-07 11:57:28 +0100","UNKNOWN","No information.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Quinlivan_x002d_California","2010-09-07 11:57:33 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Quinlivan_x002d_California","2009-05-30 20:57:48 +0100","UNKNOWN","The study did not address this outcome.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Quinlivan_x002d_California","2009-05-30 20:57:53 +0100","YES","Listed outcomes of interest are reported completely.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Quinlivan_x002d_California","2010-09-07 11:57:45 +0100","YES","No data provided. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-REACT_x002d_UK","2010-09-07 12:02:23 +0100","YES","Randomised: permuted block randomisation with a block size of eight ensuring parity between CMHT in proportions randomised to ICM.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-REACT_x002d_UK","2009-05-31 11:57:07 +0100","YES","The interviewer contacted an administrator at the trial centre who opened the appropriate numbered envelope communicating the outcome of randomisation. Participants and referrers were informed of the treatment assignment by letter.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-REACT_x002d_UK","2009-06-05 13:07:25 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-REACT_x002d_UK","2009-06-21 14:05:22 +0100","YES","YES - Secondary outcomes: number and reason for missing data are reported. Analysis carried out on an ITT basis.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-REACT_x002d_UK","2009-05-31 11:57:18 +0100","YES","All the listed outcomes of interest are completely reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-REACT_x002d_UK","2010-09-07 12:02:59 +0100","YES","Public funded (Camden and Islington Health Authority; King's Fund; Department of Health). Competing interesting declared: none. No further details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA","2009-05-31 15:36:11 +0100","YES","Randomised through coin tossing.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA","2009-05-31 15:36:11 +0100","UNKNOWN","No details (it is just reported that the assignment by coin tossing was performed by an independent researcher).","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA","2010-09-07 12:07:03 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA","2009-05-31 16:02:51 +0100","UNKNOWN","The study did not address this outcome.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA","2010-09-07 12:07:18 +0100","NO","Some listed outcomes of interest are not reported completely (i.e. substance abuse: it is reported only as a subscale score and not the general score).","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA","2010-09-07 12:07:25 +0100","YES","No details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS","2009-06-15 20:42:35 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS","2009-06-12 11:05:48 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS","2009-06-12 11:05:48 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS","2009-06-12 11:05:48 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS","2009-06-12 11:05:48 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS","2009-06-12 11:05:49 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_A_x0029_","2009-06-12 11:05:54 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_A_x0029_","2009-06-12 11:05:54 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_A_x0029_","2009-06-12 11:05:54 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_A_x0029_","2009-06-12 11:05:54 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_A_x0029_","2009-06-12 11:05:54 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_A_x0029_","2009-06-12 11:05:54 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_B_x0029_","2009-06-12 11:06:00 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_B_x0029_","2009-06-12 11:06:00 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_B_x0029_","2009-06-12 11:06:00 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_B_x0029_","2009-06-12 11:06:00 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_B_x0029_","2009-06-12 11:06:01 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_B_x0029_","2009-06-12 11:06:01 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_D_x0029_","2009-06-12 11:06:17 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_D_x0029_","2009-06-12 11:06:17 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_D_x0029_","2009-06-12 11:06:17 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_D_x0029_","2009-06-12 11:06:17 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_D_x0029_","2009-06-12 11:06:13 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_D_x0029_","2009-06-12 11:06:13 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_F_x0029_","2009-06-12 11:06:40 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_F_x0029_","2009-06-12 11:06:27 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_F_x0029_","2009-06-12 11:06:28 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_F_x0029_","2009-06-12 11:06:28 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_F_x0029_","2009-06-12 11:06:28 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_F_x0029_","2009-06-12 11:06:28 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_I_x0029_","2009-06-12 11:06:50 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_I_x0029_","2009-06-12 11:06:50 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_I_x0029_","2009-06-12 11:06:50 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_I_x0029_","2009-06-12 11:06:50 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_I_x0029_","2009-06-12 11:06:50 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_GMS-_x0028_I_x0029_","2009-06-12 11:06:51 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP","2009-06-12 11:06:59 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP","2009-06-12 11:06:59 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP","2009-06-12 11:06:59 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP","2009-06-12 11:06:59 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP","2009-06-12 11:06:59 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP","2009-06-12 11:06:59 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_C_x0029_","2009-06-12 11:07:05 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_C_x0029_","2009-06-12 11:07:05 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_C_x0029_","2009-06-12 11:07:05 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_C_x0029_","2009-06-12 11:07:05 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_C_x0029_","2009-06-12 11:07:06 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_C_x0029_","2009-06-12 11:07:06 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_E_x0029_","2009-06-12 11:07:19 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_E_x0029_","2009-06-12 11:07:19 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_E_x0029_","2009-06-12 11:07:19 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_E_x0029_","2009-06-12 11:07:19 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_E_x0029_","2009-06-12 11:07:19 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_E_x0029_","2009-06-12 11:07:19 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_G_x0029_","2009-06-12 11:07:27 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_G_x0029_","2009-06-12 11:07:27 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_G_x0029_","2009-06-12 11:07:27 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_G_x0029_","2009-06-12 11:07:27 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_G_x0029_","2009-06-12 11:07:27 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_G_x0029_","2009-06-12 11:07:27 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_H_x0029_","2009-06-12 11:07:33 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_H_x0029_","2009-06-12 11:07:33 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_H_x0029_","2009-06-12 11:07:33 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_H_x0029_","2009-06-12 11:07:33 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_H_x0029_","2009-06-12 11:07:33 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Rosenheck_x002d_USA_x002d_NP-_x0028_H_x0029_","2009-06-12 11:07:33 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Salkever_x002d_SCarolina","2009-05-31 18:25:03 +0100","UNKNOWN","Randomised. No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Salkever_x002d_SCarolina","2009-05-31 18:25:03 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Salkever_x002d_SCarolina","2009-06-05 13:08:38 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Salkever_x002d_SCarolina","2009-05-31 18:33:11 +0100","UNKNOWN","Insufficient reporting of missing data (number for missing data is provided, but reason is provided for the whole sample, it is not stated for single intervention group).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Salkever_x002d_SCarolina","2009-05-31 18:33:17 +0100","NO","Listed outcome of interest are fully reported, but any variance measurement are missing.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Salkever_x002d_SCarolina","2009-06-26 19:45:11 +0100","YES","Public funded (by NIMH and grant from universities and university centres for research). No further details. No evident other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Shern_x002d_USA1","2009-05-27 15:11:03 +0100","UNKNOWN","Randomised. No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Shern_x002d_USA1","2009-05-27 15:11:06 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Shern_x002d_USA1","2009-06-15 20:39:24 +0100","NO","Primary outcome: not provided. ","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Shern_x002d_USA1","2009-05-31 18:41:25 +0100","UNKNOWN","Authors declared ""using alternative techniques for accommodate missing observations"". Main concern regarding the high attrition rate declared by authors, but not clearly reported as presented data were already transformed through statistician techniques accounting for missing observation.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Shern_x002d_USA1","2009-05-31 18:40:52 +0100","NO","Some listed outcomes of interest are not usable due to incomplete reporting (service use, social functioning, quality of life outcomes).","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Shern_x002d_USA1","2009-06-18 11:40:14 +0100","YES","Public funded (NIMH). No further details. No evident other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Solomon_x002d_Pennsylvania","2009-06-16 09:25:00 +0100","UNKNOWN","Randomised. Authors reported that ""slightly higher number of clients were assigned to the control treatment"", but it is not clear if it was a stratified randomisation. No further details provided.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Solomon_x002d_Pennsylvania","2009-05-31 18:49:19 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Solomon_x002d_Pennsylvania","2009-06-15 20:40:49 +0100","UNKNOWN","Primary outcome: not available. ","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Solomon_x002d_Pennsylvania","2009-06-16 09:25:06 +0100","UNKNOWN","Incomplete reporting of missing data (number of missing data is reported, but reason is not provided).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Solomon_x002d_Pennsylvania","2009-05-31 18:49:30 +0100","NO","Some listed outcomes of interest are not reported (i.e. service use, quality of life, etc.)","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Solomon_x002d_Pennsylvania","2010-09-07 12:35:42 +0100","YES","No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Sytema_x002d_Netherlands","2009-05-31 19:12:20 +0100","YES","Randomised, based on block design (block size of 5).","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Sytema_x002d_Netherlands","2010-09-07 12:39:04 +0100","YES","Participant included in the study received id-number from service administration. The new id-number was emailed to a researcher who had a pre-arranged list of id-numbers randomised.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Sytema_x002d_Netherlands","2009-06-05 13:14:58 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Sytema_x002d_Netherlands","2009-06-21 14:22:50 +0100","YES","UNCLEAR - Secondary outcomes: number of missing data is provided, but reason is not stated.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Sytema_x002d_Netherlands","2010-09-07 12:39:24 +0100","YES","All listed outcomes of interest are completely reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Sytema_x002d_Netherlands","2010-09-07 12:39:29 +0100","YES","Public funded (grant from the Netherlands Organization for Health Research and Development). No further details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Test_x002d_Wisconsin","2010-09-07 12:42:47 +0100","UNKNOWN","Randomised (randomised assignment to experimental and control intervention on a ratio 6:4), no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Test_x002d_Wisconsin","2009-05-31 19:25:53 +0100","UNKNOWN","No details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Test_x002d_Wisconsin","2009-06-15 20:41:39 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Test_x002d_Wisconsin","2009-05-31 19:33:43 +0100","UNKNOWN","Number and reason for missing data are not clearly reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Test_x002d_Wisconsin","2010-09-07 12:43:41 +0100","NO","Listed outcomes of interest not reported or reported incompletely, BPRS and BSI (not reported), days in jail and days in hospital (no SD).","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-Test_x002d_Wisconsin","2010-09-07 12:43:48 +0100","YES","Public funded (grant by NIMH). No further details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK","2009-05-31 19:37:20 +0100","UNKNOWN","Randomised, randomisation stratified by centre. No further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK","2009-05-31 19:37:27 +0100","YES","Randomised allocation assigned by telephone or fax by an independent statistical centre.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK","2010-09-07 13:36:57 +0100","UNKNOWN","Primary outcome: clinician/participant mediated - rating - Unclear.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK","2009-05-31 19:46:03 +0100","YES","Number and reason for attrition stated. Analysis performed on an ITT basis.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK","2009-05-31 19:37:20 +0100","UNKNOWN","Most of the listed outcomes are reported completely (the only exception is for CPRS sub-scale: SD missing).","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK","2010-09-08 20:18:40 +0100","YES","Public funded (grants from the UK Department of Health and NHS Research and Development programme). No further details. No evidence other bias are occurring.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_A_x0029_","2009-06-15 20:41:56 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_A_x0029_","2009-06-12 11:08:11 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_A_x0029_","2009-06-12 11:08:11 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_A_x0029_","2009-06-12 11:08:11 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_A_x0029_","2009-06-12 11:08:11 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_A_x0029_","2009-06-12 11:08:11 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_B_x0029_","2009-06-12 11:08:16 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_B_x0029_","2009-06-12 11:08:16 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_B_x0029_","2009-06-12 11:08:16 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_B_x0029_","2009-06-12 11:08:16 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_B_x0029_","2009-06-12 11:08:16 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_B_x0029_","2009-06-12 11:08:16 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_C_x0029_","2009-06-12 11:08:21 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_C_x0029_","2009-06-12 11:08:21 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_C_x0029_","2009-06-12 11:08:21 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_C_x0029_","2009-06-12 11:08:21 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_C_x0029_","2009-06-12 11:08:21 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_C_x0029_","2009-06-12 11:08:21 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_D_x0029_","2009-06-12 11:08:26 +0100","UNKNOWN","","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_D_x0029_","2009-06-12 11:08:26 +0100","UNKNOWN","","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_D_x0029_","2009-06-12 11:08:26 +0100","UNKNOWN","","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_D_x0029_","2009-06-12 11:08:26 +0100","UNKNOWN","","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_D_x0029_","2009-06-12 11:08:26 +0100","UNKNOWN","","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Intensive case management for severe mental illness [v4.0-For publication].rm5","STD-UK700_x002d_UK-_x0028_D_x0029_","2009-06-12 11:08:26 +0100","UNKNOWN","","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Chen-2007","2011-01-06 09:34:52 +0000","UNKNOWN","""Randomised participants matched (age, gender, length of illness, type of schizophrenia)"". No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Chen-2007","2011-01-05 22:28:46 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Chen-2007","2011-01-05 22:29:05 +0000","UNKNOWN","No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Chen-2007","2012-06-28 11:40:43 +0100","YES","Attrition rate was 13%. Analysis on intention-to-treat basis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Chen-2007","2012-06-28 11:40:43 +0100","YES","We had no access to the protocol; there was no obvious selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Chen-2007","2011-01-05 22:39:58 +0000","YES","No clear conflicts of interest.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Hansson-2008","2011-01-04 17:12:55 +0000","YES","""Computer-generated random block number generated sequence"". Completed separately for each country and team. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Hansson-2008","2011-01-04 17:13:04 +0000","YES","""Researcher not involved in the study generated the random allocation sequence"". ""Numbered sealed envelopes"" then used to distribute allocation.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Hansson-2008","2012-06-28 11:40:43 +0100","UNKNOWN","Attempts made to mask researchers - but in 283/451 follow-up interviews (63%) researchers stated they knew allocated treatment (correct in 275/283).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Hansson-2008","2012-06-28 11:40:43 +0100","YES","Attrition rate 11%, reasons reported, data analysed by intention-to-treat (including patients with at least one post randomisation observation).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Hansson-2008","2012-06-28 11:40:43 +0100","UNKNOWN","We had no access to the protocol; there was no obvious selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Hansson-2008","2011-04-21 16:28:48 +0100","YES","No clear conflicts of interest.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Jones-2001a","2011-01-04 15:09:38 +0000","UNKNOWN","""Randomised"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Jones-2001a","2009-11-30 11:10:20 +0000","UNKNOWN","Unclear.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Jones-2001a","2009-11-30 11:11:28 +0000","NO","No blinding due to nature of interventions.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Jones-2001a","2012-06-28 11:40:43 +0100","NO","The overall attrition was 40%; assumed that those who discontinued would not have had change of condition if had remained in study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Jones-2001a","2012-06-28 11:40:43 +0100","UNKNOWN","We had no access to the protocol; there was no obvious selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Jones-2001a","2011-01-04 15:14:03 +0000","YES","No clear conflicts of interest.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Rotondi-2005","2011-01-05 21:43:31 +0000","UNKNOWN","""Randomly assigned"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Rotondi-2005","2011-01-05 21:44:48 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Rotondi-2005","2011-01-05 21:45:25 +0000","NO","No.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Rotondi-2005","2011-07-24 13:34:23 +0100","YES","All participants completed the study follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Rotondi-2005","2012-06-28 11:40:43 +0100","YES","We had no access to the protocol there was no obvious selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Rotondi-2005","2011-01-05 21:47:29 +0000","YES","No clear conflicts of interest.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Salzer-2004","2011-03-29 09:28:12 +0100","NO","""Randomly allocated"", no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Salzer-2004","2011-03-29 09:28:17 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Salzer-2004","2011-01-05 09:09:01 +0000","UNKNOWN","No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Salzer-2004","2012-06-28 11:40:43 +0100","UNKNOWN","The overall attrition rate was 28%. Only completer data were reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Salzer-2004","2012-06-28 11:40:43 +0100","UNKNOWN","We had no access to the protocol there was no obvious selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Salzer-2004","2011-04-21 16:29:02 +0100","YES","No clear conflicts of interest.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Valimaki-2010","2012-06-28 11:40:43 +0100","YES","""Patient randomisation was carried out centrally and manually"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Valimaki-2010","2011-03-29 09:26:29 +0100","YES","Randomisation ""by a research director outside the study hospitals.""","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Valimaki-2010","2011-01-05 11:37:51 +0000","NO","No blinding due to nature of interventions.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Valimaki-2010","2012-06-28 11:40:43 +0100","YES","Attrition rate 30%, reasons reported, data analysed by intention-to-treat.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Valimaki-2010","2011-01-05 11:51:17 +0000","YES","""Other outcome data will be reported later"". ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Information and communication technology in patient education and support for people with schizophrenia [v3.3-For publication].rm5","STD-Valimaki-2010","2011-01-05 11:50:25 +0000","YES","No clear conflicts of interest.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Information and communication technology based prompting for treatment compliance for people with serious mental illness [v2.2-For publication].rm5","STD-Hulsbosch-2008","2012-08-02 12:16:51 +0100","YES","Random allocation, by using block randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Information and communication technology based prompting for treatment compliance for people with serious mental illness [v2.2-For publication].rm5","STD-Hulsbosch-2008","2012-08-02 07:52:55 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Information and communication technology based prompting for treatment compliance for people with serious mental illness [v2.2-For publication].rm5","STD-Hulsbosch-2008","2012-10-17 16:51:51 +0100","UNKNOWN","No blinding. ","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Information and communication technology based prompting for treatment compliance for people with serious mental illness [v2.2-For publication].rm5","STD-Hulsbosch-2008","2012-10-17 15:06:55 +0100","UNKNOWN","No blinding. ","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Information and communication technology based prompting for treatment compliance for people with serious mental illness [v2.2-For publication].rm5","STD-Hulsbosch-2008","2012-08-02 07:54:16 +0100","YES","Attrition rate was 23%. ITT analysis was used.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Information and communication technology based prompting for treatment compliance for people with serious mental illness [v2.2-For publication].rm5","STD-Hulsbosch-2008","2012-10-15 16:02:41 +0100","NO","We do not have protocol of the study available. All instruments were not reported (CUE). However, author sent the data of the instrument.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Information and communication technology based prompting for treatment compliance for people with serious mental illness [v2.2-For publication].rm5","STD-Hulsbosch-2008","2012-08-02 07:55:41 +0100","UNKNOWN","No clear other bias. Research protocol was not available. ","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Information and communication technology based prompting for treatment compliance for people with serious mental illness [v2.2-For publication].rm5","STD-Montes-2011","2012-10-17 16:52:53 +0100","YES","Randomised. ""Randomisation codes were computer generated by our statistician and sealed in envelopes labelled with consecutive numbers. Envelopes were opened by the investigator in a ascending order and patients were allocated to the intervention or control group"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Information and communication technology based prompting for treatment compliance for people with serious mental illness [v2.2-For publication].rm5","STD-Montes-2011","2012-10-17 16:48:59 +0100","YES","""Envelopes were opened by the investigator in a ascending order and patients were allocated to the intervention or control group"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Information and communication technology based prompting for treatment compliance for people with serious mental illness [v2.2-For publication].rm5","STD-Montes-2011","2012-11-28 16:02:06 +0000","UNKNOWN","Open-label.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Information and communication technology based prompting for treatment compliance for people with serious mental illness [v2.2-For publication].rm5","STD-Montes-2011","2012-08-02 08:03:02 +0100","UNKNOWN","No further details. ","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Information and communication technology based prompting for treatment compliance for people with serious mental illness [v2.2-For publication].rm5","STD-Montes-2011","2012-10-16 18:11:02 +0100","NO","Attrition rate was 1%. Analysis sample do not consist all the enrolled participants. ""A total of 340 patients were included in the study. Twenty patients were excluded from the analysis due to major protocol deviations. An additional group of 66 patients were classified as not properly exposed to the intervention and also excluded. The analysis sample population comprised a total of 254 patients, 100 in the SMSG and 154 in the CG"". ","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Information and communication technology based prompting for treatment compliance for people with serious mental illness [v2.2-For publication].rm5","STD-Montes-2011","2014-05-26 12:07:20 +0100","NO","""After 3 months of intervention, improvement in quality of life was significantly greater in the SMSG (mean changes from baseline EQ-5D visual analogue scale (VAS) of 6.6, 95%CI 6.38, 6.82) compared to the CG (3.1, 95%CI 2.91, 3.29), P = 0.03"".","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Information and communication technology based prompting for treatment compliance for people with serious mental illness [v2.2-For publication].rm5","STD-Montes-2011","2012-11-28 13:23:45 +0000","UNKNOWN","No clear other bias. Funded by pharmaceutical industry - AstraZeneca, Spain.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-Gunderson-1984","2009-02-27 11:20:34 +0000","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-Gunderson-1984","2009-02-27 11:20:36 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-Gunderson-1984","2009-02-27 11:20:37 +0000","NO","Open study.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-Gunderson-1984","2009-02-27 11:20:40 +0000","NO","Numbers randomised were not clearly reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-Gunderson-1984","2009-02-27 11:20:43 +0000","UNKNOWN","No further details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-Gunderson-1984","2009-02-27 11:20:48 +0000","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-Karon-1981","2009-02-27 11:28:22 +0000","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-Karon-1981","2009-02-27 11:28:25 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-Karon-1981","2009-02-05 16:02:32 +0000","NO","Not reported for therapists or participants, probably open design.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-Karon-1981","2009-02-27 11:28:43 +0000","NO","Study attrition not clearly reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-Karon-1981","2009-02-27 11:28:48 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-Karon-1981","2009-02-27 11:28:50 +0000","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-May-1976","2009-02-27 11:31:01 +0000","UNKNOWN","Randomised, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-May-1976","2009-02-27 11:31:03 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-May-1976","2009-02-27 11:31:05 +0000","NO","Open study.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-May-1976","2009-02-27 11:31:09 +0000","NO","Study attrition not reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-May-1976","2009-02-27 11:31:12 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-May-1976","2009-02-27 11:31:13 +0000","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-O_x0027_Brien-1972","2009-02-27 11:37:03 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-O_x0027_Brien-1972","2009-02-27 11:37:06 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-O_x0027_Brien-1972","2009-02-27 11:37:09 +0000","NO","Open study.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-O_x0027_Brien-1972","2009-02-27 11:37:13 +0000","NO","Study attrition not adequately reported.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-O_x0027_Brien-1972","2009-02-27 11:37:16 +0000","UNKNOWN","No details.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness [v10.0-For publication].rm5","STD-O_x0027_Brien-1972","2009-02-27 11:37:18 +0000","UNKNOWN","No details.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Baandrup-2010","2013-12-10 11:50:03 +0000","UNKNOWN","Two Danish municipalities were randomly assigned to intervention (Viborg) and control settings (Esbjerg).","Adequate sequence generation","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Baandrup-2010","2013-12-10 11:50:04 +0000","UNKNOWN","No details reported.","Allocation concealment","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Baandrup-2010","2013-12-10 11:50:11 +0000","UNKNOWN","Participants might have been aware of the group (control or intervention) to which they were allocated because of the nature of the intervention. The two clusters were situated sufficiently far away from each other that contamination was avoided.","Blinding","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Baandrup-2010","2013-12-10 11:50:16 +0000","YES","The two randomly assigned units (clusters) were included in the analysis. The study consisted of two cross-sectional surveys—one carried out at baseline and the second after one year of follow-up. The primary outcome was prevalence of polypharmacy at follow-up (cross-sectional nature of the primary outcome measure).","Incomplete outcome data addressed","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Baandrup-2010","2013-12-10 11:50:21 +0000","YES","All study measures reported in the Methods were described in the analysis and reported in the Results.","Free of selective reporting","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Baandrup-2010","2013-12-10 11:50:28 +0000","YES","The control group and the intervention group were perfectly matched regarding prevalence of antipsychotic polypharmacy at baseline. The study was supported by the National Board of Health in Denmark (0-204-03-9 ⁄ 9) and the Wørzner Foundation.","Free of other bias","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Hamann-2006","2013-12-10 11:51:17 +0000","UNKNOWN","Quote: ""Selection of the wards was made so as to ensure that there were six pairs of wards, with one member of each pair being randomly assigned to the control or to the interventional condition"".","Adequate sequence generation","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Hamann-2006","2013-12-10 11:51:18 +0000","UNKNOWN","No details reported.","Allocation concealment","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Hamann-2006","2013-12-10 11:51:22 +0000","UNKNOWN","No blinding.","Blinding","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Hamann-2006","2013-12-10 11:51:22 +0000","NO","At follow-up (18 months), data were available for 66% of the initial sample.","Incomplete outcome data addressed","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Hamann-2006","2013-12-10 11:51:24 +0000","YES","All study measures reported in the Methods were included in the analysis and reported in the Results.","Free of selective reporting","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Hamann-2006","2013-12-10 11:51:30 +0000","UNKNOWN","At baseline, the two groups were not perfectly balanced in terms of length of hospitalisation and psychopathology ratings. The trial was funded by the German Ministry of Health and Social Security (217-43794-5/9) within the funding project Der Patient als Partner im medizinischen Entscheidungsprozess.","Free of other bias","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Hudson-2008","2013-12-10 11:52:06 +0000","YES","Randomisation was stratified by Veteran Integrated Service Network (VISN). In each VISN, two Veteran Affairs Medical Centers (VAMCs) were randomly assigned to experimental and control conditions (two clusters for each VISN). Quote: ""One of the two VAMCs per VISN was randomly selected, using a random numbers table, to receive the enhanced implementation strategy, and the other site within each pair received a basic education strategy for schizophrenia guidelines"".","Adequate sequence generation","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Hudson-2008","2013-12-10 11:52:06 +0000","UNKNOWN","No details reported.","Allocation concealment","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Hudson-2008","2013-12-10 11:52:10 +0000","UNKNOWN","No blinding. A combination ""self-report and provider assessment"" strategy was employed to measure the primary outcomes (detection bias cannot be excluded, i.e. non-adherence might have been underestimated).","Blinding","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Hudson-2008","2013-12-10 11:52:13 +0000","UNKNOWN","Of 349 participants enrolled at the six VAMCs, 84% (N = 293) completed both baseline and six-month follow-up assessments. Quote: ""Study participants lost to follow-up were more likely to be white (45% vs. 28%) and unmarried/separated (95% vs. 84%), but there were no other significant demographic differences between those who did or did not complete follow-up interviews"".","Incomplete outcome data addressed","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Hudson-2008","2013-12-10 11:52:16 +0000","YES","All study measures reported in the Methods were included in the analysis and reported in the Results.","Free of selective reporting","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Hudson-2008","2013-12-10 11:52:23 +0000","UNKNOWN","At baseline, the two groups were not perfectly balanced in terms of ethnic group and psychopathology rating. Funding was provided by a grant from the VA, J1SR& D (#CPG-97-027) and the VA South Central Mental Illness Research Education and Clinical Centre.","Free of other bias","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Osborn-2010","2013-12-10 11:52:57 +0000","YES","Quote: ""A statistician uninvolved in the trial randomly generated treatment allocation numbers"".","Adequate sequence generation","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Osborn-2010","2013-12-10 11:53:00 +0000","YES","Quote: ""Participating CMHTs were randomly allocated to each arm of the trial using a sealed envelope method. Once two CMHTs in each geographical area had agreed to participate, the envelopes were opened to determine the allocation for each CMHT"".","Allocation concealment","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Osborn-2010","2013-12-10 11:53:03 +0000","UNKNOWN","Quote: ""It was not possible for the researcher, the CMHT workers or the patients to remain blind to allocation. The researcher could not remain blind to which arm the CMHTs had been allocated to when she assessed satisfaction with the intervention and who had performed screening (GP, CMHT worker or nurse). Therefore, during the evaluation phase, the possibility of observer bias was decreased by obtaining information on the main outcome directly from primary care clinical notes"".","Blinding","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Osborn-2010","2013-12-10 11:39:15 +0000","YES","115 of 121 participants were included in follow-up assessments","Incomplete outcome data addressed","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Osborn-2010","2013-12-10 11:53:08 +0000","YES","All study measures reported in the Methods were included in the analysis and reported in the Results.","Free of selective reporting","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Osborn-2010","2013-12-10 11:53:15 +0000","YES","Funding: The study was funded by a Trial Platform grant from the UK Medical Research Council. Reference: G0301032.","Free of other bias","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Thompson-2008","2013-12-10 11:53:42 +0000","YES","Random numbers were generated by one of the study authors using a calculator's random number generator function.","Adequate sequence generation","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Thompson-2008","2013-12-10 11:53:44 +0000","YES","Allocation was performed by one of the study authors, who was blind to the identity of the units.","Allocation concealment","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Thompson-2008","2013-12-10 11:53:47 +0000","UNKNOWN","Quote: ""Participants were potentially aware of which group (control or intervention) they were allocated to due to the nature of the intervention"".","Blinding","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Thompson-2008","2013-12-10 11:53:50 +0000","YES","All randomly assigned units (clusters) were included in the analysis. The study consisted of two cross-sectional surveys, one carried out at baseline and the second at follow-up. The primary outcome was polypharmacy at follow-up (cross-sectional nature of the primary outcome measure).","Incomplete outcome data addressed","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Thompson-2008","2013-12-10 11:53:51 +0000","YES","All study measures reported in the Methods were included in the analysis and reported in the Results.","Free of selective reporting","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/G-P/Implementation of treatment guidelines for specialist mental health care [v2.0-For publication].rm5","STD-Thompson-2008","2013-12-10 11:53:52 +0000","UNKNOWN","Quote: ""Patients were younger, more likely to be male and detained under the Mental Health Act in the intervention arm"".","Free of other bias","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/G-P/Hypnosis for schizophrenia [v7.0-For publication].rm5","STD-Glover-1980","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Hypnosis for schizophrenia [v7.0-For publication].rm5","STD-Ihalainen-1973","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Hypnosis for schizophrenia [v7.0-For publication].rm5","STD-Lancaster-1983","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Horticultural therapy for schizophrenia [v3.0-For publication].rm5","STD-Kam-2010","2014-05-13 12:15:40 +0100","YES","Recruited by convenience sampling according to the stated selected criteria. Participants were then assigned a number and randomly allocated to the groups by an independent research assistant","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Horticultural therapy for schizophrenia [v3.0-For publication].rm5","STD-Kam-2010","2014-04-30 15:31:05 +0100","YES","Independent research assistant was blinded to the hypothesis and the intervention programme","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Horticultural therapy for schizophrenia [v3.0-For publication].rm5","STD-Kam-2010","2014-04-30 15:31:06 +0100","UNKNOWN","Single, but not tested","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Horticultural therapy for schizophrenia [v3.0-For publication].rm5","STD-Kam-2010","2014-05-13 12:15:03 +0100","NO","Two people who left early appeared in the ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Horticultural therapy for schizophrenia [v3.0-For publication].rm5","STD-Kam-2010","2014-04-30 15:31:08 +0100","YES","All measurements as stated in the 'methods' section of the paper are reported","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Horticultural therapy for schizophrenia [v3.0-For publication].rm5","STD-Kam-2010","2014-04-30 15:31:09 +0100","YES","No other potential biases were found","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Arvanitis-1997","2012-10-29 09:14:17 +0000","UNKNOWN","""Randomised"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Arvanitis-1997","2012-10-29 09:15:31 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Arvanitis-1997","2012-10-29 09:15:48 +0000","UNKNOWN","""Double-blind"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Arvanitis-1997","2012-10-29 09:14:18 +0000","UNKNOWN","""Double-blind""; ""[Blood] samples were shipped to the sponsor and analysed"". No further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Arvanitis-1997","2012-10-29 09:15:16 +0000","NO","""Of all patients evaluated, 149 (41%) completed 6 weeks of treatment. Lack of efficacy was the primary reason for withdrawal and was seen most often in the placebo group"". No further details reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Arvanitis-1997","2012-10-29 09:15:26 +0000","YES","All expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Arvanitis-1997","2012-10-29 09:15:24 +0000","NO","Supported by a grant from Zeneca Pharmaceuticals.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Beasley-1996","2012-10-29 09:16:02 +0000","UNKNOWN","""Randomised"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Beasley-1996","2012-10-29 09:16:52 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Beasley-1996","2012-10-29 09:16:02 +0000","UNKNOWN","""Double-blind"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Beasley-1996","2012-10-29 09:16:50 +0000","UNKNOWN","No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Beasley-1996","2012-10-29 09:17:17 +0000","NO"," Losses to follow-up ranged from 51% - 68% in the five treatment arms.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Beasley-1996","2013-10-21 11:18:23 +0100","NO","Patient Global Impression (PGI) assessed but not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Beasley-1996","2012-10-29 09:16:41 +0000","NO","Source of funding from industry ""From the Psychopharmacology Division, Lilly Research Laboratories, Eli Lilly and Company""","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Bechelli-1983","2012-10-29 09:18:36 +0000","UNKNOWN","""The patients were assigned to 3 groups of 30 each in a random and probabilistic manner, after stratification"", no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Bechelli-1983","2012-10-29 09:18:51 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Bechelli-1983","2012-10-29 09:17:50 +0000","UNKNOWN","""Double-blind"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Bechelli-1983","2012-10-29 09:17:56 +0000","YES","""The assessments were always performed by the same investigator in a double-blind trial. Only at the end of the study after the data were analysed were the patient group assignments identified"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Bechelli-1983","2012-10-29 09:17:59 +0000","YES","""Five patients ran away between the 6th and 27th day of the study. Three belonged to the pipotiazine group, 1 belonged to the haloperidol group, and 1 to the placebo group"". ""These patients were excluded from the analysis"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Bechelli-1983","2012-10-29 09:18:47 +0000","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Bechelli-1983","2012-10-29 09:18:45 +0000","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Borison-1989","2012-10-29 09:22:06 +0000","UNKNOWN","""...subjects were assigned on a randomized blind schedule to treatment"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Borison-1989","2012-10-29 09:22:06 +0000","UNKNOWN","""...subjects were assigned on a randomized blind schedule to treatment"" no further details reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Borison-1989","2012-10-29 09:22:06 +0000","UNKNOWN","""Double- blind"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Borison-1989","2012-10-29 09:23:39 +0000","UNKNOWN","No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Borison-1989","2012-10-29 09:31:38 +0000","YES","Losses to follow-up or missing data were balanced across intervention groups, with similar reasons for missing data. ""...three placebo-treated patients were terminated prior to study completion due to lack of efficacy. Two patients receiving haloperidol terminated early due to positive response and the desire to leave the hospital, and one patient in the haloperidol treatment group was terminated for administrative reasons. The only patient who left the study prematurely due to an apparent adverse reaction was one receiving placebo, who developed chest pain and electrocardiographic changes""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Borison-1989","2012-11-05 08:09:26 +0000","UNKNOWN","Study does not state in methods which outcomes will be measured, and/or no protocol available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Borison-1989","2012-10-29 09:23:34 +0000","NO","Researchers currently imprisoned for research fraud.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Borison-1992a","2012-10-29 09:21:44 +0000","UNKNOWN","""Randomised"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Borison-1992a","2012-10-29 09:21:44 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Borison-1992a","2013-10-21 16:47:11 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Borison-1992a","2013-10-21 16:47:20 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Borison-1992a","2012-11-05 08:08:43 +0000","UNKNOWN","No details reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Borison-1992a","2012-11-05 08:10:06 +0000","NO","Several outcomes not fully reported (BPRS, CGI, SANS, or ESRS).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Borison-1992a","2012-10-29 09:22:39 +0000","NO","Richard Borison, MD, former psychiatry chief at the Augusta Veterans Affairs medical center and Medical College of Georgia, was sentenced to 15 years in prison for a $10 million clinical trial fraud.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Chouinard-1993","2012-10-29 09:32:47 +0000","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Chouinard-1993","2012-10-29 09:32:57 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Chouinard-1993","2012-10-29 09:33:17 +0000","YES","""Double-blind"", ""Study medication was administered under double-blind conditions as identical tablets of risperidone, haloperidol and placebo"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Chouinard-1993","2012-10-29 09:32:47 +0000","UNKNOWN","""Double-blind"", ""Assessment of symptoms was based on clinical interviews conducted by a psychiatrist"". No further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Chouinard-1993","2012-10-29 09:36:12 +0000","NO","""Statistical analyses of efficacy and safety parameters were conducted according to the intent-to-treat analysis principle"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Chouinard-1993","2012-10-29 09:33:29 +0000","YES","All expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Chouinard-1993","2012-10-29 09:32:50 +0000","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Durost-1964","2012-10-29 09:36:32 +0000","UNKNOWN","""...all drugs were given at random"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Durost-1964","2012-10-29 09:53:42 +0000","UNKNOWN","No details reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Durost-1964","2012-10-29 09:52:13 +0000","YES","""...'pharmacotherapeutically blind unit,' that is, in a hospital service where all drugs were given at random and used without the service team (made up of one intern, two assistant residents, one resident, one psychologist, two to four nurses, one social worker and one occupational therapist) knowing what drugs were being investigated.""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Durost-1964","2012-10-29 09:51:47 +0000","YES","""The assessment of the patients (and the drugs) was a result of the pooling of the opinions of the different members of the team.""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Durost-1964","2012-10-29 09:48:06 +0000","YES","There were no drop-outs from the study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Durost-1964","2012-10-29 09:49:11 +0000","NO","Details on side effects were not fully reported although ""Side effects were relatively numerous and disturbing to the patients.""","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Durost-1964","2013-06-16 12:18:19 +0100","UNKNOWN","""Haloperidol was generously supplied by G. D. Searle & Co."" ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Garcia-2009","2012-10-28 14:59:32 +0000","YES","""Randomization of medication was performed using a computer-generated schedule"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Garcia-2009","2012-10-28 10:14:11 +0000","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Garcia-2009","2013-10-21 16:47:28 +0100","YES","“Double-blind”, ""...blinding was ensured by over-encapsulating all capsules to ensure the same appearance"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Garcia-2009","2013-10-21 16:47:39 +0100","UNKNOWN","“Double-blind”, no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Garcia-2009","2013-11-05 13:36:12 +0000","YES","Losses to follow-up or missing data were balanced across intervention groups, with similar reasons for missing data. Missing data have been imputed using appropriate methods (intention-to-treat analysis).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Garcia-2009","2012-10-28 10:25:18 +0000","NO"," Not all of the study's pre-specified primary outcomes have been reported (BPRS, UKU assessments).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Garcia-2009","2013-06-16 12:19:03 +0100","NO","""Laboratorios Almirall SA provided financial support for performing the study and Dainippon Sumitomo Pharma Co., Ltd funded the preparation of this manuscript. Drs Garcia, Robert and Peris are employees of Laboratorios Aimirall SA. H. Nakamura, Dr Sato and Y. Terazawa are employees of Dainippon Sumitomo Pharma Co., Ltd. Drs Garcia and Peris have received stock options from Laboratorios Almirall SA."" ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Garry-1962","2012-10-29 09:55:11 +0000","YES","Participants ""were divided into two groups on the basis of a list of random numbers supplied by the drug company""","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Garry-1962","2012-11-05 09:04:42 +0000","YES","Central allocation ""Our pharmacist allotted the patients from an alphabetical list supplied  by us""","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Garry-1962","2013-10-21 16:47:49 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Garry-1962","2013-10-21 16:48:10 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Garry-1962","2012-10-29 09:55:57 +0000","YES","""Two patients were withdrawn from the trial, one had a recurrence of a skin rash (he was eventually found to be on the placebo) and the other was found to have early pulmonary tuberculosis on routine chest X-ray. We were finally left with 50 patients (25 on drug and 25 on controls) who completed the trial"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Garry-1962","2012-10-29 09:56:00 +0000","YES","All expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Garry-1962","2013-06-16 12:19:13 +0100","UNKNOWN","Messrs. G. D. Searle and Co. Ltd. supplied the haloperidol and control tablets.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Howard-1974","2012-10-29 09:57:58 +0000","UNKNOWN","""the patients were randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Howard-1974","2012-10-29 09:58:07 +0000","UNKNOWN","No details reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Howard-1974","2012-10-29 09:58:18 +0000","YES","""The study medications were prepared in identical appearing capsules"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Howard-1974","2012-10-29 09:56:58 +0000","UNKNOWN"," No details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Howard-1974","2012-10-29 09:58:48 +0000","YES"," Losses to follow-up were balanced across intervention groups, with similar reasons for missing data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Howard-1974","2012-10-29 10:04:13 +0000","NO","All outcomes were not fully reported (no SD s were reported for BPRS and NOSIE).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Howard-1974","2012-10-29 10:00:21 +0000","UNKNOWN","Insufficient information to assess whether an important risk of bias exists (does not report source of funding).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Jann-1997","2012-10-29 10:00:48 +0000","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Jann-1997","2012-10-29 10:00:51 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Jann-1997","2012-10-29 10:01:26 +0000","YES","""Identical looking capsules"" were used.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Jann-1997","2012-10-29 10:00:52 +0000","UNKNOWN","No information provided.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Jann-1997","2012-10-29 10:01:13 +0000","NO","""Only 8 patients in the placebo group completed the 6-week study"". ""For the haloperidol group, 12 patients completed the study"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Jann-1997","2012-10-29 10:05:06 +0000","NO","All pre-stated outcomes were not reported (no data reported for the AIMS scale).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Jann-1997","2012-10-29 10:00:55 +0000","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Kane-2002","2012-10-29 10:02:38 +0000","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Kane-2002","2012-10-29 10:02:41 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Kane-2002","2012-10-29 10:02:39 +0000","UNKNOWN","""Double-blind"" no further information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Kane-2002","2012-10-29 10:03:03 +0000","YES","""The same rater conducted the assessment throughout the study and was blinded to the patient's treatment"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Kane-2002","2012-10-29 10:03:28 +0000","UNKNOWN","""Of the 414 randomised patients, 248 competed the 4-week study period"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Kane-2002","2012-10-29 10:05:35 +0000","NO","All pre-stated outcomes were not fully reported (SDs were not reported for PANSS, BPRS, CGI, AIMS, SAS and BAS scales, weight and serum prolactin levels).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Kane-2002","2012-10-29 10:05:44 +0000","NO","Sponsored by Otsuka Pharmaceutical Co. Ltd (Tokyo, Japan) and Bristol-Meyers Squibb Company (Princeton, NJ).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Kane-2010","2012-10-28 10:37:17 +0000","UNKNOWN","“Randomized”, no further details provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Kane-2010","2012-10-28 10:37:18 +0000","UNKNOWN","“Randomized”, no further details provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Kane-2010","2013-10-21 16:48:23 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Kane-2010","2013-10-21 16:48:29 +0100","UNKNOWN","""Double-blind"", no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Kane-2010","2013-10-22 10:15:01 +0100","YES","""Safety assessments were made using data from the treated population (all patients who received >1 dose of study medication); efﬁcacy analyses were based on data from the intent-to-treat (ITT) population (treated patients who had >1 postbaseline PANSS assessment)""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Kane-2010","2012-10-28 10:37:43 +0000","NO","Not all pre-specified outcomes were reported fully.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Kane-2010","2012-10-28 10:37:53 +0000","NO","""funded by Schering-Plough Corporation, now Merck & Co, Inc"" ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Klieser-1989","2012-10-29 10:06:27 +0000","UNKNOWN","""Randomised"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Klieser-1989","2012-10-29 10:06:30 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Klieser-1989","2012-10-29 10:06:27 +0000","UNKNOWN","""Double-blind"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Klieser-1989","2012-10-29 10:06:27 +0000","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Klieser-1989","2012-10-29 10:07:20 +0000","UNKNOWN","Number of losses from each treatment group and reasons for loss to follow-up not reported. ""Fourteen patients left the study on day 3, 19 patients left on day 7, and 6 patients left on day 14"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Klieser-1989","2012-10-29 10:06:46 +0000","NO","Not all expected outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Klieser-1989","2012-10-29 10:06:33 +0000","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Marder-1994","2012-10-29 10:08:53 +0000","UNKNOWN","""...randomization was in blocks of 12"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Marder-1994","2012-10-29 10:08:55 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Marder-1994","2013-10-21 16:48:34 +0100","UNKNOWN","""Double-blind"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Marder-1994","2012-10-29 10:08:57 +0000","UNKNOWN","No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Marder-1994","2012-10-29 10:10:05 +0000","NO","""early termination in 53% of the patients...62 % of the placebo patients; and 38% of patients receiving haloperidol...Both observed case and last observation carried forward (or end point) analyses were performed"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Marder-1994","2012-10-29 10:09:38 +0000","YES","All expected outcomes are reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Marder-1994","2012-10-29 10:10:01 +0000","UNKNOWN","Source of funding from a pharmaceutical company ""Supported by a grant from the Janssen Research Foundation"".","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Meltzer-2004","2012-10-28 09:29:09 +0000","UNKNOWN","“Randomized”, no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Meltzer-2004","2012-10-28 09:29:10 +0000","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Meltzer-2004","2013-10-21 16:48:47 +0100","UNKNOWN","“Double-blind”, no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Meltzer-2004","2013-10-21 16:48:53 +0100","UNKNOWN","“Double-blind”, no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Meltzer-2004","2012-10-29 07:05:02 +0000","NO","Losses to follow-up greater than 50%.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Meltzer-2004","2012-10-28 09:29:30 +0000","YES"," All expected outcomes are reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Meltzer-2004","2012-10-28 09:30:00 +0000","NO","Funding sources are pharmaceutical companies, ""Dr. Meltzer has received grant support from and is a consultant to Acadia, AstraZeneca, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutica, Lundbeck, Novartis, Pfizer, Sanofi-Synthelabo, and Solvay. He is a consultant to Psychiatric Genomics, Precision Med, Pharmacia, and Roche. Drs. Arvanitis and Rein and Ms. Bauer are employees of Sanofi-Synthelabo.""","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-NCT00044044-2002","2012-10-28 08:43:51 +0000","UNKNOWN","“Randomized”, no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-NCT00044044-2002","2012-10-28 08:43:51 +0000","UNKNOWN","“Randomized”, no further details reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-NCT00044044-2002","2012-10-28 08:43:52 +0000","UNKNOWN","The placebo was an ""Oral Capsule matching treatment"" indicating blinding of participants. Further, the study was described as “Double blind”, but there were no further details on blinding of personnel.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-NCT00044044-2002","2012-10-28 08:43:52 +0000","UNKNOWN","“Double blind”, no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-NCT00044044-2002","2013-10-21 11:37:54 +0100","NO","There was a high rate of drop-outs (> 50%).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-NCT00044044-2002","2012-10-28 08:44:23 +0000","YES","All pre-stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-NCT00044044-2002","2012-10-28 08:44:28 +0000","NO","""Sponsored by: Sumitomo Pharmaceuticals America"" ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Nishikawa-1982","2012-10-29 10:10:40 +0000","UNKNOWN","""Randomly assigned"" no further information reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Nishikawa-1982","2012-10-29 10:10:44 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Nishikawa-1982","2012-10-29 10:11:09 +0000","YES","""Double-blind"", ""Drug appearance, with respect to powder colour, taste and volumes, was made identical by adding a kind of stomachics, SMP (Sankyo, Japan).""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Nishikawa-1982","2012-10-29 10:10:40 +0000","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Nishikawa-1982","2012-10-29 10:11:55 +0000","UNKNOWN","Study does not report which treatment groups the losses to follow-up were from ""Nine patients were dropped from the study for various reasons. The reasons included: failure to report to the hospital for scheduled appointment (N=3); admissions to other hospitals (N=2); strong requests from the patient not to change the previous drug (N=3); and a suicide after admission to the hospital (N=1)"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Nishikawa-1982","2012-10-29 10:11:03 +0000","NO","Not all expected outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Nishikawa-1982","2012-10-29 10:10:58 +0000","UNKNOWN","Source of funding was not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Nishikawa-1984","2012-10-29 10:12:14 +0000","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Nishikawa-1984","2012-10-29 10:12:20 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Nishikawa-1984","2012-10-29 10:13:19 +0000","YES","""Double-blind"", ""Drug appearance, with respect to powder colour, taste and volume, was made identical by gastric aid, SMP (Sankyo, Japan)"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Nishikawa-1984","2012-10-29 10:12:14 +0000","UNKNOWN","""Double-blind"" no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Nishikawa-1984","2012-10-29 10:13:24 +0000","NO","""Among the entire group of 87 patients, 19 patients continued to receive the assigned drugs since they were in remission during the entire year of the trial, while other patients discontinued use of the assigned drugs due to overdose (N=16), relapse (N=48) and drop-out (N=4)"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Nishikawa-1984","2012-10-29 10:13:26 +0000","NO","Results not reported for placebo group for number of symptom free days and serum prolactin.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Nishikawa-1984","2012-10-29 10:12:17 +0000","UNKNOWN","Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Potkin-2008","2012-10-28 09:11:54 +0000","UNKNOWN","“Randomized”, no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Potkin-2008","2012-10-28 09:11:54 +0000","UNKNOWN"," No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Potkin-2008","2013-10-21 16:49:35 +0100","UNKNOWN","“Double-blind”, no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Potkin-2008","2013-10-21 16:49:41 +0100","UNKNOWN"," “Double-blind”, no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Potkin-2008","2012-10-29 07:08:12 +0000","NO","Losses to follow-up greater than 50%.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Potkin-2008","2012-10-29 07:08:18 +0000","NO","SDs not reported for PANSS or BPRS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Potkin-2008","2012-10-28 09:20:40 +0000","NO","Source of funding from pharmaceutical companies. ""Dr Potkin has received grant funding from Astra- Zeneca, Bioline, Bristol-Myers Squibb, Dainippon-Sumitomo, Elan, Forest Laboratories, Fujisawa Healthcare, Janssen Pharmaceutica, Merck, Novartis, Ono, Organon, Otsuka, Pfizer Inc, Solvay Pharmaceuticals, Roche""","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Selman-1976","2012-10-29 10:20:56 +0000","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Selman-1976","2012-10-29 10:21:00 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Selman-1976","2012-10-29 10:23:01 +0000","YES","""A double-blind process was used in which neither patient nor investigator knew what medication was received until after the study was completed"", ""All medication was administered in identically appearing capsules"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Selman-1976","2012-10-29 10:22:58 +0000","YES","""A double-blind process was used in which neither patient nor investigator knew what medication was received until after the study was completed"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Selman-1976","2012-10-29 10:22:06 +0000","UNKNOWN","Last observation carried forward method used ""Patients who continued beyond the fourth week but did not complete the full 12 weeks were included in the analysis through their final rating period, at either 4 or 8 weeks. These included 29 patients"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Selman-1976","2012-10-29 10:22:55 +0000","NO","All pre-stated outcomes were not fully reported (SDs were not reported for the BPRS and NOSIE scales).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Selman-1976","2012-10-29 10:22:54 +0000","NO","Loxitane (Loxapine succinate) supplied by Lederle Laboratories, Division of America Cyanamid Co, Pearle River, New York, who also supported the study.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Serafetinides-1972","2012-10-29 10:23:22 +0000","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Serafetinides-1972","2012-10-29 10:23:24 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Serafetinides-1972","2012-10-29 10:25:10 +0000","YES","""Double-blind"", ""All medications were prepared in identically appearing capsules"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Serafetinides-1972","2012-10-29 10:23:26 +0000","UNKNOWN","No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Serafetinides-1972","2012-10-29 10:25:15 +0000","YES","""Four of the 57 subjects, three on CPZ, and one on PL, failed to complete the 12 weeks of study. The PL subject and one CPZ subject were terminated because of behavioural deterioration after 4 and 8 weeks respectively. The other two CPZ subjects developed intestinal obstruction and were terminated in the 7th week of study"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Serafetinides-1972","2012-10-29 10:25:18 +0000","NO","All pre-stated outcomes were not reported (no data reported for cognitive response, no SDs reported for the BPRS, NOSIE and OBRS scales).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Serafetinides-1972","2012-10-29 10:25:21 +0000","YES","Study supported in part by US Public Health Service Grant MH 11666 and by National Institute of Mental Health Research Scientist Development Award K135278.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Simpson-1967","2012-10-29 10:46:17 +0000","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Simpson-1967","2012-10-29 10:46:24 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Simpson-1967","2013-10-21 16:49:49 +0100","UNKNOWN","""Double-blind""; ""the staff correctly guessed which patients were on active medication in a high percentage of cases"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Simpson-1967","2012-10-29 10:47:19 +0000","UNKNOWN","The code was broken at the end of the study.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Simpson-1967","2012-10-29 10:48:59 +0000","UNKNOWN","No details reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Simpson-1967","2012-12-04 07:55:16 +0000","NO","All pre-stated outcomes were not fully reported (SDs were not reported for IMPS and PRP).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Simpson-1967","2013-06-16 12:20:18 +0100","UNKNOWN","""The haloperidol (HALDOL®) used in this study was supplied by McNeil Laboratories. Inc.,"" ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Spencer-1992","2012-10-29 10:50:11 +0000","UNKNOWN","""Random assignment"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Spencer-1992","2012-10-29 10:50:19 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Spencer-1992","2012-10-29 10:50:11 +0000","UNKNOWN","""Double-blind"" no further details reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Spencer-1992","2012-11-08 13:19:29 +0000","UNKNOWN","""Double-blind"" For CPRS (one of the outcomes scales), the raters were ""all blind to treatment status"", no further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Spencer-1992","2012-10-29 10:57:59 +0000","YES","There were no drop-outs.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Spencer-1992","2012-10-29 10:50:52 +0000","NO","No SDs reported for CGI, CPRS, BPRS-C. No data reported for adverse events for placebo group. No data reported for cognitive assessments (WISC-R, WPPSI, DICA-R).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Spencer-1992","2012-10-29 10:50:24 +0000","UNKNOWN","Haloperidol and placebo tablets provided by McNeil Pharmaceutical.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Vichaiya-1971","2012-10-29 10:58:38 +0000","UNKNOWN","""Randomized"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Vichaiya-1971","2012-10-29 10:58:48 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Vichaiya-1971","2013-10-21 16:49:55 +0100","UNKNOWN","""Double-blind""; ""The code was worked out by the head of Female In-patient section, which kept it secret until the investigation had ended.""; ""...it soon became clear that the trial was not, in fact blind. The patients on haloperidol showed extrapyramidal symptoms"".","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Vichaiya-1971","2013-10-21 16:50:01 +0100","UNKNOWN","""Double-blind""; ""The code was worked out by the head of Female In-patient section, which kept it secret until the investigation had ended.""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Vichaiya-1971","2013-11-05 13:36:12 +0000","YES","Only one drop-out reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Vichaiya-1971","2012-10-29 10:58:42 +0000","UNKNOWN","Side-effects in placebo group not mentioned.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus placebo for schizophrenia [v13.0-For publication].rm5","STD-Vichaiya-1971","2012-10-29 11:00:32 +0000","UNKNOWN","Does not report source of funding.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Bi-1994","2011-03-24 15:14:01 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Bi-1994","2011-03-24 15:14:01 +0000","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Bi-1994","2013-11-17 19:28:30 +0000","NO","Not indicated, probably open.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Bi-1994","2013-11-17 19:28:31 +0000","NO","Not indicated, probably open.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Bi-1994","2011-03-24 15:16:09 +0000","UNKNOWN","Insufficient information to permit judgement about incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Bi-1994","2011-03-28 11:23:24 +0100","UNKNOWN","Insufficient information to permit judgment about selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Bi-1994","2011-04-06 14:44:20 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Blin-1996","2011-03-24 15:14:01 +0000","UNKNOWN","Randomised, no further details.        ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Blin-1996","2011-03-24 15:14:01 +0000","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Blin-1996","2013-11-17 19:26:38 +0000","UNKNOWN","Double, no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Blin-1996","2011-03-28 11:27:34 +0100","UNKNOWN","Double, no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Blin-1996","2014-06-12 11:27:31 +0100","NO","25% of the participants in the haloperidol group left the study early, as compared to 38% in the levomepromazine group. The number was clearly higher in the low-potency group and the reasons differed. Data were analysed on a LOCF method, which is an imperfect method.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Blin-1996","2011-03-24 15:14:01 +0000","YES","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Blin-1996","2011-03-24 15:14:01 +0000","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Borison-1989","2011-03-24 15:14:01 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Borison-1989","2011-03-24 15:14:01 +0000","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Borison-1989","2013-11-17 19:26:51 +0000","UNKNOWN","Double, no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Borison-1989","2011-03-28 11:28:41 +0100","UNKNOWN","Double, no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Borison-1989","2011-09-26 13:59:15 +0100","NO","1 out of 8 participants from the thioridazine group (13%) left the study early due to inefficacy of treatment. 3 out of 8 participants from the haloperidol group (38%) left the study early to due improvement and administrative reasons. Drop-outs were not included in the final analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Borison-1989","2011-03-24 15:14:01 +0000","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Borison-1989","2011-03-24 15:14:01 +0000","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Clark-1969","2013-08-24 16:56:34 +0100","UNKNOWN","Not reported. but double-blind.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Clark-1969","2011-03-24 15:14:01 +0000","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Clark-1969","2013-11-17 19:26:57 +0000","UNKNOWN","Double, no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Clark-1969","2011-03-28 11:29:41 +0100","UNKNOWN","Double, no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Clark-1969","2011-05-30 11:14:37 +0100","NO","21% of participants from the chlorpromazine group left the study early. A completer analysis was applied. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Clark-1969","2013-08-24 16:56:50 +0100","NO","CGI, BPRS, no mean and no SD.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Clark-1969","2011-03-24 15:14:01 +0000","UNKNOWN","There is insufficient information to permit judgment about other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Dufresne-1993","2011-03-24 15:14:01 +0000","UNKNOWN","Randomised, no further details.       ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Dufresne-1993","2011-03-24 15:14:01 +0000","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Dufresne-1993","2013-11-17 21:09:27 +0000","YES","Double, identical capsules.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Dufresne-1993","2013-11-17 21:09:29 +0000","YES","Double, identical capsules.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Dufresne-1993","2014-06-12 11:27:31 +0100","NO","25% of haloperidol participants left the study early. A completers-only method was used in the study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Dufresne-1993","2014-06-12 11:27:31 +0100","NO","No complete data for BPRS and HAM-D, SDs are missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Dufresne-1993","2011-03-24 15:14:01 +0000","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Fox-1964","2011-03-24 15:14:01 +0000","UNKNOWN","Randomly selected, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Fox-1964","2011-03-24 15:14:01 +0000","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Fox-1964","2013-11-17 19:27:20 +0000","UNKNOWN","Double, no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Fox-1964","2011-03-28 11:31:35 +0100","UNKNOWN","Double, no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Fox-1964","2011-03-28 11:32:15 +0100","YES","No evidence for incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Fox-1964","2011-03-24 15:14:01 +0000","NO","Incomplete BPRS results (no SDs).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Fox-1964","2011-03-24 15:14:01 +0000","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Gallant-1967","2011-03-24 15:14:01 +0000","UNKNOWN","Randomly assigned, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Gallant-1967","2011-03-24 15:14:01 +0000","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Gallant-1967","2011-03-28 11:33:31 +0100","YES","Double, all drugs were supplied in identical capsules and dispensed from individual medication bottles, which were prepared and coded prior to the study.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Gallant-1967","2013-11-17 19:27:28 +0000","YES","Double, all drugs were supplied in identical capsules and dispensed from individual medication bottles, which were prepared and coded prior to the study.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Gallant-1967","2011-03-28 11:33:55 +0100","YES","No evidence for incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Gallant-1967","2011-03-24 15:14:01 +0000","NO","SDs were not reported for any of the outcome scales.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Gallant-1967","2012-10-23 15:51:30 +0100","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Klimke-1993","2011-03-24 15:14:01 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Klimke-1993","2011-03-24 15:14:01 +0000","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Klimke-1993","2013-11-17 21:18:27 +0000","YES","Double, patients and psychiatrists were blind to treatment conditions.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Klimke-1993","2013-11-17 21:18:29 +0000","YES","Double, patients and psychiatrists were blind to treatment conditions.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Klimke-1993","2014-06-12 11:27:31 +0100","NO","13 out of 25 participants from the haloperidol group (52%) and 8 out of 25 participants from the perazine group (32%) left the study early. A LOCF methods was applied.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Klimke-1993","2011-03-24 15:14:01 +0000","NO","BPRS results only available for subgroups or independent of treatment condition.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Klimke-1993","2012-10-23 15:50:43 +0100","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-McCreadie-1977","2011-03-24 15:14:01 +0000","UNKNOWN","Randomly assigned, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-McCreadie-1977","2011-03-24 15:14:01 +0000","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-McCreadie-1977","2012-10-23 15:38:21 +0100","NO","Double, no further details, but tested at the end of the study before blind was broken. Psychiatrists guessed correctly in 8 participants, wrongly in 6.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-McCreadie-1977","2011-03-28 11:42:39 +0100","NO","Double, no further details, but tested at the end of the study before blind was broken. Psychiatrists guessed correctly in 8 participants, wrongly in 6.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-McCreadie-1977","2011-03-28 11:43:04 +0100","NO","2 out of 10 (20%) participants in the CPZ group left the study early due to adverse effects and inefficacy and were not included in the final analysis (completers only).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-McCreadie-1977","2011-03-24 15:14:01 +0000","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-McCreadie-1977","2011-09-26 14:55:50 +0100","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Nishizono-1994","2011-03-24 15:14:01 +0000","UNKNOWN","Randomised, no further details.  ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Nishizono-1994","2011-03-24 15:14:01 +0000","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Nishizono-1994","2014-06-12 11:27:31 +0100","NO","n.i., probably open.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Nishizono-1994","2014-06-12 11:27:31 +0100","NO","n.i., probably open.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Nishizono-1994","2011-03-28 11:44:16 +0100","UNKNOWN","Not enough information to permit judgement about incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Nishizono-1994","2011-03-28 11:44:23 +0100","UNKNOWN","Insufficient information to permit judgement about selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Nishizono-1994","2011-03-24 15:14:01 +0000","UNKNOWN","Insufficient information about other sources of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Prasad-1966","2014-06-12 11:27:31 +0100","UNKNOWN","Randomisation not described, but double-blind.      ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Prasad-1966","2011-03-24 15:14:01 +0000","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Prasad-1966","2011-03-28 11:44:58 +0100","YES","Double, drugs were supplied in identical bottles marked by serial number without disclosing identity.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Prasad-1966","2013-11-17 19:28:50 +0000","YES","Double, drugs were supplied in identical bottles marked by serial number without disclosing identity.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Prasad-1966","2011-03-28 11:45:19 +0100","YES","No evidence for incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Prasad-1966","2011-03-24 15:14:01 +0000","NO","Lorr Scale no means and SDs.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Prasad-1966","2011-03-24 15:14:01 +0000","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Rompel-1978","2011-03-24 15:14:01 +0000","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Rompel-1978","2011-03-24 15:14:01 +0000","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Rompel-1978","2013-11-17 21:17:47 +0000","NO","Double, tablets were in ordinary commercial form and in numbered bottles, issued by senior nursing staff, who were strictly forbidden to tell, in order to maintain investigator blind. This means that at least part of the personnel was not blind which can have led to performance bias.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Rompel-1978","2013-11-17 19:29:00 +0000","YES","Double, tablets were in ordinary commercial form and in numbered bottles, issued by senior nursing staff, who were strictly forbidden to tell, in order to maintain investigator blind.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Rompel-1978","2011-03-28 11:46:18 +0100","NO","3 out of 13 participants from the chlorpromazine group left the study early but were replaced with others to keep the total up to 25 participants, thus having a total of 28 participants.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Rompel-1978","2011-03-24 15:14:01 +0000","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Rompel-1978","2011-03-24 15:14:01 +0000","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Schmidt-1982","2011-03-24 15:14:01 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Schmidt-1982","2011-03-24 15:14:01 +0000","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Schmidt-1982","2013-11-17 19:29:06 +0000","UNKNOWN","Double, no further details.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Schmidt-1982","2011-03-28 11:46:40 +0100","UNKNOWN","Double, no further details.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Schmidt-1982","2011-09-26 13:54:03 +0100","UNKNOWN","2 out of 17 participants from the perazine group (12%) left the study early due to inefficacy and had to be switched to haloperidol.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Schmidt-1982","2011-03-24 15:14:01 +0000","NO","Outcomes of interest reported incompletely (Simpson Angus Scale - only sum scores, CGI - no data, EWL - no data, fine motor skills - no data).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Schmidt-1982","2011-03-24 15:14:01 +0000","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Serafetinides-1972","2011-03-24 15:14:01 +0000","UNKNOWN","Randomly assigned, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Serafetinides-1972","2011-03-24 15:14:01 +0000","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Serafetinides-1972","2013-11-17 21:07:07 +0000","YES","Double, all medications prepared in identically appearing capsules.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Serafetinides-1972","2013-11-17 21:07:12 +0000","YES","Double, all medications prepared in identically appearing capsules.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Serafetinides-1972","2011-09-26 13:52:58 +0100","NO","3 out of 14 participants in the CPZ group (21%) left the study early due to worsening and were not included in the final analysis (completers only). No participant from the HAL group left the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Serafetinides-1972","2011-03-24 15:14:01 +0000","NO","Incomplete data for BPRS, NOSIE and OBRS (no SD´s).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Serafetinides-1972","2011-03-24 15:14:01 +0000","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Shalev-1993","2011-03-24 15:14:01 +0000","UNKNOWN","Randomly assigned, no further details.        ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Shalev-1993","2013-11-17 14:15:17 +0000","UNKNOWN","""Treating psychiatrists were blind to the sequence in which the drugs were to be given to the patient.""","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Shalev-1993","2013-11-17 19:29:52 +0000","NO","Not described, probably open","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Shalev-1993","2013-11-17 19:29:51 +0000","NO","Not described, probably open","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Shalev-1993","2011-03-28 11:49:08 +0100","NO","15 participants left the study early but it is not mentioned how many from which drug group","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Shalev-1993","2011-05-11 11:29:06 +0100","YES","No clear selective outcome reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Shalev-1993","2012-10-23 15:51:08 +0100","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Weston-1973","2011-03-24 15:14:01 +0000","UNKNOWN","Randomly assigned, no further details.       ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Weston-1973","2011-03-24 15:14:01 +0000","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Weston-1973","2014-06-12 11:27:32 +0100","YES","Double - drugs supplied as tablets of identical colour and form, each patient being provided with a coded drug container.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Weston-1973","2014-06-12 11:27:32 +0100","YES","Double - drugs supplied as tablets of identical colour and form, each patient being provided with a coded drug container.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Weston-1973","2011-04-06 14:44:29 +0100","UNKNOWN","Two participants in the haloperidol group are missing from global assessment, yet there were no drop-outs according to the authors. It is not clear what happened with these two participants.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Weston-1973","2011-03-24 15:14:01 +0000","UNKNOWN","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Weston-1973","2011-05-16 12:28:11 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-White-1981","2014-06-12 11:27:32 +0100","UNKNOWN","Not mentioned, but double-blind.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-White-1981","2011-03-24 15:14:01 +0000","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-White-1981","2013-11-17 19:30:02 +0000","UNKNOWN","Double, no further information.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-White-1981","2011-03-28 11:50:25 +0100","UNKNOWN","Double, no further information.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-White-1981","2011-03-28 11:50:48 +0100","YES","No participant left the study early. No evidence for other incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-White-1981","2011-03-24 15:14:01 +0000","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-White-1981","2011-03-24 15:14:01 +0000","UNKNOWN","No clear evidence for other bias, the study had a short duration.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Abuzzahab-1982","2011-12-27 15:32:36 +0000","UNKNOWN","No randomisation mentioned in the publication, but the trial was described as “double-blind.” Thus, it was implied that the study was randomised.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Abuzzahab-1982","2011-07-26 18:19:23 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Abuzzahab-1982","2012-05-29 09:14:16 +0100","YES","“Double-blind”. “The study medications were administered as identical-appearing capsules.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Abuzzahab-1982","2012-05-29 09:14:21 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Abuzzahab-1982","2015-01-08 16:16:39 +0000","NO","The overall-attrition was high: 31 of 57 participants (54.4%) left the trial early. The trial authors indicated that 15 of 29 participants (51.7%) in the haloperidol-group and 16 of 28 participants (57.1%) in the thiothixene-group discontinued the drug treatment prematurely. Modified completers analyses were used (“all patients evaluated had at least 10 days of therapy”).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Abuzzahab-1982","2015-01-08 16:16:39 +0000","NO","The outcome data were not fully addressed (no total score or SDs for the BPRS, HPRSD, ESFR, and investigator global evaluation; no raw data for the ZUNG scale; the NOSIE scale is mentioned in the abstract but not in the methods and results section of the publication). There was no information regarding the number of participants who received a medication with antiparkinson drugs in each group; only for the whole study sample of the 46 analysed participants.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Abuzzahab-1982","2011-07-26 18:19:23 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Baastrup-1993","2012-05-29 09:14:52 +0100","UNKNOWN","“Randomly allocated”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Baastrup-1993","2011-08-17 13:51:45 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Baastrup-1993","2012-05-29 09:14:40 +0100","NO","“Open” study design.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Baastrup-1993","2012-05-29 09:14:42 +0100","NO","“Open” study design.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Baastrup-1993","2015-01-08 15:46:00 +0000","NO","According to the number of participants on which the BPRS- and CGI-ratings were based on, at least 6 of 19 participants (31.6%) left the trial early in the haloperidol group and at least 8 of 36 participants (22.2%) in the zuclopenthixol group. Therefore the overall attrition can be considered as being high (at least 14 of 55 participants; 25.5 %).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Baastrup-1993","2012-09-19 12:16:30 +0100","NO","The outcome data were not fully addressed (no total score for the BPRS and CGI).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Baastrup-1993","2011-08-17 13:51:53 +0100","NO","“The distribution of the patients according to sex in the 3 treatment arms differed surprisingly much.” “The analysis of the baseline values for the primary outcome measures, the BPRS scores and the CGI severity of illness scores showed a certain inhomogenity.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Bechelli-1983","2011-07-08 20:19:30 +0100","UNKNOWN","“The patients were assigned…in a random and probabilistic manner, after stratification had been performed on the basis of the following strata: I. simple schizophrenia, II. Hebephrenic schizophrenia, III. Paranoid schizophrenia, IV. Residual schizophrenia, V. Schizoaffective schizophrenia.” No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Bechelli-1983","2011-07-08 20:19:30 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Bechelli-1983","2012-05-29 09:15:05 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Bechelli-1983","2012-05-29 09:15:08 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Bechelli-1983","2015-01-08 15:47:06 +0000","YES","1 of 30 participants (3.3%) left the trial early in the haloperidol-group and 3 of 29 participants (10.3%) discontinued prematurely in the pipotiazine-group. The overall-attrition was rather low (4 of 59 participants; 6.8%). The analyses were based on completers-only data, but due to the low attrition the risk of bias might be rather low.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Bechelli-1983","2015-01-08 15:47:06 +0000","UNKNOWN","Many of the reported adverse effects data were not usable for this review. No information was available regarding the number of participants who received a medication with antiparkinson drugs.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Bechelli-1983","2012-01-28 15:06:53 +0000","NO","“All groups received 20 mg of haloperidol and 50 mg of chlorpromazine i.m. during the first 3 days, followed by wash-out for 2 days and then oral pipotiazine, haloperidol or placebo for the following 21 days.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Brannen-1981","2012-05-29 09:15:16 +0100","UNKNOWN","“Randomly assigned”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Brannen-1981","2011-06-29 08:50:03 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Brannen-1981","2011-06-29 08:50:06 +0100","YES","“Double-blind”; “All investigational medications were prepared in identical-appearing capsules.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Brannen-1981","2011-06-29 08:50:03 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Brannen-1981","2015-01-08 15:47:36 +0000","NO","The attrition was high: 7 of 24 participants (29.2%) in the haloperidol group left the trial early and 5 of 23 participants (21.7%) in the bromperidol-group. The overall-attrition was 25.5% (12 of 47 participants). The trial authors did not mention which analysis method they used regarding the continuous data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Brannen-1981","2012-06-19 10:19:19 +0100","NO","Outcome data were not fully reported (no SDs for the BPRS and NOSIE total score). Only the most prevalent adverse effects were reported. Data regarding the number of participants receiving rescue medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Brannen-1981","2011-06-29 08:50:03 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Bueno-1979","2011-11-29 19:33:58 +0000","UNKNOWN","No randomisation mentioned in the publication, but the trial was described as “double-blind.” Thus it was implied that the study was randomised.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Bueno-1979","2011-11-29 19:33:58 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Bueno-1979","2012-05-29 09:15:22 +0100","YES","“Double-blind”. The study medications were administered as identical-appearing capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Bueno-1979","2012-05-29 09:15:24 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Bueno-1979","2011-11-29 19:34:04 +0000","YES","With missing data of 2 of the 40 randomised participants (5%), the overall attrition was rather low. The analyses were based on completers-only data, but due to the small drop-out rate, the risk of bias might be considered as being low.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Bueno-1979","2012-06-19 10:19:32 +0100","NO","The outcome data were not fully addressed (no raw data for the BPRS, CGI, and NOSIE). ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Bueno-1979","2011-11-29 19:34:00 +0000","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cassano-1975","2012-05-29 09:15:38 +0100","UNKNOWN","“Entirely randomized experimental design”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cassano-1975","2011-08-27 08:16:20 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cassano-1975","2012-05-29 09:15:32 +0100","YES","“Double-blind”. “The compounds were contained in indistinguishable capsules.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cassano-1975","2012-05-29 09:15:35 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cassano-1975","2011-08-27 08:16:21 +0100","UNKNOWN","19 of 76 participants (25%) left the trail early. “In 6 patients, the study was discontinued for reasons totally independent of the treatments; on this basis, they have not been included in the analysis of the results.”","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cassano-1975","2012-06-19 10:19:45 +0100","NO","Outcome data reporting was incomplete (no raw data for the BPRS, IMPS, and the clinical evaluation of the changes of global symptomatology). The numbers of participants randomised to each treatment group (haloperidol or sulpiride) were not indicated.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cassano-1975","2011-08-27 08:16:21 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cocchi-1971","2011-12-27 09:28:21 +0000","UNKNOWN","Randomised; no further detail.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cocchi-1971","2011-08-11 07:51:04 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cocchi-1971","2012-05-29 09:15:49 +0100","YES","“Double-blind”. Identical appearing tablets.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cocchi-1971","2012-05-29 09:15:52 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cocchi-1971","2012-01-30 12:45:14 +0000","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cocchi-1971","2013-08-06 11:26:34 +0100","UNKNOWN","Adverse effects reporting was incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cocchi-1971","2011-08-11 07:51:04 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cocito-1970","2011-06-28 16:12:59 +0100","UNKNOWN","“randomly assigned”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cocito-1970","2011-06-28 16:12:59 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cocito-1970","2011-06-28 16:14:47 +0100","YES","“Double-blind”; The two drugs were administered “in identical bottles of the same potency and coded so as to be unrecognisable both to the experimentalists and to the patients.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cocito-1970","2011-06-28 16:12:59 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cocito-1970","2015-01-06 14:51:12 +0000","NO","Regarding the analysis at day 30, data of 40 of 46 randomised participants were available (13% missing data) and at day 60, data of only 12 of 46 randomised participants were provided (73.9% missing data). The trial authors used a completers-only analysis.  ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cocito-1970","2013-08-06 11:23:42 +0100","YES","The outcomes have been reported in the pre-specified way.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cocito-1970","2011-07-31 10:47:47 +0100","NO","“The basic neuroleptic treatment with either dehydrobenzperidol or haloperidol was supplemented with orphenadrine, levopromazine, and in about one half of the cases diazepam.” Antidepressants were administered in two cases. Significant between-group difference regarding the average trial duration (51 versus 75 days).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cosar-1999","2012-01-30 13:07:33 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cosar-1999","2011-08-22 12:53:19 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cosar-1999","2011-08-22 13:03:39 +0100","UNKNOWN","The study did not address this outcome. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cosar-1999","2011-08-22 13:03:41 +0100","UNKNOWN"," The study did not address this outcome.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cosar-1999","2011-08-22 12:53:19 +0100","UNKNOWN","The study did not address this outcome; insufficient information to permit judgment concerning incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cosar-1999","2012-06-19 10:20:09 +0100","NO","Outcome data reporting was incomplete (no raw data for the BPRS). Adverse effects were not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Cosar-1999","2012-01-28 15:20:49 +0000","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Darondel-1981","2011-12-20 11:08:14 +0000","UNKNOWN","Randomisation. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Darondel-1981","2011-12-20 11:08:01 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Darondel-1981","2011-12-20 11:08:01 +0000","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Darondel-1981","2011-12-20 11:08:01 +0000","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Darondel-1981","2015-01-08 15:58:56 +0000","YES","With 2 of 45 participants leaving the study early (4.4%) the overall attrition was low.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Darondel-1981","2011-12-20 11:12:02 +0000","YES","The outcomes have been reported in the pre-specified way.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Darondel-1981","2011-12-20 11:08:59 +0000","NO","Co-administration with other antipsychotics was allowed.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Denijs-1980","2011-06-29 13:41:53 +0100","UNKNOWN","Study group allocation “according to a random scheme”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Denijs-1980","2011-06-29 13:41:53 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Denijs-1980","2011-06-29 13:41:53 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Denijs-1980","2011-06-29 13:41:53 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Denijs-1980","2015-01-08 15:59:22 +0000","UNKNOWN","2 of 19 participants (10.5%) left the trial early in the haloperidol group and 3 of 23 participants (13%) in the bromperidol group. With 5 of 42 participants (11.9%) the overall attrition was moderate. Regarding the primary outcome of the systematic review, data analyses based on the intention-to-treat (ITT) approach were provided.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Denijs-1980","2012-09-19 11:08:32 +0100","NO","The outcome data were not fully addressed (no raw data for the BPRS, NOSIE, and Simpson and Angus Scale).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Denijs-1980","2011-06-29 13:42:01 +0100","NO","“A lack of double-blind medication” in one participant receiving bromperidol. “After breaking the double-blind code it was noticed that the prescription and registration of promethazine have not been as careful as they should have been.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Dufresne-1993","2011-08-03 13:51:27 +0100","UNKNOWN","“randomly assigned”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Dufresne-1993","2011-08-03 13:51:27 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Dufresne-1993","2012-05-29 09:16:09 +0100","YES","“Double-blind”. “identical capsules”.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Dufresne-1993","2012-05-29 09:16:11 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Dufresne-1993","2015-01-08 15:59:42 +0000","NO","4 of 16 participants (25%) left the trial early in the haloperidol group and 4 of 14 participants (28.6%) in the molindone group. With 8 of 30 participants (26.7%) the overall attrition was high. Completers-only analyses were used.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Dufresne-1993","2012-06-19 10:20:35 +0100","NO","The outcome data were not fully addressed (no SDs for the BPRS and HAM-D; no raw data for the CGI, CNS-RS, AIMS, REPS, and TESS). The adverse effects were not fully addressed.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Dufresne-1993","2011-08-03 13:51:33 +0100","NO","“The majority of subjects assigned to the haloperidol and thioridazine groups were female, whereas those assigned to the molindone group were mostly male.” The high level of depression of the participants could be a risk of bias in terms of this systematic review.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Engelhardt-1978","2011-07-05 17:12:41 +0100","YES","“Patients were assigned with a computer-generated randomisation scheme stratified for sex and marital status.”","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Engelhardt-1978","2011-07-05 17:06:22 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Engelhardt-1978","2012-05-29 09:16:20 +0100","YES","“Double-blind”. “Haloperidol and thiothixene were supplied in capsules of identical appearance.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Engelhardt-1978","2012-05-29 09:16:22 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Engelhardt-1978","2015-01-08 16:00:01 +0000","NO","Altogether 80 people with schizophrenia were assigned to treatment. “Of the 80 patients only 56 remained in treatment beyond the first 2 weeks.” Only 36 participants were able to remain in treatment for the full 24 weeks of the study period. So the overall-attrition was high (44 of 80 participants; 55%). 22 of 38 participants (57.9%) left the trial early in the haloperidol-group and 22 of 42 participants (52.4%) in the thiothixene-group. The trial authors provided only completers-analyses comprising altogether 36 participants.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Engelhardt-1978","2015-01-08 16:00:01 +0000","NO","The outcome data were not fully addressed (no raw data or total score regarding the Katz Adjustment Scales and SRSS). No information available regarding the number of participants who received a medication with antiparkinson drugs.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Engelhardt-1978","2015-01-08 16:00:01 +0000","NO","Occurrence of baseline imbalances: the differences between the two treatment-groups were statistically significant in terms of the mean age of the participants and the mean duration of the illness. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Escobar-1985","2012-05-29 09:16:33 +0100","UNKNOWN","“Randomly assigned”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Escobar-1985","2011-08-08 15:37:18 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Escobar-1985","2012-05-29 09:16:27 +0100","YES","“Double-blind”. “identical appearing tablets”.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Escobar-1985","2012-05-29 09:16:30 +0100","YES","“Double-blind”. “The rater was blind to the type of medication the subject received.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Escobar-1985","2015-01-08 16:00:23 +0000","NO","“Only 30 subjects completed 1 week of treatment and 25 completed 2 weeks.” Thus, at least 10 of 35 participants (28.6%) left the trial early and therefore the overall attrition can be considered as being high. It is not explicitly mentioned how many patients were randomised to each study group (haloperidol or molindone group). “Analyses [were] based on the 30 subjects who completed at least the first week of the study.”","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Escobar-1985","2012-09-19 11:09:41 +0100","NO","The outcome data were not fully addressed (no total score for the BPRS and TESS; no SDs for the CGI).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Escobar-1985","2011-08-08 15:37:28 +0100","NO","“This study is limited by…..the relatively short evaluation period.” “Because of attrition, analyses for the oral portion of the study [were] limited to ratings at baseline, days 2-3, and weeks 1 and 2.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Faretra-1970","2012-09-19 12:25:54 +0100","UNKNOWN","“Randomly assigned”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Faretra-1970","2011-11-11 09:33:31 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Faretra-1970","2012-05-29 09:16:47 +0100","YES","“Double-blind”. “Medications were prepared in identical appearing capsules”, ""Capsules were scored in bottles identified only by a number"", ""Neither the patient nor the dispensing and rating physician knew which drug was given.""","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Faretra-1970","2012-01-29 08:03:25 +0000","YES","“double-blind”. ""Neither the patient nor the dispensing and rating physician knew which drug was given.""","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Faretra-1970","2011-11-11 09:33:32 +0000","UNKNOWN","The study did not address this outcome; insufficient information to permit judgment concerning incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Faretra-1970","2012-06-04 17:56:31 +0100","UNKNOWN","The outcomes have been reported in the pre-specified way with the exception of the number of participants in each study group that received a medication with antiparkinson drugs.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Faretra-1970","2011-11-11 09:33:32 +0000","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Fuentenebro-1989","2011-11-30 12:03:15 +0000","UNKNOWN","The trial authors did not explicitly mention a randomisation, but described a double-blinding. Thus we implied that the study was randomised. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Fuentenebro-1989","2011-11-30 12:03:04 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Fuentenebro-1989","2012-05-29 09:17:00 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Fuentenebro-1989","2012-05-29 09:17:03 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Fuentenebro-1989","2011-11-30 12:03:05 +0000","UNKNOWN","With missing data of 10 of the 50 randomised participants (20%), the overall attrition was moderate. The analyses were based on completers-only data, but due to the moderate drop-out rate, the risk of bias might be considered as being unclear.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Fuentenebro-1989","2012-06-19 10:21:27 +0100","NO","The outcome data were not fully addressed (no usable data and SDs for the BPRS; no raw data for the CGI). The numbers of participants randomised to each treatment group (haloperidol or molindone) were not indicated.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Fuentenebro-1989","2011-11-30 12:03:05 +0000","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gallant-1967","2012-05-29 09:17:14 +0100","UNKNOWN","“Randomly assigned”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gallant-1967","2011-06-30 19:16:52 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gallant-1967","2012-05-29 09:17:08 +0100","YES","“Double-blind”. “All drugs were supplied in identical capsules and were dispensed from individual medication bottles which were prepared and coded prior to the study.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gallant-1967","2012-05-29 09:17:11 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gallant-1967","2011-06-30 19:16:52 +0100","UNKNOWN","The study did not address this outcome; insufficient information to permit judgment concerning incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gallant-1967","2012-06-19 10:21:39 +0100","NO","Outcome data were not fully addressed (no raw data for the MACC Behavioral Adjustment Scale and the Tubane Test Battery; no SDs were provided  for the Beckomberga Scale). Adverse effects reporting was incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gallant-1967","2011-06-30 19:16:52 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gerlach-1985","2012-05-29 09:17:25 +0100","YES","“Randomly assigned”. According to e-mail correspondence with the first author: “Referring to a random number table.”","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gerlach-1985","2011-07-22 13:46:00 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gerlach-1985","2012-05-29 09:17:19 +0100","YES","“Double-blind”. “identically looking capsules”.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gerlach-1985","2012-05-29 09:17:23 +0100","YES","“Double-blind”. According to e-mail correspondence with the first author the raters were blinded to treatments.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gerlach-1985","2015-01-08 16:01:08 +0000","NO","Regarding the whole trial duration, the overall attrition can be considered as being high (8 of 26 randomised participants). There were no information available, how many participants dropped out during the first phase of the trial. “Relatively small number of patients and the consequent Type II error.” The analyses were based on completers-only data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gerlach-1985","2012-06-19 10:21:50 +0100","NO","The outcome data were not fully addressed (no SDs for the BPRS). The numbers of participants randomised to each treatment group (haloperidol or sulpiride) were not indicated. Concerning the adverse effects reporting there were only data for the whole trial duration (both 12-week periods) provided but not separately for the first phase which was of interest for this systematic review.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gerlach-1985","2011-08-05 17:27:56 +0100","NO","“The study was carried out as a double-blind cross-over trial.” ”Dampening effect of the relatively high doses [of sulpiride] employed in this study, and the sample of chronic, long-term hospitalised patients which was studied.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Germana-1990","2012-05-29 09:17:36 +0100","UNKNOWN","“Randomised”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Germana-1990","2011-07-27 15:59:00 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Germana-1990","2012-05-29 09:17:31 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Germana-1990","2012-05-29 09:17:34 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Germana-1990","2011-07-27 15:59:00 +0100","UNKNOWN","Insufficient information to permit judgment concerning incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Germana-1990","2012-06-19 10:22:04 +0100","UNKNOWN","The outcome data were not fully addressed (no SDs for the Symptom Rating Scale).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Germana-1990","2015-01-06 15:23:51 +0000","NO","The trial was not characterised through a definite endpoint the data-analyses were based on. Seven participants in the bromperidol-group received already medication with anticholinergics when entering the trial.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Giordana-1984","2012-05-29 09:17:45 +0100","YES","Randomised (participants were drawn by lots into two groups of treatment, with always 4 participants balanced).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Giordana-1984","2011-12-12 13:39:25 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Giordana-1984","2011-12-12 13:40:18 +0000","YES","“Double-blind”. indistinguishable medication.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Giordana-1984","2011-12-12 13:39:43 +0000","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Giordana-1984","2011-12-12 13:41:02 +0000","UNKNOWN","The study did not address this outcome; insufficient information to permit judgment concerning incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Giordana-1984","2012-06-19 10:22:21 +0100","UNKNOWN","The outcome data were not fully addressed (no SDs were available regarding the hallucinatory syndrome measured by the AMDP system).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Giordana-1984","2011-12-12 13:40:46 +0000","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Glazer-1990","2012-05-29 09:17:50 +0100","UNKNOWN","“Randomly assigned”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Glazer-1990","2011-08-05 09:06:04 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Glazer-1990","2012-05-29 09:17:54 +0100","YES","“Double-blind”. “Medication was supplied in identical-appearing capsules.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Glazer-1990","2012-05-29 09:17:56 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Glazer-1990","2011-08-05 09:06:56 +0100","YES","Of the 18 randomised participants, who fulfilled the criterion for withdrawal-exacerbated TD nobody left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Glazer-1990","2012-06-19 10:22:29 +0100","NO","The outcome data were not fully addressed (no raw data for the CGI, BPRS, TESS, and the Webster Parkinsonism Rating Scale). Adverse effects reporting was incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Glazer-1990","2015-01-06 15:26:58 +0000","NO","Baseline imbalance between the two study groups in terms of post hospitalisation duration. The trial was not characterised through a definite endpoint.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Goldstein-1966","2011-06-28 13:29:58 +0100","UNKNOWN","“Patients were assigned to one of the two treatment groups at random.” No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Goldstein-1966","2011-06-28 13:30:00 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Goldstein-1966","2012-01-29 08:06:27 +0000","YES","“Trifluoperazine and haloperidol were packed in identical Number 2 gelatin capsules.” “The physicians were told that one capsule was equivalent to any of the following: 100mg chlorpromazine, 100mg thioridazine, 4mg perphenazine, 2mg trifluoperazine, 2mg haloperidol, or 1mg fluphenazine.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Goldstein-1966","2011-06-28 13:29:58 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Goldstein-1966","2015-01-08 16:01:56 +0000","NO","With 3 drop-outs (of 21 participants) the overall attrition was moderate (14.3%). It is not explicitly mentioned how many patients were randomised to each study group (haloperidol or trifluoperazine group). It can be assumed that the results were based on a completers-only analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Goldstein-1966","2012-09-19 12:18:57 +0100","NO","Outcome data reporting was incomplete (no total scores for the IMPS and WBRS).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Goldstein-1966","2011-06-28 13:29:58 +0100","NO","No information concerning the duration of the trial available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Goldstein-1969","2012-05-29 09:18:14 +0100","UNKNOWN","“Randomly assigned”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Goldstein-1969","2011-08-16 12:11:15 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Goldstein-1969","2012-05-29 09:18:09 +0100","YES","“Double-blind”. “identical appearing capsules.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Goldstein-1969","2012-05-29 09:18:11 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Goldstein-1969","2015-01-08 16:02:11 +0000","UNKNOWN","The overall attrition was moderate (41 of 250 participants (16.4%) in both study arms). ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Goldstein-1969","2012-06-19 10:22:46 +0100","NO","Outcome data reporting was incomplete (no raw data for the global assessment of the severity of illness, global assessment of the degree of improvement, IMPS, WBRS, Relatives Rating Scale, and Clyde Mood Scale). Adverse effects reporting was incomplete. No information regarding the number of participants that received a medication with antiparkinson drugs.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Goldstein-1969","2011-08-16 12:11:15 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gowardman-1973","2012-05-29 09:18:21 +0100","UNKNOWN","“Randomly allotted by the hospital pharmacist”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gowardman-1973","2011-07-31 16:46:41 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gowardman-1973","2012-05-29 09:18:26 +0100","YES","“Double-blind”. “The drugs were supplied in identical capsules.” “The capsules were indistinguishable in outward appearance.” “The investigators did not know who was receiving which drug.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gowardman-1973","2012-05-29 09:18:29 +0100","YES","“Double-blind”. “The investigators did not know who was receiving which drug.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gowardman-1973","2011-07-31 16:46:56 +0100","YES","“All patients completed the trial period of three months.”","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gowardman-1973","2012-06-05 09:12:40 +0100","UNKNOWN","The adverse effects were not fully addressed. No information regarding the number of participants that received a medication with antiparkinson drugs.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Gowardman-1973","2011-08-01 08:25:53 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Haas-1982","2011-06-29 09:05:21 +0100","UNKNOWN","The trial authors did not explicitly mention a randomisation, but described a double-blinding. Thus we implied that the study was randomised.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Haas-1982","2011-06-29 09:04:51 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Haas-1982","2011-06-29 09:04:53 +0100","YES","“Presentation of the drugs was identical in liquid form”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Haas-1982","2011-06-29 09:04:50 +0100","UNKNOWN","“Double-blind”; No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Haas-1982","2015-01-08 16:02:42 +0000","YES","There were no drop-outs in the haloperidol-group, but 2 of 15 (13.3%) participants left the trial early in the pimozide-group. The overall-attrition was 6.7% (2 of 30 participants). Altogether the attrition was rather low and the risk of bias might be considered as being low.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Haas-1982","2012-06-19 10:23:29 +0100","NO","The outcome data were not fully addressed (no SDs for the BPRS; no results for the ADMP-rating; no raw data for the CGI).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Haas-1982","2012-01-29 08:07:27 +0000","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Hall-1968","2012-05-29 09:18:37 +0100","UNKNOWN","“Randomly assigned”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Hall-1968","2011-07-04 12:04:17 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Hall-1968","2012-05-29 09:18:43 +0100","YES","“Double-blind”. “Medications for each patient were supplied by the pharmacy in an individual bottle with only the patient’s name and study number appearing on the bottle label. Both compounds dispensed in capsules identical in appearance. Therefore, the investigator who cared for the patients and all other raters did not know which of the two treatments any patient was receiving.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Hall-1968","2012-05-29 09:18:40 +0100","YES","“Double-blind”. “Medications for each patient were supplied by the pharmacy in an individual bottle with only the patient’s name and study number appearing on the bottle label….Therefore, the investigator who cared for the patients and all other raters did not know which of the two treatments any patient was receiving.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Hall-1968","2012-01-29 08:08:37 +0000","UNKNOWN","With 5 of 25 participants (20%) leaving the study early in each treatment group the attrition was moderate. Regarding the dichotomous data, the trial authors provided an ITT-analysis. The analyses-methods used for the continuous data were not explicitly mentioned in the publication.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Hall-1968","2012-06-19 10:23:49 +0100","NO","The outcome data were not fully addressed (no SDs for the BPRS; no raw data for the PIP). Adverse effects reporting was incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Hall-1968","2011-07-04 12:04:26 +0100","NO","“The patients were discontinued from any psychoactive drugs they had been receiving and placed directly on project medications with no intervening washout period.” “The patient sample (chronic) tended to make the finding of differences unlikely.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Heikkil_x00e4_-1981","2011-07-07 08:45:28 +0100","UNKNOWN","No randomisation mentioned in the publication, but the trial was described as “double-blind.” Thus it was implied that the study was randomised.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Heikkil_x00e4_-1981","2011-07-07 08:45:28 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Heikkil_x00e4_-1981","2012-05-29 09:18:51 +0100","UNKNOWN","“Double-blind, double-dummy”. “One set of tablets was active while the other set was placebo.” No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Heikkil_x00e4_-1981","2012-05-29 09:18:54 +0100","UNKNOWN","“Double-blind, double-dummy”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Heikkil_x00e4_-1981","2015-01-08 16:03:12 +0000","NO","9 of 63 participants (14.3%) left the trial early until 8 weeks and 27 participants (42.6%) until week 12. Therefore the overall-attrition was considered as high. A completers-only analysis was used concerning the CGI.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Heikkil_x00e4_-1981","2012-06-19 10:23:58 +0100","NO","Outcome data were not fully addressed (no SDs for the BPRS and NOSIE-30). Adverse effects reporting was incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Heikkil_x00e4_-1981","2011-07-07 08:45:33 +0100","NO","“A planned wash-out period preceding the start of test treatment was given up because of the severity of illness of the patients.” “Test treatment according to plan was given for only 8 weeks in 14 patients.” “Clopenthixol and haloperidol were administered rather frequently in the pre-trial period, since 11 patients received clopenthixol and 16 haloperidol.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Heikkil_x00e4_-1992","2012-05-29 09:19:00 +0100","UNKNOWN","“Randomised”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Heikkil_x00e4_-1992","2011-07-08 14:10:32 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Heikkil_x00e4_-1992","2012-05-29 09:19:03 +0100","YES","“Double-blind”. “tablets of identical appearance”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Heikkil_x00e4_-1992","2012-05-29 09:19:05 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Heikkil_x00e4_-1992","2015-01-08 16:03:27 +0000","NO","The overall-attrition was high: 38 of 49 participants (77.6%) left the trial early. The trial authors indicated that 18 of 23 participants (78.3%) in the haloperidol-group and 20 of 26 participants (76.9%) in the zuclopenthixol-group discontinued the drug treatment prematurely.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Heikkil_x00e4_-1992","2012-06-14 09:47:45 +0100","UNKNOWN","The reported adverse effects data were not usable for this systematic review.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Heikkil_x00e4_-1992","2011-07-08 14:10:32 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Hollister-1962","2012-05-29 09:19:16 +0100","UNKNOWN","“Randomised blocks of 24”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Hollister-1962","2011-07-06 08:19:20 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Hollister-1962","2012-05-29 09:19:18 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Hollister-1962","2012-05-29 09:19:20 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Hollister-1962","2011-07-06 08:21:04 +0100","NO","112 participants “were admitted to the study, for whom data were complete for six weeks of treatment in 96 and for twelve weeks of treatment in 56.” “During the entire twelve-week period of the study, 56 patients or half the original sample dropped from the study.” The analyses were based on completers-only data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Hollister-1962","2012-06-19 10:24:09 +0100","NO","The outcome data were not fully addressed (no SDs for the BPRS and the Nurse’s Evaluation Form). Adverse effects were provided only for the first six weeks of treatment. No information concerning the number of participants that received a medication with anticholinergic drugs.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Hollister-1962","2011-07-06 08:19:30 +0100","NO","“Incomplete data collection” regarding the global judgment by clinicians. 96 participated in the study for at least 6 weeks. According to table 2 in the publication 52 participants were in the haloperidol-group and 44 participants in the thiopropazate-group. But according to table 5 after 6 weeks of treatment the proportion was conversely (44 participants in the haloperidol-group and 52 participants in the thiopropazate-group).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Howard-1974","2012-05-29 09:19:31 +0100","UNKNOWN","“Randomly assigned”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Howard-1974","2011-07-05 09:04:05 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Howard-1974","2012-05-29 09:19:26 +0100","YES","“Double-blind”. “The study medications were prepared in identical appearing capsules.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Howard-1974","2012-05-29 09:19:29 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Howard-1974","2011-07-05 09:04:05 +0100","UNKNOWN","The study did not address this outcome; insufficient information to permit judgment concerning incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Howard-1974","2012-06-19 10:24:21 +0100","NO","The outcome data were not fully addressed (no raw data for the BPRS, NOSIE, and the Mental Status Checklist). No information regarding the number of participants that received a medication with antiparkinson drugs.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Howard-1974","2015-01-06 15:38:56 +0000","NO","The trial was not characterised through a definite endpoint the data-analyses were based on.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Itoh-1985","2011-07-26 19:33:47 +0100","UNKNOWN","No randomisation mentioned in the publication, but the trial was described as “double-blind.” Thus it was implied that the study was randomised.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Itoh-1985","2011-07-26 19:33:47 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Itoh-1985","2012-05-29 09:19:39 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Itoh-1985","2012-05-29 09:19:41 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Itoh-1985","2011-07-26 19:33:48 +0100","UNKNOWN","Insufficient information to permit judgment concerning incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Itoh-1985","2012-06-19 10:24:33 +0100","NO","The outcome data were not fully addressed (no SDs for the Keio University Psychiatric Rating Scale). Adverse effects reporting was incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Itoh-1985","2011-07-26 19:33:48 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kariya-1983","2011-07-09 12:48:15 +0100","UNKNOWN","“Patients were assigned at random to either the timiperone or the haloperidol group”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kariya-1983","2011-07-09 12:48:15 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kariya-1983","2012-05-29 09:19:50 +0100","YES","“Double-blind”. “Both drugs were confirmed as being indistinguishable from each other, having an identical appearance, and identical colour shades and weights, by two controllers.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kariya-1983","2012-05-29 09:19:47 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kariya-1983","2015-01-08 16:04:22 +0000","YES","With missing data of 6 of the 212 randomised participants (2.8%), the overall attrition was rather low. The analyses were based on completers-only data, but due to the small drop-out rate, the risk of bias might be considered as being low.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kariya-1983","2012-06-19 10:24:48 +0100","NO","The numbers of participants randomised to each treatment group (haloperidol or timiperone) were not indicated. These data were only available for the completers of the trial. The outcome data were not fully addressed (no raw data for the Keio University Psychiatric Symptoms Rating Scale). No information regarding the number of participants that received a medication with antiparkinson drugs.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kariya-1983","2011-07-09 12:48:15 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kinon-1993","2012-05-29 09:19:56 +0100","UNKNOWN","“Randomly assigned”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kinon-1993","2011-08-08 21:55:19 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kinon-1993","2012-05-29 09:19:58 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kinon-1993","2012-05-29 09:20:01 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kinon-1993","2015-01-08 16:04:34 +0000","UNKNOWN","13 of 58 participants (22.4%) left the investigated double-blind phase of the trail early. The numbers of participants randomised to each treatment group (haloperidol or fluphenazine) were not indicated. The trial authors provided completers-only analyses, but in terms of the outcome “response status” the responders who left the trial prematurely were included in the results but not the drop-outs who were classified as non-responder. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kinon-1993","2011-08-08 21:55:20 +0100","UNKNOWN","Adverse effects reporting was incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kinon-1993","2011-12-20 13:20:46 +0000","NO","Only non-responders to an open 4-week fluphenazine 20 mg/day trial were included in the randomised phase of the study. This can be considered as potential source of bias. Only 58 of the 78 non-responders to the open fluphenazine trial entered the double-blind phase of the study.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kodama-1984","2011-11-28 14:36:58 +0000","UNKNOWN","“Patients were assigned at random to either the bromperidol or the haloperidol group”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kodama-1984","2011-11-21 13:31:26 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kodama-1984","2012-05-29 09:20:14 +0100","YES","“Double-blind”. “Both drugs were confirmed as being indistinguishable from each other, having an identical appearance, and identical colour shades and weights.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kodama-1984","2012-05-29 09:20:19 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kodama-1984","2012-06-05 09:17:25 +0100","YES","The number of participants randomised to each treatment group were 36 for Bromperidol and 32 for Haloperidol. 2 cases left the study after 2 days and 3 days from the beginning. Therefore, the data of 2 cases from the 68 randomised participants were unable to evaluate the effect and were not subjected to statistic analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kodama-1984","2012-06-19 10:25:12 +0100","NO","The outcome data were not fully addressed (no raw data for the BPRS)","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kodama-1984","2011-11-21 13:31:26 +0000","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kurihara-1983","2011-11-28 14:24:36 +0000","UNKNOWN","“Patients were assigned at random to the clocapramine, perphenazine and the haloperidol group”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kurihara-1983","2011-11-21 14:30:41 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kurihara-1983","2012-05-29 09:20:26 +0100","YES","“Double-blind”. “Both drugs were confirmed as being indistinguishable from each other, having an identical appearance, and identical colour shades and weights.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kurihara-1983","2012-05-29 09:20:24 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kurihara-1983","2012-01-29 08:32:44 +0000","YES","There were 32 patients who left the study early, but all data of the 286 randomised participants were used.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kurihara-1983","2012-06-19 10:25:25 +0100","NO","The number of participants randomised to each treatment group (haloperidol, clocapramine, or perphenazine) was not indicated. These data were only available for the completers of the trial. The outcome data were not fully addressed (no raw data for the Global improvement rating and the Keio University Psychiatric Symptoms Rating Scale). No information regarding the number of participants that received a medication with antiparkinson drugs.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Kurihara-1983","2011-11-21 14:30:41 +0000","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Luckey-1967","2012-05-29 09:20:32 +0100","UNKNOWN","“Random assignment”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Luckey-1967","2011-06-28 13:49:03 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Luckey-1967","2012-01-29 08:33:11 +0000","YES","“Double-blind”. “Haloperidol, trifluoperazine and placebo were prepared in identical capsules.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Luckey-1967","2011-06-28 13:49:03 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Luckey-1967","2015-01-08 16:05:13 +0000","NO","The overall-attrition was very high (17 of 26 participants; 65.4%). 8 of 13 participants left the trial early in the haloperidol-group (61.5%) and 9 of 13 participants in the trifluoperazine-group (69.2%). A completers-only analysis was used regarding the main outcome (global clinical judgment) and for the other outcomes the analysis was based on the results of one month active drug treatment. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Luckey-1967","2012-06-19 10:25:41 +0100","NO","Outcome data reporting was incomplete (no SDs for the BPRS; no raw data for the MMPI). Only the most prevalent adverse effects were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Luckey-1967","2011-06-28 13:49:03 +0100","NO","“Due to the large number of dropouts and the overall limitations imposed by the small population, none of the results were statistically significant.” “The dosage ratio of 2mg trifluoperazine to 1mg haloperidol was probably too low and may have put haloperidol at a disadvantage.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Malfroid-1978","2012-05-29 09:20:39 +0100","UNKNOWN","“Randomly assigned”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Malfroid-1978","2011-06-30 08:00:38 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Malfroid-1978","2012-05-29 09:20:42 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Malfroid-1978","2012-05-29 09:20:45 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Malfroid-1978","2011-06-30 08:00:38 +0100","UNKNOWN","The study did not address this outcome; insufficient information to permit judgment concerning incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Malfroid-1978","2012-06-19 10:25:54 +0100","NO","Outcome data were not fully addressed (no raw data for the psychiatric rating scale). Adverse effects reporting was incomplete. BPRS is mentioned in the abstract but no results were presented.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Malfroid-1978","2011-08-26 19:49:46 +0100","NO","“Before the trial period, all patients were on a maintenance neuroleptic treatment.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mattke-1976","2011-08-10 08:06:32 +0100","UNKNOWN","No randomisation mentioned in the publication, but the trial was described as “double-blind.” Thus it was implied that the study was randomised.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mattke-1976","2011-08-10 08:06:32 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mattke-1976","2012-05-29 09:20:50 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mattke-1976","2012-05-29 09:20:53 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mattke-1976","2011-08-10 08:06:32 +0100","UNKNOWN","The study did not address this outcome; insufficient information to permit judgment concerning incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mattke-1976","2011-08-10 08:06:33 +0100","UNKNOWN","Insufficient information to permit judgement.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mattke-1976","2011-08-10 08:06:33 +0100","UNKNOWN","The aim of this research project was to study pupillomotorics under the influence of neuroleptic medication. Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mauri-1994","2012-05-29 09:21:10 +0100","UNKNOWN","“Randomised”. Ratio bromperidol to haloperidol 1:1. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mauri-1994","2011-08-11 14:16:09 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mauri-1994","2012-05-29 09:21:13 +0100","YES","“Double-blind”.  Identical appearing capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mauri-1994","2012-05-29 09:21:15 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mauri-1994","2015-01-08 16:05:49 +0000","NO","4 of 20 participants (20%) left the trial early in the haloperidol-group and 7 of 20 participants (35%) discontinued prematurely in the bromperidol-group. The overall-attrition was rather high (11 of 40 participants; 27.5%). The trial authors used a split-plot ANOVA for the data-analyses.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mauri-1994","2012-06-19 10:27:20 +0100","UNKNOWN","The outcome data were not fully reported (no SDs for the CGI).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mauri-1994","2011-08-11 14:16:10 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mori-1989","2011-11-28 15:34:36 +0000","UNKNOWN","“Patients were assigned at random to either the YM-09151 or the Haloperidol group”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mori-1989","2011-11-28 15:34:36 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mori-1989","2012-05-29 09:21:26 +0100","YES","“Double-blind”. “Both drugs were confirmed as being indistinguishable from each other, having an identical appearance, and identical colour shades and weights, by two controllers.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mori-1989","2012-05-29 09:21:30 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mori-1989","2012-06-05 09:18:52 +0100","YES","The number of participants randomised to each treatment group were 81 for YM-09151 and 86 for Haloperidol. 27 participants left the study early, but the uncompleted data were also subjected to statistic analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mori-1989","2012-09-19 12:20:46 +0100","NO","The outcome data were not fully addressed (no raw data for the BPRS and SANS).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Mori-1989","2011-11-28 15:34:37 +0000","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nedopil-1981","2011-12-20 14:05:40 +0000","UNKNOWN","Randomised. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nedopil-1981","2011-08-16 15:06:04 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nedopil-1981","2011-08-16 15:07:04 +0100","NO","No blinding of participants or personnel mentioned in the publication.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nedopil-1981","2011-12-20 15:21:19 +0000","YES","“Raters of this study were blind to the actual dose of benperidol given.” No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nedopil-1981","2011-08-16 15:06:05 +0100","UNKNOWN","The study did not address this outcome; insufficient information to permit judgment concerning incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nedopil-1981","2012-06-14 09:51:32 +0100","NO","The outcome data were not fully addressed (no SDs were available for all data of the AMDP-ratings). Adverse effects were not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nedopil-1981","2011-08-16 15:06:27 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nishikawa-1984","2012-05-29 09:21:39 +0100","UNKNOWN","“Randomly assigned”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nishikawa-1984","2011-08-12 10:04:31 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nishikawa-1984","2012-05-29 09:21:41 +0100","YES","“Double-blind”. “Drug appearance, with respect to powder color, taste and volume, was made identical by adding a gastric aid, SMP.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nishikawa-1984","2012-05-29 09:21:46 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nishikawa-1984","2011-08-12 10:04:31 +0100","UNKNOWN","Because the main outcome of this trial was the evaluation of the relapse-rates in both medication groups (haloperidol and propericiazine) it is not possible to judge the risk of bias in terms of the addressing of incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nishikawa-1984","2012-06-04 18:57:04 +0100","UNKNOWN","The main outcome of the trial was not of interest for this systematic review. The adverse effects were not fully addressed.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nishikawa-1984","2011-08-12 10:04:36 +0100","NO","“All patients….received ordinary, brief psychotherapy every 2 weeks by a psychiatrist”. Baseline imbalance concerning the sex distribution between the haloperidol-groups and the propericiazine-groups.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nishimatu-1975","2011-11-28 15:16:11 +0000","UNKNOWN","“Patients were assigned at random to either the methylperidol or the haloperidol group”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nishimatu-1975","2011-11-28 15:15:44 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nishimatu-1975","2012-05-29 09:21:57 +0100","YES","“Double-blind”. “Both drugs were confirmed as being indistinguishable from each other, having an identical appearance, and identical colour shades and weights.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nishimatu-1975","2012-05-29 09:21:59 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nishimatu-1975","2011-11-28 15:15:57 +0000","YES","With missing data of 10 of the 82 randomised participants. The analyses were based on completers-only data, the risk of bias might be considered as being low.                           ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nishimatu-1975","2012-06-19 10:27:52 +0100","NO","The number of participants randomised to each treatment group (haloperidol or methylperidol) was not indicated. These data were only available for the completers of the trial. The outcome data were not fully addressed (no raw data for the Global improvement rating and the Keio University Psychiatric Symptoms Rating Scale). No information regarding the number of participants that received a medication with antiparkinson drugs.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Nishimatu-1975","2011-11-28 15:15:44 +0000","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-O_x00b4_Brien-1974","2011-07-07 08:43:27 +0100","UNKNOWN","No randomisation mentioned in the publication, but the trial was described as “double-blind.” Thus it was implied that the study was randomised.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-O_x00b4_Brien-1974","2011-06-28 14:10:48 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-O_x00b4_Brien-1974","2011-06-28 14:10:51 +0100","YES","“Double-blind fashion”. “identically appearing pink capsules.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-O_x00b4_Brien-1974","2011-06-28 14:10:48 +0100","UNKNOWN","“Double-blind fashion”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-O_x00b4_Brien-1974","2011-06-28 14:10:49 +0100","UNKNOWN","The attrition was moderate (3 of 15 participants (20%) in both study arms). Completers-only analyses were used in the study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-O_x00b4_Brien-1974","2012-06-19 10:28:14 +0100","NO","The outcome data were not fully addressed (no raw data for the BPRS, GH, GP, and HAM-D). Adverse effects were not fully addressed.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-O_x00b4_Brien-1974","2011-06-28 14:11:09 +0100","NO","“Milieu therapy, group therapy, and individual sessions with a psychiatrist” were allowed during the trial.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Okuda-1979","2012-05-29 09:22:22 +0100","UNKNOWN","Two participants built one pair and two medications were assigned at random to each pair. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Okuda-1979","2011-11-28 14:57:12 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Okuda-1979","2012-05-29 09:22:07 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Okuda-1979","2012-05-29 09:22:09 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Okuda-1979","2015-01-08 16:06:29 +0000","YES","The number of participants randomised to each treatment group was 37 for Sulpiride and 37 for Haloperidol. 12 participants left the study early, but the uncompleted data were also subjected to statistical analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Okuda-1979","2012-06-19 10:28:01 +0100","NO","The outcome data were not fully addressed (no raw data for the Keio University Psychiatric Symptoms Rating Scale).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Okuda-1979","2011-11-28 14:57:12 +0000","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Paprocki-1976","2012-05-29 09:22:46 +0100","UNKNOWN","“Administered at random”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Paprocki-1976","2011-07-20 15:15:31 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Paprocki-1976","2012-05-29 09:22:51 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Paprocki-1976","2012-05-29 09:22:54 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Paprocki-1976","2011-07-20 15:15:31 +0100","UNKNOWN","The study did not address this outcome; insufficient information to permit judgment concerning incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Paprocki-1976","2012-06-19 10:28:30 +0100","NO","Outcome data were not fully addressed (no raw data for the BPRS, CGI, NOSIE, and TESS). Adverse effects reporting was incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Paprocki-1976","2011-07-20 15:15:32 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Parent-1983","2011-07-01 11:13:00 +0100","UNKNOWN","Allocation through “randomisation”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Parent-1983","2011-07-01 11:13:00 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Parent-1983","2011-07-01 11:13:02 +0100","NO","“The study was open”.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Parent-1983","2011-07-01 11:13:04 +0100","NO","“The study was open”.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Parent-1983","2015-01-08 16:07:09 +0000","YES","The overall-attrition was rather low (2 of 21 participants, 9.5%). One participant in each treatment group left the trial early. Although it was not explicitly mentioned which type of analysis was used for the BPRS, it was not  considered as bias because of the low drop-out rate in each treatment group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Parent-1983","2012-06-04 18:39:39 +0100","UNKNOWN","Raw data of the Nurses` Clinical Impression scale were not reported; but this was not relevant for the outcomes of interest in this systematic review. Adverse effects reporting was incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Parent-1983","2011-07-01 11:14:40 +0100","NO","A high dosage of flupenthixol was compared to conventional dosages of haloperidol. This can be considered as potential bias. Administration of benzodiazepines in 9 participants of each treatment group. “1 patient in each group was treated with an additional neuroleptic.” “There was some imbalance between the treatment groups with regard to previous acute episodes.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-P_x00f6_ldinger-1977","2012-05-29 09:23:40 +0100","UNKNOWN","“Assigned at random”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-P_x00f6_ldinger-1977","2011-06-30 12:49:29 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-P_x00f6_ldinger-1977","2012-05-29 09:23:42 +0100","YES","“Double-blind”. “identical-looking tablets”. Tablets “were supplied in coded packages for patients´use”.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-P_x00f6_ldinger-1977","2012-05-29 09:23:45 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-P_x00f6_ldinger-1977","2011-06-30 12:49:35 +0100","YES","“The treatment scheduled for 28 days was completed by all patients.”","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-P_x00f6_ldinger-1977","2012-01-29 09:09:52 +0000","NO","No explicit description of the outcomes in the methods section of the publication. The outcome data were not fully addressed (no SDs available).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-P_x00f6_ldinger-1977","2011-07-25 08:31:38 +0100","NO","“All but 3 patients had been on other neuroleptics before the study; the effect of the previous treatment was scored moderate in 19 cases, insufficient in 17 cases, and poor in 1 case.” Comment: The review authors assumed that many of the participants included in this trial were non-responders to previous medications.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Pool-1976","2012-05-29 09:23:07 +0100","UNKNOWN","“Random assignment”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Pool-1976","2012-05-29 09:23:10 +0100","UNKNOWN","“Prearranged randomised procedure”. No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Pool-1976","2012-05-29 09:23:12 +0100","YES","“Double-blind”. “Medication was prepared in capsules of identical appearance and was supplied in individual bottles to each of the study subjects. These bottles were labeled with each subject’s study number, thus assuring that evaluating personnel would be unable to determine the drug group to which a given patient belonged, or even that any given patients were receiving the same drug.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Pool-1976","2012-05-29 09:23:16 +0100","YES","“Double-blind”. “Medication was prepared in capsules of identical appearance and was supplied in individual bottles to each of the study subjects. These bottles were labeled with each subject’s study number, thus assuring that evaluating personnel would be unable to determine the drug group to which a given patient belonged, or even that any given patients were receiving the same drug.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Pool-1976","2011-08-26 10:35:07 +0100","UNKNOWN","No drop-out rates were provided; insufficient information to permit judgment concerning incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Pool-1976","2012-09-19 12:21:45 +0100","NO","The outcome data were not fully addressed (no raw data for the BPRS, CGI, and NOSIE). Only the most prevalent adverse effects were reported. No information regarding the number of participants that received a medication with antiparkinson drugs.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Pool-1976","2011-07-26 15:36:30 +0100","NO","“Patients who failed to complete four weeks of daily medication because of voluntary withdrawal or for administrative reasons were not included in the analyses of efficacy ratings and were replaced by new patients.” Extreme imbalance regarding sex distribution between the haloperidol-group and loxapine-group.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Rama-Rao-1981","2012-05-29 09:23:50 +0100","UNKNOWN","“Randomly allocated”. “Patients were stratified so that age and baseline morbidity were constant in each group.” No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Rama-Rao-1981","2011-07-25 08:28:36 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Rama-Rao-1981","2012-05-29 09:23:53 +0100","YES","“Double-blind”. “A double-dummy technique was used.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Rama-Rao-1981","2012-05-29 09:23:55 +0100","UNKNOWN","“Double-blind”. “A double-dummy technique was used.” No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Rama-Rao-1981","2011-07-25 08:28:43 +0100","YES","“Three patients were not sufficiently accessible to be rated on the BPRS.” According to the tables in the publication, no participants left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Rama-Rao-1981","2012-06-04 18:40:58 +0100","UNKNOWN","The outcomes have been reported in the pre-specified way with the exception of the adverse effects that were not fully addressed. The study report fails to include results for the primary outcome of the review.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Rama-Rao-1981","2011-07-26 15:43:51 +0100","NO","“The patients who received active sulpiride were in fact at a disadvantage compared to the haloperidol group who continued to receive the drug in therapeutically optimum dosage.” The trial authors “feel that a flexible dosage regime could have been even more favourable for sulpiride treatment.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Rubin-1971","2012-05-29 09:24:01 +0100","UNKNOWN","“Randomly assigned”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Rubin-1971","2011-06-28 12:49:26 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Rubin-1971","2012-01-29 09:14:43 +0000","YES","“Double-blind”; “Drug was administered in identically-appearing capsules”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Rubin-1971","2011-06-28 12:49:26 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Rubin-1971","2011-06-28 12:49:26 +0100","UNKNOWN","The study did not address this outcome; insufficient information to permit judgment concerning incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Rubin-1971","2012-09-19 11:05:09 +0100","NO","The outcome data were not fully addressed (no raw data for the Mental Status Schedule). Adverse effects reporting was incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Rubin-1971","2015-01-06 16:15:46 +0000","NO","“One patient receiving trifluoperazine began group therapy about the same time he started on drug. Two others receiving trifluoperazine began group therapy while on drug but not until the drug effect had been established.” Duration of the trial ranged from 5 to 79 days. “Because of our small sample size, the difference between the two drugs was significant only at the 0,10 level.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Selman-1976","2012-05-29 09:24:07 +0100","UNKNOWN","“Randomly assigned”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Selman-1976","2011-08-26 16:24:06 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Selman-1976","2012-01-29 09:15:38 +0000","YES","“A double-blind process was used in which neither patient nor investigator knew what medication was received until the study was completed.” “All medication was administered in identically appearing capsules.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Selman-1976","2011-08-26 16:24:13 +0100","YES","“A double-blind process was used in which neither patient nor investigator knew what medication was received until the study was completed.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Selman-1976","2015-01-08 16:08:15 +0000","NO","The overall-attrition was high: 19 of 58 participants (32.8%) left the trial early. The trial authors indicated that 11 of 29 participants (37.9%) in the haloperidol-group and 8 of 29 participants (27.6%) in the loxapine-group discontinued the drug treatment prematurely. Modified completers analyses were used (any patients who received study medication for less than 4 weeks were excluded).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Selman-1976","2012-09-19 11:05:23 +0100","NO","The outcome data were not fully addressed (no SDs for the BPRS; no raw data for the NOSIE). No information regarding the number of participants that received a medication with antiparkinson drugs.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Selman-1976","2011-08-26 16:24:18 +0100","YES","The study appears to be free of other sources of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Serafetinides-1972","2012-05-29 09:24:13 +0100","UNKNOWN","“Randomly assigned”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Serafetinides-1972","2011-07-08 08:32:31 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Serafetinides-1972","2012-05-29 09:24:15 +0100","YES","“Double-blind”. “All medications were prepared in identically appearing capsules.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Serafetinides-1972","2012-05-29 09:24:17 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Serafetinides-1972","2011-07-08 08:32:40 +0100","YES","No missing outcome data. In the two investigated (haloperidol and clopenthixol) study arms no participant left the trial early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Serafetinides-1972","2012-09-19 11:05:44 +0100","NO","The outcome data were not fully addressed (no raw data for the NOSIE and OBRS; no SDs for the BPRS).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Serafetinides-1972","2011-07-08 08:32:37 +0100","YES","The study appears to be free of other sources of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Shalev-1993","2011-08-02 15:05:54 +0100","UNKNOWN","“randomly assigned”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Shalev-1993","2011-08-02 15:05:54 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Shalev-1993","2011-08-02 15:05:56 +0100","YES","“The treating psychiatrists were blind to the sequence in which the 3 drugs were to be given to the patient.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Shalev-1993","2011-12-21 13:41:54 +0000","UNKNOWN","No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Shalev-1993","2011-08-03 08:06:06 +0100","UNKNOWN","There were only data regarding the whole study sample (treated with haloperidol, perphenazine and levomepromazine) available: 15 of 75 participants (20%) left the trial early before the termination of the investigated first cross-over-phase. Thus the overall attrition can be considered as being moderate. Completers-only analyses were used.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Shalev-1993","2011-08-03 08:10:35 +0100","NO","The outcome data were not fully addressed (in terms of the BPRS no raw data were provided for each study group separately). The adverse effects were not reported. Data regarding the number of participants receiving rescue medication with antiparkinson drugs were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Shalev-1993","2012-01-29 09:17:29 +0000","NO","Cross-over study design. “The primary goal of this study was the evaluation of drug responsiveness in the natural clinical environment and not a comparison between drugs.” Trial duration was depended on the degree of response.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Silverstone-1984","2012-05-29 09:24:27 +0100","UNKNOWN","“Randomly allocated”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Silverstone-1984","2011-06-29 09:10:53 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Silverstone-1984","2012-01-29 09:38:07 +0000","YES","“Double-blind”. “pimozide or haloperidol in matching capsules”.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Silverstone-1984","2011-06-29 09:10:53 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Silverstone-1984","2015-01-08 16:08:47 +0000","UNKNOWN","There were 3 drop-outs in the haloperidol-group (25%), and 1 participant left the trial early in the pimozide-group (10%). The overall-attrition was 18.2% (4 of 22 participants). Altogether the attrition was moderate. The trial authors provided the results of the completers-only analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Silverstone-1984","2012-09-19 11:05:58 +0100","NO","The outcome data were not fully addressed (no SDs for the MRS). No usable data were provided in terms of premature discontinuation of the trial due to adverse effects.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Silverstone-1984","2015-01-08 16:08:52 +0000","NO","Additional antipsychotic pharmacological treatment with i.m. chlorpromazine was allowed (used in 3 participants).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Spina-1992","2011-07-23 16:43:20 +0100","UNKNOWN","“Patients were randomly and blindly assigned.” No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Spina-1992","2011-07-23 16:43:20 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Spina-1992","2012-05-29 09:24:35 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Spina-1992","2011-07-23 16:43:20 +0100","UNKNOWN","“double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Spina-1992","2015-01-08 16:09:07 +0000","UNKNOWN","4 of 21 participants (19.0%) left the trial early in the haloperidol-group and 5 of 21 participants (23.8%) in the bromperidol-group. The overall-attrition was moderate (9 of 42 participants; 21.4%).  A completers-only analysis was used.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Spina-1992","2012-06-04 18:46:02 +0100","UNKNOWN","The outcomes have been reported in the pre-specified way with the exception of the SDs in terms of the CGI Severity of Illness score and the results of the Simpson and Angus Scale.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Spina-1992","2011-07-23 16:43:23 +0100","YES","The study appears to be free of other sources of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Stewart-1969","2011-08-13 12:52:48 +0100","UNKNOWN","The trial authors did not explicitly mention a randomisation, but described a double-blinding. Thus we implied that the study was randomised.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Stewart-1969","2011-08-13 12:52:48 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Stewart-1969","2012-05-29 09:24:43 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Stewart-1969","2012-05-29 09:24:46 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Stewart-1969","2011-08-13 12:53:00 +0100","YES","“All 50 patients completed all phases of the evaluation.” “Absence of any attrition in the study population.”","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Stewart-1969","2012-06-05 09:24:24 +0100","NO","The duration of the trial was not indicated. No information regarding the number of participants that received a medication with antiparkinson drugs. Some rating scales (BPRS, IMPS, and Rockland-Pollin scales) were mentioned in the abstract of the publication but no results of these scales were provided.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Stewart-1969","2011-08-13 12:52:57 +0100","NO","Cross-over study design. Because of epileptic convulsions the drug administration was temporally discontinued in one participant receiving haloperidol.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Teja-1975","2011-07-30 18:54:36 +0100","UNKNOWN","“randomised”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Teja-1975","2011-07-30 18:54:36 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Teja-1975","2011-07-30 18:54:36 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Teja-1975","2011-07-30 18:54:36 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Teja-1975","2011-07-30 18:54:36 +0100","UNKNOWN","The study did not address this outcome; insufficient information to permit judgment concerning incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Teja-1975","2012-09-19 12:23:40 +0100","NO","The outcome data were not fully addressed (no raw data for the BPRS, Mental status and global clinical change-assessment, and Burdock´s Ward Behavior Rating Scale). Adverse effects reporting was incomplete. No information regarding the number of participants that received a medication with antiparkinson drugs.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Teja-1975","2012-01-18 10:56:04 +0000","NO","The data were only “analyzed by comparing the placebo group with the [combined] active tranquilizer groups.” Study sample: “resistant chronic schizophrenic population”. Additionally to the randomised study medications, the administration of “parenteral or oral chlorpromazine in dosages of 25 to 50 mg, if the patient became an acute management problem during any phase of the trial”, was allowed.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Tobin-1980","2011-07-24 11:41:51 +0100","UNKNOWN","No randomisation mentioned in the publication, but the trial was described as “double-blind.” Thus it was implied that the study was randomised.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Tobin-1980","2011-07-24 11:41:51 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Tobin-1980","2012-05-29 09:25:02 +0100","YES","“Double-blind”. “The test medications were supplied in identical capsules.” “Only the dispenser knew the actual drug assignment. And the primary investigator remained blind until all the analyses were completed.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Tobin-1980","2012-05-29 09:24:59 +0100","YES","“Double-blind”. “Only the dispenser knew the actual drug assignment. And the primary investigator remained blind until all the analyses were completed.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Tobin-1980","2011-07-24 11:41:56 +0100","NO","“Thirty-six of the 50 patients completed the study.” Thus the overall attrition can be considered as being high: 28% (14 of 50 participants). 6 of 25 participants (24%) in the haloperidol group left the trial early and 8 of 25 participants (32%) in the bromperidol-group. Modified completers-only analyses were used.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Tobin-1980","2012-09-19 12:23:49 +0100","NO","Outcome data were not fully reported (no SDs for the BPRS; no usable results concerning the Katz Adjustment Scales). Data regarding the number of participants receiving rescue medication were missing.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Tobin-1980","2011-07-24 11:41:58 +0100","NO","“44 patients had a history of psychiatric illness not necessarily diagnosed as schizophrenia.” “In one patient in each group, treatment was discontinued because of akathisia and was resumed when the akathisia abated.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Tuason-1986","2012-05-29 09:25:09 +0100","UNKNOWN","“Randomly assigned”. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Tuason-1986","2011-08-10 09:31:53 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Tuason-1986","2012-05-29 09:25:17 +0100","NO","“Personnel administering the study medications were not blinded.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Tuason-1986","2011-12-22 08:09:24 +0000","YES","“Those responsible for evaluating medication effects, however, remained blinded throughout.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Tuason-1986","2011-08-10 09:32:09 +0100","NO","Therefore the overall attrition can be considered as being high. The trial authors provided both, intention-to-treat analyses and completers-only analyses.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Tuason-1986","2012-06-04 18:49:30 +0100","UNKNOWN","The pre-specified outcomes that are of interest in the review have been reported in the pre-specified way with the exception of the data regarding the number of participants receiving rescue medication in each treatment group.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Tuason-1986","2011-08-10 09:40:31 +0100","NO","“The haloperidol patients tended to be older by about 6 years (p=.056) and had a longer (p=.037) duration of schizophrenic illness.” The trial stopped prematurely in case of earlier discharge.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Ulmar-1990","2011-08-17 14:31:49 +0100","UNKNOWN","No randomisation mentioned in the publication, but the trial was described as “double-blind.” Thus it was implied that the study was randomised.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Ulmar-1990","2011-08-17 14:31:49 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Ulmar-1990","2012-05-29 09:25:23 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Ulmar-1990","2012-05-29 09:25:25 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Ulmar-1990","2011-08-17 14:33:02 +0100","UNKNOWN","The study did not address this outcome; insufficient information to permit judgment concerning incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Ulmar-1990","2012-09-19 11:06:41 +0100","NO","Outcome data reporting was incomplete (no raw data for the BPRS, AMDP, and DOTES). The numbers of participants randomised to each treatment group (haloperidol or trifluperidol) were not indicated. Adverse effects were not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Ulmar-1990","2012-01-29 09:40:39 +0000","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Versiani-1978","2012-05-29 09:25:38 +0100","UNKNOWN","“Randomised according to the consecutive admission criterion.” No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Versiani-1978","2011-07-30 15:03:01 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Versiani-1978","2012-05-29 09:25:31 +0100","YES","“Double-blind”. “capsules of identical appearance.”","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Versiani-1978","2012-05-29 09:25:33 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Versiani-1978","2012-01-30 11:20:29 +0000","YES","“There was a drop-out in the loxapine group” and no participant left the trial early in the haloperidol-group. Altogether the attrition was rather low and the risk of bias might be considered as being low.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Versiani-1978","2012-09-19 11:06:59 +0100","NO","The outcome data were not fully addressed (no SDs for the BPRS; no raw data for the NOSIE total score).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-Versiani-1978","2011-07-30 15:03:08 +0100","NO","At baseline “a good response to neuroleptic treatment was predicted in 20 cases in the loxapine group and in 11 cases in the haloperidol group.” “The presence of more cases of bad prognosis in the haloperidol-group than in the loxapine-group, as assessed by the raters at baseline, might diminish the value of conclusions drawn from the comparable efficacy of the two drugs, in all rated parameters.” “The sample was not evenly distributed along the range allowed by protocol.”","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-White-1981","2011-08-16 09:04:34 +0100","UNKNOWN","No randomisation mentioned in the publication, but the trial was described as “double-blind.” Thus it was implied that the study was randomised.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-White-1981","2011-08-16 09:04:34 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-White-1981","2012-05-29 09:25:44 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","(performance bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-White-1981","2012-05-29 09:25:47 +0100","UNKNOWN","“Double-blind”. No further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","(detection bias)"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-White-1981","2011-08-16 09:04:35 +0100","UNKNOWN","The study did not address this outcome; insufficient information to permit judgment concerning incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-White-1981","2012-09-19 11:07:08 +0100","NO","The outcome data were not fully addressed (no raw data for the DRI). Only the “commonest side effects” were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders [v2.2-For publication].rm5","STD-White-1981","2011-08-16 09:04:35 +0100","UNKNOWN","Insufficient information to assess whether an important risk of bias exists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol versus chlorpromazine for schizophrenia [v9.0-For publication].rm5","STD-Bailine-1981","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Haloperidol versus chlorpromazine for schizophrenia [v9.0-For publication].rm5","STD-Bi-1994","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Haloperidol versus chlorpromazine for schizophrenia [v9.0-For publication].rm5","STD-Clark-1969","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Haloperidol versus chlorpromazine for schizophrenia [v9.0-For publication].rm5","STD-Gallant-1967","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Haloperidol versus chlorpromazine for schizophrenia [v9.0-For publication].rm5","STD-Lemp_x00e9_ri_x00e8_re-1962","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Haloperidol versus chlorpromazine for schizophrenia [v9.0-For publication].rm5","STD-Man-1973","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Haloperidol versus chlorpromazine for schizophrenia [v9.0-For publication].rm5","STD-McCreadie-1977","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Haloperidol versus chlorpromazine for schizophrenia [v9.0-For publication].rm5","STD-Nishizono-1994","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Haloperidol versus chlorpromazine for schizophrenia [v9.0-For publication].rm5","STD-Reschke-1974","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Haloperidol versus chlorpromazine for schizophrenia [v9.0-For publication].rm5","STD-Ritter-1972","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Haloperidol versus chlorpromazine for schizophrenia [v9.0-For publication].rm5","STD-Rompel-1978","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Haloperidol versus chlorpromazine for schizophrenia [v9.0-For publication].rm5","STD-Serafetinides-1972","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Haloperidol versus chlorpromazine for schizophrenia [v9.0-For publication].rm5","STD-Shopsin-1969","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Haloperidol versus chlorpromazine for schizophrenia [v9.0-For publication].rm5","STD-Teja-1975","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Haloperidol plus promethazine for psychosis-induced aggression [v8.0-For publication].rm5","STD-TREC_x002d_Rio_x002d_I","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Haloperidol plus promethazine for psychosis-induced aggression [v8.0-For publication].rm5","STD-TREC_x002d_Rio_x002d_II","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Haloperidol plus promethazine for psychosis-induced aggression [v8.0-For publication].rm5","STD-TREC_x002d_Vellore_x002d_I","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Haloperidol plus promethazine for psychosis-induced aggression [v8.0-For publication].rm5","STD-TREC_x002d_Vellore_x002d_II","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bailine-1987","2011-09-08 10:13:08 +0100","YES","""random number sequence"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bailine-1987","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bailine-1987","2011-09-08 10:16:08 +0100","UNKNOWN","Not stated.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bailine-1987","2011-09-08 10:16:14 +0100","UNKNOWN","BPRS was rater blind. However, it is not clear whether other outcomes were blind.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bailine-1987","2011-09-08 10:16:08 +0100","UNKNOWN","It is reported that no one discontinued due to adverse effects, however it does not state if there were discontinuations due to any other reason.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bailine-1987","2011-09-08 10:13:08 +0100","NO","Only the significant findings/factors are reported for a number of outcomes.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bailine-1987","2011-09-08 10:13:08 +0100","NO","Small short study.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Battaglia-1997","2011-09-08 10:13:08 +0100","YES","""Computer-generated table of random numbers"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Battaglia-1997","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Battaglia-1997","2011-09-08 10:17:46 +0100","YES","""Double blind"" - participant blinding not specifically mentioned.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Battaglia-1997","2011-09-08 10:17:48 +0100","YES","""The ED [Emergency Department] psychiatrist who treated and ","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Battaglia-1997","2011-09-08 10:17:53 +0100","NO","""......two patients were excluded from the efficacy analysis. It was determined after enrolment that both received proscribed antipsychotic medication before entering the study.""","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Battaglia-1997","2012-08-09 21:10:29 +0100","NO","More details on level of significance for outcomes with P<0.05. Adverse effects for central nervous system reported only if present in ≧ 9%.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Battaglia-1997","2011-09-12 09:50:08 +0100","NO","Sponsored by drug company.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Battaglia-2002","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Battaglia-2002","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Battaglia-2002","2011-09-08 10:18:41 +0100","YES","""Both drugs and placebo were administered in identical, color-blinded, translucent standard syringes, and raters and study ","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Battaglia-2002","2011-09-08 10:18:43 +0100","YES","""Both drugs and placebo were administered in identical, color-blinded, translucent standard syringes, and ","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Battaglia-2002","2011-09-08 10:19:15 +0100","NO","The authors only account for 5 of the 26 people who did not complete the 24 hours study.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Battaglia-2002","2011-09-08 10:13:08 +0100","YES","No indication of selective reporting.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Battaglia-2002","2011-09-08 10:13:08 +0100","NO","Sponsored by the manufacturers of olanzapine.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Breier-2001","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Breier-2001","2011-09-08 10:13:08 +0100","YES","""Allocation concealed placebo-controlled trial."" Method of randomisation not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Breier-2001","2011-09-08 10:21:20 +0100","YES","""unblinded third-party personnel, who played no role in evaluating patients, were trained to handle and administer injections in identical, unmarked syringes."" ""Investigators, patients, clinical carers and raters were blinded.""","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Breier-2001","2011-09-08 10:21:14 +0100","YES","""Investigators, patients, clinical carers and raters were blinded.""","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Breier-2001","2011-09-08 10:21:12 +0100","NO","Reasons why all participants that left the study early were not reported.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Breier-2001","2011-09-08 10:13:08 +0100","UNKNOWN","It is not clear whether all side effects are reported.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Breier-2001","2011-09-08 10:13:08 +0100","NO","Trial sponsored by manufacturers of olanzapine IM.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bristol-Myers-2004f","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bristol-Myers-2004f","2011-09-08 10:13:08 +0100","YES","""Randomization was conducted via a centralized call-in system and was organized by study center using permuted block randomization"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bristol-Myers-2004f","2012-08-09 21:14:05 +0100","UNKNOWN","During the IM phase, haloperidol, aripiprazole and placebo were delivered in 1.3ml injections. However, in the oral phase a tablet was used for aripiprazole and a capsule was used for haloperidol and so it is possible that this presented a risk to blinding.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bristol-Myers-2004f","2011-09-08 10:23:00 +0100","UNKNOWN","Described as ""double blind"", however no further details are given.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bristol-Myers-2004f","2011-09-08 10:23:12 +0100","NO","Reasons why all participants that left the study early were not reported.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bristol-Myers-2004f","2012-08-09 21:14:11 +0100","NO","The author mentions that there is increased glucose levels in both aripiprazole and haloperidol group but does not provide data. The authors only report the side effects that occurred in ≥ 2% of people.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bristol-Myers-2004f","2011-09-08 10:13:08 +0100","NO","Sponsored by the manufacturers of aripiprazole.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bristol_x002d_Myers-2005b","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bristol_x002d_Myers-2005b","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bristol_x002d_Myers-2005b","2011-09-08 10:24:54 +0100","NO","No blinding was used during the preparation of injections and in most cases the person preparing the drug administered the injection.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bristol_x002d_Myers-2005b","2011-09-08 10:25:01 +0100","YES","Study investigators conducting the assessments were blinded to treatment.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bristol_x002d_Myers-2005b","2011-09-08 10:24:32 +0100","UNKNOWN","The reasons for leaving the study early were reported for those participants who did not complete the study. However, the number of participants completing different assessments at the same time point vary and reasons are not given.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bristol_x002d_Myers-2005b","2012-08-09 21:15:11 +0100","NO","The authors only report the adverse effects that occurred in ≥ 5% of people. The QTc abnormality for 9.75 mg is not reported.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Bristol_x002d_Myers-2005b","2011-09-08 10:13:08 +0100","NO","Sponsored by the manufacturers of aripiprazole.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Brook-1998a","2011-09-08 10:26:12 +0100","YES","""Computerized randomization assigned"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Brook-1998a","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Brook-1998a","2011-09-08 10:26:15 +0100","NO","Open trial.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Brook-1998a","2011-09-08 10:26:18 +0100","NO","Open trial.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Brook-1998a","2011-09-08 10:26:46 +0100","YES","No evidence of incomplete outcome data. A table is provided which presents a summary of discontinuations.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Brook-1998a","2011-10-18 09:28:10 +0100","NO","The number of participants reported as discontinuing due to adverse effects is reported inconsistently (see ","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Brook-1998a","2011-09-15 11:03:32 +0100","NO","Sponsored by drug company.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Currier-2004","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Currier-2004","2011-09-08 10:13:08 +0100","YES","""A telephone-based central service was used to randomly assign eligible patients to receive a single dose of oral treatment or IM injection."" (p.387)","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Currier-2004","2011-09-08 10:27:56 +0100","NO","Single blind study.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Currier-2004","2011-09-08 10:27:59 +0100","YES","""independent raters blinded to the treatment arm conducted efficacy assessments"". (p.387)","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Currier-2004","2011-09-08 10:27:40 +0100","UNKNOWN","A flow diagram is provided with the reasons for leaving the study early reported. However, the number of participants completing different assessments at the same time point vary and reasons are not given.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Currier-2004","2012-08-09 21:16:39 +0100","NO","The authors only report the side effects that occurred in ≥ 5% of people.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Currier-2004","2011-09-08 10:13:08 +0100","NO","Sponsored by drug company (Janssen Phamaceutica).","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Dorevitch-1999","2011-09-08 10:13:08 +0100","YES","""assigned by a table of random numbers."" (p.142).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Dorevitch-1999","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Dorevitch-1999","2011-09-08 10:28:54 +0100","UNKNOWN","Described as double blind, however further details regarding the blinding of participants and personnel are not reported.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Dorevitch-1999","2011-09-08 10:29:23 +0100","YES","""All ratings were completed by the same rater (N.K.), who was blind to the study medications."" (p.143).","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Dorevitch-1999","2011-09-08 10:29:24 +0100","YES","No evidence of incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Dorevitch-1999","2011-09-08 10:13:08 +0100","UNKNOWN","It is not clear whether all side effects are reported.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Dorevitch-1999","2011-09-08 10:28:54 +0100","UNKNOWN","Small short study.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Eli-2004","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Eli-2004","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Eli-2004","2011-09-08 10:30:09 +0100","UNKNOWN","Described as double blind, however no further details reported regarding the blinding of participants and personnel are not reported.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Eli-2004","2011-09-08 10:30:09 +0100","UNKNOWN","Described as double blind, however no further details reported regarding rater blinding.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Eli-2004","2011-09-08 10:30:11 +0100","NO","The authors assert that 45 participants out of a possible 49 participants complete the study. However, only 42 participants are included in the analysis for the CGI-I (at the end of the study), SAS, BAS, clinical laboratory evaluations, vital signs and ECG, without explanation for the missing participants.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Eli-2004","2011-09-08 10:13:08 +0100","NO","Only the CGI-S baseline score is reported.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Eli-2004","2011-09-08 10:13:08 +0100","NO","Sponsored by the manufacturers of olanzapine.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Fitzgerald-1969","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Fitzgerald-1969","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Fitzgerald-1969","2012-09-11 09:24:38 +0100","YES","""haloperidol and perphenazine were supplied in identically appearing 1-mL ampoules each containing 5 mg of drug."" (p.515).","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Fitzgerald-1969","2011-09-08 10:30:46 +0100","UNKNOWN","Described as double blind - no further details given regarding rater blinding.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Fitzgerald-1969","2011-10-18 13:08:06 +0100","UNKNOWN","It is reported that 3 participants were discontinued on the medication. According to ","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Fitzgerald-1969","2011-09-08 10:13:08 +0100","UNKNOWN","""Most adverse reactions disappeared with the use of control measures"" - author suspects that only the adverse effects severe enough for discontinuation are reported.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Fitzgerald-1969","2011-09-08 10:13:08 +0100","UNKNOWN","No clear interested funding.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Foster-1997","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Foster-1997","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Foster-1997","2011-09-08 10:35:49 +0100","UNKNOWN","Described as double blind, however it is not clear whether the study drugs appeared identical.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Foster-1997","2011-09-08 10:36:12 +0100","YES","""All raters were unaware of the specific medication received by the patient"". (p.176).","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Foster-1997","2011-09-08 10:36:15 +0100","YES","No evidence of incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Foster-1997","2011-09-08 10:35:49 +0100","NO","""patients continued to receive treatment with a benzodiazepine, if necessary, for the duration of their stay in the emergency department."" (p.176). The amount was not reported.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Foster-1997","2012-09-11 09:50:58 +0100","UNKNOWN","Small short study.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Fruensgaard-1977","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Fruensgaard-1977","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Fruensgaard-1977","2011-09-08 10:37:03 +0100","YES","""Both drugs were supplied in ampules of identical appearance."" (p.257).","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Fruensgaard-1977","2011-09-08 10:37:01 +0100","YES","Described as double blind, however no further details reported regarding rater blinding.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Fruensgaard-1977","2011-09-08 10:36:59 +0100","YES","No evidence of incomplete data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Fruensgaard-1977","2011-09-08 10:13:08 +0100","YES","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Fruensgaard-1977","2011-09-08 10:36:57 +0100","NO","Small short study.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Garza_x002d_Trevino-1989","2011-10-18 09:20:48 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Garza_x002d_Trevino-1989","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Garza_x002d_Trevino-1989","2011-09-08 10:37:43 +0100","NO","Open trial.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Garza_x002d_Trevino-1989","2011-09-08 10:37:47 +0100","NO","Open trial.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Garza_x002d_Trevino-1989","2011-09-08 10:37:54 +0100","YES","No evidence of incomplete data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Garza_x002d_Trevino-1989","2011-09-08 10:13:08 +0100","NO","There is no reporting regarding the incidence of adverse effects.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Garza_x002d_Trevino-1989","2011-09-08 10:13:08 +0100","UNKNOWN","The duration of the study is not reported.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Guo-2007","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Guo-2007","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Guo-2007","2011-09-08 10:38:48 +0100","NO","Open label.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Guo-2007","2011-09-08 10:38:51 +0100","NO","Open label.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Guo-2007","2011-09-08 10:38:53 +0100","YES","No incomplete outcome data","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Guo-2007","2011-09-08 10:13:08 +0100","NO","CGI and TESS were measured, but not reported.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Guo-2007","2011-09-08 10:13:08 +0100","UNKNOWN","None obvious.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Higashima-2004","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Higashima-2004","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Higashima-2004","2011-09-08 10:39:48 +0100","NO","Open trial.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Higashima-2004","2011-09-08 10:39:50 +0100","NO","Open trial.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Higashima-2004","2011-09-08 10:39:51 +0100","YES","No evidence of incomplete data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Higashima-2004","2011-09-08 10:13:08 +0100","NO","The discussion describes how the combination drug ""produced moderate sedation without any cardiovascular adverse effect"". However, there is no other reporting regarding the incidence adverse effects.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Higashima-2004","2011-09-08 10:13:08 +0100","NO","Small N study.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Huf-2007","2012-08-09 21:21:31 +0100","YES","A computer-generated randomised sequence was applied to a table of numbers.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Huf-2007","2011-09-08 10:40:41 +0100","YES","""Boxes were consecutively numbered, sealed, opaque, and identical appearance and weight; on the outside was a form with questions to be completed by the attending doctor while ""blind"" to the contents of the box."" (p.2).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Huf-2007","2011-09-08 10:40:44 +0100","NO","Open trial.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Huf-2007","2011-09-08 10:40:46 +0100","NO","Open trial.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Huf-2007","2011-09-08 10:40:48 +0100","YES","No evidence of incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Huf-2007","2011-09-20 09:55:34 +0100","YES","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Huf-2007","2011-09-08 10:13:08 +0100","UNKNOWN","The study was stopped early due to adverse effects, therefore it is possible that the available data may be biased.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Kewala-1984","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Kewala-1984","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Kewala-1984","2011-09-08 10:41:21 +0100","UNKNOWN","Described as double blind, however no further details reported regarding the blinding of participants and personnel.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Kewala-1984","2011-09-08 10:41:21 +0100","UNKNOWN","Described as double blind, however no further details reported regarding rater blinding.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Kewala-1984","2011-09-08 10:41:24 +0100","YES","No evidence of incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Kewala-1984","2011-09-08 10:13:08 +0100","UNKNOWN","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Kewala-1984","2011-09-08 10:41:22 +0100","NO","Recieved grant from Roerig, a division of Phizer Pharmaceuticals (thiothixene manufacturers), small short study.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Kinon-2001d","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Kinon-2001d","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Kinon-2001d","2011-09-08 10:42:13 +0100","UNKNOWN","Described as double blind, however no further details reported regarding the blinding of participants and personnel.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Kinon-2001d","2011-09-08 10:42:13 +0100","UNKNOWN","Described as double blind, however no further details reported regarding rater blinding.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Kinon-2001d","2011-09-08 10:42:36 +0100","YES","No evidence of incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Kinon-2001d","2011-09-08 10:42:13 +0100","NO","Treatment-emergent adverse effects were only reported if they occurred with a frequency ≧10% or P< .05 through the end of the study.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Kinon-2001d","2011-09-08 10:13:08 +0100","NO","Sponsored by the manufacturers of olanzapine.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Li-2006","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Li-2006","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Li-2006","2011-09-08 10:43:20 +0100","UNKNOWN","Single blind – however the author did not state who had been blinded.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Li-2006","2011-09-08 10:43:20 +0100","UNKNOWN","Single blind – however the author did not state who had been blinded.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Li-2006","2011-09-08 10:43:21 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Li-2006","2011-09-08 10:13:08 +0100","UNKNOWN","TESS and SAS was used for assessment of adverse events.  No continuous data was reported from either scales, but binary outcomes for adverse events were reported.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Li-2006","2011-09-08 10:13:08 +0100","UNKNOWN","None obvious.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Lim-2010","2011-11-23 11:05:17 +0000","YES","Participants were assigned ""according to a predefined randomization code that was balanced to ensure even distribution of patients in each treatment group."" (p.82).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Lim-2010","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Lim-2010","2011-09-08 10:44:15 +0100","NO","This was an open label study where one group received I.M. and the other group received an orodispersible tablet.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Lim-2010","2011-09-08 10:44:10 +0100","YES","The study was rater blinded.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Lim-2010","2011-09-08 10:44:04 +0100","YES","There is no evidence of incomplete outcome data. The authors give reasons for the participants who discontinued the study.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Lim-2010","2011-09-08 10:44:00 +0100","NO","The authors report that antiparkinsonian drugs could be given at the lowest effective dose, however the amount administered is not described in the results.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Lim-2010","2011-09-08 10:13:08 +0100","NO","Sponsored by drug company (Janssen Phamaceutica Korea).","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Man-1973","2011-09-08 10:13:08 +0100","NO","Not explicitly described as randomised.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Man-1973","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Man-1973","2011-09-08 10:45:07 +0100","UNKNOWN","Described as double blind, however it is unclear whether the syringes appeared identical given the varied doses.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Man-1973","2011-09-08 10:45:07 +0100","UNKNOWN","Described as double blind, however no further details reported regarding rater blinding.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Man-1973","2011-09-08 10:45:32 +0100","NO","The authors give reasons for the participants who discontinued the study. However, the results are only presented for the 27 participants who completed the study. Missing data have not been imputed using appropriate methods such as LOCF.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Man-1973","2011-09-08 10:13:08 +0100","YES","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Man-1973","2011-09-08 10:13:08 +0100","NO","Small short study.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Nobay-2004","2011-09-08 10:13:08 +0100","YES","""The administered drugs were prepared in the pharmacy using a computer generated randomisation code."" (p.745).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Nobay-2004","2011-09-08 10:13:08 +0100","YES","""The administered drugs were prepared in the pharmacy using a computer generated randomisation code."" (p.745).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Nobay-2004","2011-09-08 10:46:51 +0100","YES","""The research assistant [rater], the administering physician, and the patient were all blinded to the drug delivered."" (p.745).","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Nobay-2004","2011-09-08 10:46:53 +0100","YES","""The research assistant [rater], the administering physician, and the patient were all blinded to the drug delivered."" (p.745).","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Nobay-2004","2011-09-08 10:46:54 +0100","YES","No evidence of incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Nobay-2004","2011-09-08 10:46:48 +0100","YES","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Nobay-2004","2011-09-08 10:46:48 +0100","NO","The duration of the study was not reported, therefore it is difficult to establish how long participants were monitored for adverse effects.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Paprocki-1977","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Paprocki-1977","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Paprocki-1977","2011-09-08 10:47:40 +0100","YES","Described as double blind - ""supplied in 1ml ampules...of identical appearance, individually packaged and labelled with the code number assigned to each patient"". Capsules used in the oral phase were also of identical appearance.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Paprocki-1977","2011-09-08 10:47:36 +0100","UNKNOWN","Described as double blind - no further details given regarding rater blinding.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Paprocki-1977","2011-09-08 10:47:36 +0100","UNKNOWN","The number of participants reported is inconsistent (reported at 36 in one instance and 35 at other times) and it is not clear if this is a typing error.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Paprocki-1977","2011-09-08 10:47:36 +0100","YES","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Paprocki-1977","2011-09-08 10:47:36 +0100","NO","small study.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Reschke-1974","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Reschke-1974","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Reschke-1974","2011-09-08 10:48:41 +0100","UNKNOWN","Described as double blind, however no further details are given. It is not clear whether the study drugs appeared identical.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Reschke-1974","2011-09-08 10:48:41 +0100","UNKNOWN","Described as double blind, however no further details reported regarding rater blinding.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Reschke-1974","2011-09-08 10:48:43 +0100","YES","No evidence of incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Reschke-1974","2011-09-08 10:48:41 +0100","YES","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Reschke-1974","2011-09-16 10:02:16 +0100","UNKNOWN","Small study.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Resnick-1984","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Resnick-1984","2011-09-08 10:13:08 +0100","YES","""packages of medication were identified only by a code which was kept in the pharmacy until the conclusion of the study"" (p.298).","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Resnick-1984","2011-09-08 10:49:32 +0100","YES","""packages of medication were identified only by a code which was kept in the pharmacy until the conclusion of the study"" (p.298).","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Resnick-1984","2011-09-08 10:49:28 +0100","UNKNOWN","Described as double blind, however no further details reported regarding rater blinding.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Resnick-1984","2011-09-08 10:49:39 +0100","YES","No evidence of incomplete data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Resnick-1984","2011-09-08 10:49:28 +0100","YES","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Resnick-1984","2011-09-08 10:49:28 +0100","NO","Small short study.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Ritter-1972","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Ritter-1972","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Ritter-1972","2012-09-10 14:42:03 +0100","YES","Described as double blind - the test drugs were supplied in identically appearing ampoules.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Ritter-1972","2011-09-08 10:50:17 +0100","UNKNOWN","Described as double blind, however no further details reported regarding rater blinding.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Ritter-1972","2011-09-08 10:50:21 +0100","YES","No evidence of incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Ritter-1972","2011-09-08 10:50:17 +0100","NO","Do not report all adverse effects. The authors do not report the mean dosages/number of injections needed.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Ritter-1972","2011-09-08 10:13:08 +0100","UNKNOWN","None obvious.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Salzman-1991","2011-09-08 10:13:08 +0100","NO","Not explicitly described as randomised.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Salzman-1991","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Salzman-1991","2011-09-08 10:51:29 +0100","YES","""Parenteral medication was prepared in advance by a member of staff who had no direct clinical responsibility for the patient."" (p.177).","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Salzman-1991","2011-09-08 10:51:30 +0100","YES","""Raters were blind to the treatment condition received by the patient."" (p.178).","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Salzman-1991","2011-09-21 09:18:19 +0100","NO","It is reported that the number of participants declined after the baseline assessment because they were discharged or transferred. However, exact numbers are not given and it is not clear if the participants were transferred because they had a positive or negative outcome. Attrition approaching 50% for some outcomes at 24 hours.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Salzman-1991","2011-09-08 10:51:25 +0100","YES","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Salzman-1991","2011-09-08 10:51:25 +0100","NO","Sponsored by drug company.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Shu-2010","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Shu-2010","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Shu-2010","2011-09-08 10:52:12 +0100","NO","Open label.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Shu-2010","2011-09-08 10:52:15 +0100","YES","Rater blind.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Shu-2010","2011-09-08 10:52:24 +0100","UNKNOWN","The reasons for leaving the study early were reported for those participants who did not complete the study. However, the number of participants completing different assessments at the same time point vary and reasons are not given.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Shu-2010","2011-09-20 09:53:12 +0100","UNKNOWN","Only report side effects experienced by ≧2% of people.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Shu-2010","2011-09-08 10:52:10 +0100","NO","Sponsored by drug company.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Stotsky-1977","2011-09-08 10:13:08 +0100","UNKNOWN","Randomised in blocks of 10. Method of sequence generation not clear.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Stotsky-1977","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Stotsky-1977","2012-08-09 21:30:17 +0100","YES","""Medication was provided in identically appearing 2cc. ampules each containing 4 mg's. Prior to the administration of the drug labels were removed by a person not involved either in the prescription or administration of the drug."" (p.968).","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Stotsky-1977","2011-09-08 10:53:38 +0100","YES","""Ratings were performed by the psychiatrist ordering the medication who was not aware which drug was administered to the patient. When asked to guess which drug was given, the psychiatrists administering the drug were unable to guess significantly better than chance."" (p.968).","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Stotsky-1977","2011-09-08 10:53:40 +0100","YES","No evidence of incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Stotsky-1977","2011-09-08 10:53:22 +0100","YES","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Stotsky-1977","2011-09-08 10:53:22 +0100","NO","Small short study, sponsored by drug company.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Taymeeyapradit-2002","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Taymeeyapradit-2002","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Taymeeyapradit-2002","2011-09-08 10:54:10 +0100","NO","Open label.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Taymeeyapradit-2002","2011-09-08 10:54:08 +0100","UNKNOWN","The BPRS was completed by a psychiatric nurse who was blind to the intervention. However, it is not reported whether the rater for CGI and adverse effects was blind.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Taymeeyapradit-2002","2011-09-08 10:54:13 +0100","YES","No evidence of incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Taymeeyapradit-2002","2011-09-08 10:13:08 +0100","YES","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Taymeeyapradit-2002","2011-09-08 10:13:08 +0100","UNKNOWN","None obvious.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Tuason-1986","2011-09-08 10:13:08 +0100","UNKNOWN","Described as randomised - method of randomisation is not reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Tuason-1986","2011-09-08 10:13:08 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Tuason-1986","2011-09-08 10:54:58 +0100","NO","Staff administering the medication were not blind to the intervention.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Tuason-1986","2011-09-08 10:55:00 +0100","YES","Rater blind.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Tuason-1986","2011-09-20 10:51:56 +0100","NO","Participants who were discharged/transferred were not followed up. The number of participants reported as leaving the study is contradictory as follows; ""On Day 3, 19% of the haloperidol patients were withdrawn from the study while all loxapine patients remained"" ""the others (6 loxapine and 11 haloperidol) were dropped on Day 2, when all were still rated severely or very severely ill."" (p.127). By day 10, over 50% attrition in both groups. ","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Tuason-1986","2011-10-18 13:08:06 +0100","NO","The amount of anticholinergic and sleeping medication administered was not reported. ","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [v2.3-For publication].rm5","STD-Tuason-1986","2011-09-08 10:13:08 +0100","UNKNOWN","None obvious.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/Glutamatergic drugs for schizophrenia [v10.0-For publication].rm5","STD-Diaz-2002","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Glutamatergic drugs for schizophrenia [v10.0-For publication].rm5","STD-Duncan-2002","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Glutamatergic drugs for schizophrenia [v10.0-For publication].rm5","STD-Evins-2000","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Glutamatergic drugs for schizophrenia [v10.0-For publication].rm5","STD-Goff-1999a","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Glutamatergic drugs for schizophrenia [v10.0-For publication].rm5","STD-Goff-1999b","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Glutamatergic drugs for schizophrenia [v10.0-For publication].rm5","STD-Goff-1999c","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Glutamatergic drugs for schizophrenia [v10.0-For publication].rm5","STD-Goff-2001a","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Glutamatergic drugs for schizophrenia [v10.0-For publication].rm5","STD-Heresco_x002d_Levy-1998","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Glutamatergic drugs for schizophrenia [v10.0-For publication].rm5","STD-Heresco_x002d_Levy-1999","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Glutamatergic drugs for schizophrenia [v10.0-For publication].rm5","STD-Heresco_x002d_Levy-2002","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Glutamatergic drugs for schizophrenia [v10.0-For publication].rm5","STD-Javitt-1994","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Glutamatergic drugs for schizophrenia [v10.0-For publication].rm5","STD-Javitt-2001","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Glutamatergic drugs for schizophrenia [v10.0-For publication].rm5","STD-Potkin-1992","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Glutamatergic drugs for schizophrenia [v10.0-For publication].rm5","STD-Potkin-1999","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Glutamatergic drugs for schizophrenia [v10.0-For publication].rm5","STD-Rosse-1996","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Glutamatergic drugs for schizophrenia [v10.0-For publication].rm5","STD-Tsai-1998","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Glutamatergic drugs for schizophrenia [v10.0-For publication].rm5","STD-Tsai-1999","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/Glutamatergic drugs for schizophrenia [v10.0-For publication].rm5","STD-van-Berckel-1999","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Brown-2006","2010-12-07 13:54:29 +0000","UNKNOWN","""Randomised"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Brown-2006","2010-06-01 10:53:30 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Brown-2006","2010-06-02 13:19:58 +0100","NO","Not blinded but ""... attempted to maintain rater blindness but in many cases this was not possible"".","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Brown-2006","2010-06-02 13:24:54 +0100","UNKNOWN","11 of 28 included patients were missing at outcome. ""Subjects failed to attend or cancelled at short notice a total of 73 (out of 199) appointments"" - described but not addressed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Brown-2006","2010-06-02 13:25:26 +0100","YES","Four rating scales were listed in the methods, all four reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Brown-2006","2010-06-02 13:25:23 +0100","UNKNOWN","Supported by Eli Lilly (pharmaceutical industry) who supplied the Lilly ""Meaningful Day"" package.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Brown-2009","2010-12-07 13:55:56 +0000","UNKNOWN","""Randomised, using a hidden computer-generated random number programme"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Brown-2009","2010-06-01 11:10:53 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Brown-2009","2010-06-02 13:20:31 +0100","NO","Not blinded but ""pre and post intervention measurements were made by the same rater who was blind to the interviewees' status in the study"".","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Brown-2009","2010-06-02 13:27:23 +0100","UNKNOWN","""Five subjects (33%) did not complete the programme, most deciding not to continue with the programme after just one session"" - described but not addressed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Brown-2009","2010-06-02 13:28:32 +0100","YES","Four rating scales were listed in the methods, all four reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Brown-2009","2010-12-01 18:24:36 +0000","UNKNOWN","Health promotion operating manual was adapted from the Lilly ""Meaningful Day"" package (","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Byrne-1999","2010-06-01 11:13:18 +0100","UNKNOWN","""The homes in each strata were then randomly assigned to one of the three study groups"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Byrne-1999","2010-06-01 11:13:18 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Byrne-1999","2010-06-02 13:29:33 +0100","NO","No blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Byrne-1999","2010-06-02 13:36:51 +0100","UNKNOWN","""By time 3 only 53% of the original sample remained in the study, and those actually participating in the groups (completing more than 20% of the sessions) were 40% of the original sample"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Byrne-1999","2010-06-02 13:30:04 +0100","YES","Three rating scales were listed in the methods, all three reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Byrne-1999","2010-12-01 18:26:10 +0000","YES","State funded (Ontario Ministry of Health, Canada), no evidence of other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Chafetz-2008","2010-10-12 11:09:45 +0100","UNKNOWN","""Randomisation"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Chafetz-2008","2010-06-01 11:17:15 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Chafetz-2008","2010-06-01 11:17:15 +0100","UNKNOWN","""Baseline severity of medical comorbidity was rated by NPs [Nurse Practitioners] blind to study group......"" - no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Chafetz-2008","2010-06-01 11:18:34 +0100","UNKNOWN","""... we are confident that results for outcomes reported here are not biased by differences between study groups in number of interviews completed"" - described and addressed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Chafetz-2008","2010-06-02 13:31:41 +0100","YES","Three rating scales were listed in the methods, all three reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Chafetz-2008","2010-06-01 11:18:46 +0100","UNKNOWN","Supported by the National Institute of Nursing Research","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Danavall-2007","2014-03-26 13:19:14 +0000","YES","Using a computerised algorithm, patients were randomised to the intervention or usual care group by the project manager.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Danavall-2007","2013-08-02 12:02:19 +0100","UNKNOWN","Allocation ""by the project group manager"" - no further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Danavall-2007","2013-08-02 12:04:09 +0100","UNKNOWN","""Interviewers were blinded to subjects' randomization status"" - no further details. ","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Danavall-2007","2014-03-26 13:19:14 +0000","YES","15 participants were lost to follow-up. Stated that ""all analyses were conducted as intent-to-treat"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Danavall-2007","2013-08-24 12:00:25 +0100","UNKNOWN","All outcomes stated in the method appear to have been reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Danavall-2007","2013-08-02 12:07:40 +0100","UNKNOWN","Dr. Lorig receives royalties from Bull Publisher for being an author of Living a Healthy Life with Chronic Conditions. This book was written for the self-management course and is used in this study.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Druss-2010","2010-06-01 11:23:09 +0100","UNKNOWN","""Using a computerized algorithm, patients were randomly assigned to a care management intervention group or a usual care group"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Druss-2010","2010-06-01 11:23:19 +0100","UNKNOWN","Allocation ""by the project group manager"" - no further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Druss-2010","2010-06-01 11:23:19 +0100","UNKNOWN","""Interviewers were blinded to subjects' randomisation status"" - no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Druss-2010","2010-06-02 13:32:48 +0100","UNKNOWN","""Of those randomly assigned, 73% completed 6-month follow-up interviews and 68% completed 12-month follow-up interviews"". Lost to follow-up was ""unable to locate"", ""deceased"", and ""withdrawn"" - described but not addressed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Druss-2010","2010-06-02 13:33:04 +0100","YES","Four rating scales were listed in the methods, all four reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Druss-2010","2010-06-02 13:33:16 +0100","UNKNOWN","Lead author ""Dr Druss received research funding from Pfizer"", who manufacture a wide range of medicines for conditions such as heart disorders, cancer, raised blood pressure, high cholesterol and sexual health.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Forsberg-2008","2010-10-12 11:10:07 +0100","UNKNOWN","""Randomisation was conducted on group level by the drawing of lots"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Forsberg-2008","2010-06-02 13:34:14 +0100","YES","Allocation ""by a person not involved in the project"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Forsberg-2008","2010-06-02 11:08:37 +0100","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Forsberg-2008","2010-06-02 11:08:37 +0100","UNKNOWN","Clients leaving early: ""no informed reasons were mentioned"", or ""informed reasons were studies, health reasons"", or ""dissatisfaction of their study circle"", ""health problem"" and ""job"" - described but not addressed. Staff leaving early: ""no informed reasons"", ""new job"", dissatisfaction of study circle"" and ""sick list"" - described but not addressed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.02","All outcomes"
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Forsberg-2008","2010-06-02 11:08:37 +0100","UNKNOWN","Study reported as if not clustered - no intra-class correlation coefficient.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/G-P/General physical health advice for people with serious mental illness [v6.0-For publication].rm5","STD-Forsberg-2008","2010-06-02 11:08:37 +0100","UNKNOWN","Supported by grants from ""The Vasterbotten County Council, The Swedish Institute for Health Sciences,The Swedish Council for Working Life and Social Research, Stiftelsen J C Kempes Minnes Stipendiefond and The Foundation of Medical Research in Skelleftea"".","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication] (1).rm5","STD-Aaes_x002d_Jorgensen-1981b","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication] (1).rm5","STD-Balasubramanian-1991","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication] (1).rm5","STD-Ban-1975","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication] (1).rm5","STD-Dehnel-1968","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication] (1).rm5","STD-Fischer-1976","","NO","C - Inadequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication] (1).rm5","STD-Galderisi-1994","","NO","C - Inadequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication] (1).rm5","STD-Gravem-1978","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication] (1).rm5","STD-Gravem-1981","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication] (1).rm5","STD-Heikkila-1981a","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication] (1).rm5","STD-Heikkila-1981b","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication] (1).rm5","STD-Heikkila-1992","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication] (1).rm5","STD-Huttunen-1995","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication] (1).rm5","STD-Kingstone-1970","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication] (1).rm5","STD-Kordas-1968","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication] (1).rm5","STD-Mahadevan-1991","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication] (1).rm5","STD-Remvig-1987","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication] (1).rm5","STD-Serafetinides-1972","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication] (1).rm5","STD-Sterlin-1972","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication].rm5","STD-Aaes_x002d_Jorgensen-1981b","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication].rm5","STD-Balasubramanian-1991","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication].rm5","STD-Ban-1975","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication].rm5","STD-Dehnel-1968","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication].rm5","STD-Fischer-1976","","NO","C - Inadequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication].rm5","STD-Galderisi-1994","","NO","C - Inadequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication].rm5","STD-Gravem-1978","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication].rm5","STD-Gravem-1981","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication].rm5","STD-Heikkila-1981a","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication].rm5","STD-Heikkila-1981b","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication].rm5","STD-Heikkila-1992","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication].rm5","STD-Huttunen-1995","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication].rm5","STD-Kingstone-1970","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication].rm5","STD-Kordas-1968","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication].rm5","STD-Mahadevan-1991","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication].rm5","STD-Remvig-1987","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication].rm5","STD-Serafetinides-1972","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol dihydrochloride for schizophrenia [v5.0-For publication].rm5","STD-Sterlin-1972","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses [v5.0-For publication].rm5","STD-Ahlfors-1980","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses [v5.0-For publication].rm5","STD-Dencker-1980","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses [v5.0-For publication].rm5","STD-Martyns_x002d_Yellowe-1993","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses [v5.0-For publication].rm5","STD-Wistedt-1991","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Bahrain-1996","2011-12-01 17:29:19 +0000","UNKNOWN","Patients were randomly allocated, no further information.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Bahrain-1996","2011-12-01 17:29:20 +0000","UNKNOWN","No information.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Bahrain-1996","2011-12-01 17:29:24 +0000","NO","No blinding.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Bahrain-1996","2011-12-01 17:29:24 +0000","NO","Open label trial.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Bahrain-1996","2012-03-08 10:10:18 +0000","UNKNOWN","One patient left the study, not accounted for in analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Bahrain-1996","2011-12-01 17:29:22 +0000","NO","Details of the statistical analysis method was not specified.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Bahrain-1996","2012-01-29 22:26:10 +0000","UNKNOWN","Diazepam was used if necessary and benztropine was used to treat side effects. Not clear whether these were accounted for analysis. Also, no further information on data collection and interview process.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Canada-1994","2011-12-01 17:29:04 +0000","UNKNOWN","Randomisation was done separately for men and women but no further information regarding sequence generation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Canada-1994","2011-12-01 17:29:05 +0000","UNKNOWN","No further information.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Canada-1994","2011-12-01 17:29:09 +0000","YES","Blinded.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Canada-1994","2011-12-01 17:29:11 +0000","YES","Blinded at outcome.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Canada-1994","2011-12-01 17:29:05 +0000","YES","No attrition.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Canada-1994","2012-03-08 10:10:18 +0000","NO","For Nurses Clinical Global Impression (NCGI), only P value was given.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Canada-1994","2012-03-08 10:10:19 +0000","UNKNOWN","Double-blind conditions only.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-China-1997","2011-12-01 17:28:52 +0000","UNKNOWN","Not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-China-1997","2011-09-18 10:42:09 +0100","UNKNOWN","Although the study is double blind, allocation is not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-China-1997","2011-12-01 17:28:57 +0000","YES","Blinded.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-China-1997","2011-12-01 17:28:58 +0000","YES","Blinded.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-China-1997","2011-12-01 17:28:54 +0000","UNKNOWN","No further information.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-China-1997","2011-12-01 17:28:55 +0000","NO","No SD and mean values for BPRS and CGI outcomes.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-China-1997","2011-12-01 17:28:57 +0000","UNKNOWN","No further information on data collection process.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-France-1988","2011-12-01 17:29:49 +0000","UNKNOWN","No further information regarding randomisation process.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-France-1988","2011-12-01 17:29:49 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-France-1988","2011-12-01 17:30:34 +0000","NO","Not blinded.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-France-1988","2011-12-01 17:30:36 +0000","NO","Not blinded.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-France-1988","2011-12-01 17:29:50 +0000","UNKNOWN","Two patients were not taken in to analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-France-1988","2011-12-01 17:29:51 +0000","NO","No data with regard to some adverse events.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-France-1988","2011-12-01 17:29:52 +0000","UNKNOWN","Potential for other bias due to non-blinding.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Malaysia-1998","2011-12-01 17:30:39 +0000","UNKNOWN","No further information regarding randomisation process.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Malaysia-1998","2011-12-01 17:30:40 +0000","UNKNOWN","The randomisation code was kept by the first author and was not revealed to others to maintain blindness. No further details with regard to allocation concealment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Malaysia-1998","2011-12-01 17:30:47 +0000","YES","Blinded.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Malaysia-1998","2011-12-01 17:30:48 +0000","YES","Blinded.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Malaysia-1998","2011-10-02 23:41:15 +0100","NO","Total of 50 patients entered the study, only 44 patients completed the study and were included in the analysis. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Malaysia-1998","2011-12-01 17:30:44 +0000","UNKNOWN","Baseline comparison table shows age, sex and ethnicity only.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Malaysia-1998","2011-12-01 17:30:45 +0000","UNKNOWN","Two different dosages for initial 10 participants and it is not clear whether this was accounted for analysis.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Nordic-1993","2011-12-01 17:30:55 +0000","UNKNOWN","Stratified randomisation but no information regarding random sequence generation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Nordic-1993","2011-12-01 17:30:55 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Nordic-1993","2011-12-01 17:30:59 +0000","NO","Not blinded.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Nordic-1993","2011-12-01 17:31:00 +0000","NO","Not blinded.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Nordic-1993","2011-12-01 17:30:56 +0000","NO","169 patients entered the study, statistical analysis comprised of only 148 patients.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Nordic-1993","2011-12-01 17:30:57 +0000","UNKNOWN","Some data were presented graphically, no SD.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Nordic-1993","2012-03-08 10:10:19 +0000","UNKNOWN","Open controlled multicentre trial.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-South-Africa-1996","2011-12-01 17:31:12 +0000","UNKNOWN","Not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-South-Africa-1996","2011-12-01 17:31:13 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-South-Africa-1996","2011-12-01 17:31:16 +0000","UNKNOWN","No oral placebo.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-South-Africa-1996","2011-12-01 17:31:17 +0000","YES","Blinded.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-South-Africa-1996","2011-12-01 17:31:14 +0000","UNKNOWN","42 patients entered the study, 4 patients were excluded from the statistical analysis due to protocol violations.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-South-Africa-1996","2011-12-01 17:31:15 +0000","NO","Some adverse effects data were not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-South-Africa-1996","2011-12-01 17:31:15 +0000","UNKNOWN","Not clear whether necessary confounding factors were accounted for analysis.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-South-Africa-1997","2011-12-01 17:31:21 +0000","UNKNOWN","No further information regarding the randomisation process.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-South-Africa-1997","2011-12-01 17:31:22 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-South-Africa-1997","2011-12-01 17:31:28 +0000","UNKNOWN","No oral placebo.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-South-Africa-1997","2011-12-01 17:31:29 +0000","YES","Double blind.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-South-Africa-1997","2011-12-01 17:31:22 +0000","UNKNOWN","No further information.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-South-Africa-1997","2011-12-01 17:31:23 +0000","NO","Sedation and adverse effect results were not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-South-Africa-1997","2011-12-01 17:31:26 +0000","NO","Number of aggressive episodes and the doses of lorazepam were not outcome variables.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Thailand-2002","2011-09-18 09:38:09 +0100","YES","Attending psychiatrist undertook allocation of people to treatment groups by drawing lots.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Thailand-2002","2011-12-01 17:31:34 +0000","UNKNOWN","No further information.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Thailand-2002","2011-12-01 17:31:38 +0000","NO","No blinding.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Thailand-2002","2011-09-18 09:36:46 +0100","UNKNOWN","Blinding was present for some BPRS outcomes, not for CGI outcomes. ","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Thailand-2002","2011-12-01 17:31:34 +0000","YES","No attrition.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Thailand-2002","2011-12-01 17:31:36 +0000","YES","P values and CI were reported for all outcomes and side effects were reported separately.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses [v7.0-For publication].rm5","STD-Thailand-2002","2011-10-09 16:13:44 +0100","UNKNOWN","Some patients received other oral antipsychotics and mood stabilizers. It is not clear whether these unmeasured confounders were accounted for analysis. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Zotepine versus other atypical antipsychotics for schizophrenia [v8.0-For publication].rm5","STD-Klieser-1991","2009-12-17 12:08:06 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Zotepine versus other atypical antipsychotics for schizophrenia [v8.0-For publication].rm5","STD-Klieser-1991","2010-04-25 17:12:07 +0100","UNKNOWN","No further details. ","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Zotepine versus other atypical antipsychotics for schizophrenia [v8.0-For publication].rm5","STD-Klieser-1991","2009-12-15 19:20:29 +0000","UNKNOWN","Double, no further details. ","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","All outcomes"
"../ALL-2015-06/Q-Z/Zotepine versus other atypical antipsychotics for schizophrenia [v8.0-For publication].rm5","STD-Klieser-1991","2009-12-15 19:20:35 +0000","NO","Data on leaving early are missing. ","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Zotepine versus other atypical antipsychotics for schizophrenia [v8.0-For publication].rm5","STD-Klieser-1991","2010-05-12 21:30:13 +0100","NO","Data on laboratory measures were not presented. ","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Zotepine versus other atypical antipsychotics for schizophrenia [v8.0-For publication].rm5","STD-Klieser-1991","2010-05-17 12:24:03 +0100","NO","Biperiden co-medication was permitted.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Zotepine versus other atypical antipsychotics for schizophrenia [v8.0-For publication].rm5","STD-Lin-2003","2010-03-27 18:19:28 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Zotepine versus other atypical antipsychotics for schizophrenia [v8.0-For publication].rm5","STD-Lin-2003","2010-03-27 18:19:28 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Zotepine versus other atypical antipsychotics for schizophrenia [v8.0-For publication].rm5","STD-Lin-2003","2010-03-27 18:19:28 +0000","UNKNOWN","Single blind (blind raters). Whether the blinding strategy was successful has not been examined. There were no objective outcomes. Overall, it is unclear whether blinding was a concern.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","All outcomes"
"../ALL-2015-06/Q-Z/Zotepine versus other atypical antipsychotics for schizophrenia [v8.0-For publication].rm5","STD-Lin-2003","2010-03-27 18:19:28 +0000","NO","The number of participants leaving the study early has not been reported. Therefore, there was no attempt to address incomplete outcome data.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Zotepine versus other atypical antipsychotics for schizophrenia [v8.0-For publication].rm5","STD-Lin-2003","2010-03-27 18:19:28 +0000","NO","The study has only been published as an abstract in which only a few outcomes (global state, use of antiparkinson medication and mental state) have been reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Zotepine versus other atypical antipsychotics for schizophrenia [v8.0-For publication].rm5","STD-Lin-2003","2010-08-03 15:29:26 +0100","NO","The study used an ""enriched design"". All participants had been stable on clozapine before the study and were than randomised to either continuation of clozapine or switched to zotepine. This design can mean an advantage for clozapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Zotepine versus other atypical antipsychotics for schizophrenia [v8.0-For publication].rm5","STD-Meyer_x002d_Lindenberg-1997","2010-03-27 18:21:32 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Zotepine versus other atypical antipsychotics for schizophrenia [v8.0-For publication].rm5","STD-Meyer_x002d_Lindenberg-1997","2010-03-27 18:21:32 +0000","UNKNOWN","Not described.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Zotepine versus other atypical antipsychotics for schizophrenia [v8.0-For publication].rm5","STD-Meyer_x002d_Lindenberg-1997","2010-03-27 18:21:32 +0000","UNKNOWN","Double, no further details, unclear whether successful.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","All outcomes"
"../ALL-2015-06/Q-Z/Zotepine versus other atypical antipsychotics for schizophrenia [v8.0-For publication].rm5","STD-Meyer_x002d_Lindenberg-1997","2010-04-22 13:05:59 +0100","NO","Reasons for leaving early - not reported (overall attrition high - 34%).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Zotepine versus other atypical antipsychotics for schizophrenia [v8.0-For publication].rm5","STD-Meyer_x002d_Lindenberg-1997","2010-05-17 12:26:11 +0100","NO","Apart from 'leaving the study' all other data reported for a no longer randomised sub-sample.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Zotepine versus other atypical antipsychotics for schizophrenia [v8.0-For publication].rm5","STD-Meyer_x002d_Lindenberg-1997","2010-05-11 16:45:56 +0100","YES","Sponsored by manufacturer of zotepine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Zotepine for schizophrenia [v7.0-For publication].rm5","STD-Barnas-1987","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Zotepine for schizophrenia [v7.0-For publication].rm5","STD-Cooper-1999a","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Zotepine for schizophrenia [v7.0-For publication].rm5","STD-Cooper-1999b","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Zotepine for schizophrenia [v7.0-For publication].rm5","STD-Dieterle-1991","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Zotepine for schizophrenia [v7.0-For publication].rm5","STD-Fleischhacker-1989","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Zotepine for schizophrenia [v7.0-For publication].rm5","STD-Klieser-1996","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Zotepine for schizophrenia [v7.0-For publication].rm5","STD-Meyer_x002d_Lindberg-1996","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Zotepine for schizophrenia [v7.0-For publication].rm5","STD-Moller-2004","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Zotepine for schizophrenia [v7.0-For publication].rm5","STD-Petit-1996","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Zotepine for schizophrenia [v7.0-For publication].rm5","STD-Sarai-1987","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Zotepine for schizophrenia [v7.0-For publication].rm5","STD-Wetzel-1991","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Addington-2004","2009-02-11 15:32:56 +0000","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Addington-2004","2009-02-11 15:32:56 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Addington-2004","2009-03-06 14:16:34 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Addington-2004","2009-02-11 15:32:59 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Addington-2004","2009-08-06 14:36:56 +0100","NO","The attrition rate was 33%. The last observation carried forward method was used to account for people leaving the study early. Data on study completers were also available.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Addington-2004","2009-02-11 15:33:05 +0000","NO","Reporting on secondary outcomes was incomplete.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Addington-2004","2009-02-11 15:33:06 +0000","NO","The study was sponsored by the manufacturer of ziprasidone.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Breier-2005","2009-02-11 15:33:55 +0000","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Breier-2005","2009-02-11 15:33:55 +0000","UNKNOWN","No further details","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Breier-2005","2009-03-13 13:53:10 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Breier-2005","2009-02-11 15:34:24 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Breier-2005","2009-08-06 14:39:02 +0100","NO","The overall attrition was high (48.9%). The last observation carried forward method was used for people leaving the study early. Additionally a mixed models analysis was performed but it is unclear whether any statistical method can account for such high numbers leaving the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Breier-2005","2009-08-06 14:39:11 +0100","NO","Only adverse effects with an incidence of at least 10% were reported therefore important side-effects may have been missed by this procedure.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Breier-2005","2009-02-11 15:34:34 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006","2009-02-11 15:35:12 +0000","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006","2009-02-11 15:35:12 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006","2009-03-06 14:16:48 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006","2009-02-11 15:36:16 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006","2009-08-06 14:39:58 +0100","NO","The overall attrition was very high (62.7%). The last observation carried forward method was used for people leaving the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006","2009-02-11 15:35:19 +0000","NO","Secondary outcomes were not fully reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Kinon-2006","2009-02-11 15:35:17 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lieberman-2005","2009-02-11 15:36:54 +0000","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lieberman-2005","2009-02-11 15:36:54 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lieberman-2005","2009-03-06 14:16:57 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lieberman-2005","2009-02-11 15:37:02 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lieberman-2005","2009-03-13 13:59:58 +0000","NO","The attrition was extremely high (75%), and it is unclear whether any statistical method can account for such a high dropout rate. Efficacy outcomes were evaluated based on mixed models analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lieberman-2005","2009-02-12 18:01:03 +0000","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Lieberman-2005","2009-08-06 14:41:38 +0100","UNKNOWN","Dose ranges were quite different, the upper dose range of olanzapine was 30 mg whereas risperidone could only be titrated up to 6 mg /day. No wash-out period. An overlap in the administration of formerly given antipsychotics was permitted for the first four weeks after randomisation. Allocation to ziprasidone treatment was not possible from the start of the study because ziprasidone was only available at later stages.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Olie-2006","2009-03-06 14:17:30 +0000","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Olie-2006","2009-03-13 15:01:43 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Olie-2006","2009-03-13 15:01:49 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Olie-2006","2009-02-11 15:39:03 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Olie-2006","2009-08-06 14:42:32 +0100","UNKNOWN","The rate of leaving the study early was about 25%, the analysis was based on the 'least squares mean change' (last observation carried forward). It is unclear whether the degree of attrition and the method used to account for it led to bias.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Olie-2006","2009-07-03 11:37:32 +0100","NO","Predefined laboratory data and data on the Global Assessment of Functioning Scale have not been presented. Treatment emergent adverse events had to occur with an incidence of 5% for reporting. Important side-effects may have been missed by this procedure.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Olie-2006","2009-03-13 15:02:33 +0000","NO","The dose of ziprasidone could be increased to the maximum daily dose, whereas amisulpride could only be increased up to 200 mg which might have led to bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sacchetti-2006","2009-02-11 15:44:28 +0000","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sacchetti-2006","2009-02-11 15:44:30 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sacchetti-2006","2009-03-13 15:04:20 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sacchetti-2006","2009-02-11 15:44:13 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sacchetti-2006","2009-08-06 14:43:40 +0100","NO","The overall attrition was 38.4%. Data on reasons for dropout were not available. The last observation carried forward method was used to account for people leaving the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sacchetti-2006","2009-02-11 16:06:06 +0000","NO","Data were only presented as an abstract. Primary and secondary outcome data were reported incompletely.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Sacchetti-2006","2009-02-11 16:09:34 +0000","NO","The study was sponsored by the manufacturers of ziprasidone.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Simpson-2004","2009-02-11 15:40:24 +0000","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Simpson-2004","2009-02-11 15:40:24 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Simpson-2004","2009-03-13 15:05:42 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Simpson-2004","2009-02-11 15:40:56 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Simpson-2004","2009-08-06 14:44:45 +0100","NO","The overall attrition was high (42.8%). The last observation carried forward method was used to account for people leaving the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Simpson-2004","2009-03-13 15:05:51 +0000","NO","The study focused on acutely ill schizophrenic or schizoaffective patients but data on the positive symptom subscore were not provided.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Simpson-2004","2009-08-06 14:44:55 +0100","NO","The study was sponsored by the manufacturer of ziprasidone. The upper dose limit of olanzapine was 15 mg/day which is below the maximum dose for this medication.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Stroup-2006","2009-08-06 14:46:24 +0100","UNKNOWN","Random, 2 step randomisation before and after the availability of ziprasidone, Participants were re-randomised to a different medication than they had received in previous phase 1.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Stroup-2006","2009-02-11 15:41:45 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Stroup-2006","2009-03-13 15:19:37 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Stroup-2006","2009-02-11 15:41:49 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Stroup-2006","2009-03-13 15:19:48 +0000","NO","The attrition rate was extremely high (72.5%). Efficacy data analysis was based on mixed models, but it is unclear whether any statistical method can account for such high dropout rates.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Stroup-2006","2009-02-11 15:41:55 +0000","NO","Use of antiparkinson medication was permitted but data on this was not available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Stroup-2006","2009-08-06 14:46:45 +0100","UNKNOWN","Patients had a history of intolerance to atypical antipsychotic treatment but baseline data on this were not provided.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2005","2009-02-11 15:42:47 +0000","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2005","2009-02-11 15:42:47 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2005","2009-03-13 15:21:53 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2005","2009-02-11 15:43:28 +0000","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2005","2009-02-11 15:43:07 +0000","NO","Data on subjects leaving the study early were not available.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2005","2009-02-11 15:43:09 +0000","NO","Allowed study medication dose ranges were not indicated. A publication was not available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Ziprasidone versus other atypical antipsychotics for schizophrenia [v6.0-For publication].rm5","STD-Svestka-2005","2009-02-12 18:06:56 +0000","UNKNOWN","Insufficient information, although the first author kindly provided us some.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Ziprasidone for schizophrenia and severe mental illness [v11.0-For publication].rm5","STD-Arato-1997","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Ziprasidone for schizophrenia and severe mental illness [v11.0-For publication].rm5","STD-Brook-1998","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Ziprasidone for schizophrenia and severe mental illness [v11.0-For publication].rm5","STD-Daniel-1999","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Ziprasidone for schizophrenia and severe mental illness [v11.0-For publication].rm5","STD-Goff-1998","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Ziprasidone for schizophrenia and severe mental illness [v11.0-For publication].rm5","STD-Hirsch-1999","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Ziprasidone for schizophrenia and severe mental illness [v11.0-For publication].rm5","STD-Keck-1998","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Ziprasidone for schizophrenia and severe mental illness [v11.0-For publication].rm5","STD-Swift-1998","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vocational rehabilitation for people with severe mental illness [v6.0-For publication].rm5","STD-Beard_x002d_NewYork","","NO","C - Inadequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vocational rehabilitation for people with severe mental illness [v6.0-For publication].rm5","STD-Becker_x002d_Fort-Worth","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vocational rehabilitation for people with severe mental illness [v6.0-For publication].rm5","STD-Bell_x002d_Connecticut","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vocational rehabilitation for people with severe mental illness [v6.0-For publication].rm5","STD-Blankertz_x002d_Philadelph","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vocational rehabilitation for people with severe mental illness [v6.0-For publication].rm5","STD-Bond_x002d_Chicago1","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vocational rehabilitation for people with severe mental illness [v6.0-For publication].rm5","STD-Bond_x002d_Indiana","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vocational rehabilitation for people with severe mental illness [v6.0-For publication].rm5","STD-Chandler_x002d_LongBeach","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vocational rehabilitation for people with severe mental illness [v6.0-For publication].rm5","STD-Dincin_x002d_Chicago","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vocational rehabilitation for people with severe mental illness [v6.0-For publication].rm5","STD-Drake_x002d_New-Hampshire1","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vocational rehabilitation for people with severe mental illness [v6.0-For publication].rm5","STD-Drake_x002d_Washington","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vocational rehabilitation for people with severe mental illness [v6.0-For publication].rm5","STD-Gervey_x002d_New-York","","NO","C - Inadequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vocational rehabilitation for people with severe mental illness [v6.0-For publication].rm5","STD-Griffiths_x002d_London","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vocational rehabilitation for people with severe mental illness [v6.0-For publication].rm5","STD-Kline_x002d_Philadelphia","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vocational rehabilitation for people with severe mental illness [v6.0-For publication].rm5","STD-Kuldau_x002d_California","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vocational rehabilitation for people with severe mental illness [v6.0-For publication].rm5","STD-McFarlane_x002d_New-York","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vocational rehabilitation for people with severe mental illness [v6.0-For publication].rm5","STD-Okpaku_x002d_Nashville","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vocational rehabilitation for people with severe mental illness [v6.0-For publication].rm5","STD-Walker_x002d_Massachusetts","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vocational rehabilitation for people with severe mental illness [v6.0-For publication].rm5","STD-Wolkon_x002d_Cleveland","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Adler-1993","2010-07-22 17:00:49 +0100","UNKNOWN","'random allocation', ratio of 3 vitamin E: 2 placebo.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Adler-1993","2010-07-22 17:00:49 +0100","UNKNOWN","Double blind: no further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Adler-1993","2010-07-22 17:00:50 +0100","YES","Both rater and patients were blinded.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Adler-1993","2010-03-24 11:17:05 +0000","UNKNOWN","“One patient dropped out after 2 weeks due to non-compliance” “Two patients developed significant medical illnesses ? unrelated to study treatment”, “By prior design, treatment for the first 8 patients was terminated after 8 weeks.” (page 869). No further details.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Adler-1993","2010-07-22 17:00:54 +0100","NO","Not all expected outcomes reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Adler-1993","2010-10-07 12:44:35 +0100","UNKNOWN","Small sample size.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Adler-1999","2011-01-07 17:40:29 +0000","YES","Randomisation coordinated centrally.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Adler-1999","2011-01-07 17:40:33 +0000","YES","Allocation with ""biased coin"" method, stratified by site, age, and baseline TD.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Adler-1999","2010-07-22 17:01:03 +0100","UNKNOWN","Double blind: no further details.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Adler-1999","2011-01-07 17:40:56 +0000","UNKNOWN","“Of the 51 subjects who did not complete 1 year, most changed their minds about participating (n = 18), moved too far away from a site to continue in the study (n = 11), or were classified as “whereabouts unknown” (n = 8)” (page 838). No further details.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Adler-1999","2010-10-07 12:45:49 +0100","NO","Not all expected outcomes reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Adler-1999","2010-10-07 12:46:22 +0100","UNKNOWN","Small sample size.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Akhtar-1993","2010-07-22 17:01:09 +0100","UNKNOWN","'random allocation', no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Akhtar-1993","2010-07-22 17:01:10 +0100","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Akhtar-1993","2011-01-07 17:41:49 +0000","YES","Double blind: both investigators and raters were blinded.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Akhtar-1993","2010-07-22 17:01:12 +0100","YES","There were no dropouts.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Akhtar-1993","2010-10-07 12:46:59 +0100","NO","Not all expected outcomes reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Akhtar-1993","2010-10-07 12:47:03 +0100","UNKNOWN","Small sample size, no information about funding.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Dabiri-1994","2010-07-22 17:01:17 +0100","UNKNOWN","'random allocation', no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Dabiri-1994","2011-01-07 17:42:18 +0000","YES","""patients were randomly divided into treatment and placebo groups by a non-clinical staff member"" (page 925).","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Dabiri-1994","2010-07-22 17:01:19 +0100","YES","Double blind: raters blinded.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Dabiri-1994","2010-10-07 12:48:11 +0100","UNKNOWN","""one patient on placebo group left after 2 weeks because of diarrhoea"" (page 925). No details were provided about this patient.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Dabiri-1994","2010-10-07 12:48:31 +0100","NO","Not all expected outcomes reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Dabiri-1994","2010-07-22 17:01:21 +0100","UNKNOWN","No information about funding, very small sample size.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Dorevitch-1997b","2011-01-07 17:43:03 +0000","UNKNOWN","Randomised - no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Dorevitch-1997b","2010-07-22 16:58:52 +0100","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Dorevitch-1997b","2010-07-22 16:58:53 +0100","YES","Double blind: raters blinded.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Dorevitch-1997b","2011-01-07 17:43:17 +0000","UNKNOWN","Two patients did not complete the study. Both patients were from the placebo phase of the placebo-vitamin E sequence group. One died while choking on food and the second as the result of a traffic accident (page 115). Some of the patients were not measured at all times (page 115), no further details were given about these patients.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Dorevitch-1997b","2010-10-07 12:48:56 +0100","NO","Not all expected outcomes reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Dorevitch-1997b","2011-01-10 18:35:31 +0000","NO","Vitamin E and placebo supplied by industry (Teva Pharmaceuticals); very small sample size; cross-over design.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Egan-1992","2010-07-22 16:59:04 +0100","UNKNOWN","'random allocation', no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Egan-1992","2010-07-22 16:59:06 +0100","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Egan-1992","2010-07-22 16:59:06 +0100","UNKNOWN","Double blind: no further details.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Egan-1992","2010-03-24 11:23:56 +0000","UNKNOWN","Three patients were not included in the data analysis: one dropped out and two had inconsistent vitamin E blood levels (page 775). No further details were given.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Egan-1992","2010-10-07 12:50:00 +0100","NO","Not all expected outcomes reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Egan-1992","2011-01-10 18:35:37 +0000","UNKNOWN","Cross-over design; very small sample size; no information about funding.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Elkashef-1990","2010-07-22 16:59:13 +0100","UNKNOWN","'random allocation', no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Elkashef-1990","2010-07-22 16:59:14 +0100","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Elkashef-1990","2010-07-22 16:59:15 +0100","UNKNOWN","Double blind: no further details.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Elkashef-1990","2010-07-22 16:59:16 +0100","UNKNOWN","""Two patients did not complete the study, one because of noncompliance and the other experienced substantial side effects (nausea) while taking placebo"" (page 505). No further details.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Elkashef-1990","2010-10-07 12:51:07 +0100","NO","Not all expected outcomes reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Elkashef-1990","2011-01-10 18:35:43 +0000","NO","Vitamin E and placebo supplied by industry (Roche); very small sample size; cross-over design.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Lam-1994","2010-07-22 16:59:28 +0100","UNKNOWN","'random allocation', no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Lam-1994","2010-07-22 16:59:28 +0100","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Lam-1994","2010-07-22 16:59:29 +0100","YES","Double blind: raters blinded.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Lam-1994","2010-07-22 16:59:31 +0100","UNKNOWN","One patient died of unrelated medical illness, one contracted bacillary dysentery and was dropped from the trial, and one had poor compliance and refused to continue medication (page 113). No further details given.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Lam-1994","2010-10-07 12:52:49 +0100","NO","Not all expected outcomes reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Lam-1994","2011-01-10 18:35:49 +0000","UNKNOWN","Cross-over design; very small sample size; no information about funding.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Lohr-1996","2010-07-22 16:59:36 +0100","UNKNOWN","'random allocation', no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Lohr-1996","2010-07-22 16:59:37 +0100","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Lohr-1996","2010-07-22 16:59:38 +0100","UNKNOWN","Double blind: no further details.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Lohr-1996","2010-07-22 16:59:39 +0100","YES","2 developed manic symptoms necessitating medical changes, and 18 were non-compliant with either the vitamin E or the psychotropic medication. These 20 patients, who did not differ significantly from the remaining 35 patients in terms of age, gender, or diagnosis, were dropped from the study (page 168).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Lohr-1996","2010-10-07 12:53:42 +0100","NO","Not all expected outcomes reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Lohr-1996","2010-10-07 12:53:45 +0100","NO","Vitamin E and placebo supplied by industry (Hoffman-La Roche); small sample size.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Sajjad-1998","2010-07-22 16:59:46 +0100","YES","'random allocation' patients randomly divided into 2 groups using StatView, a computer statistics programme.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Sajjad-1998","2010-07-22 16:59:46 +0100","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Sajjad-1998","2010-03-24 11:26:54 +0000","NO","Double blind: rater blind. However, after one month, the rater performed statistical tests and, hence, the blindness was not maintained.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Sajjad-1998","2011-01-10 18:41:12 +0000","UNKNOWN","Eleven patients were assigned to the treatment group: 1 was excluded as she refused to take the medication, 1 excluded after the first month due to developing diarrhoea, 2 excluded in third month and 2 more in the fourth month. Nine patients assigned to the control group: 1 left as his phenothiazine medication was increased, 1 excluded in the third month. 12 patients completed the trial: 5 in the treatment group and seven in the control group (pages 149-51).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Sajjad-1998","2010-10-07 12:54:47 +0100","NO","Not all expected outcomes reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Sajjad-1998","2010-10-07 12:54:52 +0100","UNKNOWN","Very small sample size; no information about funding.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Schmidt-1991","2010-07-22 17:00:00 +0100","UNKNOWN","'random allocation', no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Schmidt-1991","2010-07-22 17:00:01 +0100","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Schmidt-1991","2010-07-22 17:00:02 +0100","UNKNOWN","Double blind: no further details.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Schmidt-1991","2011-01-07 17:48:40 +0000","YES","13 patients initially randomised to vitamin E: two left before the end of the study (1 died and the other withdrew); 10 patients initially randomised to placebo: two left before the end of the study (1 died and the other had his treatment modified) (page 204).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Schmidt-1991","2010-10-07 12:55:37 +0100","NO","Not all expected outcomes reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Vitamin E for neuroleptic-induced tardive dyskinesia [v14.0-For publication].rm5","STD-Schmidt-1991","2011-01-10 18:35:56 +0000","NO","Vitamin E and placebo supplied by industry (C Muller); very small sample size; cross-over design.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Chan-2010","2012-07-31 21:45:43 +0100","UNKNOWN","""Randomly assigned"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Chan-2010","2012-07-31 21:45:43 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Chan-2010","2014-04-04 09:18:09 +0100","UNKNOWN","No description of any attempt.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Chan-2010","2012-10-12 17:09:59 +0100","UNKNOWN","Undertaken by ""another occupational therapist"" - unclear of blinded.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Chan-2010","2012-10-12 17:12:10 +0100","NO","""To eliminate the effect of alteration in psychotropic medication, information of two participant was excluded from analysis""","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Chan-2010","2012-07-31 21:45:43 +0100","UNKNOWN","No protocol available.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Chan-2010","2014-06-18 12:52:50 +0100","NO","SSQ and VQ only asked of intervention group. Small-study publication bias possibility.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Park-2011","2012-07-31 21:46:06 +0100","UNKNOWN","""Randomly assigned"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Park-2011","2012-07-31 21:46:06 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Park-2011","2012-10-12 17:10:48 +0100","UNKNOWN","No description of any attempt.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Park-2011","2012-10-12 17:10:48 +0100","UNKNOWN","No description of any attempt.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Park-2011","2012-10-12 17:10:48 +0100","UNKNOWN","They have presented participant flow in ""fig. a describes the participants progress in this study"".","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Park-2011","2012-07-31 21:46:06 +0100","UNKNOWN","No protocol available.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Park-2011","2014-06-18 12:52:50 +0100","UNKNOWN","Small-study publication bias possibility.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Tsang-2013","2013-12-20 12:45:07 +0000","YES","Randomly assigned to the three groups (VRG, TAG and CG) using a computational random number generator.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Tsang-2013","2013-12-27 07:44:36 +0000","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Tsang-2013","2013-12-20 12:46:30 +0000","UNKNOWN","No further details. ","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Tsang-2013","2014-06-05 14:33:43 +0100","YES","The assessors were blinded to the group assignment. Independent assessors, who did not know the expected results of the training programs, were responsible for the pre-test and post-test outcome assessments at baseline and post-intervention.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Tsang-2013","2013-12-20 12:49:06 +0000","YES","Attrition rate 21%.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Tsang-2013","2013-12-20 12:48:52 +0000","UNKNOWN","No protocol available. ","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Virtual reality for treatment compliance for people with serious mental illness [v2.5-For publication].rm5","STD-Tsang-2013","2013-12-27 08:22:40 +0000","UNKNOWN","-","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Henderson-2004","2013-08-25 07:27:37 +0100","YES","Randomised - allocation sequence was generated by using minimization, stratified by team and by severity of patients’ condition (standard versus enhanced CPA) to ensure even distribution of these features which we expected would influence the production of the plan and its use by staff.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Henderson-2004","2013-09-10 13:52:49 +0100","YES","Predictability of allocation by the minimization process was occasionally a problem (when batches of similar patients were forwarded for allocation). To avoid this, ML reassigned the allocation of one patient, chosen at random, within each batch, before we reverted to minimization. When a patient was recruited, the project worker requested allocation by email, which was returned by a statistician as intervention or control group. Allocation was not revealed to the investigator.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Henderson-2004","2013-04-22 10:01:02 +0100","UNKNOWN","Single blind - ""the investigator was blind to allocation"" (p1). The nature of the intervention meant that the participants could not be blinded to allocation.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Henderson-2004","2013-03-27 11:42:26 +0000","YES","One investigator (CH) collected follow-up data and was blinded to treatment group.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Henderson-2004","2012-03-16 15:59:38 +0000","YES","Information on hospital admissions was available for all participants. Bed days was missing from one admission.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Henderson-2004","2013-03-27 11:38:18 +0000","YES","Yes – all outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Henderson-2004","2013-02-07 15:35:13 +0000","UNKNOWN","None detected.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Lester-2003","2013-08-24 12:02:59 +0100","YES","""176 general practices… were randomised by one of the authors (TA) to either intervention or control, using a computer generated random number schedule. These practices were stratified by list size and the number of people with schizophrenia, using minimization to adjust for imbalances within the strata.""","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Lester-2003","2013-03-27 11:42:08 +0000","YES","""To minimize selection bias, recruitment was undertaken on each day of the week over a four to eight week period depending on team caseloads. Within each team, patients were approached consecutively"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Lester-2003","2011-11-23 13:03:52 +0000","YES","Blinding of participants was not possible. ","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Lester-2003","2011-11-23 13:05:18 +0000","YES","Outcome assessors of psychopathology were blinded. Satisfaction was a patient self-report and therefore may be subject to bias as patients were not blinded.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Lester-2003","2011-11-23 13:07:39 +0000","YES","Up to 8 from intervention group (2 deaths; 5 refusals; 1 in prison) and 2 from control group. Unlikely to be related to the intervention.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Lester-2003","2012-07-09 15:49:50 +0100","YES","No protocol available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Lester-2003","2013-02-07 15:35:22 +0000","UNKNOWN","None detected.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Papageorgiou-2002","2013-03-27 11:41:56 +0000","YES","""We allocated patients randomly using a block design, stratified according to whether this was the patient’s first ever or subsequent sectioning. Blocks of twelve random combinations (six experimental, six control) were prepared and sealed in envelopes"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Papageorgiou-2002","2013-03-27 11:41:55 +0000","YES","Sealed envelopes. Research assistants telephoned an independent colleague to select the next envelope.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Papageorgiou-2002","2013-03-27 11:41:55 +0000","YES","It was not possible to blind participants. It was also impossible to mask the research assistants to the patient’s allocation as they were required to assist patients to make a directive in those allocated to the intervention group. However, systematic bias was unlikely as the primary outcome concerned compulsory hospital admission and was not based on any later assessment by the researcher.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Papageorgiou-2002","2013-03-27 11:41:53 +0000","YES","As above.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Papageorgiou-2002","2013-09-10 13:52:49 +0100","YES","75% of intervention group and 71% of the control group were assessed at follow-up. Missing outcome data are balanced across the intervention groups and for similar reasons.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Papageorgiou-2002","2012-07-09 15:49:44 +0100","UNKNOWN","No protocol available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Papageorgiou-2002","2013-02-07 15:35:30 +0000","UNKNOWN","None detected.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Warner-2000","2013-03-25 14:43:48 +0000","YES","""Practices were randomised to shared care or control status using a computer- generated algorithm (practices were number sequentially based on alphabetical order)"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Warner-2000","2011-11-23 13:54:20 +0000","UNKNOWN","Unclear. It was unclear if researchers recruiting participants were aware of which GP practice the participant was registered with. ","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Warner-2000","2011-11-23 13:55:26 +0000","UNKNOWN","Unclear. It was not possible to blind participants. ","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Warner-2000","2011-11-23 13:55:50 +0000","UNKNOWN","It is not clear who rated the outcome measures and if they were blinded.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Warner-2000","2013-03-25 14:43:45 +0000","UNKNOWN","Missing data not reported in sufficient detail.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Warner-2000","2012-07-09 15:48:55 +0100","UNKNOWN","No protocol available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/User-held personalised information for routine care of people with severe mental illness [v7.3-For publication].rm5","STD-Warner-2000","2013-02-07 15:35:41 +0000","UNKNOWN","None detected.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Coons-1962","2012-05-05 18:18:07 +0100","UNKNOWN","Randomly assigned, by Coons himself, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Coons-1962","2012-05-05 18:18:25 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Coons-1962","2013-11-17 21:39:45 +0000","YES","Pharmacist, ward physicians, ward nurses and patients were ignorant of what drugs were being administered. Drugs in identical appearing capsules. It was never necessary to break the code.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Coons-1962","2013-11-17 21:39:47 +0000","YES","Pharmacist, ward physicians, ward nurses and patients were ignorant of what drugs were being administered. Drugs in identical appearing capsules. It was never necessary to break the code.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Coons-1962","2012-05-05 18:19:24 +0100","UNKNOWN","It is not clear whether there were drop-outs, the study did not address this outcome.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Coons-1962","2012-05-08 13:06:45 +0100","UNKNOWN","Outcome of interest not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Coons-1962","2012-05-24 14:27:26 +0100","UNKNOWN","Randomisation was done by Coons himself.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hanlon-1965","2011-06-02 15:52:01 +0100","UNKNOWN","Randomly assigned, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hanlon-1965","2011-06-02 15:51:43 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hanlon-1965","2012-05-12 15:12:17 +0100","NO","Double - drugs dispensed in standard unmarked pink capsules no. 1 & 0 size, but treating ward physicians were aware of the various drugs and dosages involved in the study.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hanlon-1965","2013-11-17 21:43:48 +0000","YES","Double - drugs dispensed in standard unmarked pink capsules no. 1 & 0 size, but treating ward physicians were aware of the various drugs and dosages involved in the study. We conclude from this statement that raters were blinded.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hanlon-1965","2012-05-08 12:02:22 +0100","NO","25% participants from the trifluoperazine group and 21% from the low-potency group left the study early and were not included in the final analysis (completers only).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hanlon-1965","2011-06-02 15:52:25 +0100","NO","MSRPP, MMPI, MACC (no usable data). Not all of the study´s prespecified outcomes have been reported (IMPS and PRP).","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hanlon-1965","2011-06-02 15:52:31 +0100","UNKNOWN","Very short duration.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hollister-1960","2011-06-02 15:22:20 +0100","UNKNOWN","Random assignment, no further details.    ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hollister-1960","2011-06-02 15:22:23 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hollister-1960","2012-05-12 15:13:16 +0100","YES","Double-blind, put in capsules and packaged so they could not be identified, only code number appearing on the labels.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hollister-1960","2013-11-17 19:32:19 +0000","YES","Double-blind, put in capsules and packaged so they could not be identified, only code number appearing on the labels.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hollister-1960","2011-06-01 14:23:32 +0100","UNKNOWN","It is not clear whether there were drop-outs, the study did not address this outcome.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hollister-1960","2012-05-08 13:05:05 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Hollister-1960","2011-06-02 15:23:29 +0100","YES","No evidence for other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Leff-1971","2012-05-06 12:57:40 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Leff-1971","2012-05-06 12:57:32 +0100","YES","Trial medication was held by the unit secretary and dispensed to Julian Leff who gave it to the treating consultant. Only the unit secretary knew which pills were active drug and which were placebo.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Leff-1971","2013-11-17 21:44:20 +0000","YES","Double, no further details. Side-effects were not troublesome in any patient and therefore doctors concerned probably received no clues about whether a patient was on active drug or not.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Leff-1971","2013-11-17 21:44:24 +0000","YES","Double, no further details. Side-effects were not troublesome in any patient and therefore doctors concerned probably received no clues about whether a patient was on active drug or not.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Leff-1971","2014-05-06 13:40:48 +0100","UNKNOWN","Drop-outs were not reported separately for trifluoperazine and chlorpromazine, therefore it is unclear whether there were incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Leff-1971","2012-05-06 13:17:01 +0100","NO","Data on leaving the study early and response were not reported separately for trifluoperazine and chlorpromazine.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Leff-1971","2012-05-06 12:59:09 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Morton-1968","2012-05-06 13:03:08 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Morton-1968","2012-05-06 13:02:58 +0100","YES","The hospital pharmacist was responsible for supplying placebo and active drugs to the ward, no one concerned with the care of patients knew which patients were started on placebo.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Morton-1968","2013-11-17 21:44:47 +0000","NO","Double, identical tablets, but in most cases nurses made correct forecasts on who was on drug and who was on placebo.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Morton-1968","2013-11-17 21:44:50 +0000","NO","Double, identical tablets, but in most cases nurses made correct forecasts on who was on drug and who was on placebo.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Morton-1968","2014-05-06 13:40:48 +0100","UNKNOWN","It is unclear whether there were drop-outs.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Morton-1968","2012-05-06 13:11:11 +0100","YES","No evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Morton-1968","2014-05-06 13:40:48 +0100","UNKNOWN","Blinding was broken when a participant relapsed, but this is not a problem for our primary outcome response to treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Reardon-1966","2011-06-02 15:24:50 +0100","UNKNOWN","Randomly placed and assigned to one of three drugs, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Reardon-1966","2011-06-02 15:24:44 +0100","UNKNOWN","Randomly assigned by pharmacy, no further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Reardon-1966","2012-05-12 15:15:00 +0100","UNKNOWN","Not indicated, but assumed (“neither the ward personnel nor the investigators knew which drug the patients received”).","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Reardon-1966","2012-05-12 15:15:01 +0100","UNKNOWN","Not indicated, but assumed (“neither the ward personnel nor the investigators knew which drug the patients received”).","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Reardon-1966","2011-06-01 14:29:41 +0100","NO","Drop-outs were excluded from the final analysis (completers only). 3 out of 11 trifluoperazine (27%) and 2 out of 11 chlorpromazine (18%) participants left the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Reardon-1966","2011-06-01 14:29:57 +0100","NO","Incomplete reporting of scale of interest.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Reardon-1966","2011-06-02 15:25:44 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Schiele-1961","2013-05-25 16:44:52 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Schiele-1961","2013-05-25 16:44:41 +0100","UNKNOWN","Procedure not described.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Schiele-1961","2014-05-06 13:40:48 +0100","YES","Double, identical capsules, 'only hospital pharmacist had the code for determining which patient was receiving each kind of medication'.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Schiele-1961","2014-05-06 13:40:48 +0100","YES","Double, identical capsules, 'only hospital pharmacist had the code for determining which patient was receiving each kind of medication'.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Schiele-1961","2014-05-06 13:40:48 +0100","YES","One participant from each group left the study early, which is an acceptable rate. None left because of adverse events, one participants from the low-potency group left due to inefficacy.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Schiele-1961","2014-05-06 13:40:48 +0100","NO","Manifest Behavior Scale no usable data, no SD, no P value.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia [v2.0-For publication].rm5","STD-Schiele-1961","2013-05-25 16:39:06 +0100","YES","No clear other bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-_x002a_Bankier-1973","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-_x002a_Doongaji-1989","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-_x002a_Goldstein-1966","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-_x002a_Itil-1971","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-_x002a_Pinard-1972","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-_x002a_Simpson-1971","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-_x002a_Vestre-1970","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Amin-1977","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Andersen-1974","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Angus-1969","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Bagadia-1980","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Bankier-1968","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Bishop-1963","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Bishop-1964","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Bishop-1966","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Bishop-1967","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Bishop-1970","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Brauzer-1968","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Brauzer-1971","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Claghorn-1974","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Clark-1975","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Coons-1962","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Denber-1972","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Donlon-1978","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Edwards-1980","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Freeman-1968","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Gallant-1968","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Gallant-1968-II","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Gallant-1972","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Gross-1974","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Gwynne-1962","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Kiloh-1976","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Malik-1980","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Marjerrison-1964","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Marjerrison-1966","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Menon-1972","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Needham-1969","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-O_x0027_Brien-1974","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Perales-1974","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Prien-1969","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Ramsay-1970","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Reardon-1966","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Rubin-1971","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Schiele-1961","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Schiele-1969","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Seth-1979","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Simpson-1976","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Stewart-1969","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Sugerman-1965","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Trifluoperazine for schizophrenia [v7.0-For publication].rm5","STD-Vergara-1977","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Treatments for delusional disorder [v2.4-For publication].rm5","STD-O_x0027_Connor-2007","2015-04-16 14:55:07 +0100","YES","Quote: ""Random allocation by consecutive referral at point of entry into the study per published article."" We have established (via personal correspondence with the study's lead author) that random allocation occurred at the point of entry into the trial of consecutive patients through the use of a random number table (Fisher & Yates).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Treatments for delusional disorder [v2.4-For publication].rm5","STD-O_x0027_Connor-2007","2015-04-16 14:55:05 +0100","UNKNOWN","Not specified in the study.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Treatments for delusional disorder [v2.4-For publication].rm5","STD-O_x0027_Connor-2007","2015-04-16 14:55:03 +0100","NO","The trial was unblinded.","Blinding of participants and personnel (performance bias)","QIT-03","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Treatments for delusional disorder [v2.4-For publication].rm5","STD-O_x0027_Connor-2007","2015-04-16 14:55:02 +0100","UNKNOWN","Quote: ""The main outcome measure was the MADS rating; this test was administered by an evaluator independent of the study."" There is no mention that blinding was assured.","Blinding of outcome assessment (detection bias)","QIT-04","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Treatments for delusional disorder [v2.4-For publication].rm5","STD-O_x0027_Connor-2007","2015-04-16 14:55:01 +0100","NO","People who withdrew early were not accounted for in the final data, only completers. The study does acknowledge the attrition rate.","Incomplete outcome data (attrition bias)","QIT-05","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-05.01","All outcomes"
"../ALL-2015-06/Q-Z/Treatments for delusional disorder [v2.4-For publication].rm5","STD-O_x0027_Connor-2007","2015-04-16 14:54:59 +0100","UNKNOWN","There is some unevenness in selective reporting of positive findings, with less prominence given to less positive findings, although the study does acknowledge some weaknesses overall.","Selective reporting (reporting bias)","QIT-06","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Treatments for delusional disorder [v2.4-For publication].rm5","STD-O_x0027_Connor-2007","2015-04-16 14:54:58 +0100","YES","No other biases noted.","Other bias","QIT-07","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Anzai-2002","2011-04-03 12:42:51 +0100","UNKNOWN","""Randomised"" no further details provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Anzai-2002","2011-04-03 12:43:01 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Anzai-2002","2012-07-23 13:04:09 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Anzai-2002","2011-04-03 12:43:08 +0100","UNKNOWN","No information provided.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Anzai-2002","2012-07-24 14:49:22 +0100","UNKNOWN","""Before training started, two participants in the training group and one in the control group were discharged from the hospital. These patients were not included in calculations of the discharge rates"". No further details provided.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Anzai-2002","2011-04-04 09:58:02 +0100","YES","All stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Anzai-2002","2011-04-03 12:43:17 +0100","UNKNOWN","Small sample size. Protocol not available. Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Bauml-2007","2011-04-03 13:27:04 +0100","YES","Block randomisation of 8 to 12 patients, ""the randomisation list for each study centre was generated by a computerised random sampling in the study evaluation centre"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Bauml-2007","2011-04-03 13:27:06 +0100","YES","""The study centres could learn to which treatment condition the group was assigned via telephone"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Bauml-2007","2012-07-23 13:04:24 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Bauml-2007","2011-04-03 13:22:14 +0100","YES","""The treating study psychiatrists were blind to the randomisation"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Bauml-2007","2012-07-24 14:55:54 +0100","UNKNOWN","Nineteen patients excluded prior to index discharge and 34 patients dropped out during the 7-year follow-up. Missing patients were not included in the final analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Bauml-2007","2011-04-04 09:58:19 +0100","YES","All stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Bauml-2007","2011-04-03 13:26:23 +0100","UNKNOWN","Protocol not available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Bradley-2006","2011-04-03 13:40:50 +0100","YES","""randomised"" - participants divided into English speaking and Vietnamese speaking, randomly allocated within their group by drawing names form a canister.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Bradley-2006","2011-04-04 09:18:18 +0100","UNKNOWN","""A staff member drew names from a canister and without looking at the names, assigned them to experimental and control groups"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Bradley-2006","2012-07-23 13:04:30 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Bradley-2006","2011-04-03 13:53:24 +0100","YES","""Independent researchers, who were blind to study condition, conducted assessments"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Bradley-2006","2012-07-24 14:55:36 +0100","UNKNOWN","""Nine pairs did not complete the data collection procedure after treatment or at 18 months (four in the control group and five in the treatment group"". Missing patients were not included in the final analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Bradley-2006","2011-04-04 09:58:31 +0100","YES","All stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Bradley-2006","2011-04-03 14:04:24 +0100","UNKNOWN","Protocol not available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Buchkremer-1997","2011-04-04 09:33:36 +0100","UNKNOWN","""randomised"" - initial homogeneity of the groups was ensured by applying a randomisation technique in which the prognostic factors of sex, Strauss-Carpenter prognosis score and medication compliance were balanced by preliminary matching; then randomly assigned to one of five groups with an allocation ratio of 1:1:1:1:2.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Buchkremer-1997","2011-04-04 09:33:53 +0100","YES","""Randomisation was carried out by an independent institution"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Buchkremer-1997","2012-07-23 13:04:36 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Buchkremer-1997","2013-01-07 11:15:31 +0000","UNKNOWN","Other outcome measurements were not blind: ""data were recorded by trained project staff who were not blind with respect to the group to which the patients were assigned"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Buchkremer-1997","2013-01-07 11:15:31 +0000","YES","""In a modified intention-to-treat approach all patients who had attended at least one group session were included in the main analysis""; ""44 patients who were re-hospitalised or dropped out for other reasons during the period between randomization and the start of group treatment (2 to 6 months) had to be excluded. However, these patients were followed up as completely as possible.""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Buchkremer-1997","2011-04-04 09:58:43 +0100","YES","All stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Buchkremer-1997","2011-04-04 09:44:22 +0100","UNKNOWN","Protocol not available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chan-2007","2012-06-25 08:34:49 +0100","UNKNOWN","""Randomly assigned"", no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chan-2007","2012-06-25 08:34:56 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chan-2007","2012-07-23 13:04:44 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chan-2007","2012-06-25 08:36:12 +0100","UNKNOWN","No information provided.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chan-2007","2012-06-25 08:54:27 +0100","NO","Number of patients randomised not reported. Data reported on treatment completers only.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chan-2007","2012-06-25 08:36:30 +0100","YES","All stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chan-2007","2012-06-25 08:36:27 +0100","UNKNOWN","Protocol not available. Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chen-2003","2012-07-17 08:19:47 +0100","YES","Randomised using draw lots.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chen-2003","2012-07-17 08:19:40 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chen-2003","2012-07-23 13:04:54 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chen-2003","2012-07-23 13:05:11 +0100","UNKNOWN","""Double blind."" ","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chen-2003","2012-07-23 13:16:20 +0100","YES","One person dropped out of the control group due to myocardial infarction. The reason for this is unlikely to be related to the true outcome.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chen-2003","2012-07-17 08:21:23 +0100","YES","All measured outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chen-2003","2012-07-17 08:21:30 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chien-2004","2013-01-07 11:15:31 +0000","YES","""Randomised"" - computer-generated random numbers table.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chien-2004","2011-04-04 10:17:44 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chien-2004","2013-01-07 11:15:31 +0000","YES","Clinic staff were blinded, blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chien-2004","2011-04-10 13:05:45 +0100","YES","""An independent trained assessor (research assistant) undertook measurements at baseline (Time 1), 6 months (Time 2) and 18 months (Time 3), using a set of questionnaires. Both assessor and clinic staff were masked to treatment allocation"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chien-2004","2011-04-04 10:09:40 +0100","YES","Analysis of data was on an intention-to-treat basis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chien-2004","2011-04-04 10:17:04 +0100","YES","All stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Chien-2004","2011-04-04 10:17:32 +0100","UNKNOWN","Protocol not available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Drury-1996","2011-04-04 10:25:20 +0100","UNKNOWN","""randomised"" - no further details provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Drury-1996","2011-04-04 10:28:43 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Drury-1996","2012-07-23 13:05:46 +0100","YES","""Prescribing clinicians were blind to group allocation"", blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Drury-1996","2011-04-04 10:26:34 +0100","UNKNOWN","""All patients were rated by the first author and a random subset of patients were blindly rated by MB and JFM"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Drury-1996","2011-04-04 10:39:46 +0100","NO","22 patients were excluded after randomisation and not included in the final analyses.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Drury-1996","2011-04-04 10:31:37 +0100","NO","Not all expected outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Drury-1996","2011-04-04 10:33:02 +0100","UNKNOWN","Small sample size. Protocol not available. Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Garety-2008","2012-06-25 13:12:24 +0100","YES","""Randomisation schedules were independently generated by a trial randomisation service in a separate location from all trial centres using randomised permuted blocks""","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Garety-2008","2012-06-25 13:12:31 +0100","YES","Central randomisation ""Randomisation schedules were independently generated by a trial randomisation service""","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Garety-2008","2012-07-23 13:06:56 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Garety-2008","2012-07-23 13:06:37 +0100","YES","""Trial research assessors were independent of treatment delivery and every effort was made to ensure they were kept masked to allocation"" ""Patients were reminded by the assessors not to talk about treatment allocation"". ""The primary outcome variable, relapse, was assessed by masked panel evaluation""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Garety-2008","2012-12-12 14:33:37 +0000","YES","96% followed up for primary outcome data, secondary outcome data were available for 82% of the total sample at 12 months and for 80% at 24 months. No reasons for losses reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Garety-2008","2012-06-25 13:38:56 +0100","YES","All stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Garety-2008","2012-12-12 14:33:44 +0000","YES","Protocol pre-published (ISRCTN83557988). Source of funding: Wellcome Trust.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Granholm-2005","2011-04-04 12:39:09 +0100","YES","""randomised"" - sequential list of random numbers.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Granholm-2005","2011-04-07 08:20:56 +0100","UNKNOWN","""The project coordinator assigned participants to treatments in the order that they consented, and the coordinator was the only staff person other than therapists with knowledge of group membership"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Granholm-2005","2012-07-23 13:07:05 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Granholm-2005","2013-01-07 11:15:31 +0000","YES","The assessors were blinded to treatment group.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Granholm-2005","2011-04-04 12:43:43 +0100","YES","""Intent-to-treat analyses were used to examine all outcome variables"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Granholm-2005","2011-04-04 12:41:57 +0100","NO","Not all expected outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Granholm-2005","2011-04-04 12:46:32 +0100","UNKNOWN","Protocol not available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Gumley-2003","2011-04-04 12:57:10 +0100","UNKNOWN","""Patient randomised according to predetermined envelopes containing the treatment group, devised by researcher, which was unbeknown to the assessors, therapist or participants"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Gumley-2003","2011-09-16 09:14:06 +0100","UNKNOWN","""A member of the research team opened an envelope that informed as to which group individual participants were to be allocated. Another member of the team witnessed this procedure, and the envelope was placed in the participant's case file"".","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Gumley-2003","2012-07-23 13:07:14 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Gumley-2003","2011-04-04 13:12:10 +0100","NO","""Two research nurses, who were not blind to the treatment allocation of participants, conducted follow-up assessments"". ","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Gumley-2003","2011-04-04 13:13:18 +0100","YES","All data analysed on an intention-to-treat basis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Gumley-2003","2011-04-04 13:16:16 +0100","YES","All stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Gumley-2003","2011-04-04 13:16:44 +0100","UNKNOWN","Protocol not available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Harris-2009","2012-07-18 07:51:39 +0100","UNKNOWN","""Service users were randomly selected from each CMHP’s sample frame to form their ‘study caseload’ before CMHPs were randomised to either the training programme or training waiting list."" Does not report method of randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Harris-2009","2012-07-18 07:53:12 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Harris-2009","2012-07-23 13:07:22 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Harris-2009","2012-07-18 07:47:03 +0100","NO","“There was no ‘blind’ assessment of service user level outcomes.”","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Harris-2009","2012-12-12 14:37:35 +0000","YES","Intention-to-treat analysis used.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Harris-2009","2012-07-18 07:53:24 +0100","YES","All stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Harris-2009","2012-07-18 07:53:25 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Herz-2000","2012-12-12 14:38:12 +0000","YES","""randomised"" - computer-generated cards.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Herz-2000","2011-04-04 15:12:11 +0100","YES","Sealed envelopes.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Herz-2000","2012-07-23 13:07:28 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Herz-2000","2011-04-04 15:15:20 +0100","YES","""Assessments were done by research interviewers who were master's-level mental health professionals, blinded as to patient group assignment, not associated with clinical care and instructed not to inquire about a patient's treatment during interviews"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Herz-2000","2011-04-04 15:26:13 +0100","UNKNOWN","The study did not address this outcome.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Herz-2000","2011-04-04 15:28:17 +0100","YES","All stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Herz-2000","2011-04-04 15:36:55 +0100","UNKNOWN","Protocol not available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Hogarty-1997a","2011-04-06 12:30:37 +0100","UNKNOWN","""randomised"" - no further details provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Hogarty-1997a","2011-04-06 12:35:00 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Hogarty-1997a","2012-07-23 13:07:38 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Hogarty-1997a","2011-04-06 12:39:02 +0100","UNKNOWN","No information provided.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Hogarty-1997a","2012-07-24 14:49:57 +0100","UNKNOWN","Not intention-to-treat: ""Since missing data were relatively few and not different among treatment conditions, only the data collected were analysed.""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Hogarty-1997a","2012-07-23 13:16:31 +0100","YES","All stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Hogarty-1997a","2011-04-06 12:39:26 +0100","UNKNOWN","Protocol not available. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Horan-2009","2012-07-12 09:29:10 +0100","UNKNOWN","""randomly assigned"", no further information.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Horan-2009","2012-07-12 09:29:16 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Horan-2009","2012-07-23 13:07:46 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Horan-2009","2012-07-12 09:29:28 +0100","UNKNOWN","No information provided.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Horan-2009","2012-07-24 14:50:11 +0100","UNKNOWN","Three participants out of 34 dropped out.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Horan-2009","2012-07-12 09:39:18 +0100","NO","Not all expected outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Horan-2009","2012-07-12 09:29:48 +0100","UNKNOWN","Protocol not available. Source of funding:  US Mental Illness Research, Eduation and Clinical Center.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kopelowicz-1998a","2011-04-07 08:21:36 +0100","UNKNOWN","""Randomised"" -no further details provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kopelowicz-1998a","2011-04-06 12:51:54 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kopelowicz-1998a","2012-07-23 13:07:56 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kopelowicz-1998a","2011-04-06 13:02:39 +0100","UNKNOWN","No information provided.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kopelowicz-1998a","2012-07-24 14:50:27 +0100","UNKNOWN","Data reported on treatment completers only.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kopelowicz-1998a","2011-04-06 13:03:13 +0100","NO","Not all expected outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kopelowicz-1998a","2011-04-07 08:22:39 +0100","UNKNOWN","Protocol not available. Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kopelowicz-2003","2011-01-23 17:05:35 +0000","UNKNOWN","""randomised"" -no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kopelowicz-2003","2011-04-06 13:20:54 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kopelowicz-2003","2012-07-23 13:08:17 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention. ","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kopelowicz-2003","2012-07-23 13:08:21 +0100","YES","""All of the raters were blind to the treatment condition of the patients and relatives"", ""to ensure blindness the raters were instructed to remind patients and relative subjects at each visit to not disclose what kinds if treatment they were receiving"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kopelowicz-2003","2012-07-24 14:50:45 +0100","UNKNOWN","""Baseline comparisons were conducted with all 92 subjects who were randomised, but all subsequent analyses included only those subjects who were assessed at all three time points"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kopelowicz-2003","2011-04-06 13:23:44 +0100","YES","All stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kopelowicz-2003","2011-04-06 13:27:40 +0100","UNKNOWN","Protocol not available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kuipers-1997","2011-04-06 13:31:54 +0100","YES","Randomised permuted blocking, block size of six.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kuipers-1997","2011-04-13 14:50:28 +0100","YES","Carried out by the trial statistician.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kuipers-1997","2012-07-23 13:08:36 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kuipers-1997","2012-07-23 13:18:10 +0100","UNKNOWN","""In a trial of psychological treatment it is extremely difficult to make assessments that are totally blind to the treatment condition and this was not attempted. However, all assessments were carried out by independent research workers who were not involved in the treatments"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kuipers-1997","2012-07-24 14:53:07 +0100","UNKNOWN","'Decision to treat' analysis using the standard 'carry forward' method to impute missing values reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kuipers-1997","2011-04-06 13:41:56 +0100","NO","Not all expected outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Kuipers-1997","2011-04-06 13:44:58 +0100","NO","Protocol not available. Charitable donation from Janssen Pharmaceutica.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Li-2003","2012-07-11 17:34:37 +0100","UNKNOWN","""Random assignment"", no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Li-2003","2012-07-11 17:54:32 +0100","UNKNOWN","No details reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Li-2003","2012-07-23 13:08:46 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Li-2003","2012-07-11 17:54:43 +0100","UNKNOWN","No details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Li-2003","2012-07-24 14:53:16 +0100","UNKNOWN","There were 10 dropouts in the experimental group and 22 dropouts in the control group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Li-2003","2012-07-23 13:09:35 +0100","UNKNOWN","Number of participants for the outcome burden of care (FAS) not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Li-2003","2012-07-22 15:23:19 +0100","UNKNOWN","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Liberman-1998","2012-09-13 13:55:43 +0100","UNKNOWN","Randomised ""Cohorts of 10–12 outpatients with persistent and unremitting forms of schizophrenia were entered into the study through a randomization procedure"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Liberman-1998","2012-09-13 13:52:06 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Liberman-1998","2012-09-13 13:12:57 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Liberman-1998","2012-09-16 08:44:51 +0100","YES","Blinding of outcome assessors ""psychiatrists were blind to the psychosocial treatment assignment"", ""Blindness of the assessors was promoted by geographically distancing the treatment program from the locales for pharmacotherapy and ratings of outcome and by repeatedly instructing the subjects to refrain from mentioning their psychosocial treatment"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Liberman-1998","2013-01-07 11:15:32 +0000","UNKNOWN","Total included participants for each group was not clearly reported. ""Attrition was minimal; only 14 of 84 subjects dropped out during the 2-year period (four in the control group and 10 in the social skills training group; x","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Liberman-1998","2012-09-20 08:02:58 +0100","NO","Not all expected outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Liberman-1998","2012-09-13 13:02:18 +0100","YES","Funded by Department of Veterans Affairs and NIMH.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-McDonell-2006","2011-04-06 14:09:12 +0100","YES","Randomisation of participants conducted by (1) separating participants on the basis of 'atypical v conventional medication at status; (2) assigning a number and (3) pulling a piece of paper with the number from a hat giving a 50% chance of being in either group.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-McDonell-2006","2011-04-06 14:09:28 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-McDonell-2006","2012-07-23 13:09:42 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-McDonell-2006","2011-04-06 14:09:41 +0100","UNKNOWN","No information provided.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-McDonell-2006","2011-04-06 14:11:22 +0100","YES","Data analysed on an intention-to-treat basis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-McDonell-2006","2011-04-06 14:11:39 +0100","YES","All stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-McDonell-2006","2011-04-06 14:12:03 +0100","UNKNOWN","Protocol not available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Merinder-1999","2012-06-25 12:46:20 +0100","UNKNOWN","Patients were block randomised, stratified for gender and for illness duration.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Merinder-1999","2011-04-06 14:30:03 +0100","UNKNOWN","Randomisation by an independent institution, no further details provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Merinder-1999","2012-07-23 13:09:59 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Merinder-1999","2011-04-06 14:30:20 +0100","YES","""The ratings of psychopathology and psychosocial function were performed by researchers not involved in the intervention and not informed of the treatment allocation"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Merinder-1999","2011-04-06 14:39:43 +0100","YES","Data analyses on an intention-to-treat basis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Merinder-1999","2011-04-06 14:39:49 +0100","YES","All stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Merinder-1999","2011-04-06 14:41:56 +0100","NO","Protocol not available. Part funded by Lunbeck A/S, Denmark.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Norman-2002","2013-01-07 11:15:33 +0000","UNKNOWN","Participants were randomly assigned within matching by gender and number of previous hospitalisations, no further details provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Norman-2002","2011-04-06 14:46:57 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Norman-2002","2012-07-23 13:10:04 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Norman-2002","2011-04-06 14:48:06 +0100","YES","Data was collected by psychiatrists who ""were not responsible for the clinical care of the relevant clients and were kept blind as to the assignment of clients to the stress management or social activities conditions"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Norman-2002","2012-07-24 14:53:38 +0100","UNKNOWN","""Nine clients were lost to follow-up (five did not complete the intervention and four were unavailable for 1 year post-test assessments), leaving a net sample of 121 clients, 60 of whom were assigned to the stress management condition and 61 to the social activities. Because of sporadic instances of missing data, analyses are based on sample sizes varying between 112 and 121"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Norman-2002","2011-04-06 14:49:28 +0100","YES","All stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Norman-2002","2011-04-06 14:49:56 +0100","UNKNOWN","Protocol not available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Shin-2002","2011-04-06 14:53:52 +0100","UNKNOWN","""randomised"" - no further details provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Shin-2002","2011-04-06 14:54:07 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Shin-2002","2012-07-23 13:10:12 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Shin-2002","2011-04-07 08:23:35 +0100","UNKNOWN","""The BPRS was completed before and after the intervention in Korean by a bilingual Korean psychiatrist, who was blinded to participants' treatment modality [...] the other scales were verbally presented to the study participants by the first author in Korean and self-report answers were written down by the participants"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Shin-2002","2013-01-07 11:15:33 +0000","YES","All patients accounted for.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Shin-2002","2011-04-06 15:01:51 +0100","NO","Not all expected outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Shin-2002","2011-04-06 15:02:25 +0100","UNKNOWN","Protocol not available. Source of funding not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Shon-2002","2011-04-07 08:23:46 +0100","UNKNOWN","""Randomised"" - no further details provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Shon-2002","2011-04-06 15:04:23 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Shon-2002","2012-07-23 13:10:19 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Shon-2002","2011-04-06 15:04:30 +0100","UNKNOWN","No information provided.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Shon-2002","2011-04-07 08:26:58 +0100","UNKNOWN","The study does not address this outcome.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Shon-2002","2011-04-06 15:11:29 +0100","NO","Not all expected outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Shon-2002","2011-04-06 15:11:44 +0100","UNKNOWN","Protocol not available. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Tait-2002","2011-04-07 08:19:22 +0100","UNKNOWN","""Randomised"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Tait-2002","2011-04-06 15:17:56 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Tait-2002","2012-07-23 13:10:23 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Tait-2002","2011-04-06 15:18:13 +0100","UNKNOWN","No information provided.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Tait-2002","2011-04-07 08:19:41 +0100","UNKNOWN","""The mean postal response rate of ESM questionnaires [...] is 83%"". No further details provided.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Tait-2002","2011-04-07 08:19:18 +0100","NO","Not all expected outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Tait-2002","2011-04-06 15:39:08 +0100","UNKNOWN","Small sample size. Protocol not available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Turkington-2006","2011-04-07 08:34:02 +0100","YES","Randomisation conducted by computer-generated blocks of 6 random numbers and stratified by site.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Turkington-2006","2011-04-07 08:34:26 +0100","YES","Results of the randomisation placed in sealed envelopes and only opened at the time of treatment allocation.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Turkington-2006","2012-07-23 13:10:31 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Turkington-2006","2011-04-07 08:37:30 +0100","YES","Raters were independent. Patients were ""asked not to reveal or even hint at their treatment allocation to the raters. Raters were informed that some study material would be left with TAU patients to help preserve the blindness of the ratings"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Turkington-2006","2011-04-07 08:39:51 +0100","YES","Data analysed on an intention-to-treat basis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Turkington-2006","2011-04-07 08:40:22 +0100","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Turkington-2006","2011-04-07 08:44:17 +0100","NO","Protocol not available. Trial funded by a research grant from Pfizer.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Van-Meijel-2006","2011-04-07 11:41:15 +0100","UNKNOWN","Randomisation of nurses (therapists) and patients, nurses were divided at random per department between experimental and treatment conditions. A researcher determined at random the order in which the patients would be approached for participation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Van-Meijel-2006","2011-04-07 11:41:29 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Van-Meijel-2006","2012-07-23 13:10:46 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Van-Meijel-2006","2011-04-07 11:41:45 +0100","UNKNOWN","No information provided.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Van-Meijel-2006","2012-12-11 22:29:50 +0000","UNKNOWN","""11 patients dropped out from the experimental group and 2 from the control group. The reasons for dropping out of the experimental group were: premature discharge (n = 1); stress caused by preparing the relapse prevention plan (n = 2); psychotic relapse (n = 1); lack of motivation to prepare the relapse prevention plan (n = 5); and lack of time of the nurses (n = 2). The reason for dropping out of the control group was completion of the treatment (n = 2).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Van-Meijel-2006","2011-04-07 11:45:30 +0100","YES","All stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Van-Meijel-2006","2011-04-07 11:46:53 +0100","NO","Protocol not available. Financial support in part from Eli Lilly The Netherlands.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Vreeland-2006","2011-04-10 09:22:53 +0100","YES","Randomisation of participants based on a table of random numbers.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Vreeland-2006","2013-01-07 11:15:33 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Vreeland-2006","2012-07-23 13:10:51 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Vreeland-2006","2011-04-10 09:24:33 +0100","YES","""Trained raters who were blind to the study group assignment conducted interviews with participants to complete outcome measures at baseline, eight weeks and 24 weeks"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Vreeland-2006","2011-04-10 13:13:50 +0100","UNKNOWN","Three participants were not included in the final analysis ""because of missing data for the primary outcomes at time 1"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Vreeland-2006","2011-04-10 09:26:20 +0100","NO","Not all expected outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Vreeland-2006","2011-04-10 09:33:54 +0100","NO","Protocol not available. Funded in part by Eli Lily and Company.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Weng-2005","2011-04-10 09:35:48 +0100","UNKNOWN","""Randomly assigned"" - no further details provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Weng-2005","2011-04-10 09:35:56 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Weng-2005","2012-07-23 13:10:56 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Weng-2005","2011-04-10 13:14:00 +0100","UNKNOWN","""Double-blind assessments"", no further details provided.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Weng-2005","2012-07-24 14:54:32 +0100","YES","""61 patients in each group were successfully followed up one year after discharge"", no further details about participants lost to follow-up.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Weng-2005","2011-04-10 09:39:24 +0100","YES","All stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Weng-2005","2013-01-07 11:15:33 +0000","UNKNOWN","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Xiang-2001","2012-07-17 09:47:12 +0100","YES","Randomised using random number table.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Xiang-2001","2012-07-17 09:47:16 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Xiang-2001","2012-07-23 13:11:01 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Xiang-2001","2012-07-17 09:47:27 +0100","YES","Assessor blind.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Xiang-2001","2012-07-17 10:00:29 +0100","YES","2 people in the intervention group left the study early and 3 in the control group. Incomplete outcome data was excluded from the final analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Xiang-2001","2012-07-23 13:17:19 +0100","UNKNOWN","Insufficient information to permit judgement.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Xiang-2001","2012-07-17 09:48:47 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Xiong-1994","2011-04-10 10:04:57 +0100","UNKNOWN","""Randomly assigned"" - no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Xiong-1994","2011-04-10 10:05:08 +0100","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Xiong-1994","2012-07-23 13:11:22 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Xiong-1994","2011-04-10 13:14:28 +0100","UNKNOWN","""As in all family intervention studies, there was some difficulty in maintaining blinding [...] this problem by instructing families not to state who had provided treatment and by ensuring that the evaluators were unaware of the purpose of the study"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Xiong-1994","2011-04-10 13:14:59 +0100","UNKNOWN","One patient from the experimental group and one patient in the control group committed suicide. One patient form the experimental group died from complications of inadequately treated diabetes. ""These deaths were treated as relapses in the analysis"". ""Non-compliance does not confound the results because all subjects are included in the analysis"". ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Xiong-1994","2011-04-10 12:23:41 +0100","YES","All stated outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Xiong-1994","2011-04-10 12:32:56 +0100","UNKNOWN","Protocol not available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Zhan-2003","2012-07-23 13:17:30 +0100","YES","Randomised by a tossing a coin.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Zhan-2003","2012-07-17 10:28:53 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Zhan-2003","2012-07-23 13:11:28 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Zhan-2003","2012-07-17 10:29:08 +0100","YES","Assessor blind.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Zhan-2003","2012-07-17 10:29:37 +0100","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Zhan-2003","2012-07-17 10:29:39 +0100","YES","All measured outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Zhan-2003","2012-07-17 10:29:40 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Zhang-2004","2012-07-17 11:02:11 +0100","YES","Randomised using random number table.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Zhang-2004","2012-07-17 11:02:18 +0100","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Zhang-2004","2012-07-23 13:11:32 +0100","YES","Blinding of participants and personnel was not possible due to the nature of the intervention.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Zhang-2004","2012-07-17 11:02:30 +0100","YES","Assessor blind.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Zhang-2004","2012-07-24 14:55:00 +0100","UNKNOWN","16 people left the study early, 6 from the intervention group and 10 from the control group. Incomplete outcome data were excluded from the final analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Zhang-2004","2012-07-17 11:02:59 +0100","YES","All measured outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Training to recognise the early signs of recurrence in schizophrenia [v6.0-For publication].rm5","STD-Zhang-2004","2012-07-17 11:03:05 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Token economy for schizophrenia [v5.0-For publication].rm5","STD-Hall-1977","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Token economy for schizophrenia [v5.0-For publication].rm5","STD-Li-1994","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Token economy for schizophrenia [v5.0-For publication].rm5","STD-Maley-1973","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Barker-1969a","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Bergling-1975","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Borison-1989","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Carranza-1974","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Chen-1995","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Clark-1971","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Clark-1975","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Cohler-1966","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Dufresne-1993","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Evans-1972","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Galbrecht-1968","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Gallant-1972","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Gardos-1978","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Granacher-1982","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Grinspoon-1967","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Gui_x002d_Yun-1988","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Herrera-1990","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Ju-1997","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Judah-1958","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Keks-1994","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Kramer-1978","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Lasky-1961","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Liu-1994","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-McCreadie-1988","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Mena-1966","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Miyakawa-1973","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Montgomery-1992","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-NIMH-1964","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Nishikawa-1985","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Phanjoo-1990","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Pi-1990","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Rada-1972","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Rasmussen1976","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Realmuto-1982","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Schiele-1961","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Somerville-1960","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Stabenau-1964","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Van-Wyk-1971","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Vestre-1970","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Weston-1973","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Wolpert-1968","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Thioridazine for schizophrenia [v7.0-For publication].rm5","STD-Zhang-1999","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Testosterone for schizophrenia [v5.0-For publication].rm5","STD-Nachshoni-2005","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Testosterone for schizophrenia [v5.0-For publication].rm5","STD-Ritsner-2006","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Testosterone for schizophrenia [v5.0-For publication].rm5","STD-Strous-2002","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Coyle-1988","2013-04-23 15:24:39 +0100","UNKNOWN","Stratified random assignment according to age, sex and race. No further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Coyle-1988","2013-04-23 15:24:39 +0100","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Coyle-1988","2013-04-23 16:12:33 +0100","UNKNOWN","No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Coyle-1988","2013-04-23 16:12:36 +0100","UNKNOWN","No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Coyle-1988","2013-05-30 10:52:04 +0100","YES","""Out of the 94 subjects entering the study, 14 did not complete the treatment program. In the individual therapy method, one subject died of medical causes, one subject was hospitalised and one subject did not complete the data; in the social skills training method, three subjects dropped out and one was hospitalised; in the psychoeducational method, four subjects dropped out and two were hospitalised; in the medication only group, one subject dropped out, one was hospitalised and one subject did not complete the data. In addition, there were two subjects who completed the program but a full data package could not be collected on them.""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Coyle-1988","2013-04-24 08:21:07 +0100","NO","Reports results incompletely, no SD reported for KAS scale.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Coyle-1988","2013-04-23 16:12:15 +0100","UNKNOWN","Not enough information provided to make a judgement.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Davidson-2004","2013-03-27 16:00:24 +0000","UNKNOWN","""Randomly assigned"", no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Davidson-2004","2013-03-27 16:00:29 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Davidson-2004","2013-03-27 16:00:36 +0000","UNKNOWN","No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Davidson-2004","2013-03-27 16:00:42 +0000","UNKNOWN","No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Davidson-2004","2013-05-09 13:00:12 +0100","UNKNOWN","Losses to follow-up not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Davidson-2004","2013-03-27 16:11:29 +0000","YES","All expected outcomes are reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Davidson-2004","2013-03-27 17:38:29 +0000","YES","The study appears to be free of other sources of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Dincin-1982","2013-04-23 16:13:38 +0100","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Dincin-1982","2013-05-05 09:33:14 +0100","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Dincin-1982","2013-05-05 09:33:16 +0100","UNKNOWN","No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Dincin-1982","2013-05-05 09:33:18 +0100","UNKNOWN","No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Dincin-1982","2013-05-05 09:37:33 +0100","UNKNOWN","“Unable to contact 5 subjects from the comprehensive treatment and 14 from the supportive treatment programs. In the majority of these cases we reconstructed rehospitalisation data by talking to reliable informants and corroborating their reports with hospital records. Thus we were able to obtain verified outcome data for 50 of the 51 active subjects in the comprehensive treatment group and for 43 of the 51 active subjects in the supportive treatment group.""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Dincin-1982","2013-04-24 08:29:33 +0100","NO","Reports results incompletely, no SDs reported for time to hospitalisation and time spent in hospital.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Dincin-1982","2013-04-24 08:29:33 +0100","YES","""Research was supported by grant 518 from the Illinois Department of Mental Health and Developmental Disabilities"" .","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Durham-2003","2013-05-05 09:38:13 +0100","YES","""Randomisation procedure (sealed envelope technique) was devised by the project statistician, and administered centrally by the non-clinical project coordinator, It was carried out separately within each treatment centre using randomised permuted blocking"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Durham-2003","2013-04-24 08:56:43 +0100","YES","""Randomisation procedure (sealed envelope technique) was devised by the project statistician, and administered centrally by the non-clinical project coordinator”.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Durham-2003","2013-04-24 08:56:43 +0100","UNKNOWN","Patients not blinded: ""Patients also were asked not to mention any details of their treatment during post-treatment assessments, but three patients did."" No details reported for personnel.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Durham-2003","2013-05-09 09:30:49 +0100","UNKNOWN","""Work of the independent assessors and therapists were kept strictly separate in order to maintain the blindness of the assessor"". ","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Durham-2003","2013-05-05 09:39:26 +0100","YES","""The analyses were repeated with the missing values replaced either with previous values carried forward or with group means.""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Durham-2003","2013-04-24 09:02:00 +0100","NO","Reports results incompletely, no data reported for self-reported symptom severity, self-esteem, and attitude to illness, results not reported by group for self-rating of degree of improvement.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Durham-2003","2013-04-24 08:56:43 +0100","YES","The study appears to be free of other sources of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Eckman-1992","2013-04-24 09:00:57 +0100","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Eckman-1992","2013-04-24 09:00:59 +0100","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Eckman-1992","2013-04-24 09:01:06 +0100","UNKNOWN","Patients not blinded, no details reported for personnel.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Eckman-1992","2013-05-05 09:39:50 +0100","UNKNOWN","""Although attempts were made to keep the raters blind to the subjects' treatment conditions, a few patients revealed this information"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Eckman-1992","2013-05-09 13:01:25 +0100","UNKNOWN","""Over the full I8 month study period, more subjects in the skills training (15/21) than in the supportive therapy (12/21) remained  in the study"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Eckman-1992","2013-05-09 14:40:22 +0100","NO","Reports results incompletely, data not reported by group for BPRS and SANS, SD not reported for skills assessment.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Eckman-1992","2013-05-09 13:20:14 +0100","YES","""Supported by Medical Research Service, US Department of Veterans Affairs and by NIMH grants"".","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Falloon-1982","2013-04-24 12:44:48 +0100","UNKNOWN","“Randomized”, no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Falloon-1982","2013-04-24 12:44:48 +0100","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Falloon-1982","2013-05-09 09:33:28 +0100","UNKNOWN","""All patients were seen monthly at the clinic by a research psychiatrist or a clinical pharmacist, who was blinded to the type of treatment and responsible for managing the pharmacologic aspects of treatment."" No details reported about other staff. ","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Falloon-1982","2013-06-05 11:53:17 +0100","YES","Outcomes either self-assessments or by blinded assessors. “The raters were the prescribing doctors who were blinded to the assignment to treatment.""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Falloon-1982","2015-02-05 12:47:33 +0000","YES","“Two patients receiving family therapy and one receiving individual therapy withdrew from the study in the early stages of treatment”. Patients who withdrew were not analysed for any outcome. Losses to follow-up or missing data balanced across intervention groups, with similar reasons for missing data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Falloon-1982","2013-05-08 15:26:17 +0100","NO","Reports results incompletely, data not reported for Hopkins' Symptom Checklist and episode of depression, SDs not reported for average number of days in hospital.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Falloon-1982","2013-04-24 12:44:49 +0100","YES","Funded by an NIH grant.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Haddock-1999","2013-05-05 09:42:02 +0100","UNKNOWN","""Randomly allocated"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Haddock-1999","2013-05-05 09:41:59 +0100","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Haddock-1999","2013-05-05 09:41:59 +0100","UNKNOWN","No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Haddock-1999","2013-05-09 09:36:45 +0100","YES","""Independent assessment using the BPRS and PSYRATS was carried out by the project psychiatrist, who was blind to treatment allocation, and took place on entry to the study, at end of treatment and following the final booster session (4 months following discharge). Days in hospital for the initial episode and any subsequent episodes, number of relapses, time to relapse of  psychotic symptoms and time to first readmission were recorded for each patient from entry to the study and for 2 years following entry to the study by a blind independent assessor using patient case notes"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Haddock-1999","2013-05-05 09:42:25 +0100","YES","“One patient in the CBT treatment withdrew from the study after three sessions because he did not find it was helpful.” Unclear if patient who withdrew imputed into outcomes.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Haddock-1999","2015-02-05 12:47:33 +0000","NO","Reports results incompletely, SDs not reported for global state: number of relapses per participant; data not reported for mental state: PSYRATS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Haddock-1999","2013-05-09 13:21:45 +0100","UNKNOWN","Not enough information provided to make a judgement.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Hogarty-1997_x002d_study-1","2013-05-05 09:43:14 +0100","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Hogarty-1997_x002d_study-1","2013-05-05 09:43:10 +0100","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Hogarty-1997_x002d_study-1","2013-05-05 09:43:10 +0100","UNKNOWN"," No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Hogarty-1997_x002d_study-1","2013-05-05 09:43:25 +0100","NO","""The ratings of treating clinicians who were not blind to the treatment conditions, thereby raising the question of rater bias"", ""results should be viewed cautiously in the absence of independent and blind clinical assessors.""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Hogarty-1997_x002d_study-1","2015-02-05 12:47:33 +0000","YES","8 patients in the supportive therapy group had treatment-related terminations, one in the personal therapy group, five in the family therapy group and 1 in the combined personal and family therapy group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Hogarty-1997_x002d_study-1","2013-05-08 15:26:02 +0100","NO","Reports results incompletely, data not reported for Global state: GAS, Subjective Response Questionnaire; Mental state: BPRS, Raskin Depression Scale, Covi Anxiety Scale, Wing Negative Symptom Scale, Everyday Worries Scale; General functioning: KAS, SAS II, Major Role Adjustment Inventory; data not reported by group for Satisfaction with treatment.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Hogarty-1997_x002d_study-1","2013-05-09 13:21:56 +0100","YES","""Supported by a MERIT extension of NIMH grant.""","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Hogarty-1997_x002d_study-2","2013-05-05 09:48:27 +0100","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Hogarty-1997_x002d_study-2","2013-05-05 09:48:32 +0100","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Hogarty-1997_x002d_study-2","2013-05-05 09:48:34 +0100","UNKNOWN","No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Hogarty-1997_x002d_study-2","2013-05-05 09:49:01 +0100","NO","""The ratings of treating clinicians who were not blind to the treatment conditions, thereby raising the question of rater bias"", ""results should be viewed cautiously in the absence of independent and blind clinical assessors.""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Hogarty-1997_x002d_study-2","2015-02-05 12:47:33 +0000","YES","Five patients in the supportive therapy group and four in the personal therapy group had treatment-related terminations.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Hogarty-1997_x002d_study-2","2013-05-08 15:27:27 +0100","NO","Reports results incompletely, data not reported for  Global state: GAS, Subjective Response Questionnaire; Mental state: BPRS, Raskin Depression Scale, Covi Anxiety Scale, Wing Negative Symptom Scale, Everyday Worries Scale; General functioning: KAS, SAS II, Major Role Adjustment Inventory; data not reported by group for Satisfaction with treatment.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Hogarty-1997_x002d_study-2","2013-05-05 09:49:42 +0100","YES","""Supported by a MERIT extension of NIMH grant.""","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Kemp-1996","2013-05-05 09:50:10 +0100","YES","""Randomly assigned by means of a table of random numbers to compliance therapy or control treatment""","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Kemp-1996","2013-05-05 09:50:00 +0100","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Kemp-1996","2013-05-05 09:50:12 +0100","UNKNOWN","No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Kemp-1996","2013-05-05 09:51:26 +0100","UNKNOWN","""Initial compliance was rated blind to intervention by the patients' primary nurses,""; ""The evaluations at six months were carried out by an independent assessor (a community psychiatric nurse) blind to intervention.""; ""Most of the ratings of functioning and compliance initially and at three months were made by a research psychiatrist, who was not blind to intervention group. However, the compliance ratings were based on information from impartial sources, including community psychiatric nurses and outpatient doctors on the clinical teams. By contrast, the ratings at six months were carried out by a researcher trained in the use of all the ratings, who was blind to intervention group."" Some outcome assessors blinded, except third month assessment.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Kemp-1996","2015-02-05 12:47:34 +0000","YES","""Overall, 35% were lost during the follow-up period (11 (28%) from the compliance therapy group and 15 from. the control group (43%); Ten participants were lost during the first six months of follow-up, five from each group; Subsequently, a further 14 could not be directly re-interviewed at 12-month follow-up, Post-treatment drop-out occurred due to refusal (11), patients either being uncontactable (7) or moving out of the area (2) or recovered patients who were working or at college and no longer having psychiatric out-patient treatment (2). One patient was in prison, There were two deaths, one resulting from stroke, and one from myocardial infarction"". Details reported for imputing missing data by method of maximum likelihood.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Kemp-1996","2013-05-08 15:31:29 +0100","NO","Reports results incompletely, data not reported for adverse effects: Simpson-Angus scale for extra-pyramidal side effects, Barnes akathisia scale, NART; data not reported by group for death; scale not peer reviewed for medication compliance measure.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Kemp-1996","2013-05-05 09:52:33 +0100","YES","Funding from the Medical Research Council.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Klein-1998","2013-03-25 14:12:36 +0000","UNKNOWN","""The study sample was randomly selected from ICM caseload lists...The remaining 51 clients in the study population served as a comparison group"", no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Klein-1998","2013-03-25 14:02:54 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Klein-1998","2013-05-08 16:13:06 +0100","UNKNOWN","No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Klein-1998","2013-03-25 14:03:13 +0000","UNKNOWN","No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Klein-1998","2013-03-25 14:31:21 +0000","YES","""One participant who originally consented to the study and was assigned an FC withdrew after a few weeks. We did not replace her as she was already part of the study group, and all analyses include her"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Klein-1998","2013-10-08 07:10:50 +0100","NO","The study did not report SDs for hospitalisation, quality of life, activities of daily living and social functioning. No data were reported for use of community resources.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Klein-1998","2013-05-08 16:29:33 +0100","YES","Appears free of other sources of bias. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Levine-1998","2013-05-05 09:52:48 +0100","UNKNOWN","""Randomly assigned"" . No further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Levine-1998","2013-05-05 09:54:34 +0100","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Levine-1998","2013-05-05 09:54:37 +0100","UNKNOWN","No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Levine-1998","2013-05-05 09:54:15 +0100","YES","""The PANSS scale was scored by an independent, board certified, senior psychiatrist well trained in the use of the PANSS. The psychiatrist was not aware of the group assignment of the subjects.""  No further details reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Levine-1998","2013-05-09 13:02:21 +0100","UNKNOWN","Losses to follow-up not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Levine-1998","2013-05-09 12:15:52 +0100","NO","Not all expected outcomes are reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Levine-1998","2013-05-09 14:38:28 +0100","UNKNOWN","Not enough information provided to make a judgement.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Lewis-2002b","2013-06-05 11:55:08 +0100","YES","""Independent, concealed, randomisation of individuals with minimisation was then performed by trial administrator at each centre. Stratification was undertaken with variables"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Lewis-2002b","2013-06-05 11:55:12 +0100","YES","""independent, concealed, randomisation of individuals with minimisation was then performed by trial administrator at each centre. Stratification was undertaken with variables""","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Lewis-2002b","2013-05-09 12:26:40 +0100","YES","""Interventions carried out independently of clinical staff who were kept unaware of treatment allocation.""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Lewis-2002b","2013-05-05 09:58:56 +0100","YES","""All outcome assessments were made blind to treatment allocation. Extensive steps were taken to maintain blindness of raters. In all cases randomisation was carried out by a trial administrator independently of rater or therapist. Therapist and rater were not to communicate details about individual patients to each other. Office space and data storage were kept separate and secure. Clinical staff were instructed not to divulge details of therapist contacts to the raters."" ","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Lewis-2002b","2015-01-19 15:19:34 +0000","YES","“Fifteen patients (CBT 4; supportive counselling 4; routine care 7) withdrew consent to participate during the follow-up period, but are included in the analysis prior to their withdrawal; 13 of these withdrawals occurred during the first 2 weeks. One patient died during the follow-up period (in the supportive counselling group). ""Analyses were conducted on an intention-to-treat basis, with patients analysed in the treatment group to which they were randomised""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Lewis-2002b","2013-05-09 12:26:43 +0100","YES","All expected outcomes are reported","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Lewis-2002b","2013-06-05 12:01:25 +0100","YES","The trial was funded as follows: UK Medical Research Council (41%): Northwest England NHSE Office (27%); Trent NHSE Office (7%); the following health authorities: Manchester (8%); Salford and Trafford (2%); Liverpool (3%); Sefton (3%); St Helens and Knowsley (3%); North Nottinghamshire (6%).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Malm-1982","2013-05-05 10:02:34 +0100","UNKNOWN","""By randomisation they were allocated to the therapy or the control group."", stratified randomisation based on sex.  ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Malm-1982","2013-05-05 10:02:39 +0100","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Malm-1982","2013-05-05 10:02:40 +0100","UNKNOWN","No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Malm-1982","2013-05-05 10:02:24 +0100","UNKNOWN","“Ratings agreed closely with those of the independent blind raters.” Raters that were blinded not specified, “There were 7 independent raters, 5  physicians and 2 psychologists.”","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Malm-1982","2013-05-05 10:03:22 +0100","YES","”Six patients in the therapy  group and six in the control group either did not start or did not complete the study” Details of dropouts further reported in table.  Dropouts not included in analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Malm-1982","2013-05-05 10:03:40 +0100","NO","Reports results incompletely, data not reported for CPRS - global rating of illness, all items except derealisation and inability to feel; KAS - socially expected activities subscale, offensive behaviour syndrome and work and study item","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Malm-1982","2013-05-05 10:03:56 +0100","YES","The study appears to be free of other sources of bias. The study has been supported by grants from the Einar Hansen Fund for Research, the Leo Research Fund, the Lundbeck Foundation and the Stiftelsen Psykiatriska Forskningsfonden, Goteborg.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-O_x0027_Donnell-1999","2013-05-05 10:04:30 +0100","UNKNOWN","""Randomly allocated"" . No further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-O_x0027_Donnell-1999","2013-05-05 10:04:33 +0100","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-O_x0027_Donnell-1999","2013-05-05 10:04:35 +0100","UNKNOWN","No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-O_x0027_Donnell-1999","2013-05-05 10:04:36 +0100","UNKNOWN","No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-O_x0027_Donnell-1999","2015-02-05 12:47:34 +0000","YES","15 participants from the standard case management group left the study early, 7 from the client-focused case management group, 18 from the client-focused case management plus advocate group. Reasons similar across groups.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-O_x0027_Donnell-1999","2013-05-13 12:37:27 +0100","NO","Reports results incompletely, data not reported for global state: HoNOS, general functioning; service outcomes: hospitalisation, duration of hospital admissions, use of crisis services, mental state: response to treatment; satisfaction with treatment; quality of life; Family Interview Schedule and compliance.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-O_x0027_Donnell-1999","2013-05-05 10:09:48 +0100","YES","""Commonwealth Innovative Grants Program of the National Mental Health Strategy (Grant No. 22004) for funding this study""","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Penn-2009","2013-06-05 12:04:43 +0100","YES","""Randomisation was stratified by gender to ensure equal numbers across groups using a computer randomisation generator"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Penn-2009","2013-05-09 10:28:36 +0100","YES","""Randomisation to treatment condition (with condition being designated by a random number), was conducted by two research assistants who were blind to the correspondence between random number and treatment group.""","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Penn-2009","2013-05-09 10:36:21 +0100","UNKNOWN","Participants not blinded. No information reported about personnel.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Penn-2009","2013-03-27 17:17:01 +0000","YES","""Participants were assessed...by research assistants blind to treatment group.""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Penn-2009","2013-03-28 09:25:59 +0000","YES","""We analysed data on all participants irrespective of treatment adherence (i.e., intent-to-treat analyses) and number of post treatment assessments"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Penn-2009","2013-03-27 17:24:27 +0000","YES","All expected outcomes are reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Penn-2009","2013-03-27 17:25:14 +0000","YES","Appears free of other sources of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Pinto-1999","2013-05-05 10:10:13 +0100","UNKNOWN","""Randomly assigned  "" No further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Pinto-1999","2013-05-05 10:10:15 +0100","UNKNOWN","No information reported..","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Pinto-1999","2013-05-05 10:10:17 +0100","UNKNOWN","No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Pinto-1999","2013-05-05 10:10:19 +0100","UNKNOWN","No information reported.","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Pinto-1999","2015-01-19 15:53:34 +0000","YES","“One subject in the cognitive-behavioral group did not complete the study; the client developed leukopenia, and clozapine was discontinued. In the supportive therapy group, two subjects withdrew because of refusal to participate further, and a third developed seizures and his clozapine was stopped.” Losses to follow­up not included in analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Pinto-1999","2013-05-05 10:10:43 +0100","NO","Reports results incompletely, data not reported for dose of antipsychotic medication.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Pinto-1999","2013-05-09 14:38:38 +0100","UNKNOWN","Not enough information provided to make a judgement.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Sensky-2000b","2013-05-05 10:11:08 +0100","UNKNOWN","""Simple randomisation applied"". No further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Sensky-2000b","2013-05-05 10:11:14 +0100","YES","""The randomisation was by members of the research team not involved with either the assessments or the treatments.""","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Sensky-2000b","2013-05-05 10:11:00 +0100","UNKNOWN","No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Sensky-2000b","2013-05-05 10:12:21 +0100","YES","""Assesors were independent of the randomisation process and remained blind to each patient's assigned group throughout the study"".","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Sensky-2000b","2013-05-05 10:12:19 +0100","YES","Missing data have been imputed using appropriate methods ""intention to treat analysis"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Sensky-2000b","2013-06-05 12:06:38 +0100","YES","Patient satisfaction score scale not peer reviewed.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Sensky-2000b","2013-05-05 10:12:31 +0100","YES","Funded by grant from Welcome trust, further financial support was provided by Hounslow and Spelthorne community and mental health service trust.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Spaulding-1999","2015-02-05 12:47:34 +0000","UNKNOWN","""Patients in the cohort were matched pair-wise, as closely as possible, for gender, chronicity, and overall levels of personal and social functioning. Each patient in the pair was then assigned to one of two groups. When there was an odd number of patients in the cohort, the unmatched individual was randomly assigned to one of the groups. One of the groups was then randomly assigned to the experimental condition and the other to the control condition"". No further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Spaulding-1999","2013-05-05 10:13:52 +0100","UNKNOWN","Matched pair randomisation. No further details reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Spaulding-1999","2013-06-05 12:06:48 +0100","YES","""All clinical and research personnel were blind to experimental condition, except for the cognitive and supportive therapists, the observers who performed the process measures in the project's first year, and the principal investigator.""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Spaulding-1999","2013-06-05 12:06:53 +0100","UNKNOWN","""All NOSIE-30 raters were blind to treatment group assignment"" ; ""There definitely were no breaches with any staff directly involved in clinical or laboratory assessments"". ""All clinical and research personnel were blind to experimental condition, except for the cognitive and supportive therapists, the observers who performed the process measures in the project's first year, and the principal investigator.""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Spaulding-1999","2013-05-09 12:53:36 +0100","YES","“One subject who dropped out after the intensive treatment period began.”","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Spaulding-1999","2013-05-05 10:20:14 +0100","NO","Reports results incompletely, data not reported for BPRS, PANSS, TLC, NOSIE-30, AIPSS, Symptom Management skill assessment, Medication Management skill assessment, Leisure Skills assessment, Conversational Skills assessment, COGLAB cognitive assessment battery, Trailmaking test, Tactile Performance Test, Categories, Rey Auditory and Visual Learning Tasks, Denman Neuropsychological Memory Test","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Spaulding-1999","2013-06-05 12:09:16 +0100","YES","Funded by an NIH grant","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Stanton-1984","2013-05-05 10:21:31 +0100","YES","""Assignment to EIO or RAS was achieved by a random numbering system within an unrelated office.""; ""On those occasions where imbalances appeared, a weighting was introduced into the randomisation procedure to reestablish comparability of the EIO and RAS groups at baseline.""","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Stanton-1984","2013-05-05 10:20:59 +0100","UNKNOWN","""Assignment to EIO or RAS was achieved by a random numbering system within an unrelated office"" Details of method not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Stanton-1984","2013-06-05 12:09:22 +0100","NO","""We knew that significant others, ward staff, and project staff also would not be blind to the patient's experimental condition.""","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Stanton-1984","2013-06-05 12:09:27 +0100","UNKNOWN","""Four different groups of people administered the measures: (1) project psychiatrists; (2) blind evaluators; (3) psychological testers; and (4) research assistants.""; ""Psychological testers were clinical psychologists with expertise in psychological testing. They were blind to the experimental conditions to which patients were assigned and also unfamiliar with the study design and hypotheses.""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Stanton-1984","2013-05-05 10:40:44 +0100","NO","High attrition rates reported throughout both groups during all three follow-up periods (See Notes above).  Reasons for attrition not reported. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Stanton-1984","2013-05-05 10:40:50 +0100","NO","Reports results incompletely, data not reported for Menninger Health-Sickness Rating Scale, Psychotherapy Outcome Interview, Psychiatric Status Schedule, IMPS, Inpatient Multidimensional Psychiatric Scale, Camarillo Dynamic Assessment Scale , WAIS, KAS, Gottschalk Social Alienation/ Personal Disorganisation Scale, Rorschach test, Thematic Apperception Test, Visual-Verbal Test, Soskis Attitude Toward Illness Questionnaire;","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Stanton-1984","2013-05-05 10:40:53 +0100","YES","""supported in part by NIMH Grant ""","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Tarrier-1998","2013-05-05 10:48:44 +0100","YES","""Patients were allocated on a stratified block randomised procedure with block size equal to nine by using severity of symptoms and sex to one of three treatment groups""","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Tarrier-1998","2013-06-05 10:57:48 +0100","UNKNOWN","""Allocation, contained in sealed envelopes, was carried out independently by a third party.""","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Tarrier-1998","2013-05-05 10:48:36 +0100","UNKNOWN","No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Tarrier-1998","2015-01-19 15:31:56 +0000","YES","""Effort was made to blind the independent assessors to treatment allocation by using separate offices in a different part of the hospital for the assessors and therapists, using separate administrative procedures, instructing patients to not reveal details of their care, data entry being carried out independently of the assessors, and using a multiple coding system for treatment groups."" ","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Tarrier-1998","2013-05-05 10:49:15 +0100","YES","""Analysis by intention to treat was completed on the 87 allocated patients, with last observations (scores before treatment) being carried forward for the eight patients for whom scores after treatment were missing"". Missing data have been imputed using appropriate methods (intention to treat analysis), and losses to follow-up or missing data balanced across intervention groups.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Tarrier-1998","2013-05-05 10:49:26 +0100","NO","Reports results incompletely, data not reported for BDI, BHS, KGV, SFS, and dose of antipsychotic medication; SDs not reported for PSE.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Tarrier-1998","2013-05-05 10:49:40 +0100","YES","Funded by a Wellcome Trust grant.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Turkington-2000","2013-05-05 10:51:46 +0100","UNKNOWN","Patients randomised on 2:1 basis after initial assessments made. No further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Turkington-2000","2013-05-05 10:51:53 +0100","UNKNOWN","Details of method not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Turkington-2000","2013-05-05 10:52:01 +0100","YES","""Patients randomly allocated to two groups…with the patients, assessors, and clinical team remaining blind to the allocation.”","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Turkington-2000","2013-05-05 10:52:06 +0100","YES","""Patients randomly allocated to two groups…with the patients, assessors, and clinical team remaining blind to the allocation. ","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Turkington-2000","2013-05-05 10:52:13 +0100","YES","“One patient in the cognitive techniques group withdrew consent after the initial interview, and so had to be excluded from the study”, “Calculations were also made excluding his results, from the analysis” ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Turkington-2000","2013-05-05 10:52:17 +0100","NO","Reports results incompletely, SDs not reported for time spent in hospital, CPRS, MADRS.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Turkington-2000","2013-05-05 10:53:40 +0100","YES","The study appears to be free of other sources of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Uzenoff-2007","2013-03-27 17:27:37 +0000","UNKNOWN","""Randomised"",' no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Uzenoff-2007","2013-03-27 17:26:10 +0000","UNKNOWN","No information reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Uzenoff-2007","2013-05-09 10:49:19 +0100","UNKNOWN","No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Uzenoff-2007","2013-06-05 12:09:39 +0100","YES","""Assessments were conducted at baseline, mid treatment (3 months), and posttreatment (6 months) by interviewers blind to treatment condition.""","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Uzenoff-2007","2015-01-19 14:26:50 +0000","YES","""Of the 24 participants randomized to receive treatment, a total of 5 participants were excluded from outcome data analyses""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Uzenoff-2007","2013-05-09 14:40:13 +0100","YES","All expected outcomes are reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Uzenoff-2007","2013-05-09 14:39:13 +0100","YES","The study appears to be free of other sources of bias.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Wirshing-1991","2013-05-05 10:54:05 +0100","UNKNOWN","""Randomly assigned"" no further details reported.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Wirshing-1991","2013-05-05 10:54:09 +0100","UNKNOWN","Details of method not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Wirshing-1991","2013-06-05 12:10:12 +0100","UNKNOWN","No information reported.","Blinding of participants and personnel (performance bias)","QIT-07","Performance bias due to knowledge of the allocated interventions by participants and personnel during the study","QIG-07.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Wirshing-1991","2013-05-05 10:54:28 +0100","NO","""The rater was a clinician who was not blind to the psychosocial treatment condition."" ","Blinding of outcome assessment (detection bias)","QIT-08","Detection bias due to knowledge of the allocated interventions by outcome assessors","QIG-08.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Wirshing-1991","2013-06-05 12:10:17 +0100","UNKNOWN","Losses to follow-up not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Wirshing-1991","2013-05-05 11:07:53 +0100","NO","Reports results incompletely, data not reported for BPRS, SANS, exacerbation, severity of exacerbation, prodrome, latency from prodrome to exacerbation, SAS-II, Amount of medication needed to control an exacerbation, and degree of life disruption during an exacerbation.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supportive therapy for schizophrenia [v7.2-For publication].rm5","STD-Wirshing-1991","2013-06-05 12:10:22 +0100","YES","""This project was supported in part by research grants from the Veterans Administration Medical Research Service and the National Institute of Mental Health (MH141573 and MH30911)"".","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Bond-2007","2013-08-02 11:35:06 +0100","YES","Randomisation was achieved by means of a computerised randomisation list. Probably done.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Bond-2007","2013-08-02 11:35:13 +0100","YES","After the baseline interview was completed, the interviewer called the offsite project director to report the new participant's identification number, program location (North or South), and work history (experienced/inexperienced). The project director responded with study condition as determined by an a priori computerised randomisation list prepared for each work history level within site. Probably done.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Bond-2007","2013-08-01 21:52:20 +0100","NO","Participants could identify the given intervention by contents of the program. Interviewers not blind to assignment.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Bond-2007","2013-08-06 20:40:27 +0100","NO","Number of lost to follow-up reported, but no reasons for missing data provided. Among n = 200 randomised, n = 6 were dropped administratively after randomisation as they were subsequently found to be ineligible for study, with a total of n = 194 left. A further n = 4 from IPS and n = 3 from DPA were lost to follow-up, with a total of n = 187 (94%) providing data. Out of n = 194, n = 51 dropped-out within first 10 days, with n = 82 remaining in IPS and n = 65 in the DPA group (27% lost) (LOCF).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Bond-2007","2013-08-01 22:28:37 +0100","YES","All listed outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Bond-2007","2013-08-01 21:43:58 +0100","UNKNOWN","Funding: supported by Grant R01MH59987 from the National Institute of Mental Health; participants were paid between $5 to $15 for each interview depending on length.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Burns-2007","2013-08-02 12:05:14 +0100","YES","Randomisation was done centrally with MINIM. Probably done.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Burns-2007","2010-12-21 13:58:42 +0000","YES","The allocation sequence was concealed until the services had been assigned.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Burns-2007","2010-12-21 09:53:45 +0000","NO","Participants could identify the given intervention by contents of the program.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Burns-2007","2013-08-06 20:40:27 +0100","YES","Total of 81% completed the study to final follow-up; n = 24 dropped-out of IPS group (n = 21 refused interview, n = 3 died 'of natural causes'); n = 38 dropped-out of VS group (n = 21 between assessment and service uptake, n = 15 before being assessed, no reasons provided; n = 2 died, 'from natural causes'). All follow-up participants receiving IPS were treated; in follow-up participants in VS group, n = 93 were treated and n = 27 were not treated. The study conducted ITT.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Burns-2007","2013-08-02 15:21:18 +0100","YES","All listed outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Burns-2007","2013-08-02 15:21:31 +0100","YES","Funding: quote, ""The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication."" (p1149). ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Drake-1996","2013-08-02 16:07:27 +0100","UNKNOWN","Randomised: quote, ""stratified on the extent of previous employment"" (p394). ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Drake-1996","2010-12-21 14:10:21 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Drake-1996","2010-12-21 09:54:31 +0000","NO","Participants could identify the given intervention by contents of the program.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Drake-1996","2013-08-06 20:40:27 +0100","NO","Number and reason for attrition reported: data were obtained for 140 of 143 participants, with reasons for drop-out including n = 1 drop-out after baseline interview; n = 1 death of cancer after 7 months; n = 1 drop-out after 12 months of study (IPS loss n = 1; GST loss n = 2). Data for n = 133 only available for 18 month outcomes of mean hours worked and mean earnings.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Drake-1996","2013-08-05 08:39:17 +0100","YES","All listed outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Drake-1996","2013-08-05 09:34:36 +0100","YES","Funding: supported by U.S. Public Health Services Grant MH00839 from the National Institute of Mental Health and Grant MH47650 from the National Institute of Mental Health and the Substance Abuse and Mental Health Services Administration and by the New Hampshire Divisions of Mental Health and Vocational Rehabilitation, the Mental Health Center of Greater Manchester, the Central New Hampshire Community Mental Health Services, and the Employment Connection Specialists.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Drake-1999","2013-08-05 09:32:39 +0100","YES","Randomisation was achieved by means of computer-generated random numbers; stratified according to work history. Probably done.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Drake-1999","2010-12-21 14:15:58 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Drake-1999","2010-12-21 09:54:43 +0000","NO","Participants could identify the given intervention by contents of the program.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Drake-1999","2013-08-06 20:40:27 +0100","UNKNOWN","Complete vocational data obtained for n = 150. Number of lost to follow-up reported, but no reasons for missing data provided.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Drake-1999","2010-12-21 14:18:21 +0000","YES","All listed outcomes of interest reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Drake-1999","2013-08-05 09:35:10 +0100","YES","Funding: supported by grant MH51346 from Substance Abuse and Mental Health Services Administration and the National Institute of Mental Health, Washington DC; and grant MH00839 from National Institute of Mental Health. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Gold-2006","2013-08-05 09:44:27 +0100","YES","SAS-generated restricted random assignment sequence was used (permuted blocks of 3).","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Gold-2006","2013-08-05 09:44:45 +0100","YES","No investigator was permitted to access to the assignment sequence.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Gold-2006","2011-01-08 01:46:52 +0000","NO","Participants could identify the given intervention by contents of the program.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Gold-2006","2013-08-05 10:54:32 +0100","YES","N=108 (61%) completed study. Last observation carried forward used.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Gold-2006","2013-08-05 09:55:50 +0100","YES","All listed outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Gold-2006","2013-08-05 09:53:41 +0100","NO","Project redesign and deviation from a prespecified random assignment process may have compromised study internal validity and program construct validity.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Howard-2010","2013-08-05 11:08:59 +0100","YES","Randomised: stratified by gender and age (10-year bands); randomisation by minimisation performed by Institute of Psychiatry Mental Health and Neuroscience Clinical Trials Unit. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Howard-2010","2010-12-21 14:22:24 +0000","YES","Probably done. Randomisation with minimisation was used, performed by the Institute of Psychiatry Mental Health and Neuroscience Clinical Trials Unit, a unit independent of the study to maintain concealment.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Howard-2010","2010-12-21 14:23:01 +0000","NO","Participants could identify the given intervention by contents of the program.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Howard-2010","2013-08-06 20:40:27 +0100","NO","N=11 in each group lost to follow-up and excluded from analysis; in the intervention group, n = 9 were withdrawn, n = 1 was out of the country, n = 1 unable to find. In the control group n = 8 were withdrawn, n = 2 were out of the country, and n = 1 unable to find. Total N=197/219 included in analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Howard-2010","2013-08-05 11:25:49 +0100","YES","All listed outcomes of interest reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Howard-2010","2013-08-05 11:29:52 +0100","YES","Funding: study supported by the Wellcome Trust (GR071272MA); the supported employment programme was funded partly by the King’s Fund and the South London and Maudsley Charitable Trust.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Killackey-2008","2013-08-05 11:45:30 +0100","YES","Randomisation was done using computer-generated random numbers by statistician independent of the study.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Killackey-2008","2013-08-05 11:45:38 +0100","YES","The statistician was contacted by the leader of the project when a new participant enrolled and the statistician informed the leader of the group allocation. Probably done.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Killackey-2008","2013-04-30 13:51:24 +0100","NO","Information about group allocation was given to each participant and his/her case managers. The research assistant was not involved in the randomisation process, but there were no formal tests of her masking to allocation.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Killackey-2008","2013-08-06 20:40:27 +0100","YES","One person from the intervention group and n = 5 from the treatment as usual (TAU) group dropped-out. Reasons included n = 4 from TAU felt that the intervention was not helping them obtain work; the other n = 2 (one from each group) were sent to prison for offences committed before study recruitment. All participants gave permission for follow-up to be determined by their case manager and medical records - the study conducted ITT analysis. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Killackey-2008","2013-08-05 11:56:47 +0100","YES","All listed outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Killackey-2008","2013-08-05 11:59:36 +0100","UNKNOWN","Funding: supported by National Health and Medical Research Council Program Grant 350241 and an unrestricted study grant from Bristol Myers Squibb. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Latimer-2006","2013-08-05 12:08:37 +0100","YES","Randomised: stratified by work history and clinical site. The biostatistician generated 16 random assignment sequences. Probably done.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Latimer-2006","2013-08-05 12:10:32 +0100","YES","The project coordinator prepared an opaque envelope containing the assignment and gave it to the interviewer before the baseline interview.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Latimer-2006","2010-12-21 14:32:44 +0000","NO","Assignment was revealed (to both interviewer and participant) at the conclusion of the baseline interview.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Latimer-2006","2013-08-06 20:40:27 +0100","YES","Number and reason for attrition reported, with n = 9 lost to follow-up in the usual service group, and n = 16 lost in the supported employment group. Intention to treat analysis used. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Latimer-2006","2013-08-05 12:30:14 +0100","YES","All listed outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Latimer-2006","2013-08-05 12:31:45 +0100","UNKNOWN","Funding: Canadian Institutes of Health Research, Quebec Health Research Fund and AETMIS. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Lehman-2002","2013-08-05 14:35:25 +0100","UNKNOWN","Randomised using pre-prepared sealed envelopes. ","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Lehman-2002","2011-01-08 05:35:23 +0000","YES","Using pre-prepared sealed envelopes.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Lehman-2002","2011-01-08 05:42:47 +0000","NO","Participants could identify the given intervention by contents of the program.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Lehman-2002","2013-08-05 14:40:54 +0100","UNKNOWN","N=148 (68%) completed study. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Lehman-2002","2013-08-05 15:01:54 +0100","YES","All listed outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Lehman-2002","2013-08-05 15:03:29 +0100","UNKNOWN","Participants received $20 for baseline interviews, $10 for each of next two follow-up interviews and $15 for the 18 and 24 month interviews. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Macias-2006","2011-01-07 13:13:13 +0000","UNKNOWN","Participants were randomly assigned to one of the two conditions by picking a card from a hat.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Macias-2006","2011-01-07 13:14:11 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Macias-2006","2011-01-07 13:14:25 +0000","NO","Participants could identify the given intervention by contents of the program.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Macias-2006","2013-08-06 20:40:27 +0100","NO","N=121 (68%) completed the study (n = 25 from ACT; n = 31 from Clubhouse) - reasons not described.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Macias-2006","2013-08-05 15:36:04 +0100","YES","All listed outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Macias-2006","2013-08-05 15:14:45 +0100","UNKNOWN","Funding: grant SM-51831 from the Substance Abuse and Mental Health Service Administration. Data analysis was supported from 2001 to 2006 by interdiscipliary research grant from the National Institute of Mental Health (NIMH). ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Mueser-2004","2013-04-30 13:51:24 +0100","YES","A computer-generated randomisation list was used.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Mueser-2004","2011-01-07 12:41:05 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Mueser-2004","2011-01-07 12:41:21 +0000","NO","Participants could identify the given intervention by contents of the program.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Mueser-2004","2013-08-06 20:40:27 +0100","YES","N=6 participants were lost to follow-up; n = 3 IPS; n = 2 standard services; n = 1 PSR. Intention to treat analysis performed. N=166 (81%) completed the 24-month interview; last observation carried forward. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Mueser-2004","2013-08-05 16:42:11 +0100","YES","All listed outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Mueser-2004","2013-08-05 15:43:50 +0100","UNKNOWN","Funding: supported by cooperative #UD7 SM51818 from the U.S. Department of Health and Human Services (DHHS) Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Mental Health Services (CMHS) as part of the Employment Intervention Demonstration Program (EIDP). Additional support provided by National Institute of Mental Health (NIMH) Grants MH00842 and MH56147.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Tsang-2009","2013-08-05 16:39:47 +0100","YES","Randomised using SPSS.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Tsang-2009","2010-12-21 14:59:04 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Tsang-2009","2010-12-21 09:55:08 +0000","NO","Participants could identify the given intervention by contents of the program.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Tsang-2009","2013-08-06 20:40:27 +0100","UNKNOWN","N=127 (77.9%) completed the 15-month intervention; n = 43/52 completed ISE; n = 41/56 completed IPS; n = 43/55 completed TVR. Unclear whether ITT used.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Tsang-2009","2013-08-05 16:42:06 +0100","YES","All listed outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Tsang-2009","2013-08-05 16:22:06 +0100","UNKNOWN","Funding: study was funded by the Health Services Research Fund, Health, Welfare and Food Bureau, HKSAR (HSRF Project No.: S121014).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Twamley-2008","2010-12-21 15:03:17 +0000","UNKNOWN","Randomised. No further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Twamley-2008","2010-12-21 15:03:17 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Twamley-2008","2010-12-21 09:55:15 +0000","NO","Participants could identify the given intervention by contents of the program.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Twamley-2008","2013-08-06 20:40:27 +0100","UNKNOWN","N=11 dropped-out of the study; n = 6 from IPS and n = 5 from CVR, with 'not wanting to work' most common reason. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Twamley-2008","2013-08-05 16:41:58 +0100","YES","All listed outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Twamley-2008","2013-08-05 16:41:51 +0100","YES","Funding: supported by a grant from the National Institute of Mental Health (MH066011).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Wong-2008","2011-03-12 15:15:54 +0000","YES","Randomisation was done using computer-generated random numbers.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Wong-2008","2010-12-21 15:06:26 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Wong-2008","2010-12-21 09:55:22 +0000","NO","Participants could identify the given intervention by contents of the program.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Wong-2008","2013-05-20 21:21:21 +0100","YES","Number and reason for attrition reported. One participant from the control group was lost to follow-up after randomisation because of ""loss of the contact point"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Wong-2008","2010-12-21 15:08:09 +0000","YES","All listed outcomes of interest reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Supported employment for adults with severe mental illness [v5.0-For publication].rm5","STD-Wong-2008","2013-08-05 16:54:39 +0100","UNKNOWN","Funding: supported by grant 216033 from the Health Care and Promotion Fund, Food and Health Bureau, Hong Kong. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Sulpiride versus placebo for schizophrenia [v6.0-For publication].rm5","STD-Blanco-1972","2013-08-16 09:53:12 +0100","UNKNOWN","""Random""; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Sulpiride versus placebo for schizophrenia [v6.0-For publication].rm5","STD-Blanco-1972","2009-01-19 12:11:15 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Sulpiride versus placebo for schizophrenia [v6.0-For publication].rm5","STD-Blanco-1972","2009-01-19 12:11:53 +0000","NO","No blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Sulpiride versus placebo for schizophrenia [v6.0-For publication].rm5","STD-Blanco-1972","2009-02-02 11:07:43 +0000","YES","No missing outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Sulpiride versus placebo for schizophrenia [v6.0-For publication].rm5","STD-Blanco-1972","2013-08-16 09:53:12 +0100","NO","Continuous outcome data were reported without SDs, so cannot be entered into analysis.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Sulpiride versus placebo for schizophrenia [v6.0-For publication].rm5","STD-Blanco-1972","2013-08-16 09:53:13 +0100","UNKNOWN","Authors thank ""Delagrange Labs"" who manufacture sulpiride for providing the medication for free and for ""helping"" in the investigation.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Sulpiride versus placebo for schizophrenia [v6.0-For publication].rm5","STD-Soni-1990","2013-08-16 09:55:05 +0100","UNKNOWN","""Allocated randomly""; no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Sulpiride versus placebo for schizophrenia [v6.0-For publication].rm5","STD-Soni-1990","2008-12-08 15:54:39 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Sulpiride versus placebo for schizophrenia [v6.0-For publication].rm5","STD-Soni-1990","2013-08-16 09:55:05 +0100","UNKNOWN","""Double blind""; no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Sulpiride versus placebo for schizophrenia [v6.0-For publication].rm5","STD-Soni-1990","2013-08-16 09:55:06 +0100","NO","6 of 24 included participants were missing at outcome.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Sulpiride versus placebo for schizophrenia [v6.0-For publication].rm5","STD-Soni-1990","2013-08-16 09:55:06 +0100","NO","Abnormal involuntary movements and extrapyramidal effects data reported as ""virtually zero throughout""; inadequate detail for data to be included.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Sulpiride versus placebo for schizophrenia [v6.0-For publication].rm5","STD-Soni-1990","2013-08-16 09:55:06 +0100","NO","One author was an employee of the drug company.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Sulpiride for schizophrenia [v9.0-For publication].rm5","STD-Asada-1976","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride for schizophrenia [v9.0-For publication].rm5","STD-Blanco-1972","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride for schizophrenia [v9.0-For publication].rm5","STD-Bratfos-1979","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride for schizophrenia [v9.0-For publication].rm5","STD-Cassano-1975","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride for schizophrenia [v9.0-For publication].rm5","STD-Dreyfus-1985","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride for schizophrenia [v9.0-For publication].rm5","STD-Edwards-1980","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride for schizophrenia [v9.0-For publication].rm5","STD-Lepola-1989","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride for schizophrenia [v9.0-For publication].rm5","STD-Mahadevan-1991","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride for schizophrenia [v9.0-For publication].rm5","STD-Nishikawa-1989","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride for schizophrenia [v9.0-For publication].rm5","STD-Petit-1987","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride for schizophrenia [v9.0-For publication].rm5","STD-Rama-Rao-1981","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride for schizophrenia [v9.0-For publication].rm5","STD-Shiloh-1997","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride for schizophrenia [v9.0-For publication].rm5","STD-Soni-1990","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride for schizophrenia [v9.0-For publication].rm5","STD-Taverna-1972","","UNKNOWN","D - Not used","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride for schizophrenia [v9.0-For publication].rm5","STD-Toru-1972","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride for schizophrenia [v9.0-For publication].rm5","STD-Wiesel-1984","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride for schizophrenia [v9.0-For publication].rm5","STD-Yamagami-1988","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride for schizophrenia [v9.0-For publication].rm5","STD-Yamagami-1993","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Shiloh-1997","2009-11-09 21:25:00 +0000","YES","Randomised, 'according to a table of random numbers in a double-blind design to receive'.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Shiloh-1997","2009-09-24 10:17:51 +0100","UNKNOWN","No description.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Shiloh-1997","2009-09-24 10:18:16 +0100","YES","Placebo-controlled double-blind.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Shiloh-1997","2009-11-11 12:05:58 +0000","YES","No people leaving the study early.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Shiloh-1997","2009-09-24 10:18:20 +0100","YES","All data reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Shiloh-1997","2009-09-24 10:17:51 +0100","UNKNOWN","No description.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Wang-1994","2009-11-09 21:32:33 +0000","UNKNOWN","'Randomised into groups' without further detail.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Wang-1994","2009-09-24 10:19:49 +0100","UNKNOWN","No description.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Wang-1994","2009-09-24 10:19:49 +0100","NO","Open study.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Wang-1994","2009-11-09 21:32:41 +0000","NO","Reasons for leaving early not described.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Wang-1994","2009-11-09 21:33:54 +0000","NO","Item scores and total scores of SAPS and SANS, TESS score, not reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Wang-1994","2009-09-24 10:19:49 +0100","UNKNOWN","No description.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Xu-2006","2009-11-09 21:35:11 +0000","UNKNOWN","'Randomised into 2 groups' with no further detail.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Xu-2006","2009-09-24 10:20:25 +0100","UNKNOWN","No description.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Xu-2006","2009-09-24 10:20:25 +0100","UNKNOWN","No description.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Xu-2006","2009-11-09 21:35:19 +0000","YES","No attrition.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Xu-2006","2009-09-24 10:20:26 +0100","YES","Report all data.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Xu-2006","2009-09-24 10:20:25 +0100","UNKNOWN","No description.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Zhu-1999","2009-11-09 21:37:27 +0000","UNKNOWN","Quote: ""Randomised into 3 groups' with no detail.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Zhu-1999","2009-09-24 10:20:59 +0100","UNKNOWN","No description.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Zhu-1999","2009-09-24 10:20:59 +0100","UNKNOWN","No description.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Zhu-1999","2009-11-09 21:37:40 +0000","YES","No attrition.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Zhu-1999","2009-09-24 10:21:03 +0100","NO","Data of blood, EKG, EEG, not reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Sulpiride augmentation for schizophrenia [v6.0-For publication].rm5","STD-Zhu-1999","2009-09-24 10:21:00 +0100","UNKNOWN","No description.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Chien-2003","2011-02-14 12:42:50 +0000","UNKNOWN","""A table of random numbers was used to select 28 subjects from the first subgroup and randomly assigned 14 of them to the experimental group or control group. This same procedure was repeated with the second and the third subgroups of subjects"".","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Chien-2003","2011-03-10 11:17:49 +0000","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Chien-2003","2011-02-14 12:48:41 +0000","NO","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Chien-2003","2011-03-10 11:17:37 +0000","NO","""Two subjects in the experimental group withdrew from the study before treatment one because of medical disease that required an inter-hospital transfer and the other who stabilized discharge from the hospital. Two subjects in the experimental group withdrew because they refused to participate. One subject in each of the groups withdrew during the training because of being transferred to another ward. Two subjects in the experimental group were excluded from the study because they were able to participate in less than half of the training sessions (four times)"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Chien-2003","2011-03-01 09:14:19 +0000","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Chien-2003","2011-02-14 12:50:21 +0000","UNKNOWN","Protocol not available. Sample size not calculated.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Cui-2004","2013-06-11 14:00:13 +0100","YES","Randomisation was done with random number tables.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Cui-2004","2011-03-15 15:17:36 +0000","UNKNOWN","Not stated.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Cui-2004","2011-03-06 08:41:19 +0000","NO","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Cui-2004","2013-06-11 14:00:31 +0100","NO","There were five dropouts from the social skills training group and four from the control group. People who left the study early were not included in the final analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Cui-2004","2011-03-06 08:55:16 +0000","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Cui-2004","2011-03-10 09:58:53 +0000","UNKNOWN","Protocol not available. Sample size not calculated.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Dobson-1995","2011-02-23 09:32:51 +0000","UNKNOWN","""randomly assigned"" no further information given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Dobson-1995","2011-02-23 09:33:08 +0000","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Dobson-1995","2011-03-09 12:33:28 +0000","NO","Single blind: ""None of the assessments were completed by the group therapists for subjects in the study, and none of the treatment groups were led by the investigators"".","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Dobson-1995","2011-03-22 14:28:09 +0000","NO","There were 5 dropouts: 2 from the social milieu group and 3 from the social skills group. ""The reasons they gave for dropping out were unrelated to the treatment"".","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Dobson-1995","2011-03-10 11:34:40 +0000","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Dobson-1995","2011-02-23 09:51:04 +0000","NO","Protocol not available. The follow-up period for social milieu group was limited mid-study so they could also receive social skills training, which they had expressed interest in to the investigators.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Hayes-1995","2011-02-23 10:20:22 +0000","UNKNOWN","""subjects were assigned randomly"" no further information.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Hayes-1995","2011-03-01 10:35:00 +0000","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Hayes-1995","2011-03-03 10:39:14 +0000","NO","Not stated. ""All research assistants conducting interviews and rating measures were uninformed to the treatment condition of participants"".","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Hayes-1995","2015-03-10 15:43:19 +0000","NO","18 dropouts at post treatment assessment, another 11 had dropped out at follow-up assessment. Dropouts were reported as either in hospital, unable to be reached or declined to participate, it was not reported to which groups they had been assigned.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Hayes-1995","2011-02-23 10:21:43 +0000","NO","Reported insufficient funds to code time diary data for follow-up assessment.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Hayes-1995","2011-03-01 10:37:41 +0000","UNKNOWN","Protocol not available. Sample size not calculated. Source of funding: National Health and Medical Research Council of Australia and University Queensland.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Huang-2005","2011-03-10 09:57:28 +0000","UNKNOWN","Randomised, no further details given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Huang-2005","2011-03-10 09:57:40 +0000","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Huang-2005","2011-03-10 09:57:53 +0000","NO","Raters were blinded.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Huang-2005","2011-03-10 09:58:12 +0000","NO","Four participants dropped out of the social skills training group and two from the control group. Dropouts were excluded from the final analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Huang-2005","2011-03-10 09:58:37 +0000","YES","All stated outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Huang-2005","2011-03-10 09:59:01 +0000","UNKNOWN","Protocol not available. Sample size not calculated.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Kopelowicz-1998","2011-03-01 12:00:58 +0000","UNKNOWN","""Randomised"", no further details provided.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Kopelowicz-1998","2011-03-01 12:01:16 +0000","UNKNOWN","No information given.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Kopelowicz-1998","2011-03-01 12:17:04 +0000","NO","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Kopelowicz-1998","2011-03-01 12:19:10 +0000","NO","""Two patients dropped out of skills training because they obtained full time employment and were thus unable to participate."" No further details given.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Kopelowicz-1998","2011-03-15 16:07:32 +0000","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Kopelowicz-1998","2011-03-01 12:32:34 +0000","UNKNOWN","Protocol not available. Sample size not calculated. ","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Lu-2004","2011-03-09 10:17:44 +0000","UNKNOWN","Randomisation method is not described.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Lu-2004","2011-03-09 10:17:53 +0000","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Lu-2004","2011-03-09 09:38:47 +0000","NO","Not stated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Lu-2004","2011-03-15 15:53:42 +0000","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Lu-2004","2011-03-09 10:20:02 +0000","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Lu-2004","2011-03-10 09:59:09 +0000","UNKNOWN","Protocol not available. Sample size not calculated.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Ma-2003","2011-03-09 11:03:45 +0000","UNKNOWN","Randomised with random number tables.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Ma-2003","2011-03-09 11:03:57 +0000","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Ma-2003","2011-03-09 11:04:29 +0000","NO","Not blinded.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Ma-2003","2011-03-15 15:54:06 +0000","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Ma-2003","2011-03-09 11:04:52 +0000","YES","All stated outcomes reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Ma-2003","2011-03-15 16:08:26 +0000","UNKNOWN","Protocol not available. Sample size not calculated.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Mayang-1990","2011-03-02 10:39:26 +0000","UNKNOWN","""Randomly assigned"", no further details given.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Mayang-1990","2011-03-02 10:39:33 +0000","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Mayang-1990","2011-03-02 12:02:51 +0000","NO","Not blinded.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Mayang-1990","2011-03-15 16:02:59 +0000","UNKNOWN","No information provided.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Mayang-1990","2011-03-02 12:16:30 +0000","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Mayang-1990","2011-03-02 12:17:37 +0000","UNKNOWN","Protocol not available. Sample sizes not calculated","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Ng-2006","2011-02-27 10:45:34 +0000","YES","Patients were randomised using a random number table, and stratified for gender, medication type and hospitalisation duration.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Ng-2006","2011-02-23 11:28:00 +0000","YES","""Randomisation was done by an administrator...The administrator was only aware of the code number, name, date of birth, and stratification criteria for each patient.""","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Ng-2006","2011-02-27 10:45:48 +0000","NO","Raters were blinded.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Ng-2006","2011-03-21 08:27:16 +0000","UNKNOWN","""All patients who relapsed and were withdrawn from the trial during the treatment phase were included as treatment failures. All missing data were given mean values of that particular variable at that particular assessment point.""","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Ng-2006","2011-02-23 11:28:07 +0000","YES","All pre-specified outcomes were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Ng-2006","2011-02-23 12:09:06 +0000","UNKNOWN","Protocol not published a priori. Funding: not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Potelunas-1982","2015-03-10 15:43:20 +0000","UNKNOWN","A table of random numbers was used.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Potelunas-1982","2015-03-10 15:43:20 +0000","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Potelunas-1982","2011-03-15 15:22:14 +0000","NO","The primary experimenter was not seen by participants on a regular basis, but it is not stated whether they were blind to group allocation. Three research assistants blind to treatment condition independently rated the videotapes.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Potelunas-1982","2011-03-15 15:58:23 +0000","UNKNOWN","No information provided.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Potelunas-1982","2011-03-06 16:03:39 +0000","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Potelunas-1982","2011-03-06 16:03:59 +0000","UNKNOWN","Sample size calculation done. Source of funding not reported. Protocol not available.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Saren-2004","2011-03-09 12:25:36 +0000","YES","Randomised using random number table","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Saren-2004","2011-03-09 12:25:31 +0000","UNKNOWN","No information provided.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Saren-2004","2011-03-09 12:25:34 +0000","NO","Not blinded.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Saren-2004","2011-03-09 12:25:13 +0000","NO","Two participants dropped out of the social skills training group due to a change of address; In the control group 3 participants left dropped out, also due to a change of address. These were not included in the final analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Saren-2004","2011-03-09 12:25:48 +0000","YES","All stated outcomes reported","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Saren-2004","2011-03-15 16:08:36 +0000","UNKNOWN","Protocol not available. Sample size not calculated.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Tsang-2001","2015-03-10 15:43:20 +0000","UNKNOWN","Randomly assigned by residential facility, not individually.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Tsang-2001","2015-03-10 15:43:20 +0000","UNKNOWN","Not addressed.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Tsang-2001","2015-03-10 15:43:20 +0000","UNKNOWN","""During the entire process of data collection, all participants and those responsible for rating participants' performance were blind to the group status of the participants, and participants did not know that there were groups with and without follow up."" It is unclear if the control group was blinded.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Tsang-2001","2011-03-22 14:37:58 +0000","UNKNOWN","There were no dropouts reported from the two intervention groups, but no information whether there were dropouts in the control group.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Tsang-2001","2011-02-27 14:48:25 +0000","NO","Not all expected outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Social skills programmes for schizophrenia [v4.8-For publication].rm5","STD-Tsang-2001","2011-02-27 10:49:20 +0000","UNKNOWN","Protocol not available. Sample sizes not calculated.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Sertindole versus other atypical antipsychotics for schizophrenia [v7.0-For publication].rm5","STD-Azorin-2006","2009-02-02 19:10:06 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Sertindole versus other atypical antipsychotics for schizophrenia [v7.0-For publication].rm5","STD-Azorin-2006","2009-02-02 19:10:07 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sertindole versus other atypical antipsychotics for schizophrenia [v7.0-For publication].rm5","STD-Azorin-2006","2009-02-16 09:25:33 +0000","UNKNOWN","Double, identical capsules.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Sertindole versus other atypical antipsychotics for schizophrenia [v7.0-For publication].rm5","STD-Azorin-2006","2009-02-05 08:32:04 +0000","YES","Outcomes such as laboratory measures or death - unlikely to have been much affected by lack of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Sertindole versus other atypical antipsychotics for schizophrenia [v7.0-For publication].rm5","STD-Azorin-2006","2009-02-05 08:34:20 +0000","NO","Data for leaving study early were available but total was high (35.8%). ","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Sertindole versus other atypical antipsychotics for schizophrenia [v7.0-For publication].rm5","STD-Azorin-2006","2009-02-18 10:58:10 +0000","NO","Adverse events - only reported if > 5% occurrence.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Sertindole versus other atypical antipsychotics for schizophrenia [v7.0-For publication].rm5","STD-Azorin-2006","2009-02-05 08:35:32 +0000","NO","Sponsored by manufacturers of sertindole.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Sertindole versus other atypical antipsychotics for schizophrenia [v7.0-For publication].rm5","STD-Kane-2005","2008-12-17 12:03:40 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Sertindole versus other atypical antipsychotics for schizophrenia [v7.0-For publication].rm5","STD-Kane-2005","2009-02-02 19:14:02 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sertindole versus other atypical antipsychotics for schizophrenia [v7.0-For publication].rm5","STD-Kane-2005","2009-02-16 09:24:33 +0000","UNKNOWN","Double, no further details.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Sertindole versus other atypical antipsychotics for schizophrenia [v7.0-For publication].rm5","STD-Kane-2005","2009-02-16 09:25:05 +0000","YES","Outcome measures such as leaving the study early are unlikely to be influenced by lack of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Sertindole versus other atypical antipsychotics for schizophrenia [v7.0-For publication].rm5","STD-Kane-2005","2009-02-05 08:54:05 +0000","NO","Data for leaving study early were available but total was high (32.4%).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Sertindole versus other atypical antipsychotics for schizophrenia [v7.0-For publication].rm5","STD-Kane-2005","2009-02-16 09:24:37 +0000","NO","Adverse events - only reported if > 10% occurrence.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Sertindole versus other atypical antipsychotics for schizophrenia [v7.0-For publication].rm5","STD-Kane-2005","2009-02-05 08:57:13 +0000","NO","Sponsored by manufacturers of sertindole.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Sertindole for schizophrenia [v8.0-For publication].rm5","STD-Daniel-1998","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sertindole for schizophrenia [v8.0-For publication].rm5","STD-Hale-2000","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Sertindole for schizophrenia [v8.0-For publication].rm5","STD-Van-Kammen-1996","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Blin-1996","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Borison-1991","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Bouchard-1998","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Ceskova-1993","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Chouinard-1993a","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Claus-1991","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Csernansky-1999","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Emsley-1995","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Heck-2000","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Hoyberg-1993","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Huttunen-1995","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Kaleda-2000","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Liu-2000","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Mahmoud-1998","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Malyarov-1999","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Marder-1994","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Mesotten-1991","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Min-1993","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Peuskens-1995","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Potkin-1997","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Purdon-2000","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-See-1999","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus typical antipsychotic medication for schizophrenia [v12.0-For publication].rm5","STD-Wirshing-1999","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Addington-2004","2009-01-13 00:13:22 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Addington-2004","2009-01-13 00:13:00 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Addington-2004","2010-11-17 15:43:23 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Addington-2004","2009-07-30 12:31:37 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Addington-2004","2010-11-17 15:43:40 +0000","NO","The overall attrition was rather high (33.3%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. Data on study completers were also available. It is unclear whether this led to bias.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Addington-2004","2009-01-30 11:24:02 +0000","NO","Reporting on secondary outcomes was incomplete.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Addington-2004","2009-02-06 11:24:00 +0000","NO","The study was sponsored by the manufacturer of ziprasidone.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Atmaca-2003","2009-02-06 10:41:04 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Atmaca-2003","2009-02-06 10:41:04 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Atmaca-2003","2010-11-17 15:45:53 +0000","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Atmaca-2003","2009-07-30 12:32:42 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Atmaca-2003","2009-02-10 13:36:59 +0000","YES","Three subjects in the control groups left the study early (5.4%). Reason for drop-out were not assessed, only completer data were presented. But due to the very low rate we do not think that there was a risk of bias.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Atmaca-2003","2009-02-12 12:17:36 +0000","YES","Probably free of bias. The study focused on serum leptin and triglyceride levels which were adequately described.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Atmaca-2003","2009-02-12 12:17:14 +0000","UNKNOWN","Data on the allowed dose range have not been presented. Furthermore, the pre-study treatment was quite heterogeneous as 19 participants had never taken any psychotropic drugs while most other participants had a long history of previous treatment.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Azorin-2001","2009-01-13 17:47:31 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Azorin-2001","2009-01-13 17:47:27 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Azorin-2001","2010-11-17 16:21:36 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Azorin-2001","2009-07-30 12:44:02 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Azorin-2001","2010-11-17 16:21:45 +0000","UNKNOWN","The overall attrition was moderate (26.7%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. It is unclear whether this led to bias.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Azorin-2001","2009-02-16 13:42:13 +0000","NO","Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Azorin-2001","2009-02-15 17:42:50 +0000","NO","The study was sponsored by the manufacturer of clozapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Azorin-2006","2009-02-06 10:45:40 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Azorin-2006","2009-02-06 10:45:40 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Azorin-2006","2010-11-17 16:22:37 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Azorin-2006","2009-07-30 12:45:32 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by lack of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Azorin-2006","2010-11-17 16:22:56 +0000","NO","Data on reasons for leaving the study early were available, but total number was considerably high (35.8%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Azorin-2006","2009-02-16 13:42:26 +0000","NO","Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Azorin-2006","2009-02-06 11:28:12 +0000","NO","The study was industry sponsored by the manufacturer of sertindole.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Bondolfi-1998","2009-01-13 17:49:20 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Bondolfi-1998","2009-01-13 17:49:16 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Bondolfi-1998","2010-11-17 16:24:10 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Bondolfi-1998","2009-07-31 09:55:36 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Bondolfi-1998","2010-11-17 16:24:24 +0000","UNKNOWN","The overall attrition was moderate (20.9%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Bondolfi-1998","2010-11-23 21:13:38 +0000","NO","Secondary outcomes were not fully reported. For treatment emergent adverse events there was an incidence of at lest 5% occurrence for being reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Bondolfi-1998","2009-02-12 13:10:34 +0000","NO","The study was sponsored by the manufacturer of risperidone.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Breier-1999","2009-01-13 17:50:06 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Breier-1999","2009-01-13 17:50:03 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Breier-1999","2010-11-17 16:25:28 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Breier-1999","2009-07-30 12:53:11 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Breier-1999","2009-01-30 11:58:37 +0000","NO","Data on subjects leaving the study early were not available. ","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Breier-1999","2009-02-15 17:44:39 +0000","NO","Exclusion of 5 participants after randomisation, incomplete information.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Breier-1999","2009-02-15 17:45:03 +0000","UNKNOWN","One of the authors is an employee of a pharmaceutical company producing olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Canive-2000","2009-02-10 10:56:18 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Canive-2000","2010-11-17 16:26:17 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Canive-2000","2010-11-17 16:26:20 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Canive-2000","2009-07-30 12:54:15 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Canive-2000","2009-02-10 10:59:56 +0000","NO","Data on leaving the study early were not available.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Canive-2000","2009-02-10 10:56:47 +0000","NO","Data were only presented as a poster, data on primary outcomes were missing.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Canive-2000","2009-02-10 11:01:56 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Chan-2007","2009-02-09 12:14:39 +0000","UNKNOWN","Random, permuted block randomisation stratified by centre.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Chan-2007","2009-02-06 10:46:59 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Chan-2007","2010-11-17 18:24:56 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Chan-2007","2009-07-30 12:55:26 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Chan-2007","2010-11-17 18:25:07 +0000","UNKNOWN","Total number of participants leaving the study early was possibly acceptable (25%).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Chan-2007","2009-02-06 10:46:59 +0000","NO","Only adverse events with an incidence of at least 5% in any treatment group were reported, therefore important side effects may have been missed by this procedure.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Chan-2007","2009-02-06 10:46:59 +0000","NO","The study was industry sponsored by the manufacturer of aripiprazole.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Conley-2001","2009-01-13 17:51:36 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Conley-2001","2009-01-13 17:51:46 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Conley-2001","2010-11-17 18:26:18 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Conley-2001","2009-07-30 12:56:27 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Conley-2001","2010-11-17 18:26:28 +0000","UNKNOWN","The overall attrition was moderate (25.5%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. It is unclear whether this led to bias in a study with moderate attrition.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Conley-2001","2009-02-16 13:44:03 +0000","NO","Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Conley-2001","2010-11-17 18:26:39 +0000","NO","The study was sponsored by the manufacturer of risperidone. The total number of participants was very low (n = 13), which may limit the validity of results.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Conley-2005","2009-02-06 10:48:37 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Conley-2005","2009-02-06 10:48:37 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Conley-2005","2010-11-17 18:27:30 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Conley-2005","2009-07-30 12:57:09 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Conley-2005","2009-02-15 17:47:47 +0000","NO","The drop-out rate was considerable (36%). The analysis was based on the intention-to-treat sample and a mixed effects model. It is unclear whether any statistical method can account for higher drop-out rates.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Conley-2005","2009-02-06 10:48:37 +0000","NO","Not all of the predefined adverse effects were assessed.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Conley-2005","2009-02-15 17:47:59 +0000","UNKNOWN","There was a slight baseline imbalance in terms of mean age and previous numbers of hospitalizations (14 in the risperidone and 9.7 in the quetiapine group).","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Daniel-1996","2009-01-13 17:53:02 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Daniel-1996","2009-01-13 17:53:21 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Daniel-1996","2010-11-17 18:28:19 +0000","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Daniel-1996","2009-07-30 12:59:53 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Daniel-1996","2009-02-15 17:48:52 +0000","UNKNOWN","The overall attrition was moderate (15%). Further details were not provided.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Daniel-1996","2010-11-17 18:28:29 +0000","NO","Outcomes were reported incompletely. Six weeks' interim data before crossover were hardly reported. The study was only published as an abstract.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Daniel-1996","2009-02-10 11:02:22 +0000","NO","The study was sponsored by the manufacturer of risperidone.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Dollfus-2005","2009-01-13 17:53:50 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Dollfus-2005","2009-01-13 17:54:00 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Dollfus-2005","2010-11-17 18:29:19 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Dollfus-2005","2009-07-31 09:55:06 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Dollfus-2005","2009-02-16 13:55:04 +0000","NO","Data on leaving the study early were not published separately for each group, the overall attrition was moderate (25%). (Data on both treatment attrition were provided from contact of the author).","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Dollfus-2005","2009-02-01 10:38:32 +0000","NO","Data on efficacy outcomes were incompletely reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Dollfus-2005","2009-02-10 11:02:32 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Dolnak-2001","2009-02-10 10:58:03 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Dolnak-2001","2009-02-10 10:58:03 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Dolnak-2001","2010-11-17 18:29:58 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Dolnak-2001","2009-07-31 09:54:54 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Dolnak-2001","2009-02-10 10:58:06 +0000","NO","No data on leaving the study early available.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Dolnak-2001","2009-02-10 10:58:04 +0000","UNKNOWN","Insufficient data.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Dolnak-2001","2009-02-10 10:58:04 +0000","UNKNOWN","Insufficient data.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Gureje-2003","2009-01-13 17:54:37 +0000","YES","Random, computer-generated randomisation.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Gureje-2003","2009-01-13 17:54:48 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Gureje-2003","2010-11-17 20:24:28 +0000","UNKNOWN","Double, double-dummy design. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Gureje-2003","2009-07-31 09:54:42 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Gureje-2003","2010-11-17 20:24:55 +0000","NO","The overall attrition was high (55.4%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Gureje-2003","2009-02-16 13:45:08 +0000","NO","Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Gureje-2003","2009-02-15 17:50:10 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Heinrich-1994","2009-01-13 17:55:32 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Heinrich-1994","2010-11-23 21:14:20 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Heinrich-1994","2010-11-17 20:26:12 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Heinrich-1994","2009-07-30 13:08:06 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Heinrich-1994","2010-11-17 20:26:28 +0000","NO","The overall attrition was high (48.3%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Heinrich-1994","2010-11-23 21:17:08 +0000","NO","Acutely ill subjects were included but data on the reduction of positive symptoms were not available. Secondary outcome data in terms of adverse effects were reported incompletely.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Heinrich-1994","2009-02-11 10:32:21 +0000","UNKNOWN","Fixed doses of 4mg/day and 8mg/day of risperidone were compared with a fixed dose of 400mg of clozapine, for a fixed dose regimen it might be difficult to decide which doses are appropriate.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Hwang-2003","2009-02-06 10:50:27 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Hwang-2003","2009-02-06 10:50:27 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Hwang-2003","2010-11-17 20:27:48 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Hwang-2003","2009-07-30 13:10:12 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Hwang-2003","2010-11-17 20:28:18 +0000","YES","The rate of participants leaving the study early was below 10% and data on reasons for drop-out were available. The data were analysed on an intent-to-treat basis with the LOCF method. This method is not perfect, but due to the very low attrition the risk of bias was low.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Hwang-2003","2009-02-15 17:52:32 +0000","NO","Data on the extrapyramidal symptom scale have not been presented. Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Hwang-2003","2009-02-12 13:17:15 +0000","NO","The study was sponsored by the manufacturer of amisulpride.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Jeste-2003","2009-01-13 17:56:42 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Jeste-2003","2009-01-13 17:57:00 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Jeste-2003","2010-11-17 20:29:22 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Jeste-2003","2009-07-30 13:11:31 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Jeste-2003","2010-11-17 20:29:36 +0000","UNKNOWN","Number of participants leaving the study early was moderate (23.9%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. It is unclear whether this led to bias.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Jeste-2003","2009-02-16 13:45:48 +0000","NO","Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Jeste-2003","2009-02-15 17:54:05 +0000","NO","The study was sponsored by the manufacturer of risperidone. The mean age of included subjects was about 71 years. Probably due to this reason the upper dose range limit of risperidone was rather low (3mg/day), compared to that of olanzapine (20mg/day).","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Kane-2005","2009-02-06 10:51:27 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Kane-2005","2009-02-06 10:51:27 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Kane-2005","2010-11-17 20:30:32 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined. Both compounds differ substantially in side effects which can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Kane-2005","2009-07-30 13:12:31 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Kane-2005","2010-11-17 20:30:49 +0000","NO","Data on reason for drop-out were available but total numbers was considerably high (32.4%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Kane-2005","2009-02-16 13:46:06 +0000","NO","Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Kane-2005","2009-02-12 13:17:57 +0000","NO","The study was sponsored by the manufacturer of sertindole.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Keefe-2006","2009-01-13 17:59:33 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Keefe-2006","2009-01-13 17:59:42 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Keefe-2006","2010-11-17 22:20:52 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Keefe-2006","2009-07-30 13:13:24 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Keefe-2006","2010-11-17 22:21:03 +0000","NO","The overall attrition was high (62.8%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Keefe-2006","2009-02-16 13:46:38 +0000","NO","Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Keefe-2006","2009-02-10 11:03:29 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Lieberman-2005","2009-02-06 10:38:03 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Lieberman-2005","2009-02-06 10:38:03 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Lieberman-2005","2010-11-17 22:22:47 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Lieberman-2005","2009-07-30 13:14:05 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Lieberman-2005","2010-11-23 21:14:38 +0000","NO","The overall attrition was high (75%), and it is unclear whether any statistical method can account for such a high drop-out rate. Efficacy outcomes were evaluated based on mixed effects model analysis.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Lieberman-2005","2009-02-15 17:55:31 +0000","YES","There was no evidence for selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Lieberman-2005","2010-11-17 22:23:26 +0000","UNKNOWN","Dose ranges were quite different, the upper dose range of olanzapine was 30 mg whereas risperidone could only be titrated up to 6mg /day. There was no wash-out period. An overlap in the administration of formerly given antipsychotics was permitted for the first four weeks after randomisation. Allocation to ziprasidone treatment was not possible from the start of the study due to the later availability of ziprasidone.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McEvoy-2006","2009-02-06 10:38:55 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McEvoy-2006","2009-02-06 10:38:55 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McEvoy-2006","2010-11-17 22:33:09 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McEvoy-2006","2009-07-30 13:14:56 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McEvoy-2006","2009-02-15 17:56:55 +0000","NO","The overall attrition was high (74%). It is doubtful that the validity was not affected by this high rate.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McEvoy-2006","2009-02-12 13:22:27 +0000","NO","Due to small numbers and the very high attrition only data on 26 weeks treatment (rather than 52 weeks) were presented.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McEvoy-2006","2010-11-17 22:33:22 +0000","UNKNOWN","Dose ranges were quite different, the upper dose range of olanzapine was 30 mg whereas risperidone could only be titrated up to 6mg /day. Patients had a history of former inefficacy to one of the medications. It was excluded that the same medication could be given again but still this might implicate a risk of bias due to baseline imbalance in terms of former treatment. There was no wash-out period.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McEvoy-2007","2009-02-06 10:39:56 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McEvoy-2007","2009-02-06 10:39:56 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McEvoy-2007","2010-11-17 22:34:47 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McEvoy-2007","2009-07-30 13:15:38 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McEvoy-2007","2009-02-15 17:57:56 +0000","NO","The attrition was high (70.3.%). The primary analysis was based on a mixed effect model, secondary approaches used the last-observation-carried forward approach or included only study completers. Nevertheless, it is unclear whether any statistical method can account for such a high attrition.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McEvoy-2007","2009-02-06 10:39:57 +0000","NO","Adverse events were presented only in case of moderate or worse severity.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McEvoy-2007","2009-02-06 10:39:57 +0000","NO","The study was sponsored by the manufacturer of quetiapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McGurk-2005","2009-01-13 18:02:08 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McGurk-2005","2009-01-13 18:02:17 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McGurk-2005","2010-11-17 22:35:56 +0000","UNKNOWN","Double, double-dummy protocol. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McGurk-2005","2009-07-30 13:19:21 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McGurk-2005","2009-02-15 17:59:03 +0000","NO","The overall attrition was high 63.9%. The analysis was based on mixed effect models, but it is unclear whether any statistical method can account for such a high drop-out rate.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McGurk-2005","2010-11-17 22:36:08 +0000","NO","Outcome reporting was incomplete. Quote: ""...adverse events data have been reported elsewhere (unpublished study of N.R. Schooler et al.).","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-McGurk-2005","2009-01-30 12:21:31 +0000","YES","Review authors did not find other sources of bias. Probably yes.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Mori-2004","2009-02-06 10:53:51 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Mori-2004","2009-02-06 10:53:51 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Mori-2004","2010-11-17 22:36:59 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Mori-2004","2009-07-30 13:20:03 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Mori-2004","2009-02-15 18:27:47 +0000","NO","There was no data on attrition available.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Mori-2004","2009-02-12 13:26:07 +0000","NO","Adverse events were not reported. Numbers on use of antiparkinson medication have not been presented.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Mori-2004","2010-11-17 22:37:10 +0000","NO","There was no wash-out period. The previous antipsychotic treatment was gradually tapered over 4 weeks. Thus, during a period of 4 weeks the participants were on two drugs.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-M_x00f6_ller-2005","2009-02-06 10:54:39 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-M_x00f6_ller-2005","2009-02-06 10:54:39 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-M_x00f6_ller-2005","2010-11-17 22:38:32 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-M_x00f6_ller-2005","2009-07-30 13:20:39 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-M_x00f6_ller-2005","2009-02-15 18:28:10 +0000","NO","Numbers of participants leaving the study early were only reported for the category ""due to adverse effects"". The statistical method used to account for incomplete data was not described.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-M_x00f6_ller-2005","2009-02-15 18:28:25 +0000","NO","The study is only available as an abstract. The data for primary outcomes were either not available or only available in percentage change without a standard deviation.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-M_x00f6_ller-2005","2009-02-15 18:28:31 +0000","NO","The study was sponsored by the manufacturer of amisulpride. Whether there was a baseline imbalance could not be judged due to insufficient data.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Peuskens-1999","2009-02-06 10:55:20 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Peuskens-1999","2009-02-06 10:55:20 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Peuskens-1999","2010-11-17 22:40:31 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds in side effects. This may be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Peuskens-1999","2009-07-30 13:21:57 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Peuskens-1999","2009-02-16 13:48:04 +0000","NO","The rate of leaving the study early was moderate (30.3%). The statistical analysis was based on a last-observation-carried-forward method to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Peuskens-1999","2009-02-16 13:48:34 +0000","NO","Data on general functioning (secondary outcome) were not available. Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Peuskens-1999","2009-02-06 10:55:20 +0000","NO","The study was sponsored by the manufacturer of amisulpride.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2003","2009-02-06 10:56:02 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2003","2009-02-06 10:56:02 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2003","2010-11-17 22:42:51 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2003","2009-07-30 13:22:59 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by lack of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2003","2010-11-17 22:43:05 +0000","NO","The overall drop-out rate was high (36.9%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2003","2010-11-17 22:43:21 +0000","NO","For efficacy outcomes standard deviations or standard errors had not been indicated which had to be back calculated from P values. Only adverse events with an incidence of more than 5% were reported. This procedure may have missed important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2003","2010-11-17 22:43:27 +0000","UNKNOWN","The study was sponsored by the manufacturer of aripiprazole. The study used a fixed-dose regimen. It is difficult to say whether the chosen doses were appropriate.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2006","2009-02-06 10:56:45 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2006","2010-11-17 22:44:41 +0000","YES","Quote: were assigned using a centralised interactive voice response system. Probably done.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2006","2010-11-17 22:44:48 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2006","2009-07-30 13:23:52 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2006","2010-11-17 22:45:00 +0000","YES","The overall attrition was rather low (12%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. Nevertheless, due to the overall low attrition it is unlikely that the results have been affected.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2006","2009-02-16 13:49:43 +0000","NO","Data on some adverse effects were not available. Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Potkin-2006","2009-02-06 10:56:46 +0000","NO","The study was sponsored by the manufacturer of risperidone.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Purdon-2000","2009-01-13 18:06:59 +0000","YES","Random, computer-generated randomisation.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Purdon-2000","2009-01-13 18:06:58 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Purdon-2000","2010-11-17 22:46:50 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Purdon-2000","2009-07-30 13:24:38 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Purdon-2000","2010-11-17 22:46:59 +0000","NO","The overall attrition was high (54.8%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Purdon-2000","2009-02-15 18:32:08 +0000","YES","The study focused on neuropsychological changes, but data for efficacy and some side effects were also presented. Probably no bias.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Purdon-2000","2009-02-10 11:06:28 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Ren-2002","2010-11-17 22:48:06 +0000","YES","Allocation: random, ball drawing out of a covered box. Probably yes.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Ren-2002","2009-02-12 14:03:05 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Ren-2002","2010-11-17 22:48:13 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Ren-2002","2009-07-30 13:26:32 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Ren-2002","2009-02-15 18:32:34 +0000","NO","Data on leaving the study early were not provided.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Ren-2002","2009-02-15 18:33:03 +0000","NO","Secondary outcomes were poorly reported.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Ren-2002","2009-02-15 18:33:22 +0000","UNKNOWN","The allowed dose ranges were not indicated.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Riedel-2005","2009-02-06 10:57:39 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Riedel-2005","2009-02-06 10:57:39 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Riedel-2005","2010-11-17 22:49:23 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Riedel-2005","2009-07-30 13:27:16 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Riedel-2005","2010-11-17 22:49:37 +0000","NO","The overall attrition was high (45.2%). The data were analysed using both a LOCF method and a study completer approach. Nevertheless, it is questionable whether any statistical method can account for such a high attrition.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Riedel-2005","2009-02-12 13:38:04 +0000","NO","Data on negative symptoms (SANS) and some adverse effects were not available.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Riedel-2005","2009-02-06 10:57:40 +0000","NO","The study was sponsored by the manufacturer of quetiapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Robinson-2005","2009-01-13 18:09:24 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Robinson-2005","2009-01-13 18:09:34 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Robinson-2005","2010-11-17 22:50:36 +0000","UNKNOWN","Single-blind, rater-blinded. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Robinson-2005","2009-07-30 13:28:11 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Robinson-2005","2010-11-17 22:50:49 +0000","UNKNOWN","The overall attrition was possibly acceptable (28%), but data on leaving the study early were incompletely reported. Eight patients were excluded from the analysis for various reasons. The statistical analysis was based on mixed model approach.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Robinson-2005","2009-02-15 18:36:45 +0000","NO","Data on the general mental state (PANSS total score) were not presented. The data available for adverse effects were incomplete. Data on weight gain were missing.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Robinson-2005","2010-11-17 22:51:00 +0000","UNKNOWN","Quote: "".. the study was designed to detect differences in our primary analysis at alpha = 0.05 with 80% power based upon 130 subjects, the stability analysis included only 47 subjects and therefore might lack adequate power.""","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sacchetti-2004","2009-02-06 10:58:43 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sacchetti-2004","2009-02-06 10:58:43 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sacchetti-2004","2010-11-17 22:52:20 +0000","UNKNOWN","Single: rater-blind. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sacchetti-2004","2009-07-30 13:28:57 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sacchetti-2004","2010-11-17 22:52:31 +0000","UNKNOWN","The overall attrition was moderate (18.6%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sacchetti-2004","2010-11-17 22:52:39 +0000","NO","Efficacy data (PANSS) were only presented as percentage change without standard deviations, standard errors, P values or ranges. Only interim data after recruitment of half the patients have been presented","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sacchetti-2004","2009-02-06 10:58:44 +0000","NO","The study was sponsored by the manufacturer of quetiapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sechter-2002","2009-02-06 10:59:16 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sechter-2002","2009-02-06 10:59:16 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sechter-2002","2010-11-17 22:53:35 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sechter-2002","2009-07-30 13:30:05 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sechter-2002","2010-11-17 22:53:46 +0000","NO","The rate of participants leaving the study early was high (40%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sechter-2002","2009-02-16 13:51:50 +0000","NO","Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sechter-2002","2009-02-06 10:59:16 +0000","NO","The study was sponsored by the manufacturer of amisulpride.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sikich-2004","2009-01-13 18:12:02 +0000","YES","Random, computer-generated randomisation.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sikich-2004","2009-01-13 18:11:58 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sikich-2004","2010-11-18 04:25:26 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sikich-2004","2009-07-30 13:30:56 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sikich-2004","2010-11-18 04:25:38 +0000","NO","The overall attrition was high (33.3%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sikich-2004","2009-02-15 18:39:02 +0000","YES","No evidence for selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Sikich-2004","2010-11-23 21:15:00 +0000","NO","Quote: ""...this study has a number of limitations including limited sample size, differences in the diagnosis of participants, use of concomitant medication, variations in age and pupertal status"".","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Stroup-2006","2009-02-06 11:00:01 +0000","UNKNOWN","Random, 2 steps of randomisation before and after availability of ziprasidone, subjects received other medication than in previous phase 1 treatment. Re-randomised.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Stroup-2006","2009-02-06 11:00:01 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Stroup-2006","2010-11-18 04:27:03 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Stroup-2006","2009-07-30 13:32:15 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Stroup-2006","2009-02-15 18:39:59 +0000","NO","The overall attrition was high (72.5%). The main statistical analysis used a mixed effects model approach. It is unclear whether any statistical method can account for such high rates of leaving the study early.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Stroup-2006","2009-02-12 13:43:28 +0000","NO","Use of antiparkinson medication was permitted but data on this outcome have not been presented.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Stroup-2006","2009-02-06 11:00:02 +0000","UNKNOWN","Patients had a history of former intolerance to atypical antipsychotic treatment but baseline data on this was not provided.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Svestka-2003","2009-01-13 18:13:17 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Svestka-2003","2009-01-13 18:13:52 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Svestka-2003","2010-11-18 04:27:38 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Svestka-2003","2009-07-30 13:32:49 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Svestka-2003","2009-02-01 11:07:26 +0000","NO","Data on subjects leaving the study early were not available.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Svestka-2003","2009-02-06 14:05:27 +0000","NO","Allowed study medication dose ranges were not indicated. A publication was not available.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Svestka-2003","2009-02-06 14:05:30 +0000","UNKNOWN","Insufficient information. ","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Tran-1997","2009-01-13 18:14:47 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Tran-1997","2009-01-13 18:15:01 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Tran-1997","2010-11-18 04:28:39 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Tran-1997","2009-07-30 13:33:47 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Tran-1997","2010-11-18 04:28:49 +0000","NO","The overall attrition was high 47.5 %. The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Tran-1997","2009-02-15 18:40:46 +0000","NO","Adverse effects were only reported in the case of a significant difference between groups. Important side effects may have been missed by this procedure.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Tran-1997","2009-02-10 11:10:09 +0000","NO","The study was sponsored by the manufacturer of olanzapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Van-Nimwegen-2006","2009-01-13 18:15:50 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Van-Nimwegen-2006","2009-01-13 18:16:01 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Van-Nimwegen-2006","2010-11-18 04:29:52 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Van-Nimwegen-2006","2009-07-30 13:34:26 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Van-Nimwegen-2006","2009-02-01 11:09:52 +0000","NO","Data on leaving the study early were not provided.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Van-Nimwegen-2006","2009-02-15 18:40:58 +0000","NO","Outcome reporting was incomplete, standard deviations were not published.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Van-Nimwegen-2006","2009-02-16 13:52:52 +0000","UNKNOWN","Additional usage of cannabis.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Volavka-2002","2009-01-13 18:16:31 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Volavka-2002","2009-01-13 18:16:41 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Volavka-2002","2010-11-18 04:31:07 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Volavka-2002","2009-07-31 09:53:06 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Volavka-2002","2010-11-18 04:31:25 +0000","NO","The overall attrition was high (41.7%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Volavka-2002","2009-02-15 18:41:54 +0000","NO","Some outcomes were reported on subgroup from the entire sample. Quality of life data were not presented.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Volavka-2002","2009-02-15 18:42:05 +0000","NO","Quote: ""The olanzapine arm was added in November 1997 and required a modified randomization procedure""...It entails the potential for a bias that could be manifested as a cohort effect.""","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wahlbeck-2000","2009-01-13 18:17:18 +0000","YES","Random, computer-generated randomisation.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wahlbeck-2000","2009-01-30 12:36:16 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wahlbeck-2000","2010-11-19 04:14:59 +0000","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wahlbeck-2000","2009-07-30 13:39:05 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wahlbeck-2000","2010-11-19 04:15:15 +0000","NO","The overall attrition was high (35%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wahlbeck-2000","2009-02-15 18:42:29 +0000","YES","No evidence for selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wahlbeck-2000","2009-02-15 18:42:43 +0000","NO","The number of participants included was rather low. Quote: ""...readers have to bear in mind, that the statistical power of this study may hide some clinically relevant differences in drug efficacy.""","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wang-2006","2009-01-13 18:17:44 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wang-2006","2009-01-13 18:17:58 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wang-2006","2010-11-19 04:16:50 +0000","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wang-2006","2009-07-30 13:39:51 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wang-2006","2009-02-01 11:11:59 +0000","NO","Data on leaving the study early were not available.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wang-2006","2009-02-15 18:43:11 +0000","NO","Standard deviations for the primary outcome were not available.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wang-2006","2009-02-10 11:11:07 +0000","NO","Dose ranges were not indicated. The study was sponsored by the manufacturer of risperidone.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wynn-2007","2009-01-13 18:19:03 +0000","UNKNOWN","Random, 33 participants were assigned to a three-arm randomisation (1:1:1, blocks of 15) and 18 participants with a history of adverse experiences with haloperidol were assigned to a two-arm randomisation (1:1) for risperidone and olanzapine only.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wynn-2007","2009-01-13 18:18:54 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wynn-2007","2010-11-19 04:19:04 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wynn-2007","2009-07-30 13:41:18 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wynn-2007","2009-02-01 11:13:18 +0000","NO","Data on leaving the study early were not available.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wynn-2007","2009-02-15 18:43:57 +0000","NO","Efficay outcomes such as the general mental state (PANSS total score) were not presented.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Wynn-2007","2009-02-10 11:11:19 +0000","NO","The study was sponsored by the manufacturer of risperidone.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Zhong-2006","2009-02-06 11:01:35 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Zhong-2006","2009-02-06 11:01:35 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Zhong-2006","2010-11-19 04:20:00 +0000","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Zhong-2006","2009-07-30 13:42:10 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Zhong-2006","2010-11-19 04:20:11 +0000","NO","The overall attrition was high (52.1%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. Data on study completers were also available. Nevertheless it is unclear whether any statistical method can account for such a degree of attrition.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Zhong-2006","2009-02-16 13:53:28 +0000","NO","Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Zhong-2006","2009-02-06 11:01:35 +0000","NO","The study was sponsored by the manufacturer of quetiapine.","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Zhou-2000","2009-01-13 18:20:13 +0000","UNKNOWN","Random, no further details.","Adequate sequence generation?","QIT-01","Was the allocation sequence adequately generated?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Zhou-2000","2009-01-13 18:20:24 +0000","UNKNOWN","No further details.","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Zhou-2000","2010-11-19 04:21:11 +0000","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.01","subjective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Zhou-2000","2009-07-30 13:44:17 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding?","QIT-03","Was knowledge of the allocated interventions adequately prevented during the study?","QIG-03.02","objective outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Zhou-2000","2009-02-15 18:45:08 +0000","YES","No participant left the study early.","Incomplete outcome data addressed?","QIT-04","Were incomplete outcome data adequately addressed?","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Zhou-2000","2009-02-15 18:45:46 +0000","YES","No clear evidence for selective reporting.","Free of selective reporting?","QIT-05","Are reports of the study free of suggestion of selective outcome reporting?","",""
"../ALL-2015-06/Q-Z/Risperidone versus other atypical antipsychotics for schizophrenia [v4.0-For publication].rm5","STD-Zhou-2000","2009-02-15 18:46:22 +0000","UNKNOWN","The description of blinding differed between the abstract (double-blind) and the method section (single-blind).","Free of other bias?","QIT-06","Was the study apparently free of other problems that could put it at a high risk of bias?","",""
"../ALL-2015-06/Q-Z/Risperidone versus olanzapine for schizophrenia [v7.0-For publication].rm5","STD-Casey-2003","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus olanzapine for schizophrenia [v7.0-For publication].rm5","STD-CATIE-2005","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus olanzapine for schizophrenia [v7.0-For publication].rm5","STD-Chan-2003","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus olanzapine for schizophrenia [v7.0-For publication].rm5","STD-Conley-2001","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus olanzapine for schizophrenia [v7.0-For publication].rm5","STD-de-Haan-2002","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus olanzapine for schizophrenia [v7.0-For publication].rm5","STD-Gureje-2003","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus olanzapine for schizophrenia [v7.0-For publication].rm5","STD-Harvey-2003","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus olanzapine for schizophrenia [v7.0-For publication].rm5","STD-Jeste-2003","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus olanzapine for schizophrenia [v7.0-For publication].rm5","STD-Keefe-2005","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus olanzapine for schizophrenia [v7.0-For publication].rm5","STD-Littrell-1999","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus olanzapine for schizophrenia [v7.0-For publication].rm5","STD-Malyarov-1999","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus olanzapine for schizophrenia [v7.0-For publication].rm5","STD-Namjoshi-2002","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus olanzapine for schizophrenia [v7.0-For publication].rm5","STD-Purdon-1998","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus olanzapine for schizophrenia [v7.0-For publication].rm5","STD-Ritchie-2003","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus olanzapine for schizophrenia [v7.0-For publication].rm5","STD-Tran-1997-_x0028_HGBG_x0029_","","YES","A - Adequate","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Risperidone versus olanzapine for schizophrenia [v7.0-For publication].rm5","STD-Volavka-2002","","UNKNOWN","B - Unclear","Allocation concealment?","QIT-02","Was allocation adequately concealed?","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Ai-2007","2010-02-03 09:36:13 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Ai-2007","2010-02-03 09:36:31 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Ai-2007","2010-02-03 09:36:34 +0000","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Ai-2007","2010-12-21 09:04:08 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Ai-2007","2013-03-26 13:16:18 +0000","NO","TESS measured, but not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Ai-2007","2010-12-21 09:04:19 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-AstraZeneca-2005","2010-05-18 05:44:15 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-AstraZeneca-2005","2010-05-18 05:44:20 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-AstraZeneca-2005","2013-03-26 13:16:18 +0000","UNKNOWN","Double blind, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-AstraZeneca-2005","2010-05-18 05:45:06 +0100","YES","Data for leaving study early were available but total was high (31.5%).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-AstraZeneca-2005","2010-05-18 05:45:18 +0100","YES","Evidence for selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-AstraZeneca-2005","2010-05-18 05:45:28 +0100","NO","Sponsored by manufacturers of quetiapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Bai-2005","2010-02-03 09:47:31 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Bai-2005","2010-02-03 09:47:42 +0000","UNKNOWN","no details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Bai-2005","2010-02-03 09:47:49 +0000","UNKNOWN","no details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Bai-2005","2010-01-30 21:23:24 +0000","NO","ITT was not used. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Bai-2005","2010-01-30 21:23:47 +0000","NO","PANSS was not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Bai-2005","2010-12-21 09:07:01 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Cao-2005","2010-02-03 09:51:04 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Cao-2005","2010-02-03 09:51:07 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Cao-2005","2013-03-26 13:16:18 +0000","NO","Open-label.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Cao-2005","2011-08-30 03:04:05 +0100","NO","Drop outs were excluded from analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Cao-2005","2010-02-03 09:51:15 +0000","YES","All measured outcomes reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Cao-2005","2010-12-21 09:07:10 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Chen-2001","2011-08-30 03:04:26 +0100","YES","Randomised using random number table.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Chen-2001","2010-02-03 09:58:33 +0000","YES","Pharmacist produced identical pills, only they know which pill contains experimental drug.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Chen-2001","2010-02-03 09:59:41 +0000","UNKNOWN","Whether blinding was successful was not examined.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Chen-2001","2010-01-27 20:13:49 +0000","YES","ITT was used. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Chen-2001","2010-02-03 09:59:49 +0000","YES","Outcomes reported as measured.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Chen-2001","2010-12-21 09:08:44 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Chen-2007b","2010-02-03 10:03:47 +0000","UNKNOWN","Randomisation, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Chen-2007b","2010-02-03 10:04:16 +0000","UNKNOWN","Not reported.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Chen-2007b","2010-02-03 10:04:12 +0000","UNKNOWN","Not reported.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Chen-2007b","2010-02-03 10:04:04 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Chen-2007b","2010-01-27 16:47:49 +0000","NO","TESS was measured, but not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Chen-2007b","2010-12-21 09:09:16 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Guo-2003","2010-02-03 10:15:01 +0000","YES","Randomised by tossing a coin.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Guo-2003","2010-02-03 10:15:04 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Guo-2003","2010-02-03 10:15:09 +0000","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Guo-2003","2010-02-03 10:15:29 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Guo-2003","2010-01-15 15:28:28 +0000","NO","TESS scale score measured but not reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Guo-2003","2010-12-21 09:15:59 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Guo-2007","2010-02-03 10:16:41 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Guo-2007","2010-02-03 10:16:43 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Guo-2007","2010-02-03 10:16:46 +0000","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Guo-2007","2012-11-18 10:08:47 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Guo-2007","2010-01-29 09:29:06 +0000","NO","TESS was measured, but not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Guo-2007","2010-12-21 09:16:11 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-He-2003","2010-02-03 10:18:14 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-He-2003","2010-02-03 10:18:12 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-He-2003","2010-02-03 10:18:20 +0000","NO","Open label.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-He-2003","2012-11-18 10:09:20 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-He-2003","2010-01-15 13:47:39 +0000","NO","TESS score measured, but not reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-He-2003","2010-12-21 09:16:18 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Hu-2003","2011-08-30 03:09:08 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Hu-2003","2012-06-19 06:35:13 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Hu-2003","2012-06-19 06:35:18 +0100","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Hu-2003","2012-11-18 10:09:34 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Hu-2003","2010-12-21 09:16:25 +0000","YES","Evidence of selective reporting was no found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Hu-2003","2010-12-21 09:16:31 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Ji-2004","2010-02-03 10:24:15 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Ji-2004","2010-02-03 10:24:24 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Ji-2004","2011-08-30 03:09:51 +0100","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Ji-2004","2013-03-19 13:56:20 +0000","NO","Drop outs are excluded from analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Ji-2004","2010-12-21 09:16:53 +0000","YES","Evidence of selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Ji-2004","2010-12-21 09:16:54 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Jiang-2006","2010-02-04 07:48:12 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Jiang-2006","2010-02-04 07:48:09 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Jiang-2006","2010-02-04 07:48:27 +0000","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Jiang-2006","2011-08-30 03:10:05 +0100","YES","Drop outs were included in final analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Jiang-2006","2010-01-29 15:47:01 +0000","NO","PANSS measured, but not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Jiang-2006","2010-12-21 09:18:01 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Jin-2007","2010-02-09 02:33:41 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Jin-2007","2010-02-09 02:33:46 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Jin-2007","2010-02-09 02:33:51 +0000","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Jin-2007","2010-12-21 09:18:15 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Jin-2007","2010-01-28 15:13:11 +0000","NO","TESS measured, but not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Jin-2007","2010-12-21 09:18:21 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Li-2003","2010-02-04 07:52:40 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Li-2003","2010-02-04 07:52:39 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Li-2003","2010-02-04 07:52:51 +0000","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Li-2003","2010-01-27 15:30:27 +0000","NO","ITT was not used.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Li-2003","2010-02-04 07:53:16 +0000","YES","Evidence of selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Li-2003","2011-08-30 03:10:39 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Link-1997","2010-02-04 07:53:55 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Link-1997","2010-02-04 07:54:00 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Link-1997","2009-05-02 12:39:29 +0100","UNKNOWN","Double-blinded, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Link-1997","2013-03-26 13:16:18 +0000","YES","Data for leaving study early were available.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Link-1997","2010-02-04 07:53:28 +0000","YES","Evidence of selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Link-1997","2009-05-02 12:38:29 +0100","NO","Sponsored by manufacturer of quetiapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Mei-2007","2010-02-04 07:56:03 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Mei-2007","2010-02-04 07:56:09 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Mei-2007","2010-02-04 07:56:19 +0000","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Mei-2007","2011-08-30 03:12:16 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Mei-2007","2010-01-28 14:36:23 +0000","NO","TESS measured, but not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Mei-2007","2011-08-30 03:12:14 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Peng-2006","2010-02-09 03:54:11 +0000","YES","Randomised using random number table.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Peng-2006","2010-02-04 07:58:20 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Peng-2006","2013-03-26 13:16:18 +0000","UNKNOWN","Double blind, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Peng-2006","2010-12-21 09:19:28 +0000","UNKNOWN","Unclear whether people dropped out are included in the analysis.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Peng-2006","2010-02-09 03:54:48 +0000","YES","No evidence of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Peng-2006","2010-12-21 09:19:20 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Tian-2006","2010-02-04 08:05:57 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Tian-2006","2010-02-04 08:06:06 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Tian-2006","2010-02-04 08:06:13 +0000","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Tian-2006","2010-02-09 03:59:44 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Tian-2006","2010-02-04 08:06:34 +0000","YES","Evidence of selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Tian-2006","2010-02-04 08:06:55 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Wang-2004","2010-02-04 08:21:18 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Wang-2004","2010-02-04 08:21:28 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Wang-2004","2010-02-04 08:21:35 +0000","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Wang-2004","2010-01-27 10:46:20 +0000","YES","ITT was used.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Wang-2004","2010-02-04 08:21:51 +0000","YES","Evidence of selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Wang-2004","2010-12-21 09:20:44 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Wang-2005","2010-02-04 08:22:19 +0000","UNKNOWN","Randomisation, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Wang-2005","2010-02-04 08:22:26 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Wang-2005","2010-02-04 08:22:32 +0000","NO","open label.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Wang-2005","2012-06-19 06:37:19 +0100","UNKNOWN","No details.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Wang-2005","2011-08-30 03:44:33 +0100","NO","TESS score measured not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Wang-2005","2011-08-30 03:44:34 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhang-2002","2011-08-30 03:45:12 +0100","YES","Randomised by tossing a coin.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhang-2002","2010-02-04 08:25:16 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhang-2002","2013-03-19 14:34:18 +0000","UNKNOWN","Whether blinding was successful was not examined.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhang-2002","2010-02-09 04:11:09 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhang-2002","2010-02-04 08:26:47 +0000","YES","Evidence of selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhang-2002","2010-12-21 09:21:42 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhang-2003","2013-03-19 14:35:11 +0000","YES","Randomised using computer-generated random number.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhang-2003","2010-02-04 08:28:17 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhang-2003","2013-03-26 13:16:18 +0000","UNKNOWN","Whether blinding was successful was not examined.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhang-2003","2012-06-19 06:37:56 +0100","YES","ITT was used.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhang-2003","2010-01-15 11:22:43 +0000","NO","CGI and adverse events were measured, but data not reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhang-2003","2010-12-21 09:22:16 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhong-2005","2010-02-04 08:29:21 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhong-2005","2010-02-04 08:29:27 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhong-2005","2010-02-04 08:29:34 +0000","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhong-2005","2011-08-30 03:45:55 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhong-2005","2010-01-27 14:01:32 +0000","NO","TESS measured, but not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhong-2005","2010-12-21 09:24:24 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhou-2003","2010-02-04 08:30:05 +0000","YES","Randomised using random number table.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhou-2003","2010-02-04 08:30:14 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhou-2003","2010-02-04 08:30:17 +0000","UNKNOWN","Blinding, but unclear whether single or double blind (assessors are blinded anyway).","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhou-2003","2012-11-18 10:10:04 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhou-2003","2011-04-27 07:31:25 +0100","YES","Evidence of selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhou-2003","2010-02-04 08:30:45 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhou-2004","2010-02-04 08:31:23 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhou-2004","2010-02-04 08:31:29 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhou-2004","2010-02-04 08:31:35 +0000","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhou-2004","2010-05-18 05:51:28 +0100","UNKNOWN","No n number reported, so not clear what happened to people who dropped out.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhou-2004","2010-02-04 08:31:56 +0000","YES","Evidence of selective reporting was not clear.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zhou-2004","2010-12-21 09:24:38 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zou-2006","2010-02-04 08:32:38 +0000","UNKNOWN","Randomised, no further details","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zou-2006","2010-02-04 08:32:47 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zou-2006","2010-02-04 08:32:54 +0000","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zou-2006","2010-02-04 08:32:59 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zou-2006","2010-01-29 10:19:55 +0000","NO","TESS scores measured, but not reported. ","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-CPZ-_x002d_-Zou-2006","2010-02-04 08:33:03 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-FLUPHEN-_x002d_-Conley-2005","2010-05-18 05:21:31 +0100","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-FLUPHEN-_x002d_-Conley-2005","2010-05-18 05:21:43 +0100","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-FLUPHEN-_x002d_-Conley-2005","2010-05-18 05:21:56 +0100","UNKNOWN","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-FLUPHEN-_x002d_-Conley-2005","2010-05-18 05:22:46 +0100","NO","Data for leaving study early were available but total was high (47%).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-FLUPHEN-_x002d_-Conley-2005","2010-05-18 05:23:02 +0100","YES","Evidence of selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-FLUPHEN-_x002d_-Conley-2005","2010-05-18 05:23:22 +0100","NO","Sponsored by manufacturers of quetiapine and risperidone.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Arvanitis-1997","2010-02-03 09:38:21 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Arvanitis-1997","2010-02-03 09:38:26 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Arvanitis-1997","2009-05-02 13:01:38 +0100","UNKNOWN","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Arvanitis-1997","2009-05-02 13:02:43 +0100","YES","Data for leaving study early were available but total was high (59%).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Arvanitis-1997","2010-02-03 09:38:45 +0000","YES","Evidence for selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Arvanitis-1997","2009-05-02 13:02:47 +0100","NO","Sponsored by manufacturers of quetiapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Atmaca-2002","2010-02-03 09:39:49 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Atmaca-2002","2010-02-03 09:39:53 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Atmaca-2002","2010-02-03 09:40:33 +0000","NO","Open label; however, some outcome measures such as prolactin level are unlikely to be influenced by lack of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Atmaca-2002","2009-04-28 10:09:16 +0100","YES","All participants completed the study. ","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Atmaca-2002","2010-02-03 09:40:54 +0000","YES","Evidence for selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Atmaca-2002","2010-12-21 09:06:51 +0000","NO","Only female participants could be included in the study; therefore, gender bias can not be excluded.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Copolov-2000","2010-02-03 10:07:15 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Copolov-2000","2010-02-03 10:07:19 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Copolov-2000","2009-04-28 12:54:48 +0100","UNKNOWN","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Copolov-2000","2010-02-05 02:37:46 +0000","YES","Data for leaving study early were available but total was high (33%).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Copolov-2000","2010-02-03 10:07:59 +0000","YES","Evidence of selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Copolov-2000","2009-04-28 15:19:52 +0100","NO","Sponsored by manufacturers of quetiapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Emsley-1999","2010-02-03 10:08:32 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Emsley-1999","2010-02-03 10:08:36 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Emsley-1999","2013-03-26 13:16:18 +0000","UNKNOWN","Double blind, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Emsley-1999","2009-04-28 15:17:03 +0100","YES","Data for leaving study early were available.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Emsley-1999","2010-02-03 10:08:57 +0000","YES","Evidence of selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Emsley-1999","2009-04-28 15:18:14 +0100","NO","Sponsored by manufacturers of quetiapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Emsley-2004","2010-02-03 10:09:32 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Emsley-2004","2010-02-03 10:09:36 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Emsley-2004","2009-05-02 12:39:39 +0100","UNKNOWN","Single-blinded (investigator-blinded), no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Emsley-2004","2010-02-05 02:37:56 +0000","YES","Data for leaving study early were available but total was high (38%).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Emsley-2004","2010-02-03 10:10:02 +0000","YES","Evidence of selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Emsley-2004","2010-12-21 09:15:17 +0000","NO","Sponsored by manufacturer of quetiapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Fl_x0027_hacker-2005","2009-05-12 04:58:28 +0100","YES","Randomised, web-based online system.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Fl_x0027_hacker-2005","2010-02-03 10:10:31 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Fl_x0027_hacker-2005","2009-05-12 04:58:41 +0100","NO","Open label.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Fl_x0027_hacker-2005","2010-02-05 02:48:01 +0000","YES","Data for leaving study early were available but total was high (42%).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Fl_x0027_hacker-2005","2010-02-03 10:11:13 +0000","YES","Evidence of selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Fl_x0027_hacker-2005","2010-12-21 09:15:27 +0000","NO","Sponsored by manufacturer of quetiapine and other drug companies.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Huang-2007","2010-02-03 10:22:57 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Huang-2007","2010-02-03 10:22:54 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Huang-2007","2010-02-03 10:23:02 +0000","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Huang-2007","2010-02-03 10:23:04 +0000","YES","No incomplete outcome data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Huang-2007","2010-12-21 09:17:34 +0000","YES","Evidence of selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Huang-2007","2011-08-30 03:09:30 +0100","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-McCue-2006","2010-02-09 03:41:19 +0000","YES","Ramdomised, using computer random number generator.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-McCue-2006","2010-02-09 03:42:28 +0000","YES","Staff and patients did not have assess to the list.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-McCue-2006","2010-02-09 03:42:39 +0000","NO","Open label.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-McCue-2006","2013-03-26 13:16:18 +0000","YES","Data for leaving study early were available.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-McCue-2006","2010-02-09 03:46:11 +0000","YES","No evidence of selective reporting was found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-McCue-2006","2010-02-09 03:46:18 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Murasaki-1999","2010-02-04 07:57:26 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Murasaki-1999","2010-02-04 07:57:31 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Murasaki-1999","2009-04-28 10:27:45 +0100","UNKNOWN","Double, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Murasaki-1999","2013-03-26 13:16:18 +0000","NO","Data for leaving study early were available but total was high (39%).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Murasaki-1999","2010-02-09 03:53:23 +0000","YES","No evidence of selective reporting was found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Murasaki-1999","2009-04-28 15:41:46 +0100","NO","Sponsored by manufacturer of quetiapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Purdon-2001","2010-02-04 08:00:36 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Purdon-2001","2010-02-04 08:00:41 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Purdon-2001","2013-03-26 13:16:18 +0000","UNKNOWN","Double-blinded, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Purdon-2001","2010-02-09 03:58:22 +0000","YES","Data for leaving study early were available but total was high (48%).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Purdon-2001","2010-02-04 08:01:00 +0000","YES","Evidence of selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Purdon-2001","2009-05-02 06:26:21 +0100","NO","Sponsored by manufacturer of quetiapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Taneli-2003","2010-02-04 08:04:05 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Taneli-2003","2010-02-04 08:04:10 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Taneli-2003","2010-02-09 03:59:05 +0000","NO","Open label.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Taneli-2003","2010-12-21 09:20:17 +0000","YES","Data for leaving study early were available.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Taneli-2003","2010-02-04 08:04:44 +0000","YES","Evidence of selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Taneli-2003","2009-05-02 21:18:37 +0100","NO","Sponsored by manufacturer of quetiapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Velligan-2002","2010-02-13 09:45:39 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Velligan-2002","2010-02-04 08:19:56 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Velligan-2002","2013-03-26 13:16:18 +0000","UNKNOWN","Double blind, no further details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Velligan-2002","2013-03-26 13:16:18 +0000","NO","Data for leaving study early were available but total was high (50%).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Velligan-2002","2010-02-04 08:20:10 +0000","YES","Evidence of selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Velligan-2002","2009-05-02 14:20:51 +0100","NO","Sponsored by manufacturers of quetiapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Zou-2007","2010-02-04 08:33:43 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Zou-2007","2010-02-04 08:33:49 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Zou-2007","2010-02-04 08:33:55 +0000","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Zou-2007","2012-11-18 10:07:17 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Zou-2007","2010-01-29 10:50:24 +0000","NO","TESS scores, and some of the PANSS outcomes measured, but not reported, even though these are subscale scores.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-HLP-_x002d_-Zou-2007","2010-02-04 08:34:00 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-PERPHEN-_x002d_-Chen-2007a","2010-02-03 10:01:46 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-PERPHEN-_x002d_-Chen-2007a","2010-02-03 10:01:49 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-PERPHEN-_x002d_-Chen-2007a","2010-02-03 10:01:53 +0000","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-PERPHEN-_x002d_-Chen-2007a","2012-11-18 10:07:47 +0000","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-PERPHEN-_x002d_-Chen-2007a","2010-12-21 09:09:05 +0000","NO","TESS was measured, but not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-PERPHEN-_x002d_-Chen-2007a","2010-12-21 09:09:03 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-PERPHEN-_x002d_-L_x0027_rman-2005","2010-02-03 09:52:51 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-PERPHEN-_x002d_-L_x0027_rman-2005","2010-02-03 09:52:54 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-PERPHEN-_x002d_-L_x0027_rman-2005","2013-03-26 13:16:18 +0000","UNKNOWN","Double blind, identical-appearing capsules.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-PERPHEN-_x002d_-L_x0027_rman-2005","2010-12-21 09:08:09 +0000","YES","Data for leaving study early were available but total was high (74%).","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-PERPHEN-_x002d_-L_x0027_rman-2005","2010-02-03 09:55:36 +0000","YES","Evidence for selective reporting was not found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-PERPHEN-_x002d_-L_x0027_rman-2005","2010-05-18 05:47:38 +0100","UNKNOWN","Allocation to ziprasidone treatment was not possible from the start.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-PERPHEN-_x002d_-Yi-2006","2010-02-04 08:23:29 +0000","UNKNOWN","Randomised, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-PERPHEN-_x002d_-Yi-2006","2010-02-04 08:23:35 +0000","UNKNOWN","No details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-PERPHEN-_x002d_-Yi-2006","2010-05-18 05:50:51 +0100","UNKNOWN","No details.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.03","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-PERPHEN-_x002d_-Yi-2006","2011-08-30 03:44:49 +0100","YES","No incomplete data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-PERPHEN-_x002d_-Yi-2006","2010-01-29 11:20:52 +0000","NO","TESS scores measured, but not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus typical antipsychotic medications for schizophrenia [v2.124-For publication].rm5","STD-vs-PERPHEN-_x002d_-Yi-2006","2010-12-21 09:21:20 +0000","YES","None obvious.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Astrazeneca-1998","2013-10-23 08:57:25 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Astrazeneca-1998","2013-10-23 08:57:26 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Astrazeneca-1998","2013-10-23 08:57:29 +0100","UNKNOWN","Double-blind. Whether blinding was successful has not been examined, but the compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Astrazeneca-1998","2013-10-23 08:57:35 +0100","UNKNOWN","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Astrazeneca-1998","2013-10-23 08:57:51 +0100","NO","36% attrition, early leavers not adequately accounted for.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Astrazeneca-1998","2013-10-23 08:57:59 +0100","NO","Not all pre-defined outcomes were described, including CGI scores, PANSS subscales and adverse event rating scales.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Astrazeneca-1998","2013-10-23 08:58:00 +0100","UNKNOWN","Study sponsored by manufacturer of quetiapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Atmaca-2003","2013-10-23 09:25:24 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Atmaca-2003","2013-10-23 09:25:27 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Atmaca-2003","2013-10-23 09:25:29 +0100","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Atmaca-2003","2013-10-23 09:25:31 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Atmaca-2003","2013-10-23 09:25:37 +0100","YES","Overall attrition was low (5.4%). Reasons for leaving early were not assessed; only completer data were presented. Because of the very low rate of attrition, we do not think that a risk of bias was present.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Atmaca-2003","2013-10-23 09:25:38 +0100","YES","Probably free of bias. The study focused on serum leptin and triglyceride levels, which were adequately described.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Atmaca-2003","2013-10-23 09:25:45 +0100","UNKNOWN","Data on the allowed dose range have not been presented. Furthermore, the pre-study treatment was heterogeneous, as 19 participants had never taken any psychotropic drugs, but most other participants had a long history of previous treatment.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Byerly-2008","2013-10-23 09:43:51 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Byerly-2008","2013-10-23 09:43:52 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Byerly-2008","2013-10-23 09:43:55 +0100","UNKNOWN","Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Byerly-2008","2013-10-23 09:43:56 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Byerly-2008","2013-10-23 09:44:00 +0100","UNKNOWN","No discussion of participants leaving the study early or of missing data. 100% retention with no missing data is unusual for this type of study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Byerly-2008","2013-10-23 09:44:01 +0100","YES","We did not find evidence for selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Byerly-2008","2013-10-23 09:44:03 +0100","UNKNOWN","No washout period was provided, and a one-week overlap of risperidone in the quetiapine group was described.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Canuso-2008","2013-10-23 09:52:44 +0100","YES","Stratified according to site but method unclear, likely adequate.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Canuso-2008","2013-10-23 09:52:45 +0100","YES","Voice response system.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Canuso-2008","2013-10-23 09:52:46 +0100","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Canuso-2008","2013-10-23 09:52:47 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Canuso-2008","2013-10-23 09:52:51 +0100","YES","Relatively low attrition (15%) for monotherapy phase of study. Difference of 5 participants between randomly assigned and ITT population that are unaccounted for Unlikely to affect final data.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Canuso-2008","2013-10-23 09:52:52 +0100","NO","Not all pre-defined adverse effects were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Canuso-2008","2013-10-23 09:52:53 +0100","NO","The study was sponsored by the manufacturer of paliperidone.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Conley-2005","2013-10-23 09:53:49 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Conley-2005","2013-10-23 09:53:50 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Conley-2005","2013-10-23 09:53:52 +0100","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Conley-2005","2013-10-23 09:53:53 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Conley-2005","2013-10-23 09:53:57 +0100","NO","Overall attrition was moderate at 36%. The analysis was based on mixed-effect models. It is unclear whether this statistical method can account for such a relatively high attrition rate.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Conley-2005","2013-10-23 09:53:59 +0100","NO","Not all pre-defined adverse effects were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Conley-2005","2013-10-23 09:54:03 +0100","UNKNOWN","A slight baseline imbalance was noted in terms of mean age and mean number of previous hospitalisations (14 in the risperidone group and 9.7 in the quetiapine group).","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Deberdt-2008","2013-10-23 10:38:02 +0100","UNKNOWN","Randomisation method not reported, statistically significant baseline differences in mean PANSS total and BMI between groups.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Deberdt-2008","2013-10-23 10:38:02 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Deberdt-2008","2013-10-23 10:38:05 +0100","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Deberdt-2008","2013-10-23 10:38:06 +0100","YES","Objective outcomes such as laboratory measures are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Deberdt-2008","2013-10-23 10:38:10 +0100","NO","Overall attrition was very high (57%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change in his condition if he had remained in the study. This assumption obviously can be wrong.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Deberdt-2008","2013-10-23 10:38:11 +0100","NO","Not all pre-defined outcomes were described, including PANSS scores.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Deberdt-2008","2013-10-23 10:38:14 +0100","NO","The study was sponsored by the manufacturers of olanzapine. Mean modal dose rather than mean dose reported. Study inadequately powered for primary outcome because of recruitment difficulties.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Eerdekens-2007","2013-10-23 10:39:32 +0100","YES","Computer randomisation with block permutation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Eerdekens-2007","2013-10-23 10:39:33 +0100","YES","Central call centre.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Eerdekens-2007","2013-10-23 10:39:34 +0100","YES","Unlikely that ECG interpretation could have been unblinded. No other subjective outcomes. All medication was identical over encapsulated.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Eerdekens-2007","2013-10-23 10:39:37 +0100","YES","Unlikely that ECG interpretation could have been unblinded.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Eerdekens-2007","2013-10-23 10:39:41 +0100","NO","17.2% attrition in treatment groups. Only completer data were assessed for cardiac effects.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Eerdekens-2007","2013-10-23 10:39:43 +0100","UNKNOWN","Details for concomitant medication prescription in each treatment arm not mentioned.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Eerdekens-2007","2013-10-23 10:39:45 +0100","UNKNOWN","Study sponsored by the manufacturer of paliperidone.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Hatta-2009","2013-10-23 10:44:05 +0100","UNKNOWN","Implied but not stated.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Hatta-2009","2013-10-23 10:44:06 +0100","YES","Sealed envelopes.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Hatta-2009","2013-10-23 10:44:07 +0100","UNKNOWN","Single, rater blinded. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Hatta-2009","2013-10-23 10:44:10 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Hatta-2009","2013-10-23 10:44:11 +0100","NO","How attrition was accounted for is not described. Half of the participants in the aripiprazole and quetiapine groups dropped out of the study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Hatta-2009","2013-10-23 10:44:15 +0100","YES","Pre-stipulated outcomes are reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Hatta-2009","2013-10-23 10:44:16 +0100","NO","Study was powered for discontinuation of treatment only. Not powered for any other outcomes.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Hu-2008","2013-10-23 10:46:00 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Hu-2008","2013-10-23 10:46:01 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Hu-2008","2013-10-23 10:46:01 +0100","UNKNOWN","Single, rater blinded. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Hu-2008","2013-10-23 10:46:02 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Hu-2008","2013-10-23 10:46:05 +0100","UNKNOWN","No attrition reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Hu-2008","2013-10-23 10:46:09 +0100","UNKNOWN","Not all pre-defined adverse effects were reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Hu-2008","2013-10-23 10:46:10 +0100","UNKNOWN","No dropouts were reported. Funding source was not reported.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Kinon-2006b","2013-10-23 10:50:53 +0100","YES","Random, computer-generated randomisation.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Kinon-2006b","2013-10-23 10:50:54 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Kinon-2006b","2013-10-23 10:50:55 +0100","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Kinon-2006b","2013-10-23 10:50:57 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Kinon-2006b","2013-10-23 10:51:01 +0100","NO","Overall attrition was very high (54.9%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change in his condition if he had remained in the study. This assumption obviously can be wrong.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Kinon-2006b","2013-10-23 10:51:02 +0100","NO","The numbers of participants who received antiparkinson medication or who had leukopaenia were not indicated.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Kinon-2006b","2013-10-23 10:51:04 +0100","NO","The study was sponsored by the manufacturer of olanzapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li-2002","2013-10-23 10:52:55 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li-2002","2013-10-23 10:52:55 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li-2002","2013-10-23 10:52:56 +0100","UNKNOWN","Double, probably identical capsules. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li-2002","2013-10-23 10:52:57 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li-2002","2013-10-23 10:53:00 +0100","UNKNOWN","Two participants left the study early as the result of adverse events in the clozapine group. Some doubt continues about whether all data on leaving the study early have been presented.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li-2002","2013-10-23 10:53:01 +0100","YES","We did not find evidence of selective reporting.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li-2002","2013-10-23 10:53:02 +0100","UNKNOWN","No data on pre-study medication were provided; therefore baseline imbalance cannot be excluded.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li-2003","2013-10-23 10:53:48 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li-2003","2013-10-23 10:53:49 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li-2003","2013-10-23 10:53:50 +0100","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li-2003","2013-10-23 10:53:51 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li-2003","2013-10-23 10:53:53 +0100","UNKNOWN","One participant in the quetiapine group left the study early because of inefficacy. This participant was not included in the analysis. Some doubt continues about whether all data on leaving the study early have been presented.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li-2003","2013-10-23 10:53:54 +0100","NO","The study duration was eight weeks, but only outcomes at four weeks were available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li-2003","2013-10-23 10:53:55 +0100","UNKNOWN","The allowed dose range was not indicated.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li--2005","2013-10-23 10:51:52 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li--2005","2013-10-23 10:51:53 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li--2005","2013-10-23 10:51:54 +0100","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li--2005","2013-10-23 10:51:56 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li--2005","2013-10-23 10:51:57 +0100","NO","Overall attrition was 9.1%. Numbers leaving early were reported only for any reason. Only completer data were assessed.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li--2005","2013-10-23 10:51:58 +0100","NO","No reporting of adverse effects was provided.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Li--2005","2013-10-23 10:52:02 +0100","UNKNOWN","Baseline characteristics have not been presented for both groups separately. Therefore, baseline imbalance cannot be excluded. Furthermore, no washout period was provided.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Lieberman-2005","2013-10-23 10:54:57 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Lieberman-2005","2013-10-23 10:54:57 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Lieberman-2005","2013-10-23 10:54:59 +0100","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but the examined compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Lieberman-2005","2013-10-23 10:55:00 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Lieberman-2005","2013-10-23 10:55:02 +0100","NO","The attrition rate was very high (75%). Continuous outcomes were evaluated on the basis of a mixed-effects model. It is unclear whether any statistical method can account for such a high attrition rate.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Lieberman-2005","2013-10-23 10:55:03 +0100","YES","No evidence of selective reporting was found.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Lieberman-2005","2013-10-23 10:55:21 +0100","UNKNOWN","Dose ranges were very different; the upper dose range of olanzapine was 30 mg, whereas risperidone could be titrated only up to 6 mg/d. No washout period was provided. An overlap in the administration of formerly given antipsychotics was permitted for the first four weeks after randomisation.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Liu-2004","2013-10-23 10:56:16 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Liu-2004","2013-10-23 10:56:17 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Liu-2004","2013-10-23 10:56:18 +0100","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Liu-2004","2013-10-23 10:56:21 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Liu-2004","2013-10-23 10:56:22 +0100","UNKNOWN","Five participants left the study early: three because of adverse events in the clozapine group and two for unclear reasons in the quetiapine group. These five participants were not included in the analysis. Some doubt continues about whether all data on leaving the study early have been presented.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Liu-2004","2013-10-23 10:56:25 +0100","NO","Mean doses of the medications used were not indicated.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Liu-2004","2013-10-23 10:56:26 +0100","NO","Clozapine was titrated to 400 mg/d within 10 days. Such a fast dose increase can be accompanied by a higher rate of adverse effects.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Lu-2006","2013-10-23 10:57:17 +0100","YES","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Lu-2006","2013-10-23 10:57:18 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Lu-2006","2013-10-23 10:57:21 +0100","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Lu-2006","2013-10-23 10:57:22 +0100","UNKNOWN","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Lu-2006","2013-10-23 10:57:25 +0100","UNKNOWN","96 participants were recruited, but data are available on only 64 participants. How these missing data were addressed statistically is not stated.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Lu-2006","2013-10-23 10:57:26 +0100","UNKNOWN","Mean doses of the medications used were not indicated.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Lu-2006","2013-10-23 10:57:26 +0100","UNKNOWN","Quetiapine dose range was below therapeutic range.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Luo-Xin-2008","2013-10-23 10:58:16 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Luo-Xin-2008","2013-10-23 10:58:17 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Luo-Xin-2008","2013-10-23 10:58:18 +0100","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Luo-Xin-2008","2013-10-23 10:58:18 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Luo-Xin-2008","2013-10-23 10:58:29 +0100","UNKNOWN","No leaving early reported. This is unusual for this type of study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Luo-Xin-2008","2013-10-23 10:58:32 +0100","NO","PANSS scores and akathisia were the only outcomes reported. No other adverse events mentioned.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Luo-Xin-2008","2013-10-23 10:58:36 +0100","UNKNOWN","Funding source is unclear.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-McEvoy-2006","2013-10-23 10:59:32 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-McEvoy-2006","2013-10-23 10:59:32 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-McEvoy-2006","2013-10-23 10:59:33 +0100","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-McEvoy-2006","2013-10-23 10:59:34 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-McEvoy-2006","2013-10-23 10:59:37 +0100","NO","Overall attrition was extremely high (74%). We doubt that the validity of the findings was not affected by this high number.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-McEvoy-2006","2013-10-23 10:59:38 +0100","NO","Because of small numbers and the very high attrition, only data on 26 weeks of treatment (rather than the full duration of 52 weeks) were presented.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-McEvoy-2006","2013-10-23 10:59:40 +0100","UNKNOWN","The dose ranges were very different, and the upper dose range of olanzapine was 30 mg/d, whereas risperidone could be given only in a maximum dose of 6 mg/d. Participants had a history of former inefficacy of one of the medications. It was excluded that the same medication could be given again, but still this might implicate a risk of bias due to baseline imbalance in terms of former treatment. No washout phase was provided.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-McEvoy-2007","2013-10-23 11:00:25 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-McEvoy-2007","2013-10-23 11:00:27 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-McEvoy-2007","2013-10-23 11:00:27 +0100","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-McEvoy-2007","2013-10-23 11:00:30 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-McEvoy-2007","2013-10-23 11:00:31 +0100","NO","Overall attrition was high (70.3%). The primary analysis was based on a mixed-effects model; secondary outcomes used the last-observation-carried forward approach and included only study completers. Nevertheless, it is unclear whether any statistical method can account for such high attrition.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-McEvoy-2007","2013-10-23 11:00:36 +0100","NO","Adverse events were presented only in cases of moderate or worse severity.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-McEvoy-2007","2013-10-23 11:00:37 +0100","NO","The study was sponsored by the manufacturer of quetiapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Mori-2004","2013-10-23 11:01:13 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Mori-2004","2013-10-23 11:01:14 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Mori-2004","2013-10-23 11:01:16 +0100","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but the compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Mori-2004","2013-10-23 11:01:18 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Mori-2004","2013-10-23 11:01:19 +0100","NO","Data on leaving the study early have not been presented.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Mori-2004","2013-10-23 11:01:20 +0100","NO","Adverse events were not reported. Numbers on use of antiparkinson medication have not been presented.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Mori-2004","2013-10-23 11:01:23 +0100","NO","No washout period was provided. The previous antipsychotic treatment was gradually tapered over four weeks. Thus, during a period of 4 weeks, participants were taking two drugs.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Ozguven-2004","2013-10-23 11:01:49 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Ozguven-2004","2013-10-23 11:01:50 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Ozguven-2004","2013-10-23 11:01:51 +0100","UNKNOWN","Single, rater blind. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Ozguven-2004","2013-10-23 11:01:53 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Ozguven-2004","2013-10-23 11:01:56 +0100","YES","The overall attrition rate was 13%. The method used to address incomplete outcomes has not been presented. Nevertheless, because of the low attrition rate, we consider the risk to be low.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Ozguven-2004","2013-10-23 11:01:57 +0100","NO","The study has been published only as an abstract. Efficacy data have been presented only as percentage change from baseline.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Ozguven-2004","2013-10-23 11:01:59 +0100","UNKNOWN","Only female participants could be included, so a possible gender bias cannot be excluded.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Peng-2007","2013-10-23 11:03:06 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Peng-2007","2013-10-23 11:03:12 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Peng-2007","2013-10-23 11:03:13 +0100","UNKNOWN","Single, rater blinded. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Peng-2007","2013-10-23 11:03:14 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Peng-2007","2013-10-23 11:03:15 +0100","NO","Dropouts not reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Peng-2007","2013-10-23 11:03:18 +0100","UNKNOWN","Number on parkinsonian medication not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Peng-2007","2013-10-23 11:03:19 +0100","UNKNOWN","Funding source unclear.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Potkin-2006","2013-10-23 11:04:19 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Potkin-2006","2013-10-23 11:04:20 +0100","YES","Participants were assigned using a centralised interactive voice response system. Probably a correct method.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Potkin-2006","2013-10-23 11:04:21 +0100","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differsubstantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Potkin-2006","2013-10-23 11:04:22 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Potkin-2006","2013-10-23 11:04:27 +0100","YES","Overall attrition was 12%. The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change in his condition if he had remained in the study. This assumption obviously can be wrong. Nevertheless, because of the overall low attrition, it is unlikely that the results have been affected.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Potkin-2006","2013-10-23 11:04:30 +0100","NO","Data on some adverse effects were not available. Side effects had to occur in at least 10% to be reported. Important side effects may have been missed by this procedure.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Potkin-2006","2013-10-23 11:04:31 +0100","NO","This study was sponsored by the manufacturer of risperidone.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Riedel-2005","2013-10-23 11:05:38 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Riedel-2005","2013-10-23 11:05:39 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Riedel-2005","2013-10-23 11:05:41 +0100","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Riedel-2005","2013-10-23 11:05:45 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Riedel-2005","2013-10-23 11:05:48 +0100","NO","Overall attrition was considerable (45.2%). The data were analysed using last-observation-carried-forward and a completer analysis. Nevertheless, it is questionable whether any statistical method can account for such high attrition.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Riedel-2005","2013-10-23 11:05:49 +0100","NO","Data on negative symptoms (SANS) and some adverse effects were not available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Riedel-2005","2013-10-23 11:05:52 +0100","NO","The study was sponsored by the manufacturer of quetiapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Riedel-2007","2013-10-23 11:07:00 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Riedel-2007","2013-10-23 11:07:01 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Riedel-2007","2013-10-23 11:07:02 +0100","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Riedel-2007","2013-10-23 11:07:03 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Riedel-2007","2013-10-23 11:07:09 +0100","NO","Overall attrition was very high at 61.5%.The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change in his condition if he had remained in the study. This assumptionobviously can be wrong.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Riedel-2007","2013-10-23 11:07:10 +0100","NO","Data on global state have not been presented.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Riedel-2007","2013-10-23 11:07:11 +0100","NO","The study was sponsored by the manufacturer of olanzapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Sacchetti-2004","2013-10-23 11:08:05 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Sacchetti-2004","2013-10-23 11:08:06 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Sacchetti-2004","2013-10-23 11:08:07 +0100","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Sacchetti-2004","2013-10-23 11:08:10 +0100","YES","Single, rater-blind. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Sacchetti-2004","2013-10-23 11:08:14 +0100","UNKNOWN","The attrition rate was 18.6%. The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change in his condition if he had remained in the study. This assumption obviously can be wrong.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Sacchetti-2004","2013-10-23 11:08:17 +0100","NO","Efficacy data (PANSS) were presented only as percentage change, without indications of standard deviations, standard errors, P values or ranges. Only interim data after half of the participants had been recruited have been presented.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Sacchetti-2004","2013-10-23 11:08:17 +0100","NO","The study was sponsored by the manufacturer of quetiapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Sirota-2006","2013-10-23 11:09:14 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Sirota-2006","2013-10-23 11:09:15 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Sirota-2006","2013-10-23 11:09:16 +0100","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Sirota-2006","2013-10-23 11:09:19 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Sirota-2006","2013-10-23 11:09:22 +0100","YES","Overall attrition was low (12%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change in his condition if he had remained in the study. This assumption obviously can be wrong. Nevertheless, because of the low attrition, we do not think that this led to bias.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Sirota-2006","2013-10-23 11:09:23 +0100","NO","Efficacy data (PANSS, SANS) have been presented only as median change. No data on extrapyramidal side effects and cardiac effects were provided.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Sirota-2006","2013-10-23 11:09:26 +0100","NO","This study was sponsored by the manufacturer of quetiapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Song-2008","2013-10-23 11:10:08 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Song-2008","2013-10-23 11:10:09 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Song-2008","2013-10-23 11:10:13 +0100","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Song-2008","2013-10-23 11:10:14 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Song-2008","2013-10-23 11:10:14 +0100","UNKNOWN","No dropouts were reported. This is unusual for this type of study.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Song-2008","2013-10-23 11:10:16 +0100","UNKNOWN","Not all stipulated outcome measures were reported, including adverse events, weight and ECG changes.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Song-2008","2013-10-23 11:10:20 +0100","NO","Whether informed consent was obtained is unclear, and the funding source was not stated.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Stroup-2006","2013-10-23 11:11:45 +0100","UNKNOWN","Random; two steps of randomisation before and after availability of ziprasidone; subjects received other medication than in previous phase 1 treatment. Re-randomised.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Stroup-2006","2013-10-23 11:11:46 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Stroup-2006","2013-10-23 11:11:47 +0100","UNKNOWN","Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Stroup-2006","2013-10-23 11:11:52 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Stroup-2006","2013-10-23 11:11:55 +0100","NO","The attrition rate was very high (72.5%). Continuous data were analysed on the basis of mixed-effects models. It is unclear whether any statistical method can account for such high rates of leaving the study early.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Stroup-2006","2013-10-23 11:11:59 +0100","NO","Use of antiparkinson medication was permitted, but data on this outcome have not been presented.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Stroup-2006","2013-10-23 11:12:00 +0100","UNKNOWN","Participants had a history of former intolerance to atypical antipsychotic treatment, but baseline data on this were not provided.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Svestka-2003b","2013-10-23 11:13:10 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Svestka-2003b","2013-10-23 11:13:11 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Svestka-2003b","2013-10-23 11:13:12 +0100","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Svestka-2003b","2013-10-23 11:13:13 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Svestka-2003b","2013-10-23 11:13:14 +0100","NO","Data on the overall attrition rate were not available.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Svestka-2003b","2013-10-23 11:13:17 +0100","NO","For some metabolic parameters, no data were available.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Svestka-2003b","2013-10-23 11:13:18 +0100","UNKNOWN","A slight baseline imbalance in mean age was described as non-significant.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Voruganti-2007","2013-10-23 11:13:47 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Voruganti-2007","2013-10-23 11:13:47 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Voruganti-2007","2013-10-23 11:13:49 +0100","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Voruganti-2007","2013-10-23 11:13:52 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Voruganti-2007","2013-10-23 11:13:53 +0100","NO","A discrepancy has been noted between the abstract and the text. According to the abstract, fewer participants left the study early; however, this finding was no longer mentioned in the text, according to which the overall attrition was only 1.2%.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Voruganti-2007","2013-10-23 11:13:57 +0100","NO","Use of antiparkinson medication was permitted, but the numbers have not been presented.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Voruganti-2007","2013-10-23 11:13:57 +0100","NO","The study was sponsored by the manufacturer of quetiapine.No washout period was provided.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wang-2006","2013-10-23 11:14:18 +0100","YES","Random number table.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wang-2006","2013-10-23 11:14:19 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wang-2006","2013-10-23 11:14:22 +0100","UNKNOWN","Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wang-2006","2013-10-23 11:14:23 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wang-2006","2013-10-23 11:14:23 +0100","UNKNOWN","No dropouts reported.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wang-2006","2013-10-23 11:14:33 +0100","UNKNOWN","ECG changes not reported.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wang-2006","2013-10-23 11:14:34 +0100","UNKNOWN","Funding source is unclear. Ethics approval and informed consent not stated.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wei-2006a","2013-10-23 11:15:24 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wei-2006a","2013-10-23 11:15:27 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wei-2006a","2013-10-23 11:15:30 +0100","UNKNOWN","Single, rater blinded.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wei-2006a","2013-10-23 11:15:33 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wei-2006a","2013-10-23 11:15:37 +0100","UNKNOWN","12.1% attrition. How this attrition was accounted for statistically is unclear.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wei-2006a","2013-11-04 17:22:23 +0000","NO","Use of antiparkinson medication was permitted, but numbers have not been presented. Adverse events not described.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wei-2006a","2013-10-23 11:15:47 +0100","UNKNOWN","Ethics approval unclear.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wei-2006b","2013-10-23 11:16:54 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wei-2006b","2013-10-23 11:17:17 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wei-2006b","2013-10-23 11:17:19 +0100","UNKNOWN","No further details. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wei-2006b","2013-10-23 11:17:22 +0100","UNKNOWN","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wei-2006b","2013-10-23 11:17:28 +0100","NO","Seven participants left the study early s the result of adverse events (4 in quetiapine group and 3 in aripiprazole group). Intention-to-treat analysis not done.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wei-2006b","2011-07-28 10:00:38 +0100","NO","PANSS positive and negative scores only reported. Details on adverse events not provided","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Wei-2006b","2013-10-23 11:17:36 +0100","UNKNOWN","No data on pre-study medication; therefore, baseline imbalance cannot be excluded. Funding source unclear.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Zhong-2006","2013-10-23 11:18:19 +0100","UNKNOWN","Random, no further details.","Random sequence generation (selection bias)","QIT-01","Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Zhong-2006","2013-10-23 11:18:21 +0100","UNKNOWN","No further details.","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Zhong-2006","2013-10-23 11:18:40 +0100","UNKNOWN","Double, no further details. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.01","Subjective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Zhong-2006","2013-10-23 11:18:42 +0100","YES","Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.","Blinding (performance bias and detection bias)","QIT-03","Performance bias or detection bias due to knowledge of the allocated interventions after assignment","QIG-03.02","Objective outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Zhong-2006","2013-10-23 11:18:53 +0100","NO","Overall attrition was high (52.1%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change in his condition if he had remained in the study. This assumption obviously can be wrong. Data on study completers were also available. Nevertheless, it is unclear whether any statistical method can account for such a degree of attrition.","Incomplete outcome data (attrition bias)","QIT-04","Attrition bias due to amount, nature or handling of incomplete outcome data","QIG-04.01","All outcomes"
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Zhong-2006","2013-10-23 11:19:01 +0100","NO","Adverse events were presented only with an incidence of at least 5% among participants; therefore, important side effects may have been missed by this procedure.","Selective reporting (reporting bias)","QIT-05","Reporting bias due to selective outcome reporting","",""
"../ALL-2015-06/Q-Z/Quetiapine versus other atypical antipsychotics for schizophrenia [v4.2-For publication].rm5","STD-Zhong-2006","2013-10-23 11:19:03 +0100","NO","The study was sponsored by the manufacturer of quetiapine.","Other bias","QIT-06","Bias due to problems not covered elsewhere in the table","",""
"../ALL-2015-06/Q-Z/Quetiapine for schizophrenia [v13.0-For publication].rm5","STD-Africa_x002d_Europe-1994","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine for schizophrenia [v13.0-For publication].rm5","STD-Canada-2000","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine for schizophrenia [v13.0-For publication].rm5","STD-Europe_x002d_USA-1994","","YES","A - Adequate","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine for schizophrenia [v13.0-For publication].rm5","STD-Japan-1999a","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine for schizophrenia [v13.0-For publication].rm5","STD-Japan-1999b","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine for schizophrenia [v13.0-For publication].rm5","STD-Multi_x002d_country-1995","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine for schizophrenia [v13.0-For publication].rm5","STD-Multi_x002d_country-1996","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine for schizophrenia [v13.0-For publication].rm5","STD-Multi_x002d_country-1999","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine for schizophrenia [v13.0-For publication].rm5","STD-North-America-1996","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine for schizophrenia [v13.0-For publication].rm5","STD-USA-1990","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine for schizophrenia [v13.0-For publication].rm5","STD-USA-1994","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
"../ALL-2015-06/Q-Z/Quetiapine for schizophrenia [v13.0-For publication].rm5","STD-USA-2000a","","UNKNOWN","B - Unclear","Allocation concealment (selection bias)","QIT-02","Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment","",""
